51||These pooled results showed that PAN is superior to a BZ regimen at P = .05 level, despite additional BZs.
26|efficacy of PCIT,adherence rate,structure,autonomy,parental anger and physical discipline/force, and family problems,low attrition rate,autonomy-support,overall levels of parental anger and physical discipline/force,moderate stability and parent-child correspondence|Twenty-six maltreating families were randomly assigned to one of two conditions: the 16-hour weekly intervention group, or the 4-month wait list control group.
45|nausea,mean migraine headache frequency,Valproic acid serum levels,migraine headache rate,frequency of headache attacks, the frequency of use of drugs for the acute management of migraine, the patients' opinion of treatment and the Hamilton anxiety and depression rating scales,Frequency, intensity, and duration of migraine headaches as well as MIDAS score and symptomatic medications,initial migraine frequency,symptomatic medication per episode,mean standard deviation (SD) of monthly migraine frequency,frequency of migraine attacks and the number of migraine headache days,frequency, severity and duration of the attacks,efficacy and safety,migraine attack frequencies,migraine frequency,various side effects,reductions with extended-release divalproex sodium,headache days,Adverse events,severity and duration of the migraine attacks,migraine headache frequency,migraine headache rates,number of responders,reduction of headache severity,average peak severity or duration of individual migraine headaches,Responder rate,Migraine frequency,frequency of migraine attacks,mean SD of monthly headache frequency,Migraine headaches,4-week migraine attack frequency,Migraine headache days,mean score of the 21-item Hamilton rating scale for depression,Tolerance and safety,headache duration,migraine attacks,headache intensity,nausea, dizziness and tremor in which incidence rates,Side effects,incidence of any specific treatment-emergent adverse event,Frequency, intensity, duration, associated symptoms with headaches, analgesics use, as well as drugs' side effects,number of days with migraine,visual analog scale (VAS), and headache duration,migraine headache,duration, monthly frequency, and intensity of headache,functional restriction,symptoms with migraine|The outcome of group 1 (low serum level) was significantly better than that of group 2 with respect to both parameters (P<.05).
not found|response to treatment: at least 20% improvement from basal conditions on clinical, laboratory, or specific neurological testing variables,response rate|Of the 32 patients studied, 18/19 receiving Cy and 7/13 receiving MP responded to treatment (p<0.03).
                
220|length of stay, mortality, readmission, complications, satisfaction, and cost,functional dependence (Barthel Index), discharge destination and length of hospital stay,quality of care, job satisfaction, length of patient stay,nurse job satisfaction,Length of hospital stay, discharge destination, functional dependence (Barthel index) and direct healthcare costs,daily cost of care,functional independence,discharge destination or dependence,Patients' length of stay, functional status, subsequent move to more dependent living arrangement,length of stay, mortality, or complications,cost savings,initial length of stay,average total cost of delivering care,mean total cost,Quality of care scores,mortality, functional status, or living arrangements at any time,Length of inpatient stay,Inpatient length of stay,decision making and quality of care|Few significant differences were found between the two groups in length of stay, mortality, or complications.
161|CAP,overall toxicity,time to progression and survival,larger proportion of 48-month survivors,Pathologic complete response rates,response rate of AC, FU, and CY,complete pathological response rate,toxicity deaths,survival superiority,partial response,Nausea, vomiting and alopecia,neuromuscular toxicities,overall survival,toxicity and efficacy,therapeutic index,hearing loss,Median survival CAP,clinical complete response rates,median progression free survival (PFS,efficacy and tolerance,response rates,response rate to CMF,toxicity/refusal,progressive disease (PD), nonresponse, or toxicity,macroscopic disease left,Toxicity,response to therapy, time to treatment failure, and overall survival,early nausea and vomiting and later hematologic toxicity,alopecia,response rate,incidence of side effects,Toxicity and treatment efficacy assessed by pathological response rate, progression-free survival, and survival,myelosuppression, especially thrombocytopenia,clinical complete response (CR) rate for CA,progression-free interval,Optimal survival with minimal toxicity,Median survival times,leucopenia,5-year survival rates,efficacy and toxicity,survival rates,median survival,clinical complete response,overall survival and activity index,life-threatening toxicities, including hematologic toxicity,response duration,side-effects and haematological toxicity,thrombocytopenia,Survival,myelosuppression, particularly thrombocytopenia,renal toxicity,partial response rates,median survival durations,survival or progression-free survival,complete and partial response rate,clinical toxicities and abnormalities in laboratory findings,bone marrow disorders and death due to toxicity,superior progression-free survival,better survival,progression free survival,median time to progression,complete and partial response rates,Overall response rates,clinical complete response rates and longer time to failure,Mortality,overall response rate,survival of CRs,survival curves,Response rates,hematologic and gastrointestinal toxicity,complete remissions (CRs,lethal toxicities, including gastrointestinal hemorrhage (1 patient) and neutropenic sepsis,nadir blood counts,5-year relapse-free survival rates,severe hematological toxicity,complete response,Time to progression and survival,pathologic response rate,clinical response rate,toxicity,nausea and emesis,small survival,survival,median response duration,median survivals,myelosuppression,Efficacy,overall median response rate,response rate, time to progression, disease-free survival and overall survival,median duration of CRs,Likewise, time to treatment failure,Survival and time to treatment failure,survival or response,anemia,median duration of response,tinnitus,Clinical response rates,overall pathological response rate,unacceptable toxicity,Cell differentiation and volume of postoperative disease|Failure to achieve a significant degree of leucopenia was associated with worse progression free survival (P less than 0.001).
56|Time to achieve full feeds,Gastric emptying,feeding tolerance,Gastroesophageal reflux,time taken to attain full enteral feedings,total parenteral nutrition or to the time needed to regain birthweight,time to full feeding,gastrointestinal function,mean birth weight,gastric emptying, maturation of gastrointestinal motor patterns, and time to achieve full enteral feedings,gastrointestinal dysmotility,Gastric emptying and characteristics of antroduodenal motor contractions,efficacy and safety,full enteral feeding earlier,gestational age at birth,median gestational age, birth weight and postnatal age at start of feeds,episodes of sepsis, necrotizing enterocolitis, and cholestasis,full enteral feeding,episodes of large residual gastric aspirates,mean time to attain full enteral feedings,episodes of gastric residuals (P<0.05) and shorter duration of parenteral nutrition (PN,Feed toleration, time taken to establish full enteral feeding, vomiting, prescription of glycerine suppositories and occurrence of necrotising enterocolitis,tolerated,cardiac dysrhythmia, pyloric stenosis, or septicaemia,length of time taken to establish full enteral feeding since enrollment,Times to full feeding,symptoms of gastroesophageal reflux,cholestatic jaundice,gastric emptying and feed tolerance,time taken to attain full enteral feedings of at least 130 mL/kg/d,time to establish full enteral feeds,necrotizing enterocolitis,number of withheld feeds,feeding outcome,feed tolerance|Oral erythromycin is effective in facilitating enteral feeding in preterm very low birthweight infants with moderately severe gastrointestinal dysmotility.
||
39|VO2 during recovery,adverse cardiac outcome,Total operative time,IL-1beta and TNF-alpha,overall incidence of myocardial ischemia,cardiac filling pressure and systemic vascular resistance,Myocardial ischemia,surgical intensive care stay,Postoperative outcomes,cardiovascular failure,Gastrin levels,gastrin AUC,complications,myocardial ischaemia or morbidity,Myocardial ischaemia,total duration of ischemia,plasma vasopressin and adrenaline,cortisol, epinephrine, norepinephrine, total catecholamines, CRP, and IL-6 in the postoperative period,postoperative morbidity,incidence of most side effects,perioperative myocardial ischaemia,length of stay in intensive care,Analgesic efficacy and side effects,SvO2,Postoperative ischaemia,Times to intensive care unit discharge, ward admission, first bowel sounds, first flatus, tolerating clear liquids, tolerating regular diet, and independent ambulation,mean arterial pressure and in calculated systemic vascular resistance,intubation time and intensive care stay,respiratory rate, vital capacity, peak expiratory volume in the first second, PaO2, PaCO2, arterial pH, heart rate, and systolic and diastolic blood pressure,EGG activity and serum gastrin secretion,cardiac index,blood loss, volume replacement or in the number of patients requiring postoperative ventilation,intraoperative decrease in SvO2,hospital costs,shorter time to extubation,plasma noradrenaline,duration of intensive care unit and hospital stay,intraoperative cardiovascular changes and postoperative complications,endotracheal intubation time,neuroendocrine response,power ratio (postprandial/fasting total power,Respiratory inductive plethysmographic data,O2 delivery (QO2) and consumption (VO2,Surgical "risk,early myocardial ischemia,risk of respiratory or cardiac complications,postoperative pain control,frequency of electrical waves (tachygastria,Intraoperative ischaemia,analgesic medication,Postoperative analgesia at rest and during coughing and movement,incidence of new myocardial infarction, stroke, and respiratory failure,visual analog pain scores,Urinary cortisol excretion, a marker of the stress response,time of hospitalization,death, myocardial infarction, myocardial ischemia, reoperation, pneumonia, and renal failure,perioperative outcome,Cardiovascular and hormonal responses,lowest value of SvO2 after extubation,length of hospitalization,death and major complications,haemodynamic stability,72-hour fluid requirement,electrogastrographic activity and serum gastrin secretion,stress response indices,Postoperative myocardial ischemia,Heart rate,postoperative pain, time of ambulation, and length of hospital stay,oxygen supply-demand ratio (QO2/VO2,Postoperative pain scores,heart and respiratory rate,Plasma catecholamines,myocardial ischemia,lung volume,overall incidence of death and major complications,hypotension,postoperative apneas, slow respiratory rates, desaturation, and S-T segment depression,hypertension and tachycardia,major infectious complications,Postoperative forced pulmonary volumes,EGG parameters or the serum gastrin integrated value (area under the curve [AUC,Perioperative ischaemia,Length of stay and direct medical costs,operative outcome,pain relief,plasma vasopressin,postoperative hospital length of stay, direct medical costs, selected postoperative morbidities, and postoperative recovery milestones,Values of cardiac index (CI) and QO2,serum gastrin secretion,total number or type of postoperative complications,Postoperative analgesia,CRP, IL-1beta, IL-6, and TNF-alpha levels,systemic hemodynamic function and systemic oxygen supply-demand relationship,VO2, CI and mixed venous O2 saturation,gastric electrical activity and serum gastrin secretion,Visual analog pain scores,hypotensive,serum cortisol, epinephrine norepinephrine, total catecholamines, interleukin (IL)-1beta, IL-6, tumor necrosis factor (TNF)-alpha, and C-reactive protein (CRP,intraoperative vasopressors,postoperative myocardial ischemia,morbidity or mortality,overall postoperative complication rate,postoperative pain relief,stress response,incidence of death and major complications,duration of postoperative ventilation|All patients showed a significant increase in cortisol, epinephrine, norepinephrine, total catecholamines, CRP, and IL-6 in the postoperative period (P < 0.05).
80|Amblyopia,1-year visual acuity outcome,responder rates,4-month visual acuity,rapid visual acuity recovery,Visual acuity,residual visual acuity deficit,BCVA, binocular function, and refractive errors,Single letter and linear acuity (near and distance) and contrast sensitivity,Visual outcome,Corrected amblyopic logMAR visual acuity and contrast sensitivity function,amblyopic eye visual acuity,Visual acuity in the amblyopic eye,average number of training sessions,BCVA,mean time to the resolution of amblyopia,visual acuity outcome,acuity,unilateral visual loss,unilateral acuity loss,severe amblyopia,mean visual acuities of the amblyopic eyes,binocular function,visual outcome,moderate to severe amblyopia,visual acuity, contrast sensitivity and resolution of amblyopia,contrast sensitivity and slight linear acuity improvement,mean time for patching,Resolution of amblyopia,median spherical equivalent refractive error,visual acuity of the amblyopic eye,visual acuity and contrast sensitivity,visual acuity,mean dose rates,median anisometropia,mean change in visual acuity of the amblyopic eye,amblyopic eye acuity|The median spherical equivalent refractive error increased significantly during the study in the amblyopic eyes (P<0.05) and the fellow eyes (P<0.001).
32|wheezing, respiratory rate, retractions, and general condition) and measured S(pO(2)) and heart rate,respiratory rate,mean clinical score for respiratory disability,retractions,child's comfort,Frequency of vomiting and transient respiratory destabilization,Median time to recovery,mean length of illness in hospital,Wheezing score,time to recovery, defined as 8 hours without oxygen supplementation associated with minimal or no chest recession, and ingesting more than two-thirds of daily food requirements,exhalation technique (IET) and assisted cough (AC,wheezing,heart rate,intensive care admission,intensive care unit admissions, artificial ventilation, antibiotic treatment, description of side effects during procedures, and parental perception of comfort,Average hospital stay,ventilatory support,bradycardia with or without desaturation|The treatment group showed a mean clinical score for respiratory disability at admission of 5.56 (+/-
10|density dependence of expiratory airflow,bronchoconstrictor response,overall bronchodilatory effects,ventilatory effect,Specific airway conductance, finger tremor amplitude, heart rate, and blood pressure,exercise heart rate,airways obstruction (FEV1, specific airways resistance,FEV1 and in PEFR,peak expiratory flow rate (PEFR,ventilation,time to exhaustion on a cycle ergometer,plasma levels,resting heart rate and FEV1,left or right ventricular ejection fraction,dyspnea,lung function, heart rate and blood pressure,resting airways obstruction and reduction in bronchodilator response,hyperventilation and exercise tolerance,heart rate and fall in diastolic blood pressure,Vital capacity (VC) and forced expiratory volume in one second (FEV1,heart rate,heart rate, blood pressure, and derived indexes at peak plasma drug levels,CO2 production,Resting heart rate and forced expiratory volume in one sec (FEV1,beta 1-Selectivity,beta-blocking activity,bronchodilator response,maximal expiratory flow rates,ventilatory indices, HR or BP,PEFR, FEV1, and VC,bronchial reactivity,forced expiratory volume in 1 second and specific airway conductance,slopes of the salbutamol dose-response curves of specific airway conductance,ventilatory indices,cardioselectivity,heart rate and FEV1,Mean reduction in resting pulse rate,Overall changes in FEV1,average monthly asthma attacks,histamine bronchial provocation,heart rate (HR,heart rate (HR), systolic blood pressure (SBP), and diastolic blood pressure (DBP,highest plasma levels,1 Cardiovascular and airways response,bronchomotor tone, skeletal muscle, and the circulatory system,forced vital capacity (FVC) and maximal midexpiratory flow (MMEF,cardiac and pulmonary function,specific airway conductance,AWR and increased PEFR, FEV1, and VC,Ventilatory effects,clinical exam, spirometry, or ejection fraction,baseline forced expiratory volume in 1 second (FEV1,12-min walking distance,effect of bronchodilator,Systolic and diastolic blood pressure (BP,forced vital capacity and peak expiratory flow,resting or exercise Pao2 or Paco2,FEV1 and FVC,dilevalol,forced expiratory volume,O2 consumption,expiratory airflow parameters,pulmonary function, heart rate and blood pressure,arterial O2 or CO2 tension (Pao2 and PaCO2, respectively,blood pressure,Pulmonary function,Monthly asthma attacks,FEV1,resting minute ventilation,FEV1 and the forced vital capacity (FVC,bronchial obstruction largely,resting heart rate,lung function,FEV1 and vital capacity (VC,basal forced expiratory volume,heart rate and systolic blood pressure,ventilatory function,Mean plasma levels,pre- and postexercise values of MEF50 and MEF25,evening peak flow rate,Changes in forced one-second expiratory volume (FEV1) and mid-maximal expiratory flow (MMEF,Pulse rate, forced expiratory volume in one second (FEV1) and specific airways conductance,respiratory function,HR, SBP, and DBP 2 h postmedication,HR and BP,exercise tolerance,lung function parameters--vital capacity (VC), airway resistance (AWR), peak expiratory flow rate (PEFR), forced expiratory volume (FEV1)--at baseline and at predetermined intervals following each medication and salbutamol challenge,forced expiratory volume in 1 s and forced vital capacity,diastolic blood pressure,AWR,degree of reactivity with each active drug,maximal expiratory flow-volume (MEFV) curves,resting pulse rate,pulmonary function,bronchial tone,Changes in FEV1,FEV1 and PEFR,expiratory volume (FEV1) and maximal midexpiratory flow rate,FEF,median cumulative salbutamol concentrations,cardiovascular parameters,Nonspecific bronchial reactivity,MEFV curves,airway resistance,improvement of airflow,bronchoconstriction,Ventilation, heart rate, and arterial blood gas tensions,FEV1 or forced vital capacity|Mean reduction in resting pulse rate was statisitcally greater after acebutolol compared with placebo but not after practolol compared with placebo.
not found|hemodynamics,Right-sided and pulmonary artery wedge pressures and systemic arterial pressures,cardiac sympathetic activity, and increased ventricular arrhythmias,cardiac norepinephrine uptake,myocardial norepinephrine uptake,24-hour urinary potassium excretion,pulmonary oedema of breathlessness,Heart failure,blood pressure to hypertensive values,right-sided, pulmonary arterial wedge pressure or cardiac outputs,mild hypokalemia,symptom-limited exercise tolerance,pulmonary wedge pressure,serum creatinine levels,Perceived exertion during submaximal exercise,plasma magnesium,Echocardiographic-determined measurements of left ventricular systolic and diastolic function,Pulmonary arterial pressure,diastolic pressure,blood, physical, ECG, and audiometric examinations,pulmonary artery pressure on exercise,systolic blood pressure,visual analogue scores for dyspnoea, fatigue, and general well-being,Pulmonary wedge pressure,reduced urinary magnesium excretion,BUN,24-hour urinary sodium excretion,urinary sodium/potassium ratio,plasma renin activity, plasma aldosterone,Heart rate,New York Heart Association functional class status,ventricular arrhythmias on 24-hour ambulatory electrocardiography,Cardiac output,heart size and echocardiographically measured ventricular volume,Blood pressure,NYHA functional class,Plasma potassium levels,pulmonary oedema,plasma urea,occasional kaliuretic response,diuretic therapy,time taken to walk 100 m at a self-selected slow speed,Exercise tolerance,ankle oedema|Cardiac output decreased at rest, but not significantly, and on exercise not at all.
1294|death at day 28 and 36 weeks postmenstrual age (PMA), air leaks, neuroimaging abnormalities, and other complications related to either prematurity or RDS,alive without BPD,incidence of RDS,major dosing complications,RDS-related mortality rates,rates of RDS at 24 hours and the rates of death related to RDS,incidence of BPD,morbidity and mortality rates,corresponding mortality rate,efficacy and safety,incidences of common complications of prematurity, including intraventricular hemorrhage (grades 3 and 4) and cystic periventricular leukomalacia,air leaks, and causes of death,mortality rate,BPD,mortality rates, bronchopulmonary dysplasia (BPD) rates, and rates of other complications of prematurity,excess mortality rates,incidence of being alive without bronchopulmonary dysplasia (BPD|Lucinactant is a more effective surfactant preparation than colfosceril palmitate for the prevention of RDS.
13|muscle power, functional ability, locomotor score, contractures, and forced vital capacity,Muscle strength, contractures, functional ability, cardiopulmonary changes, and laboratory data,number of calcium-positive muscular fibres,muscular power, muscle state, muscular functional ability (Vignos), serum myoglobin and serum creative phosphokinase,Satisfactory blood levels,muscular X-ray density,flushing, dizziness, and leg edema|Compared with before therapy, the number of calcium-positive muscular fibres was remarkably reduced in the treated DMD patients, but not in the placebo group.
not found|analgesic effects,VAS score reduction,epidural labor analgesia,intensity of low-back pain,Visual analogue scale (VAS,Operative delivery,intensity and unpleasantness of pain,Analgesia,suprapubic pain,Mean pain intensity,level of control and satisfaction with labor and delivery,pain component,pain relief,intensity of pain,labour pain,duration of analgesia,change of pain,intensity of low back pain and abdominal pain,Kaplan-Meier survival analysis and Mantel-Cox log rank analysis,pain (VAS), sensory level (pinprick), motor blockade (Bromage), cervical dilatation, and duration of analgesia, and at delivery on fetal and neonatal outcome,duration of the spinal portion of the CSE,number of requests for pethidine/promethazine,minimal or moderate low-back pain,unpleasantness,Pain relief,quality of analgesia,back pain,rate of VAS score,visual analogue pain scale,Course of labor, uterine activity and fetal heart patterns,pain concept or relief,Apgar score, assays of blood samples from the umbilical vein including blood lactate, plasma hypoxanthine and blood gas, and neurobehavioral assessment,duration of labor,quality or duration of labour analgesia,operative delivery rate,Labour Agentry Scale and the Labor and Delivery Satisfaction Index,relieving pain,pain relief, amount of administered analgesics, obstetrical and neonatal outcome, and side effects,degree of pain relief,low-back and suprapubic pain,visual analog scale (VAS), sensory level (pinprick), motor blockade (Bromage score), cervical dilation, and duration of analgesia,pain,relief of pain|No significant differences occurred between groups in the number of requests for pethidine/promethazine.
not found|CBZ concentration,CBZ dosage reductions,plasma CBZ concentration|CBZ dosage reductions ranging from 14 to 50% were required by 63% of patients who received REM.
89|Clinical activity index (CAI) and endoscopic index (EI,Recurrence rates|Recurrence rates evaluated on the basis of intention to treat showed significant difference between curcumin and placebo (P=.049).
144|psychosocial functioning, prophylaxis against recurrences of mood episodes, or compliance with pharmacotherapy,rate of recovery from mood episodes of bipolar I disorder,mental health problems,depressive and anxiety symptoms and family conflict|This study was designed to answer, in part, the following question: What is the relative efficacy of hospitalization with family intervention as compared with hospitalization without family intervention for patients with major psychiatric disorders who are in need of hospital treatment and for whom both treatments are judged clinically feasible?
20|free-rate of cardiac events,total number of hemodialyses due to oligo-/anuria,creatinine clearances (CCr,renal blood flow (RBF) and radiocontrast-induced nephropathy (RCIN,LV function,anuria,serum creatinine levels,plasma renin-activity,Plasma ANP levels,bleeding volume, homologous blood transfusion volume, furosemide dose, and corrected KCl volume,dialysis-free survival at day 21 and creatinine clearance,Age, sex, etiology of ARF, entry serum creatinines (SCr,serum creatinine and urea,Baseline serum creatinine level,rapid onset of diuresis,serum creatinine values,medications, and quantity of radiocontrast,Hemodynamics, levels of atrial and brain natriuretic peptides (BNP), angiotensin-II and aldosterone, renin activity, and left ventricular (LV) function,baseline serum creatinine, change in serum creatinine, or the incidence of RCIN,Mortality rates,stable diuresis,duration of hemofiltration and frequency of hemodialysis,incidence of postoperative arrhythmias,urine volume,Dialysis and mortality status,Delayed hypertension (HT) and renal dysfunction (RD,incidence of postoperative ventricular arrhythmia and the postoperative peak level of creatine kinase-MB,hemodynamics, urine output, intensive care unit (ICU) and hospital stay, bleeding volume, homologous blood transfusion volume, furosemide dose, corrected KCl volume, and postoperative respiratory, hepatic, and renal function,Acute renal failure,morbidity and mortality rates,frequency of hemodialysis,renal blood flow,needed dialysis,oliguria,Diuresis,and/or hyperkalemia,postoperative hypertension and renal dysfunction,creatinine clearance,fractional sodium excretion,BUN levels,rate of dialysis-free survival,glomerular filtration, urinary output, and renal histopathology,dialysis or death,glomerular filtration rate or RBF,Postoperative creatinine clearance,Dialysis,serum creatinine concentration, and mortality,renal excretory function,systolic blood pressures,Plasma ANP, brain natriuretic peptide and cyclic guanosine monophosphate (cGMP) levels, hemodynamic variables and renal function,safety and efficacy of ANP,probability of dialysis, and improves dialysis-free survival,oliguria / anuria and required subsequent hemofiltration / hemodialysis,hemodynamics, urine volume, dosage of furosemide, respiratory index, pleural effusion, ANP, cyclic guanosine monophosphate, renin activity (renin), angiotensin-II, aldosterone, and glomerular filtration rate,Central venous pressure, systemic vascular resistance index, and pulmonary vascular resistance index,plasma ANP levels,ANP levels,postoperative LV remodeling,Acute renal failure (ARF,glomerular filtration rate,renal vasodilatory response,renin activity and lower levels of angiotensin-II and aldosterone,acute renal failure,Cumulative duration of hemofiltration,CCr,dialysis-free survival,incidence of RCIN,glomerular filtration rate and renal blood flow,incidence of RCIN: placebo,RBF,Peak serum creatinine,postoperative brain natriuretic peptide,Dialysis-free survival rates,urine output,systemic vascular resistance,hemodynamic status,overall rate of dialysis-free survival,plasma cyclic guanosine monophosphate levels, urine output and fractional sodium excretion, and decreased preload, afterload and plasma brain natriuretic peptide levels,natriuresis and systemic vasodilation,oliguria, dialysis-free survival,diuresis,hemodynamic status and renal function,postoperative peak levels of creatine kinase-MB,systolic blood pressure,frequency of hemodialysis/hemofiltration,renal function,levels of ANP, cyclic guanosine monophosphate, glomerular filtration rate, and respiratory index, and significantly lower levels of renin, angiotensin-II, aldosterone, and pleural effusion,Mean arterial blood pressure,Aldosterone level,Plasma cyclic guanosine monophosphate levels,serum creatinine,incidence of postoperative hemodialysis,incidence of mechanical renal replacement therapy,preoperative median serum creatinine|ANP levels rose significantly from baseline at 5, 15, 65 and 120 minutes in both groups (p less than 0.05).
21|severity of illness scores,survival analysis techniques,antimanic response,extrapyramidal side-effects (EPS,Serum valproate concentrations,Extrapyramidal Symptom Rating Scale total scores,Brief Psychiatric Rating Scale (BPRS), the Bech-Rafaelsen Mania Rating Scale (BRMAS) (only manic patients) and globally on the Clinical Global Impression (CGI,extrapyramidal side effects,extrapyramidal symptoms,efficacy and safety,manic and psychotic symptoms,quality of life on several dimensions,magnitude of or time to response,serious haematological changes, nor abnormalities in clinical chemistry,hypokinesia,overall remission of bipolar mania,Brief Psychiatric Rating Scale, the Clinical Global Impression scale, and safety measures,adverse events,total score for all rating scales,quality of life,Standard ratings of psychopathology and side effects,Young Mania Rating Scale,Young Mania Rating Scale total scores,tolerated,manic symptoms without sedation,psychotic features, rates of remission,rate of extrapyramidal symptoms,drowsiness,HP, and gastrointestinal symptoms,Rates of remission (Young-Mania Rating Scale score of < or =12 and 21-item Hamilton Rating Scale for Depression score,Relapse into an affective episode (mania and/or depression,Weight gain,Mania Rating Scale, Brief Psychiatric Rating Scale, Physician Global Impression Scale, and side effects scales,YMRS scores,Young Mania Rating Scale scores,rapid remission of symptoms on the BRMAS,mean Young Mania Rating Scale (YMRS) score reductions,Side effects,side effects|Groups B and C did not differ from each other, either in degree of improvement or in side effects.
75|seroresponse rates,seroconversion and seroresponse rates,VZV reactivation,stimulation index,clinical disease,Seroconversion rates,antibody response,risk of zoster,vaccination response,mean stimulation index,protective antibody titres of > or = 4 to poliovirus type 1 (PV1), poliovirus type 2 (PV2) and poliovirus type 3 (PV3,Induration, erythema, or local pain,poliovirus antibody titres,mean (+/-SE) stimulation index (SI,protective antibody titre,neutralizing antibody levels,severity scores,influenza A/H3 neutralizing antibody levels,respective rates,antibody titers,Zoster|Disease severity associated with VZV reactivation was decreased dramatically in vaccinees given three doses; severity scores were 6.4 +/-
not found|liver enzymes,baseline CD(8,adverse reactions,Plasma viral load (PVL) and CD(4)/CD(8) counts,incidence of new allergic reactions,Liver enzymes and hematological parameters,serious reaction,hypersensitivity reactions,ability to take single-strength TMP-SMZ daily,mean CD(4) counts,mean PVL|Seventy-five percent of the dose-escalation group and 57% of the direct-rechallenge group continued to receive daily single-strength TMP-SMZ for 6 months (P= .014).
44|active cirrhosis,complete response rate,inflammatory and fibrotic activity,chronic active hepatitis,lost hepatitis B virus DNA,safety and effectiveness,rate of anti-HBe seroconversion,hepatic decompensation,HBeAg disappearance and HBeAg to anti-HBe seroconversion,flu-like syndrome, granulocytopenia (1), depression (3) and thyroid dysfunction (2,Alanine aminotransferase values,periportal necrosis,persistent loss of hepatitis B virus DNA,chronic hepatitis B (HB) infection,response rate,Partial or complete antiviral responses,Biopsy score,Baseline transaminases levels and HBV-DNA concentrations,spontaneous seroconversion rate,loss of DNA-polymerase activity,efficacy of interferon therapy,chronic persistent hepatitis,inflammation and disappearance of core antigen in liver tissue,severe cytolytic episode,Hepatitis B e antigen and hepatitis B viral DNA,galactose elimination capacity and aminopyrine breath test,Reversion to HBeAg and HBV DNA negativity,alanine aminotransferase normalization,normal serum aminotransferase levels,e antigen (HBeAg) and hepatitis B virus (HBV)-DNA,posttreatment histologic scores,loss of HBeAg with anti-HBe seroconversion,late seroconversion,loss of HB surface antigen (HBsAg,HBeAg clearance,normal transaminase levels,Response rates,Anti-HBe seroconversion,baseline aspartate aminotransferase (AST) level,Loss of hepatitis B,HBeAg disappearance and HBeAg to anti-HBe seroconversion rates,HBeAg clearance and seroconversion to anti-HBe,response rates,elevated transaminase levels,active viral replication,HBV-DNA or degree of histological activity,hepatorenal syndrome,Transaminase levels,surface antigen (HBsAg,hepatitis B viral DNA,Clearance of serum hepatitis B virus-DNA and HBeAg (complete response,loss of HB virus DNA and HBeAg from serum,Baseline clinical, biochemical, and histological features,normal alanine aminotransferase (ALT) activity,normalized alanine aminotransferase|Interferon induced a sustained cessation of HBV replication as judged by loss of DNA-polymerase activity in 26 (59%) patients, 20 (45%) patients seroconverted to anti-HBe.
not found|sputum production,Flutter Valve,sputum bacteriology, FEV(1), FVC, FEF(25-75%), MIP or MEP,did exercise capacity,SGRQ total score,Impedance at 5 Hz (R5), resistance as a function of oscillation frequency (dR/dF), reactance at 5 Hz (X5), resonant frequency (f(0) ) and integral of reactance between 5 Hz and resonant frequency (AX,removal of pulmonary secretions,total and peripheral airway resistance,lung hyperinflation,R5,total LCQ score,24-h sputum volume, forced expiratory volume in 1 s (FEV(1)), forced vital capacity (FVC), forced expiratory flow at 25-75% of FVC (FEF(25-75%)), maximum inspiratory pressure (MIP), maximum expiratory pressure (MEP), exercise capacity, sputum microbiology and St George's Respiratory Questionnaire (SGRQ,yield of sputum,Leicester Cough Questionnaire (LCQ,residual volume (RV), functional residual capacity (FRC) and total lung capacity (TLC) (p<0.05,24-h sputum volume,radioaerosol clearance,respiratory mechanics and sputum production|No significant differences were seen in sputum bacteriology, FEV(1), FVC, FEF(25-75%), MIP or MEP.
19|dermatological, genitourinary, gastrointestinal, respiratory and cardiovascular systems; falls; pain; and psychiatric and nutritional disturbances,cost of assessing and treating these acute conditions,continence levels,endurance, strength, and urinary incontinence,Older American Research and Service Physical and Instrumental Activities of Daily Living scales, Folstein Mini Mental State Examination, Clock Drawing Test, Geriatric Depression Scale, Performance-Based Toileting Assessment, bladder diaries, and physical examination,structured continence and medical histories,Mini-Mental Status Exam,frequency of incontinence,daytime incontinent episodes,change in incontinence,number of wet episodes,frequency of correct toileting,strength, mobility endurance, urinary and fecal incontinence,urinary incontinence,Timed measures of walking or wheeling a wheelchair (mobility), sit-to-stand exercises, independence in locomotion and toileting as assessed using the Functional Independence Measure (FIM), one-repetition maximum weight for several measures of upper and lower body strength, frequency of urine and stool incontinence, and appropriate toileting ratios,Urodynamic analysis (including cystometrogram), provocative stress test, and behavioral assessment,functional outcomes|Among all subjects completing the treatment protocol, there was a 22% reduction in daytime incontinent episodes compared with true baseline (immediately following the control phase for those crossing over from the control group).
                
not found|positive wound cultures,Complete wound healing,wound dehiscence, six of them needed re-suturing under general anesthesia,epithelialization,time to healing, change in ulcer area, incidence of infection, costs per healed ulcer, adverse events and quality of life,bacterial contamination and promoting wound healing,itching,admission point of time,incidence of healing, effective desloughing and a lower incidence of infection,Cosmetic and functional results,mean percentage of blood volume,proportion of ulcers healed,Reparative activity,safety and effectiveness,healing,mean healing times,Infection,itching and pain,ulcer healing,Median reduction in wound size,amniotic membrane,eradication of bacterial infections,mean hospital stay,Healthy granulation tissue,Mean wound area covered in slough,probability of healing,Mean healing times,Residual scars,healing rates,average duration of healing,control of infection,skin grafting,healing rate,median rate of healing,adverse events,bacterial infections, (2) reduce period of antibiotic use and hospital stay, (3) accelerate wound healing, (4) prevent wound dehiscence and need for re-suturing and (5) result in minimal scar formation,healing earlier,mild dehiscence,complete wound healing without wound disruption or need for re-suturing,graft take rate,average cost,time (days) taken for complete re-epithelialisation of the nail bed,unadjusted hazard ratio,Relief of pain,complete cure,Size of postoperative scar,median time to healing,healing times,Histological evidence of reparative activity,healing rates of wounds healing,wound healing,venous ulcer healing,mean healing time,complete wound healing,hazard ratio,healing outcomes,satisfactory epithelialization,Wound healing,control of infection and quicker wound healing,healing times of shallow wounds and abrasions; side-effects; patient satisfaction with treatment; and amount of honey and IntraSite Gel used,reparative activity with inflammatory changes,pain,Bacterial colonisation, wound size, wound ASEPSIS score and pain,skin grafting take rate|Honey impregnated gauze dressed wounds showed healing earlier as compared to OpSite (mean 10.8 versus 15.3 days).
41|withdrawal time,total number of adenomas,number of total and mean per-patient adenomas,neoplasm detection rate,adenoma detection rate,prevalence of non-polypoid and the total number of adenomas,neoplasm detection rates,Demographics, indication for colonoscopy, and quality of preparation,miss or detection rates,increased adenoma detection rate means of NBI colonoscopy,adenoma detection rates,flat adenoma detection rates,rates steadily,Extubation time,adenoma detection rate (ie, number of adenomas/total number of patients,Detection rates,general adenoma detection rate,colorectal neoplasm miss rate,neoplasm miss rate,adenoma rates,prolongation of extubation time,number of diminutive|The adenoma detection rates were 57.3% for patients examined by NBI and 58.3% for those examined by WL (P = .88).
205|median time to the next exacerbation,shortness of breath, wheezing, or exacerbations of cough with or without sputum production,Peak flow,need for additional courses of antibiotics,Clinical and microbiologic response, serum C-reactive protein (CRP) level (cutoffs 5 and 50 mg/L), and serum procalcitonin level (PCT,Changes in symptoms, peak expiratory flow, and sputum flora,duration of mechanical ventilation and hospital stay,death in hospital and need for additional antibiotics,CRP levels,dyspnea, sputum production, and sputum purulence,rate of failure with deterioration,low PCT levels,Resolution of symptoms,clinical cure at end of therapy visit (EOT,Symptoms,clinical success rate,death in hospital and need for an additional course of antibiotics, both separately and in combination,symptom scores (wheeze, dyspnoea, cough with and without mucus production, and awakening with dyspnoea), peak expiratory flow values (PEF, expressed as % predicted), and sublingual temperature,success rate,peak flow and symptom scores,PCT levels,Gasometric and spirometric measures,number of relapses,Side effects|Although CRP levels were higher in the presence of bacteria (median, 33.0 mg/L [interquartile range, 9.75-88.25] vs 17 mg/L [interquartile range, 5.0-61.0] [P = .004]), PCT levels were similar.
50|focal spastic muscle contractions,symptom, well-being and intoxication scores on a daily basis using visual analogue scales,muscular tonus,resistance to passive stretch, clonus and hyperreflexia,intractable neurogenic symptoms,functional status,Increase weakness,good overall tolerability,Sedation,variables: spasticity, clonus, flexor spasms, gait and bladder function,alleviating flexor and extensors spasms,subjective sensation of relief with reference to the symptoms of spasms,spasms and clonus (patient diaries,clinical spasticity and hyperreflexia,sleepiness, muscular weakness and dry mouth,muscle strength, bladder function and the activities of daily living,efficacy and tolerability,hyperactive stretch reflexes and ankle clonus,motor weakness,observer rated severity and frequency of symptoms on numerical rating scales, administered standard measures of disability (Barthel Index), mood and cognition, and recorded adverse events,Overall spastic state, spasms and clonus,Tiredness,total number and severity of side-effects,joint and muscle pain,adverse reactions,ease of nursing care,flexor spasms, pain and stiffness, resistance to passive joint movements, and tendon stretch reflexes,side-effects,muscle tone (Ashworth Scale) and type and frequency of muscle spasms (patient diaries,frequency of spasms, and clonus,Cybex flexion scores,hepatic, renal, or hematological function,range of joint movement,Adverse events,spasticity of the leg adductors,antispastic efficacy,sedation, nausea and vomiting,spasticity,painful spasms,spasticity, clonus, and hyperreflexia, and the complaints of muscle stiffness,Somnolence and xerostomia,moderate quadriceps spasticity,Safety, tolerability, and efficacy,antispastic effect,Pain relief,objective rating scale,mild depressive effect on blood pressure,tolerated,muscle tone,physical or psychological dependence,Impaired bladder control, muscle spasms and spasticity,Levels of threonine,toxic effects on hepatologic, hematopoietic, or renal function,efficacy of baclofen,elevated liver function test,antispastic effect and tolerability,efficacy and tolerance,Cybex II isokinetic unit, timed gait, Ashworth scale,Muscle weakness,adverse effects,Side effects,clonus,antispasmodic efficacy and safety,dry mouth and drowsiness,muscle strength,Efficacy and tolerability parameters,electromyographic recording of deep tendon reflexes,functionality and nursing care,antispastic efficacy of tizanidine|There was not statistically significant superiority of either diazepam or ketazolam, but both relieved symptoms significantly better than the placebo, as measured clinically and by electromyographic recording of deep tendon reflexes.
201|median survival time,excellent performance status, minimal weight loss, and visible disease on radiography,objective response,Rates of survival,adjusted survival rate and disease-free survival rate,overall response rates (complete response [CR] plus partial response [PR,local control rate and survival,partial response,improved survival,overall survival,Survival analysis,whole survival,Local tumor response,histology, performance status, extent of operation, and tumor and nodal status,Toxic effects,response rate, time to progressive disease and overall survival,median number of chemotherapy cycles,5-year survival,survival and 58 for response and toxicity,serious infections requiring hospitalization,Toxicity,overall survival time,response rate and survival,peripheral neuropathy and hematologic and renal toxic effects,overall survival, disease-free survival, and relapse pattern,response rate,recurrence,survival and response rates,Median survival,severe neurotoxicity,5-year survival rates,survival rates,mean survival,median survival,5-year disease-free survival rate,local response,incidence of death with metastases, metastasis-free survival (MFS) nor overall survival (S,reversible renal toxicity grade 2,Survival,Response rate,5-year survival rate,survival benefit,3-year disease-free survivals,median time to progression,Time to progressive disease,long-term survival,severe vomiting,survival time,overall response rate,quality of life,Median time to progression,death,Response rates,survival or delayed recurrence of disease,toxic death,complete response,toxicity,acute or late radiation pulmonary or oesophageal toxicity,survival,5-year survivals,response and toxicity,survival advantage,distant metastasis rate,time to recurrence or overall survival,drug mortality,serious toxicity,response rates or in survival,toxic symptoms of varying severity,severe weight loss,gastrointestinal toxicity grade 3 to 4 (WHO,Myelosuppression,2-year survival rate,progressive disease in arm B. Median survival,median survival times (5-year survival,Acute toxicity (dysphagia, myelosuppression,performance status (Karnofsky), and weight loss,Toxic reactions,disease-free and overall survival,Karnofsky performance status score,Acute toxicity,Major clinical responses,unacceptable toxicity,Five-year survival,leukopenia of severe,response rate and morbidity|The overall response rate to chemotherapy was 28%; there were no significant differences according to major prognostic criteria.
40|Functional enuresis (FE,remaining dry and time to dry, non-attendance and dropout rates,maternal tolerance scale,Maternal anger|Two studies examined the effectiveness of the body-worn alarm in out-patient treatment of childhood nocturnal enuresis.
||
64|total IgE or IgG4,intensity of wheezing,Dyspnea,oxatomide,Efficacy,slight drowsiness,efficacy and safety,monitoring cough, dyspnea at rest, dyspnea following exercise, wheezing, sleep disorders,body weight gain,levels of eosinophil cationic protein and total asthma symptom scores,Persistent coughing,bronchodilatation and normalizing pulmonary function,Sleep disorders|The levels of eosinophil cationic protein and total asthma symptom scores were significantly reduced during treatment with oxatomide.
106|nausea,ACR20 response rates,serious treatment-related adverse events,Transiently abnormal liver function,serious adverse drug effects,disease progression,adverse events (AEs,incidence of side reactions,safety and effectiveness,ACR 50% response rate,ESR, tender and swollen joint counts, the duration of morning stiffness, disease activity score-28 (DAS 28), visual analogue scale (VAS) and health assessment questionnaire (HAQ,ACR20 responder rates,symptoms, signs and joint functions,DAS28 response,disease activity,Diarrhea and nausea,safe and well tolerated,Asymptomatic transaminase elevations,mean time to initial response,rate of achievement of 20% improvement in ACR criteria (ACR20,DAS28 response rate, and secondary efficacy outcomes,incidence of AEs,improvement in EULAR criteria and secondary endpoints were patient and physician global evaluation, incidence of remission and biochemical and clinical adverse events,rheumatoid arthritis,DEMRI scans,erosive joint counts,rheumatoid arthritis activity,initial rate of enhancement (IRE) and the maximal signal intensity (SI) enhancement (ME,American College of Rheumatology improvement response rates,response rates,Function and health-related quality of life,Mean DAS28,Radiographic disease progression,mean ,global assessments, ACR20% response,efficacy and safety profile,Gastrointestinal symptoms, weight loss, allergic reactions, skin rash, and reversible alopecia,rates of remarkable improvement,gastrointestinal complaints, skin rash, and reversible alopecia,general effective rate and notable effective rate,Health Assessment Questionnaire Disability Index,measures of function and heath-related quality of life (MHAQ scores, all scales and disability index of the HAQ, weighted top 5 score of the PET, 5 of 8 scales and physical component score of the SF-36, and work productivity,alopecia,elevated transaminases,response rate,physical function and health-related quality of life,MHAQ scores, 5 of 8 scales and disability index of the HAQ,remission,safety and efficacy,diarrhea, nausea, and alopecia,HAQ Disability Index (DI,Efficacy and safety,symptoms, signs, and joint function,IRE,DeltaHAQ disability index,Comparable Disease Activity Score 28 reduction rates,functional disability,incidence of infections,improvement and remission,functional ability ,Health Assessment Questionnaire (HAQ,upper respiratory tract infections, diarrhea, nausea and vomiting, rash, reversible alopecia, and transient liver enzyme elevations,severe gastrointestinal symptoms and hepatotoxicity,signs and symptoms of active RA, delayed disease progression,disease activity parameters,Discontinuation rates,mean change in total Sharp radiologic damage scores,function and health-related quality of life,patients' functional ability,incidence of adverse events,Improved HAQ scores,tolerated,MHAQ scores, HAQ disability index, weighted top 5 score of the PET, physical component score of the SF-36, and bodily pain scale,PET score, SF-36 physical component score, and work productivity,opportunistic infections,ACR response and success rates,overall incidences of adverse events,physical function,Disease activity assessed by DAS 28,Adverse events (AEs) resulting in treatment withdrawal,Larsen scores and erosive joint counts,Health Assessment Questionnaire (HAQ) disability index (HAQ DI) and the physical component score of the Medical Outcomes Survey 36-item short,toxicity,slowing of disease progression,SF-36 scales and component scores,synovial inflammation,clinical signs and symptoms,RA activity,Sustained retardation of radiographic progression,Mean HAQ scores,radiographic progression,overall rates of effectiveness,efficacy and safety,diarrhoea,Safety and effectiveness,Adverse events,Diarrhoea, nausea, and alopecia,gastrointestinal symptoms, skin rash, alopecia, nervous system symptoms, decreased leukocyte count, and elevation of alanine aminotransferase (ALT,adverse events,mean DAS28,ACR response rates,Health Assessment Questionnaire (HAQ), modified Health Assessment Questionnaire (MHAQ), Problem Elicitation Technique (PET), Medical Outcomes Study Short Form 36 (SF-36), and questions regarding work productivity,HAQ scores,tender joint count,tender and swollen joint counts and investigator's and patient's overall assessments,Larsen scores,tender joint count (TJC), swollen joint count (SJC) and Health Assessment Questionnaire Disability Index (HAQ DI,reversible agranulocytosis,HAQ DI with LEF4(-0.60,functional ability,adverse events or late toxicity,side effects,rate of withdrawal due to adverse events|Comparable Disease Activity Score 28 reduction rates were noted at trial termination for all 3 treatment arms:
12|survival,Intracerebral hemorrhage,overall survival of ECMO|Extracorporeal membrane oxygenation allows lung rest and improves survival compared to conventional ventilator therapy in newborn infants with severe respiratory failure.
not found|daily consumption of analgesics,sclerosis or stabilisation of lytic metastases,pain score, performance status, and changes in analgesic use,healing of lytic lesions,VAS scores for general pain, pain at rest, and pain,pain and mobility,median time to radiotherapy,Quality of life,Pain parameters, analgesic consumption and performance status,performance status and reduced consumption of analgesics,severe adverse reactions or worsening of chemotherapy-induced toxicities,radiologic skeletal lesions,Bone resorption markers measured included urinary calcium (uCa), hydroxyproline (Hyp), and the collagen breakdown products: NTx, Crosslaps and Free Dpd,bone pain (visual analog score), analgesic use, and compliance with therapy,average change in DMED,Skeletal pain relief,metastatic bone pain,symptomatic improvement,Serum calcium and urinary calcium excretion,Visual analog pain score,occurrence of hypercalcemia, severe bone pain, and symptomatic impending fractures,daily oral morphine equivalent analgesic requirement,Daily visual analogue scales (VAS) and analgesic diaries,total-body bone mineral density,skeletal events,median time to the occurrence of the first skeletal complication,bone pain and no deterioration in performance status and quality of life,Visual Analogue Scales (VAS,skeletal-related morbidity,Mean pain scores,Mean overall pain,excretion of hydroxyproline,pain scores,palliative effects,pain score,urinary calcium levels,urinary hydroxyproline levels,Median duration of pain response,narcotic scores, urinary calcium/creatinine and hydroxyproline/creatinine ratios, serum osteocalcin and bone alkaline phosphatase concentrations, and bone lesion (radiologic) response,Toxicity,bone resorption,Thickening of the preexisting osteolytic lesions,totally free of bone pain,Symptomatic response,Delayed progression of bone metastases,time to progressive bone disease (evaluated by blind extramural review), and improvement in pain (according to a 6-point self-assessment scale,fasting calcium excretion,opioid requirements,Compliance,bone pain, analgesic-drug use, performance status, and quality of life,event-rates of systemic treatment and radiotherapy,safety and efficacy,body height,time to the first skeletal complication,control of bone pain,bone alkaline phosphatase levels,Analgesic use increased with disease progression,patient survival,Pain relief,event-free period (EFP), radiologic course of disease, and survival,urinary calcium, hydroxyproline (OHP) and serum cross-linked carboxyterminal telopeptide region of type I collagen (ICTP) levels,skeletal complications: pathologic fractures, spinal cord compression, irradiation of or surgery on bone, or hypercalcemia,osteoclast number,Subjective benefit,visual analogue scale assessments,pain with dichloromethylene diphosphonate,frequency of pathologic fractures, hypercalcemia, and bone pain,median survival or survival rates,urinary calcium/creatinine and hydroxyproline/creatinine ratios, and bone alkaline phosphatase concentrations,Gastrointestinal toxicity,urinary calcium,vertebral index,efficacy,number and/or size of bone lesions,episodes of severe pain,deterioration of performance status,myalgia,vertebral deformity,Bone pain, use of analgesics, quality of life, performance status, bone tumor response, and biochemical parameters,Urinary calcium, OHP and serum ICTP levels,clinical (pain, Karnofsky, survival), biological and radiological,Analgesics requirement,Resorption markers,EFP,Skeletal complications, including pathologic fractures, the need for radiation to bone or bone surgery, spinal cord compression, and hypercalcemia (a serum calcium concentration,Bone-derived isoenzyme alkaline phosphatase values,Histologic bone parameters,Gastrointestinal adverse events,rate of bone resorption,degree of hypercalcaemia and hypercalciuria, and decreases pain,symptomatic response rate or analgesic requirement,proportion of patients with progression of osteolytic bone lesions,incidence of bone-related complications (pathological fractures, tumor-induced hypercalcemia, need for radiotherapy), sclerotic response of lytic lesions, WHO performance status, and analgesic score,nausea and vomiting,trabecular bone volume,quality of life,pain scores or analgesic requirements,pain palliation,tolerated,Skeletal events (pathologic fracture, irradiation of or surgery on bone, and spinal cord compression), hypercalcemia (symptoms or a serum calcium concentration,Progression of vertebral fractures,iliac bone biopsy,mean baseline pain,Median time to bone progression,activity scores,skeletal morbidity,clinical and laboratory parameters of toxicity,Serum calcium concentration,pain intensity, pain frequency, general well-being and WHO pain score,mean pain,skeletal morbidity and the radiologic course of metastatic bone disease,height loss,toxicity,skeletal morbidity rate,Bone resorption,bone pain,Side-effects,Pain score,skeletal complications,deoxypyridinoline,skeletal complication,Bone pain, use of analgesic drugs, performance status, and quality of life,intensity of pain,osteolysis of multiple myeloma,survival or in objective bone response rate,gastrointestinal toxicity,bone pain, episodes of hypercalcemia, or development of pathologic fractures,Karnofsky performance status, pain score (measured by a visual-analogue scale) and analgesic requirement,Visual analog pain scores and adverse events,bone remineralization,analgesic efficacy,Adverse events,occasional gastroenteric discomfort,analgesic effect,percentage of patients feeling no pain,bone pain and mobility scores,event-rates,hypercalcemia or hypercalciuria,Fasting urinary calcium excretion,Karnofsky performance status,Pain intensity,pain intensity,pain|Oral pamidronate produced either sclerosis or stabilisation of lytic metastases for at least 24 weeks in 5 of 24 and 3 of 23 patients at the 300 and 150 mg dose levels, respectively.
not found|Pain scales,serious side effects,average pain scales,morphine requirements,numeric rating scales,pain relief|No serious side effects were observed in this study.
                
not found|IOP,efficacy and safety,IOP, medications, need for surgery, or visual function,intraocular pressure (IOP), peripheral anterior synechiae, corneal endothelial cell count, and complications,peripheral anterior synechiae|There was no significant difference in IOP, medications, need for surgery, or visual function between groups at the 1-year visit.
                
241|knowledge of asthma shown,cost and effectiveness,resources, productive output and in health status,hospital admissions,mean duration of illness,scheduled visits,arterial oxygen tension,evening peak expiratory flow rate percentage,Psychosomatic Discomfort Scale,number of days lost through sickness,asthma morbidity,Health status,diurnal variation rating,number of days in hospital,patients' perceptions of asthma severity and both medication severity rating,quality of life,scores of knowledge of drugs,number of days in hospital and emergency visits,severe asthmatics,knowledge scores,mortality or morbidity,quality of life, knowledge and need for nursing,self-management ability or asthma morbidity,asthma-related emergency visits,severity of their asthma,asthma-related emergency department visits,number of urgent care visits,forced expiratory volume in one second (FEV1|The intervention group had significantly fewer asthma-related emergency visits (16 visits per 100 persons) than did the control group (39 per 100 persons); p = 0.0005 for the 12 months of follow-up.
not found|activity of atopic dermatitis,mean concentration of essential amino acids in plasma,percentage of surface area,eczema,mean reduction in surface area affected by eczema,SCORAD index,skin severity score,length standard deviation score,weight-for-length values,energy intake,serum total and milk-specific IgE concentrations,dermatitis severity,pruritus, sleeplessness and antihistamine consumption,atopic eczema,circulating eosinophilocytes, serum IgE, orosomucoid, HLA-antigens, and immunofluorescence of skin biopsies,severity score,gastrointestinal reactions,eczema activity, number of areas affected, pruritus, sleeplessness, and antihistamine usage,Disease activity|Thirty seven breast fed infants with eczema were studied to see whether changes in their mothers' diets affected their skin condition.
100|QOL or survival,PS and QOL scores,quality of life (QOL,Standardized assessment of pain, mood, and disability due to pain,survival,hospital mortality or complications, return to oral intake, or length of hospital stay,pain intensity and QOL scores,nausea and/or vomiting,Mean (SD) baseline pain,pain relief,Morphine consumption, VAS, PS, and self-assessed QOL scores,morphine consumption, visual analogue pain scale (VAS), performance status (PS) determined by medical and nursing staffs, and answers to QOL questionnaires,existing pain,pain relief, quality of life, and survival,frequency of opioid adverse effects,moderate or severe pain (pain intensity rating,pain relief and quality of life (QOL,Immediate and long-term efficacy, mean analgesic consumption, mortality and morbidity,VAS scores,Morphine consumption,visual analogue scale (VAS) pain scores,quality of life,Mean analgesic consumption,QOL,transient diarrhoea and hypotension,pain, mood, and disability,Self-assessed QOL scores,PS score slightly,gastric ulcer and one gluteal abscess,Morphine consumption and the VAS score,pain relief, QOL, and survival,Pain intensity (0-10 numerical rating scale), QOL, opioid consumption and related adverse effects, and survival time,pain scores and delayed or prevented the subsequent onset of pain,Mean pain scores,opioid consumption,pain,side effects|The first week after randomization, pain intensity and QOL scores were improved (pain intensity, P< or =.01 for both groups; QOL, P<.001 for both groups), with a larger decrease in pain for the NCPB group (P =.005).
101|QT and QTc dispersion,Mode-M echocardiograms and 24-hour ambulatory ECGs,abnormal antimyosin uptake,Grade 1 cardiac toxicity,congestive heart failure (CHF,Elevations of troponin T,overall survival,minimum QT interval,subclinical cardiotoxicity,LVFS,hematologic toxicity,Troponin T levels,systolic and diastolic diameters,noninvasive testing and clinical CHF,incidence and degree of cardiotoxicity, response rates to four cycles of chemotherapy, event-free and overall survival, and incidence and severity of noncardiac toxicities,mean EF,plasma lipid profile and relative mRNA levels of key enzymes of oxidative metabolism (carnitine acyltransferases,incidence of clinical congestive heart failure,cardiac toxicity,mean EF at control echocardiography,value of radioimmunoscintigraphy (RIS,Toxicities,Noncardiac toxicity, objective response, progression-free survival, and overall survival,occurrence and severity of anthracycline-induced cardiotoxicity,oxidative metabolism,died,Control EF,ejection fraction changes or congestive heart failure (CHF,frequency of adverse events,cumulative probability of developing cardiotoxicity,incidence of transient grade 1 serum transaminase elevations,noncardiac toxicity,antitumor activity,Systolic and diastolic echocardiographic parameters,cardiotoxicity,rates of fever, infection, or hemorrhage,doxorubicin cardiotoxicity,Cardiac toxicity,excellent survival,cardiac function,clinical activity and the noncardiac toxicity of epirubicin,ototoxicity and nephrotoxicity,E velocities and E/A ratios,risk of developing short-term subclinical cardiotoxicity,ICRF-187 cardiac protection,LVEF,hazards ratio (HR) of PLA to DZR,systolic and diastolic functions,Toxicity prevention,relative mRNA levels,renal toxicity,Cardiotoxicity,myocardial injury,assessable endomyocardial biopsy,elevated troponin T levels,Percentage left ventricular fractional shortening (%LVFS,plasma carnitine,cardiac events,QT interval dispersion,progressive disease,serum cardiac troponin T,severe incidence of congestive heart failure,E velocities,antitumor response rates, time to progression, and survival,Time to progression and survival,event-free or overall survival,toxicity,noncardiac toxicity or antitumor efficacy,pain on injection,Grade 1 and 2 audiologic toxicity,survival,QTc dispersion,Resting left ventricular ejection fraction (LVEF,Response rates to chemotherapy, event-free and overall survival, and noncardiac toxicities,resting left ventricular ejection fraction (LVEF,Tumor response rate,arrhythmic risk,Left ventricular ejection fraction,Interventricular septum wall thickening,severe supraventricular arrhythmia,rate of event-free survival,renal, hearing and cardiac toxicity,Left ventricular ejection fraction (EF) and systolic and diastolic diameters,Objective response rates,Septum wall motion abnormalities,response rate with DZR, but time to progression and survival,QT dispersion,objective response rates|Serial measurements of serum cardiac troponin T were obtained in 76 of 101 patients in the doxorubicin group and 82 of 105 patients in the group given dexrazoxane and doxorubicin.
not found|substance use and/or sexual activity,30-day use of alcohol and marijuana and lower intentions to smoke, drink, and take illicit drugs,positive 2-year outcomes,rates of weekly alcohol consumption,adolescent smoking and drinking prevalence,prevalence of smoking cigarettes and drinking alcohol,violent behavior,initiation of alcohol, tobacco, drug use, and/or sexual activity found AA youth,drug use harm or delinquency,girls' and mothers' substance use and mediator variables related to girls' substance use risk and protective factors,alcohol initiation and frequency, and marijuana initiation and frequency (p's<.05,sexual risks,chances of initiating sex or substance use,rate of change in attitudes about drug use or frequency of delinquent or violent behavior,self-efficacy,Incidence of (heavy) weekly alcohol use and frequency of monthly drinking,heavy weekly drinking, weekly drinking and frequency of drinking|Following program delivery and 1 year later, girls randomly assigned to the intervention arm improved more than girls in a control arm on variables associated with reduced risks for substance use, including communication with their mothers, knowledge of family rules about substance use, awareness of parental monitoring of their discretionary time, non-acceptance of peer substance use, problem-solving skills, and ability to refuse peer pressure to use substances.
25|activity,visual analog scales for pain and the functional index questionnaire,pain and function scores,WOMAC, visual analogue, and HAD scores,patellofemoral pain,subjective visual analog scale and changes in isokinetic strength and electromyographic activity of the quadriceps muscle,pain and function,WOMAC and HAD,visual analogue pain score; the WOMAC lower limb function score; the Hospital Anxiety and Depression scale (HAD); and quadriceps strength,WOMAC, visual analogue, and the anxiety score,symptoms,quadriceps muscle isokinetic strength,isokinetic quadriceps strength, quadriceps length, pain measured during four activities and maximum eccentric, posturally controlled, pain-free knee flexion angle during a step-down|Likewise, both groups demonstrated significant improvement in quadriceps muscle isokinetic strength (P < 0.05) and activity (P < 0.001), but no difference in improvement was noted between groups.
53|horizontal and vertical stability of the B-point and the pogonion,lateral gonial deviation,condyle position,postoperative changes of the proximal and distal segments,Radiographic measurements|One year later the condyle position demonstrated a tendency to approximate the preoperative position, especially with respect to the posterior part, but there was still a significant (p less than 0.01) difference when related to the original position.
not found|tracheal aspirate mass,Positive end-expiratory pressure (PEEP) and recruitment maneuvers (RMs,Arterial blood gases,lower venous admixture (Q(VA)/Q(T,Tidal volumes,survival,hospital mortality rates,arterial oxygen tension (Pa(O2,survival to hospital discharge,body weight and normal arterial carbon dioxide levels,Barotrauma rates,arterial carbon dioxide tension (Pa(CO2,gas exchange and respiratory mechanics,PaO2,rates of clinical barotrauma,rate of barotrauma,rates of weaning from mechanical ventilation,rates of refractory hypoxemia,gas exchange, hemodynamics, respiratory mechanics, and the end expiratory lung volume (EELV,Barotrauma,Systolic blood pressure,LR manoeuvre end-expiratory lung volume,Pao2/Fio2 and Qs,lower Q(VA)/Q(T,Fio2/PEEP requirements,CPPV(VRM,oxygenation and venous admixture,target tidal volumes of 6 mL/kg of predicted body weight, plateau airway pressures not exceeding 30 cm H2O, and conventional levels of positive end-expiratory pressure,negative pressure,EELV,death with refractory hypoxemia,Protective ventilation involved end-expiratory pressures,oxyhemoglobin saturation by pulse oximetry (SpO2), Fio2/PEEP, blood pressure, and heart rate,mean positive end-expiratory pressures,partial arterial oxygen tension (PaO2) and end-expiratory lung volume,higher PEEP and mean airway pressures,mortality|Compared to CPPV(LO), CPPV(VRM) resulted in higher PaO2 (117.9 +/-
812|exercise time,tidal volume and minute ventilation,Daily beta(2) short acting prn consumption,mean number of severe exacerbations,daily symptoms score,exacerbations,Morning PEF,morning peak expiratory flow rate (PEF); transition dyspnea index; chronic respiratory disease questionnaire; chronic bronchitis symptom questionnaire; exacerbations,prolonged time to first exacerbation,postdose IC,respiratory function (such as FEV(1), morning PEF), and and symptom score,daily symptoms,Predose and postdose spirometry, plethysmography, and constant-load cycle cardiopulmonary exercise test evaluations,symptom scores and use of reliever beta2-agonists,exercise endurance time,prebronchodilator FEV1,frequency of adverse events, bruising, or clinically significant falls in serum cortisol concentration,efficacy and safety,lung function measurements, symptoms and rescue treatment use, the number of exacerbations, patient withdrawals, and disease-specific health status,lung hyperinflation,predose FEV(1,morning PEF (l/s), the daily symptom score, and the number of exacerbations,morning lung function,lung function and health status,exercise performance,mean prebronchodilator forced expiratory volume,Transition Dyspnea Index,severity of dyspnea,postdose FRC and increased inspiratory capacity (IC,biopsy CD45+ and CD4+ cells and cells expressing genes for tumor necrosis factor-alpha and IFN-gamma and sputum total eosinophils,adverse events, serum cortisol concentrations, skin bruising, and electrocardiograms,Postmedication FEV1 improved by 0.21 L and health-related quality of life using the St George's Respiratory Questionnaire (SGRQ,lung hyperinflation and exercise endurance,antiinflammatory effects,pretreatment forced expiratory volume in 1s (FEV1,lung function, symptoms, and health status and reduced use of rescue medication and frequency of exacerbations,FEV1,morning predose (ie, trough FEV(1)) for FSC compared with SM and 2-h postdose FEV(1,mean FEV(1,Efficacy and safety,tolerated,average daily morning PEF,morning predose FEV(1,adverse effects,2-hour postdose FEV(1,lung function,Severe exacerbations and FEV1 (primary variables), peak expiratory flow (PEF), COPD symptoms, health-related quality of life (HRQL), mild exacerbations, use of reliever beta2-agonist and safety variables,mean number of exacerbations/yr,dyspnea, quality of life, and symptoms of chronic bronchitis,pretreatment FEV1,FEV(1,IC,2-h postdose FEV(1,health status,CD68+ cells,biopsy CD8+ cells,prebronchodilator peak expiratory flow|Morning PEF improved significantly on day 1 versus placebo and budesonide; after 1 week, morning PEF was improved versus placebo, budesonide and formoterol.
not found|maternal and foetal toxicity,asymptomatic bacteriuria,symptoms of urinary tract infection,clinical and microbiological efficacy,efficacy and tolerability,number of reinfections,Bacteriological cure rates,number of persistences,Bacteriologic cure rates,Asymptomatic bacteriuria,mean age and mean duration of pregnancy,eradication rate,Therapeutic success,cure rate difference,bacteriologic cure on day 14 of treatment,adverse effects,cure rates,development of symptomatic urinary infections,Significant bacteriuria,Mean birth weight and mean gestational age at delivery,Side effects,Cure rates|According to recent studies, long course antibiotherapy did not prove to be more effective than a single-dose one in the case of non-complicated bacteriuria.
30|Renal function,serious drug-related toxicity,mean clinical-activity score fell,clinical improvement, discharge from the hospital, and remission,severe attacks of ulcerative colitis,renal function|At 12 months, 7 of 9 patients (78%) initially controlled with cyclosporine maintained their remission vs. 3 of 8 (37%) initially treated with methylprednisolone.
not found|energy cost,bioenergetic efficiency,Contralateral toe off times,knee flexion reflected delayed dorsiflexion and tibial advancement,walking abilities,Mean free walking speed,free or fast walking,physiologic measurements, self-selected walking velocity, and physical activity,Foot and shank mobility,energy expenditure, gait efficiency, and relative exercise intensity,metabolic rate or efficiency,peak foot and shank velocities,oxygen consumption,initial peak of the vertical ground reaction force on the sound limb,residual limb EMG data,self-selected walking velocity (SSWV), and steps per day (daily activity,Physiologic responses (energy expenditure, gait efficiency, exercise intensity, rating of perceived exertion [RPE,shank velocity,energy cost, efficiency, and relative exercise intensity,Oxygen uptake (VO2,loading response knee flexion,gait performance,SACH, single axis and multiple axis foot in the velocity, cadence, stride length and single limb stance,walking velocity,physiologic responses,peak knee flexion,free velocity,rate of energy consumption,Comfortable walking speed and the nadir of metabolic rate and efficiency,knee flexion and prolonged heel only support,rate of energy expenditure,subjective responses and gait patterns,gait kinematics,terminal stance dorsiflexion,cardiocirculatory effects,walking under different speeds and different inclines,energy expenditure,energy expenditure and gait efficiency,whole body gait kinematics and lower limb kinetics,Free walking,symmetry indexes of the knee range of motion, cadence, and walking speed,energy consumption,peak shank velocity, peak ankle plantarflexion and peak knee flexion compromised shank and knee stability,ankle mobility,Prosthetic mobility,metabolic efficiency,metabolic parameters,Gait analysis and energy consumption,distal pressure measurements, pulse plethysmography, transcutaneous oxygen tension,stride length,decline walking tests,Stride characteristics, joint motion, and ground reaction forces,foot and shank velocity as the thigh velocity|Compared with conventional hydraulic knee controls, the oxygen consumption of transfemoral amputees provided with an electronically controlled hydraulic knee joint is reduced.
not found|Incidence of late-onset sepsis,incidence of death or NEC,faecal reservoir of potential pathogens,viable counts of Enterobacteriaceae (log(10) values,gastrointestinal tolerance,hospital stay,cell counts of bifidobacteria,weight gain,death or necrotizing enterocolitis (Bell's stage ,L/M ratio,Intestinal permeability,number of bifidobacteria and staphylococci in the stools,incidence and severity of necrotizing enterocolitis,death or NEC (Bell's stage ≥2,incidence and severity of NEC,urinary tract infection, bacterial sepsis and necrotizing enterocolitis,urinary tract infections (UTIs), bacterial sepsis and necrotizing enterocolitis (NEC,Bacterial sepsis,necrotizing enterocolitis (NEC,bifidobacterial numbers,D-Xylose and lipid absorption,Lactobacilli,Gram-negative enteric organisms,supplementation median bifidobacteria counts,Median counts of stool bifidobacteria and lactulose/mannitol ratios,cell counts of enterobacteria and clostridia,numbers of fungal isolates,incidence of fungal enteric colonization,deaths,Head growth,incidence of UTIs, NEC and sepsis,incidence of a first episode of late-onset sepsis,intestinal microbiota,colonisation rates of administered bacteria,birth weight, treatment with antibiotics, and the starting time of breast-feeding,adverse effect, such as sepsis, flatulence, or diarrhea,Feeding intolerance,gastrointestinal bacterial colonization,fecal excretion of calprotectin,colonisation rates,Median log of colony forming units per gram of faeces for Escherichia coli and enterococci,incidence of death or necrotizing enterocolitis,somatic growth, tolerance, rates of sepsis and necrotizing enterocolitis,SB tolerance and weight gain, faecal flora analysis, intestinal D-xylose absorption and faecal lipid excretion,death or NEC ,percentage of infants receiving >50% of their nutritional needs via enteral feeding on the 14th day of life,incidence of NEC,acceptance and tolerance of the formula,number of Enterobacteriaceae present,necrotizing enterocolitis,duration of Lactobacillus GG and placebo supplementation,bacterial and fungal sepsis,gastrointestinal microbiota,intestinal permeability,time to reach full enteral feeding,Bifidobacterial numbers|The incidence of NEC was reduced in the study group (4% vs 16.4%; P=.03).
not found|retinopathy of prematurity,ROP stage II or graver,gestational age, birth weight, Apgar scores, the time of exposure to oxygen and in the incidence of PDA or in the number of exchange transfusions and RBTs|The two groups did not differ significantly in gestational age, birth weight, Apgar scores, the time of exposure to oxygen and in the incidence of PDA or in the number of exchange transfusions and RBTs.
571|thrombocytopenia,died,incidence of grade 2 or worse peripheral neuropathy,survival,overall survival or disease-free survival,dermatologic events,median PFS,Overall survival,Late intestinal radiation reactions,partial response,infection/fever,disease-free survival and/or overall survival,number of recurrences,RFI,progression-free survival (PFS,recurrence-free interval (RFI) and safety profile,2-year overall survival rates,progression-free survival rates,Neutropenia,probability of surviving 5 years,pathologic remission, progression-free survival,PFS,Grade 2 or greater motor neurotoxicity and sensory neurotoxicity,progression-free survival or overall survival,Death,Hazard ratio of progression,Median overall survival time,median disease-free survival,late radiation reactions,Peritoneal relapses,cumulative probability of recurring,side effects|The incidence of grade 2 or worse peripheral neuropathy (15.5% vs. 6%), infection/fever (19.9% vs. 8.7%), and dermatologic events (70.8% vs. 52.1%) was higher on the maintenance regimen (p<0.001).
32|caregiver ratings of quality of movement,Motor Activity Log and Action Research Arm (ARA) test,feasibility and efficacy,peak force of the pinch grip and generalized,peak force of the pinch grip using a force transducer and manipulation functions of the upper extremity (Jebsen-test,activities of daily living (Barthel Index,Action Research Arm test and the upper extremity section of the Fugl-Meyer Assessment,demographic variable or movement scale,Fugl-Meyer Assessment of Motor Recovery (Fugl-Meyer) and Action Research Arm Test (ARA,ARA scores,Fugl-Meyer and ARA scores,daily arm function|Subjects receiving MP showed significant reductions in affected arm impairment and significant increases in daily arm function (both at the P<0.0001 level).
15994|rates of hospital admission, diagnosis, and length of stay,anxiety scores,proportion of women with five or less visits,Number of antenatal visits, antepartum and intrapartum referrals, utilization of health centre for delivery and perinatal outcomes,cesarean delivery,quality of care and an economic evaluation,adverse perinatal outcomes,low birth weight,levels of satisfaction,level of satisfaction,urinary-tract infection,likelihood of haemoglobin testing,preeclampsia,proportion of antenatal referrals,labour referrals for severe hypertension or eclampsia,fetal and maternal morbidity, health service use, psychosocial outcomes, and maternal and professional satisfaction,postpartum anaemia,ultrasound scans,satisfaction with provider subscale,treated urinary-tract infection,median maternal age, parity and gestational age at booking,referrals for pregnancy-induced hypertension,rates of preterm delivery or low birthweight,pregnancy outcome, including antenatal referrals for other causes, labour referrals, obstetric interventions, low birthweight, and perinatal and maternal mortality and morbidity,pregnancy outcomes of infant and maternal morbidity and mortality, anxiety and satisfaction,patient satisfaction regarding the number of prenatal visits,median number of visits,rates of low birthweight,number of antenatal day admissions and ultrasound scans,perinatal outcomes or anxiety,satisfaction with quality of prenatal care,perinatal outcomes, anxiety and maternal satisfaction,perinatal mortality,intrapartum transfers,low birthweight (<2500 g), pre-eclampsia/eclampsia, severe postpartum anaemia,Preterm delivery, preeclampsia, cesarean delivery, low birth weight and patient's satisfaction with care,number of prenatal visits,satisfaction with the prenatal care system subscale|There were no other significant differences between the programmes in other major indices of pregnancy outcome, including antenatal referrals for other causes, labour referrals, obstetric interventions, low birthweight, and perinatal and maternal mortality and morbidity.
                
18|parkinsonian and dyskinesia scores,Dyskinesia severity,motor response complications,daily off-time,self-scoring dyskinesia diaries,dyskinesia assessments on the Unified Parkinson's Disease Rating Scale, part IV,Motor fluctuations and dyskinesias,patient-kept diaries and Unified Parkinson's Disease Rating Scale (UPDRS) interviews,dyskinesia severity,total dyskinesia score,Motor fluctuations,levodopa dyskinesias|In the 14 patients completing this trial, amantadine reduced dyskinesia severity by 60% (p = 0.001) compared to placebo, without altering the antiparkinsonian effect of levodopa.
86|Functional status, lower extremity functioning, health-related quality of life, satisfaction with care, and use and cost of healthcare services,satisfaction with access to care,fatal complications,SD) total length of stay,carer burden,SD) total cost,Oxford Hip Score,RAND 36-item health survey I and the functional status index,hospital at home care and hospital care,earlier ambulation,lower readmission rate,function and quality of life,mean length of stay,Mean hospital stay,functional status, health-related quality of life, or lower extremity functioning,hospital stay on function, pain and quality of life (QOL,Home healthcare costs,quality of life with hospital at home care,rapid attainment of short-term functional milestones,Total length of stay and cost from orthopedic and rehabilitation hospital admissions, functional performance|These data showed that high-risk individuals were able to tolerate early intensive rehabilitation, and this intervention yielded faster attainment of short-term functional milestones in fewer days using less total cost.
32|cardiac filling pressures and fluid intake,minimum regional CBF,regional cerebral blood flow,CBF ((133)xenon clearance,CBF or blood volume,Symptomatic vasospasm,cerebral blood flow,mean global CBF,clinical outcomes, clinically evident and transcranial Doppler sonography-evident vasospasm, SPECT findings, complications, and costs,incidence of clinical vasospasm,incidence of preoperative vasospasm,pulmonary artery diastolic and central venous pressures,minimum regional CBF values,Cerebral blood flow (CBF,cerebral vasospasm,SPECT findings and neuropsychological function results,net fluid balance or on blood volume|No differences were observed between the two groups with respect to cerebral vasospasm (as observed clinically or on transcranial Doppler recordings).
20|rate of remission,rate of clinical response,HDRS scores,UKU Side Effect Rating Scale,remission rates,remission rate (SIGH-SAD <8,SIGH-SAD score, CGI-S and CGI,efficacy and tolerability,SIGH-SAD score and CGI severity score,efficacy and safety,Hamilton Depression Rating Scale (SAD version; SIGH-SAD), the Clinical Global Impression (CGI) and the Social Adaptation Self Evaluation Scale (SASS,SASS score,remission rate,29-item modified Hamilton Depression Rating Scale, administered by experienced clinicians, and the self-rated Beck Depression Inventory; adverse events and safety data,response rate,Hamilton Depression Rating Scale (SAD version; SIGH-SAD) and the Clinical Global Impression (CGI,remission rate (SIGH-SAD<8,number and severity of side effects,SIGH-SAD, CGI severity, SASS, and SDS scores,time to response and to remission,24-item Hamilton Depression Rating Scale,tolerated,atypical symptoms,response rate (SIGH-SAD,seasonal affective disorder (SAD, fall-winter depression,greater treatment-emergent adverse events (agitation, sleep disturbance, palpitations,effectiveness and tolerability,productivity,lower depression scores,clinical response rates,Hamilton depression rating scale, SAD version (SIGH-SAD), the clinical global impression of severity (CGI-S) and improvement (CGI-I) and the UKU side effect rating scale,Clinical response,SIGH-SAD score,negative social consequences of SAD,Social Adaptation Self Evaluation Scale (SASS), the Sheehan Disability Scale (SDS), and assessments of days lost due to illness and days with reduction in productivity,overall response,Side effects,depression score|The response rate (SIGH-SAD<50% of baseline value) after treatment for 8 weeks was 95%, the rate of remission (SIGH-SAD < or =7) was 85%.
not found|occurrence of seizures,mean serum carbamazepine levels,occurrence of dizziness,bioavailability of CBZ,time-lapse before CBZ reached its peak,mean total values of NTRS,seizure frequency,Peak concentrations of CBZ and CBZE,mean total number of seizures,mean CBZ daily dose,serum CBZ concentration,quality and severity of side effects,mean serum CBZ concentration,blood samples,Fluctuations of total CBZ and 10, 11-epoxide plasma level daily profiles at steady-state,occurrence of headache, dizziness and disturbances of vision, speech and coordination,fluctuation in serum CBZ concentrations,serum carbamazepine concentrations,number of epileptic seizures,systemic toxicity (STRS) and neurotoxicity (NTRS,intermittent side effects,Mean CBZ concentrations,CBZ levels and summation of CBZ and CBZ-E levels,mean fluctuation of serum CBZ concentration (Cmax-Cmin/Css,mean carbamazepine levels,Diurnal fluctuations,stability in serum CBZ and CBZE concentrations,Serum concentrations of unchanged CBZ and its main metabolite, carbamazepine-10,11-epoxide (CBZE,frequency of seizures,cognitive performance,serum concentration of CBZ,Peak serum CBZ concentrations,total score of STRS,bioavailability,tolerability and pharmacokinetics,Side effects,side effects,fluctuations in serum CBZ and CBZE|A systematic tendency was found toward higher test performance in the CR condition.
not found|BMD measurement and osteoporosis medication,electronic data and linear regression,osteoporosis management,BMD measurement or osteoporosis medication, provider reminder plus patient education|The effect of provider advice combined with patient education was not significantly different from provider advice alone (P=.88).
not found|disease-specific quality of life,Walking distance and quality of life,walking distances,aggregate severity score,disease activity (5 grade scale), WOMAC index subscales and concomitant treatments,pain on getting up from a seated position,patient's assessment of activity,talar tilt angle,aggregate score,assessment of disease activity, in WOMAC pain, joint stiffness, and physical functioning subscales,femorotibial angle and symptomatic relief,alignment, degree of OA, origin of OA, and age,Compliance,Symptoms of knee OA,Western Ontario and McMaster University Osteoarthritis Index (WOMAC) and the McMaster-Toronto Arthritis Patient Preference Disability Questionnaire (MACTAR), and function,symptomatic improvement,NSAIDs consumption,VAS pain score,number of days with NSAIDs intake,Visual analog scale (VAS) score for subjective knee pain,WOMAC subscales,femorotibial angle,maximum distance walked,pain,WOMAC physical function scores,Pain severity and knee function score,Compliance and tolerance|The reported walking distances at 3 months, 12 months and overall were significantly longer in the brace group (P=0.03, P=0.04 and P=0.02, respectively).
not found|Mortality,proportion of patients with RSE,While infections and arterial hypotension,effectiveness (RSE control, adverse events,mechanical ventilation,tolerability measures|While infections and arterial hypotension did not differ between groups, barbiturate use was associated with a significantly longer mechanical ventilation (P = 0.03).
90|Nausea, vomiting, itching and urinary retention,hypoalgesia to pin prick,visual analogue pain scales, total morphine consumption, and stress hormones,analgesic requirements,Perioperative blood loss, frequency and quantity of transfusions,pain relief and faster knee rehabilitation,visual analog scale scores,pain score,actual discharge time,pain scores,Pain,nonfatal pulmonary embolism,Total blood loss,Pain reduction,postoperative knee rehabilitation,total incidence of deep vein thrombosis,Somnolence,pain relief,pain and consumption of postoperative analgesics,respiratory depression,postoperative complications,incident pain,knee flexion,postoperative convalescence parameters, such as ambulation, patient activity including need for nursing care, fatigue or hospital stay,pain relief (visual analogue scale), attainment of physical therapy goals and cardiopulmonary complications,area under the curve (AUC) of pain score versus time,Pain scores, supplemental analgesia, side effects, degree of maximal knee flexion, day of first walk, and duration of hospital stay,early postoperative knee mobilization levels,pain control,pain scores, pain reduction and additional analgesia requirement (i.v. paracetamol,visual analog scales,Postoperative analgesia,incidence of calf vein thrombosis,Antithrombotic efficacy,postoperative venous thrombosis,postoperative pain,Late postoperative pain, fatigue and conservative attitudes and routines,Postoperative pain intensity,Plasma concentrations of pethidine,Supplemental analgesia,hypotension,beta-endorphine release,early postoperative maximal amplitude of knee flexion,plasma clearances of pethidine, and the time to peak concentration,bradycardia,median time for first passage of flatus,Nausea and vomiting,faster ambulation, and shorter hospital stay,total pain score (TOTPAR,urinary retention,perioperative blood loss,adverse effects,durations of stay,stress hormones,pulseoximetry, arterial blood gas analysis and rate of breathing,visual analogue scale (VAS,degree of analgesia, the adverse effects,postoperative pain and knee rehabilitation,Minimum respiratory rates,postoperative pain relief,visual analogue pain scales,convalescence and hospital stay,hypercapnia exceeding 6.0 kPa,TOTPAR VPS,Low pain scores,pain,Side effects,surgical outcome and duration of rehabilitation,side effects,catabolic response,pruritus|The median time for first passage of flatus was shorter in the EDA group than in the GA/PCA group (26 vs. 47 h).
20543|seroconversion rate,Safety and immunogenicity,mild local reaction,rate of blood-culture-positive typhoid fever,Efficacy and side effects,Rates of typhoid fever,safety, immunogenicity, and efficacy,Erythema and/or induration,levels of serum IgG Vi antibodies,Antibody levels,serious adverse reactions,attack rate of typhoid,Mild and moderate fever,Clinical and serum antibody responses,frequencies of adverse reactions and mean Vi antibody levels,protective rate and index of vaccine,overall incidence of side-effects,immune responses,serum Vi antibody levels (RIA,frequencies of rises of fourfold or greater and of maximal Vi antibody levels,typhoid fever,Protective efficacy,Vaccine efficacy,protective efficacy,Fever (oral temperature ,fever seen,anti-Vi antibodies,degree of fever,serum antibodies|Rates of typhoid fever were 379/100,000 per year for subjects who received the liquid formulation of vaccine and 468/100,000 per year for subjects who received enteric coated capsules.
not found|number of infants treated with antibiotics and 2) the number of infants with infections missed at the initial evaluation,antibiotics and analysis was by intention to treat,antibiotic costs, length of stay, need to restart intravenous antibiotics, in-hospital mortality, and 30-day readmissions,quality of care,antibiotics in caesarean section and use of polyglycolic acid sutures,resistance among P. aeruginosa,cervical cytology history,Serum calcitonin precursor concentrations,duration of antibiotic treatment for VAP,cost of development, dissemination and implementation,Clostridium difficile-associated diarrhoea (CDAD,acquisition rate falling,VRE infection,Diagnostic yields, feasibility, and costs of real-time polymerase chain reaction (PCR,Pneumonia Severity Index, the hazard ratio of antibiotic discontinuation,acquisition rate of GRE,nosocomial MRSA infections,antibiotic choice,IV antibiotic duration, and appropriateness of the IV route and switching,antimicrobial portion of the total pharmacy drug budget,Clinical and laboratory outcome,febrile neutropenic episodes,Readmissions,Reducing door-to-antibiotic time,minimal fever diagnostic tests,rate of unjustified prescriptions,time elapsed from randomization until a first modification of the initial intravenous antibiotic therapy,clinical, laboratory, and microbiology characteristics, and Pneumonia Severity Index,readmission rate,proportion of antibiotic courses,number of antibiotics,resistance to gentamicin and tobramycin,reintroduction of gentamicin,rate of MRSA isolation,CDAD fell,overall SSI rates,Median patient charges for radiology, laboratory, pharmacy, and room were reduced by $4404/intervention, and median hospital costs,quality of prophylaxis,mortality odds ratio (OR,incidence of surgical site infections (SSI,mean lengths of time to provision of susceptibility and identification test results,ICU length of stay,Per patient antibiotic charges,Antimicrobial use,nosocomial MRSA infection rate,rates of discontinuation and hospital discharge,performance of a sputum (P<.01) and blood (P<.001) cultures, antibiotic administration within 4 hours of hospital admission,clindamycin susceptibility,VRE prevalence,Duration of stay,Time to modification of intravenous antibiotic therapy,hospital length of stay or mortality,Mortality rates,Length of hospital stay, adverse events, mortality (interventional trial) and antibiotic costs (both studies), including costs related to future antibiotic resistance,total antibiotic prescribing costs,Bloodstream infections,mean overall mortality rate,response rates,Median length of stay,Clostridium difficile-associated diarrhea and cost,level of compliance,Severity of illness using APACHE (acute physiology and chronic health evaluation) II score,total expenditures,Clinical and microbiological response, antibiotic-associated toxic effects, in-hospital mortality, and readmission rates,Aminoglycoside resistance,VRE infection rate,Calculated cost savings,laboratory studies, imaging procedures, days of intubation, and days in an intensive or intermediate-care area,Mortality and length of ICU stay,incidence and prevalence of patients with multiresistant Enterobacteriaceae,annual rate of fluoroquinolone use,infection rate,total antibiotic exposure,Decreased mortality,Rates of ventouse delivery,quality, efficiency, and patient understanding of care,Concordance with national antibiotic guidelines,rate of appropriate empirical antibiotic treatment,quality and efficiency of pneumonia care,Length of stay, intensive care unit transfers, readmission rates, and in-hospital death rates,partial or total cessation of antibiotic treatment,median duration of IV therapy,time-specific mortality risk,number of courses of therapy or cost,reduced length of stay, a potential cost savings,nosocomial infection and mortality,VRE rates,incidence of toxicity,postoperative infection rate or death,nosocomial Clostridium difficile-associated diarrhea,antibiotic treatment duration,antibiotic choice, duration, timing, antibiotic volume and costs,Antibiotic cost savings,training of the whole health care team, emphasizing measures to reduce cross-colonization, and the importance of rational usage of antibiotics and (2) suppression of usage of third-generation cephalosporins,febrile neutropenia and nosocomial infections,30-day mortality,gram-negative resistance to gentamicin,proportion of patients receiving appropriate antibiotics within 4 h of admission to hospital,cefamandole, cefoxitin, and ticarcillin costs,mean costs of antimicrobials per episode,diarrhea,cost of antimicrobials per inpatient day fell,proportion of ceftazidime-resistant organisms acquired late,Mortality OR,Glycopeptide usage,acuity of patient care,cost savings,total number of courses of therapy,number of antibiotic entities stocked,hospital antibiotic prescribing,30-day mortality preintervention,patients response and mortality,clinical, laboratory, and radiographic outcome,antibiotic expenditure,quality of surgical prophylaxis,serum procalcitonin concentrations,total use and cost,serum aminoglycoside concentration data,peak incidence,Mortality rates and length of hospital stay,clinical outcomes,turnaround time,Amikacin resistance,30-day all-cause mortality, length of hospital stay, and readmission rate,adjusted relative risk of antibiotic exposure,gentamicin and tobramycin resistance,duration of intravenous antibiotic therapy,amikacin resistance,mean durations of therapy,number of days that unnecessary levofloxacin or ceftazidime,acute exacerbation of chronic obstructive pulmonary disease,Lastly, patient costs for hospitalization,vancomycin use,Mean,overall antibiotic use,rate of unnecessary use of the 2 target antibiotics,surgical site infection rate,microbiologically documented infections (MDI,intervention markedly improved door-to-antibiotic time,actual cost of Alert Antibiotics,incidence of nosocomial infections,number of doses prepared and quarterly purchase data,nosocomial infections,compliance with other recommendations, patient satisfaction and costs of the implementation strategy (secondary outcomes,rate of MRSA infection,CEFX use,Hospital mortality,occurrence of a secondary episode of VAP,Coagulase-negative Staphylococcus and Enterococcus infection rates,overall and timely administration of prophylaxis,carriage of GRE,Mortality from staphylococcal bacteraemia,Real-time PCR results,annual cost savings,clinical pulmonary infection score,Serological evidence of viral infection,antibiotic prescriptions on admission,Infections,rate of surgical-site infection,mean antibiotic costs,mean risk of infection-related mortality,appropriateness of cefotaxime prescribing,time to first dose of antibiotics, proportion receiving antibiotics within 8 h, timely switch to oral antibiotics, timely discharge, length of stay, or patient education outcomes,infection rates,incidence of regimens involving 12-hour intervals,Antibiotic expenditures,Prolonged prophylaxis,ICU vancomycin use and VRE prevalence,Annualized savings,diagnostic costs,genital tract infection,SD) hospital stay,Antibiotic use,incidence of C. difficile diarrhoea,mortality,pharmacy's 1985 average cost per antibiotic day and its monthly expenditures,antimicrobial therapy costs, antimicrobial resistance, and superinfections without adversely affecting the length of stay or mortality,shorter length of stay,Ticarcillin,antibiotic use and VRE prevalence,hospital admissions,labor costs,monthly incidence of C. difficile infection,mean durations of hospital stay,hospital admission,C. difficile diarrhoea,mean risk of Clostridium difficile-associated diarrhea,Overall, mean monthly acquisition cost savings,mortality, rehospitalization, and return to usual activities,Average length of stay,Length of hospital stay, costs related to future resistance and total antibiotic costs,cephalosporins,medical complications,Intraoperative redosing,mean number of cases of C. difficile-associated diarrhea,crude mortality rates,medication costs,mortality, morbidity, and cost,Antibiotic use, hospital admissions, and mortality,Guideline compliance,turnaround time of the microbiological cycle,numbers of intravenous piggyback cefazolin, cephalothin, cefamandole, cefoxitin, carbenicillin, and ticarcillin doses,MRSA isolation,incidence density of tobramycin-resistant organisms,rate of nosocomial methicillin-resistant Staphylococcus aureus infection,mean lengths of hospitalization,usage of cephalosporins, imipenem, clindamycin, and vancomycin and increased usage of beta-lactam/beta-lactamase-inhibitor antibiotics,hospital admission, severity of pneumonia, and 30-day mortality,IV antibiotic expenditure,prevalence of MRSA and CRP,length of stay,30-day mortality rates,antibiotic costs,incidence of colonization and infection,mortality rates,VRE infections,mean numbers of defined daily doses of appropriate antibiotic therapy,turnaround time of microbiological procedures,parenteral broad-spectrum antibiotics,Mean length of total hospital stay|In the years since, the incidence has remained at this low level, and the antibiotic costs have decreased to a level lower than before intervention.
300|hormonal changes,Hormone levels,progesterone levels,24-month life-table pregnancy rate,serum estradiol and progesterone levels and urinary estradiol and pregnanediol levels obtained during the luteal phase before, 1 year and 2 years after sterilization,Surgical difficulties and injuries and technical failures,average surgical time for minilaparotomy,Demographic characteristics, educational level and operator experience,surgical complications,Pain,midluteal progesterone levels,Serum estradiol and progesterone and urinary pregnanediol and estradiol,mean duration of the procedure,operating time,peri-operative complications,perioperative outcomes|The results showed little differences among patients in the three groups for age, number of living children, contraceptive and abortion histories and pre-existing medical conditions.
23|GFR,Height velocity,serum insulin-like growth factor binding protein (IGFBP)-1 and -2 levels,GFR or the incidence of rejection,IGF-II plasma concentrations,bone formation rates,mean (SE) HV and delta HSDS,HVSDS,serum IGFBP-2 levels,Phosphate, ALP, PTH, and insulin,pretreatment elevation of IGF-binding protein-1 (IGFBP-1) levels,acute rejection episode,lipid and parathyroid concentrations,serum IGFBP-1 levels,Serum calcium, phosphorus, osteocalcin, and PTH levels,mean delta height age minus the delta bone age,incidence of rejection,Growth rate, standardized height, bone age, fasting and 2-hour postprandial glucose and insulin levels, biochemical values, and insulin-like growth factor,Growth, bone maturation, renal graft function, plasma insulin-like growth factors, serum binding proteins,growth and glomerular filtration rate,growth rates,GH-induced height-velocity increase,accelerated bone maturation,pretreatment elevation of IGF-binding protein-1,number of adverse events,body length, body weight, bone age, biochemical and hormonal analyses, renal function, bone mass, and adverse effects,height velocity,Plasma IGF-II levels,Anthropometric measurements and circulating growth factors,IGFBP-3 levels,Renal function deterioration,delta SDS (standardized height,bone maturation, renal failure progression, or metabolic control,calculated creatinine clearance,IGF,Bone mass,IGF-I/IGFBP-3 ratio,growth rate,adverse events,fructosamine levels,Bone maturation,deterioration of graft function,height,prestudy height velocity and height-velocity increase,overt insulin dependent diabetes mellitus,Phosphate, alkaline phosphatase (ALP), parathyroid hormone (PTH), and fasting insulin concentrations,Standardized height,efficacy (height velocity (HV), change in height standard deviation score (delta HSDS)), and safety (glomerular filtration rate (GFR), incidence of rejection, and calcium and glucose metabolism) of recombinant human growth hormone (rhGH,Growth rate and standardized height,Mean fasting and 2-hour postprandial glucose values,Mean fasting and postprandial insulin values,elevated pretreatment IGFBP-3 levels,height SDS,Length gain,glomerular filtration rate,integrated insulin levels (AUC,Glomerular filtration rate and effective renal plasma flow,forearm bone mass and increased serum concentrations of total and free IGF-I and IGF-binding protein 3 (IGFBP-3), whereas IGF-II, IGFBP-1, IGFBP-2, GH-binding protein, ghrelin, and leptin,Serum IGF-I levels,severe growth retardation,linear growth and maintains bone mass,serum ALS, IGFBP-3, total IGF, IGF-I, IGF-II and free IGF-I levels,Anthropometric measurements and blood for serum calcium, phosphorus, parathyroid hormone (PTH), osteocalcin, and insulin-like growth factor-I,plasma insulin-like growth factor-I,IGF-I. Fructosamine, lipid, and parathyroid concentrations,efficacy and safety of rhGH,rejection episodes,serum levels of IGF-I, IGF-II, free IGF-I, IGFBP-3 and acid labile subunit (ALS,height velocity SD score,Annual growth velocity increased and standard deviation scores for height,Height velocity SDS (HVSDS,Bone formation rates|Serum calcium, phosphorus, osteocalcin, and PTH levels did not differ between the treated and control groups.
2722|HIV infection rates,HIV-free survival,HIV infection or death of the child by 24 months,HIV infection,risk of HIV-1 transmission,mortality rate,frequency of breast-feeding,2-year mortality rates,time-to-mortality distributions,median duration of breast-feeding,child survival,safety (occurrence of infant adverse events,efficacy and safety,maternal CD4-cell counts,grade 3 or 4 serious adverse events,child mortality and HIV-1 transmission through breastfeeding,rates of HIV-1 infection,estimated rate of HIV-1 infection,Cumulative mortality or HIV infection rates,mortality rates and HIV-1-free survival,rate of HIV-1-free survival,Infant HIV-1 infection and death,erythrocyte sedimentation rate,Cumulative infant mortality,postnatal HIV transmission,number of adverse events (primarily neutropenia,median duration of cumulative exclusive breastfeeding,breastfeeding transmission,HIV-1 infection,higher mortality,risk of transmission,Median duration of breastfeeding,rate of HIV-free survival,transmission through breastfeeding, and mortality,acquire infection,estimated rate of breast milk transmission,Cumulative 3-month mortality,relation to transmission of HIV-1 through breastfeeding and early child mortality,death and prolonged HIV-free survival,transmission of HIV-1,postnatal HIV-1 infection,Primary efficacy (HIV infection by age 7 months and HIV-free survival,cumulative probability of HIV-1 infection,HIV-1-free survival,HIV-1 transmission risks and survival,total risk of HIV-1 transmission,mortality|Breastfed infants who also received solids were significantly more likely to acquire infection than were exclusively breastfed children (HR 10.87, 1.51-78.00, p=0.018), as were infants who at 12 weeks received both breastmilk and formula milk (1.82, 0.98-3.36, p=0.057).
not found|Number of days from admission to delivery, gestational age at delivery, rates of preterm delivery, low birthweight, maternal infections and neonatal infections,upper genital tract infection,mean cervical dilatation,composite of neonatal death, chronic lung disease, or major cerebral abnormality on ultrasonography before discharge from hospital,Rate of cesarean section,perinatal mortality and morbidity,higher gestational age at delivery,postpartum infections,interval to delivery or duration of pregnancy,frequency of preterm birth,frequency of contractions, cervical Bishop's score, and white blood cell count on admission,duration of pregnancy,prolongation of pregnancy,neonatal death, respiratory distress syndrome, proven sepsis, and birthweight,preterm premature rupture of membranes,rate of delivery,neonatal morbidity,episodes of recurrent labor requiring parenteral tocolysis,safe and well tolerated,Survival analysis,overall prevalence of microbial invasion of the amniotic cavity,Suspected sepsis,tolerated,incidence of preterm birth,pregnancy outcome,neonatal hospitalization time,infectious morbidity,maternal and neonatal infectious morbidity,neonatal outcomes,maternal outcomes, including duration of randomization-to-delivery interval, frequency of preterm delivery (< 37 weeks), frequency of preterm premature rupture of membranes, clinical chorioamnionitis, endometritis, and number of subsequent admissions for preterm labor,necrotising enterocolitis,prolongation of gestation,prolongation of pregnancy, the rate of preterm birth, and neonatal morbidity,success of magnesium sulfate tocolysis,shorter interval to delivery, lower gestational age at delivery, lower mean birth weight,time to delivery,likelihood of a beta error,rate of neonatal suspected sepsis,rate of admission to neonatal intensive care unit,interval to delivery, birth weight, and neonatal outcomes,interval to delivery,efficacy, safety, and tolerance,birth weight,respiratory distress syndrome, bronchopulmonary dysplasia, intraventricular hemorrhage, sepsis, and admission and duration of newborn intensive special care unit hospitalization,delivery interval or rate of delivery,maternal outcomes, including duration of randomization-to-delivery interval, frequency of preterm delivery, and frequency of clinical chorioamnionitis and endometritis,rate of cesarean section,genital microflora|In our population adjunctive ampicillin-sulbactam with indomethacin did not improve the success of magnesium sulfate tocolysis.
19|satisfactory pain relief,complete pain relief|de Quervain's disease of pregnancy and lactation is usually self-limited and responds well to nonsurgical treatment.
not found|physical appearance,knowledge,symptom scales,self-esteem; social acceptance, physical appearance, and athletic ability,metabolic control,self-esteem measures,eating disturbance,risk of bulimic attitudes,dieting behaviors,media-related attitudes and behaviors including internalization of sociocultural ideals, self-efficacy to impact weight-related social norms, and print media habits,body mass index,body image, eating attitudes, and behaviors,Self-Report Symptom Check-List (SCL-90-R,body dissatisfaction,body-related knowledge and attitudes,body size acceptance, puberty knowledge, and perceived weight status,body weight,lasting changes in body image and dieting behaviors,physical appearance to their self-esteem,weight, Eating Attitudes Test and Eating Disorders Inventory,eating disorder risk factors,students' anxiety or depression,Eating Disorder Examination Questionnaire (EDE-Q), the children's version of the Eating Attitudes Test (EAT), the Rosenberg Self-Esteem Scale (RSES), and a Knowledge Questionnaire (KQ,lower drive for thinness and greater body satisfaction,weight-losing behaviors,disturbed eating attitudes and behavior,body image and eating attitudes and behaviors,weight concern,disturbed eating behaviour,body satisfaction,frequency of purging by insulin omission or hemoglobin A1c levels,dieting behaviors, body image attitudes, and media knowledge, attitudes, and habits,Restraint and Eating Concern subscales of the Eating Disorder Examination (EDE) and on the Drive for Thinness and Body Dissatisfaction subscales of the Eating Disorder Inventory|The program significantly improved the body satisfaction of the intervention students and significantly changed aspects of their self-esteem; social acceptance, physical appearance, and athletic ability became less important for the intervention students and more important for control students.
not found|Mean contraction values,WOMAC, visual analogue, and the anxiety score,quadriceps strength and hamstring range of motion,contraction values of the vastus medialis and the vastus lateralis muscles,peak torque,vastus lateralis muscles,overall knee function,Pain and functional status,PFP and PFC,pain and improvements in torque, vertical jumping ability, and physical activity level,Cincinnati Rating System and traditional measures of leg strength and flexibility,VAS and FIQ differences,functional performance,PFC and joint function improved, and PFP,Perceived functional status,visual analog scale (VAS) and the Functional Index Questionnaire (FIQ), respectively,Kujala patellofemoral score (KPS), and pain, through a visual analog scale (VAS,isokinetic strength on a Cybex II+ dynamometer,walking, stair activity, running, jumping/twisting, and overall activity level,muscular strength,Patellofemoral pain (PFP) and abnormal patellofemoral congruence (PFC,patellar pain, position, and function,knee functional capacity,physical activity, pain, and muscle function,Contraction values,WOMAC, visual analogue, and HAD scores,PFC, KPS, and VAS,WOMAC and HAD,visual analogue pain score; the WOMAC lower limb function score; the Hospital Anxiety and Depression scale (HAD); and quadriceps strength,closed kinetic chain testing and perceived functional status,pain,Muscle characteristics, subjective symptoms, and functional performance,quadriceps muscle performance,patellofemoral pain syndrome|The clinical improvement was better on patients of groups I and III.
not found|treatment efficacy, onset of symptom amelioration, or maintenance of therapeutic gains,anxiety,Y-BOCS, SCL-90-R OC and GSI scales, and POMS,Yale-Brown Obsessive Compulsive Scale (Y-BOCS), Symptoms Checklist-90-Revised Obsessive Compulsive (SCL-90-R OC) and Global Severity Index (SCL-90-R GSI) scales, Profile of Moods scale (POMS), Perceived Stress Scale (PSS), and Purpose in Life (PIL) test,PSS and PIL test,Y-BOCS, SCL-90-R OC, SCL-90-R GSI, POMS, PSS, and PIL|Within-group statistics (Student's paired t-tests) showed that Group 1 significantly improved on all six scales, but Group 2 had no improvements.
not found|Pain related to motion and pain on load,Quality of Well-Being Scale (QWB) and Current Health Desirability Rating (CHDR,High levels of co-morbidity,strength and function,outcome assessments (muscle strength dynamometry, six minute walk test, WOMAC OA Index, total drugs, SF-12 quality of life, Adelaide Activities Profile, and the Arthritis Self-Efficacy Scale,knee ROM, thigh girth, and time for a 1-mile walk,right quadriceps strength,lower limb OA,Quality of life,functional levels,arthritis-specific Health Assessment Questionnaire (HAQ), Center for Epidemiologic Studies-Depression Scale (CES-D), and Perceived Quality of Life Scale (PQOL,WOMAC pain,Aquatic exercise,functional activity and quality of life,left quadriceps strength,Aquatic exercisers reported equal (QWB) or better (CHDR, HAQ, PQOL) health-related quality of life,Functional gains,strength,Compliance rates,disability rating index (DRI), global self-rating index (GSI), and visual analogue scale (VAS,Subjective pain levels,knee range of motion (ROM), thigh girth, subjective pain scale, and time for a 1-mile walk,mean pain score,physical function,Costs/QALY gained discounted,walk speed and self efficacy satisfaction,quality of life, cost-effectiveness and physical function measurements,Disability in functional activities,Pain score on the Western Ontario and McMaster Universities OA index (WOMAC,Cost per quality-adjusted life year (QALY,WOMAC physical function,pain,strength and physical function|Pain related to motion and pain on load was reduced up to 3 months after last the treatment in the hydrotherapy group and up to 6 months in the EA group.
15|perceptual evaluation of voice quality and a questionnaire on the occurrence of vocal symptoms,psychological distress and lower quality of life,voice quality,average (median) time taken to complete voice therapy,Voice-Related Quality of Life (VRQOL) and the Voice Symptom Severity Scale (VoiSS,voice therapy (perceptual auditory rating of voice quality measurement,laryngeal status,voice severity, electrolaryngograph, and shimmer measurements and on ratings provided by a patient questionnaire,voice care knowledge areas,Ratings of laryngeal features, Buffalo voice profile, amplitude and pitch perturbation, voice profile questionnaire, hospital anxiety and depression scale, clinical interview schedule, SF-36.
                Voice therapy improved voice quality|Results revealed a significant difference between the 3 treatment groups in the amount of change for the voice severity, electrolaryngograph, and shimmer measurements and on ratings provided by a patient questionnaire (P<0.05).
40|medical events,time to return to uninterrupted sleep,Pain,rash healing,pain severity achieving statistical significance,lesion healing, resolution of pain, return to usual activity, and return to uninterrupted sleep,full crusting,prevalence of pain,incidence of ulceration,chronic pain,Safety,time to return to usual daily activity,intraocular complications,period of viral shedding,extent and duration of the rash,Time to total crusting and healing,Total analgesic use,total crusting,chronic pain and quality-of-life outcomes,local neurological symptoms,accelerated time to cessation of acute neuritis,duration and severity of acute pain,persistent pain,proportion of patients with pain scores,laboratory adverse events,quality of life,median duration of postherpetic neuralgia,active ocular disease,times to last new lesion formation,Famciclovir accelerated lesion healing,post-zoster pain,loss of vesicles,duration of viral shedding,risk ratios,reduction pain,weekly prevalence of pain,frequency or severity of post-herpetic neuralgia,resolution of pain,resolution of postherpetic neuralgia,analgesic requirements each day, and adverse events and laboratory abnormalities,frequent formation of new lesions|Total analgesic use in the first 4 weeks was reduced by acyclovir, but during follow up there was no difference in the prevalence of analgesic use between groups.
not found|transmission rates,number of sexual partners or other risk behaviors,HIV-1 transmission rates,seroconversion rate,plasma HIV-1,rate of transmission,Heterosexual transmission,Unprotected sexual intercourse as a risk factor for HIV-1 infection,median viral loads,Seroconversion rates,Seroconversion,incidence rate difference,HIV Heterosexual Transmission,HIV-1 incidence and sexual risk behaviors,genetically-linked HIV-1 transmission,quality of life score,CD4 counts,incidence of seroconversion,Viral load,Incidence rates of seroconversion,HIV-1,highest HIV-1 transmission rate,incidence of heterosexual transmission,Median viral loads,Six HIV-1 seroconversions,sexual activity,HIV seroprevalence,risk of seroconversion,rate of HIV seroconversion and last recorded CD4 cell count level,CD4 cell count,signs of disease progression (symptoms of acquired immunodeficiency syndrome, p24 antigen positivity, or CD4+ cell counts|Men with signs of disease progression transmitted infection to their partners more frequently and were more frequently treated with zidovudine.
11|attacks|Stilboestrol 5 mg daily was better than the placebo in preventing attacks.
181|Total pregnancy rates and time for success,pregnancy rate and pregnancy maintenance,pregnancy rate and the miscarriage rate,pregnancy rates|Although the results were not statistically significant in the group of women with intramural and intramural-subserosal fibroids, this study confirms the important role of the position of the uterine fibroid in infertility as well as the importance of fibroids removal before the achievement of a pregnancy, to improve both the chances of fertilization and pregnancy maintenance.
60|hepatic reasons,alkaline phosphatase and alanine aminotransferase activities,severity of symptoms or physical findings,mean alkaline phosphatase and alanine aminotransferase values,BSP elimination kinetics,cumulative mortality from liver disease,histologic progression,serum alkaline phosphatase (ALP) levels,serum immunoglobulin G levels,variceal bleeding,liver function and immunoglobulin levels,albumin levels,Procollagen type III aminoterminal peptide (PIIINP), hyaluronic acid, and sulfobromophthalein (BSP) elimination kinetics,Clinical events, laboratory test results, and liver histology,mean serum levels of alkaline phosphatase, total bilirubin, gamma-glutamyltranspeptidase, alanine aminotransferase, aspartate aminotransferase, and IgM,blood test results, symptoms, and/or liver histology,pruritus score,Serum total bilirubin levels,total globulin levels,mean pruritus score,Bilirubin values,histological grading score,Pruritus,histological scores,immunoglobulin G levels,liver function test,serum cholesterol levels, and UDCA also reduced high-density lipoprotein cholesterol levels,mean alkaline phosphatase values,number of treatment failures (i.e. dead, orthotopic liver transplantation (OLT), complications of cirrhosis, doubling of bilirubin, untreatable pruritus,progression of esophageal varices,diarrhea,levels of serum albumin, serum bilirubin, alkaline phosphatase, cholesterol, and aminotransferases,survival estimate,alanine aminotransferase (ALT) level,Mayo score values,histologic changes noted at liver biopsy,elevated serum level of aminoterminal propeptide of type III procollagen,ductular proliferation,serum albumin and bilirubin levels,liver histology,Serum bilirubin levels,mean alanine aminotransferase values,serum activities of aminotransferases, alkaline phosphatase, and gamma-glutamyltransferase,ALP level,symptoms, laboratory findings (serum bilirubin level, alkaline phosphatase and alanine transaminase [ALT] activities, immunoglobulin [Ig] M level), serum markers of fibrosis, or histological features, except lobular inflammation,serum level of carboxyterminal propeptide of type I procollagen,mean bilirubin and immunoglobulin M values,number of markers of liver disease,serum levels of immunoglobulin (Ig) M and IgG, and colchicine reduced IgG levels,improvement of liver enzymes related to cholestasis and cytolysis and of amelioration of pruritus,disease activity|However, there was no such improvement in the severity of symptoms or physical findings; moreover, there was no significant difference in the histologic changes noted at liver biopsy in the two treatment groups.
80|Pain scores,duration of anaesthesia,postoperative nausea and vomiting or psychomotor reactions,normal blood pressure, non-oliguric renal failure, proteinuria, hypostenuria and abnormal urinary sediment,nausea/vomiting,mPCA,age, weight, type of operation or induction of anaesthesia, 4-h sedation and pain scores and further analgesic requirements,Nausea and vomiting scores, sedation scores and pain scores,discomfort,Aseptic tissue necrosis,mean total morphine consumption,satisfactory sedation scores,pain-free children,nausea, vomiting, apnea, desaturation, reintubation within 24 h and constipation,postoperative haemorrhage and vomiting,Pain Rating Scale,efficiency of postoperative analgesia,quality of oral intake,Mean (SD) morphine concentrations,degree of pain,postoperative morbidity,post-operative pain scores,OPS scores and requirement for supplementary analgesics,enlarged hyperechoic kidneys,incidence of reactionary post-operative haemorrhage,pain and postoperative morbidity,incidence of postoperative vomiting,Renal biopsy,Oral fluid intake,pain score or the need for rescue analgesia,total paracetamol consumption,score for stridor,nausea and vomiting scores,perioperatively scores (open scale 1-9) for stridor, sedation, bleeding, nausea, pain, heart rate, the need for analgesics and registered psychotomimesis and well-being at home,diclofenac, 4'-hydroxydiclofenac and 5'-hydroxydiclofenac concentrations,postoperative pain scores,episodes of bleeding,Worst pain,postoperative pain and behaviour,analgesia [behavioral pain scale (BPS) score of 3,time to first solid intake,heart rate and blood pressure,quality of recovery,symptoms of disorientation, restlessness, inconsolable crying and thrashing resemble an acute psychosis,scores for salivation,pain scores,Postoperative pain relief,Acta Anaesthesiologica Scandinavica,degree of postoperative sedation,normal activity,pain score,leucocyte and differential counts, lymphocyte and their subset counts, lymphocyte proliferative responses, and in serum cortisol, C-reactive protein, plasma interleukin-6 and group II phospholipase A2 concentrations,volumes of distribution of parent diclofenac and its hydroxyl metabolite,Plasma diclofenac and beta-endorphin concentrations,full Aldrete scores,swallowing-evoked pain,incidence and frequency of vomiting,postoperative complications,otitis media,postoperative analgesia,Vt and total plasma clearance,Adverse effects and duration of PCA,Cumulative morphine consumption,side-effects,Pain and demeanour,total morphine consumption,blood loss,Times to leave recovery,Tissue necrosis,morbidity and pain,postoperative pain,sedation score,Postoperative vomiting,vomiting,phenotype and plasma morphine,relevant pain-relief medication,visual-analogue 10-point scale and the 0-4 point verbal pain assessment scale,post-operative pain,postoperative analgesic efficacy,Postoperatively, time to first eye opening, sedation score, pain score, time for further analgesia requests and incidence of nausea and vomiting,Efficacy and safety,rate of recovery,postoperative bleeding,fatigue, fever, gastrointestinal disturbances, anorexia and weight loss,headache, arthralgias and maculopapular rash,Nausea, vomiting and pain,bleeding and restlessness,spontaneous and swallowing-evoked pain,Renal function,pain scores in recovery and pain scores,Elimination clearance of hydroxyl metabolites,pain, less elevation of temperature, more oral intake, and started drinking,point Verbal Pain Rating Scale (VPRS,Analgesic efficacy,postoperative analgesia made by analgin and promedol,median of the VAS,overall incidence of postoperative vomiting,pain intensity and morphine requirements,child behavior,incidence of PONV,nausea and vomiting and allowed safer and earlier hospital discharge,onset of eating at home,Pre-surgical child behavior ratings and pain management,concentration ability,time to awaken from anaesthesia or incidence of postoperative vomiting,hemodynamic changes,Functional parameters,Low urine specific gravity,rescue analgesia,C3 and C4 levels,postoperative morphine titration,Overall, CHEOPS scores,rate of postoperative nausea and vomiting,Total plasma clearance,serious adverse events,Child Behavior Checklist (CBCL,plasma morphine concentrations,Analgesic requirements,postoperative pain and anxiety,rescue analgesic,respiratory depression,demographics, tracheal extubation times, and pain scores,operating theatre blood loss, the frequency of bleeding on the ward, or the need for operative haemostasis,median (range) episodes of vomiting,arousal,mean VAS score,validated Wong and Baker scale (FACES,ischaemia and ulceration,formation clearance to 4'-hydroxydiclofenac, diclofenac volume of distribution, absorption half-time and lag time for the suppository,formation clearance to 4'-hydroxydiclofenac,Hannallah objective pain scale,nausea/vomiting, analgesics and parents' aspects,nausea and vomiting,severe vomiting,incidence of motor block, urinary retention, postoperative vomiting or postoperative sedation,plasma beta-endorphin level,relative bioavailability,postoperative pain scores, analgesic requirements, sedation scores, signs of respiratory depression and nausea and vomiting, as well as antiemetic requirements,pain scale,phenotype nor morphine concentration,effective pain relief,CBCL rating and experience of pain,Ketamine efficacy,Colon perforation,pain severity,Plasma morphine concentration,postoperative nausea,ESR, plasma urea and creatinine concentrations,Mean postoperative hospital stay,intra-operative bleeding,total incidence of nausea/vomiting,Immediate postoperative analgesia,agitation score,abdominal pain and peritonism,Pain control,need analgesia,median pain scores,objective pain scale (OPS,severe agitation,severe arthralgia,stridor scores,maximum pain score and pain score,Muscle relaxation,Pain scores, emetic episodes and supplemental morphine requirements,longest analgesia duration,marked restlessness,demographics, induction technique, duration of anaesthesia and time between premedication and induction of anaesthesia,Hourly visual analogue pain scores and morphine patient controlled analgesia (mPCA) usage,Side effects,CHEOPS pain scoring,Mean operative time,Postoperative comfort,sedation scores and the heart rates,formation clearances of diclofenac to hydroxyl metabolites,analgesic effects,incidence of airway irritation or emergence delirium,plasma proteins and IgG levels,objective pain score,urinalysis, complete blood count, erytrocyte sedimentation rate (ESR), plasma creatinine, glomerular filtration rate (GFR), electrolytes, proteins, IgG, C3, C4 antinuclear-antibodies (ANA), antistreptolysin-O and antibodies to hantaviruses,Postoperative nausea and vomiting (PONV,median time to first analgesia,secondary hemorrhage,Pain,hypertension, oedema or evidence of acute infection,postoperative pain, oral intake, vomiting, temperature and complications,visual pain scale (VAS) (0-100), side-effects such as vomiting and postoperative haemorrhage,severity of the postoperative pain,salivation,pain relief,Severe delirium,incidence of above average bleeding,duration of postoperative analgesia,pre-operative anxiety and pain,pain scores and postoperative morphine requirements,Blood loss,Clearance,Pain and appearance,analgesic efficacy,Postoperative analgesia,postoperative analgesic requirement,End-tidal volatile agent concentration,analgesic effect,bleeding,emergency department visit for pain and dehydration,incidence of vomiting or dreaming,pain and restlessness,glycosuria, aminoaciduria and decreased tubular reaposrption of phosphate (TRP,unpleasant psychotomimesis,absorption half-life,Wong and Baker Pain Scale,Recovery time,Nurse pain assessments,reduced enzyme activity,frequency of vomiting and the degree of nausea,Postoperative pain,movement pain scoring,sedation score or frequency of use of postoperative analgesics,Acceptable pain scores,pain score [verbal analogue scales (VAS), 0-10] and sedation level at 5-min intervals and recorded the total morphine consumption of the first hour in the PACU,self-report visual analogue scale to record pain,rapid return to calm wakefulness,Postoperative analgesia and side-effects,median duration of analgesia,number of children rating severe pain,analgesic requirements and modified objective pain score,pain,side effects,modified Aldrete score, a Pain/Discomfort scale|In children 1-3 yr, sevoflurane provided more rapid early recovery but not discharge after anaesthesia of <30-min duration.
14|Complete remission|At the 6-month follow-up timepoint, tumour volume had decreased by >/=10% in a total of 7 patients with a 37.9% (95% CI 31.3-44.5%) mean volume reduction in this subgroup.
34|blood gases,lower incidence of failed extubation,demographics, severity of initial illness and associated complications, time to extubation, ventilatory management before extubation, weight, age, or nutritional status at the time of extubation,Mean birth weight,peak inspiratory pressure of </=16 cm H(2)O, positive end expiratory pressure of </=5,H(2)O, intermittent mandatory ventilation rate,extubation failure,Pulmonary function tests (PFT,apnea/bradycardia episodes,incidence of abdominal distension or feeding intolerance,Respiratory failure|Thirty-two (94%) of 34 infants were extubated successfully with the use of SNIPPV versus 18 (60%) of 30 with the use of NCPAP (P <.01).
120|Mean duration of hospital stay,anthropometric, high-precision knee-height, and plasma zinc measurements,Serum zinc levels,serum testosterone levels,linear growth in beta-thalassemia,incidence of infections and hospital admissions,Sickle cell crisis,growth velocity (height,Body composition,Serum vitamin E levels,sitting height,Zinc deficiency affects adversely T-helper1 (TH1) functions and cell mediated immunity and interleukin (IL)-2 production,bacteriologically positive infections,BMI,serum testosterone, neutrophil zinc, and neutrophil alkaline phosphatase activity,number of hospitalizations and decreased number of vaso-occlusive pain crisis,Height-for-age and weight-for-age z scores,Mean SOD activity and TAC,knee height,height,Mean GPX activity,serum zinc and vitamin E, superoxide dismutase (SOD), glutathione peroxidase (GPX), total antioxidant capacity (TAC) and body mass index (BMI,interleukin-2 production,antioxidant status,mean number of infective episodes and associated morbidity,body weight increased and serum lactic dehydrogenase activity,mean height velocity of early-zinc supplemented children,lymphocyte and granulocyte zinc,circumference z scores,mean number of episodes of crisis,serum testosterone level,growth and body composition,acceleration of growth in height|Mean GPX activity in group1, 2 and 3 decreased significantly (P<0.015, P<0.032 and P<0.029, respectively).
569|general health,Subscales of acuity,Health economic benefits and quality of life,Quality-of-life treatment differences (SD units) for symptom distress,Glycosylated hemoglobin,glycated hemoglobin, serum PIIINP, and physical activity,depression,cognitive functioning,Psychomotor speed and concentration,sleep,psychophysical tests and measurements of glucose balance, serum lipids, aminoterminalpropeptide (PIIINP) concentration, and body weight,VAS emotional health,Cognitive function,mean (+/-SE) HbA1c and fasting blood glucose levels,overall visual analog scale (VAS,body weight,cognitive deficits,glucose and hemoglobin A1c (HbA1c) levels and symptom distress, QOL, and health economic indicators by questionnaires and diaries,disorientation and detachment,productive capacity,absenteeism,vitality,Ginseng therapy elevated mood, improved psychophysical performance, and reduced fasting blood glucose (FBG) and body weight,general perceived health,serum lipid profile|Quality-of-life treatment differences (SD units) for symptom distress (+0.59; P<.001), general perceived health (+0.36; P= .004), cognitive functioning (+0.34; P=.005), and the overall visual analog scale (VAS) (+0.24; P=.04) were significantly more favorable for active therapy.
not found|abdominal fat distribution, glycemic control, and insulin sensitivity,Body weight, total and HDL cholesterol, glucose, and insulin,Submaximal exercise heart rate and rate pressure product,BRS, HRV, and hemodynamics,visceral abdominal fat,glycemic control and body composition,plasma levels of triglycerides, fructosamine and glycohemoglobin,Triglycerides,2-h glucose and insulin,Glycosylated hemoglobin,lipids, glucose, insulin, glycosylated hemoglobin and cardiovascular fitness,metabolic control,baroreflex sensitivity (BRS) and heart rate variability (HRV,abdominal fat and glucose metabolism,Muscular strength and endurance,VO2 peak,subcutaneous AT, visceral AT, and muscle density,beta-cell function,VO2max,responses of plasma insulin and C-peptide to oral glucose,fasting glucose, insulin, serum lipids and lipoproteins, or resting blood pressure,glycemic control,beta-cell responses,2 hour plasma glucose in oral glucose tolerance test,glycemic control, cardiorespiratory fitness, muscular strength and body composition,functional capacity, lean body mass, strength and glycemic control,Cardiac index, systemic vascular resistance index, stroke index, and pulse wave velocity,VO(2max), standard time and frequency domain measures of HRV during 24-h recording, and BRS,BRS sensitivity,VO(2max,glucose disposal by hyperinsulinemic-euglycemic clamp and computed tomography scans of abdominal AT and mid-thigh skeletal muscle,self-monitored glucose levels,visceral adipose tissue (VAT,Fat free mass (FFM,muscle strength, and glycemic control,muscle density,waist:hip ratio,time or frequency domain measures of HRV or in systemic hemodynamics,insulin sensitivity,Increased insulin response,beta-cell response,lean body mass (LBM,Fasting serum glucose and insulin,glycosylated hemoglobin A1 fell,glucose metabolism,insulin sensitivity and Hb A(1c) levels,Improved glucose disposal,reduced abdominal subcutaneous and visceral AT and increased muscle density,BRS,Coronary risk factors,body weight,ventilatory threshold,Glycosylated haemoglobin (HbA 1c ), fasting glucose and insulin, glucose and insulin 120 minutes (2h) after a 75 g oral glucose load, body composition and muscular strength and endurance,fasting glucose and insulin,resting heart rate,Muscular strength,Glucose infusion rates,Percent body fat,Fat mass (FM,glycaemic control and lowers fasting insulin levels,exercise capacity and muscle strength and improving glucose control,insulin resistance,risk for coronary artery disease,fasting glucose and HbA 1c,Vo(2 max,baroreflex sensitivity,change in self-monitored glucose levels and insulin area under the curve,heart rate,physical fitness,peak oxygen uptake (P<0.05) and exercise test duration (P<0.001) increased following training, whilst glycated hemoglobin (P<0.05) and fasting blood glucose,insulin sensitivity and Hb A(1c) concentration,Resting systolic blood pressure,mean fall in fasting plasma glucose,cardiovascular risk factors: physical fitness, systolic blood pressure, plasma triglycerides, and glycemic control,glycaemic control,glycemic control and fitness|During the 3 mo of sedentary lifestyle, insulin and C-peptide responses to the clamp procedures were unchanged in both moderate and low secretors.
not found|Signs or symptoms of venous insufficiency,average size of the thrombi,Complete lysis,deep venous insufficiency,major bleeding and pulmonary emboli,number of closed vein segments and the occurrence of postthrombotic syndrome,deep vein thrombosis,Clot lysis and deep venous reflux,blood transfusions,number of closed vein segments,Minor bleeding and slight rise in temperature,lysis rate,venographic severity,plasma fibrinogen concentration,pulmonary emboli,Postthrombotic syndrome,Segmental valve preservation,mean change in venographic score,risk of bleeding,efficacy and safety,initial thrombi,symptoms of the postphlebitic syndrome,serious post-thrombotic changes,peripheral edema,major bleeding,patency rate,No lysis,clinical symptoms of post-thrombotic syndrome,Venous reflux,rates of complete recanalization,Significant thrombolysis,Overt bleeding,major bleeding complications,degree of thrombosis, evaluated phlebographically,nonfatal intracranial hemorrhage,short- and long-term efficacy,clot lysis,level of serum glutamic oxaloacetic transaminase|We found no superiority in the regimen consisting of urokinase preceding heparin infusion, compared with that of heparin infusion alone.
150|antithrombotic efficacy,postoperative swelling,bilateral thrombosis,haemorrhagic complications,thromboembolic events,frequency of major thrombosis,wound hematoma or infection rate,deep vein thrombosis,DVT,venographycally proven deep vein thrombosis (DVT,deep venous thrombosis (DVT,pulmonary embolism,overall frequency of thrombosis,frequency of postoperative deep-vein thrombosis,occurrence of DVTs,incidence of observed bleeding complications,incidence of DVT,Bleeding and transfusions,Deep vein thrombosis,thromboembolic disease,fatal pulmonary embolism,incidence of thromboembolism,efficacy and safety,incidence of a venous thromboembolic event,rate of venous thrombosis,frequency of deep-vein thrombosis,incidence of P. E,incidence of proximal deep-vein thrombosis,thigh DVTs,postoperative thromboembolic complications,pulmonary embolism and/or deep vein thrombosis,Mortality,incidence of wound complications,protection against postoperative deep vein thrombosis,frequency of pulmonary perfusion defects,Calf and thigh circumferences,Postoperative haemorrhagic complications,Doppler ultrasonography,Efficacy and safety,Pulmonary embolism,major hemorrhagic complication,haemorrhagic complications and blood loss indices,efficacy or safety,deep-vein thrombosis,thromboembolic incidence,thromboembolic event,bleeding complications or transfusion requirements,safe; operative blood loss,frequency of thrombosis,deep venous thromboses,bleeding or other complications,overall frequency of venous thrombosis,venous thromboembolism,pulmonary embolism and venous thrombosis,Distal and proximal thrombosis,deep venous thrombosis,incidence of pulmonary embolism,Deep venous thrombosis (DVT,mean blood transfusions,deep-vein thrombosis and swelling,overall incidence of DVT,absence of propagation or tail formation,deep vein thromboses,frequency of deep vein thrombosis, in blood loss or bleeding complications,thromboembolic event incidence|There was significantly less D. V. T. in the heparinized group than in the control group (p < 0.01) and the incidence of P. E. was smaller in the heparinized group, 0 and 4 per cent respectively.
not found|physical examination, PSA assay and compilation of IPSS, IIEF-5 and EORTC-QLQ-C30/PR25 questionnaires,5-year biochemical disease-free survival rates,longer lasting rate of urinary irritative disorders and better erective function,quality of life aspects,functional outcomes|With regards to oncological outcomes, similar 5-year biochemical disease-free survival rates were reported for RRP (91.0%) or BT (91.7%).
not found|incidence of wrong-site tooth extraction,incidence of erroneous extraction,annual incidence rates of erroneous extraction,Cognitive failure,annual incidence of erroneous extraction|There was a significant difference in the incidence of erroneous extraction between the preintervention and intervention periods (P<.01).
not found|Major limb amputation,Limb salvage rate,Graft occlusions,median postoperative ankle-arm blood pressure index,Cumulative patency rates,number of patent crural arteries,primary patency,incidence of major limb amputation,history of myocardial infarction,number of patent crural vessels,overall cumulative limb salvage,bypass graft patency and limb salvage,Overall secondary patency rates,limb salvage,Primary patency rates for HUV,secondary patency or limb salvage,rest pain, ulceration, or gangrene,Secondary patency rate for HBD,cumulative 3-year patency rate,30-days mortality and complications (wound infections,prosthetic patency,died with patent grafts,long-term graft performance,patency rate,secondary patency rates,primary patency rate,previous cerebro-vascular events,preoperative risk factors and operative and postoperative treatment,primary 3-year patency for Dacron grafts,hospital mortality,secondary patency,primary "assisted" patency rate,PTFE patency rate,no perioperative (30 day) limb loss or death,ankle-brachial pressures or imaging in case of doubt,patency rates for Dacron and PTFE,cumulative 5-year patency rate,PTFE failure,5-year patency rate,Primary patency rate, measured with Kaplan-Meier survival analysis,3-year secondary patency,mortality, primary assisted patency and secondary patency,major amputation,patency rates,limb salvage rate,mortality rates,distal gangrene,cumulative primary patency rates|Miller cuffs had no effect on patency rates for femoral to above-knee popliteal bypasses at 5 years and did not improve limb salvage in either group.
                
43|Survival,Grade 3 to 4 toxicity,OS,Gastric cancer,curative resection rate,survival,year survival rate,3-year survival rates,expression rate of PD-ECGF,disease-free survival,5-year survival,cell degeneration (p<0.001), necrosis (p<0.01) and the expression of nm23 (p<0.001,ECF-related adverse effects,5-year survival rate,positive lymph nodes,numbers of deaths,Rates of postoperative complications,survival benefit,apoptotic index (AI,progression-free survival nor overall survival,complete resections with clear margins,International Union Against Cancer R0 resection rate,Expressions of nm23 and CD44,overall survival,expression rates of Fas and FasL,frequency of Fas expression,postoperative 5-year survival rate,survival rate,Resectability rates,postoperative morbidity,patient mean age, gender, white blood cell count, haematoglobin (HB),thromboplastin, perioperative complication incidence, radical or palliation resection, invasion depth (T), lymphonode involvement (N),metastasis (M) and TNM staging,number of tumour emboli,PCNA index (PI,Fas/FasL,PD-ECGF and PCNA,curative resection rate, disease-free survival, and OS,intensity of CD44 expression,Median survival,lymphatic spread,Postoperative complications,tolerated,lymph node metastases,resectability and survival,invasion depth,progression-free and overall survival,median survival,disease-free and overall survival,survival, response, and patterns of failure of trimodality therapy,UICC stages,expression rate of FasL,R0 resection rate,overall survival, tumour response, toxic effects, patterns of failure, and quality of life,Disease-free survival, relapse pattern,type of resection (R0, R1, R2, or no resection,palliative or radical resection,median survival since randomisation,Complete or partial response,stomach tumor localization,overall survival (OS,Five-year survival,alive and free of disease,median survival rates,progression-free survival,progression-free or overall survival|Survival at 3 years was 16% in arm I and 30% in arm II (P = .15).
not found|preterm delivery resulting from spontaneous preterm labor,Trichomonas vaginalis vaginal infection,Delivery,birth weights and gestational age at delivery,delivery before 37 weeks of gestation|The birth weights and gestational age at delivery were similar in all three groups.
812|mean number of severe exacerbations,exacerbations,Morning PEF,morning peak expiratory flow rate (PEF); transition dyspnea index; chronic respiratory disease questionnaire; chronic bronchitis symptom questionnaire; exacerbations,prolonged time to first exacerbation,daily symptoms,tolerated relative,efficacy and tolerability,symptom scores and use of reliever beta2-agonists,frequency of adverse events, bruising, or clinically significant falls in serum cortisol concentration,efficacy and safety,lung function measurements, symptoms and rescue treatment use, the number of exacerbations, patient withdrawals, and disease-specific health status,Dyspnoea scores and HR-QOL,predose FEV(1,morning lung function,efficacy for pulmonary function,lung function and health status,mean prebronchodilator forced expiratory volume,Transition Dyspnea Index,adverse events, serum cortisol concentrations, skin bruising, and electrocardiograms,number of exacerbations resulting in hospitalization,severity of dyspnea,Postmedication FEV1 improved by 0.21 L and health-related quality of life using the St George's Respiratory Questionnaire (SGRQ,pretreatment forced expiratory volume in 1s (FEV1,lung function, symptoms, and health status and reduced use of rescue medication and frequency of exacerbations,tolerated,FEV1,morning predose (ie, trough FEV(1)) for FSC compared with SM and 2-h postdose FEV(1,Efficacy and safety,average daily morning PEF,morning predose FEV(1,incidence of pneumonia,2-hour postdose FEV(1,lung function,adverse effects,Severe exacerbations and FEV1 (primary variables), peak expiratory flow (PEF), COPD symptoms, health-related quality of life (HRQL), mild exacerbations, use of reliever beta2-agonist and safety variables,dyspnea, quality of life, and symptoms of chronic bronchitis,pretreatment FEV1,incidence of individual non-fatal serious adverse events,Dyspnoea (measured using the Breathlessness Diary) and health-related quality-of-life (HR-QOL) scores (based on the St George's Respiratory Questionnaire total score,2-h postdose FEV(1,pre-dose forced expiratory volume in 1 second (FEV(1)) and 1-hour post-dose FEV(1,health status,efficacy,prebronchodilator peak expiratory flow|Morning PEF improved significantly on day 1 versus placebo and budesonide; after 1 week, morning PEF was improved versus placebo, budesonide and formoterol.
15|detectable ELISA anti-HAV antibodies,attack rate,cumulative attack rate for hepatitis A,incidence rates,quantitative anti-HAV response,Anti-HAV seroconversion,Symptomatic infection,geometric mean titer of antibodies,RIA seropositivity in iHAV vaccines,anti-HAV seroconversion,safety, tolerability, and immunogenicity,Safety, tolerability, and immunogenicity,attack rates|Administration of a booster dose given 1 or 2 months after primary immunization did not significantly improve the quantitative anti-HAV response at 6 months as compared to the effect of the primary dose.(ABSTRACT TRUNCATED AT 250 WORDS)
not found|A1C test ordering,osteoporosis medication prescribing,quality of care,Blood pressure data,number of radiograph requests,total charges,Overall attitudes of Dutch and Norwegian doctors,cervical cytology history,cost of tests per patient ordered,communication skills,lumbar decompressions,prescribing of lipid lowering drugs,total length of stay and ICU length of stay fell,quality of rural ICU care,cumulative PPV claims coverage,Information-giving and communication skills,patient care processes (lab work, nursing, dietary management, ventilator management, ventilator weaning,health care provider behavior,proportion of elderly survivors of AMI,physician performance,total tests,hypertension, peptic ulcer/dyspepsia and depression,number of consultations involving AIDS prevention and the number of talks about AIDS initiated by the GP, and some elements of the content were registered on a chart,compliance rates with evidence-based recommendations pertaining to discussion of body weight control, discussion of problems with medication, blood pressure measurement, foot examination, eye examination, initiating anti-diabetic medication or increasing the dosage in cases of uncontrolled blood glucose, and scheduling a follow-up appointment,eye examination,glycemic control,mean total number of tests ordered by physicians,Moderate rates of improvement,prescription rate,per cent of time,Referral and completion rates,Median weighted rates of generic prescribing,acute myocardial infarction (AMI) care,facility-specific mean urea reduction ratio (URR,quality of selective case finding and quality of diagnostic procedures,peritoneal dialysis,overall intern-documented cholesterol management,objective assessment of attacks,HbA1C testing rates,overall chlamydia testing (odds ratio (OR) ,individual process-of-care indicators, a hospital report card impact survey, and all-cause AMI and CHF mortality,rates of preventive services,chlamydia screening,proportion of oral corticosteroid use for exacerbation treatment,malaria and diarrhoea,prescribing preferences,LDL testing,special blood chemistry,rates of practice specific PPV coverage,Compliance rates,SBP,RBC transfusions,physician documentation and knowledge of child sexual abuse,rates of three screening behaviors (cholesterol, blood pressure, and cervical screening,duration of pain, prior history of low back pain, and number of visits,cotinine levels,accurate classification of hazardous or harmful alcohol drinkers,Glycosylated hemoglobin (HbA1C) measurements,clinical and histologic diagnosis, and excisions of skin lesions,systolic blood pressure (sBP) and LDL cholesterol,inappropriate prescribing according to the Medication Appropriateness Index (MAI,rates of influenza immunization,adjusted prescription rates,mammography utilization,performance of clinical breast examination,adequate surgical excision of skin lesions,proportions of patients dialyzed with prescribed blood flow,percentage of smears lacking endocervical cells,physician compliance,tetanus immunization,mean percentage reduction,influenza immunization,mean proportion,technical quality of data,total prescribing charges,mean number of encounters with an inappropriate antibiotic with respect to diagnosis, doses and/ or duration of therapy,acute ischemic stroke care quality,statin prescribing,vaccination rates,acetylsalicylic acid,rates of GIOP management,Task performance,NSAID-related safety practices,number of targeted tests requested by primary-care practices,hospital ventilator days,asthma education and peak flow meter usage,risk of falls and fractures, motor vehicle accidents and cognitive impairment,total number of requests per practice,diabetes outcomes,rates of foot examination and eye examination,Guideline adherence,acute, in-hospital, or discharge care,guideline-consistent behavior,Postintervention immunization levels,guideline adherence and resource utilization,compliance rates,LDL,time spent in target INR range,pneumococcal vaccination rates,blood pressure screening,rate of antibiotic prescribing for all indications, for URTI and prescribing of select antibiotics for tonsillitis/streptococcal pharyngitis,post-intervention 'out-of-control' episodes,unscheduled emergency visits,efficacy of QCs,continuity and medical care,SMA-6s,WA-MRSA rates,proportion of long-acting benzodiazepine prescriptions,Antibiotic prescribing,diastolic pressure,Counseling rates,Hemoglobin A1c and lipid monitoring, and the achievement of intermediate clinical outcomes (hemoglobin A1c <7.0%, LDL cholesterol <100 mg/dL, and blood pressure,proportion of episodes with antibiotics,glycated hemoglobin (HbA1c) levels,quality of management of oral anticoagulation,length of in-hospital stay, physician visits after discharge, waiting times for invasive cardiac procedures, and readmissions for cardiac complications,charges, SMA-6, or complete blood cell counts (CBCs,number of tests per patient ordered,Minimum Data Set (MDS,test usage and cost savings,antibiotic prescribing,number of patients with hemoglobin A(1c,Delivery of individual emergency plans,A1C values,asthma steps,initial blood pressure,influenza and pneumococcal immunisation rates,low-density lipoprotein (LDL) cholesterol level, blood pressure, annual hemoglobin A(1c) testing, annual LDL screening, annual eye exam, annual foot exam, and annual renal assessment,Mammography,proportion with peak flow,pneumococcal immunization,reduced emergency visits,mean systolic pressure,BMD testing or osteoporosis medication prescribing,Patient satisfaction scores,overall cost,angina pectoris,median prescription cost,total number of encounters with antibiotics,final HbA1c (A1C) with feedback + reminders,number of inappropriate prescriptions,Time to next visit,rates of BMD testing,CHF quality indicators,rates of skin cancer prevention counseling,baseline performance,number of requests,Mean blood pressure,preventive cardiovascular care,quality,mean charge for a prescription,lower costs for carotid endarterectomies,risk factors (blood pressure, cholesterol, and smoking status); prescribing of hypotensive agents, lipid lowering drugs, and antiplatelet drugs; blood pressure, serum cholesterol level, and plasma cotinine levels,cost-effectiveness ratio,health care quality,Care quality,glucose control, cholesterol level, and triglyceride level,quality indicators,ordering of laboratory and radiologic tests,prescription rate recordings,LDL cholesterol values,malaria, diarrhoea and pneumonia,compliance with other recommendations, patient satisfaction and costs of the implementation strategy (secondary outcomes,mean number of tests per physician,vaginal birth rates,requests for spinal examinations,tonsillitis/streptococcal pharyngitis,antibiotic prescription rate and 2) the fraction of prescriptions for narrow-spectrum antibiotics,low hemoglobin levels,quality or safety of diabetes care and worsened A1C control,diabetes care processes,Immunization rates,beta-blockade,antibiotic resistance,Odds ratios (ORs,response to an asthma symptom questionnaire or the Seattle Angina Questionnaire, and levels of patient satisfaction,Overall compliance,Mammography, breast exam, colorectal screening, and Pap testing compliance rates,Medication appropriateness,red blood cell (RBC) transfusions,fecal occult blood testing, pneumococcal vaccination,attainment of American Diabetes Association goals,risky prescribing events,Median prescribing rates,Mammography rates,total cholesterol,Behavior changes,patient care processes, patient morbidity and mortality outcomes, and resource use,mean overall physical examination rating,rate of adherence,practice performance,CBCs,QIs measuring falls, behavioral symptoms, little or no activity, and pressure ulcers,cholesterol management,AMI care,bone mineral density (BMD) testing and osteoporosis medication prescribing,quality of cardiac care,hypertension,IMA intervention sites,influenza vaccination,LDL cholesterol test ordering,clinical outcomes of mortality or nosocomial events,overall cesarean section rate,missed immunization opportunity rates and appointment failure rates,immunization level,genital tract infection,percentage of records containing at least one periodontal diagnostic notation,time on dialysis,influenza and pneumococcal vaccination rates,glycemic, lipid and blood pressure control,inappropriate transfusions,serum cholesterol and triglycerides,adjusted mortality,performance scores,mean change in MAI and number of medications,effectiveness and cost-effectiveness,Kruskal-Wallis test, Mann Whitney test, Wilcoxon test and Chi-square test,rates of BMD testing and osteoporosis medication prescribing,Request numbers,internal QI,clinical data and receipt of complete blood count (CBC), creatinine testing, and cytoprotective agents (process measures,diagnoses of hypertension,cost of unnecessary tests,Delayed feedback of physician performance,quality assurance intervention, quality of performance,Duration of hospital stay,transfusion appropriateness,overall antibiotic prescribing,diabetic population,post-intervention chlamydia testing rates,hospital mortality rates for CHF,recording of peak flow,blood cholesterol levels,mean 30-day AMI mortality rates,mean total number of requested tests per 6 months per physician,blood pressure control,time in total compliance scores,overall glycemic control,Actual performance of audits improved ordering of mammography,Mean scores per CEP dimension,costs per practice,Diagnostic performance,provider behavior and lowered HbA1c levels,mean total number of inappropriate tests,fractional prescribing rates for proton-pump inhibitors,cost-effectiveness,total preventive health, diabetes, hypertension, and total disease management,Rates of delivery of selected preventive services,frequency of consultations involving AIDS prevention,Rationality,quantity of cholesterol testing,quality of cervical smears,hemoglobin A1c testing,telephone referrals,change in fraction of asthmatics treated with inhaled steroids and incidence rate of treatment with inhaled steroids,physician's median antibiotic cost and proportion of episodes of care in which a prespecified first-line antibiotic was used first,G1 average treatment cost,intern documentation concerning a low-fat hospital diet, cholesterol history, screening blood cholesterol level assessment,Quality circles (QCs,generic prescribing,Prescribing rates,systolic blood pressure,composite AMI and CHF indicators based on 12 AMI and 6 CHF process-of-care indicators,prescribing behaviour,cholesterol screening,compliance,urinary tract infection,SMA-12s,provision of preventive care,prescribing preference for thiazides,quality of documentation and physician knowledge,emergency visits,sustained control of hypertension,safety or quality of diabetes care,hemoglobin A(1c) level,venous thromboembolism,quality of osteoporosis care,End-stage renal disease (ESRD,Physician questionnaires,clinical breast examination,lumbar spine,mean center URR,risk factors,mortality rates,hemoglobin A1c, low density lipoprotein-cholesterol and systolic blood pressure,upper abdominal complaints,Practice facsimile (fax) referrals,meeting patient preferences, metabolic status, and complication rates|Centralized mailings of guideline summaries, performance feedback reports, and chart reminders had no observable impact on quality of care in this setting.
92|Peak serum netilmicin concentrations,Mean trough concentrations,bacteriologic failures,Bacteremia,successful eradication,overall cure rate,symptomatic reinfections,reduction in inflammatory indices, and percentage with sterile urine,bacteriological efficacy (sterilization of the urine), and biological efficacy,urinary tract infection (acute pyelonephritis or cystitis,recurrence rate of first lower UTI,Total or partial persistence of renal abnormalities,Peak serum levels,prevalence of scarring,efficacy and safety,no relapse,Rates of cures and recurrence,bacteriologic eradication,duration of hospitalization,Drug-related clinical adverse events,GOT and 1 with increased GPT,urinary tract infections,Nephrotoxicity,Renal scarring,GPT,Rates of efficacy by severity, presence or absence of underlying and/or complication diseases, daily dose and causative microorganisms,Mean costs,rate of recurrent infection,Eradication rates,therapeutic effect and usefulness evaluated by physicians in charge,mean extent of scarring,safety and efficacy,radiological abnormality,bacteriologic efficacy,rate of reinfection,health care expenditure,Bacteriologic eradication,nephro- or ototoxicity,time-courses of improvement of clinical signs and symptoms,Clinical and bacteriological response rates,frequency of side effects,Trough serum levels,Ototoxicity,Clinical efficacy,Mean peak gentamicin concentrations,circulatory compromise and renal cortical scintigraphic defects,percentage of patients with sequelae,satisfactory clinical response,persistent infection, and 6 infection relapses,rate of renal scarring,efficacy and tolerance,urine culture,Median gentamicin treatment durations,history of recurrences,suppression upon rectal,Therapeutic effectiveness rates,blood cell count, and erythrocyte sedimentation rate (P>.05,upper urinary tract infection,resolution of vomiting, fever, general appearance, abdominal tenderness, and hydration state (P>.05,serious adverse effects,development of renal scarring,trough level,recurrence rate,urine sterilization rate, degree of clinical improvement, or subsequent hospital admission rate,white blood cell count and erythrocyte sedimentation rate,renal scarring,recurrence of urinary infection,Late DMSA,mean time to defervescence,severity of the urinary tract infection (risk of renal scars,serum creatinine level|In group B, the percentage of patients with sequelae was significantly higher (P<0.01) when the delay was more than 1 week.
not found|Overall, nasal CPAP,Failures,likelihood of extubation failure,severe apnea and/or respiratory failure,ventilator rate of 6/minute,successfully extubated to NCPAP,oxygen dependency,overall success rate of early extubation,mean respiratory rate,clinical characteristics,respiratory acidosis,oxygen requirements,failure rate,individual successful extubation rate of post-extubation,oxygen requirement greater,severe apnea, or predefined clinical deterioration, and extubation success,PaCO2 values,respiratory distress syndrome,alveolar-arterial oxygen gradient,Postextubation nasal continuous positive airway pressure,failure rates,pulmonary status, fraction of inspired oxygen (FIO2,Extubation failure,failure rate of extubation,FiO2, PaO2, and respiratory rates,stable condition, fraction of inspired oxygen (FIO2) of < or = 35%, peak inspiratory pressure (PIP,total number of days of ventilation,birth weight and duration of intubation,intraventricular haemorrhage rate,total number of days of assisted ventilation or the duration of inpatient stay,apnoeas and respiratory acidosis requiring rescue nasal CPAP,rates of successful extubation|There was no significant difference between the groups in the total number of days of assisted ventilation or the duration of inpatient stay.
                
not found|neurodevelopmental benefits,Transcutaneous oxygen tension (tcPO2) and heart rate,proportion of infants with recurrent hypoxaemic episodes,gestational age, birth weight, delivery mode, sex distribution, and Apgar scores,mean proportion of infants with more than six hypoxaemic episodes,mean serum concentration ,Odds ratios,bradycardia,death or disability,hypoxaemic episodes,transcutaneous PO2|The size and direction of the caffeine effect on death or disability differed depending on PPV at randomization (P = .03).
260|average daily calcium intake,hypertensive disorders of pregnancy (gestational hypertension and preeclampsia,low birth weight,Urinary excretion of calcium and creatinine,risk of preeclampsia and preterm birth,hypertensive disorders,risk of hypertension and preeclampsia,Preeclampsia,mean systolic and diastolic blood pressures,low ratios of urinary calcium to urinary creatinine,blood pressure and urinary protein excretion,duration of pregnancy,systolic and diastolic blood pressure,preeclampsia,incidence of pregnancy induced hypertension,Compliance,early preterm delivery,pregnancy-induced hypertension,blood pressure,reduction of pre-eclampsia,severity, maternal morbidity, and neonatal mortality,Blood pressure (BP,calcium intake and BP reduction,pregnancy induced hypertension,Eclampsia,incidence of pregnancy-induced hypertension,risk of both gestational hypertension and preeclampsia,incidence or severity of preeclampsia or delay its onset,risk of preeclampsia,incidence of preeclampsia,preeclampsia, pregnancy-associated hypertension, or adverse perinatal outcomes,incidence of preterm delivery,Dietary calcium intake,initial blood pressure (BP,systolic/diastolic blood pressure,frequency of pregnancy-induced hypertension, preeclampsia and preterm birth,diastolic and systolic blood pressure,severe preeclamptic complications index,severe gestational hypertension,neonatal mortality rate,rate of pregnancy induced hypertension,occurrence of pre-eclamsia,diagnosis of preeclampsia,incidence of gestational hypertension,prevalence of pregnancy-associated hypertension without preeclampsia,hypertensive disorders of pregnancy,hypertension,risk of preterm birth,severe maternal morbidity and mortality index,numbers of preterm deliveries, small-for-gestational-age births, or fetal and neonatal deaths,spontaneous labor and preterm delivery,preterm birth,Pre-eclampsia,risk of pregnancy-induced hypertension,mean systolic and diastolic BP value,urinary tract infection, and chlamydial infection,preeclampsia and preterm delivery; secondary outcomes focused on severe morbidity and maternal and neonatal mortality rates,systolic BP,frequency of pregnancy-induced hypertension,rates of hypertensive disorders of pregnancy,serum ionized calcium levels,mean duration of calcium supplementation|Calcium supplementation was associated with a significantly decreased risk of preeclampsia (risk reduction 12.35%; P < .001), with 3.2% (n = 4) developing preeclampsia in the treatment group versus 15.5% (n = 21) in the placebo group.
105|success rate|The effect of ZBD is superior to that of progesterone in treating women of early threatened abortion with dark area surrounding pregnancy sac.
not found|baseline FEV1 and prevented exercise-induced bronchoconstriction,histamine responsiveness,bronchoconstrictor response,Gaw/VL,FENO measurements,reduction in bronchoconstriction,serum caffeine concentrations,forced expiratory flow,airway reactivity,exhaled nitric oxide measurements,exercise-induced bronchoconstriction,pulmonary function,tolerated,caffeine consumption increases or decreases FENO,Serum caffeine levels,peak theophylline level,Exhaled nitric oxide (FENO) measurements,serum levels of caffeine and theophylline, forced expired volume and flow, specific airway conductance (Gaw/VL), vital signs, and reported symptoms,average peak serum concentration,FENO,bronchoconstriction,Peak caffeine concentration|Caffeine (10 mg/kg) significantly reduced bronchoconstriction compared to placebo (p = 0.02).
112|adverse events,Mini-Mental State and the SCAG score,MMSE scores (ITT and VC,mean total SCAG score,Benton Visual Retention Test, P = 0.002) and attention and concentration (Letter Cancellation Test,Global improvement (CGI item 2,Clinical Global Impression, 3 subtests of the Weschsler Adult Intelligence Scale and Blessed A scale for activities of daily living, and all endpoints in 2-month intervals,WAIS-R Digit Symbol subtest,efficacy and safety,therapeutic efficacy and safety,Tolerance of nicergoline,delta and theta, increase in alpha 2 and beta activity and an acceleration of the centroid of the total power spectrum,nine neuropsychological tests exploring memory, concentration, verbal and motor performances,P300 latency,Rezek score,delayed recall of the Auditory Verbal Learning Test (AVLT,memory function (AVLT short term recall,Sandoz Clinical Assessment Geriatric Scale (SCAG) and Mini-Mental State Examination (MMSE) scores|EEG mapping demonstrated in NIC-treated SDAT and MID patients a significant decrease in delta and theta, increase in alpha 2 and beta activity and an acceleration of the centroid of the total power spectrum as compared with pretreatment, while opposite changes occurred in PLAC-treated SDAT and MID patients.
80|Complications of cirrhosis and worsening of the performance status test,survival,Response,baseline performance status maintenance,progression of hepatocellular carcinoma,baseline performance status, and tumor stage,Cumulative survival,Adverse drug reactions,probability of disease progression,complete remission,1-month mortality rates,Median survival,tolerated,survival rates,median survival,Survival curves,survival outcome,tolerated and no marked side effects,1-year survival rate,median survival times,risk of death|The 1-year survival rate was similar in both groups (30% in group 1 vs 37.8% in group 2; p = 0.31).
76|nausea,rates of major postoperative complications,Pneumonia,length of hospital stay,Postoperative fever,first passage of stool,Length of hospital stay,hospital stay,morbidity and delayed return of gastrointestinal function,Overall failure rate,subsequent insertion of a nasogastric tube,Mechanisms of injury, Injury Severity Score, operative findings, NGT removal times, morbidity, laboratory data, and reasons for failure,longer times to first passage of flatus and tolerance of a clear liquid diet,subsequent nasogastric decompression,earlier bowel sounds, return of flatus, oral intake and first bowel movement,hematological indices and electrolytes,pharyngolaryngitis,history of upper gastrointestinal bleeding and pyloric obstruction,intensive care unit stay,pneumonias,incidence of vomiting and nasogastric tube insertion,occurrence of postoperative nausea, vomiting, abdominal distension, complications and day of clinical release,hospital mortality,average daily nasogastric output,Duration of postoperative stay,Overall failure,median and average days to the first passage of flatus,Major complications, eg, pneumonia, atelectasis, gastrointestinal bleeding, and wound breakdown or infection,nasogastric decompression,Clinical therapeutic outcome and incidence of complication,medical morbidity,pulmonary infection,duration of ileus,volume of gastric juice,incidence of vomiting or the duration of intubation,overall postoperative mortality,postoperative fever, nausea, vomiting, anastomotic leaks, or pulmonary or wound complications,incidence rate of fever, pharyngolaryngitis and pulmonary infection,premature removal of the tube,length of the first passage of gas by anus and defecation,postoperative nasogastric decompression,severe discomfort,Time to passage of first flatus, time to taking liquid diet, length of operation, and postoperative hospital stay,rate of reinsertion of nasogastric tube and morbidity,operative times,Abdominal distention,incidence of vomiting,pain, abdominal distention, and vomiting,Gastrointestinal decompression,longer time until passage of flatus, bowel movement, and cessation of intravenous fluids,incidence of pharyngolaryngitis,postoperative complications,risk of pulmonary complications,risk of respiratory complications and the length of hospital stay,postoperative mortality or morbidity, especially fistula or intra-abdominal sepsis,shorter postoperative stay,nasogastric reintubation,Postoperative abdominal distention,vomiting,Complications,morbidity and mortality and hospital stay,Hindered deglutition and nasal soreness,occurrence of respiratory complications,gas passage, defecation and bowel sounds (BSs) auscultation, as well as the duration of postoperative hospitalization, nausea and vomiting, abdominal distension, pulmonary complications, wound complications, anastomosis leak, and the need for placing/replacing the NG tube,overall surgical complications,abdominal distention, nausea, and vomiting,time to tolerance of a regular diet and hospital stay,mean+/-SD time to passage of flatus,incidence of nasogastric tube insertion,nasopharyngeal or gastric bleeding, inability to cough effectively, respiratory infections, wound disruptions, reoperation, and wound infection rates,return of bowel function, return to a regular diet, and postoperative length of hospital stay,nasogastric intubation,febrile morbidity,fever,overall incidence of complications,abdominal distension, pyrosis, otalgia, dysphagia, odynophagia and atelectasis,mean length of hospitalization,postoperative complications, mortality, and postoperative course,Passage of flatus,postoperative abdominal distention and vomiting,occurrence and duration of nausea and vomiting, postoperative peroral fluid intake and time for defecation,Severe discomfort,gastrointestinal tract pressure,tolerance of NGT withdrawal and postoperative complications,time until the first bowel movement,nausea postoperatively,emesis,prolonged operating times, or difficult endotracheal intubation,Gastrointestinal function, postoperative course, and complications,nausea and vomiting,earlier passage of flatus and feces and the lower incidence of postoperative gastrectasy,length of hospital stay, duration of postoperative ileus, adequacy of intraoperative intestinal decompression, gastric dilatation, and operative complications,feasibility, safety, and tolerance of early feeding,length of hospitalization,incisional hernias,length of postoperative stay,Rates of nausea and vomiting,acute dilation of stomach,Anastomotic disruption,tolerated,start of oral intake,postoperative ileus,incidence of complications,postoperative length of hospital stay,feasibility, safety, and tolerance,incidence of incisional hernia,frequencies of postoperative complications,atelectasis,decompression,occurrence of nausea and vomiting,incidence of postoperative complications,recurrent nausea and vomiting,nausea, vomiting, time to first passage of flatus and stool, time elapsed before adequate tolerance of a regular diet, postoperative stay, and complications,Duration of postoperative perfusion,rates of anastomotic leak,Injury severity score, morbidity, and lab values,aspiration pneumonia, gastric dilatation, or wound dehiscence,rate of minor symptoms of nausea, vomiting, and abdominal distention,duration and severity of postoperative paralysis,time to first passage of flatus, the time to first passage of stool, the time elapsed postoperative stay, and postoperative complications such as anastomotic leakage, acute dilation of stomach, wound infection and dehiscense, fever, pulmonary infection and pharyngolaryngitis,pulmonary complications,incidence of mortality, complications (including vomiting) or time to return of intestinal motility,Time to pass flatus,reinsertion rate,incidence of anastomosis leak,Morbidity, mortality, and speed of recovery,incidence of abdominal distention or nausea and vomiting,Preoperative risk factors, aortic cross-clamp time, estimated blood loss, length of procedure, length of intensive care unit stay, numbers of days with nasogastric tube, number of days until clear liquid and regular diets commenced, and the length of hospital stay,subjective complaints, eg, ear pain, painful swallowing, and nasal soreness,rate of abdominal distention, nausea, and vomiting,adverse events,mean time of gas passage, defecation, BS auscultation, and the duration of postoperative hospitalization,feasibility and safety,vomiting or abdominal distention,wound complications,postoperative complications such as anastomotic leakage,nasogastric output,sore throat,presence of atelectasis, postoperative fever, wound infections and anastomotic leaks,pain with and frequency of swallowing, and nose/throat discomfort,postoperative pain, or postoperative abdominal distention,Postoperative loss of fluid,duration of hospitalization, time to begin peroral fluid intake, occurrence of hiccups, vomiting, nausea, parotiditis, nasal septum necrosis, anastomotic leak and wound dehiscence,Postoperative course, morbidity, and mortality|The return of bowel function, return to a regular diet, and postoperative length of hospital stay were similar in both groups.
400|Symptomatic intracranial hemorrhage,bleeding complications,asymptomatic hemorrhagic lesions,rate of symptomatic hemorrhage,major intracranial hemorrhage,distribution of outcomes at 3 months after stroke using the modified Rankin Scale (mRS) based on an ordinal regression model of outcomes, adjusting for baseline severity of stroke, age, and interval from stroke,higher rate of minimal residual disability,mRS scores,Asymptomatic parenchymal hemorrhages,Asymptomatic hemorrhagic transformation|Symptomatic intracranial hemorrhage within 5 days was diagnosed in 7 of 195 (3.6%) patients treated with abciximab and 2 of 199 (1%) patients given placebo (odds ratio [OR], 3.7; P=0.09; 95% confidence interval [CI], 0.7 to 25.9).
69|nausea,clinical efficacy and safety,UPDRS sum scores,Mean daily Sinemet dosage decreases, time increased (1.7 h) and 'off' time,efficacy, Parkinsonian symptoms,change in hours and percent of daily "on" time and "on" time without troublesome dyskinesia, Unified PD Rating Scale motor and activities of daily living subscales, Beck Depression Inventory-II, PDQ-39 subscales of mobility, activities of daily living, emotional well-being, stigma and communication, and PD Sleep Scale,UPDRS total scores, subscores part II, III (activities of daily living and motor examination), and IV (complications of therapy,Dopamine antagonistic actions,Unified Parkinson's Disease Rating Scale (UPDRS,efficacy and safety of Zydis selegiline,levodopa/benserazide in walking speed, stride length and the range of motion of hip, knee and ankle joints,Unified Parkinson's Disease Rating Scale Subscale II,absolute change in total hours "off" (assessed by home diaries,Levodopa dosage,platelet MAO-B inhibition,total scores of the UPDRS Part II, Part III, and Parts II and III combined,levodopa dosage,daily OFF time,Unified Parkinson's Disease Rating Scale (UPDRS) parts II and III,Disability,Dryness of mouth, urine discoloration and diarrhoea,percent "on" time,dopaminergic and nondopaminergic adverse events,safe and well tolerated,five-dimension questionnaire (EQ-5D,daily off time,employment rate,Mean scores,wearing-off phenomena and frozen gait,UPDRS activities of daily living and motor scores,Unified Parkinson's Disease Rating Scale (UPDRS) part II activities of daily living (ADL) and the Parkinson's Disease Questionnaire (PDQ)-39 summary index,UPDRS scores,hepatic enzyme activity, ECG or haemodynamic parameters,nausea, cramps, dyskinesia, and dystonia,subitems motivation/initiative and depression in a subpopulation with increased Unified Parkinson's Disease Rating Scale I scores,unified Parkinson disease rating scale (UPDRS), and recording of daily levodopa dose,total "on" time,Principal adverse events (mainly dyskinesia and nausea,Efficacy, safety, and tolerance,fatigue, dyskinesia, and vivid dreams,Motor Examination,bradykinesia,mean reduction in daily "off" time,off-periods,nausea, light-headedness, dyskinesias, and hallucinations, all of which abated after the Sinemet dose,motor fluctuations and PD symptoms,safety, tolerance, and efficacy,total Parkinson's score, scores of activities of daily living, motor function, number of "off" hours, Hoehn and Yahr stage, and numerous parameters of parkinsonian function including bradykinesia, rigidity, gait, and dexterity,wearing off and symptom severity,advanced PD,mean reduction in L-dopa requirement,safety and tolerability,side-effect,Responder rates,hours "off,Frequency of adverse events,therapeutic effectiveness,number of daily levodopa intakes,effective and well tolerated,improvement of "on" and "off" time while awake (Patient Diary and UPDRS part IV Item 39), Investigators' Global Assessment, the SF-36 Health Survey, and changes in levodopa dosages,levodopa requirement,mean total daily levodopa dose,levodopa requirements,Adverse reactions,quality of life (sickness impact profile) scores,efficacy, safety,PDQ-39 subscores, the SF-36 variables or the EQ-5D utility score,severity of "off" periods, decreased disability and PD severity,activity and tolerability,Mean hourly overall symptom control,daily levodopa dose,total number of off hours,parkinsonian disability and health-related quality of life (QoL,Efficacy and safety,Efficacy and tolerability,daily on-time without troublesome dyskinesia,mean percentage of "Asleep" time,number of discontinuations,total Unified Parkinson's Disease Rating Scale (UPDRS) score,total daily off-time (intention-to-treat population,ADL scores,levodopa,Aggravated parkinsonism,Bromocriptin dosage,duration of off periods as assessed by self-scoring diary cards,ADL, global function, motor performance and was well tolerated,gastrointestinal and cardiovascular tolerability,percentage of "on" time (relief of parkinsonism,reduction in hours of daily "off" time,Mean UPDRS total score,frequency of withdrawals because of adverse events,motor function and overall efficacy,UPDRS part II,Increased dyskinesias,somnolence,motor fluctuations,UPDRS motor scores,proportion of daily ON time,cardiac or electrocardiographic abnormalities,nonserious dopaminergic adverse events,efficacy and tolerability,quality of life and activities of daily living,mean UPDRS total scores,Total score on the Unified Parkinson's Disease Rating Scale (UPDRS,rasagiline treatment, including scores on an investigator-rated clinical global impression scale and the Unified Parkinson's Disease Rating Scale (activities of daily living in the off state and motor performance in the "on" state,Dopaminergic adverse events,adverse reactions,dizziness, insomnia, nausea, and postural hypotension,levodopa requirements, improvement in patients' clinical status, duration of improvements, and tolerability of tolcapone,United Parkinson's Disease Rating Scale motor subscale and "on/off" and dyskinesia assessments,Dyskinesia,mean daily levodopa dose,tolerated,side effects (orthostatic hypotension, exogenous psychotic symptoms,motor function,Mean hourly self-assessment of gait,total score of the unified Parkinson's disease rating scale (UPDRS,Unified Parkinson Disease Rating Scale,time spent in "off" periods,adverse effects,Activities of Daily Living,safety and tolerability profile,total score of the Webster and the NUDS scales,both motor and non-motor PD symptoms,average number of dyskinesia-free,dyskinesia,vital signs, ECG or laboratory results,clinical laboratory test results (blood chemistry, hematology, and urinalysis), vital signs, and electrocardiograms,dyskinesia and nausea,adverse events, vital signs, laboratory measurements, and ECG recordings,safety data,mean daily levodopa dose requirement,toxicity, fluctuations,objective quality of the "on" state,CGI scores,mean daily off-time,Entacapone efficacy,clinical global improvement (CGI) score and unified Parkinson's disease rating scale (UPDRS) scores, time,overall safety profile,UPDRS (activities of daily living; ADL,number of full-time-employed patients at study end, cumulative days of medical absenteeism, patient-completed disability assessments, diary records, and the Unified Parkinson's Disease Rating Scale-based measures of motor fluctuations and dyskinesias,stride length and angular excursion of the hip and knee joints,Diarrhea,Employment, medical absenteeism, and disability perception,safety evaluation of adverse events (AEs), vital signs, ECG, and laboratory parameters,Efficacy,number of "off" hours,efficacy and safety,beneficial response,average Hoehn and Yahr stage of disease, and Schwab and England activities of daily living index,activities of daily living, motor function, state,Adverse events,Global Assessment of Change, PDQ-39 subscores, and the Short-Form (SF)-36 and the European Quality of Life,safety, tolerability,mean daily L-dopa dose,wearing off,mean adjusted total daily off time,unified Parkinson's disease rating scale motor and total scores,Efficacy, safety, and tolerability,Safety and tolerability,UPDRS part III (motor) scores,percent awake time spent "off,dyskinesia, nausea, dizziness, somnolence, hallucinations, and orthostatic hypotension and AEs led to study withdrawal,dyskinesias,UPDRS "overall dyskinesia score,rasagiline efficacy and safety,adverse events, laboratory safety and vital signs,total levodopa requirements,mean daily off-time and improves symptoms of Parkinson's disease,occurrence of drug-related adverse events,lower absenteeism rate,home diaries ('on' and 'off' times), Unified Parkinson's Disease Rating Scale (UPDRS) and changes in levodopa dosage, and safety by adverse-event inquiry, vital signs, electro cardiography (ECG) and laboratory tests,absolute ON time (mean (SD,off" time,retirement rate,safety, tolerability, and efficacy of rasagiline,self-perception of disability progression,quality-of-life measures,side effects|Total score on the Unified Parkinson's Disease Rating Scale (UPDRS) for the intent-to-treat population was significantly improved in the pramipexole-treated group compared with the placebo-treated group (16.9 +/-
60|fasting plasma glucose (FPG), lipids, body mass index (BMI), body composition, blood pressure, insulin sensitivity estimates using the minimal model, glucose and insulin responses to a meal challenge, quality of life, adverse events, or other safety indices,safety and effectiveness,fasting glucose,HbA1c, fasting glucose, lipids, blood pressure, and weight,efficacy and safety,liver enzymes, kidney function tests, hematologic parameters, blood glucose, insulin, and C-peptide assays,glycosylated haemoglobin (HbA1c) and fasting blood sugar (FBS), alteration of lipid profile by serum cholesterol, LDL, VLDL, HDL and triglycerides,glucose control,HbA(1c,low-density lipoprotein (LDL) cholesterol,tolerated,total cholesterol,change in HbA(1c,levels of fasting and postprandial blood glucose, cholesterol, triglycerides, glycated hemoglobin (Hb A(1C)) and fasting insulin,satisfactory and no adverse effects,liver function tests, hematologic parameters, or the kidney function tests,hypoglycemic effect,mean change, with Inolter, in serum cholesterol,fasting blood sugar,serum triglyceride,HbA(1c) reductions,HDL|Cogent db did not alter the liver function tests, hematologic parameters, or the kidney function tests.
                
not found|hyponatremia,Blood chemistry, liver, kidney and endocrine functions,adephagia obesity and cerebral infarction,severe complications,Blood chemistry, liver, kidney, pituitary and endocrinal functions,index and lactate dehydrogenase (LD) of the cystic fluids, blood and cerebrospinal fluids and the endocrine function|At follow-up, the volumes of the cysts in groups A and B regressed from 92 to 0%, while the drug-free cysts enlarged.
not found|Fatal falls,incidence of occupational injuries,rate of falls from height,injury rates,fatality rate,rate of decline in falls,fatal falls,cost savings,mean cost per fall,overall injury rates,rate of fatal injury,fatal construction falls|The drug-free workplace intervention was associated (p < .05) with a statistically significant decrease in injury rates for three industry groups: construction, manufacturing, and services.
not found|mean Crohn's Disease Activity Index and quality-of-life scores,full remission,plasma orosomucoid levels,Disease activity,serious adverse events,median time to worsening of disease,use of prednisone and 5-amino-salicylates, mean score on the Crohn's Disease Activity Index and mean quality-of-life score, and the need for surgery,clinically important worsening of Crohn's disease, defined as a 100-point increase in the Crohn's Disease Activity Index,Crohn's Disease Activity Index|The condition of more patients worsened with cyclosporine than with placebo (91 of 151, or 60.3 percent, vs. 80 of 154, or 51.9 percent; P = 0.10).
192|hospitalized with MTX toxicity, none died of MTX toxicity,2-year actuarial survival rate,Overall crude survival,Confluent mucositis and dry skin desquamation,rate of progression-free survival,longer survival,Hematologic and non-hematologic toxic effects,poor survival,late reactions and overall rates of secondary neoplasms,acute skin effects and late mucosal and skin toxicities,Acute morbidity and deaths,similar activity (complete response, progression-free and overall survival rates,incidence of first failure in the neck nodes,3-year disease-free survival,progression-free and overall survival,median progression-free survival,median survival time (MST,disease-free survival (DFS) and overall survival,Grade 3+ (World Health Organization) acute skin and mucosal reactions,Estimated 2-year disease-free and overall survival rates,peripheral neuropathy,disease control and survival,hematological toxicity,alopecia,Stage IV, hemoglobin level,rate of radiologic complete response (CR,safety and efficacy,complete remission,Overall response,local and regional recurrences,6-year survival rate,tolerated, with moderate hematologic and gastrointestinal toxicity,overall 3-year primary locoregional tumour control, disease-specific and overall survival rates,occurrence of persistent G3 xerostomia,recurrences, new tumours, and deaths,clinical CR rate,moderate myelosuppression and renal toxicity,risk of death,locoregional recurrence,survival and postoperative quality of life,Long-term survival rates,Leukopenia,fatal nephrotoxicity, only hematologic G3+ (Grade 3 or higher) acute sequelae,G3+ acute mucositis,local efficacy,Progression-free survival,rate of block dissection of the neck,metastatic rate,feasibility and efficacy,cause-specific survival rate,CR + PR rates,rate of locoregional control of disease,10-year disease-free survival rates,5-year Kaplan-Meier estimates of progression-free survival,mean duration response,year rate of local and regional control,Severe (grade 3 or higher) adverse effects,median overall survival,complete response (CR) rates,adverse effects,rate of overall survival,thrombocytopenia, nausea, vomiting, stomatitis, and hearing loss,phlebitis,severe hematological toxicity,frequency of complete responses,survival rate,overall survival, specific disease-free survival, and locoregional control rates,incidence of late adverse effects,Loco-regional tumour control,longer survival time,incidence or severity of acute and late radiation side effects,tumour response rates,superior disease-free survival,Tumour regression,Total clinical healing of the lesion,septic shock,overall survival (from randomisation), and event-free survival (EFS; recurrence, new tumour, or death,response rates and locoregional control,acute high grade toxicity,Gender, haemoglobin drop, tumour site, tumour and nodal stage,Five-year recurrence-free rates and disease-free survival,complete remission rate,tumor objective response rate,locoregional control,3-year overall survival and of 3-year loco-regional control,Acute toxicity,satisfactory efficacy and acceptable toxicity profile,response and survival rates,EFS events,CR rates,toxic effects and lethal reactions,relapse-free survival,4-year actuarial survival rate,locoregional control and overall survival rates,acute mucositis, pneumonitis and dermatitis,Four-year progression-free survival,overall median survival duration,incidence of distant metastases,overall response rates,year failure-free survival rates,chemotherapy responses and toxicities, surgical complications, radiotherapy toxicities, patient compliance, survival time, and patterns of treatment failure,3-year locoregional control rate,cardiac toxicity,complete remission rate and overall survival,3-and 5-year survival rates,year survival,overall survival and disease-free interval,overall tumor response rates,Toxicity,local late mucosal and skin toxicities,rates of secondary localization and distant metastasis,complete clinical and pathologic response rate,postoperative complications,event-free survival,Grade 3-4 neutropenia,median peak MTX dose,febrile neutropenia and grade 3 or 4 late mucous membrane toxicity,Mucositis and vomiting,overall long-term survival,favourable response rate,Objective response rate,mucosal toxicity,survival rates,higher locoregional progression-free survival (LRPFS,excellent survival,10-year local-regional recurrence-free survival rates,Actuarial 3-year locoregional control rates,confluent mucositis,l- and 2-year local-regional control (LRC) rates,disease-free survival or survival,disease-free survival,Severe mucositis,relapse-free survival rate,1-year survival with local control (SLC,uncontrolled disease and local recurrence,Serious toxicities,distant metastases,Overall response rate,complete lymph node response,incidence of distant metastasis,nausea and vomiting,Late high grade toxicity,3-year overall survival rate,death,voicing and oral intake,Median disease-free survival,Grade 3 and 4 toxicity rates,complete response,radical neck dissections of recidive metastases,toxicity,mucosal reaction,median time to loco-regional and distant progression,rates of complete and partial responses,survival,locoregional recurrence rates,regional lymph node and distant metastasis control,CR rate,incidence of local recurrences,overall survival, progression free survival, or locoregional control,serious late morbidity,Disease-free survival,Myelosuppression,died of recurrence or regional metastasis,anemia,rates of complete tumor resorption,Complete responses,10-year local-regional recurrence-free survival rates in stage IV disease,Median progression-free survival and overall survival,median survival time,failure-free rate,grade 3 to 4 complications,actuarial overall survival rates,quality of life (QOL,complete response rate,5-year LRFS,postoperative quality of life,clinical regression rate (RR,morbidity,remaining tumour cells,locoregional control rate,overall survival and locoregional control of stage III or IV oropharynx carcinoma,Overall duration of mucositis,hematologic toxicity,overall survival and locoregional control rates,Rates of residual and recurrent disease,acute morbidity,clinically tumor free,significant long-term toxicity rate,rate of local and regional control,response rates,tube feeding,median overall survival and progression free survival,survival time differences,severe late morbidity,occurrence of local toxic effects (i.e., mucositis and epidermatitis,radiation toxicity,leukopenia, thrombopenia, vomiting and nephrotoxicity,Total treatment time,haematological side effects of MMC,Survival data,Voice quality,5-year disease-free actuarial survival rate,Serious late side effects,Locoregional control and distant disease-free survival,median survival and doubles the probability of survival,efficacy and toxicity,overall survival rates,LRPFS and DMFS,Late toxicity,hematologic adverse events,loco-regional control,thrombocytopenia,1-year SLC,Response rate,overall survival (OS), disease-free survival (DFS), and specific survival (SS,local/regional failure rate,patient refusal or cumulative toxicity,locoregional control or survival,corresponding recurrence-free rates and five-year survival rates,remission rate,mucosal and skin toxicity,stage IV disease,overall incidence of distant metastases,rates of local and regional control and disease-free survival,survival curves,Overall immediate effectiveness,toxicity and response,progression-free survival,loco-regional tumour control, survival or morbidity,incidence of acute adverse effects,oropharyngeal carcinoma only: disease-free survival,Hematologic toxicity,initial tumor clearance rates,Median time to local recurrence (MTLR) and 5-year local recurrence-free survival (LRFS,survival advantage,cerebral vascular damage,local disease control or actuarial survival rates,disease-free survival rates,survival at acceptable toxicity,survival and toxicity,5-yr progression-free survival,Mucosal tolerance,3-year projected overall survival,2-year survival rate,local tumour control and survival,tumor-free survival,Favorable outcomes (complete response [CR] plus any grade of toxicity and PR plus grade 0 to 3 toxicity,higher distant metastasis-free survival (DMFS,failure-free survival, time to locoregional failure, or quality of life as measured by Functional Assessment of Cancer Therapy-Head and Neck,loco-regional failure or in disease-free or overall survival,proportion of patients without relapse,overall survival (OS,mucositis, moist desquamation, and erythema,response rate to induction chemotherapy for lymph node metastases,survival and recurrence,disease progression,Progression-free and freedom from metastases rates,Local disease-free and disease-free intervals,overall survival improvement,acceptable toxicity profiles,overall survival,locoregional failure-free rates,survival improvement,Haematological toxicity Grade 3-4,local control and overall survival,granulocytopenia, asthenia and stomatitis,Hematologic high-grade toxicity,disease free survival,2-year survival rates,overall survival rate,corresponding median EFS,rate of freedom from recurrence,time to any treatment failure; secondary end points were locoregional failure, metastatic relapse, overall survival, and late toxicity,5-yr overall survival,rate of mutilating surgery,Toxicities,unresectable disease,Tolerance,G3+ skin, s.c. tissue, and mucosal late side effects (RTOG scale,duration of objectives remission,response rate,2-year OS rates,radiotherapy,patient survival,3-year survival,5-year survival rates,response (CR + PR) rate,complete remissions (CR) and four partial remissions (PR,leukopenia and neutropenia,median survival,severe mucosal adverse effects,acute toxicity,Rates of neutropenia and febrile neutropenia,5-year disease-free actuarial survival rates,Overall QOL,Actuarial 3-year overall survival and progression free survival,Mucositis,rates of death from toxic effects,Overall survival,local control,Confluent mucositis,Grade 3 or worse toxicity,relapse while no relapses,2-year disease-free survival,cumulative incidence of local or regional relapses,actuarial DFS,tolerated,incidence of either acute or late high-grade RT-induced toxicity,5-year overall survival rate,Severe complications,Overall chemotherapy response,severe side effects, affecting mainly digestive tract, and bone marrow,Side effects,Acute mucositis grade,Severe mucositis (WHO level 5 reactions,survival of such patients,recurrence at death,incidence of moderate to severe mucositis,toxic deaths,5-year survival and late toxicity,rates of distant metastasis,pathological macroscopic regression,local control and survival,disease-free and overall survival,Grade 3-4 acute mucositis,activity and toxicity,Median time to any treatment failure,prognostic factors of short survival and locoregional failure,side effects,grade 4 cardiac dysfunction|At 24 months, the proportion of patients without relapse was 42% for Arm C vs. 23% for Arm A and 20% for Arm B. Patients in Arm A less frequently developed G3+ acute mucositis than their counterparts in Arm B or C (14.7% vs. 40.3% vs. 44%).
16|serum GH,Basal GH|In response to L-dopa and arginine hydrochloride stimulation, serum GH rose to above 7 mg/ml in all patients.
66|Sustained virologic response,CD3 CD8 HLA-DR T-cell percentages,CD3, CD3 CD4, CD3 CD8, CD3 CD4 human leucocyte antigen ,rate of sustained virologic response (an HCV RNA level,Negative serum HCV-RNA values,HIV infection,EVR,CD3 CD4 and CD3 CD8 T-cells counts,Serum HCV RNA,median residual concentration of intracellular stavudine-TP,Early virological response,pancreatitis or symptomatic hyperlactatemia,sustained virologic responses,predictive values of early virological response (EVR,safety, tolerability, and efficacy,virologic efficacy and safety,virologic response,peak concentrations,efficacy and safety,serum HCV-RNA,moderate and transient CD4 lymphopenia,Neutropenia and thrombocytopenia,fibrosis index,response rate,sustained virologic response (SVR), defined as an undetectable HCV RNA level,CD4 cell count,serum HCV RNA level,early virological response,Premature interruptions,HCV RNA,Adverse events,safety and efficacy,rate of drop-outs,sustained virological response (SVR: negative HCV-RNA,HLA)-DR and CD3 CD8 HLA-DR lymphocyte subsets,serum HCV RNA levels,Plasma HIV RNA levels,CD4 counts,tolerability and feasibility,chronic HCV infection,SVRs,Viral response,Histologic activity,sustained virological response,sustained response,frequent blood lactate measurement and relative quantitation of mitochondrial DNA (mtDNA) content in peripheral blood mononuclear cells,Sustained virological response (SVR,reversible CD4 lymphopenia,plasma HIV RNA level,deaths or opportunistic infections,normal transaminase levels,positive predictive value of EVR,rates of sustained virologic response,Lymphopenia concerned mainly CD8 T-cells,HCV-RNA levels,sustained virological response (SVR,early virologic response,Hyperlactataemia,Drug interactions, toxicity, tolerance and acceptance,Intracellular peripheral blood mononuclear cells' stavudine-triphosphate (TP) concentrations,serious adverse event,overall SVR,overall rate of sustained virologic response,SVR rate,SVR,HCV-RNA,virologic response or histologic improvement,Histologic responses,clinical and biological events,sustained response rates,Side effects,CD4 lymphocyte counts and HIV-1 RNA remained stable,sustained virologic response|Treatment with peginterferon and ribavirin was associated with a significantly higher rate of sustained virologic response (an HCV RNA level of less than 60 IU per milliliter 24 weeks after completion of therapy) than was treatment with interferon and ribavirin (27 percent vs. 12 percent, P=0.03).
not found|labour and delivery performance measures,pain using a visual analogue scale (VAS) and a verbal descriptor scale (VDS,pain of childbirth,acute pain,pain,childbirth pain|However, no difference between effectively trained electromyographic, ineffectively trained skin-conductance and control groups was found on labour and delivery performance measures.
100|rate of epithelial healing,Rate of healing of corneal epithelial defect, visual acuity, extent of corneal vascularisation, corneal clarity and formation of symblepharon,final visual outcome, symblepharon formation, corneal clarity and vascularisation with or without amniotic membrane transplantation|There was no overall difference in the final visual outcome, symblepharon formation, corneal clarity and vascularisation with or without amniotic membrane transplantation.
                
400|Postoperative infections,operative blood loss,postcesarean endometritis and operative blood loss,postcesarean febrile morbidity,Cesarean section intraoperative blood loss and mode of placental separation,postcesarean endometritis,mean maternal age, parity, gestational age, presence and duration of membrane rupture and number of vaginal examinations,change in hemoglobin, reflecting operative blood loss,Endometritis,postoperative endometritis or blood loss,incidence of postpartum infectious morbidity,postoperative endometritis rate,incidence of postoperative infections with spontaneous placental removal,perioperative hemorrhage,Hemoglobin levels,incidence of postcesarean infections,endometritis,incidence of postoperative endometritis,incidence of postpartum endometritis,post-cesarean endometritis,postoperative complications,Blood loss,blood loss during cesarean section and postoperative endometritis rate,postpartum maternal infectious morbidity,incidence of endometritis, wound infection, and the need for blood transfusion,Febrile morbidity and endometritis rates,operative time,blood loss,febrile morbidity, endometritis, maximums and durations of elevated temperatures, as well as other demographic, intrapartum, and postpartum variables,postoperative hemoglobin levels,rate of postoperative endometritis and amount of blood loss,postoperative hemoglobin and hematocrit values, and postcesarean endometritis,Preoperative hemoglobin levels,incidence of endometritis,perioperative blood loss and postpartum maternal infectious morbidity,placenta extracted,hematocrit,frequency of febrile morbidity,risk of post-cesarean endometritis,hematocrit values,postcesarean infection, defined as postecsarean endometritis or wound cellulitis requiring drainage and antibiotic therapy,hemoglobin levels,febrile morbidity,Outcome measures (frequency of endometritis and quantitative decrease in hemoglobin,incidence of endometritis, wound infection, and need for blood transfusion,mean gestational age, frequency or duration of ruptured membranes, frequency or duration of labor, or mean number of vaginal examinations,postdelivery infections,Manual removal of the placenta and postcesarean endometritis,postoperative hemoglobin,Operative blood loss,Blood loss measured at cesarean delivery,postoperative endometritis|No difference in postoperative complications was noted between the groups.
19|skin temperature,peak flow,symptomatic limbs, reactive hyperemic flow,heart rate, blood pressure, calf blood flow and vascular resistance,claudication distance,postexercise calf blood flow and symptoms of claudication,calf blood flow and vascular resistance,heart rate, blood pressure as well as on resting and hyperaemic calf blood flow and vascular resistance,blood pressure,Mean arterial pressure,calf blood flow,hyperaemic flow,objective and subjective measures of walking performance and foot temperature,walking distance,limb circulation,Calf blood flow,Heart rate,symptoms of claudication,Blood flow,Maximal exercise heart rate,blood pressure changes,vascular resistance|Calf blood flow was not affected by either drug compared with placebo at rest or at either workload.
128|clinical score,length of hospital stay,mean LOS ,severity score, number of nebulisations required,peak inspiratory pressure and respiratory system resistance,accessory muscle score,Respiratory and heart rates, clinical score, and oxygen saturation,Improvement rates and duration of hospitalization,duration of hospitalization,clinical score or hospital duration,oxygen saturation rates,tidal expiratory flows,respiratory rate, pulse oximetry, and a clinical score based on the degree of wheezing and retractions,Health care revisit and admission rates,shorter hospitalization,Respiratory rate, heart rate, oxygen saturation and presence of cyanosis, wheezing, retractions,fraction of tidal volume exhaled at peak tidal expiratory flow (PTEF) to total tidal volume (VPTEF/VE), and the fraction of exhaled time at PTEF to total expiratory time (tPTEF/tE,heart rate,respiratory rate and clinical score,wheezing, retractions and respiratory rate,tidal breathing flow-volume loops,Respiratory and heart rates, clinical score, oxygen saturation (Spo2), and the infant's state,ie, asleep, awake, or feeding,time to resolution of illness,changes in clinical scores and oxygen saturations,heart rate, respiratory rate, oxygen saturation, and clinical variables related to respiratory compromise with the use of a standardized respiratory distress index (RDI,VPTEF/VE and tPTEF/tE,rate of improvement and the final score,length of hospitalisation,time from admission until the infant had normal hydration, oxygenation, and minimal respiratory distress,Inspiratory respiratory system resistance,respiratory syncytial virus (RSV) positivity and enrollment score,bronchial obstruction,time to normal feeding, normal sleeping, quiet breathing, resolved cough, and coryza,wheeze scores,clinical scores or oxygen saturations,arterial oxygen saturation (SaO2,Oxygen saturation,respiratory score,and RDI scores,respiratory rate,Clinical score, oxygen saturation and heart rate,respiratory distress,bronchodilation,SaO2,improvement in oxygen saturation (SaO2) during hospitalization and survival analysis to assess the time required to reach preestablished discharge criteria on three measures: SaO2, accessory muscle use, and wheezing,need for hospital admission or home oxygen,mild accessory muscle use, and respiratory distress assessment instrument (RDAI) score,demographic characteristics, initial oxygenation, and clinical score,fall in SaO2,wheeze and retraction score, respiratory and heart rates, and pulse oximetry,respiratory failure,clinical score, oxygen saturation or reduction in duration of hospitalization,Clinical scores and oxygen saturation levels,Respiratory Distress Assessment Instrument (RDAI) score, respiratory rate, oxygen saturation, heart rate and the duration of hospitalization,improvement in respirations,respiratory rate, RDI, and oxygen saturation,peak inspiratory pressure,adverse effects,clinical score and length of hospital stay,Heart rate,actual length of hospital stay,heart rate or respiratory rate,Time for resolution of illness (ROI), duration of fever, cough,coryza, noisy breathing, time to achieve normal feeding and normal sleep, and frequency of hospitalization and adverse effects,shortest hospital stay,Median (SE, 95% CI) duration of resolution of overall illness,condition of hospitalised mild bronchiolitis,mean duration of fever, cough, coryza, noisy breathing, time to achieve normal feeding and normal sleep; and frequency of hospitalization or adverse effects,decrease in respirations,mean SaO2,oxygen saturation rates and clinical scores and duration of hospitalization,lengths of hospitalization,clinical scores,Desaturation,oxygen saturation,length of hospital stay (LOS,bronchodilation, peak inspiratory pressure and inspiratory respiratory system resistance,symptomatology of acute viral bronchiolitis,tidal expiratory flow,RDAI score, oxygen saturation in room air, rate respiratory and heart rate,Tidal breathing flow-volume loops,remaining tidal volume (TEF10, TEF25, and TEF50), and the wheeze score,Chest radiographs, leukocyte counts, blood culture specimens, and nasal aspirate for viral antigen detection,RDI,PTEF,total scores,time to reach discharge criteria as defined by SaO2, accessory muscle use, or wheezing|Nebulized albuterol significantly improved the clinical score and reduced the respiratory rate of those with recurrent wheezing relative to those in the randomized groups.
53|Pain scores,McGill-Melzack Pain Questionnaire,average pain reduction,disability,Daily hours of headache, pain intensity per episode, and daily analgesic use, as recorded in diaries,headache-related and demographic characteristics,overall function (Sickness Impact Profile), and mental well-being (Mood Adjective Check List) and the intensity and frequency of headache,number of headaches,average response,mean daily headache,measured rotation,tension headache pain,subjective level of headache,headache,tension headache,episodic tension-type headache,myogenic headache,Episodic tension-type headache,overall function,migraine frequency,headache frequency and intensity, and the neck pain and effects,pain on neck movement, upper cervical joint tenderness, a craniocervical flexion muscle test, and a photographic measure of posture,headache intensity and duration, the Northwick Park Neck Pain Index, medication intake, and patient satisfaction,frequency, intensity (visual analogue score), duration, disability, associated symptoms, and use of medication for each migraine episode,change in headache frequency,headache activity,side effects that included drowsiness, dry mouth and weight gain,headache intensity per episode,Safety and effectiveness,migraine activity,headache frequency,pain/paraesthesia,muscle tension,cervicogenic headache,headaches,headache index scores,intensity of headache,frequency and intensity of cephalalgia,pain reduction,pain index,lateral flexion,mean pain index,Headache pain intensity,daily headache intensity, weekly headache frequency, over-the-counter medication usage and functional health status (SF-36,standard headache diaries,headache intensity,morbidity of each episode,quantity of muscle tension (motor unit potential spikes per time unit,pain or stiffness in the neck, and pain/paraesthesia,headache pain,intensity and frequency of headache,EMG activity,mean number of analgesics,headache index score,neck soreness and stiffness,symptoms of cervicogenic headache,Pain level,number of headache hours per day,pain intensity,headache reduction,pain,headache pain levels,side effects,Migraine headache|The use of analgesics decreased by 36% in the manipulation group, but was unchanged in the soft-tissue group; this difference was statistically significant (p = .04, chi 2 for trend).
not found|24 hour sputum volume,sputum volume,exacerbation frequency, forced expiratory volume in 1 second, forced vital capacity, or sputum purulence score,exhaled nitric oxide (eNO) levels,pulmonary function, number or severity of exacerbations, or microbiological profile of the sputum,sputum production,FEV1, FVC, 24 h sputum volume or number of bronchiectatic segments,symptoms, pulmonary function and sputum production,forced expiratory volume,adverse reactions,morning peak expiratory flow rate,Symptom scores for cough,daily sputum production,quality of life,dyspnea,eNO levels,sputum purulence score,exacerbation frequency ,HRQoL,sputum leukocyte density and IL-1beta, IL-8, and LTB4,spirometry, 24-h sputum volume, sputum leukocyte density, bacterial densities, and concentrations of interleukin (IL)-1beta, IL-8, tumor necrosis factor-alpha (TNF-alpha), and leukotriene B4 (LTB4,episodes of exacerbation,eNO|The group administered FP 1000 microg daily showed significant improvement in dyspnea (1.03 [2.1]-1.24 [2.2] points; P = 0.01-0.04), sputum production (P = 0.001),
29|facial appearance,participants' knowledge, realistic expectations, and decisional conflict,anxiety scores,general health,lower levels of decisional conflict,adherence and optimize glycemic control,knowledge,decisional conflict score,hemoglobin A(1c) (HbA(1c)) levels,postdecisional regret or actual genetic testing decision,adherence or HbA(1c) levels,amniocentesis or chorionic villus sampling,change in knowledge,Questionnaires assessing knowledge, anxiety, and satisfaction,decisional conflict and knowledge about genetic testing,Perception of absolute risk of breast cancer,mental health functioning,frequency of screening, patient knowledge, decisional conflict, and time spent discussing screening,Mean state anxiety scores,greater knowledge,proportion of patients choosing allogeneic blood,realistic risk perceptions,Congruence between personal values and decisions about HRT,Symptom and functional outcomes,questionnaire assessed knowledge, attitudes, perceived risk and intention to have a PSA test,Hysterectomy rates,knowledge, satisfaction with decision, decisional conflict or HT use,Participants' knowledge, risk perception, intention to undergo genetic testing, decisional conflict, satisfaction with decision, anxiety, and satisfaction,percentage of women making an informed choice about whether to continue or stop screening and the percentage of women participating in the screening,good' level of knowledge,values clarity,overall beneficial effect,Mean (SD) decisional conflict scores,mean level of anxiety and increased satisfaction,knowledge scores,satisfaction or anxiety,mean consultation duration,acceptability of information delivery (1-7), knowledge about statins and coronary risk (0-9), and decisional conflict about statin use,patient satisfaction with the decision-making process,breast cancer prevention knowledge postvisit,level of knowledge, decisional conflict score, women's preference for mode of birth, and recorded mode of birth,decisional conflict and mode of delivery,decreased anxiety, increased knowledge, and enhanced satisfaction,decisional conflict, knowledge, state anxiety, intentions regarding starting treatment, and actual treatment decision,patient satisfaction,Knowledge scores,knowledge of NHPs,median duration of NVAF,higher knowledge and lower risk-perception scores,patient decision process and the decision outcome,change in antithrombotic therapy,rate of vaginal birth,planned screening tests,SDMI improved decision making,Test decision, subjective expected utilities, knowledge, informed decision-making, risk perception, decisional conflict, anxiety, perceived usefulness and directiveness of consultation information,HbA(1c) levels,knowledge about menorrhagia,Unadjusted mean knowledge scores,CHD risk,decision, decisional conflict scores, treatment choice and prostatectomy rate, American Urological Association symptom scale, costs, anxiety, utility, and general health status,perceived clarity of values and overall congruence between values and choices,knowledge score,PSA knowledge,decisional conflict,equally sharing decision responsibility,surgery rate,decisional conflict post intervention,Knowledge of coronary artery disease, satisfaction, self-reported physical and mental health functioning, and the proportion of patients who were referred for coronary revascularization,Menorrhagia Specific Utility quality-of-life scale, knowledge about menorrhagia, and anxiety and process measures,Preferences for watchful waiting,test scores of knowledge,Total score on decisional conflict scale, and mode of delivery,intent to begin or continue fecal occult blood testing (FOBT), flexible sigmoidoscopy, or both,mean knowledge scores,risk of stroke,prostate cancer screening,realistic expectations,Back surgery rates,decisional conflict scores,prostate cancer,Anxiety levels,Decisional Conflict Scale and State-Trait Anxiety Inventory anxiety scale,decisional conflict regarding colorectal cancer screening decisions,DCS,positive attitudes,postoperative satisfaction,ICC,lower decisional conflict,risk of procedure-related miscarriage,survival rates,knowledge about risk management options,PSA screening,percentage of preference matches,complete or partial screening,decisional conflict scale (DCS,total decisional conflict score,knowledge, satisfaction, and anxiety,anxiety, general health status, prostatic symptoms, utility, or costs (excluding costs associated with the video disc equipment,decisional conflict scale,screening decisions overall,decisional conflict and greater self-advocacy,realistic expectations about the risk of stroke and hemorrhage,decision making and quality of life,Shared decision-making program scores,psychological distress,comparable demographics, prior computer experience, medical literacy, and baseline knowledge of breast cancer and genetic testing, and both counseling and computer use,realistic personal expectations of the benefits and risks, decisional conflict, and perceived acceptability of the intervention,active decision-making role,Decisional self-efficacy, preparedness to participate in decision-making, and arthritis self-efficacy,satisfaction with decision-making process scores,initial decision for and the final uptake of the prenatal screening test,satisfaction,CRC mortality risk reduction,quality of life,knowledge levels,physicians' decisional conflict scores,proportion of colorectal cancer screening plans carried out,perceived limitations and risks of BRCA1 testing,Fecal occult blood testing or flexible sigmoidoscopy,state anxiety,higher knowledge scores,final management decision, decisional conflict, decisional satisfaction, and receipt of risk reducing mastectomy,satisfaction with decision making,knowledge or SEU scores,Anxiety,Perceived clarity of values, a sub-scale of the decisional conflict scale; congruence between personal values of benefits and risks (measured on 0-10 importance rating scale) and choices (accept, decline, unsure regarding preventive hormone therapy [HRT,mean costs,Knowledge, decisional conflict, satisfaction with health care provider, and self-efficacy,number of patients receiving appropriate care,mortality due to early-stage prostate cancer, PSA screening performance, treatment-related complications, and disadvantages of screening,General health and angina scores,knowledge and perceived risk,screening frequency,PSA test choice, prostate cancer treatment preferences, knowledge and concern about prostate cancer, and decisional conflict,uptake rates of treatment options, length of consultation with the surgeon, time point of treatment decision making, perceived involvement in decision making, neither decision related nor general patient satisfaction,rates of noncompliance and rehospitalization,knowledge, decisional conflict, state anxiety, satisfaction, use of PND, and pregnancy outcomes,Knowledge (Kn) scores,number of knowledge questions,match between the patient's preferred and actual roles during consultation with the physician,anxiety,anxiety, use of health service resources, general health status, or utility,knowledge scores relative,complete screening (i.e., having a digital rectal exam (DRE) and prostate specific antigen (PSA) testing), and (2) complete or partial screening (i.e., having a PSA test with or without DRE,psychological or acceptability outcomes,patient-reported level of control over the decision to be screened,patient knowledge and satisfaction,satisfaction-with-decision scale,participants' ratings of convenience, effort, or satisfaction,elevated self-image expectations,screening interest,Levels of depression,general knowledge of the risks and benefits of HRT, personal expectations and values concerning these risks and benefits, and women's views on HRT,undergoing PSA screening,diagnostic procedure,IMDA,decision quality,knowledge about hypertension,10-year CHD risk,patient knowledge (measured using 20 questions about knowledge deemed necessary for an informed treatment decision), treatment decision, patient-angiographer agreement on decision, and general health scores,knowledge, risk awareness, intervention satisfaction, decisional conflict, and among women aged at least 35 years, use of invasive diagnostic testing,colorectal cancer,rate of uptake of trial of labor or elective repeat cesarean section,anxiety, knowledge, or decisional regret,patient interest in undergoing PSA screening measured on a 5-point Likert scale,Median consultation times,knowledge questions correctly,mean scores for decisional conflict,Decisional conflict and satisfaction,likelihood of reaching a management decision,outcomes and satisfaction; surgery rates,national rates of caesarean section,overall surgery rate,Decisional conflict,number of patients receiving therapy appropriate to their stroke risk,surgery rates,menorrhagia quality of life,undergone revascularization,intrusive thoughts,factual knowledge, reduced anxiety,physical functioning,health status,informed choice and decisional conflict, and the secondary outcomes, anxiety, depression, attitudes to the pregnancy/fetus and acceptability of the resource,number of surgical procedures used, improve knowledge, or influence satisfaction or anxiety,referral for coronary revascularization,state anxiety levels,general knowledge increased and of women with realistic expectations,realistic expectations about the benefits and risks of lung transplantation|Information-giving was the most frequent activity for both GPs and patients, although GPs did this at twice the rate compared to patients and at higher rates in consultations involving computerised decision aids.
not found|6MWD and steps,quality of life,quality of life indices,6MWD or steps,laboratory exercise performance,6MWD or steps achieved while breathing supplemental oxygen,exercise performance (step tests and 6 min walking distance [6MWD,Degree of desaturation|Supplemental oxygen increased 6MWD and steps by small, statistically significant increments acutely at baseline and after 6 and 12 wk, without corresponding falls in Borg score.
219|change insulin resistance,Baseline cross-sectional changes and 1-year changes in insulin resistance, fasting serum levels of insulin, C-peptide, proinsulin, glucose, and lipids as well as weight, mean blood pressure, and plasminogen activator inhibitor 1 (PAI-1) values,cumulative incidence of diabetes,calculated insulin resistance,insulin resistance,mean blood pressure (mBP,calculated insulin resistance and BMI,PAI-1,insulin resistance and changes in BMI,total cholesterol,incidence of diabetes,intake of fish and reduced total fat intake,baseline BMI and fasting glucose, the diet, exercise, and diet-plus-exercise interventions,rate of development of diabetes|The 1-year diet intervention gave a significant decrease in the calculated insulin resistance from 4.6 to 4.2 and a positive correlation between the changes in insulin resistance and changes in BMI (r = 0.40).
38|Brief Psychiatric Rating Scale and Clinical Global Impression Scale,severity of illness scores,hypokinesia,acute psychosis with aggression,BPRS or CGI scores,Sedation,tardive dyskinesia,Serum creatinine phosphokinase levels,minimal side effects,rapid remission of symptoms on the BRMAS,Brief Psychiatric Rating Scale (BPRS) and the Clinical Global Impression Scale (CGI,reduction of aggression based on BPRS rating,efficacy and side effects,Brief Psychiatric Rating Scale (BPRS), the Bech-Rafaelsen Mania Rating Scale (BRMAS) (only manic patients) and globally on the Clinical Global Impression (CGI,BPRS and CGI scores,Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression (CGI) and UKU Side Effects Scale,extrapyramidal side effects|Both ZPTA and HAL were effective in the treatment of acute psychosis with aggression, but frequency of administration was lower in the ZPTA group
420|incidence of persistent trophoblastic disease,time interval from evacuation of the mole to diagnosis of persistent trophoblastic disease,toxicity,persistent trophoblastic disease,until complete remission,tumor resistance and morbidity,complication of the prophylactic chemotherapy,severe complication nor death,metastatic trophoblastic disease,stomatitis, nausea/vomiting, sore throat with oral ulcer and hair loss,incidence of malignant sequelae,secondary trophoblastic disease,complete remission with therapeutic chemotherapy,occurrence of choriocarcinoma|Choriocarcinoma after the molar pregnancy developed in two patients (0.7%) of the prophylactic chemotherapy group and two (1.6%) of the control.
279|Survival,disease-free survival curve,survival nor the quality of life,liver decompensation,tumour response (assessed by arteriography, ultrasonography and serum alphafetoprotein,recurrence of hepatocellular carcinoma (HCC,survival,4-year survival rates,local recurrence,Pugh score,death from liver failure,tumor size and serum alpha-fetoprotein concentration,apoptosis of hepatocellular carcinoma (HCC) cells,risk of hepatocellular carcinoma (HCC) recurrence,expressions of Bcl-2 and Bax protein,partial response,HCC recurrence and survival,probability of complications,incidence of portal obstruction,level of Bcl-2 protein and ratio of Bcl-2 to Bax protein of HCC cells,intrahepatic recurrence rate,2-year overall survival,spontaneous 1-year survival rate,overall survival,Disease-free survival rates and prognostic factors,Actuarial survival rates,overall recurrence,self-limited postembolization syndrome,nausea and loss of appetite,recurrence rate, the time to tumor recurrence and the median survival,rate of portal-vein invasion,abdominal pain,Pugh's grade, Okuda stage, or performance status test (PST,survival time,Spitzer Index level assessing the quality of life,apoptotic index(AI) and level of Bax protein in HCC cells,time to tumor recurrence,overall survival and quality of life,disease-free survival rate,Tumor size, tumor number, PVTT location,median survival,Survival probabilities,relative risk of death,survival: alpha-fetoprotein,objective tumoral response,recurrence rate,catheter obstruction,liver failure,Liver failure,survival benefits,apoptosis of hepatocellular carcinoma cells,risk of death,actuarial survival,probability of tumor progression,estimated survival rates|Chemoembolization resulted in a marked tumor response, and the actuarial survival was significantly better in the chemoembolization group (1 year, 57%; 2 years, 31%; 3 years, 26%) than in the control group (1 year, 32%; 2 years, 11%; 3 years, 3%; P =.002).
395|Efficacy,rate of adverse events,Neuropsychiatric Inventory (NPI,change of the THI, GHSI and hearing,Tinnitus Handicap Inventory (THI), Glasgow Health Status Inventory (GHSI) and average of hearing threshold at 0.5, 1, 2, 4 kHz,SKT total score,Efficacy and tolerability,Verbal Fluency Test, the Clock-Drawing Test, the NPI, the Hamilton Rating Scale for Depression (HAMD), and the Gottfries-Bråne-Steen Scale (GBS|Under EGb 761 treatment the SKT total score improved by -3.0+/-2.3 and -3.4+/-2.3 points in patients with AD and VaD, respectively, whereas the patients on placebo deteriorated by +1.2+/-2.5 and +1.5+/-2.2 points, respectively (p<0.01 for both drug-placebo differences).
not found|Electromyogram (EMG) patterns and stride parameters,gait velocity,velocity,Unified Parkinson's Disease Rating Scale (UPDRS,stride length,mean UPDRS scores,UPDRS scores (activities of daily living and motor sections|Patients who trained with RAS significantly (p < 0.05) improved their gait velocity by 25%, stride length by 12%, and step cadence by 10% more than self-paced subjects who improved their velocity by 7% and no-training subjects whose velocity decreased by 7%.
not found|polyp size|We found that betamethasone nasal drops showed a statistically significant reduction in polyp size in comparison to placebo.
not found|Survival,secondary cytoreduction,Complete cytoreduction,survival,largest size of recurrent tumor,5-year survival,number of recurrence sites,cytoreductive outcome and survival,number of radiographic recurrence sites (median survival,survival benefit,recurrent epithelial ovarian cancer,Complete optimal cytoreduction (COC,median progression-free interval,performance status (PS) [Eastern Cooperative Oncology Group (ECOG,median patient age at recurrence,median and estimated 5-year survival,longer survival,overall survival,median postrecurrence survival,International Federation of Gynecology and Obstetrics (FIGO) stage at initial diagnosis,residual disease,recurrent ascites,endometrioid histologic type,prolonged survival,median survival and estimated 5-year survival,Age, tumor grade, histology, CA-125 level, ascites, and tumor size,probability of complete cytoreduction,recurrence-free interval (RFI,2-year survival rates,Prognosis of survival,completeness of cytoreduction,median survival,median diagnosis-to-recurrence interval,Residual disease after SCR, treatment-free interval (TFI,lengthened survival,residual disease (median survival,survival benefits,Median survival time (MST|Age, tumor grade, histology, CA-125 level, ascites, and tumor size were not associated significantly with survival.
                
not found|major hemorrhagic complications,functional activity level of survivors,asymptomatic ICH (7 events), major systemic hemorrhage (no event), or 90-day mortality,frequency of proximal thrombi,mortality rate,deep venous thrombosis (DVT,haemorrhagic,thromboembolic complications,absence of pulmonary embolism or drug-induced haemorrhage,Glasgow Outcome Scale score of I or II and a modified Barthel Index,neurologic deficits,fatal pulmonary embolism,Symptomatic ICH,degree of neurologic change; incidence of stroke progression,laboratory values (PT, PTT, alkaline phosphatase, GOT, GPT, cholesterol and triglycerides, fibrinogen, blood glucose, azotemia and creatinine,serious intracranial bleeding events,deaths,Time interval (from stroke to admission) and lactic dehydrogenase (LDH) concentration,tolerated,deep-vein thrombosis,lethal pulmonary embolism,symptomatic intracranial hemorrhage (ICH,tolerated and no side-effects,deep-vein thrombosis rate,frequency of DVT,mean Factor Xa inhibitory activity levels at peak concentration,deaths and pulmonary emboli,development of DVT,number of deep-vein thromboses, pulmonary emboli and deaths,Cerebral bleeding,death rate,mortality|A statistically significant reduction was observed in deep-vein thrombosis as assessed by isotope leg scanning.
not found|Inulin clearance and urinary beta(2)-microglobulin and N-acetyl-beta-D-glucosaminidase (NAG) excretion,renal function impairment,perioperative renal function,tubular damage markers,MPO levels,inulin clearance,myeloperoxidase (MPO) release,Venous stasis,low mean arterial pressure at anesthesia induction,lactic acid levels,renal function|Lactate determinations did not contribute to the quantification of the systemic and regional tissue oxygenation during OLT.
not found|working smoke alarms,hot water temperatures,safety consultation and provision of free and fitted stair gates, fire guards, smoke alarms, cupboard locks, and window locks,operational smoke detectors,annualized fire-injury rates,injury prevention counseling,frequency and severity of medically attended injuries,attendance rate,proportion of families,rate of burn injuries,hot water temperature,presence and functional status of smoke alarms,Safety knowledge and practices,probability of having a working detector,safety knowledge and behavior scores,injury rate per 100 fires,home hazards requiring major effort to correct,self reported safety practices, possession and use of safety equipment, knowledge and confidence in dealing with first aid, and perceptions of risk of injury and risk of hazards assessed by postal questionnaire,rates of fires and rates of fire related injury,feasibility, acceptability, and effectiveness,smoke alarm safety,Parents' knowledge, beliefs, and home safety behaviors,Knowledge gains,functioning alarms,working alarms,injury visits,total costs of care for injuries,smoke alarms,parents' safety practices,Physician counseling and parent satisfaction, knowledge, beliefs, and behaviors,discharge book improved the burn-care-related knowledge of caregivers,Rates of fires and related injuries,mean hazard score,Incidence of fires and related injuries,socket covers,home safety modifications,medical attendance,number of safety practices,fireplace safety,Demographic and fire safety data,safe practice in storage of sharp objects,injury prevention knowledge or behavior,range of safety practices,installed alarms,frequency of minor unintentional injuries,overall occurrence of injuries,admissions to hospital and deaths,child in the family had at least one injury that required medical attendance and rates of attendance in primary and secondary care and of hospital admission for injury over a two year period,unintentional injuries,possession of safety equipment and safety practices,socket safety,Parental safety knowledge,hot-water temperature, poison storage, and presence of smoke alarms, safety gates for stairs, and ipecac syrup,window safety,similar risk factors for injury, sociodemographic characteristics, safety practices, possession and use of safety equipment, knowledge and confidence in dealing with first aid, and perceptions of risk,safety practices,storage of medicines|Households that reported participatory exposure to the interventions had higher safety knowledge and behavior scores than those that received other community exposure or no exposure to intervention activities.
179|recurrent preterm uterine activity,shortest length of triage stay,mean days to delivery, the number of repeat triage visits, the incidence of preterm labor,frequency of preterm deliveries,pregnancy outcomes|There were no intergroup differences in the mean days to delivery, the number of repeat triage visits, the incidence of preterm labor at < 34 weeks, or the frequency of preterm deliveries at < 34 weeks and < 37 weeks.
61|specific physiological, psychological and cognitive functions,functional work capacity,depression,resting systolic blood pressure,work capacity (W.kg(-1,fatigue, sleep, disability, and mood,SF-36 physical functioning subscale,fatigue,physical work capacity, as well as in specific psychological and cognitive variables,satisfactory outcome in physical functioning,Rating of perceived exertion scores,Fatigue, functional capacity, and fitness,net blood lactate production,health perception,efficacy and acceptability,functional work capacity and fatigue|Following the graded exercise intervention, scores were improved for resting systolic blood pressure (P = 0.018), work capacity (W.kg(-1))
not found|BMD and bone metabolism,rate of bone loss,total hip,BMD and bone biochemical markers,bone turnover,bone mineral density and bone metabolism,distal forearm,lumbar spine,rate of bone turnover and bone loss,Low bone mineral density (BMD|After 12 months, the treatment group (n=15) showed a reduced rate of bone loss compared with the control group (n=15) in the lumbar spine (mean difference 1.9% [CI -0.9% to 4.6%])
16608|body composition,fibrinogen,bone mineral density (BMD,Breast pain,serum cholesterol level,endometrium against hyperplasia,Total and LDL cholesterol levels,plasma homocysteine levels,levels of total serum cholesterol and LDL-cholesterol,plasma homocysteine concentration,initial levels of oestradiol,weight or girth changes,Plasma homocysteine levels,elevated LDL cholesterol levels,serum lipids and coagulation factors,bone mineral density,final values of fibrinogen, FVII, ATIII, protein S and HCII,Breakthrough bleeding,abdominal fat after menopause,Serum cholesterol levels,nonfatal myocardial infarction and CHD death,extremity/trunk ratio,rate of hyperplasia and proliferative status,Body weight,low-density lipoprotein (LDL) cholesterol,balance, muscle performance and falls,ratio of high-density lipoprotein cholesterol to low-density lipoprotein cholesterol,body weight,levels of lipids and lipoproteins,body weight and waist and hip girths,levels of serum triglycerides,fasting plasma homocysteine concentrations,Hispanic ethnicity,muscle strength,serum oestradiol and serum oestrone,Total serum cholesterol and LDL-cholesterol levels,fibrinogen levels,overall values for body weight and blood pressure,lumbar BMD,postmenopausal bone loss,HDL2-C and lipoprotein(a,Blood pressure and body mass index,serum lipoproteins,PAI-1) levels,serum triglycerides and HDL-cholesterol levels,triglycerides,total and low density lipoprotein cholesterol levels,skin tolerability,weight gain,alcohol consumption,frequency of moderate-to-severe hot flushes,high-density lipoprotein-2 cholesterol (HDL2-C,waist girth,HDL cholesterol,coronary heart disease (CHD) ,Total serum cholesterol and LDL-cholesterol,stroke, pulmonary embolism (PE), endometrial cancer, colorectal cancer, hip fracture, and death due to other causes,HDL cholesterol level,Total exercise time (time spent on the treadmill until exhaustion during testing,incidence of diabetes,secretion of growth hormone (GH) and IGF,high-density-lipoprotein (HDL) cholesterol,total cholesterol level, high-density lipoprotein cholesterol level, blood pressure, and body mass index,Total serum cholesterol levels,total body bone mineral content (TBBMC,physical activity level,low-density-lipoprotein (LDL) cholesterol,Fibrinogen, factor VII (FVII), factor VIII,fasting glucose level and incident diabetes,hot flushes,total mortality,overall activity,change high-density lipoprotein cholesterol (HDL-C), triglycerides, or plasminogen activator inhibitor-1 (PAI-1,spine density and total body density,daily creatinine excretion,Hand grip strength,weight and waist circumference,total body calcium,Physical fitness levels,lowered lipoprotein(a,biochemical markers of cardiovascular risk by decreasing LDL-C, fibrinogen, and lipoprotein(a,spine density, total body calcium, or radial density,Overall health risks,Fasting glucose levels,estradiol/estrone ratio,changes of other lipid profiles,urinary creatinine excretion rate,TBBMC,radial density,percent of body fat,levels of apolipoprotein B and lipoprotein(a,antithrombin III activity (mean levels,lipid levels and coagulation parameters,spine density,glucose tolerance or on fibrinogen levels,time for homocysteine levels,LDL cholesterol levels,Height loss,endometrial proliferation and hyperplasia,fasting glucose levels,Serum estradiol concentrations,loss of femoral neck BMD,BMD,Plasma fasting homocysteine concentrations,bone density, endometrium, and lipids of continuous hormones,total cardiovascular disease (arterial and venous disease,sway, leg extensor power and self-paced walking speed,baseline blood pressures and body weights,Serum lipids and lipoproteins,femoral neck BMD,rate of new vertebral fractures,high-density lipoprotein cholesterol/total cholesterol fraction,muscle performance and balance,endometrial hyperplasia,Baseline biochemical values,total cholesterol,trunk fat mass,serum E2 levels,bone mineralization defects,incidence of estrogen-related side effects,LDL cholesterol,vaginal cytology profile (maturation index,lipids and lipoproteins,anthropometry, lipoprotein levels, antithrombin III activity, and endometrial histology,Fasting glucose level,muscle performance, improve balance or reduce falls,body cell mass and body fat mass,urinary creatinine/body weight ratio,Bone mineral density,growth hormone secretion patterns,high-density lipoprotein (HDL) cholesterol-LDL ratio,lipid changes, measurement of serum total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL), high density lipoprotein (HDL), apolipoprotein A-1 (Apo-A) and apolipoprotein B (Apo-B,height loss,Levels of HDL cholesterol, HDL2, HDL3, triglycerides, lipoprotein populations and apolipoproteins AI and AII,Serum triglycerides levels,apolipoprotein A1,low-density lipoprotein cholesterol (LDL-C,ratio of fat in the trunk/extremities,cardiovascular risk,HDL-C and PAI-1,Bone mineral density (BMD,plasma homocysteine,maximum oxygen uptake,efficacy and safety,cortical and trabecular bone,leg extensor power,cholesterol, triglycerides, and LDL cholesterol, and an increase in the HDL-LDL ratio,antithrombin III (ATIII), protein C, protein S, heparin cofactor II (HCII) and plasminogen activator inhibitor,Fasting plasma total homocysteine concentrations,Vaginal bleedings,hip, work activity,exercise performance,total body fat mass or total lean body mass,serum lipids and lipoproteins,high density lipoprotein (HDL) cholesterol levels,Glycemic effects,GH and IGF,triglyceride,body weight, blood pressure, lipoprotein levels, antithrombin III activity, and the endometrium,PAI-1,lipid metabolism,systolic blood pressure,bone loss,HDL-cholesterol levels,Levels of follicle-stimulating hormone,bone turnover, including bone-specific alkaline phosphatase, and urinary hydroxyproline:creatinine ratios,hip and spine BMD,Levels of lipids, lipoproteins, apolipoproteins, fibrinogen and glucose tolerance,lipid profile,GH- and IGF,metacarpal cortex,Estimated hazard ratios (HRs,triglyceride levels,lumbar spine,serum lipids or lipoproteins,lipid measures,Cardiovascular risk factors|Corresponding HRs (nominal 95% CIs) for composite outcomes were 1.22 (1.09-1.36) for total cardiovascular disease (arterial and venous disease), 1.03 (0.90-1.17) for total cancer, 0.76 (0.69-0.85) for combined fractures, 0.98 (0.82-1.18) for total mortality, and 1.15 (1.03-1.28) for the global index.
161|overall incidence of air leaks,air leakage volumes,chest tube drains,Postoperative hospitalisation time,mean numbers of intraoperative AAL after application of SLS,hospital stay,air leakage volume,safety and effectiveness,postoperative quantification of air leakage on postoperative days 1 and 2,alveolar air leaks,morbidity,incidence of postoperative leakages,intraoperative leaks,Alveolar air leaks,mean times to chest drain removal and to hospital discharge,leak-free,intercostal chest drainage,control of air leaks intraoperatively and the time to postoperative air leak cessation,postoperative morbidity and mortality,mean duration of postoperative air leakage,incidence of dead pleural space,duration of stay in hospital,air leakage,procedure costs,percentage of patients free of air leakage throughout hospitalization,Air leakage,reduction of intra-operative air leakage,Air leaks,PAAL,volume of chest tube drainage or LOS,air leak duration, chest drainage time, and hospital stay,Overall incidence of air leakage,mean air leak duration,control of air leaks,Efficacy and safety,Postoperative air leakage intensity,postoperative leakage,mean times to last observable air leak,airway-tolerance-pressure test,incidence and duration of AAL, prolonged AAL (PAAL), the volume of pleural drainage, the time to tube removal, and the postoperative length of stay (LOS), as well as any complications related to treatment,mean intraoperative post-treatment air leakage,mean time to last observable AAL,Median length of hospitalization,median duration of intercostal drainage and in-hospital stay,overall incidence of AAL,air leaks,length of hospitalization,surgical morbidity and costs,reduced time to chest tube removal and earlier discharge,length of the postoperative hospital stay,mean percentage of patients free of AAL,quality of aerostasis, the post-operative drainage, the persistance of residual collection or faulty reexpansion,mean time to chest drain removal and mean time to hospital discharge,Persisting air leakage,postoperative air leaks,postoperative hospitalization,duration of air leaks, chest tube drainage, or hospitalization,Postoperative air leakage,reduction of intra-operative air leak intensity,duration of postoperative chest tube time, hospital stay, or cost,efficacy and safety,Intraoperative air leaks,free of air leaks during hospitalization,fever, intraoperative and postoperative intubation times,mean duration of AAL,incidence of PAAL,mean time to chest tube removal,incidence of air leakage,shorter median duration of air leaks,Time to chest tube removal, time to hospital discharge, and safety outcomes,Duration of air leak, intercostal drainage, and hospital stay,healing of healthy bronchial and lung tissues,duration of air leaks,mean bleeding/exudate volumes,mortality, morbidity, duration of chest tubes, or immune responses,postthoracotomy alveolar air leak,localized empyema and incomplete lung expansion|Intraoperative air leaks were sealed in 77% of the sealant group compared with 16% in the control group (p < 0.001).
812|Pneumonia,morning peak expiratory flow rate (PEF); transition dyspnea index; chronic respiratory disease questionnaire; chronic bronchitis symptom questionnaire; exacerbations,risk of time to first exacerbation,annual rate of moderate/severe exacerbations,Dyspnoea scores and HR-QOL,morning lung function,efficacy for pulmonary function,Transition Dyspnea Index,pre-dose forced expiratory volume in 1 second (FEV1) and 1-hour post-dose FEV1. ,mean time to first exacerbation,annualized rate of moderate and severe exacerbations,annual rate of moderate to severe exacerbations,morning predose FEV(1,frequency of moderate/severe exacerbations,dyspnea, quality of life, and symptoms of chronic bronchitis,IC,pre-dose forced expiratory volume in 1 second (FEV(1)) and 1-hour post-dose FEV(1,albuterol use, dyspnea scores, and nighttime awakenings and numerical benefits on quality of life,Daily beta(2) short acting prn consumption,exacerbations,moderate/severe exacerbations,Predose and postdose spirometry, plethysmography, and constant-load cycle cardiopulmonary exercise test evaluations,exercise endurance time,frequency of adverse events, bruising, or clinically significant falls in serum cortisol concentration,COPD exacerbations and impact on patient outcomes,pulmonary function and reduced symptoms and exacerbations,predose FEV(1,morning PEF (l/s), the daily symptom score, and the number of exacerbations,morbidity and mortality,postdose FRC and increased inspiratory capacity (IC,Efficacy and safety,morning predose (ie, trough FEV(1)) for FSC compared with SM and 2-h postdose FEV(1,mean FEV(1,Efficacy and tolerability,incidence of pneumonia,health-related quality of life, peak expiratory flow, and use of rescue medication,efficacy,exercise time,tidal volume and minute ventilation,daily symptoms score,prolonged time to first exacerbation,respiratory function (such as FEV(1), morning PEF), and and symptom score,tolerated relative,efficacy and tolerability,lung function measurements, symptoms and rescue treatment use, the number of exacerbations, patient withdrawals, and disease-specific health status,moderate and severe exacerbations,mean prebronchodilator forced expiratory volume,adverse events, serum cortisol concentrations, skin bruising, and electrocardiograms,severity of dyspnea,pretreatment forced expiratory volume in 1s (FEV1,lung function, symptoms, and health status and reduced use of rescue medication and frequency of exacerbations,tolerated,FEV1,total number of exacerbations,rate of moderate/severe exacerbations,average daily morning PEF,2-hour postdose FEV(1,adverse effects,lung function,controlling dyspnoea and improving health status (St George's Respiratory Questionnaire,mean number of exacerbations/yr,worsening symptoms of COPD requiring antibiotics, oral corticosteroids and/or hospitalization,pretreatment FEV1,FEV(1,annual rate of moderate/severe exacerbations requiring hospitalization,annual rate of exacerbations requiring oral corticosteroids,mean number of severe exacerbations,rate of COPD exacerbations,rate of moderate to severe exacerbations,Morning PEF,postdose IC,daily symptoms,symptom scores and use of reliever beta2-agonists,efficacy and safety,lung hyperinflation,lung function and health status,Adverse events,exercise performance,number of exacerbations resulting in hospitalization,adverse events,Postmedication FEV1 improved by 0.21 L and health-related quality of life using the St George's Respiratory Questionnaire (SGRQ,lung hyperinflation and exercise endurance,Moderate/severe exacerbations,Severe exacerbations and FEV1 (primary variables), peak expiratory flow (PEF), COPD symptoms, health-related quality of life (HRQL), mild exacerbations, use of reliever beta2-agonist and safety variables,COPD exacerbations,incidence of individual non-fatal serious adverse events,Dyspnoea (measured using the Breathlessness Diary) and health-related quality-of-life (HR-QOL) scores (based on the St George's Respiratory Questionnaire total score,2-h postdose FEV(1,health status,reporting of pneumonia,prebronchodilator peak expiratory flow|Morning PEF improved significantly on day 1 versus placebo and budesonide; after 1 week, morning PEF was improved versus placebo, budesonide and formoterol.
91|clinical remission, defined as a score of 150 or less on the Crohn's Disease Activity Index,median CDAI decrease,Remission,remission of CD (CDAI < 150) and decrease of at least 60 points,entered remission or improved their symptoms,median AUC of the CDAI,Crohn's Disease Activity Index (CDAI,morning plasma cortisol value,CDAI,total numbers,Clinical improvement,mean 17-week CDAI scores,Activity Index,CDAI median score value,mean activity index,activity index,response of active Crohn's disease to sulphasalazine,efficacy and safety,severe adverse events,disease activity,serious adverse reactions,Crohn's Disease Activity Index,intention-to-treat basis remission rates,small bowel and colon disease,numbers of patients with adverse events,corresponding CDAI change,serum albumin, ESR, body weight released to height, abdominal mass, temperature, stool consistency, bowel resection, and extraintestinal symptoms related to Crohn's disease,clinical activity (Harvey-Bradshaw Index) or laboratory indicators of inflammation,Crohn's disease activity index (CDAI,rates of remission,Diarrhoea,active CD response rates,faecal granulocyte excretion,Clinical improvement in Crohn's disease,disease deterioration,achieving partial or complete remission,remission rate or withdrawal rate for active disease,72 CDAI points,response of active symptomatic disease,change in the Crohn's Disease Activity Index (CDAI,small bowel disease,respective rates,side effects,morphologic remissions|There was no difference in the remission rate or withdrawal rate for active disease in the two groups.
74|occurrence of invasive fungal infection (IFIs,False-positive reactions,median index of the initial NASBA,Invasive aspergillosis,GM antigenemia,positive predictive value,PCR and BDG tests,incidence of proven IFI,GM,During hospitalization, serum galactomannan levels,PCR and ELISA,sensitivity,negative predictive value,radiologic examination or Aspergillus isolation,survival,overall sensitivity, specificity, and positive and negative predictive values,Diagnostic levels of both BG and GM,Aspergillus antigenemia,ELISA,serum galactomannan (GM,sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of GM detection in CT-based BAL fluid,positive results for AGA (OD index,Positive and negative predictive values,invasive aspergillosis,positive and negative predictive values,Sensitivity,likelihood ratio of a positive test,Serum ELISA results,Detection of serum galactomannan (GM,specificity,sensitivity, specificity, PPV and NPV of GM detection in CT-based BAL fluid,false-positive and false-negative results,Minor pulmonary signs,False-positive tests,radiologic signs,diagnosis of invasive aspergillosis (IA,Sensitivity of the ELISA,overall specificity,overall sensitivity,serologic positivity,overall positive and negative predictive values,rate of false-positive results,patient survival,ROC curve,sensitivity and specificity of the GM EIA,EIA and latex agglutination test,predictive positive and negative values,positive predictive and negative predictive values,sensitivity of diagnosis,incidence of invasive fungal infections,major pulmonary signs,sensitivity, specificity, and positive and negative predictive values for GM and BG,sensitivity and specificity,consecutive serum GM titres,Galactomannan positivity,serum enzyme-linked immunosorbent assay (ELISA) test,Overall specificity of the ELISA,Positive GM titres,fever and pulmonary infiltrates,Specific DNA,Galactomannan antigenemia preceded post-mortem histological diagnosis of invasive aspergillosis,concentration of galactomannan,Sensitivity and specificity for the ELISA test,signs of IFI,ELISA cutoff value,kinetics of NASBA values: failure of negative conversion,abnormal CT signs,Diagnostic levels of GM,false single-positive rate,Sensitivity and specificity rates,Galactomannan antigenemia,cutoff OD index for positivity|Although the ELISA test did not have any role in the anticipation of the diagnosis, it clarifies the diagnosis of IA in allo-HSCT.
81|Analgesic effect,crying time and pain,total duration of crying,physiological (heart rate and oxygen saturation) and behavioural parameters [duration of crying and modified Neonatal Facial Coding Scores (NFCS,lowest neonatal facial score,crying time, duration of the first cry, percent change in heart rate or maximum heart rate,Relative crying time and recovery time,premature infant pain profile scale,Neonatal Facial Coding System score; cry duration; and autonomic variables obtained from spectral analysis of heart rate variability before, during, and after heel-lancing,mean duration of crying,Median pain scores,Crying time,mean heart rate,duration of crying,Sucking frequency,median values of crying time, recovery time and percentage change in heart rate,Neonatal Facial Actions (Neonatal Facial Activity Coding System-upper face), sleep-wake state,mean pain scores,pain response,heart rate,Median Premature Infant Pain Profile scores,pain scores,pain reduction,lowest pain score,analgesic effect of skin,Neonatal Facial Activity Coding System and sleep-wake state scores and heart rates changes,mean oxygen saturation levels,pain score,Heart rate, oxygen saturation changes and length of crying,heart rate and oxygen saturation changes and behavioural responses,oxygen saturation and heart rate and neonatal infant pain scale,median recovery time,lowest cry duration,sampling duration and numbers of heel lances,parasympathetic tone,pain reaction,highest pain manifestation,multidimensional acute pain rating scale of the Premature Infant Pain Profile, heart rate increase, oxygen saturation decrease, crying behavior (duration of first cry, cry percentage in 2 minutes, and during blood sampling), duration of sampling, and the number of performed heel lances,babies' pain on a Visual Analogue Scale (VAS,pain score and crying time with parents' assessment,pain and the PIPP score and crying time,crying time,medians for crying time and the pain scores,pain of heel pricks,response to pain,Neonatal Infant Pain Scale (NIPS,heart rate differences,Crying and grimacing,duration of breastfeeding,Crying times,median heart rate increase, oxygen saturation decrease, and duration of first cry,mild pain,crying and pain scores,Heart rate,median pain scores,Median crying times,Pain related behaviours evaluated with two acute pain rating scales: the Douleur Aiguë Nouveau-né scale (range 0 to 10) and the premature infant pain profile scale,clinical characteristics and time spent squeezing the heel,analgesic effects,Pain,Median crying time, duration of the first cry, percent change in heart rate, maximum heart rate and neonatal facial coding system scores,heart rate and oxygen saturation,Douleur Aiguë Nouveau-né scores,pain relief,Duration of cry and Douleur Aiguë du Nouveau,heart rate despite pain reactivity and extreme crying,analgesic effect of breast feeding,median crying times,analgesic effect,né (DAN) score,behavioural responses to pain,nociceptive reaction,Premature Infant Pain Profile (PIPP,relative crying time and recovery time: behavioural state,pain and duration of crying,heart rates, oxygen saturation levels and length of crying,relieving pain,pain,PIPP score|The change in heart rate and oxygen saturation was significantly lower in the EBM group and returned to baseline values sooner than in the DW group.
                
1417|severe trachoma|A clean face at two or more follow-up visits was protective for any trachoma (odds ratio 0.58 [0.47-0.72]) and severe trachoma (0.35 [0.21-0.59]).
2|Menstrual disruption,Menstrual irregularities,Amenorrhoea|Menstrual disruption was the main side effect among both treatment groups.
not found|Women's self-assessed motivation to attempt vaginal birth,rate of vaginal birth,back and pelvic pain and headache,Pregnancy outcomes,cesarean deliveries and stays in neonatal intensive care units,probability of vaginal delivery,Rates of vaginal birth after cesarean section,supportive behaviors,dystocic deliveries and cesarean section,rates of preterm births,women's satisfaction, knowledge of risk conditions, and perceived mastery in their lives,vaginal birth,Measurable clinical, obstetrical, and neonatal advantages|Rates of vaginal birth after cesarean section were similar in the verbal and document groups: verbal, 339 of 641 (53%); document, 310 of 634 (49%); relative risk 1.1, 95% confidence interval 1.0 to 1.2.
207|sweating, rhinitis, headache, nausea, and urinary frequency,symptomatic relief,symptomatic relief by questionnaires and visual analog scales (VAS), and for saliva production by sialometry,comfort of the mouth and tongue,Speaking ability,serious drug-related adverse experiences,saliva production and relieved symptoms of xerostomia,oral comfort agents such as artificial saliva, hard candy, and water,overall global assessments,oral dryness,Saliva production,parotid salivary flow,safety and efficacy,production of saliva and other manifestations of xerostomia,side effects|Pilocarpine improved saliva production and relieved symptoms of xerostomia after irradiation for cancer of the head and neck, with minor side effects that were predominantly limited to sweating.
241|bleeding incidence,cerebral infarctions,Recurrent cerebral ischemic events,recurrent ischemic stroke or death or in the rate of major hemorrhage,frequency of or time to the primary end point or major hemorrhage,number of patients with TIA/RIND,composite event "death from all vascular causes, nonfatal stroke, nonfatal myocardial infarction, or nonfatal major bleeding complication,efficacy and safety,HR for ischaemic events,rates of major hemorrhage,myocardial infarctions,Cerebral infarction,Severe hemorrhage,myocardial infarction or sudden death,adverse events,recurrent cerebral ischemic events,death,incidences of TIA and TIA-IR,mean achieved INR,gastrointestinal disorders,death or recurrent ischemic stroke,composite of death from all vascular causes, non-fatal stroke, non-fatal myocardial infarction, or major bleeding complication, whichever occurred first,rate of death from nonvascular causes,rate of death from vascular causes,major bleeding complications,recurrent ischemic stroke,major hemorrhage,cerebral hemorrhage,severe stenosis or occlusion of a large artery,ischemic stroke, brain hemorrhage, or death from vascular causes other than stroke|Cerebral infarction was recorded in 4 patients in each of these treatment groups during a mean follow-up period of 20 months.
||
not found|actual maternal behaviors,maternal behavior scores,favorable attitudes toward feeding and communication,adolescents' mothering behaviors|Brief culturally sensitive videotapes may be effective strategies to promote parenting skills and to prevent social and health problems among adolescents.
not found|weight, coronary heart disease (CHD) risk factors, and incidence of diabetes,prevalence of central obesity,consecutive fasting plasma glucose (FPG) values,cumulative incidence of diabetes,Body mass,progression to diabetes,multiple metabolic/inflammatory abnormalities,type 2 diabetes as diagnosed using World Health Organization criteria,3-year cumulative incidences of diabetes,measures of eating, exercise, and fitness; weight losses,glucose tolerance,obesity and whole body insulin sensitivity,risk of type 2 diabetes,behavior, weight, or physiological parameters,metabolic syndrome,incidence of diabetes,total fat consumption,changes from baseline in: nutrient intake; physical activity; anthropometry, glucose tolerance and insulin sensitivity,rate of development of diabetes,total/saturated fat intake and increased polyunsaturated fat/fiber intake and exercise level,Weight losses,mean (+/-SD) amount of weight lost,hypertriglyceridemia,Body weight,relative risk reduction,risk of diabetes,body weight,gradual deterioration of behavioral and physiological changes,plasma glucose values and higher BMI values,modest weight loss,Weight, waist circumference, high-sensitivity C-reactive protein, and most of the metabolic syndrome components,cumulative 4-year incidence of diabetes,metabolic abnormalities,net loss,weight loss,risk of developing diabetes, and weight loss,baseline BMI and fasting glucose, the diet, exercise, and diet-plus-exercise interventions,short insulin tolerance test (ITT|The relative risk reduction was 28.5% with LSM (95% CI 20.5-37.3, p=0.018), 26.4% with MET (95% CI 19.1-35.1, p=0.029) and 28.2% with LSM + MET (95% CI 20.3-37.0, p=0.022), as compared with the control group.
57|mean hearing loss,hearing loss,recovery time,pure-tone average and subjective symptoms,vertigo, nausea and headache with spontaneous recovery,total effective rate,rate of side effects,side effects|No significant differences were observed in the improvements of pure-tone average and subjective symptoms between the PGE1 and the placebo groups.
236|nausea,mean (+/- SD) pain visual analog score,final VAS score; secondary measures included final pain relief rating scores, subject/investigator overall medication assessments, rate and time to discontinuation due to lack of efficacy, and selected quality-of-life/physical functioning scores,somnolence,multidimensional 'Western Ontario and McMaster Universities Osteoarthritis Index' (WOMAC) questionnaire (pain, stiffness and functional impairment,intestinal function,antinociceptive action,bowel functions and symptoms,rapid pain relief,synovial fluid concentrations of SP,synovial fluid concentrations,functional parameters,Pain,serious adverse events,mean final pain relief rating scores,adverse event,pain scores,efficacy and tolerability,pain relief,efficacy and safety Demographic data,Arthritis Pain Intensity Visual Analogue Scale (VAS), Western Ontario and McMaster Universities Arthritis Scale (WOMAC) Pain, Stiffness, Physical Function VAS subscales, Patient and Physician Global Assessment of Therapy, Sleep, dropouts due to insufficient therapeutic effect, and adverse events,constipation,intensity of joint pain,MEND,osteoarthritis flare pain,efficacy and safety,OA flare pain,Lequesne functional discomfort index, global efficacy assessed by the patient and the investigator, time to improvement, and use of acetaminophen as rescue analgesic medication,Sensation and pain thresholds,synovial fluid concentrations of SP and IL-6,Average daily pain intensity and pain relief scores,Electrical sensation and pain thresholds,WOMAC Pain, Stiffness and Physical Function subscales, the WOMAC Composite Scale, dropouts due to insufficient therapeutic effect, Patient and Physician Global Assessment of Therapy, and Sleep,Rates of response,Pain intensities,plasma and synovial fluid the concentrations of M1,efficacy of tramadol LP,adverse events,antinociceptive effects,Mean final VAS scores for tramadol/APAP plus COX-2 NSAID,analgesic effectiveness,median pain intensity,Pain at rest,mean pain intensity score,IL-6 synovial fluid concentrations,Efficacy and safety,plasma and synovial fluid concentrations of tramadol and its active metabolite (O-desmethyl-tramadol, M1,effective and safe,Western Ontario and McMaster Universities Osteoarthritis Index Questionnaire,Efficacy and tolerability,pain, stiffness, physical function, global status, and sleep,alleviating pain,physical function,tolerated and effective,Orocaecal transit time,adverse event-related withdrawals,pain and functional capability,average daily pain intensity and average daily pain relief scores,Huskisson visual analog scale for pain,nausea, vomiting, and dizziness,Global tolerability,synovial fluid concentrations of interleukin (IL)-6 and substance P (SP,Colonic transit times,pain relief and functional improvement in osteoarthritis,minimum effective naproxen dose (MEND,Arthritis Pain Intensity VAS,global efficacy,WOMAC Physical Function and the Medical Outcome Study Short Form-36 Role-Physical measures,pain reduction|There was a significant difference (P = 0.040) in the treatment effect between the naproxen responders and nonresponders, thus demonstrating a difference in the way responders and nonresponders react to a decrease in naproxen dosage after the addition of tramadol.
905|rates of response,rates of sustained response and remission if natalizumab,rescue medication,CDAI,remission rates,Serious adverse events,rates of adverse events,highest response rate,response and remission rates,Elevated circulating lymphocyte levels,Crohn's Disease Activity Index (CDAI) score,sustained response through week 36,changes in scores for the Crohn's Disease Activity Index,remission,safety and efficacy,adverse events,circulating B and T lymphocytes,quality of life,change in CDAI,quality of life and C-reactive protein levels,disease remission (a CDAI score of less than 150,health-related quality of life, and C-reactive protein levels,response rates,rates of clinical remission and response,higher rates of sustained response,highest remission rate,rate of clinical remission|Natalizumab, a humanized monoclonal antibody against alpha4 integrin, inhibits leukocyte adhesion and migration into inflamed tissue.
                
not found|lean mass and physical function,protein malnutrition assessed by midarm muscle circumference, creatinine-height index and serum albumin,total protein and total calorie intake,number of falls,non-protein nitrogen appearance rate (nPNA,Short Form-36 health change score,change of ventilatory parameters,antibiotic prescriptions,Quality of life,Body composition,Calorie and protein intake,mean total energy,food intake,handgrip strength,nutritional outcome, morbidity, and quality of life (QOL,total lean mass,weight, skinfold thickness measurements, or quality of life,severe loss,nutritional intake and status,dry weight and BMI,Katz ADL index,energy intake,median time to progression and overall duration of survival,body composition and dietary intake,Karnofsky Performance Status Scale,shorter time of survival,nutritional status, morbidity, and quality of life,Intake,Nutritional intake,overall QOL,Lean body mass determined by bioelectrical impedance analysis,body weight,Mild hyperphosphatemia,BMD at the spine, femoral neck and total hip,Energy intake and nutritional status,serum CTX, a marker of bone resorption,maximum mean (SD,Body weight and BCM,bone metabolism,Body composition and bone mineral density (BMD,adequate intake or nutritional status,nutritional repletion,energy intake and gained weight,serum albumin level,body weight and somatic protein compartments,Main Outcome Measures: (1) Nutritional status parameters, BMI and serum albumin; (2) functional status on a 10-point Karnofsky scale; (3) adverse metabolic effects, hyperphosphatemia at start and end of study; and (4) subjective scoring for appetite, and acceptability of and tolerance to supplement,weight,enhanced gain of LBM,Total daily protein and caloric intake, food-derived protein and caloric intake, and supplement-derived protein and caloric intake,whole body protein metabolism,response rates, median time to progression, or overall duration of survival,energy intake and weight,serum albumin, calorie and protein intake, and nPNA,weight, anthropometry, and grip strength,regain of lean body mass,QoL ratings,Body cell mass and weight gain,baseline food intake,Weight, skinfold thickness, fat-free mass, grip strength, quality of life, and cognitive function (Buschke test,Nutritional status,food intake, body weight, response rate, survival, and quality of life,reduced symptomatology,weight gain,Nutritional behaviour and quality of life,frequency of patients with moderate or severe malnutrition,Ottery's Subjective Global Assessment), and QOL (determined by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire version 3.0 [EORTC QLQ-C30,O(2) saturation and a decrease in PaCO(2,Whole body leucine kinetics and leucine oxidation rate,bone resorption,Equal weight loss,Body weight, biochemical indices ,goal for energy intake and gained weight,hand-grip strength,body composition (body cell mass,BMI,anthropometric parameters and improved Subjective Global Assessment evaluation,energy and protein intake,acceptability and palatability of the HP blend formula, ease of use, and cost,intake of protein,Nutritional intake (diet history), status (Ottery's Subjective Global Assessment), and QoL (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire version 3.0,mean protein intake,efficacy and cost-effectiveness,Subjective Global Assessment,total caloric and protein intake,weight maintenance,immune responses,Mean intake per kilogram of body weight,function and symptom scales,physical performance,nutritional intake and gain in lean body mass (LBM,Serum albumin Levels,body weight, nutritional status, and quality of life,Complications, namely wound infection, chest infection, and antibiotic use,energy intake or percent ideal body weight,body weight development,oral intake, body weight, response rate, survival, and quality of life,tumor response rates,rates of anorexia, nausea, vomiting, and diarrhea,Medical Research Council dyspnoea score,energy intake increased in G1/G2,QoL,Katz activities of daily living (ADL) index, mini mental status examination (MMSE) and quality of life (QoL,weight loss,fat-free mass and grip strength,Total energy intake,Progressive loss of kidney function,fiber intake,Biochemical markers of bone turnover,respiratory function or skeletal and respiratory muscle strength,peak flow,morbidity, and quality of life (QoL,mean intervention time,maintain nutrient intake,initial nutritional status,Fat free mass,incidence of disease remission,serum albumin,body composition, muscle function and quality of life (QoL,patient outcomes,Quality of life (QOL,CD4 counts and viral load,skin fold thickness,daily energy intake,functional status, QoL and rehospitalization,gain in fat mass,fat mass,Triceps skinfold thickness (TSF) and midarm muscle area (MAMA,Dietary intake (protein, energy, fiber,Serum osteoprotegerin (OPG,reactivity to skin test antigens,Crohn's disease activity index,bone-specific alkaline phosphatase,tumor response rate,Protein intake,Refeeding and weight gain,weight overall,triceps skinfold thickness, dietary intake, fecal fat, and pain score,grip strength,G3,serum albumin level and functional scoring,caloric intake,body cell mass,weight (B), [mean (SD) % change in BMD lumbar spine,Quality-of-Life index (QL-index,Inspiratory muscle strength,readmissions,Weight loss and protein malnutrition,weight loss and improved ADL functions,nutritional status (Subjective Global Assessment), and energy and protein intake (3-day food record,reduction of incidence/severity of grade 1+2 anorexia, nausea/vomiting, xerostomia, and dysgeusia,quality of life (QoL,function, symptoms, and single-item scores,absolute lymphocyte count,Anthropometry, grip strength, and QOL,total body weight,BMD at the lumbar spine and total hip,changes in handgrip strength, general well-being score, perception of health and number of falls,For colorectal cancer, serum albumin, alkaline phosphatase, lactic dehydrogenase (LDH) levels, and percent targeted caloric intake (TCI,e.g. insulin-like growth factor,body weight, but triceps skinfold measurement,peritoneal transport rate and MAMA,functional status,nutritional status, respiratory and skeletal muscle strength, respiratory function, perceived dyspnoea, activities of daily living (ADL) and quality of life,Mean daily energy intake,nutritional intake,dietary intake,survival advantage,fat-free mass,Serum osteocalcin,Age, body cell mass (BCM), muscle function, gender distribution and QoL,weight and QoL,body weight gain,RT toxicity,nutritional status, QOL, and morbidity,factors: 'malaise', 'psychological distress', 'therapy side-effects,weight and arm muscle circumference,protein intake,metabolic rate,improvement/deterioration of QoL,St George's Respiratory Questionnaire total score,Leucine oxidation (protein catabolism,body weight and tricipital skinfold,dietary intake (24-h recalls), body weight, and QoL (EORTC-QLQ C-30,physical performance such as muscle strength, balance, mobility and activities of daily living, as well as nutritional aspects such as energy intake, body weight and fat-free mass,Energy intake after RT,QOL function scores,lower- extremity muscle strength,lymphocyte CD4 counts, on plasma TNFR 55, TNFR 75 and ILR 2 concentrations and on quality of life,rapid weight gain,expiratory muscle strength,Response rate and overall survival,Nutritional behaviour,muscle function and quality of life,Serum IGF-I levels,total energy intake,weight loss, serum albumin concentration, and presence of liver metastases,subjective global assessment, body composition by bioelectrical impedance and anthropometry, muscle function with hand-grip strength and peak flow,nutritional status,body composition (increased lean mass, decreased fat mass,Involuntary weight loss,SA levels|The nutrition intervention group had a higher mean total energy (P=0.029) and protein intake (P<0.001) compared with the standard practice group.
132|rate of antenatal hospitalization,Preterm delivery and birth weight,diastolic blood pressure (dBP,Mean dBP,preterm birth,serious maternal complications,systolic and diastolic BP levels,serious perinatal and maternal complications,neonatal intensive care unit (NICU) admission,serious perinatal complications,severe hypertension,gestational age at delivery,Clinician compliance,development of severe hypertension,Control of Hypertension|Mean dBP was significantly lower with tight control:
not found|CD4 cell counts,rates of viral clearance,virologic failure (loss of HIV suppression,plasma HIV-1 RNA concentration,patients' adherence and minimise toxicity,initial virion-clearance rate,viral loads,loss of viral suppression,undetectable plasma HIV-1 RNA concentration,virologic failure,detectable HIV-1 RNA,suppression of plasma HIV RNA,risk of virologic failure,viral suppression|Similar results were obtained when the one abstract was excluded (odds ratio, 5.48; 95% confidence interval, 2.82 - 10.65).
not found|AMI volume,CABG volume,quality of cardiac care,HMO choices,health plan choices,individual process-of-care indicators, a hospital report card impact survey, and all-cause AMI and CHF mortality,composite AMI and CHF indicators based on 12 AMI and 6 CHF process-of-care indicators,hospital mortality rates for CHF,mean 30-day AMI mortality rates|The strongest effects were among white patients and those with HMO coverage in California, and among white or other patients and those with Medicare in New York.
                
200|total drainage volume, hourly zero drainage, heart rate, or occurrence of arrhythmias,volume of drainage,drainage, incidence of cardiac tamponade, incidence of surgical reentry, hemodynamic values, and number of manipulation episodes|Statistical analyses revealed no difference in any of the dependent variables when milking and stripping were used.
60|Headache,visual analog scale,severity of the headache,PDPH,pain ,mean of headache intensity,post-puncture headache,mean headache intensity,Relief of PDPH measured as delta VAS (initial VAS - VAS,10-cm visual analogue scale, severity of headache,postdural puncture headache,mean pain score,headache intensity,severity of headache or requirement for epidural blood patch,headache,Intensity of headache, quantitated using a visual analogue pain scale (VAS|After 24 hours, mean headache intensity was 3.87 (+/- 1.63) in conventionally treated group versus 0.73 (+/- 0.74) in hydrocortisone group (p <0.001).
271|toxicity,morbidity and prolongs hospital stay,Postoperative infections,Therapeutic concentrations,rate of postoperative infections,septic complications,majority of wound infections,occurrence of both anaerobic and aerobic bacteria,incidence of postoperative wound infection,incidence of anaerobic wound infection,hospital wound infections,number of aerobic organisms,frequency of non-clostridial anaerobic infection,overall incidence of infection,wound infection rate,wound infections,overall rate of wound infection,rate of infectious complications,Septic morbidity,Postoperative wound infections,post-operative wound sepsis rate,Anaerobic infection,Blood levels,safety and efficacy,postoperative wound infections,erythematous rash,Late sepsis,overall infection rate,rate of wound infection,incidence of wound infection,overall infection rates,incidence of complications,Nonperforative appendicitis,average length of hospitalization and convalescence,rate of post-operative infections,infection rates,rate of postoperative wound infection,wound infection,anaerobic infection,postoperative wound infection,Sepsis rates,wound-infection rate,days of hospitalization,anaesthetic complication,duration of postoperative hospital stay,incidence of infectious complications,incidence or severity of wound infection or post-operative intra-abdominal sepsis,rate of postoperative infectious complications,wound infection, the hospital stay,Wound sepsis,infection rate|In those receiving both drugs the infection rate was 3%, a highly significant difference from that in the other three groups.
63|Energy restriction,Dietary intake,prevalence of gestational diabetes mellitus (GDM,Key obstetric and fetal outcomes,diastolic blood pressure and no adverse effects on blood lipids,Fasting levels of beta-hydroxybutyrate,Self-perception,blood pressure, glycemic control, lipids and insulin sensitivity,Self-monitored-blood-glucose (SMBG), maternal and infant weight,Adherence,Glycaemic control,postprandial glucose values,pregnancy outcomes,prevalence of macrosomia,Glycemic control,effectiveness, tolerability and safety,diastolic blood pressure,ketonemia,frequency of insulin therapy,Metabolic effects,Glucose concentration,Energy intake adequacy,blood glucose,Dietary intakes,effectiveness, safety and tolerability,blood pressure and glucose metabolism,energy intake adequacy,Fasting plasma insulin,pre-pregnancy BMI,blood pressure,Mean birthweight,birth weight centile,insulin sensitivity,Average adherence,Optimal glycemic control,glucose concentration,urine ketones,mean glucose levels,pregnancy outcomes, neonatal anthropometry, and maternal metabolic profile,Ketonuria,adverse pregnancy outcomes,fasting plasma glucose and glucose tolerance,fasting blood glucose,birth weight,ambulatory blood pressure, blood lipids, glycemic control and insulin sensitivity estimated by an intravenous glucose tolerance test,glycaemia,Obstetrical outcomes|A low-glycemic index diet is effective as a treatment for individuals with diabetes and has been shown to improve pregnancy outcomes when used from the first trimester.
37|nausea,satisfactory response, eradication of the infecting organism, development of superinfections, and occurrence of adverse events,median duration of neutropenia and defervescence of fever,persistent bacteremia,Excellent response,microbiological eradication of gram-negative,infection, and unexplained fever,overall cure rate,febrile infective episodes,Defervescence,efficacy and cost effectiveness,fever and neutropenia,Infection,success rates,overall successful outcome,febrile neutropenic episodes,duration of hospitalization,neutrophil counts of <100/microL. Microbiologically documented infection,infections and unexplained fever,median time to fever defervescence,overall response rates,average cost of antibiotics,initial clinical response,median neutrophil count,nephrotoxicity,total episode cost,876 febrile, neutropenic episodes,Amikacin levels,Duration of fever,overall treatment costs and duration of hospitalization,acute leukemia,durations of fever, neutropenia, and hospitalization,nephrotoxicity nor hypokalemia alone,Costs of hospitalization, antimicrobial drugs, and supportive therapy,Blood cultures,cure rates,bacteremia,rates of superinfection,clinical response rates,infection eradication success,response rates,Control of infection,duration of neutropenia,lower potassium level,Allergic reactions,per episode antibiotic cost,efficacy, safety and tolerance,Median duration for defervescence,mean total antibiotic drug cost,infection rate,Urinary beta-NAG,reversible side effects,infection-related death,granulocytopenic episode,renal side effects,febrile neutropenia,depth and duration of granulocytopenia as well the distribution of the infection categories and rate of bacteremia,adverse event,Global response,Overall success,haematological malignancies,incidence of gram-negative and gram-positive isolates,leukemia or lymphoma,median durations of neutropenia,Fifty febrile netropenic episodes,successful outcomes,tolerated and produced response rates,response rate,incidence of side effects,febrile events,nausea or vomiting,rate of treatment modification,morbidity and mortality,success or failure,proportion of patients that became afebrile,clinical response,Gram positive cocci,febrile neutropenia episodes,infection-related mortality,Superinfection,Efficacy and tolerability,Hodgkin's lymphoma (NHL,Severe neutropenia,Duration of fever, neutropenia, and hospitalization, mortality, and the need for additional antibiotics or antifungal drugs,adverse events, duration of hospitalization, and cost between both groups,severe hypokalemia,early death,granulocytopenia,Clinical and laboratory adverse effects,efficacy,rates of clinical cure or improvement and of elimination of causative pathogens,serum levels of creatinine, urea and beta 2-microglobulin and the urinary excretion of alanine aminopeptidase, N-acetyl-beta-D-glucosaminidase (beta-NAG) and beta 2-microglobulin,efficacy, safety, and tolerance,leukopenia,Microbiological adverse effects,Efficacy and costs,Infectious mortality,nausea/vomiting or seizure,cost effective,efficacy and tolerability,clinical efficacy and tolerability,cure rates for gram-negative bacteremias,cost of change of antibiotics,duration of fever, clinical symptoms, antibiotic therapy, and granulocytopenia,Partial response rates,overall initial response,renal tubular damage,clinical sites of infection, degree of neutropenia underlying malignancy, and organisms,Superinfections and toxicity,superinfections of fungal origin,overall response rate,Mortality,overall clinical rate of response to imipenem,urinary excretion of AAP,withdrawals or deaths,gram-positive,tolerated,adverse experiences; drug-related adverse events,skin rash and vomiting,Gram-positive bacteremia,clinical efficacy,median duration of antibiotic therapy,Gram-positive infections,Response rates,adverse effects,prolonged neutropenia,unexplained fever,treatment failure,persistent Staphylococcus aureus bacteremia,toxicity,percentages of patients responding to therapy,response rate regarding gram-negative infections,occurrence of gram-negative bacteria,Bacteremia,renal failure,febrile neutropenia (FN,Efficacy,efficacy and safety,overall success rate,failure rate,69 febrile granulocytopenic episodes,initial clinical response rate,Adverse events,costs of the antimicrobial drugs, hospitalization, and total cost,complete response rates,adverse events,fever of unknown origin,episodes of profound neutropenia,tolerability,mean neutrophil counts,gram-negative,success rate,efficacy, safety, and cost of cefepime,Serum peak and trough concentrations of the antibiotics,mean duration of neutropenia,median total duration of neutropenia,febrile episodes,Overall treatment success,serum creatinine,rates for gram-negative rod bacteremia,Duration of fever, hospitalization, and antimicrobial drug administration,Clinical cure or improvement,Six febrile episodes,side effects,occurrence of further infections|Gram-positive bacteremia responded poorly in the meropenem and ceftazidime/amikacin group (29% versus 25%), whereas all gram-negative bacteremias responded except for one in the meropenem group caused by Pseudomonas aeruginosa.
33|general health,decreased anxiety,peak oxygen uptake (VO2peak), a dynamic strength endurance test (maximum number of repetitions for chest and leg press exercise,sleep medications,change in QOL,quality of life (QOL,longer sleep duration,Quality of life,maximum heart rate,vigor and a reduction in fatigue,QoL. Physical performance and activity level,overall well-being and quality of life,Changes in QOL (eg, Functional Assessment of Cancer Therapy,QOL and the overall physical fitness,aerobic fitness,cardiorespiratory fitness, strength endurance, task specific functional muscle capacity, body composition and quality of life (QOL,Peak oxygen consumption,Quality of life and physical performance and activity,depressive and state anxiety scores,patient-rated physical functioning assessed by the Trial Outcome Index-Anemia,sleep quality and quality of life of cancer patients,peak oxygen consumption,Good adherence,body fat,faster sleep latency,quality of life and social body image,overall QOL,decreased depression,overall quality of life (QoL,Cancer QLQ-C30 (EORTC-C30) questionnaire,physical quality of life,Self-esteem,higher satisfaction,overall QoL, psychosocial functioning, cardiovascular fitness, and body composition,muscle strength,mental distress or HRQOL,body mass index and percent body fat,depression, (Beck Depression inventory), anxiety (Speilberger State-Trait Anxiety Inventory), and self-esteem (Rosenberg Self-Esteem Inventory,HRQL and self-esteem,performance in leg press,global QOL scores,CES-D scores,Fatigue (p<0.001), depression (p<0.001), body mass index,aerobic capacity,mild fatigue levels, sleep disturbance, and mild pain,quality of life, fatigue, mood and inflammation,Sleep actigraphy,subjective sleep quality,Median adherence,Exercise and quality of life,exercise behavior,fatigue and health-related quality of life,Quality of life and symptoms,Exercise and dietary behavior, fatigue, health-related quality of life (QOL), aerobic exercise tolerance, functional capacity, muscle strength, and anthropometery,Strength and QOL variables,social functioning,physical functioning and quality of life (QoL,back/leg muscle strength,Taiwanese version of the Pittsburgh Sleep Quality Index, the Medical Outcomes Study Short Form-36, the Taiwanese Version Ratings of the Perceived Exertion Scale, and a walking exercise log,depression,Strength and Health subscale,body composition measurement, quantified walking activity and patient-reported outcomes (physical activity, fatigue and health-related quality of life,Isometric muscle strength and aerobic capacity,Tai Chi Chuan, health-related quality of life and self-esteem,fatigue,QoL. Physical activity level,QOL and depressive symptoms,fatigue (P=.005), aerobic exercise tolerance (P=.010), chair sit-to-stand performance (P=.003), and waist-to-hip ratio,Health-related quality of life (HRQL) and self-esteem,strength and QOL changes,sleep quality,sleep quality and quality of life,psychosocial global score,fatigue (Multidimensional Fatigue Symptom Inventory-Short Form and Functional Assessment in Chronic Illness Therapy-Fatigue subscale,quality of life benefits,fatigue score,Baseline quality of life,Piper Fatigue Scale, General Sleep Disturbance Scale, Center for Epidemiological Studies-Depression Scale, and Worst Pain Intensity Scale,cancer-related fatigue,Reductions in distress,QoL, depression, exercise behavior, aerobic fitness; outcomes,enhanced sleep quality,risk of disease recurrence/progression,upper extremity strength and endurance, range of motion, fatigue, and quality of life,self-esteem and depressive and anxiety symptoms,physical performance,self-perceived psychosocial function and diurnal salivary cortisol secretion,anxiety, depression, body image, and health-related quality of life,waist-to-hip ratio,sleep scores,self-perceptions of appearance, health, physical strength, sexuality, relationships, and social functioning,physical activity,fatigue (t(153) ,fatigue and diurnal salivary cortisol concentration,global QoL,QoL,chronic fatigue and quality of life,lean body mass,Psychological adjustment and sleep quality,physical fitness test and QOL measures (e.g. Functional Assessment of Cancer Therapy scales,psychosocial wellbeing, individual body image, and physical fitness,peak cardiovascular fitness,fatigue, energy level, and emotional distress,Overall QOL,cardiovascular fitness,lower morning and 5 p.m. salivary cortisol and improved emotional well-being and fatigue scores,quality of life, mood, and spiritual integration,inflammation (CRP,psychosocial variables of emotional irritability, gastrointestinal symptoms, cognitive disorganization, mood disturbance, tension, depression, and confusion,initial fighting spirit,Functional Assessment of Cancer Therapy-Breast, social/family well-being, functional well-being, and breast cancer subscale scores,biomarkers, fatigue, sleep disturbances, and depressive symptoms,Body Image and Relationship Scale,mental health, depression, positive affect, and spirituality (peace/meaning,QOL and fatigue,sleep disturbance scores,Adherence,physical global QOL score,psychological distress,Quality of life (QOL,quality of life, physical functioning, positive and negative affect, depression, body composition, sleep dysfunction and self-reported physical activity,physiological and psychological function,Functional Assessment of Cancer Therapy-Breast scale,total minutes of PA, more minutes of moderate-intensity PA, and higher energy expenditure,psychosocial adjustment and quality of life,depressive and anxiety symptoms and self-esteem,Anxiety, depression, body image, and quality of life,fatigue and pain,range of motion of the shoulder joint, and psychosocial adjustment and quality of life,mood disturbance (t(122) ,inflammatory marker serum C-reactive protein (CRP,VO(2max,cardiopulmonary function and QOL,overall QoL,sleep,cardiorespiratory fitness and health-related quality of life,shoulder pain and disability,quantified physical performance and self-reported physical functioning,fatigue, sleep disturbance, depression, and pain,Shoulder pain and disability,joint stiffness,quality of life,depressive and anxiety symptoms,QOL,neck dissection impairment, fatigue, and quality of life,upper extremity strength,Pittsburgh Sleep Quality Index (PSQI), the Piper Revised Fatigue Scale, and the Center for Epidemiological Studies-Depression Scale,upper body strength,fatigue, social physique anxiety, and physical fitness,physical, cognitive and emotional status and somatic complaints with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core Module (EORTC-QLQ-30) questionnaire, and maximal physical performance,psychosocial (i.e. global quality of life, emotional function, and diarrhea) variables,Strength and QOL improvements,spiritual,Quality of Life questionnaire,intrusion or avoidance, state anxiety, depression, or fatigue,symptoms of side effects of cancer treatment and inflammation biomarker (CRP,fatigue and physical performance,quality of life (QoL,cortisol, serotonin, interleukin-6, and bilirubin biomarkers and fatigue, sleep disturbances, and depressive symptoms,Functional Assessment of Cancer Therapy-General and Functional Assessment of Cancer Therapy-Fatigue,global health,patient-rated shoulder pain and disability,quality of life (QOL), fatigue, distressed mood, and spiritual well-being,BIRS total score,lower-body flexibility,shoulder pain and disability and improved upper extremity muscular strength and endurance,changes in QOL (CARES short form) and depressive symptoms (CES-D,distressed mood,bodily pain,measures of Spiritual Integration,Fatigue and global health scores,upper extremity endurance,helplessness/hopelessness,physical fitness and quality of life outcomes,physical global score,peak oxygen consumption and overall QOL,decreased confusion,accelerometer physical activity counts,Psychological health outcomes,lean mass,anxiety,depression and state and trait anxiety,global quality of life, physical well-being, and functionality,Adherences,time interaction for overall QoL,body image (Physical Condition and Weight Concerns subscales,HRQL,self-esteem,self-reported emotional, health-related quality of life, and symptom outcomes,cardiopulmonary function and quality of life (QOL,Serotonin levels,sleep disturbance,Maximal oxygen uptake (VO(2)max/kg,PSQI,individual body image,fatigue and improving energy level, quality of life (mental and physical), fitness (VO 2submax), and emotional distress,12-month BIRS total and subscale scores, upper and lower body strength, and general quality of life (QOL,Fatigue, sleep disturbances, depressive symptoms, biomarkers, and exercise,quality of life (QoL) and physical performance and activity,mental distress, as assessed by the Hospital Anxiety and Depression Scale, and HRQOL, as assessed by the European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire,cardiorespiratory fitness (CRF), mental distress, and health-related quality of life (HRQOL) parameters,Physical activity,Baseline BIRS scores,dietary fiber intake,happiness, depressive symptoms, anxiety, stress, self-esteem, and quality of life,objective physical functioning,physical performance measures,EORTC QLQ-C30, FACIT-F, RBDI, and WHQ (for vasomotor symptoms) questionnaires,PA and improved fitness and specific aspects of psychological well-being,Functional Assessment of Cancer Therapy-Colorectal,physical functioning and quality of life,Physical performance,dietary behavior, fatigue, aerobic exercise tolerance, functional capacity, and waist-to-hip ratio,mental health dimension of quality of life,quality of life over time,overall mood and body esteem,change in CRF, as determined by Astrand-Rhyming indirect bicycle ergometer test (maximum oxygen uptake [VO(2max)]), between baseline (T0) and follow-up (T1|Significant differences favouring the intervention group were observed for fatigue at 12 weeks and 6 months follow-up (12 week:
28|FVC,arterial oxygen saturation, FEV1 or forced vital capacity,expectoration and lung function,total lung capacity,Slow vital capacity,mean (SEM) functional residual capacity,sputum production or change in lung function,Wet and dry weight of sputum,lung function parameter,positive expiratory pressure,clearance of lung radioactivity,postural drainage (PD,Mucus clearance,Mucus transport,forced expiratory volume,Wet and dry weights of sputum,number of hospitalizations and antibiotic use,Mean clearance of tracer from the right lung by postural drainage, PEP and physical exercise,whole lung or regional TBC,sputum production, symptom score or peak expiratory flow rate,Shwachman-Kulczycki clinical score,Residual volume,pulmonary function studies,regards growth, Shwachman score, Chrispin-Norman score or pulmonary function tests,forced expiratory flow,Functional residual capacity and total lung capacity,positive expiratory pressure breathing,lung function, sputum expectoration, and SpO(2,Skin oxygen tension, PSO2,Sputum clearance,whole lung and regional tracheobronchial clearance (TBC,Lung function,pulmonary function,mean annual rate of decline in forced vital capacity,pulmonary function tests (PFTs,forced expiratory volume in the first second of expiration (FEV1), forced expiratory flow,airway resistance (Raw), or specific airway conductance (sGaw,Clinical status, pulmonary function, and compliance,Huang scores,symptoms and lung function,PEP-induced lung function improvement per milliliter of sputum,acceptability and subjective efficacy,increased hospitalizations,PSO2,Lung volumes,symptom scores, sputum production, or simple lung function tests,Lung function parameters (peak expiratory flow, forced vital capacity (FVC), forced expiratory volume in one second, maximal midexpiratory flow, maximal expiratory flow at 25% of FVC, thoracic gas volume, total lung capacity, residual volume/total lung capacity, airway resistance and specific airway conductance) and changes in transcutaneous oxygen haemoglobin saturation,FEV(1,number of spontaneous coughs,radioactivity content,quantity of sputum,whole lung TBC,ventilation distribution, gas mixing, lung volumes, expiratory airflow, percentage of arterial blood oxyhemoglobin saturation (SpO(2)), and sputum volume,Clinical status and pulmonary function (forced vital capacity [FVC], FEV1, and FEF25-75|At the end of the trial, no significant difference was found between the programmes as regards growth, Shwachman score, Chrispin-Norman score or pulmonary function tests.
467|toxicity,median survival time,survival,longer survival time,severe or worse thrombocytopenia,severe myelotoxicity,percentage of patients alive,histologic type (Astrocytoma with anaplastic foci, versus glioblastoma multiforme), initial performance status, time since first symptoms and presence or absence of seizure,longer survival,median time to progression,total survival,Median survival times,median time,survival curves,cure rate,reversible leukopenia and thrombocytopenia,long-term (18-month) survival,transient myelosuppression,longer survival period,median survival,survival rate,time to progression|The combination of carmustine plus radiotherapy produced a modest benefit in long-term (18-month) survival as compared with radiotherapy alone, although the difference between survival curves was not significiant at the 0.05 level.
19|BMD and BMC of lumbar spine and femur and on bone metabolism,low-density lipoprotein cholesterol,areal bone mineral density (aBMD) of the femoral neck and the lumbar spine,mean NTx urine concentrations,bone mineral density (BMD,bone mineral density (BMD) and metabolic bone parameters,urinary pyridinoline and deoxypyridinoline,Lumbar spine BMD,greater trochanter,femoral neck,bone mineral density,Pyridinoline and deoxypyridinoline levels,skeletal effects,baseline BMD, body mass index (BMI) and difference in BMI,SHBG,BMD and BMC of lumbar,urinary levels of PYR and D-PYR,bone metabolism and bone mineral density,serum osteocalcin (BGP), urinary pyridinoline (PYD) and deoxypyridinoline (D-PYD,protein C antigen,lumbar BMD,lumbar bone mineral density,bone formation,baseline demographic or anthropometric characteristics, or in BMD of users of either model of implant,bone turnover,serum lipid and bone density patterns,bone resorption,safe and well-tolerated,mean lumbar spine BMD,serum and urinary calcium, osteocalcin and urinary pyridinoline (PYD) and deoxypyridinoline (D-PYD) levels,lumbar bone mineral density values,alkaline phosphatase,Radial trabecular vBMD,urinary levels of pyridinoline and deoxypyridinoline, in calcium levels and in BGP levels,maximum bone mass,urinary PYD and D-PYD levels,periosteal bone formation,bone mineral density (BMD) changes and contraceptive efficacy,bone geometry and volumetric bone mineral density (vBMD,haemostasis, lipids, carbohydrates, bone metabolism, and sex hormone-binding globulin (SHBG,vertebral aBMD,efficacy, safety, and user satisfaction,Urine hydroxyproline and creatinine ratio (Hop/Cr,Total and LDL cholesterol, and apolipoproteins,maintaining BMD,bone turnover and bone mineral density,intermenstrual bleeding and spinal bone density,urinary levels of PYD and D-PYD,urinary levels of PYD and D-PYD, in calcium levels and in osteocalcin levels,BMD,bone mineral density and bone metabolism,percentage of change from baseline bone mineral density at the lumbar spine,levels of sex hormone-binding globulin (SHBG,endometrial hyperplasia,bone density,total cholesterol,incidence of bleeding anomalies,2-year treatment-failure cumulative pregnancy rate,serum and urinary calcium, osteocalcin, urinary pyridinoline, and deoxypyridinoline,Bone mineral density (BMD) and bone mineral content (BMC,bone turnover and bone mineral density (BMD,Areal bone density,percentage of change from baseline bone mineral density,total cross-sectional area,SHBG levels,duration of bleeding days,total triglycerides, HDL and HDL(2) cholesterol, and IDL lipoproteins,bone resorption (urinary levels of pyridinoline (PYR) and dexoxypyridinoline (D-PYR,Recovery of BMD,bone density and bone metabolism,spinal BMD values,Adverse events,Forearm bone density (BMDprox,mean BMD loss,total body,areal BMD,BMD loss,biological estrogenic effect,serum and urinary calcium, osteocalcin (BGP), urinary pyridinoline and deoxypyridinoline,bone turnover and bone-sparing effect,lumbar spine,serum calcium levels|Differences of lesser statistical magnitude were seen at the femoral neck (between group differences at 2 yr: 2.7%, P = 0.24), Ward's triangle (5.0%, P = 0.055), greater trochanter (3.6%, P = 0.056), total body (1.3%, P = 0.046), legs (1.3%, P = 0.065), and trunk (2.0%, P = 0.029).
not found|Survival,local recurrence of disease,died,Local control,survival,5-year disease-free and overall survival,local recurrence,disease-free survival,3-year actuarial disease-free survival,Relapse-free survival rates,3-year actuarial disease-free and overall survivals,actuarial disease-free survival,survival advantage,survival benefit,vaginal recurrence,distant metastases,5-year disease-free survival,overall survival,progression-free interval or survival,Actuarial 3-year overall survival,local recurrence rate,overall actuarial survivals,freedom from local recurrence and/or metastases and overall survival,overall survival advantage,5-year overall survival,overall survival rates,overall actuarial survival,suffered recurrences,local control, metastasis-free survival, disease-free survival, and survival,Partial suppression of distant metastasis,actuarial percentage survival figures,recurrence rates in specific cell types (leiomyosarcoma, homologous mixed mesodermal sarcoma, or heterologous mixed mesodermal sarcoma,cardiotoxicity presenting as pulmonary edema,congestive heart failure|The difference between the two groups is statistically significant (P less than .005, log rank test).
173|efficacy and tolerance,dropout rate,myasthenic muscular scores,duration of improvement,QMGS,quantified MG clinical score (QMGS,MSS variation,QMGS, and IVIg,tolerated,variation of a myasthenic muscular score (MSS,quantitative MG Score (QMG,QMG Score for Disease Severity,Quantitative Myasthenia Gravis (QMG) Score for Disease Severity,myasthenic muscular score|However, the difference between the 2 groups was not significant (effect size, 3.84 [95% confidence interval, -1.03 to 8.71];
not found|ESR, tenderness on palpation and subjective pain,serum Ca value,mineral metabolism parameters (serum calcium, phosphorus, alkaline phosphatase, 24-h urinary calcium, phosphate and 24-h hydroxyproline excretion) and radial bone mineral content (BMC,efficacy and safety,bone density (GS max, GS min and sigma GS/D,ratio of OKT-4/OKT-8,bone density,BMC,duration of morning stiffness, number of joints with pain, number of joints with swelling and Lansbury's index,bone atrophy,Activity indexes (ESR and clinical parameters,percentage of patients with slight improvement,side effects,serum alkaline phosphatase and 24-h hydroxyproline excretion|Furthermore, serum alkaline phosphatase and 24-h hydroxyproline excretion decreased significantly only in Group A, and BMC decreased significantly in Group B but rose slightly in Group A.
70|consciousness,neuropsychologic function,driving capacity,renal failure,acute hepatic encephalopathy,Acute hepatic encephalopathy,plasma AAA/BAA ratio,liver function tests,psychomotor functions (line tracing, tapping, steadiness, auditory reaction time), attention (digit table), and practical intelligence (digit symbol, number connection test,Survival and discharge,adverse reactions,Semiquantitative nitrogen balance,mental state,safety and efficacy,cerebral state and on nitrogen homeostasis,psychomotor disturbances,negative nitrogen balance,index of portal-systemic encephalopathy,encephalopathy,semiquantitative nitrogen balance,renal and two respiratory failure, and one remained encephalopathic,coma score,recovery rate|No significant difference was noted based on clinical evolution, even though the plasma AAA/BAA ratio was corrected using the modified AA solution.
19|Urinary sodium, potassium, and chloride losses,Pulmonary mechanics,tidal volume and compliance,urine output,lung compliance and decreased airway resistance,static respiratory compliance,efficacy and safety,Six hour urine output,pulmonary function measurements,diuresis or renal side effects,pulmonary function,Total respiratory resistance,excretion of urinary electrolytes,hypokalemia, chloride deficiency, hypercalciuria, nephrocalcinosis, and rickets,lung compliance,pulmonary resistance,urine volume,airway resistance,tidal volume and pulmonary compliance,pulmonary mechanics,birth weight,tidal volume,urinary electrolyte losses|Single dose nebulised frusemide improves pulmonary function in premature infants with evolving chronic lung disease without adverse effects on fluid and electrolyte balance.
788|Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-cog/11) and the Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) total score,cognitive function deteriorated,safety and tolerability,activities of daily living,Efficacy,Safety and tolerability,efficacy and safety,cognition, daily function, and behavior,improving cognition, including executive function,ADCS-ADL score,cognitive function,ADAS,cognitive performance as assessed using the eleven-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog/11,Clinician's Interview Based on Impression of Change-Plus Caregiver Input (CIBIC-plus), Neuropsychiatric Inventory, and EXIT-25 for assessment of executive functioning,global functioning,cognition|Patients treated with galantamine had a greater improvement in ADAS-cog/11 after 26 weeks compared with placebo (-1.8 vs -0.3; p < 0.001).
426|Bracket failures,strength of adhesion,frequency of failed brackets,debonding time for GIC,bracket survival,survival time and cariostatic potential,survival time distributions,bracket survival time,bracket failure rates,risk of bond failures,Survival time distributions|The survival time distributions for brackets bonded with each bonding agent were not significantly different (P = .74, paired Prentice-Wilcoxon test; P = .75, Akritas test), with bracket failure rates of 17% and 20% recorded for compomer and resin adhesive, respectively.
23|Mini-Mental State Examination,Alzheimer's Disease Assessment Scale--Cognition,secondary endpoint Montgomery Asberg Depression Rating Scale (MADRS,relevance of discourse, (b) performance of functional abilities, (c) emotional symptoms, (d) quality of life, and (e) overall global function,cognitive tests, activities of daily living scale, neuropsychological battery and scales to evaluate caregivers' depressive and anxiety symptoms,Mini-Mental State Examination (MMSE) scores,behavioural and functional outcomes,IG(MCI,discourse abilities, functional abilities, emotional symptoms, and overall global performance,cognitive function and quality of life,Cognitive-communication, neuropsychiatric, functional performance, and quality of life evaluations,cognitive and non-cognitive functions,backward digit span scores,specific cognitive and psychopathological ratings,negative emotional symptoms,cognitive and functional performance,psychiatric symptoms,cognitive and behavioural measures,apathy, irritability, and patient-reported quality of life,MMSE score,Quality of Life - Alzheimer's Disease scales,cognitive and neuropsychological tests,Alzheimer's Disease Assessment Scale - Cognition (ADAS-Cog,tests of information and orientation and various aspects of memory,scores of MMSE, OSGP and GDS,change in global cognitive function as determined by the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and the Mini Mental Status Examination (MMSE,emotional symptoms of apathy and irritability|At the end of the 3 months of therapy significant differences emerged in the scores of MMSE, OSGP and GDS obtained by the two groups.
not found|caries increment,approximal dental caries,dental caries incidence,dental caries,incidence of dental caries,effectiveness against caries|There was no significant difference in effectiveness against caries between the use of the organic or inorganic fluoride products.
1469|visual analog pain scales and Roland-Morris activity scales,mean pain intensity,patient-specific function (PSFS, 3-30) and global perceived effect (GPE, -5 to 5) at 8weeks,Pain scores,disability,Sick-leaves and visits to health centers,levels of disability and perceived pain,LVVA-SM and HVLA-SM,leg and low back pain,perceived disability,best extension effort and fatigue time,pain, general health and functional disability levels,spinal flexion,mean functional status,Pain, health and functional disability level,vertebral manipulation effectiveness,SF-36 Health Survey, a 10-cm visual analog scale for overall back pain, the Roland-Morris Disability Questionnaire, lost work or school days because of back pain, and satisfaction with back care,back pain and physical functioning and greater satisfaction,pain- and disability-score changes,pain relief,mean improvement in RMDQ,back pain, greater satisfaction with back care,measure of dysfunction,dropout rate,function (Oswestry scale score decrease,regarding pain [risk difference,pain and activity scores,leg pain,FD,Oswestry Back Pain Index, Neck Disability Index, Short-Form-36, and Visual Analogue Scales,physical functioning and mental health,physical outcome measures (range of motion, fatigue, strength or pain,disability index,average and most severe low back pain intensity in the past week, assessed with 0 to 10 numerical rating scales, and low back-related disability, assessed with the 24-item Roland-Morris Disability Questionnaire,Rates of full compliance,Patient-rated low back pain, disability, and functional health status,Adjusted mean Roland Morris Disability change scores,average in functional status,back pain,Pain, disability, and perceived recovery,flexion and pain,low back pain intensity and disability,visual analog scale, range of motion, maximum voluntary extension effort, straight leg raising and Biering-Sorensen fatigue test,6-month disability outcomes,Oswestry disability scores,Roland-Morris Disability Questionnaire (RMDQ) and Numerical Rating Scale,Roland Morris disability questionnaire,pain and better function,back pain and disability,leg and low back pain intensity and disability (Roland-Morris Disability questionnaire,recurrent pain and moderate to severe symptoms,patient confidence,pain and disability index,visual analogue scale (VAS) for perceived pain, the Roland Morris (RM) Questionnaire for low back function, and the SF-36 for overall health status,low back-related disability assessed with the 24-item Roland Morris Disability questionnaire,Oswestry Disability Questionnaire,physical functioning,Sick-leaves,intensity of low back pain, disability, handicap, medication, and quality of life,Pain improvement,mean disability questionnaire scores,perception of pain and disability,relief from pain,pain,pain (visual analogic scale score decrease,pain reduction,stabilizing and flexibility exercises, the use of modalities, and cardiovascular training|The mean changes in low back pain intensity and disability of participants in the medical and chiropractic care-only groups were similar at each follow-up assessment (adjusted mean differences at 6 months for most severe pain, 0.27, 95% confidence interval, -0.32-0.86; average pain, 0.22, -0.25-0.69; and disability, 0.75, -0.29-1.79).
29|seizure-free,dizziness (0/14), difficulty with coordination (0/29), depression (7/14) lack of energy or strength (20/43), insomnia (40/43), mood instability|In the LEV group, 13 patients (87%) were seizure-free.
38|frequency of inadvertent rupture of the ovarian masses,postoperative pain and analgesic requirement, hospital stay, and recovery period,postoperative pain and minor complications,Surgical difficulty,Mean hospitalization,Endometriotic cysts and dermoid cysts,Surgical times, estimated blood loss, post-surgical pain, time in hospital, speed of recovery and complications,operative and hospitalization times and postoperative course,intensity of pain,intensity of postoperative pain and the length of convalescence,hospitalization time,Operative times,size of ovarian masses, adnexal adhesion score, or frequency of bilateral disease,Post-operative pain, duration of stay in hospital and duration of convalescence,Operating time,Post-surgical pain,operative morbidity,postoperative stay,C-reactive protein; interleukin-6 before, during, and after surgery; intensity and duration of postoperative pain; and complications and recovery period,Mean blood loss,Recurrence of ovarian teratomas,demographic characteristics,intensity of postoperative pain,operative morbidity, postoperative pain, analgesic requirement, and recovery period,recurrence of mature ovarian teratomas,intraoperative rupture rate of the cyst,operative time, intraoperative complications, ileus, length of stay and recovery time,milder pain, faster hospital discharge,relative risk for intraperitoneal spillage,levels of the interleukin-6 and C-reactive protein|No complications were reported in either group.
not found|nausea,Peak analgesic effect,total pain relief over 8 hours (TOPAR8,supplemental analgesia sooner,analgesic activity,time to rescue medication,longer median time to use of rescue medication,adverse experiences of nausea,time to onset of effect,Rescue analgesia,total pain relief (TOPAR) score over 8 hours (TOPAR8; primary end point), TOPAR score over 12 hours (TOPAR12), sum of pain intensity difference (SPID) over 8 and 12 hours (SPID8 and SPID12), patient's global assessment of study drug at 8 hours, time to confirmed perceptible pain relief (ie, time to onset of analgesic effect), peak pain intensity difference (PID), peak pain relief, time to first dose of rescue medication (ie, duration of analgesic effect), and percentage of patients using rescue medication,adverse events overall,tolerated; the overall incidence of adverse experiences,greater TOPAR8 scores,duration of analgesia,pain, osteoarthritis, and rheumatoid arthritis,patient global assessment of response to therapy (PGART) at 6 hours, onset of analgesia, peak analgesic effect, and duration of analgesia,onset of analgesia, peak pain relief, and duration of response,ex vivo COX-isoform specific assays (serum thromboxane B2 [TXB2,peak pain relief and peak PID,gastrointestinal safety profile,duration of action,shorter time to onset of analgesia,total pain relief over 8 h (TOPAR8,adverse experiences, physical findings, and laboratory measurements,scores of pain intensity, pain relief, and global assessment at prespecified time intervals,overall efficacy (total pain relief and patient global assessment,Summed Pain Intensity Difference,onset of analgesic effect,pain and inflammation,pain relief, and lower pain intensity,overall analgesic efficacy,Tolerability,total pain relief,total pain relief (TOTPAR,analgesic efficacy and adverse effects,postsurgical pain,duration of effect,number-needed-to-treat (NNT,tolerated and adverse events,peak pain relief,faster onset of analgesic effect,analgesic efficacy and tolerability,time-weighted sum of total pain relief,nausea, postextraction alveolitis, and vomiting,total pain relief over 6 hours (TOPAR6, the primary end point) and 4 hours (TOPAR4), patient's global assessment of treatment at 6 hours (GLOBAL6) and 24 hours (GLOBAL24), summed pain intensity difference over 6 hours (SPID6), onset of analgesic effect (time to perceptible/meaningful pain relief, using a 2-stopwatch method), peak pain relief (PEAKPR), peak pain intensity difference (PEAKPID), and duration of analgesic effect (time to use of rescue analgesia,mean time-specific pain intensity difference and pain relief scores,supplemental analgesia,incidence of clinical and drug-related adverse events,Overall analgesic efficacy,median times to use of rescue medication,Interference Domain,gastrointestinal and nervous system adverse events,longer duration of analgesic effect,adverse-events (AE) profile,orthostatic blood pressure,dizziness and orthostatic blood pressure reduction,adverse experiences,vomiting,peak analgesic effect,peak effects,overall analgesic effect was total pain relief over 6 hours (TOPAR6,TOPAR4, patient global assessment, peak pain relief, and duration of analgesic effect,adverse events and nausea,time to rescue analgesia,Adverse effects,Adverse experiences,mean TOPAR12 scores,Brief Pain Inventory Severity,level of pain and pain relief,Severe pain,Onset of action,Analgesic efficacy,frequency of patient-reported adverse events,rescue analgesia,global assessment, onset of analgesia, or AEs,24-h Pain Severity scores,TOPAR12 scores,time to confirmed perceptible pain relief,pain intensity and pain relief for 24 h using visual analogue scales (VAS) and verbal rating scales (VRS,overall analgesic effect, onset of action, peak effect, and duration of effect,pain intensity difference and pain relief scores,pain relief and intensity,efficacy and tolerability,pain intensity, pain relief, and global evaluations,pain intensity, pain relief, and global assessments,TOPAR6,time-weighted pain relief score,median times to confirmed perceptible pain relief,onset of analgesia, pain intensity levels, and pain relief over 24 hours, time-weighted sum of total pain, sum of pain intensity difference, the percentage of patients requiring rescue medication and experiencing regimen failure, and patients' global evaluation,total pain relief, onset time, and duration of response,maximum possible pain relief,Peak pain relief,time to rescue medication, time to pain relief, and mean pain intensity difference (MPID), as well as safety profile,TOPAR12,overall analgesic effect,nausea and vomiting,time to meaningful pain relief,median times to meaningful pain relief,pain on global evaluations,tolerated,median time to first rescue medication,Median onset of analgesia,perceptible pain relief, and patient evaluations of pain intensity, pain relief, and global assessments,maximum pain relief,meaningful pain relief,pain severity,total pain relief over 8 hours (TOPAR8) and 24 hours (TOPAR24) and patient global assessments,patient global assessment for rofecoxib,analgesic effect and peak analgesic effect,moderate pain,total pain relief (TOPAR), sum of pain intensity difference (SPID), and patient global assessment of response to therapy (PGART,dizziness,severe pain,analgesic effects,clinical adverse experiences (AEs) and vital signs,duration of analgesic effect,Pain,median times to first rescue medication,pain relief,peak pain relief scores,analgesic onset and peak,peak pain relief score,Efficacy,scores [TOPAR8, TOPAR12, SPID8, SPID12, and patient's global assessment,analgesic efficacy,Adverse events,median time to use of rescue medication,analgesic effect,safety profile,adverse events,TOPAR over 6 h; SPID,analgesic efficacy and tolerability profile,Onset of analgesia,supplemental narcotic analgesia,overall analgesic effects, onset of analgesia, and peak analgesic effects,MPID,quicker onset of analgesia,moderate postoperative pain,pain|Onset of action was significantly faster with valdecoxib 40 mg (30 minutes) compared with rofecoxib 50 mg (45 minutes), as measured by pain intensity difference and pain relief scores (P <or= 0.05).
298|admittance and discharge and hospital-acquired infections and pressure sores were scored and costs related to nutrition, infections and length of hospital stay,Frequency of dietician referral,average weight,number of patients with pressure sores,Frequencies of dietician referral and documentation of weight,nutritional status, hospital-acquired infections and pressure sores,Body mass,frequency of problem detection or intervention,number of hospital acquired infections,health status,malnutrition/weight loss, visual impairment, hearing loss, cognitive impairment, urinary incontinence, depression, physical limitations, and reduced leg mobility,Cost-effectiveness,Hearing loss,detection of, and intervention for conditions screened, and health status 6 months,Costs|The number of hospital acquired infections was significantly lower in the intervention group (33/140 versus 58/158, p=0.01) but no significant difference in number of patients with pressure sores (23/140 versus 33/158) was found.
not found|Initial uric acid level,Blood levels of uric acid, creatinine, phosphorus, calcium, lactate dehydrogenase and complete blood count,metabolic problems,incidence of sepsis,anuria,metabolic complications,severe allergic reaction to urate-oxidase,highest risk to develop a TLS,initial plasma uric acid levels,efficacy, safety, and pharmacokinetic profile of rasburicase,TLS,plasma uric acid,renal dialysis,Response rates,area under the serial plasma uric acid concentration curves,incidence of TLS and anuria,Incidence of tumor lysis syndrome,rate of renal and metabolic complications,Uric acid levels,hyperphosphatemia,acute renal failure,TLS or anuria,metabolic problems that included hypocalcemia,antirasburicase antibodies|Initial uric acid level decreased significantly by 4 hours (from 343 micromol/L to 58 micromol/L, p<0.001), except for one steroid-resistant patient who required hemodialysis on day 14 after having introduced combined cytostatic treatment.
160|risk of acid aspiration,gastric volume and pH,gastric secretion,Nalbuphine consumption,Mean pH1 and pH2 values,gastric pH and aspirated gastric volumes,narrowest range of pH values of gastric contents,gastric contents,Gastric volumes,pH values of gastric fluid,Gastric content,pain relief,Pain intensity score on sitting and sedation,mean pH,innate pH of gastric juice,incidence and severity of nausea and vomiting,Intragastric pH and volume,volume and pH of the gastric contents,smaller volumes of aspirated gastric contents,Mean pH,alkaline values of gastric pH,effective means to control and neutralize gastric secretion,PI pH,Apgar score, cord blood gas analysis, and neurobehavioural assessment,Gastric pH,gastric pH,Gastric aspirate pH and volume,mean pH1 and pH2 values,Mean gastric pH,higher intragastric pH but larger intragastric volumes,gastric volume,risk of acid aspiration of gastric contents,adverse effects,neutralize acidity,gastric pH less,Mean pH1 and mean pH2 values,volume of the gastric content,gastric volumes,intragastric pH less,median gastric fluid pH|Patients receiving omeprazole in single oral dose regimen retained a greater gastric volume (> or = 0.4 ml/kg) than those who received famotidine or ranitidine (p < 0.005).
24|respiratory symptoms,volume of airway surface liquid, restore mucus clearance, and improve lung function,respiratory function,forced expiratory volume in one second (FEV1) and forced vital capacity (FVC,mucus clearance and improved lung function,forced expiratory volume,total lung capacity (RV:TLC,time to reach peak FVC,forced expiratory volume in one second, forced vital capacity, oxygen saturation, body weight, sputum volume, culture and rheology, serum urea, and electrolytes, white cell count and erythrocyte sedimentation rate,1-hour rates of mucus clearance,Mucus clearance and lung function,Forced vital capacity (FVC), the forced expiratory flow,frequency of infective exacerbations,FEV1,FVC and secondarily on FEV(1), FEF(25-75), the number of days on antibiotic therapy, the Shwachman score, a nutritional index (weight/height(2)), the change in sputum bacterial flora, and nocturnal cough,Bronchopulmonary exacerbations,lung function,time to reach peak FEV1,forced vital capacity (FVC), forced expiratory volume in 1 sec (FEV(1)), and forced mid-expiratory flow (FEF(25-75,24-hour rates of mucus clearance|A comparison of the changes in lung function in the two groups showed no significant difference.
not found|Rates of condyloma and dysplasia,detection rate of dyskaryosis,Endocervical detection of CIN,rate of any pathology,number of positive Papanicolaou smears,incidence of smears containing cylindrical and/or metaplastic cells,serious adverse events,Endocervical cells,abnormal epithelial changes,production of smears containing endocervical cells (EC,cellular composition of cervical smears,Red blood cells,Multispatula samples,condyloma, dysplasia, and cancer; dysplasia and cancer; moderate dysplasia, severe dysplasia, and cancer,Cytologic abnormalities,Efficacy,adequacy of ectocervical smears,risk of bleeding,epithelial abnormalities,endocervical cells,presence of columnar cells or squamous metaplasia,concentration of endocervical cells,number of adequate smears,rate of cervical intraepithelial neoplasia (CIN) diagnosis,detection rate,endocervical cell pickup rates,endocervical cell yield,incidence of smears with endocervical cells,Rocket samples,smear quality and endocervical cell recovery,dyskaryotic smears,proportion of smears containing one or other type of indicator cell,contain immature metaplastic cells,rate of pathology and abnormal cytology,detection of grade III cervical intraepithelial neoplasia (CIN III,bloody Papanicolaou smears,cellular quality of the smears,false negative rate,incidence of scanty or unsatisfactory smears,presence or absence of endocervical cells,success rate,cervical intraepithelial neoplasia,rate of adequate smears,Endocervical or metaplastic cells,detection of endocervical cells,yield of endocervical cells,number of moderately and severely atypical epithelial changes,endocervical cells, and rate of cervical neoplasia,Cervex-Brush,percentage of smears containing endocervical cells,cytological detection of persistent cervical intraepithelial neoplasia,effectiveness in obtaining satisfactory Papanicolaou smears,detection rate of cervical condyloma acuminatum and squamous dysplasia,sensitivities of cervical cytology|The sampling methods had similar abilities to obtain a satisfactory smear (Cytobrush/spatula 63%, cotton swab/spatula 57%; P = .23).
1123|mean sitting diastolic BP (msDBP,mean sitting systolic blood pressure,Adverse event rates,adverse events and number of patients discontinuing therapy,DBP and SBP,mean sitting systolic,mean sitting systolic/diastolic blood pressure,antihypertensive efficacy and safety,trough mean sitting DBP and systolic blood pressure (SBP,efficacy and tolerability,BP,Rates of adverse events and laboratory abnormalities,mean sitting diastolic BP (DBP,safety and tolerability,antihypertensive efficacy, safety and tolerability,Hypokalemia,mean sitting DBP and systolic BP (SBP,mean sitting DBP,BP lowering,blood pressure,PRA,change in MSDBP,incidence of adverse events,tolerated,Efficacy and safety,trough SBP,BP reductions,BP (maximum MSSBP/MSDBP reduction,safety and tolerability profile,mean sitting diastolic BP,MSDBP and mean sitting systolic blood pressure (MSSBP,blood pressure (BP) reduction,antihypertensive effect,Tolerability,msDBP,plasma renin activity (PRA,successful treatment response (diastolic blood pressure,control rates,BP reductions (mean sitting systolic BP/mean sitting diastolic BP,mean sitting diastolic blood pressure,BP reduction|Once-daily oral treatment with aliskiren 300 mg significantly (P < .0001) lowered mean sitting DBP and systolic BP (SBP) compared with placebo; aliskiren monotherapy demonstrated a safety and tolerability profile comparable to placebo.
1774|preterm birth rate,Preterm birth rates|There was no evidence to suggest that the secondary interventions provided added benefit over the primary intervention protocol of preterm birth prevention education and increased visits.
                
55|cure rate according to general practitioner completed questionnaires and recurrence of symptoms between days 21 and 42,pain parameters,clinical symptom score,microbiologic eradication rates,swelling,equivalent cure rates,frequency of adverse events,glacial acetic acid,efficacy and tolerability,visual analogue scale and a six-step infection score,Success rates,clinical symptom score (consisting of the subscores redness, swelling, pain, and secretion) and of the visual analogue scale (VAS) rating for pain,frequency and type of adverse events,CSS,swelling, pain, and redness,overall cure rates,rates of adverse events,change of an aggregate clinical symptom score (CSS) (subscores: redness, swelling, pain and secretion,clinical or microbiological and clinical cure,pain relief,pain-relieving tablets,time to end of pain, symptom scores (otalgia and tenderness) and microbiological eradication,edema,efficacy and safety,Median time to end of pain,glacial acetic acid, dexamethasone and neomycin sulphate,Cure]); microbiologic eradication,relief of severe pain,severe redness,severe symptom score,infected mastoid cavities,Recurrence of symptoms,safety and efficacy,severe secretion,pain,clinical response,reduction in ear inflammation,Ear pain,inflammation,clinical cure rates,tolerated,Cure,redness, pain and secretion,effective and safe,Efficacy and safety,overall clinical response,efficacy, safety, and ear-pain resolution,Efficacy and tolerability,tolerability and efficacy,eradication rates,pain severity,resolution of discharge,efficacy and tolerance,inflammation score,efficacy, safety, and pain relief,change of the CSS from Visit 1 to the study termination, and the changes in the subscores and of a visual analog scale for pain,duration of symptoms (days) according to patient diaries,resolution of discharge, swelling, pain, and redness and the incidence of adverse side effects,reduction of swelling,overall clinical-microbiological response,low systemic exposure, absence of ototoxicity,audiometric measurements,relief of significant pain (moderate or severe pain,Signs and symptoms of AOE, including ear inflammation, tenderness, edema and discharge,severe pain,Staphylococcus aureus and Pseudomonas pyocyanea,relief of pain|S. aureus seemed to be most resistant to treatment, while P. pyocyanea was less of a therapeutic problem.
10|rheumatic disease activity,inflammatory activity,number of tender joints,VAS and RAI,thrombocyte count,disease activity measures,disease activity variables,erythrocyte sedimentation rate (ESR,adverse effects (nausea, diarrhoea,radiological destruction,average level of pain,Furthermore, levels of antibodies against gliadin and beta-lactoglobulin,ESR, CRP and haemoglobin,Ritchie score,reduced pain, stiffness, consumption of analgetics, several clinical variables, and serum concentration of orosomucoid,Body Mass Index,disease activity according to composite symptoms (Paulus index) of arthritis,objective signs of improvement,immunoglobulin G (IgG) antibody levels against gliadin and beta-lactoglobulin,pain intensity, morning stiffness, HAQ-score, number of swollen joints, joint tenderness, erythrocyte sedimentation rate, and patient's global assessment of health,swollen joint score,fibre intake,food intolerance, reduced gastrointestinal permeability,controls concerning symptoms, drug consumption, or clinical and biochemical variables,rheumatologic, laboratory, immunologic, radiologic, or nutritional findings,clear remission,Pain, stiffness, medication, and clinical and biochemical findings,subjective symptoms of rheumatoid arthritis,grip strength,vitality,Assessments of duration of early morning stiffness (EMS), pain on a 10 cm visual analog scale (VAS), the Ritchie articular index (RAI), swollen joint score, the Stanford Health Assessment Questionnaire, global patient and physician assessment, body weight, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and haemoglobin,tolerated and the rate of drop-outs,A composite disease activity index (DAS28), a physical function index (Health Assessment Questionnaire (HAQ)), a health survey of quality of life (Short Form-36 (SF-36)), and the daily consumption of non-steroidal anti-inflammatory drugs,physical function, and improved vitality,subjective relief of rheumatic symptoms,DAS28,weight,ESR, CRP, thermographic joint score or functional score,disease activity (Health Assessment Questionnaire, duration of morning stiffness, pain at rest and pain on movement,HAQ-score,disease activity|A significant improvement was found in the number of tender joints (p = 0.04) in the experimental group, whereas improvement was found in the erythrocyte sedimentation rate (ESR) (p = 0.03) and in the thrombocyte count (p = 0.02) in the control group.
50|Pain,transient sensory disturbance,recovery of isometric grip strength,sustained maximal voluntary isometric contraction,roentgenographic loss of position during fracture union,complication rate,upper extremity MFA domain scores, overall Jebsen Taylor scores, and pinch and grip strength tests,Colles' type distal radial fracture,function,isometric grip strength,Radiographic evaluation and range of motion,mean Jebsen Taylor scores and SF 36 bodily pain scores,noncomplicated pin-tract infection,radial shortening,Global function and pain,angulation of the distal radius,grip strength,excellent or good outcome and patient satisfaction,Upper extremity MFA scores, Jebsen Taylor scores, SF-36 bodily pain scores, and grip strength,Upper extremity function,overall function, range of movement and activities of daily living,Grip strength,radiological signs of post-traumatic arthritis,better length and palmar tilt restoration,distal radial fractures|The functional result correlated with the anatomical result, which was significantly better in patients treated by external fixation.
not found|adverse reactions|Over a battery of cognitive tests, indomethacin patients improved 1.3% (+/-
6|mean (+/-SE) heart rate,monitoring heart rate and perceived exertion during exercise,mean plasma glucose level,exercise tolerance,exercise endurance of the forearm muscles,heart rate and perceived exertion,maximal oxidative work capacity,mean peak free fatty acid levels and reduced exercise capacity,muscle complaints with creatine,skeletal muscle function,median frequency in surface electromyograms during contraction,neurologic adverse effects,BCAA meal tripled plasma BCAA levels, increased BCAA catabolism,serum creatine and serum creatine kinase levels, phosphorus 31 magnetic resonance spectroscopy, and surface electromyograms,body mass index,intensity of exercise-induced pain in working muscles,tolerance to everyday activities,exercise capacity,depletion of phosphocreatine,peak oxygen consumption or level of leg fatigue,limitation of daily activities,electromyographic amplitude,heart rate, level of perceived exertion, and venous blood glucose levels,level of perceived exertion fell,phosphorus 31 magnetic resonance spectroscopy variables,Calorific intake,work capacity,Phosphocreatine depletion,plasma glutamine and alanine|Both sucrose treatments dramatically improved exercise tolerance, compared with the placebo.
40|relative tachycardia,mean proportionate increase in FEV,adverse events,oxygen tension,nausea,ASS,clinical asthma score over time, length of pediatric intensive care unit stay, or incidence of adverse events,Peak expiratory flow rates,length of hospital stay,Blood gas pressures,clinical asthma score over time, length of pediatric intensive care unit stay, and incidence of adverse events,median hospital cost of medication and theophylline blood levels,rate of recovery,longer duration of oxygen therapy,length of stay in hospital,asthma severity score (ASS,synergistic bronchodilator effect,pulse rate of 8 beats per minute and 2 beats per minute|The median hospital cost of medication and theophylline blood levels was significantly lower in group 1 compared with groups 2 and 3 (280 US dollars vs. 3,908 US dollars vs. 4,045 US dollars, respectively, p < .0001).
                
983|Mean blood pressure,Concentration of low density lipoprotein cholesterol,Blood pressure and high-density lipoprotein cholesterol,coronary heart disease,risk factors (blood pressure, cholesterol, and smoking status); prescribing of hypotensive agents, lipid lowering drugs, and antiplatelet drugs; blood pressure, serum cholesterol level, and plasma cotinine levels,Restriction of everyday activities, dietary habit, smoking habit, frequency of physical exercise; blood pressure, body mass index, and serum total cholesterol concentration,cholesterol lowering drugs,patient risk of cardiovascular death and satisfaction,lipid concentrations (serum total cholesterol,event rates and all-cause mortality,number of patients admitted to hospital,consultation rates, process of care measures,diastolic blood pressure,consultations for coronary heart disease, the recording of risk factors, and advice given,serum cholesterol concentrations,Low density lipoprotein cholesterol,aspirin management,Body mass index,health outcome,blood pressure (diastolic pressure,total cholesterol concentration,quality of life,cotinine levels,satisfaction score,Serum total cholesterol concentration, blood pressure, distance walked in 6 minutes, confirmed smoking cessation, and body mass index,systolic blood pressure,total cholesterol,lipid management,smoking cessation,quality of life (SF-36,low density lipoprotein cholesterol,limits: systolic blood pressure,total National Health Service cost,numbers on aspirin or lifestyle measures,smoking habit, systolic or diastolic blood pressure, cholesterol concentration, or body mass index,physical activity,dietary habits,taking daily physical exercise,blood pressure management,appropriate treatment [derived from the National Service Framework (NSF)], health status (SF-36, EQ-5D) and an economic evaluation,non-fatal cardiovascular event,blood pressure and total cholesterol concentration|Blood pressure and high-density lipoprotein cholesterol were more frequently within recommended levels in the intervention group than in controls: odds ratio 1.63, 95% confidence interval 1.05-2.51, and odds ratio 2.61, 95% confidence interval 1.32-5.18, respectively.
                
32|Mood and energy regulation in seasonal and non-seasonal depression,psychological subscale of the Beck Depression Inventory (BDI,depressive state,strength, morale, and quality of life,physiologic capacity, quality of life, morale, function and self-efficacy without adverse events,maximal oxygen uptake,major depressive disorder (MDD) and a HAM-D score,depression measured by the Cornell Scale for Depression in Dementia, mood measured by the Dementia Mood Assessment Scale and the Alzheimer's Mood Scale, and affect measured by the Observed Affect Scale,mood, body weight and oxygen consumption,cognitive abilities,Depression,severe depressive symptoms,oxygen consumption,depression according to HRSD,health and wellbeing,17-item Hamilton Rating Scale for Depression (HAM-D(17,HAM-D or BDI scores,social functioning,remission rates,reduction of depression scores,depression,depression, neuroendocrine stress hormones and physiological fitness,role emotional,depressive state, hormonal response to stress and physiological fitness,peak oxygen uptake and lung capacity,strength measured by 1 repetition maximum for chest press,fastest initial response,Hamilton Depression Rating Scale (HAM-D,17-item Hamilton Rating Scale for Depression (HRSD,Strength,CES-D rating scale, urinary cortisol and epinephrine levels, and cardiorespiratory factors at rest and during exercise endurance test,aerobic capacity,depression measures (Beck Depression Inventory,strength,Weight loss,Inventory of Depressive Symptoms (clinician and self-report), HRSD scores at 24 weeks, cardiorespiratory fitness, self-efficacy, and quality of life,lower HAM-D scores,adverse events,Quality of life subscales of bodily pain,SF-36 mental health scores and clinician-rated depression scores,HAM-D and BDI scores,mood nor metabolic parameters,depression scores,Geriatric Depression Scale, Clinical Global Impression and Patient Global Impression,BRMS scores,aerobic capacity, life satisfaction, self-esteem, anxiety, and dysfunctional cognitions,depressive symptoms,HAM-D, GAF and CGI score,vitality,resting heart rate,Hamilton Rating Scale for Depression (HRSD,Severity of depression assessed with the Bech-Rafaelsen Melancholy Scale (BRMS) and the Center for Epidemiologic Studies Depression scale (CES-D,lower depression scores,GAF and CGI scores,mean change in HAM-D(17) score,psychiatric scores,Symptoms of depression,Aerobic capacity,Median compliance,physical functioning,Hamilton Rating Scale of Depression,measures of both emotional (clinician and self-report) and physical (observed and self-report) functioning,presence and severity of MDD using Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria and Hamilton Rating Scale for Depression (HAM-D) and Beck Depression Inventory (BDI) scores,percentage of days absent from work during the last 10 working days,Muscle strength,trait anxiety and a standard psychiatric interview,somatic symptoms of the BDI,Depressive status, physical and mental health and quality of life,HAM-D(17) score,CES-D total depressive score|Quality of life subscales of bodily pain (p = .001), vitality (p = .002), social functioning (p = .008), and role emotional (p = .02) were all significantly improved by exercise compared to controls.
15524|Morbidity and Mortality (M&M) entries and anonymous adverse/near-miss events,inpatient deaths,number of submissions|Only 25% of complications and 42% of inpatient deaths were reported.
204|adverse emergence phenomena,postoperative airway symptoms,haemodynamic changes,Induced hypotension,incidence or severity of postoperative sore throat, hoarseness or dysphagia,Sore throat and dysphagia,Severity of sore throat,Sputum incidence,postoperative throat problems,incidence and severity of sore throat,arterial blood pressure and heart rate,Nausea, postoperative vomiting, dysphonia, and hoarseness,effectiveness and safety,postoperative sore throat and cough,peak cuff pressure,postoperative sore throat,No laryngospasm, rupture of ETT cuff, or depression of the swallowing reflex,visual analog scale,postoperative sore throat, hoarseness and dysphagia,nausea, vomiting, dysphonia and hoarseness,Pressure and volume changes of tracheal tube cuff,incidence of side-effects,occurrence of high cuff pressures,Endotracheal cuff pressures,Plasma concentrations,pressure and volume of a tracheal tube cuff,verbal analogue scale, Melzack's Present Pain Intensity Scale of the McGill Pain Questionnaire,Pressures in Lido cuffs,sore throat, cough and hoarseness,sore throat, hoarseness or dysphagia,sore throat and cough,Hoarseness, bucking, dysphonia, dysphagia, cough, restlessness, and postoperative nausea and vomiting,sore throat incidence,frequency of postoperative cough and sore throat,Plasma lidocaine levels,systolic arterial pressure,lower ET discomfort and sore throat incidence,hemodynamic effects, restlessness, dysphonia, and hoarseness,arterial blood pressure and cardiac frequencies,Plasma lidocaine concentrations,ET cuff pressures,post-operative side-effects,sore throat and hoarseness,ET discomfort before tracheal extubation, and sore throat, hoarseness and coughing incidence,incidence or severity of sputum,frequency of sore throat,peak cuff pressures, the incidence of reaction ('bucking,postoperative airway symptoms of sore throat, cough, and sputum,Cough and restlessness before tracheal extubation,ETT tolerance,disturbance of haemodynamic responses,Effectiveness and safety,sore throat,incidence and severity of postoperative sore throat, hoarseness and dysphagia,ET discomfort and postoperative sore throat incidence,postoperative cough and sore throat,cuff pressure,incidence of sore throat,Cough incidence,Postoperative sore throat occurs,number of side-effects,incidence of sore throat, hoarseness, or tracheal irritability,Tracheal complaints,postoperative sore throat, including endotracheal cuff design, endotracheal tube size, intubation technique, laryngoscopy blade, airway placement, suctioning technique, and anesthetic technique|The frequency of sore throat was significantly different among the six groups at 1 hour and at 24 hours, with greater frequency in the G3, G2, and G6 groups.
                
51|Spontaneous pregnancy,pregnancy rate (PR,subclinical or recurrent varicoceles, normal semen parameters, and azoospermia,seminal volume, sperm motility and abnormal sperm morphology,sperm concentration increased and sperm motility,occurrence of adverse events,seminal improvement and pregnancy rates,semen parameters,Improvement of semen and pregnancy rate,sperm density and total motile sperm count,semen parameters, regardless of pregnancy occurrence,sperm concentration,pregnancy rates,spontaneous pregnancy rate,semen analysis and hormonal parameters,Mean ,sperm density and motility,pregnancy rate,Pregnancy,cumulative pregnancy rates,seminal improvement and pregnancy rate,Sperm parameters (sperm density, motility and morphology,incidence of pregnancy 1 year after randomisation,sperm parameters and pregnancy rate,progressive motility,male fertility,infertility such as anovulation or tubal blockage|During an observation period of 53 months (range 36 to 74 months) we found no statiscally significant improvement in the semen crude variables, the morphology or the progressive motility in the series of men submitted to surgery.
not found|adverse events, vital signs, and physical, neurologic, and laboratory examinations,Mean plasma concentrations of LTG,sleep latency,tolerated|Mean plasma concentrations of LTG, were linearly related to dose, although there was substantial interindividual variation.
100|cerebral malaria,level of consciousness became normal,neurologic sequelae,Complications, including pneumonia and gastrointestinal bleeding,Coma or hyperparasitemia,parasitemia|There were eight deaths in the dexamethasone group and nine in the placebo group (no significant difference; P = 0.8); at post-mortem examination the brain showed features diagnostic of cerebral malaria in all but one patient who died.
151|CS score,mean zinc serum level,functional parameters,Snellen equivalent visual acuity,contrast sensitivity,gastrointestinal irritation rate,stabilization of VA,serous pigment epithelial detachment developed without angiographic evidence of CNV,choroidal neovascular membrane (CNV,visual and retinal acuity, color vision, and contrast sensitivity,visual acuity outcome,visual acuity, contrast sensitivity, color discrimination, and retinal grating acuity, as well as serum levels of zinc and copper, red blood cell count, hemoglobin, and morphologic changes detected by grading of monochrome fundus photographs and fluorescein angiograms,nonexudative alterations (drusen size, drusen confluence, hyperpigmentation, and focal degeneration of the retinal pigment epithelium,final mean NEI VFQ-25 composite scores,mean eye macular pigment optical density,visual acuity, contrast sensitivity, and light flash recovery time,contrast sensitivity (CS,contrast sensitivity (CS) and National Eye Institute visual function questionnaire (NEI VFQ-25) scores,VA, CS, and visual function,visual acuity and visual function,net subjective improvement,macular function,Macular light flash recovery time,Serum levels of copper, hemoglobin, and red blood cell count,visual acuity,mean changes in visual acuity (VA,VFO-14 questionnaires conceming subjective glare recovery,visual loss,Macular degeneration|Although some eyes in the zinc-treated group lost vision, this group had significantly less visual loss than the placebo group after a follow-up of 12 to 24 months.
44|distress,respiratory rate and oxygen saturation levels,effective level of anesthesia,Pain response,percentage of circumcision procedure time a neonate spent crying,behavioral characteristics and amount of crying,pain and stress,Pain reduction,Behaviors (clarity of cues and responsiveness,plasma cortisol levels,small hematomas,crying,redness and blistering of the foreskin,Behavioral (facial activity and time spent crying) and physiologic (heart rate and blood pressure) responses,neonatal circumcision pain,pain-related measurements,time spent crying,heart rate, smaller drops in oxygen saturation, and less crying,Newborn distress,agitation,baseline cry duration, tissue oxygenation, and heart rate,mean increase in their occurrence,pain distress (percentage of time crying and heart rate,Indices of perceived pain including crying time, behavioral state, oxygen saturation, and heart and respiratory rates,spent less time crying,loss of oxygen saturation data,Blood methemoglobin concentrations,crying and lower heart rates,pre- and postcircumcision cortisol levels,plasma,mean Gomco time, 209 seconds) and percentage of respiratory rate change,behavioral distress,behavioral and physiologic indicators of neonatal pain,Cortisol levels,pain of circumcision,facial activity,pain response,Crying,physiologic and subjective stress reactions,heart rate,salivary cortisol changes,crying duration and type, vomiting, gagging, breath holding, and jitteriness,systolic,pain reduction,heart rate, rhythm, dysrhythmias, blood pressure, transcutaneous oxygen (tcpO2), rate pressure product, and behavioral state,Surgical complications and adverse effects,shortened crying time,rate of improvement or recovery curve,heart rate and crying time,percentage of the procedure time neonates spent crying,Heart rate, oxygen saturation, systolic and diastolic blood pressure, and crying time,facial actions indicative of pain,neonatal pain,Mean peak heart rates,Demographic characteristics such as gestational age and birth weight,Distress scores and heart rates,Methemoglobin level,Feeding behavior,safety and efficacy,Plasma for cortisol levels,Heart rates and oxygen saturations,local or systemic complications,Methemoglobin levels,Serum beta-endorphin concentrations,Efficacy and safety,sensitivity to cues and social-emotional growth-fostering scales,baseline behavioral state,SBP and DBP,dorsal penile nerve block (DPNB,pain and physiologic stress,Heart rate, cry, and methemoglobin level,pain responses,heart rate, respiratory rate, and crying during circumcision,diastolic,Blood pressure,neonatal circumcision pain with and without dorsal penile nerve block (DPNB,transcutaneous oxygen pressure levels,circumcision (choking and apnea,Pain ratings,Physiologic stress reduction,higher oxygen saturation,heart rate, respiratory rate, and crying time,heart rate, respiratory rate, and behavioral score,percentage change in heart rate from baseline, the percentage of oxygen saturation, and the score from the modified behavioral pain scale,Heart rate, transcutaneous oxygen saturation, facial activity, and crying,Oxygen perfusion, blood pressure, respiratory rate, heart rate, and cardiac rhythm,pain of neonatal circumcision,cardiac rate, rhythm, blood pressure, and transcutaneous oxygen,Oxygen saturation,adrenal cortisol response to surgery,mild erythema,Neonatal cortisol response,Facial-activity scores,respiratory rate,neonatal stress,infant pain response,Peak plasma concentrations,percentage of crying time and percentage of SaO2 change,Oxygen saturation differences,Physiologic and behavioral parameters,postoperative cortisol levels,subjective observation, measurement of heart rate, and the percent of time spent crying,heart rate and oxygen saturation changes,pain control,physiologic variables (heart rate, blood pressure, oxygen saturation, and respiratory rate) and behavioral score 20 minutes,arousal,uncomplicated pregnancies and vaginal deliveries,blood pressure,average oxygen saturation,preoperative and postoperative serum beta-endorphin and lidocaine concentrations,systolic blood pressures (SBP,heart rate and high-pitched cry,Facial expressions,Safety and efficacy,Physiological and behavioral monitoring,penile edema,stress reactions,pain responses; sucrose alone,heart rate and less crying,Heart rate, respiratory rate, SaO2, cortisol changes, and duration of crying,Heart rate and blood pressure,observational pain intensity rating scale and the physiologic parameters of heart rate, respiratory rate, oxygen saturation levels, salivary cortisol levels, and length of cry,heart rate during circumcision,severe pain,heart rate better,NIPS scores,pain, crying, agitation, and physiologic stress,total number,excursion from baseline heart rate, tissue oxygenation, and cry duration,spectral crying parameters,neonatal stress indicators,adrenal response,distress and cortisol response,Pain,heart-rate,Heart rate changes and total crying time,Behavioral observations,untoward reactions,elevation of heart rates,Respiratory rates,pain relief,transcutaneous oxygen levels, crying time, heart rate, and respiratory rate,efficacy and safety,Mean heart rate,mean systolic blood pressure,oxygen saturation,distress scores,behavioral distress and adrenocortical responses,Heart rate, transcutaneous oxygen saturation, and crying,heart rate and oxygen saturation, and subjective determinations of behavioral state,pulse rate and oxygen saturation,Heart rate, oxygen saturation, and crying time,heart rate, respiratory rate, and behavioral distress scoring,heart rate, respiratory rate, oxygen saturation levels, seconds of crying time, and overt generalized reaction,Brazelton Neonatal Assessment Scale (BNAS,duration of the crying and grimacing,Neonatal Infant Pain Scale (NIPS) score; secondary: heart rate, respiratory rate,Postoperative comfort scores,Postoperative pain,Heart rate, respiratory rate, and oxygen saturation (SaO2,Seconds of crying time,Infant state, salivary cortisol levels, and respiratory rates,diastolic blood pressures (DBP,pain,pulse rate|Feeding behavior deteriorated in breast- and bottle-fed neonates in both groups, and acetaminophen did not seem to influence this deterioration.
                
220|Bone alkaline phosphatase,GFR,Serum calcium and ionized calcium concentrations,serum Ca rose steadily and Cr.cl,mineralizing boundaries (M.Bd,hypercalcaemia or hyperphosphataemia,femoral neck,Serum Al levels,bone mineral density,initial serum 1,25(OH)2D levels,terminal renal failure,renal bone disease,Glomerular filtration rate (GFR,Bone histology,hypercalcemia,iPTH without causing hypercalcemia,respective median iPTH concentrations,bone metabolism and bone density,iPTH level,hypercalcaemia,rate of progression of renal failure,PTH levels,intestinal absorption of calcium and in plasma-calcium,serum iPTH, calcium, and phosphorus levels,parathyroid hormone levels,Serum C- and N-telopeptide and bone-specific alkaline phosphatase levels,Resorption indices,parathyroid hormone (PTH) suppression,serum phosphorus and alkaline phosphatase concentrations,creatinine clearances,plasma-phosphorus, plasma-alkaline-phosphatase, or in the degree of bone mineralisation,1,25(OH)2D3 quickly corrected hypocalcaemia, reduced serum-alkaline-phosphatases and serum-immunoreactive-parathyroid-hormone,serum calcium and phosphorus levels,Biochemical, radiographic, and histological indices of bone metabolism,height z scores,bone mineral content,mean iPTH decrease,S-calcium, S-phosphate, and urinary excretion of calcium,bone disease,Incidences of hypercalcemia, hyperphosphatemia, and elevated calcium-phosphorus product levels,Baseline 1,84 iPTH concentrations,final S-creatinine or change in S-creatinine,median intact PTH (iPTH) level,BMD,incidence of hypercalcemia (serum calcium concentration,PICP,parathyroid hormone (PTH) levels,urinary calcium and phosphorus excretion or deterioration in kidney function,glomerular filtration rate,iPTH,preservation of Ob,Serum iPTH (Allegro Nichols), 1-25 vitamin D (IRMA-MAB), total and ionized calcium (Nova 8 Pabish), serum phosphate, alkaline phosphatase and creatinine clearance,mineralizing activity,symptomatic or had radiological evidence of bone disease,Adverse-event rates and changes in GFR,Hypercalcaemic episodes,Bone mineral density,mean serum calcium or phosphorus or urinary calcium levels or incidence of hypercalcemia, hyperphosphatemia, or hypercalciuria,urinary excretion rate of calcium,p-osteocalcin and bone alkaline phosphatase,elevated resorption and osteoid indices,plasma iPTH, serum calcium and phosphorus, urinary calcium, bone-specific serum markers, and serum lalpha,25-dihydroxyvitamin D levels,serum A1 levels,bone mineral density (BMD) estimated by dual energy X-ray absorptiometry and plasma levels of biochemical markers of bone turnover [osteocalcin, bone alkaline phosphatase, propeptide of type-I collagen (PICP) and telopeptide of type-I collagen] and parameters of calcium homeostasis,Histological indices of bone turnover,mean serum alkaline phosphatase activity and intact parathyroid hormone concentration,percentage fall in creatinine clearance,Serum iPTH,risk of hypercalcemia,plasma levels of parathyroid hormone,renal function,iPTH concentration,Mean plasma iPTH level,femoral neck and lumbar spine,Serum PTH, urinary cAMP excretion, and bone resorption indices,iPTH levels,plasma levels of vitamin D metabolites,iPTH level reductions,calcium levels, phosphorus balance, and kidney function|Paricalcitol capsule was well tolerated and effectively decreased iPTH levels with minimal or no impact on calcium levels, phosphorus balance, and kidney function in patients with stages 3 and 4 CKD.
90|Neonatal rSO(2) and Apgar scores,fetal gasometric parameters,oxygen content,Arterial blood gases,demographic or hemodynamic variables, time from uterine incision to fetal extraction, neonatal birth weight, presence of umbilical cord abnormalities, type of resuscitation required by the neonate, or Apgar score,1- or 5-minute Apgar scores,umbilical arterial or venous pH, partial pressure of oxygen and partial pressure of carbon dioxide,maternal mean arterial pressure, heart rate and peripheral oxygen saturation,maternal and neonatal regional cerebral oxygenation (rSO(2,Fetal gasometric parameters,UA PO2 levels,fetal partial oxygen pressure,UA and UV PO2,cord vein-artery PO2 differential,UV PO2 levels,fetal arterial blood gases,maternal PaO2 levels and umbilical vein (UV) and umbilical artery (UA)PO2 levels,umbilical arterial and venous blood,Umbilical arterial and venous blood samples,Mean values of the UA blood samples,umbilical cord arterial blood,free radical activity and lipid peroxidation,Oxygen saturation and blood O2 contents,Apgar score,UV or UA blood gases, oxygen content or Apgar scores,umbilical venous PO2,oxygen free radical activity,maternal and fetal oxygenation and oxygen free radical activity,cord gas values,UV oxygen content,UA and UV blood samples,Oxygenation,fetal oxygenation,blood gases and the products of lipid peroxidation (8-isoprostane, malondialdehyde (MDA), hydroperoxide (OHP)) and purine metabolites,Maternal arterial, UV, and UA base excess values,maternal FiO2 and umbilical arterial (UA) and venous (UV) PO2, PCO2, pH, and neonatal Apgar score,Umbilical artery (UA) and venous (UV) blood samples,UV PO(2) or oxygen content,inspired fraction of oxygen, maternal partial oxygen pressure, and fetal partial oxygen pressure,cord vein PO2,Maternal arterial blood,maternal inspired fraction of oxygen,Maternal arterial samples and fetal UV and UA samples,maternal and fetal oxygenation and lipid peroxidation,Neonatal rSO(2), UA pH, UV pH and UA base excess (BE,fetal oxygen stores,Maternal PaO2 levels,maternal arterial PO2,Maternal and umbilical plasma concentrations of lipid peroxides (8-isoprostane, MDA, OHP,cord artery PO2,Oxygen saturation in maternal blood by pulse oximetry,UV PO(2,mean maternal rSO(2,pulmonary function, maternal oxygenation,PO2 in venous blood,Mean values of the UV blood samples,U-D interval, umbilical arterial (UA) and venous (UV) blood gases and oxygen content and Apgar scores|The Apgar score (1 min) in Group FM was lower than that of Group RA (p = 0.046).
                
not found|insulin concentrations,lethality rate,quinine toxicity,Coma mean durations,cerebral malaria,mean trough and peak plasma quinine levels,cardiovascular toxicity,Peak concentrations,cardiovascular side effects,mean cost,mean peak concentrations,time taken to clear parasites,hypoglycemia after admission,Transient partial hearing loss,clinical and parasitological response,Parasite clearance time,Hypoglycaemia,All blood concentrations,Mild toxic effects,body temperature,Fever clearance time,evolution of parasitemia,mean high and low quinine concentrations,Case-fatality rates|Transient partial hearing loss occurred significantly more in the study than control group (p < 0.05).
5|internal carotid artery dissection,initiation of heparin,TIA without CAD recurrence,cerebral infarction,Bleeding complications,chronic arterial stenosis,subsequent stroke,brain infarction,Arterial recanalization,extracranial bleeding complications,functional independence,recanalization rate,arterial hypertension,mental status, headache, unprovoked fall, focal weakness, neglect, and dysphasia,Resolution of the angiographic appearances,rates for death and stroke,Carotid recanalization,Ischemic optic neuropathy (ION,Migraine,retinal ischemia in 8, and local symptoms and signs (headache, neck pain, Horner syndrome, cranial nerve palsy,neurologic outcome,severe ipsilateral headache and orbital pain,PH pattern,recurrence (stroke and death) and clinical outcome at 6 months,visual aura,subjective bruit or painful,Ischemic optic neuropathy,risk of suffering a disabling stroke,recurrent CAD without stroke,Frontal and parietal localizations,cervical perforating wound nor atheromatous predisposing lesion,Bilateral VAD,Painful SCAD,Cerebral ischaemia,Intracranial haemodynamics,transient ischemic attacks,CAD recurrences,occipital and nuchal pain, with vertebral artery dissection,retinal ischemia,recanalization rate of CAD,massive stroke, embolic mechanism and lack of local recanalization,neck pain,Neurologic outcomes,overt cerebral ischemia manifest by paresis (three), sensory deficits,New ischemic events,traumatic extracranial CCAD,seizures,Functional outcome,Cerebral infarction,Irregular expansion, double lumen and aneurysmal dilation,Noniatrogenic traumatic extracranial internal carotid artery dissections,Recurrence of a dissection,Hemorrhagic complications,Recanalization,good recovery and early reopening of the occluded ICA,Ischemic and hemorrhagic complications, occurrence of seizure and rates of arterial recanalization,central retinal artery occlusion or ischemic ocular syndrome,hemorrhagic adverse events,Headache, facial pain, a subjective bruit, oculo-sympathetic palsy and transient monocular blindness,disabling stroke,Preceding traumata, vascular risk factors, presenting local and ischemic symptoms, and patient-outcome,overall mortality,Brachiofacial hemiparesis,risk of stroke, TIA, or dissection recurrence,transient ischemic symptoms or arrested progression of established neurologic deficits,Stagnating blood flow velocities,bilateral dissections,verified CAD recurrence,result of distal thromboembolism,efficacy and safety,variables stroke and arterial occlusion,Complete recanalization of vertebral dissections,contralateral ICAD,new cerebral ischemic events, defined as ischemic stroke, TIA, or retinal ischemia, 2) symptomatic intracranial hemorrhage, and 3) major extracranial bleeding,Risk of stroke and recurrent dissection,initiation of anticoagulation,modified Rankin Scale (mRS) and Barthel Index (BI,ischemic events or dissection recurrences,fibromuscular dysplasia,clinical symptoms of sudden unilateral headache and facial pain,recurrent ischemic stroke,deficit), fair (moderate deficit needing some assistance), poor (requiring institutionalization), and dead|Five patients with spontaneous dissection of the cervical internal carotid artery (CICA) are reported.
242|HRQL,systemic reaction after a deliberate sting challenge,size and duration of the large local reactions,recurrences of systemic reactions,generalized urticaria,accidental stings,positive skin-test reaction,health-related quality of life,VQLQ score,size and duration of large local reactions,Vespid allergy Quality of Life Questionnaire (VQLQ), Burden of Treatment and Expectation of Outcome,health-related quality of life (HRQL,median of the peak maximal diameter of the LLRs,objective systemic reactions,18 systemic reactions,systemic reaction|Sixteen of these 18 reactions were judged to be milder than the patient's reaction to the first sting, 2 were similar in severity, and none were more severe.
                
12|cumulative rebalance of excitability,HAM-D scores, response and remission rates,Motor disability,frequency of motor-evoked potentials in biceps and triceps, muscle function (torque about elbow), and purposeful movement (Action Research Arm Test,Fugl-Meyer scores,Motor function,motor function improvement and corticospinal excitability change,motor function performance,dexterity, force, interhemispheric inhibition, and corticospinal excitability,motor function and corticospinal excitability,motor-evoked potential (MEP), lower-extremity Fugl-Meyer score, and gait performance,basal rating scales,Cortical excitability,change in laterality indices as quantified by activation positron emission tomography,simple and choice reaction time and improved performance of the Purdue Pegboard test,activation shift toward the right hemisphere,Cognitive performance and electroencephalogram,Safety,standardized Behavioral Inattention Test (BIT,Greater behavioral and neurophysiologic outcomes,effective rate,Wolf Motor Function Test (WMFT) and the Motor Activity Log (MAL)--Amount of Use, and on secondary outcome measures including the Box and Block Test (BBT) and the MAL,cognitive functioning,pinch force,rating scales,Disability,age, laterality indices, or mean Aachen Aphasia Test scores,cortical excitability and walking performance,safety and efficacy,motor function recovery,NHPT baseline repetitions,motor-evoked potential frequency,Motor control and walking ability,spatial asymmetry of gait,cortical excitability,motor learning,Day 10 MAUEF score,hyperexcitability of LH parieto-frontal circuits,motor function,clinical efficacy,Corticospinal excitability,neglect symptoms,Aachen Aphasia Test total score,grip strength,depressive symptoms,Disability scales,mild adverse effects,clinical disability,excitability of the stroke hemisphere,excitability of the non-stroke hemisphere and increased excitability of the stroke hemisphere,neuropsychologic battery and electroencephalogram,Arterial ischaemic stroke (AIS,poststroke recovery and mortality,Fugl-Meyer score, Barthel index, and central spinal cord motor conduction time (CMCT,Stimulus intensity,excitability,reduction of Ham-D scores and frontal gray and white matter volumes,BIT scores,mean grip strength,grip strength and the Melbourne assessment of upper extremity function (MAUEF|Increasing evidence suggests that the contralesional motor cortex (M1) inhibits the ipsilesional M1 in stroke patients.
138|Alzheimer's Disease Assessment Scale cognitive and noncognitive subsections, Global Deterioration Scale, Clinical Global Impression of Change, Mini-Mental State Examination, Instrumental Activities of Daily Living, Physical Self-Maintenance Scale, and a caregiver-rated Global Impression of Change,Alzheimer's Disease Assessment Scale-Cognitive Behavior (ADAS-cog) composite score and the week 52 Clinician's Interview-Based Impression of Change Plus (CIBIC,cognition (assessed with the mini-mental state examination [MMSE]) and functional ability (assessed with the Bristol activities of daily living scale [BADLS,time to formal domiciliary or institutional care, progress of disability, behavioural symptoms, caregiver wellbeing, and care time,Cog score, 1-step worsening on the global Clinical Dementia Rating scale, 15-point decline on the ADCS activities of daily living inventory, institutionalization, or death,cognitive subscale of the AD Assessment Scale (ADAS-cog) and score on the Clinician's Interview Based Impression of Change with caregiver input (CIBIC,serious adverse events,rate of cognitive decline,intention to treat,cognitive progression of Alzheimer's disease,bleeds that led to admission to hospital,Mini-Mental State Examination, the Clinician's Interview Based Impression of Change with caregiver input, the noncognitive subscale of the ADAS, the Neuropsychiatric Inventory, and the Interview for Deterioration in Daily life in Dementia,Fatigue, dizziness, and hypertension,Alzheimer Disease Assessment Scale- Cognitive (ADAS-Cog) subscale score,1-year mean (SD) change in ADAS-Cog scores,mean BADLS score,efficacy and safety,adverse reactions,cognitive decline,behavioral decline,1-year change in the cognitive subscale of the AD Assessment Scale,Clinical Dementia Rating scale sum-of-boxes, the Neuropsychiatric Inventory, the Quality of Life-AD, and the time to attainment of significant end points (4-point decline from baseline ADAS,Alzheimer's disease progression,slow cognitive decline,tolerated,ADAS-Cog score worsening,cognitive subscale of the AD Assessment Scale (ADAS-cog,fatal cerebral bleeds,total assessment scores of measures of cognition, clinical status, activities of daily living, affect, and behavior,1-year change in the Alzheimer Disease Assessment Scale-Cognitive (ADAS-Cog) subscale score,changes in MMSE, CDR, Basic and Instrumental Activities of Daily Living scales, and Neuropsychiatric Inventory (NPI,CIBIC+ scores,Alzheimer disease progression,change in ADAS-cog scores,Alzheimer's disease,mean MMSE score,Withdrawal rates|There was no difference in cognitive decline between the prednisone and placebo treatment groups in the primary intent-to-treat analysis, or in a secondary analysis considering completers only.
46|central processing speed or postural stability,change in cognitive or 36-Item Short-Form General Health Survey scores,mental state and quality of life,Extraversion,dementia or cognitive decline,immediate recall condition,mild cognitive impairment,aggressivity,cognitive functioning,Beck Depression Inventory (BDI) scores,psychological function,global cognitive function, verbal and visuospatial memory, language, executive function, and semantic memory,Postural instability and falls,actual performance of the verbal and nonverbal memory tasks,Cognitive speed and accuracy, attention, and memory,Memory, frontal lobe functions (inhibition and planning) and visuospatial abilities (mental rotation,cognitive performance measures,cognitive performance,balance scores, performance measures,physical measures of mobility, ability to rise from a chair, self-reported activities of daily living, physical activity scores, or falls,postural stability,mild cognitive impairment (MCI,State anxiety,associative verbal memory,verbal memory performance,Instrumental Activities of Daily Living,negative affect, or depressive symptoms,cortisol plasma levels,cognitive function and quality of life,memory and mood: verbal memory changes,mental rotation task,walking normal,verbal and visual memory,HPA response to task-induced stress,correct reproductions,overall quality of life,physical performance,cognitive performance and serum E2 levels,estradiol levels and mood changes,specific cognitive functions,working memory,Estrogen plasma levels,performance, mood and personality,mood, cognitive function and quality of life,executive functioning,Beck Depression Inventory,Folstein Mini-Mental State Examination ,Cortisol plasma levels,Incidence rates,cognition and health-related quality of life,error rates,time to rise from a chair, timed walking, balance, Instrumental Activities of Daily Living, Physical Activity Scale of the Elderly, Folstein Mini-Mental State Examination, and falls,adverse reactions,Wechsler Adult Intelligence Scales, measuring both digit span and digit symbol,brain activation patterns,health-related quality of life in physical and mental domains,bone density,estradiol levels,cognition or balance,visuospatial abilities,frontal lobe functions,incidence of dementia and mild cognitive impairment,mean (SD) time,health risks,rising time,verbal memory,cognitive function or in health-related quality of life,physical performance measures, functional ability, physical activity, falls, and cognitive function,pupillary and skin conductance variables,plasma estrone and estradiol levels,dementia or MCI incidence,memory, visuospatial abilities and frontal lobe function,hazard ratio (HR) for probable dementia,cognitive function, mood and quality of life,Plasma estradiol levels,change from baseline and rate of change from baseline for the following psychometric tests: Verbal Fluency Test, Weschler Paired Associate Learning and 20 min Delayed Recall, Trailmaking A and B Tests, Cancellation Random Letter and Random Form Tests,cognition,Cognitive performance,Memory function,baseline Modified Mini-Mental State Examination scores,Serum estradiol (E2) and FSH levels,memory function,cognitive test scores or on the 36-Item Short-Form General Health Survey,income management scale of the Profile of Adaptation to Life,Wechsler Adult Intelligence Scales,Physical Activity Scale of the Elderly ,overall HR for probable dementia,cognitive effects,immediate or delayed recall of visual material, delayed recall of paragraphs, or digit span scores,Minnesota Multiphasic Personality Inventory-168, the Profile of Adaptation to Life, and the Beck Depression Inventory,somatic complaints and trait anxiety,mood, cognition and quality of life,noopsyche, thymopsyche, personality and psychophysiological measures,memory performance,figural memory,quality of life scores (as measured by the SF-36) and cognitive function (CAMCOG, Block Design, Memory for Faces, California Verbal Learning Test (CVLT) and verbal fluency (VF|Treatment with estrogen increased activation in the inferior parietal lobule during storage of verbal material and decreased activation in the inferior parietal lobule during storage of nonverbal material.
281|Vein graft patency,oxidative stress and inflammation,Major adverse cardiac-related events and health-related quality of life,level of TNF-alpha,arterial partial pressure of oxygen,myocardial damage,pancreatic function,clinical, angiographic, neurocognitive, and quality of life outcomes,Peak systolic and early diastolic velocities,1-year graft patency, cost, and quality-of-life outcomes,resternotomy for bleeding,IL-10,elastase,Fasting blood glucose,frequency of no need for transfusion,mortality and morbidity,urinary RBP,adhesion molecule expression,early mortality and morbidity,S-100 protein levels,neurocognitive function,overall graft patency rate,Permanence on the ventilator,myocardial ischemic markers,number of circulating endothelial cells and apoptotic endothelial cell death,postoperative mortality and morbidity,and -10, C-reactive protein (CRP) and neutrophils,Insulin-like growth factor-1 standard deviation score,time of inotrope drugs support,preoperative characteristics and risk factors,postoperative impairment,endothelial response,response of T lymphocytes and their activation markers, as well as B lymphocytes and their activation markers,area under the curve of troponin T levels,operation time,roTEG signs of fibrinolysis,oxygenation, shunt (%) and ventilation-perfusions mismatch, described as DeltaPO(2) (kPa,cardiac index,Cardiac outputs and clinical outcomes,Blood glucose and lactate,Neurocognitive status,Plasma levels of complement (C3a), cytokines (IL-8, TNF-alpha), endothelin-1 and neopterin,worse composite outcomes and poorer graft patency,Permeability and absorption,Hemoglobin levels,clinical outcomes and S-100 protein, neuron-specific enolase, and maximum creatine kinase-MB levels,worsening of renal function,microvascular damage,neutrophil activation,Small intestine function,safety and efficacy,coronary bypass graft patency,White cell and neutrophil counts,plasma level of proinflammatory cytokine tumor necrosis factor (TNF)-alpha,stenosis-free patency rate,renal function and clinical outcomes,Renal tubular and glomerular functions,health-related quality of life,Systemic release of interleukin (IL)-6, -8,salvaged mediastinal blood available for autologous transfusion,chest tube drainage,cardiac-related death,hospital death,Neurocognitive outcomes,time to extubation,MDA levels,total amount of cardiac troponin I released,plasma total antioxidant status,maximum myocardial lactate production,severely stenosed carotid arteries,systemic inflammatory response syndrome and early catecholamine requirement,overall fibrinolysis potential,neuron-specific enolase levels,blood collection times,5-year cognitive or cardiac outcomes,mean health-related quality of life,Platelet function,Troponin I,aerobic metabolic activity,intramyocardial levels of glucose, pyruvate and urea,Oxidative stress,Oxygen metabolism variables,anginal status or quality of life,age, gender, New York Heart Association class, Canadian Cardiovascular Society functional classification of angina grade and number of CABG,main morbidity and hospital moratlity,Postoperative cognitive testing,postoperative VO(2), DO(2), and ExO(2) levels,Glomerular and tubular injury,rate of the 30-day composite outcome,Arachidonic acid-induced platelet aggregation,glucose homeostasis,Length of hospital stay and use of blood products,total antioxidant status,Central venous blood samples,risk of graft occlusion,postoperative peak values of creatine kinase-MB mass,neurologic and clinical morbidity,Cardiac outcomes and health-related quality of life,Protein C1 esterase inhibitor and von Willebrand factor concentrations,abnormal regional function,transcardiac pH differences,Immediately postoperatively IL-10 levels,Mean number of anastomoses,earliest extubation time,neuropsychologic and quality-of-life outcomes,Release of inflammatory markers,IL-6. IL-1,CPB, PTX3 levels,Interleukin-1, interleukin-6 and myocardial enzyme response,Mean temperature,exercise capacity improvement and attenuation of symptoms,Intramyocardial lactate/pyruvate ratio,Inferotemporal retinal arterial embolization and microinfarction,overall rate of graft patency,Oxygen metabolism,Serum Cr and blood urea,health related quality of life,lactate/pyruvate ratio and the lactate/glucose ratio, indicating the aerobic and anaerobic tissue metabolism status,shorter hospital stay,serial blood samples, plasma malondialdehyde (MDA) as index of lipid peroxidation, red blood cells glutathione peroxidase (GPx) and superoxide dismutase (SOD,alpha2-macroglobulin, protein C1 esterase inhibitor, fibronectin, and von Willebrand factor concentrations,Nonfatal myocardial infarctions,Renal functions,Inflammatory response and myocardial ischaemia,PAI-1,incidence of neurocognitive impairment,Graft patency,CABG and OPCAB in oxygen consumption (VO(2)), delivery (DO(2)), or extraction (ExO(2,low SVR index,Creatine Kinase-MB (CK-MB) release, the amount of bleeding and intensive care unit (ICU) stay (p<0.05,C-reactive protein and systemic levels of TNF-alpha, TNF specific receptors Rp1 and Rp2, Interleukin-6 (IL-6) and soluble IL-2 receptors (sIL-2r,peripheral tissue metabolism and microvascular blood flow,inflammatory response (interleukin (IL)-6, interleukin-10, ICAM-1, P-selectin) and of myocardial injury (myoglobin, creatine kinase-MB (CK-MB), troponin I,Volume of homologous blood transfusion,time of mechanical ventilation,Systemic inflammation,pyruvate and glycerol interstitial concentrations, lactate/pyruvate ratio and lactate/glucose ratio,occurrence of cardiovascular events (all-cause mortality, stroke, myocardial infarction, and coronary reintervention), anginal status, and quality of life,intraoperative mediastinal blood loss,expression of adhesion molecules,Postoperative ET levels,peripheral endothelial function,mechanical ventilation support and length of intensive care unit and postoperative stay,homologous blood,intensive care unit stay,Postoperative hepatocellular injury,urinary albumine excretion,arterial graft patency,postoperative morbidity,Endothelial apoptosis and circulating endothelial cells,postoperative gas exchange,Retinal microvascular damage,length of stay in ICU,PAI-1 values,hospital mortality,incidence of low SVR, and patterns of SVR changes,CABG iPF2alpha-III levels,completeness of revascularization, graft patency at 1 year, neuropsychological outcomes, and the use of major resources,CABG performance,Isoprostanes and oxidative stress,contractile cardiac function,inflammatory markers,renal dysfunction,fresh frozen plasma,cerebral microemboli,neuropsychological outcomes or short-term use of major resources,collateralized chronic total occlusions of native coronary arteries,troponin T levels,Postoperative S-100 serum levels,Postoperative blood loss,Cognitive outcomes,Insulin-like growth factor-1,systemic release of IL-8,PAI-1 antigen levels,expression of adhesion molecules (CD11, CD18) of leukocytes,Revascularization,neutrophil elastase levels,Endothelial function,Clinical morbidity and costs,bilirubin level,patency of grafts, better clinical outcome, shorter hospital stay, and better neurocognitive function,peripheral tissue (skeletal muscles) energy metabolism,mean intraoperative S100,Myocardial function,CABG and OPCAB in inflammatory markers,postoperative renal functions,post-operative gastrointestinal complications,Troponin-T and creatine kinase isoenzyme MB (CK-MB) levels,blood loss,clinical outcomes and neuropsychological functioning,Pulmonary artery pressures, ventilation requirement, and hospital stay,postoperative clinical outcome (ICU stay, ventilation duration, length of hospital stay,protein carbonyls,length of ICU stay,mean mechanical ventilation time,Cr,echocardiographic markers of right ventricular function,Mean total hospitalization cost per patient at hospital discharge,expression of CD97 and adhesion molecules (CD11, CD18,death, neurological injury, renal failure, respiratory failure, and operative myocardial infarction,Release of interleukin-6,Differential white cell counts,30-day mortality, no stroke, and no acute renal failure,total amount of heart-type fatty acid-binding protein, cardiac troponin,number of HITS,Rates of death, stroke, myocardial infarction, angina, and reintervention,proportion of patent grafts,Static and dynamic lung compliance measurements,incidence of high SVR,Forced vital capacity (FVC) values,endothelial activation,index admission mortality, stroke, low-output cardiac failure, return to the operating room for bleeding, and postoperative troponin release,graft patency, survival, and health-related quality of life,Glucose, lactate, pyruvate and glycerol as markers of basic metabolism and tissue perfusion,inflammatory markers, troponin I, protein S100, and free hemoglobin,Neuropsychologic and quality-of-life outcomes,shorter duration of mechanical ventilation,Mean on-pump and off-pump SF-36 scores,Peak S100 levels,release of IL-6,Interstitial lactate levels,transient neurologic dysfunction,Intensive care stay,Plasma tissue factor levels,graft patency, clinical and quality-of-life outcomes, and cost,Volume of intraoperative autologous blood transfusion, postoperative mediastinal blood loss and homologous blood transfusion requirements,neurologic deficit,Levels of the same markers and blood lactate,postoperative neutrophil counts,mortality or renal complication,rate without stenosis,patency rate,hospital mortality and morbidity,time on the relation between VO(2) and DO(2,systemic inflammatory response, postoperative morbidity, and hospital stay,quality of life,energetic metabolism,graft-patency rates,urinary excretion of microalbumin and retinol binding protein (RBP) indexed to creatinine (Cr,ET levels,Peak creatine kinase,Intensive care unit stay, duration of intubation, hospital stay and bleeding,adverse renal outcome,Platelet activity and aspirin efficacy,mammary artery patency,I concentrations,systolic and diastolic function,Blood glucose,global systolic right ventricular function,atrial fibrillation,SOD levels,Renal tubular function,rate of active CD97-positive lymphocytes,Risk ratios,Overall, T lymphocytes,lymphocyte activation,Levels of creatine kinase mass,dialysate concentrations of ethanol,Complement C3a and elastase levels,release of creatinine kinase,activation of coagulation and fibrinolysis,Fibrin D dimer and prothrombin fragment 1+2 concentrations,Neurocognitive deficit,total operation time 205.10 ,Fibrinogen and t-PA levels,Inflammatory response and myocardial injury,higher incidence of atrial fibrillation,Inotropic,MACCE,deterioration in scores,Postoperative morbidity and blood loss,Glucose homeostasis,Mean SVR index,Amylase levels,length of the operation,Intraoperative and postoperative data,WBC and neutrophil counts,graft patency,intraoperative blood loss and homologous blood transfusion,cumulative blood release of troponin-T,renal function,composite of death or complications (reoperation, new mechanical support, cardiac arrest, coma, stroke, or renal failure,serum levels of cardiac troponin I,Graft occlusion,Postoperative morbidity,inflammatory response reactions,Free hemoglobin levels,incidence of in-hospital death and outcomes (low cardiac output syndrome, prolonged mechanical and pharmacologic cardiac support, prolonged mechanical ventilation support, and postoperative length of stay in intensive care unit and hospital,Doppler high-intensity transient signals (HITS,perioperative complications,neuropsychological outcomes or use of major resources,heart-type fatty acid-binding protein levels,1-year angiographic patency,Ophthalmic function,hospital stay,GSH levels,haemoglobin concentration,Interleukin-1 (IL-1,Demographic, hemodynamic, and respiratory parameters,peak and total S100 levels, and N-acetyl-glucosaminidase activity,CRP,discharge in vitro bleeding times,dialysate concentrations of glucose and lactate,morbidity,coagulation parameters,CK-MB mass release,CPB inclusive of cardioplegic arrest, left ventricular ejection fraction <50%, emergency surgery, prolonged aortic cross clamp and CPB time, post-operative low cardiac output syndrome, post-operative inotropic requirement, new onset atrial fibrillation (AF), excessive post-operative blood loss and redo thoracotomy,hospital deaths or major postoperative complications,mean number of grafts per patient,Postoperative increases in fibrinogen and hs-CRP,Preoperative clinical characteristics,SVR index responses,Forced expiratory volumes,CD11b levels,elevated D-dimer levels,platelet function and increased thrombin formation,demographic makeup, Parsonnet score, functional status and extent of coronary revascularization,prevalence of postoperative hemodialysis,functional class and positive treadmill exercise tests,early activation of CD69+ and late activation of CD25+ on T lymphocytes,local blood flow,Early mortality,Myocardial metabolism,P-selectin expression,CABG,systemic nitric oxide production, total nitrate/nitrite (NOx,leukocyte activation,Plasma IL-6 levels,deterioration renal function,interstitial concentrations of the glucose, glycerol, pyruvate and lactate,plasmatic creatinine, urinary creatinine, creatinine clearance, proteinuria or osmolality,incidence of in-hospital death,D-dimers release,oxygen consumption (VO(2)) and delivery (DO(2,number of arterial grafts,Urinary isoprostane iPF2alpha-III levels, plasma levels of free malondialdehyde, and total antioxidant status,cognitive decline,cardiovascular event,C-reactive protein levels,Bleeding,mortality or perioperative myocardial infarction,monobasic (MB) fraction of the creatinine kinase 24 h after the operation,homologous blood consumption,Interleukin-6 (IL-6) levels,serum CK-MB mass fraction, Troponin I, and interleukin (IL)-6, IL-8, and IL-10 levels,OPCAB and sharp increases during CABG,hemodynamic data (cardiac index, systemic vascular resistance, left- and right-ventricular stroke-work indices, inotropic and mechanical support needs) and enzyme levels (CK-MB and SGOT), as well as mortality, perioperative infarction rate, homologous transfusion requirements, and the symptomatology in the first follow-ups,neurocognitive deficit,postoperative bleeding,CD97 expression of granulocytes (PMN) and monocytes (MC,leukocyte elastase, platelet beta-thromboglobulin, and complement C3a,Mean number of grafts,Raw graft patency rate,myocardial infarction,plasminogen activator inhibitor-1,Saphenous graft patency,ratio of insulin-like growth factor-1 concentration,Oxygenation and release of inflammatory mediators,Platelet count,Interleukin-6, interleukin-8, C3a, and troponin I levels after surgery,nuclear derangement,aggregation,Major postoperative complications,postoperative VA,Blood samples,myeloperoxydase content,TNF-alpha and elastase levels,inflammatory response and organ function,neutrophils,Postoperative systemic arterial ET levels,gastric mucosal oxygenation,Pre- and postoperatively prothrombin time and partial thromboplastin time,Hepatic metabolic function,neurocognitive function assessed using a 19-test neurocognitive battery at baseline, discharge, and 6 months,IL-6,Interleukins (IL)-6, IL-8, IL-10, myeloperoxidase, elastase, and terminal complex of the complement (TCC,Early graft patency,Mean number of bypass grafts,cardiac troponin,alveolar-arterial oxygen gradient,Blood pressure responses,death, myocardial infarction, further revascularization (surgery or angioplasty), or stroke,cardiac troponin I concentration,myocardial metabolism,mortality or morbidity,All-cause mortality,Postoperative atrial fibrillation,functional class and exercise capacity,serum cytokines and myocardial tissue markers,rate of atrial fibrillation,Patency,troponin release,Serum cytokine levels,Pulmonary abnormalities,graft patency, major adverse cardiac-related events, and health-related quality of life,Serum insulin, insulin-like growth factor-1 and its binding protein,Venous serum levels of S-100 protein,Right ventricular function,monoethylglycinexylidide/lidocaine ratios and by serial measurements of transaminases (aspartate transaminase and alanine-amino transferase), bilirubin, and alkaline phosphatase,C3a and neopterin concentrations,CD11b surface expression on neutrophils,IL-6 expression,Creatinine clearance,pyruvate concentrations,rate of the 1-year composite outcome,high-sensitivity C-reactive protein (hs-CRP) and fibrinogen,blood requirements,regional function,Hemodynamic variables (including creatine kinase-MB and troponin levels), intubation time, postoperative bleeding, and blood transfusions,platelet count,Overall hemostasis potential, overall coagulation potential, and overall fibrinolysis potential,Global myocardial function,TCC,frequency of neurocognitive deficit,Levels of tissue-plasminogen activator,Gastrointestinal complications,TNF-system and sIL-2r,Liver function,Maximum creatine kinase-MB levels,postoperative stay,pulmonary function,intramyocardial concentrations of glucose, urea and lactate,average stay in the intensive care unit,platelet activity,cardiac-related late deaths,Gastric intramucosal pH (pHi), gastric-arterial carbon dioxide partial pressure difference (CO(2) gap), whole-body oxygen delivery (DO(2)) and consumption (VO(2)) and whole-body oxygen extraction fraction,postoperative hospital stay,Rey Auditory Verbal Learning Test (total and recognition scores,VO(2) and DO(2,Thrombin formation,health status,neutrophil counts,postoperative inflammatory response,renal complication or serum markers of kidney dysfunction,angina recurrence,Plasma tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) levels,retinal microvascular damage,Average blood glucose,hospital deaths,major adverse events and neuropsychological functioning,cerebral perfusion,expression of systemic proinflammatory cytokines,mean CEC-number,Aspartate transaminase and alanine-amino transferase levels,Thirty-day complications, neuropsychological functioning, and one-year clinical and functional outcomes,overall early graft patency rate,circulating markers of inflammation and organ injury, (2) operative results, and (3) outcome at 1-year follow-up,likelihood of graft occlusion,postoperative tissue factor and P-selectin expression,TNF-alpha and IL-8,Cardiac release of interleukin-6, tumor necrosis factor-alpha, and blood lactate,levels of Troponin I and activation of cytokines,levels of tumor necrosis factor-alpha,hazard of death,CEC numbers and proportions of apoptotic hEC,cognitive deficits,TNF-alpha and IL-8 release or endothelial function,blood loss and homologous blood transfusion requirements,Glutathione peroxidase levels,IL-8, TNF-alpha, and sE-selectin,systemic NOx levels,survival free of any cardiac-related event,nitric oxide,resolution visual acuity (VA), and cerebral injury, by transcranial Doppler ultrasound-detected emboli and S100 protein values,global systolic function and tricuspid early/late (atrial) ratio as a marker of the global diastolic function,respiratory morbidity,incidence of low cardiac output syndrome,occluded graft,Interleukin 8 concentrations,mean (+/-SD,perioperative oxidative stress,expression of lymphocyte activation markers,Platelet expression of P-selectin,lower release of cardiac troponin,Protein S100 levels,Neurologic and clinical morbidity,inflammatory response, myocardial, neurologic, and renal injury,Quality-of-life assessments,oxidative stress,cumulative release of myoglobin,insulin-like growth factor binding protein-1,graft-patency rate,deterioration of DeltaPO(2,gastric mucosal hypoxia,quality-of-life,allogeneic blood transfusion,Mean cardiac index,Release of troponin T,Myocardial preservation,Platelet activity,shorter ventilatory support,Soluble P-selectin levels in plasma,right ventricular function,gastrointestinal complications,stroke risk score,reoperation for bleeding,CD11b expression,pulmonary artery pressures, ventilation requirement, and hospital stay,myocardial metabolism and inflammation (glutathione (GSH), superoxide dismutase (SOD) and myeloperoxidase (MP)) and plasma samples for indicators of oxidative stress (conjugated dienes (s-BDC), oxidative products of proteins (s-ox-Prot) and low-density lipoprotein (LDL)-total peroxyl radical trapping antioxidant potential (s-TRAP,renal failure and lesions of the circumflex artery and its branches,postoperative pulmonary shunt,Aspirin efficacy,median postoperative length of stay,Fluid balance, serum Cr and blood urea,CABG and OPCAB,blood transfusions,diastolic function,roTEG signs of hyperfibrinolysis,neurocognitive impairment,S100 levels,evaluation of myocardial infarct size measured by the perioperative serum release of cardiac troponin,CPB time,expression of P-selectin,MDRD GFR and serum creatinine levels,composite of death from any cause, a repeat revascularization procedure, or a nonfatal myocardial infarction,Cerebral perfusion with OPCAB,free water clearance values,Hospital mortality,strength of the relationship between VO(2) and DO(2,respiratory failure,median value of HITS,right ventricular systolic and diastolic function,major adverse cardiac-related events or death,angiographic graft patency,postoperative red cell count, hemoglobin level and Hct,composite of major adverse cardiac and cerebrovascular events (MACCE) including all-cause mortality, acute myocardial infarction, cardiac arrest with successful resuscitation, low cardiac output syndrome/cardiogenic shock, stroke and coronary reintervention,inflammation activation,organ function and inflammatory response,Pancreatic function,Myocardial energy metabolism and tissue injury during CABG,inflammatory response,CEC numbers and proportions of endothelial apoptosis,white blood cell (WBC) and neutrophil count,Overall hemostasis potential and overall coagulation potential,Overall tissue factor production,creatinine levels,vitro bleeding time,Hospital mortality and morbidity,negative fluid balance,Saphenous graft patency per patient,mortality,OPCAB,coronary artery bypass graft patency,Troponin I release,inhospital outcomes, similar completeness of revascularization, and shorter lengths of stay,inflammatory reaction and myocardial metabolism,Splanchnic organ injury,hEC apoptosis,nitrotyrosine,OPCAB iPF2alpha-III excretion,Apoptotic and normal cells,major deterioration,systemic inflammatory response,minor adverse events (wound infection,PTX3 levels,complete revascularization,peak S-100 protein,number of grafts per patient,appearance of graft patency, myocardial function, and clinical outcome,CD11a and CD18 expression of leukocytes,platelet activity and aspirin efficacy,Plasma levels of interleukin-6 and tumor necrosis factor-alpha,serial measurements of insulin/glucagon ratio, amylase, and glucose,postoperative atrial fibrillation,S100 concentration,homologous transfusion,Temperature, SVR index, cardiac index, and blood pressure,stroke nor transient ischemic attack,CEC and proportions of apoptotic hEC,Expression of CD25, CD26, CD69, and DR on T (CD3+) and B (CD19+) lymphocytes on peripheral blood,Operative mortality and morbidity,mean static and dynamic lung compliance postoperatively,prior anesthesia values of lipid hydroperoxides|In low-risk patients undergoing CABG surgery, avoiding the use of cardiopulmonary bypass had no effect on 5-year cognitive or cardiac outcomes.
                
4447|GFR,microalbuminuria and albumin excretion rate,annual rate of change in albuminuria,Lower systolic BP levels,progression of diabetic retinopathy,overnight albumin excretion rate,progression to incipient and overt diabetic nephropathy,hazard ratio [HR,serum lipid fractions,mean low-density lipoprotein cholesterol,mean entrance BP,urinary albumin excretion rate,systolic and diastolic blood pressure,FBS and 2-hr PMBS,acute myocardial infarction, stroke, or hospitalized angina,glomerular filtration rate and effective renal plasma flow determined with inulin and para-aminohippuric acid clearances,death, cardiovascular events, and/or renal events (need for renal replacement therapy or doubling of baseline plasma creatinine,antiproteinuric effect of losartan,new microalbuminuria (3 or 4 collections of urinary albumin excretion rate,blood pressure, kidney biopsies and kidney function tests,change in creatinine clearance,Urinary albumin excretion rate (AER,albumin excretion rate (AER,HbA1c, triglycerides, and BMI,renal function and albuminuria,GFR decline per year,dBP,blood pressure (systolic/diastolic,left ventricular end-diastolic volume index nor the left ventricular ejection fraction,Microalbuminuria,urinary albumin excretion (UAE) measurements,albumin excretion,antihypertensive effect,creatinine clearance or serum creatinine,Metabolic parameters,estimated GFR,blood-pressure control,antihypertensive efficacy,lowering blood pressure,seated and 24-h ambulatory systolic blood pressure,retinopathy severity scale,Glycemic control and blood pressure,Systolic blood pressure (sBP) and diastolic blood pressure (dBP,high-density lipoprotein cholesterol,serum lipids,glomerular filtration rate (GFR,absolute risk reduction,biochemical measures,rate of deterioration in renal function,nonfatal cardiovascular events--81,normoalbuminuria to microalbuminuria,creatinine clearance,ACR,Mean BP,incidence of side effects,microalbuminuria to overt albuminuria,major renal outcomes,normal glomerular filtration rate (GFR,Degree of albuminuria at 24 hours, creatinine clearance, blood pressure, and hemoglobin A1c values,composite renal outcome,MBP or GFR,risk for microalbuminuria,times to the onset of renal and cardiovascular events,risk for renal events,fraction of glomerular volume occupied by mesangium in kidney-biopsy specimens,complete renal-biopsy and retinopathy data,Albuminuria,Renal function,higher rate of fatal cardiovascular events,baseline UAE,Hemoglobin A1c values,total cholesterol, HDL cholesterol, and LDL cholesterol,clinical outcomes,glycated haemoglobin,Urinary albumin excretion rate,systolic and diastolic blood pressure (captopril,albuminuria,mean BP,sBP,rate of death from cardiovascular causes,target blood pressure,mean BP (diastolic + 1/3 pulse pressure,mean CCr,Resting blood pressure,microalbuminuria and/or hypertension,serum triglycerides,Mean blood pressure,risk of major vascular events,prevalence of microalbuminuria,time to the onset of microalbuminuria,24-hour UAE,fasting plasma glucose and glycated hemoglobin (HbA1c) levels, and both maintain constant AERs,risk of hypoglycaemic events,efficacy and tolerability,BP,Fasting and post-prandial plasma glucose, glycosylated haemoglobin and plasma lipids,kidney function,systolic blood pressure (24-h systolic blood pressure) reduction,beneficial effect on triglycerides,diabetic vascular complications,baseline systolic or diastolic BP,antihypertensive effects,plasma glucose, insulin or lipid concentrations,blood pressure,number of events,plasma clearance of 51Cr-labeled EDTA,incidence of stroke,Composite renal outcome of dialysis or doubling of serum creatinine, changes in estimated glomerular filtration rate (GFR), and changes in albuminuria,hypoglycaemic events,values of GFR, AER, and systolic and diastolic BP,tolerated,doubling of serum creatinine,progression of UAE,total cholesterol,blood pressure (BP), creatinine clearance (Ccr) and urinary albumin excretion (UAE,LDL cholesterol,cardiovascular events,Estimated glomerular filtration rate (eGFR,highest frequency of clinical events,blood sugar and glycosylated hemoglobin,Renal disease,5-year cumulative incidence of microalbuminuria,time to the first onset of microalbuminuria,mesangial matrix volume and mesangial volume,mean fall in the systolic and diastolic blood pressure,duration of diabetes,24-hour UAE, creatinine clearance (CCr), and the regression coefficient of the yearly plasma creatinine reciprocal (beta-1/Cr,Chronic cough,rate of change in albuminuria,glycosylated hemoglobin and 12-hr urinary microalbuminuria,albumin excretion rate,particularly HbA1c, BMI, triglycerides, and cholesterol plasma values,urinary albumin excretion (UAE,urinary albumin excretion,response (SBP and/or DBP normalized, or DBP fall,total serum cholesterol, HDL cholesterol, HbA1c, fasting serum glucose, or plasma insulin,microalbuminuria incidence or rate of change in albuminuria,renal disease,UAE rate,BP response,renal events,microalbuminuria,efficacy and safety,Adverse events,long-term antihypertensive efficacy, tolerability, and metabolic effects,retinopathy progression,Urine albumine/creatinine ratio (ACR), mean blood pressure (MBP) and index of glomerular filtration rate (GFR) based on S-creatinine,duration of diabetes and hypertension, systolic and diastolic blood pressure at rest, degree of LVH, metabolic control, and albumin excretion rate (AER,Office blood pressure,mesangial fractional volume,composite of dialysis, doubling of serum creatinine, and death,diastolic blood pressure (BP,Transition to microalbuminuria,systolic blood pressure,urinary albumin excretion, progression of retinopathy and neuropathy and the incidence of cardiovascular disease,diabetic glomerulopathy,likely to revert to being normoalbuminuric,secondary renal outcome, dialysis or doubling of serum creatinine,renal function,GFR decline,AER,serum lipids and diabetes control,geometric mean x:tolerance factor,renal outcomes,serum lipids and glucose metabolism,serum creatinine level,side effects|Slightly fewer patients in the olmesartan group than in the placebo group had nonfatal cardiovascular events--81 of 2232 patients (3.6%) as compared with 91 of 2215 patients (4.1%) (P=0.37)--but a greater number had fatal cardiovascular events--15 patients (0.7%) as compared with 3 patients (0.1%) (P=0.01), a difference that was attributable in part to a higher rate of death from cardiovascular causes in the olmesartan group than in the placebo group among patients with preexisting coronary heart disease (11 of 564 patients [2.0%] vs. 1 of 540 [0.2%], P=0.02).
                
31|percentage change in bone mineral density of the lumbar spine,bone remodeling (alkaline phosphatase and osteocalcin,bone mass,incidence of vertebral fracture,Bone density,S.D. bone mineral density of the lumbar spine,bone mineral density (BMD,loss of bone in the lumbar spine,generalised pruritus,bone turnover assessed by biochemical markers, bone loss assessed by serial measurement of lumbar spine density, and rates of bone fractures,severe side effects,mean BMD,cortical and cortical and trabecular bone mineral content,Bone mineral density (BMD,lumbar bone loss,efficacy and safety,BMD,spinal bone mass,dual-energy X-ray absorptiometry (DXA) of the lumbar spine and hip, and spine radiographs to detect vertebral fractures,biochemical parameters,axial bone loss,risk of osteoporosis and fracture,Bone loss at the femoral neck and distal radius,back pain,bone preservation,bone density,bone loss,lost lumbar bone,DXA lumbar spine density,spinal bone loss|Nasal salmon calcitonin prevented loss of bone in the lumbar spine as measured by dual-energy X-ray absorptiometry.
106|proportion who vomited while receiving oral rehydration,number of vomiting episodes, fluid intake, parents' assessment of well-being, number of diarrheal episodes, and admission rate to hospital,Admission rates,hospitalization rates,number of episodes of vomiting,return visits to the emergency department,rank sum of episodes of diarrhea,weight gain,number of diarrhea episodes,admission rate,Vomiting,tolerated oral hydration,tolerance of oral fluids,vomiting and diarrhea,efficacy and safety,rates of hospitalization,Hospital admission,Hospital admission rate, fluid intake, general well-being of the children, and potential adverse effects,frequency of emesis during an 8-h-period after enrollment,Change of weight,intravenous hydration,rates of intravenous fluid administration and hospital admission,greater oral intake,number of emetic episodes,proportion of patients experiencing no emesis,nausea and vomiting,mean length of stay in the emergency department,vomiting,diarrhea,tolerated,Oral fluid tolerance,free of vomiting,mean number of vomiting episodes,median number of episodes of vomiting,diarrheal episodes,hospital admission rate,Antiemetic activity,number of episodes of emesis,number of mean episodes of vomiting or repeat visits to health care,revisit rate,vomiting episodes,frequency of vomiting|Eleven of 51 (21.6%; 95% confidence interval [CI] 11.3% to 35.3%) of subjects who received ondansetron required intravenous hydration and 30 of 55 (54.5%; 95% CI 40.6% to 68%) of placebo subjects required intravenous hydration (p <0.001) for a difference of 32.9% (95% CI 14.54% to 48.37%).
10881|GFR,plaque regression,Overall mean blood pressure,blood pressure 168.9 ,24-hour ambulatory systolic/diastolic blood pressure changes,fatal and nonfatal myocardial infarction,adverse cardiovascular events,rate of progression of mean maximum intimal-medial thickness (IMT,Systolic and diastolic blood pressure,mortality and morbidity outcomes,total cardiovascular events,peripheral oedema,carotid IMT progression and number of plaques per patient,cardiovascular disease and total mortality,SD systolic and diastolic blood pressure (SBP and DBP, respectively) of 149.7 ,acute myocardial infarction, stroke, or hospitalized angina,mean GFR decline,SBP,non-fatal myocardial infarction (including silent myocardial infarction) and fatal CHD,blood pressure, blood glucose and lipid concentrations, and smoking behavior,cardiovascular morbidity and mortality,stroke, myocardial infarction, or cardiovascular disease-related death,incidence and progression of complications of diabetes,rate of change in GFR,incidence of developing diabetes,blood pressure, clinical safety,serum creatinine levels, end-stage renal disease, and death from any cause,heart rate,Deaths,lowering blood pressure,renal disease progression,biochemical measures,fatal and non-fatal myocardial infarction,triglyceride level,asthenia,cardiovascular mortality,systolic and diastolic blood pressures,cardiac morbidity and mortality,rate of progression of mean maximum IMT,rates of cardiovascular events,Fatal and non-fatal stroke,total serum cholesterol,composite cardiovascular event rate,4-year CBM(max) progression,fatal or nonfatal myocardial infarction,strokes,total cholesterol: high-density lipoprotein cholesterol ratio,overall cardiovascular or cerebrovascular complications,treatment blood pressures,vascular events,blood pressure change, side effects and quality-of-life indices; incidence of electrocardiographic and echocardiographic abnormalities; and incidence of cardiovascular clinical events, including death,incidence of vascular events,myocardial infarction,fatal or nonfatal stroke,Blood pressure,cardiovascular disease-related death,marked systolic blood pressure reduction,congestive heart failure,risk of major vascular events,major cardiovascular events,cardiovascular disease-related events,serious adverse events,risk of clinical end points,composite of cardiovascular and cerebrovascular events,composite of cardiovascular events,fatal and nonfatal myocardial infarctions,hyperuricemia and hypokalemia,nonmajor vascular events and procedures (eg, transient ischemic attack, dysrhythmia, aortic valve replacement, and femoral popliteal bypass graft,relative risk for stroke, major cardiovascular events, and mortality,blood pressure,Cardiovascular outcomes,Clinic blood pressure reductions,rates of hyperuricemia (plasma urate,Time to cardiovascular death, myocardial infarction, congestive heart failure, strokes, and coronary revascularization,major vascular events (eg, myocardial infarction, stroke, congestive heart failure, angina, and sudden death,cardiovascular events,mean DBP,Nonstroke hemorrhage,yearly IMT progression rate,JNC VI blood pressure goals,plaque progression,antihypertensive efficacies, tolerabilities and cardiovascular event rates,composite index of the clinical end points of reduction in GFR of more than 50% or 25 mL/min per 1.73 m(2), end-stage renal disease, or death,occurrence of death (all cause), nonfatal myocardial infarction, or nonfatal stroke; other: cardiovascular death, angina, adverse experiences, hospitalizations, and blood pressure control at 24 months,occurrence of cardiovascular events,mean SBP,urinary protein to creatinine ratio,hypokalemia,total serum cholesterol, HDL cholesterol, HbA1c, fasting serum glucose, or plasma insulin,Morbidity and mortality,Rate of progression of mean maximum IMT,cardiovascular death, myocardial infarction, heart failure, or stroke,cardiac mortality and morbidity,cardiovascular mortality and morbidity,blood pressure control,diastolic blood pressure,mean diastolic values,blood pressure of the sitting subject, heart rate, and a standard clinical safety profile (electrocardiogram, laboratory tests, adverse events, cardiovascular events, and deaths,Adverse events,cardiovascular disease,rate of myocardial infarction,blood pressure goals,cardiovascular outcomes,systolic blood pressure,Total mortality,cardiovascular morbidity or mortality,fatal and non-fatal stroke,fatal and non-fatal stroke, myocardial infarction, and other cardiovascular death,cardiovascular events and total mortality,serum lipids and diabetes control,renal outcomes,serum lipids and glucose metabolism,cardiac disease|Fatal and non-fatal stroke occurred in 159 patients in the diltiazem group and in 196 in the diuretic and beta-blocker group (6.4 vs 7.9 events per 1000 patient-years; 0.80 [0.65-0.99], p=0.04) and fatal and non-fatal myocardial infarction in 183 and 157 patients (7.4 vs 6.3 events per 1000 patient-years; 1.16 [0.94-1.44], p=0.17).
                
not found|Hospital cost savings,incidence of VAP,arterial blood gas samples, shorter weaning times, and less time spent outside acceptable RR and TV parameters,number of days of intensive care and hospital care,hospital mortality rates,VAP frequency,Intubation time,rates of reintubation, non-invasive ventilation post-extubation, tracheostomy, sedation, neuromuscular blockade and use of corticosteroids,shorter durations of mechanical ventilation,Mortality and ventilator discontinuation failure rates,hospital costs,median time to successful extubation,Simplified Acute Physiologic Score II,Complications -- removal of the breathing tube by the patient, reintubation, tracheostomy, and mechanical ventilation,Total costs,weaning time and incidence of ventilator-associated pneumonia,median time of mechanical ventilation,severe disease,rates of reinstituting mechanical ventilation,VAP,number of minutes per hour outside acceptable limits,median duration of mechanical ventilation,Duration of mechanical ventilation, length of intensive care unit stay, mortality, rate of tracheotomy (secondary end points,hospital mortality,duration of mechanical ventilation from tracheal intubation until discontinuation of mechanical ventilation,synchronized intermittent mandatory ventilation rate and pressure support (PS) based on predetermined limits of patient respiratory rate (RR) and tidal volume (TV,MV interval and hospital length of stay,ICU length of stay,number of arterial blood gas samples drawn,PaO2/FiO2 ratio,median time,incidence of ventilator-associated pneumonia (VAP,Pulse oximeter oxygen saturation,median interval,Glasgow Coma Scale (GCS) score,estimated probability of reaching "separation potential,Tracheostomies,average time on mechanical ventilation prior to weaning,ICU,SIMV rate and PS reduction,discontinuation of mechanical ventilation,duration of mechanical ventilation,rate of reintubation,Overall complications included death,need for reintubation, length of hospital stay, hospital mortality rate, and hospital costs,successful extubation,Rate of reintubation,partial pressure of arterial oxygen/fraction of inspired oxygen ratio,rate of successful weaning|Twelve patients in the surgical control group had VAP, compared with 5 in the surgical VMP group (p = 0.061).
436|Neutralizing antibodies,time to confirmed progression in disability,Annual relapse rate,mean change in EDSS score from baseline, relapse-related measures, MRI activity, and a standardized neuropsychological function test,Expanded Disability Status Scale (EDSS,Median MSFC Z-score change,time to sustained disability,efficacy and safety,EDSS (hazard ratio (HR) ,Regional Functional Status Scale,first time in a large-scale MS trial,sensitive disability measure and relapse rate,tolerated,time to progression by > or =1.0 EDSS point (0.5 point if EDSS score,EDSS scores,time to confirmed progression of disability,Neutralizing antibodies to IFNbeta-1b,11 MS Quality of Life Inventory subscales,time to becoming wheelchair-bound, relapse rate and severity, number of steroid treatments and hospital admissions,New or enlarging T2-hyperintense brain MRI lesions and gadolinium-enhancing lesions,MSFC progression, relapses, quality of life, and MRI activity,MS Functional Composite (MSFC), comprising quantitative tests of ambulation (Timed 25-Foot Walk), arm function (Nine-Hole Peg Test [9HPT]), and cognition (Paced Auditory Serial Addition Test [PASAT,disability measures,clinical relapses, newly active MRI lesions, and accumulated burden of disease on T2-weighted MRI,neurological deterioration|New or enlarging T2-hyperintense brain MRI lesions and gadolinium-enhancing lesions were reduced at months 12 and 24 (both p < 0.001).
200|Time to readmission, days in hospital, and health care costs,rate of first rehospitalization for heart failure,length of hospital stay,hospital days,recurrent hospital stay,cost/utility ratios,cardiovascular hospitalizations,cause death and heart failure hospital admissions,recurrent readmission and event-free survival,hospitalisation and health care costs,1-year cumulative incidence of readmission or death,rate of unplanned readmissions and associated health-care costs, prolong event-free and total survival,cost-effective,total number of emergency department visits,physical dimension of quality of life,effectiveness and cost/utility ratio,mortality and morbidity,chronic heart failure (CHF) hospital readmissions and mortality,quality of life, which was self-assessed using the Minnesota Living with Heart Failure questionnaire,unplanned readmission,rate of rehospitalization for heart failure,Time to first rehospitalization or death, number of rehospitalizations, quality of life, functional status, costs, and satisfaction with care,year readmission or mortality and costs of care,cardiac death,hospital readmission costs,spent fewer days in hospital for heart failure,lower risk of re-admission,number of unplanned re-admissions, six-minute walking distance, London Handicap Scale and public health care and personal care costs,patient satisfaction,mean total costs,NYHA functional class,heterogeneous changes in NYHA functional class,mean days of hospital stay,death or unplanned readmission (event-free survival) and rate of recurrent, all-cause readmission within 6 months of hospital discharge,Unplanned outpatient visits,C+HBI,recurrent hospitalisation,hospital admissions or mortality,died,re-admission rates,health care costs,cause hospitalizations and total hospital days,number of hospital readmissions and hospital days and improved quality of life,cost/utility ratio,heart failure,hospital costs,composite of the number of CHF hospital admissions and deaths,greater uptake of beta-blocker therapy,total hospital readmissions,cost of care,quality of life improved and overall cost of care,QoL or readmission rate,time to death or rehospitalization because of HF and the number of days lost to death or hospitalization,number of days in hospital,deaths,adverse clinical outcomes and costs,six-minute walking distance,overall quality of life,cost savings,median number of re-admissions,quality of life (QoL) and secondary end points were hospitalisation and mortality,self-care abilities, self-care behavior, and quality of life,incidence of readmission, mortality, and emergency department admission,risk of death or readmission,time to first event, time to first all-cause and HF readmission, and time to death,mortality, morbidity and self-care behaviour,performance, effectiveness, and cost/utility ratio,Management (rate of readmissions, therapeutic interventions), functional parameters (New York Heart Association [NYHA] functional class, left ventricular diameters, and ejection fraction, deceleration time of early diastolic mitral flow, peak oxygen uptake, and mitral regurgitation) and hard outcomes (cardiac death and urgent cardiac transplantation,total number of readmissions,hospitalization days,ACE inhibitor adherence,events (death or admission,survival and self-care behaviour,year survival rate,Hard cardiac events,functional status, quality of life and beta-blocker prescription rate,lower mortality,total number of emergency department visits, quality of life and total mortality,mortality and quality of life (Minnesota living with heart failure questionnaire and EQ-5D,admissions for heart failure,quality of life,readmitted because of HF or died,satisfaction scale,median total public health care and personal care costs,readmission or died,QoL or health care consumption,Minnesota living with heart failure questionnaire scores,death or hospital readmission,events (readmission or death,hospital readmissions,symptom frequency and symptom distress,All-cause mortality,readmitted or died,readmissions,unplanned readmissions and survival,rate of readmission or death and hospital costs,rate of all-cause rehospitalization,number of days lost to death or hospitalization,self-care abilities (Appraisal of Self-care Agency Scale), self-care behavior (Heart Failure Self-care Behavior Scale), 3 dimensions of quality of life (functional capabilities, symptoms, and psychosocial adjustment to illness), and overall well-being (Cantril's ladder of life,mortality,effectiveness and cost-effectiveness,quality of life and reduced total hospital admissions and total bed days,hospital admissions,quality-of-life score,length of time between hospital discharge and readmission or death, reduced total number of rehospitalizations, and decreased healthcare costs,cardiovascular-related emergency room visits,43 CHF hospital admissions and 7 deaths,ACE inhibitor use,target doses of angiotensin converting enzyme (ACE) inhibitors,moderate to severe HF,Hospital-based costs,cause hospital admission rates and total number of days in hospital at 6 months,readmission and death rates,required readmission to hospital,frequency of unplanned readmission plus out-of-hospital death,Self-care and quality of life,higher level of treatment compliance,hospitalizations,134 admissions,Time to first readmission or death,Emergency department admission,quality of life and death or hospital readmissions,rate of unplanned re-admission,Hospital re-admissions, days of hospital stay, treatment compliance, satisfaction with the care received, and quality of life (EuroQol,handicap in independence,59 CHF hospital admissions and 13 deaths,readmitted with heart failure,higher self-care scores,EQ-5D scores,cause readmissions and all-cause deaths,hospital readmissions, improved survival and quality of life,readmissions for any reason,mean time to readmission,admissions,risk of readmission,unplanned readmissions,appearance of hard events,number of short hospitalizations,Self-care abilities|There were 43 CHF hospital admissions and 7 deaths in the intervention group, as compared with 59 CHF hospital admissions and 13 deaths in the nonintervention group (p = 0.09).
335|relapse rate,plasma AAG levels,PANSS total, PANSS positive, PANSS-derived BPRS core, and CGI-Severity scores,incidence of extrapyramidal symptoms,Blood samples,BPRS scores,Negative Symptoms [SANS]-composite), Olz-L and Olz-H,QTc interval,Plasma AAG levels,Prolactin elevations,clinical improvement,efficacy, safety, and tolerability,BPRS scores and plasma AAG levels,antidyskinetic effect,efficacy, rapidity of therapeutic onset, and safety,positive symptom improvement (BPRS-positive), Olz-M, Olz-H, and Hal,quicker onset of antipsychotic activity,somnolence, agitation, asthenia, and nervousness,Positive and Negative Syndrome Scale (PANSS) total, PANSS positive, PANSS negative, PANSS-derived Brief Psychiatric Rating Scale (BPRS) core, Clinical Global Impressions (CGI)-Severity of Illness, and mean CGI-Improvement scores,variables (basic data, MMPI, AMDP, HAM-A, HAM-D,tardive dyskinesia,Mean plasma haloperidol levels,rate of Hal, and akathisia,Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression (CGI), and Modified Scale for the Assessment of Negative Symptoms (SANS) summary scores,safety and efficacy,signs of tardive dyskinesia,total Positive and Negative Syndrome Scale (PANSS) score and positive subscale, superiority to placebo,EPS or prolactin elevation,negative symptoms,incidence of extra-pyramidal side effects,total scores on the Positive and Negative Syndrome Scale for Schizophrenia,number of days of remission,Prolactin levels,Plasma alpha-one acid glycoprotein and haloperidol concentrations,moderate EPS and drowsiness,Serum prolactin levels,Positive symptom scores,Efficacy and safety,BPRS total, BPRS positive-symptom cluster, and CGI Severity of Illness item scores,assessment scales of extrapyramidal side effects,body weight,Brief Psychiatric Rating Scale (BPRS) and Abnormal Involuntary Movement Scale,Extrapyramidal Symptom Rating Scale,total PANSS, General Psychopathology, and Brief Psychiatric Rating Scale subscales,Global evaluation, BPRS, and target symptom ratings,overall symptomatology improvement (Brief Psychiatric Rating Scale [BPRS]-total), Olz-M, Olz-H, and Hal,Blood samples to measure plasma alpha-one acid glycoprotein (AAG), haloperidol and reduced haloperidol concentrations,acute dystonia,Safety and tolerability evaluations included extrapyramidal symptoms (EPS), weight gain, serum prolactin level, and QTc interval,number of symptom-free days dose,remission state,positive symptoms,PANSS negative score|The most common treatment-emergent adverse events included somnolence, agitation, asthenia, and nervousness.
not found|rate of the response,GFR,hemoglobin concentration,Cardiac output, plasma renin activity and aldosterone,chronic renal failure,Maximal oxygen consumption during exercise,Renal function, cardiac output, plasma renin activity and aldosterone,residual renal function,glomerular filtration rate (GFR,Quality of life,appetite, activity level, and sense of well-being,Serial GFRs,hematocrit; mean hematocrit,average systolic and diastolic blood pressure,serum ferritin and percent transferrin saturation (plasma iron/total iron-binding capacity,clearances of inulin and p-aminohippurate, fractional excretions of albumin and immunoglobulin G, cardiac output, plasma renin activity and aldosterone concentration,hematocrit increased with r-HuEPO,deterioration of renal function,Energy levels and work capacity,cumulative renal survival rates,blood pressure and hematocrit,Anemia,rate of the decline in renal function,slope of l/serum creatinine,51Cr red cell mass,blood pressure,safety and efficacy,Hypertension,slope of l/serum creatinine with time,exercise capacity,tolerated,serum creatinine and reciprocal of serum creatinine,degree of control of dietary protein and blood pressure and the frequency of angiotensin-converting enzyme inhibitor administration,anemia,renal survival rate,hematocrit,GFR, mean arterial blood pressure, and daily protein intake,packed cell volume (PCV,physical exercise capacity,renal function,Renal function,hematocrit rose,total hemoglobin (THb,erythroid, megakaryocyte, and granulocyte-monocyte progenitor cells,Blood pressure,erythrocyte mass,progression of renal failure (1/serum creatinine v time) or change in serum potassium,survival rate,median hematocrit,THb|Six of seven treated patients had a significant decrease in serum ferritin and percent transferrin saturation (plasma iron/total iron-binding capacity).
not found|mortality of tetanus,mortality|In the other age group of 13-30 years, there were 27 and 38 patients in the treatment and control groups respectively.
40|eating attitudes, eating behavior, and general psychopathology,eating behavior,items 'restraint', 'weight concern' and 'shape concern,target-eating behaviors,bulimic symptomatology,energy intake and lost a modest amount of weight,dietary preoccupation and hunger,body weight,Eating Disorder Examination (EDE,recurrence of symptoms,tolerated and had only minor adverse effects,binge eating and purging rates,symptoms of depression and anxiety,binge eating and depression|In self-ratings and expert ratings concerning attitudes towards eating, eating behavior, and general psychopathology, significant improvements over time were observed in both groups.
579|several instances (oppositional/aggressive symptoms, internalizing symptoms, teacher-rated social skills, parent-child relations, and reading achievement|For most ADHD symptoms, children in the combined treatment and medication management groups showed significantly greater improvement than those given intensive behavioral treatment and community care.
242|time to onset of relief and overall analgesic efficacy,Analgesic effect,analgesic effects,onset of meaningful relief,Drug tolerability,duration of analgesic effect,number of patients requiring rescue medication,serious adverse events,postoperative dental pain,patient self-rating of pain intensity, pain relief, time to meaningful pain relief, need for additional analgesic medication, and patient global evaluation,Analgesia,pain relief,sum pain intensity difference, total relief of pain, and overall evaluation parameters,mean response with zomepirac,analgesic efficacy measures sum PI (SUMPI), sum PID (SPID), and total PAR (TOTPAR,adverse reaction,pain intensity and relief and stopwatch onset of meaningful relief,Ratings of pain intensity and pain relief,pain intensity differences, peak pain intensity differences, total relief, peak relief, and hours of 50% relief,efficacy and safety,pain relief, pain intensity difference, total pain relief (TOTPAR), and summed pain intensity difference (SPID,pain intensity (PI) and pain intensity difference (PID,adverse reactions,pain intensity and pain relief and summary measures,small additive effects,overall pain scores (AUC(0,360 min), maximum pain relief, pain relief at 1 h after dosage and the number of patients taking escape analgesics,peak pain intensity difference (visual analog scale), summed pain intensity differences, total pain relief, peak pain relief, time to reduction of pain,overall pain relief,analgesic efficacy,overall analgesic effect,rapid analgesia,median times to onset of relief,relative analgesic efficacy and safety,postsurgical dental pain,Pain intensity, pain relief, and side effects,severe postoperative pain,incidence of adverse events,Pain relief,median time to onset of analgesia,tolerated,frequency of adverse effects,later time to taking escape analgesics,tolerability,faster relief and superior overall efficacy,onsets of first perceptible relief and meaningful relief,peak and overall analgesic effects,pain relief (PAR,relative onset of analgesic response, overall analgesic efficacy, duration of effect, and safety,number of hours until remedication,pain intensity difference, pain relief, and global evaluation,pain relief and pain intensity difference,serious adverse effects,meaningful relief,median time to meaningful pain relief,Analgesic efficacy,SUMPI, TOTPAR and maximum PAR (MAXPAR,Overall pain scores,total and peak analgesia,analgesia,marginal numerical superiority,Pain intensity,analgesic efficacy and safety,mean scores,rapid onset to meaningful relief,pain intensity,analgesic efficacy and tolerability,pain,Analgesic efficacy and safety,pain scores,side effects,intensity of pain, relief of pain, and side effects|At 4 hours after administration, the pain relief was significantly better with tablet acetaminophen than with effervescent acetaminophen.
240|admissions for other health problems,readmissions and mortality,evolution of dyspnea, lung function, quality of life scores, lifestyle factors, or medical treatment,questionnaires, visual analog scales, and other psychosocial measures,numbers of visits to an accident and emergency department, hospitalizations, and unscheduled visits by physicians,quality indicators, patient satisfaction, or use,pulmonary rehabilitation programme,self-efficacy for managing dyspnea,technical quality of VVs,Chronic Respiratory Questionnaire,chronic obstructive pulmonary disease (COPD,mortality,forced expiratory volume,Telehomecare: quality, perception, satisfaction,hospital utilization,impact subscale and total quality-of-life scores,health care use ,hospitalisations, emergency room admissions, urgent GP calls or exacerbations,risk factors of COPD readmission,Pulmonary function tests and dyspnea index scores,knowledge, behavior and status scales,hospitalisation rate,SF-36 general health subscale,body mass index,hospitalisations,unscheduled physician visits,quality indicators (medication compliance, knowledge of disease, and ability for self-care); extent of use of services; degree of patient satisfaction,clinical and functional status, quality of life, lifestyle, and self-management,total mean costs of care, excluding home health care costs,hospitalisations and, secondly, exacerbations, general practitioner (GP) calls and related cost-effectiveness of tele-assistance (TA,acute exacerbations,Morbidity,self-efficacy scores,average overall cost,unnecessary clinic visits,patient self-efficacy,Chinese Self-Efficacy Scale,dyspnea with ADL,scores for activities of daily living at study discharge,urgent GP calls,physical functioning,Self-reported endurance exercise time,Hospital admissions for exacerbation of COPD,number of hospitalizations; secondary outcomes included emergency visits and patient health status,serum theophylline levels,average visit costs,exercise behavior, exercise performance, COPD exacerbations, and mediators, such as self-efficacy and social support,Emergency department visits|Only COPD patients, as a separate group, had fewer hospitalisations, emergency room admissions, urgent GP calls or exacerbations.
89|70-point reduction in Crohn's Disease Activity Index,efficacy and safety,overall clinical response rate|Lenalidomide was generally well tolerated with only one serious adverse event, a deep vein thrombosis, being attributed to treatment.
                
not found|lung function,quality of life,efficacy and safety,airways obstruction,tolerated,dyspnea,Bronchodilator response,symptoms,Adverse effects,daytime symptom scores and morning peak expiratory flow,area under the curve for forced expiratory volume in 1 s (FEV(1,FEV1,Salmeterol xinafoate,bronchodilator response,FEV1 and sGaw,area under the curve for FEV(1,diary symptoms and quality of life,specific airway conductance (sGaw|There was added benefit from the combination therapy in terms of improvement in airways obstruction, but not for improvement in symptom control or need for rescue salbutamol.
70|relapse rate,drug intolerance symptoms,Plasma TRAb levels,serum basal thyrotrophin (TSH) level and TSH receptor antibody activity,relapse rates,Total T3, TSH-receptor antibodies,serum total T4 and tri-iodothyronine (T3), free T4 and T3, TSH, TSH-receptor antibodies (TSHR-Ab), thyroid scintigraphy and echography,levels of antibodies to TSH receptors,mean duration of treatment,final outcome and recurrence rates,Thyroid antibodies, serum thyroglobulin and pertechnetate uptake,relapse and remission groups, regardless of treatment duration, for HLA ABDr, serum T3 and T4, and T3/T4 ratio,goiter size, frequency of ophthalmopathy, TSH and TRAb levels,level of antibodies to TSH receptors,goiter size with recurrence,clinical characteristics or hormonal or antibody values,level of antibodies to TSH receptors further,relapse of overt hyperthyroidism,recurrences of hyperthyroidism,recurrence of Graves' disease,normalize elevated TSH serum concentrations,thyrotropin-receptor antibody (TRAb) positive,serum tri-iodothyronine (T3) and thyroxine (T4) concentrations,serum thyrotropin concentrations,early iodine uptake,remission rates,recurrence risk,production of antibodies to TSH receptors and the frequency of recurrence of hyperthyroidism,ophthalmic symptoms,Recurrence rate,Relapse rates of Graves' disease,relapse,recurrence,remission,relapse of Graves' disease,gastrointestinal side effects or leucopenia,Relapse,TRAb levels and goiter weight,Hyperthyroidism,lasting remission,normalized antithyroperoxidase (TPO) antibody and anti-TSH receptor stimulating antibody (TSAb) levels and early iodine uptake,serum TSH level and TBII activity,recurrence rate 20 times lower,goitre size during treatment, and TSH levels and TBII values,Serum levels of FT4, T3, sTSH and TSH receptor antibody (TRAb,complications of Graves' disease,Serum TSH,relapse of hyperthyroidism, initial thyroid size,suffered relapse,recurrence of hyperthyroidism,TSH secretion,2-year post-treatment remission rates,High TRAb levels and goiter weight,area of low-to-moderate iodine intake (prevalence of 24h urinary iodine excretion,relapse rates of Graves' disease,Median duration,regular cigarette smoking,rate of normalization of serum thyroid function tests or in serum thyroid auto-antibody levels,remission rate,percentage of recurrence equalled,rate of relapse,recurrence rates,Cigarette smoking,Recurrence,goiter size,normal serum thyrotropin concentration,overall relapse rate,goitre size, pertechnetate uptake and presence of detectable plasma TSH,recurrence rate,number of side-effects,thyroid echostructure,frequency of Graves' disease complications and thyrotoxicosis recurrence,antibodies to TSH receptors,frequency of relapse,rapid goitre growth,serum free T4 and T3 and TSH concentrations,relapse of hyperthyroidism,long-term remission rates,target TSH concentration,TSHR-Ab titers,mean serum thyroxine concentration,serum TSH,positive TSHR-Ab,clinical parameters, thyroid hormones, or TSH binding inhibitory immunoglobulins (TBII) levels,serum TSH level and thyrotrophin binding inhibitor immunoglobulin (TBII) activity normalized,course of endocrine eye signs,median relapse-free interval,thyroid volume,percentage of recurrence,Thyroid volume,remission rates or delays relapse,Serum basal TSH levels and TBII activities,disease relapse,thyroid-stimulating antibody levels,Dropout rate,serum thyrotropin concentration,rate of normalization of serum thyroid function tests, changes in serum thyroid auto-antibody levels and the rate of side-effects|By 2 years after stopping treatment, recurrence had occurred in 50% of the HD and 66% of the TD group.
not found|cognitive variables (knowledge, attitude towards asthma, self-efficacy) and day and night peak flow ratings,baseline characteristics (anxiety, depression, psychophysiological disorders), emotional reactions to asthma attacks (panic-fear, etc,) and cognitive variables (external control, psychological stigma, internal beliefs, external chance, etc.) involved in the perceived illness,6 POMS-BI scores,asthma symptoms (wheezing, coughing, sleep, activity, attacks, peak flow) and self-report assessments of Profiles of Mood States (POMS-BI) (anxiety, hostility, depression, uncertainty, fatigue, confusion); Knowledge, Attitude, and Self-Efficacy Asthma Questionnaire (KASE-AQ); Health Attribution Test (HAT) for locus of control (LoC); and the Revised Asthma Problem Behavior Checklist (RAPBC,Oscillation resistance,respiratory function,relaxation,bronchial hyper-responsiveness,heart rate variability (HRV) biofeedback,occurrence of severe asthma flares,peak expiratory flow rates,asthma symptoms,feasibility and effectiveness,total power scores,feasibility and efficacy,respiratory sinus arrhythmia (RSA,symptoms and asthma management,Psychophysiological Questionnaire,External Control Subscale,daily asthma symptoms and twice-daily peak expiratory flows,reduction of anxiety and depression scores,number of visits of the general practitioner,asthma knowledge, attitude, self-efficacy, internal LoC, and peak flow,External Chance Scale,respiratory impedance,forced expiratory flow,pulmonary impedance,relaxation during EMG or RSA biofeedback,POMS-BI scores except anxiety, increased internal LoC, and reduced problematic behaviors,For BTI, data collection (symptoms, lung function,McMaster Asthma Quality of Life Questionnaire, Asthma Symptom Checklist, Negative Emotionality Scale, Knowledge, Attitude and Self-Efficacy Asthma Questionnaire, Adherence Scale, and peak flow measurements,Mesoexpiratory Flow,pulmonary function,bronchial hyper-reactivity,measures of perceived stress,lung function,panic and asthma outcomes,WLC, BTI reduced wheezing, anxiety, and chance LoC, and increased asthma knowledge, attitude, and self-efficacy, Spirometry (FEV1); 2) medication use; 3) Asthma Quality of Life Questionnaire; 4) Beck Depression Inventory; 5) Spielberger Anxiety Scales (A-State and A-Trait,choices sub-scale,symptoms (obstruction, fatigue), better quality of life (activity, symptoms, emotions), decreased negative affectivity, and increased adherence,CTAM, BTI reduced wheezing and chance LoC, increased internal LoC,Forced Vital Capacity (FVC), Forced Expiratory Volume in the first sec (FEV1), Forced Expiratory Flow,pulmonary function, asthma symptoms, quality of life, depression, anxiety, and power differ over time,morning peak-flow expiratory rate and asthma-related quality of life,asthma morbidity, and asthma-related behaviour and cognitions|No significant changes were observed in the control group.
not found|baseline lung function,adverse reactions,random nasal eosinophils,Bronchial reactivity,positive reactions,histamine sensitivity (PC20,Methacholine challenges and random circulating and sputum eosinophils|Only 4 of 156 patients (all Polish) had positive reactions in a double-blind test, as evidenced by a fall in FEV1 greater than 25% from baseline and corresponding clinical symptoms.
672|Recurrence of hernia,Recurrence rates, symptoms (including patient satisfaction), and infections,hernia recurrence, nerve damage, testicular atrophy and patient satisfaction,chronic groin pain,recurrence rate, technical difficulty, convalescence and chronic pain,redoubtable and litigious sequelae of testicular atrophy and chronic ilioinguinal pain,lowest recurrence rates,duration of operation, pain score, or incidence of postoperative complications,wound hematomas, seromas, and superficial wound infection,actual 2-year recurrence rate,Hernia recurrence rate,cost-effective,postoperative complications, return to work, and recurrences rate,complication rate,Patient satisfaction,longer operation time,duration of surgery, the technique of anesthesia, the perioperative complications, the duration of postoperative care,Duration of operation, postoperative pain assessed by visual analogue scale (VAS), complications within 30 days, duration of sick leave, and recurrence within one year,postoperative pain, duration of narcotic use, and time to resumption of usual activity and employment,Postoperative pain, narcotic use, and time to resumption of usual activities and employment,number of recurrences,recurrence rates,Chronic groin pain,Hernia recurrence,operative time; postoperative pain,Postoperative pain and patient's comfort,Postoperative pain, analgesia requirements, limitation of daily activities, and return to work did not differ between laparoscopic and open tension-free repair,actuarial recurrence rate,sick leave,direct hernia, repair for recurrent hernia, hernial sac diameter,Recurrence,pain scale 1-10) need for analgesia, ambulation (evaluated by a four-point scale), complications and return to work,re-recurrence rate,sliding hernias,recurrence rate,Actual (not actuarial) recurrence rates,narcotic analgesics,Nerve injuries,Ambulation grades,operating time,pain of a higher scale|Both types of hernia repair are comparable and effective, but long-term results favor the Lichtenstein technique for reducing recurrences (to a P value of .10), ease of technical mastery, and application to the outpatient setting by use of a local anesthetic.
not found|rate, length, or severity of URIs,cold symptoms,mean illness duration,Whole-blood ascorbic acid levels,mean illness,development of symptoms of URT infection,sickness experience,number of episodes,daily observations of cold symptoms, and multiple biochemical, anthropometric, and psychological measurements,incidence or morbidity of the common cold and other respiratory illnesses,total number of days of upper respiratory tract infection,postrace symptoms of upper-respiratory-tract infection,shorter duration of severe symptoms,incidence of URIs,duration or severity of cold symptoms,Total number of common colds,duration and severity of respiratory infections,duration of respiratory infections,severity,Duration of symptoms and cold episodes; cumulative symptom severity scores,duration of infections,reduction of colds,overall complicated illness rate,Plasma ascorbic acid levels,incidence and severity of winter illness,shortest duration of nasal, systemic and overall symptoms,upper respiratory or general constitutional symptoms,cold duration or severity,Symptoms of URT infections,severe illness,duration and severity of symptoms of URT infections,incidence of symptoms of upper-respiratory-tract (URT) infections,incidence or duration of colds,duration or severity of the common cold,personality trait of neuroticism,throat cultures yielding beta-hemolytic streptococcus,duration and severity of colds,Respiratory symptoms,severity of URIs,severe illness episodes,colds,rate of respiratory infections,side effects|No apparent reduction was seen for the severity and duration of the common cold.
                
not found|pain or stiffness (VAS, physical tests,neck pain,low back pain,individual patient's pain score,pain score,medication-related side-effects,pain severity on visual analogue scale (VAS); (2) pain subscale of Nottingham Health Profile (NHP); (3) number of analgesic tablets consumed in previous week; (4) spinal flexion from C7 to S1,Neck Disability Index, and (3) three visual analogue scales of local pain intensity,gastro-enteric side effects,estimates of pain (on a Visual Analogue Scale) and disability by both physician and patient, physical measures of trunk strength and spine range of motion, as well as the patient's perceptions of the relative contribution of the education, exercise training, and the electrical stimulation,chronic low back pain,spinal flexion,pain or stiffness,VAS,psychological distress,psychotropic drug intake,disability scale,Aberdeen LBP scale, lumbar spinal active range of movement (AROM), and the isokinetic strength,mean spinal flexion,pain intensities,intensity of pain,Mean VAS value,spinal AROM and isokinetic trunk concentric strength,McGill Pain Questionnaire,VAS and NHP,JOA Score,Numerical Rating Scale (NRS,return to work, quality of sleep, and analgesic intake,Initial pain levels correlated with state-anxiety, depression, pain duration, and abnormal illness behavior measures,analgesic effect,tablet count,pain relief scale (100 mm visual analogue scale: VAS) and a LBP score recommended by the Japanese Orthopaedic Association (JOA Score,mean global transition score,analgetic drugs,modified Roland Disability Questionnaire (RDQ,MPQ scores,NRS and Aberdeen LBP scale,spinal manipulation,visual analogue scale measure of average pain,pain disability,pain, disability, and functional improvement scores,RDQ score,pain intensity and in pain disability, and secondary in psychological distress and in spine flexion,new episodes of low back pain,McGill Pain Questionnaire (MPQ) and visual analog scales (VAS) for pain,adverse effects,relapse of low back pain and number of days on sickness leave,NHP,neck disability index, and (3) reductions on the visual analogue scale,Analgesic drug intake,average pain score,depression, neuroticism, and hypochondriasis scores,scores of the (1) Oswestry Back Pain Disability Index, (2,initial pain severity,pain diaries to score pain intensity twice daily, analgesic intake, and quality of sleep daily, and activity level weekly,activity related to pain; mobility; verbal descriptors of pain and the patient's subjective assessment of his condition,pain rating scores,pain intensity,change in RDQ score,pain,Side effects,pain scores,pain reduction|During the first phase of treatment, patients receiving acupuncture had a greater but not significantly different reduction in pain rating scores compared with those receiving placebo (t = 0.52; p greater than 0.6).
not found|reoperation, readmission and repeat resection rates for recurrent Crohn's disease,incisional hernia repair,Major complications,Flatus and first bowel movement,Conversion rate,SF-36 and GIQLI questionnaires,incisional hernia and adhesion-related problems,clinical recurrences,SF-36 and GIQLI questionnaire,Incidences of anorectal disease, anorectal surgery, endoscopic or radiologic recurrence, and medication use,operating time, morbidity, hospital stay, postoperative morphine requirement, pain, and costs,morbidity, hospital stay, and costs,quality of life (QOL), body image and cosmesis,number of patients with postoperative morbidity,Hospital stay,GIQLI score,relapse free after ileocolic resection,Median length of the incision,QOL,Minor complications,postoperative quality of life (QoL,amount of morphine equivalents,Median overall costs,body image and cosmesis scores,forced expiratory volume (one second) and forced vital capacity,Median length of stay,QoL,Median operating time,Overall reoperation rates,Demographic data, recurrence rates, need for additional surgery related to primary procedure, and medication use|OC patients requiring operation during follow-up were significantly more likely than LC to require multiple operations (P = .006).
                
not found|severe hyperbilirubinemia,number of bilirubin determinations,median hours to case closure,moderated hyperbilirubinemia and reduced phototherapy (PT) time,exchange transfusion or interruption of breast-feeding,bilirubin measurements|No adverse effects of SnMP use were observed.
                
14|educated guesses,Visual Analog Scale (VAS) and increased relaxation,job satisfaction, burnout, and sick leave,Chinese version of State-Trait Anxiety Inventory and the Chinese version of the General Health Questionnaire,semantic differential questionnaire, occupational stress,scores on 2 of 3 subscales of the Maslach Burnout Inventory,Cost savings,Nursing Stress Scale, attitudes with a Semantic Differential Questionnaire, CS,Nursing Stress Scale and communication skills,Perceived Stress Scale (PSS) and Rathus Assertiveness Schedule (RAS,anxiety,level of occupational stress,Anxiety measures,knowledge and attitudes, and increase in burnout,pre- and post-treatment anxiety scores,mean change in physiologic parameters,levels of stress,sick leave,mean scores on the Nurse Stress Checklist (NSC) and the Chinese General Health Questionnaire (CGHQ,Total Mood Disturbance (TMD,cost savings,burnout rates,knowledge and attitudes about serious mental illness,facilitative behaviours (open questions,multiple burnout and mood dimensions,job turnover,anxiety, stress, self-care and caring relationships,work-related anxiety,psychophysiologic health level,Mental health status,mental health,psychoendocrine stress,stress hormone levels,Blood pressure,prolactin levels,inhibitory behaviours,stress levels,nurses' satisfaction levels,TMD scores,attitudes, communication skills and occupational stress,importance of touch in nursing care, stress reduction, increased self-awareness, the need for self-care,emotional exhaustion and lack of personal accomplishment, two dimensions of burnout|Results suggested that stress management training was effective in reducing work-related anxiety among inexperienced nurses but not among experienced nurses.
not found|sensory antidromic nerve conduction velocity,hand pain,Phalen test time,pain/paresthesia,carpal bone mobilization and median nerve mobilization,sleep disturbance, Tinel sign, and median nerve motor and sensory conduction time,Score of subjective symptom ratings assessed by visual analogue scale; electroneurographic measures (for example, motor distal latency and sensory antidromic nerve conduction velocity,pain severity and greater satisfaction,Pain,Symptoms and functional deficits,carpal tunnel syndrome,global symptom score (GSS,electroneurographic variables (motor distal latency,efficacy and tolerability,motor nerve conduction velocity and increased motor distal latency,grip strength, pain intensity, sleep disturbance, Phalen sign, and Tinel sign, and in median nerve motor and sensory conduction time,beginning pain, pain at 15 minutes, pain at 30 minutes, or pain,superior distal latency improvement,pre- and postassessments of self-reported physical and mental distress, nerve conduction studies and vibrometry,hand function or median nerve latency,Patient satisfaction,overall neurophysiological classification,BCTQ symptomatic score,symptoms, function, and impairment in carpal tunnel syndrome (CTS,perceived comfort and function, nerve conduction and finger sensation overall,manipulation of the soft tissues and bony joints of the upper extremities and spine,sensory distal latency improvement,lateral pinch strength value,electrophysiologic signs, clinical signs, or significant symptoms,Subjects' Global Impression of Change Questionnaire (SGICQ), median distal motor latency, sensory conduction velocity and amplitude, and neurophysiological class of severity,Pain Relief Scale,mean score,pain perception and function, and lastly numbers of patients continuing to surgery,numbness, tingling, burning, and pain,clinical findings, pain severity, functional hand status, and comfort,global symptom scores,Relief of symptoms,Phalen sign,functional status scale, and a symptom severity scale,occasional daytime wear,pain and other symptoms of carpal tunnel syndrome (CTS,grip strength,visual analogue scale,functional score,standardized symptom questionnaire, rating five categories of symptoms (pain, numbness, paresthesia, weakness/clumsiness, and nocturnal awakening) on a scale from 0 (no symptoms) to 10 (severe,Boston Carpal Tunnel Questionnaire (BCTQ) score,frequency of awakening at night,active range of wrist movement (ROM flexion and extension), upper limb tension test with a median nerve bias (ULTT2a,mean MNMDL, MNSV, and GSS,symptom severity,electrophysiological measurements,median nerve sensory and motor distal latency,mean median nerve motor distal latency (MNMDL), median nerve sensory velocity (MNSV), and global symptom score (GSS,grip strength and pain,pain severity and hand function,Levine's self-administered questionnaire, and physiologic impairment,pain,sensory distal latency,functional deficits,pain reduction|We evaluated the effectiveness of low-dose, short-term oral prednisone in ameliorating the pain and other symptoms of carpal tunnel syndrome (CTS) in a randomized, double-blind, placebo-controlled study of patients with mild to moderate CTS.
244|bilateral impairment,leukocyte count and inflammation markers,hearing impairment,respiratory function,change in forced expiratory volume in 1s (FEV1), over the 14 days of treatment, expressed as a percentage of the predicted normal value for age, sex, and height,Efficacy, tolerance, and pharmacokinetics,mean change in FEV1,forced vital capacity,forced expiratory volume,Efficacy,efficacy and safety,serum potassium and magnesium levels, equivalence,Nephrotoxicity,Tobramycin concentrations,Tobramycin concentration,acute dizziness,safety and efficacy,respiratory function and changes in renal function and hearing,weight/height,forced expiratory flow,leukocyte count, and the secondary end-points were clinical and lung function parameters, Pseudomonas quantification in sputum, and inflammation markers (immunoglobulin G, C-reactive protein) in serum,Mean% change in FEV1,variables forced expiratory volume in one second and forced mid-expiratory flow % pred and serum creatinine levels,hearing loss,creatinine,forced mid expiratory flow rate,change in serum creatinine,Forced expiratory volume,renal function,Cochlear and renal tolerance,Serum peak concentration of tobramycin,forced vital capacity (FVC,PA density,Mean body weight,serum trough,plasma prealbumin,Toxicity and practicability,nephrotoxic|The mean change in FEV1 (% predicted) over 14 days was similar on the two regimens (10.4% [once daily] vs 10.0% [three-times daily]; adjusted mean difference 0.4% [95% CI -3.3 to 4.1]).
not found|manual dexterity, depression, and anxiety,socialization and self-esteem,time taken to walk 10 m,gait speed,self-care independence,Rivermead Mobility Index scores,level of depression, self-esteem, and socialization,Barthel Activity of Daily Living Index (BI) scores, "poor global outcome", (defined as deterioration in BI score, or death) and the Rivermead Mobility Index,mobility including gait speed, functional ambulation categories, the Nottingham extended activities of daily living index, and individual items from the Barthel activities of daily living index and the Frenchay activities index,Functional Independence Measure (FIM), Brunnstrom stages of motor recovery, timed mobility tasks, and the Jebson hand evaluation|At 3 months BI score in survivors had increased by 0.6 (SD 3.9) in the intervention group and decreased by 0.9 (2.2) in the control group; a difference of 1.5 (95% CI allowing for cluster design, -0.5 to 3.5).
151|discontinuation rates, adverse event rates, vital signs, and laboratory tests,HAMD(17) total score,Safety,nausea, dry mouth, vomiting, yawning, and irritability,number of early discontinuations and overall TEAE,total MADRS score,nausea and palpitations,Estimated probabilities of remission,CGI-I, MADRS, and HAM-D(6,incidence of acute treatment-emergent sexual dysfunction,17-item Hamilton Rating Scale for Depression (HAMD(17,mean change from baseline in the 17-item Hamilton rating scale for depression (HAMD(17)) total score,Mean baseline MADRS total scores,Nausea,Tolerability,HAMD17 total score and subscales, HAMA, CGI-S, and PGI-I. Safety and tolerability were assessed via analysis of reasons for discontinuation, treatment-emergent adverse events (TEAEs), discontinuation-emergent adverse events, and changes in vital signs, weight, and laboratory analytes,mean change on the HAMD(17,discontinuation-emergent adverse events,laboratory values, vital signs, weight or electrocardiograms,Clinical Global Impressions-Improvement (CGI-I) score, Montgomery Asberg Depression Rating Scale (MADRS) score, Clinical Global Impressions-Severity (CGI-S) score, and 6-item Hamilton Rating Scale for Depression, Bech version (HAM-D(6,remission at endpoint [17-item Hamilton Depression Rating Scale,safety and tolerability,depression,therapeutic efficacy and safety/tolerability,constipation,Visual Analog Scales for pain, Clinical Global Impression of Severity, Patient's Global Impression of Improvement, and Quality of Life in Depression Scale,rate of discontinuation due to adverse events,Efficacy, safety and tolerability measures,morbidity and mortality,safety and efficacy,VAS back pain,deaths,insomnia and asthenia,tolerated and safe,Clinical Global Impressions (CGI)-Severity of Illness scale score,CGI-I, MADRS, CGI-S, and HAM-D(6,overall withdrawal rates,estimated probability of remission,change from baseline to week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) total score,dry mouth, sedation, and somnolence for quetiapine XR and nausea, headache, dizziness, and dry mouth for duloxetine,Estimated probabilities of response and remission,mean 17-item Hamilton Depression Rating Scale total change,MADRS,withdrawal rate due to adverse events,duloxetine, escitalopram, and placebo rates of remission or response,Hypertension incidence,somnolence,Remission rates (MADRS score,Montgomery-Asberg Depression Rating Scale, CGI-Severity of Illness and CGI-Improvement, and Patient Global Impression of Improvement,efficacy and tolerability,primary efficacy measure (Maier subscale,Discontinuation rates,MADRS total score,17-item Hamilton Depression Rating Scale,increased sweating,tolerated,insomnia,HAMD(17) subscales, Hamilton Rating Scale for Anxiety, Clinical Global Impressions-Severity, Patient Global Impressions-Improvement, Somatic Symptoms Inventory and Visual Analog Scales (VAS) for pain,major depressive disorder (MDD,Response rates,HAM-D(17,Hamilton Rating Scale for Depression, Hamilton Rating Scale for Anxiety, and Clinical Global Impressions-Severity of Illness total scores and the proportion of patients with Clinical Global Impressions-Improvement scores,adverse events, vital signs, ECGs, laboratory tests, and the Arizona Sexual Experiences Scale (ASEX,acute phase; efficacy and safety/tolerability outcomes,treatment-emergent adverse events (TEAE), vital signs, weight, laboratory analyses and electrocardiograms,17-item Hamilton Rating Scale for Depression (HAM-D-17) total score,total score, HAMD(17) subscales, the Montgomery-Asberg Depression Rating Scale (MADRS), the Hamilton Anxiety Rating Scale (HAMA), Visual Analog Scales (VAS) for pain, the Clinical Global Impression of Severity (CGI-S) and Patient Global Impression of Improvement (PGI-I) scales, the 28-item Somatic Symptom Inventory (SSI), and the Sheehan Disability Scale (SDS,MADRS, HAMA, CGI-S, and PGI-I scales,Tolerability assessments included discontinuation rates, adverse events (AEs), vital signs, and laboratory tests,overall pain severity,17-item Hamilton Depression Rating Scale improvement,GBR assessment,occurrence of discontinuation rates and treatment-emergent adverse events and by measurement of vital signs and laboratory analytes,response and remission rates,Efficacy,efficacy and safety,HAM-D-17 total score,HAM-D(17) total score,Adverse events,TEAE reporting rates,Maier subscale,Safety and tolerability,systolic blood pressure,mean MADRS total score,adverse events (TEAEs), vital signs, and weight,onset of antidepressant efficacy,safety measures,Probabilities of meeting onset criteria|The difference in mean change from baseline in MADRS total score favoured escitalopram at weeks 1, 2, 4, 8, 12 and 16 (p < 0.05).
not found|Subclinical Vitamin A deficiency,mean number of diarrheal episodes,maternal and infant serum retinol concentrations, modified relative dose-response (MRDR) ratios and breast milk vitamin A concentrations,serum retinol concentrations,Incidence of diarrhea and Acute Respiratory Infection (ARI,Mean,duration of respiratory tract infection and febrile illness,infant serum retional and the breast milk retinol level,mean duration of respiratory tract infection,Milk retinol,liver stores) and higher milk vitamin A concentrations,H pylori infection,Breastmilk retinol concentration,cord blood levels,infant gut mucosal damage,lower maternal MRDR ratios,mean maternal serum retinol concentrations,maternal vitamin A concentration,infant mortality,MRDR ratios,serum retinol of infants and the breast milk retinol levels,antipolio antibody titer, antitetanus toxoid antibodies, and avidity of antibodies to tetanus,gram fat, milk retinol,morbidity and mortality,safety and efficacy,Mothers' serum retinol concentrations,Infant serum retinol,Serum retinol and incidence of illness,adverse events,maternal and infant plasma vitamin A, reduce infant Helicobacter pylori infection and nasopharyngeal pneumococcal carriage, and improve infant gut epithelial integrity,mean incidence of febrile illness,serum retinol,Serum retinol levels,tolerated,Maternal serum and breastmilk retinol levels and infant morbidity and anthropometry,levels of maternal and infant plasma vitamin A, H pylori infection, pneumococcal carriage, and gut epithelial integrity,incidence of diarrhea,breastmilk retinol concentration,prevalences of low vitamin A stores,Antibody titers,low serum retinol concentration,clinic attendances,Serum retinol concentrations,milk retinol concentrations,Hazard ratios,relative risk of VAD,vitamin A status,Maternal serum retinol,infant pneumococcal carriage,serum retinol and infant stores,VAD,serum retinol levels,milk retinol,Infant retinol stores,breast milk retinol levels,maternal pneumococcal carriage,mean MRDR ratio,subclinical vitamin A deficiency,milk vitamin|The milk retinol concentrations of the vitamin A group were higher than those of the placebo group by 0.48 to 1.18 mumol/L at 1-8 mo postpartum (P < 0.05).
76|sucrose pain scores,pain response and clinical outcomes (e.g., health status and neurodevelopmental status,Pain scores,distress,crying time and pain,total duration of crying,mean crying time, recovery time, maximum heart rate, and percent change in heart rate,average crying time,crying and the autonomic effects,maximum heart rate,procedural pain,Crying duration,standard deviation of pulse rate and number of doses of sucrose,facial scores,pain-induced crying,Pain reduction,facial expression,plasma cortisol levels,PIPP scores,majority of time actively crying,Salivary cortisol,mean (SD) plasma lidocaine level,Adverse events and lidocaine levels,overall physiological stability,Motor development and vigor, and alertness and orientation components of the Neurobehavioral Assessment of the Preterm Infant,duration of crying,time spent crying,Mean crying times,Pain response measurements,discomfort and crying,distress responses,frequency distribution of CT,Vital signs (i.e., pulse rate, respiratory rate, and oxygen saturation), crying time, and time for the vital signs to return to baseline values,median values of crying time, recovery time and percentage change in heart rate,premature infant pain profile (PIPP,loss of oxygen saturation data,validated infant pain measure, the Premature Infant Pain Profile (PIPP), which includes measures of facial expressions, heart rate, and oxygen saturation and takes behavioral state and gestational age into consideration,Facial scores,Nociceptive brain activity,mean glucose levels,neonatal infant pain scale (NIPS) score, on crying time (CT) and subsequent NIPS score,duration of crying whilst the blood collection,Mean (SD) DAN pain scores,Crying and the total procedure time,Heart rate, thoracic movements, and transcutaneous blood gases,mean pain scores,pain response,time crying,motor development and vigor, and alertness and orientation at 36 weeks', lower motor development and vigor,Crying,behavioural and physiological pain scores,Baseline pain scores,heart rate,behavioural and physiological pain responses,cortisol response,skin conductance (number and amplitude of the waves) and heart rate,pain-specific brain activity evoked by one time-locked heel lance, recorded with electroencephalography and identified by principal component analysis,Median Premature Infant Pain Profile scores,pain scores,NFCS scores,lowest pain score,pain and discomfort,procedural pain relief,pain scores, crying, or time to return to baseline behavior,Douleur Aiguë Nouveau-né (DAN) behavioral scale,Electroencephalographic (EEG) activity, heart rate activity, and infants' facial behaviors,pain score,HR, RR, O(2) saturation, BP, pain (premature infant pain profile) and percent of time spent crying during the eye exam,heart rate and lower vagal tone,efficacy (pain response as measured using the Premature Infant Pain Profile,vital signs,facial actions indicative of pain,neonatal pain,oxygen saturation and heart rate and neonatal infant pain scale,Newborn Acute Pain scale (DAN) and with the Neonatal Facial Coding System (NFCS,duration of cry and by facial expression (pain score,Heart rate, oxygen saturation (SaO2), Neonatal Facial Coding Score and presence or absence of cry,safety,median recovery time,baseline behavioural and physiological measures, observational pain scores (PIPP), and spinal nociceptive reflex withdrawal activity,pulse rate variability,HR, BP, and pain score,Neonatal Facial Coding System (NFCS,facial expression of pain,sampling duration and numbers of heel lances,Premature Infant Pain Profile (PIPP) scores,longer crying time,Premature Infant Pain Profile (PIPP) scoring system,Plasma for cortisol levels,pulse rate,median Premature Infant Pain Profile score,Pain relief,Efficacy and safety,Cerebral blood volume,pain reaction,cerebral blood volume,multidimensional acute pain rating scale of the Premature Infant Pain Profile, heart rate increase, oxygen saturation decrease, crying behavior (duration of first cry, cry percentage in 2 minutes, and during blood sampling), duration of sampling, and the number of performed heel lances,neonatal facial coding system (NFCS,neonates' facial activity (NFCS), behavioral state, and heart rate,CT and NIPS scores,Neuro-Biological Risk Score (NBRS,pain responses,magnitude or latency of the spinal nociceptive reflex withdrawal,effectiveness and safety of sucrose,pain and distress,Mean DAN and NFCS scores,overall crying time and heart rate,behavioural and physiological pain response,lowest mean Premature Infant Pain Profile scores,crying in response to heel stab,duration of first cry, the percentage of time spent crying,neonatal heel prick responses,lowest pain scores,crying time,Physiological responses of heart rate and oxygen saturation,medians for crying time and the pain scores,overall mean pain score,pain of heel pricks,Pain assessment,response to pain,NFCS score,effective and safe for relieving pain,mean gestational age at birth, mean birth weight or corrected gestational age,heart rate and oxygen saturation changes,lower PIPP scores (single sucrose pain scores,pain control,procedural pain control,crying time, behavioural state, skin conductance and heart rate,SG neonates with facial actions signaling pain,vagal tone,average score on the scale of discomfort,Adverse effects, such as apnoea or oxygen desaturation,crying time, duration of the first cry and tachycardia, time needed for return to baseline heart rate, and the average and 1- and 5-minute NFCS scores,CT and subsequent NIPS scores,Physiological (heart rate) and behavioural (facial actions) responses,behavioral (crying and facial activity) and physiological (heart rate, vagal tone) responses,cry with catheterization,pain-related behaviour,adverse events, clinical outcomes, or neurobiological risk status,Crying times,facial expression score, incidence and duration of crying, heart rate and oxygen saturation changes,Neonatal pain,mean PIPP score,scores of the scale of discomfort,pain vocalizations,Local skin reactions,Premature Infant Pain Profile (PIPP), a validated behavioral acute pain scale,median heart rate increase, oxygen saturation decrease, and duration of first cry,pain-specific brain and spinal cord activity,crying and pain scores,Pain responses,SG neonates crying,Heart rate,severity of illness, postnatal age, or number of painful procedures,O(2) saturation,median pain scores,Mean PIPP scores,Analgesic effects,Mean SaO2,Median crying times,Premature Infant Pain Profile scores,immediate pain response,negative electroencephalographic response,pain scores, less crying,physiologic or behavioral responses to the eye exam,Neonatal Facial Coding Score during nasogastric tube passage,crying time and pain score,NIPS scores,crying time and the level of behavioural state,analgesic effects,efficacy and immediate and long-term adverse events,neurobiological risk status,Pain,mean recovery time,Venipuncture-induced pain,pain or heart rate,blood collection, incidence and duration of crying,Behavioral observations,quiet sleep,elevation of heart rates,heart rate and oxygen saturation,pain relief,Duration of cry and Douleur Aiguë du Nouveau,Facial grimacing scores,Duration of crying,efficacy and safety,episodes of desaturations or bradycardia,incidence of spitting up,Neonatal Acute Physiology,oxygen saturation,heart rate and duration of crying,analgesic effect,distress scores,né (DAN) score,behavioural responses to pain,Frontal EEG asymmetry scores,relative right frontal EEG activation,newborn infant pain responses,mean pain score,responses of neonates to pain and distress,duration of the crying and grimacing,Median (interquartile) pain scores,pain/distress,mean PIPP scores,Facial activity,pain and duration of crying,heart,median Neonatal Pain, Agitation and Sedation Scale (N-PASS) score,Pain and discomfort,relieving pain,duration of cry, vagal tone, and salivary cortisol,pain,PIPP score,pain behaviors,Facial actions|The combination of sucrose and EMLA cream revealed a higher analgesic effect than sucrose alone during venipuncture in these preterm infants.
                
60|functional, neuromuscular, and cognitive status,Huntington's Disease Activities of Daily Living Scale (ADL-an index of functional status) and the Quantified Neurologic Examination (QNE,Total Motor Score 4 subscale (TMS-4,maximal static torque,TFC,peak oxygen uptake,Total functional capacity,functional checklist of the UHDRS,total functional capacity (TFC) score,symptomatic improvement,benefit of ethyl-EPA,chorea,adverse events,neurologic symptoms,progression of early Huntington disease,Unified Huntington's Disease Rating Scale (UHDRS,TMS-4,motor function,rate of deterioration,muscle functional capacity,neurologic and neuropsychiatric symptoms,neurologic and neuropsychologic symptoms,Cognitive functioning, bimanual coordination ability, and general motor function (total motor scale, UHDRS,quantified neurological examination and a set of cognitive and motor tests,behavioral severity and frequency|Total functional capacity was not favorably influenced by baclofen treatment.
not found|Median OS,interval between HDCT1 and HDCT2,hematopoietic recovery time,Response durations,local recurrence and metastasis rate,peripheral leukocyte count,median hospital stay,Growth of metastatic nodules,partial response,Reversible Grade 4 myelosuppression,hepatic veno-occlusive disease, no serious complications,overall survival,median time to progression (TTP) and overall survival,haematological complications, no WHO grade III-IV complications,median number of granulocyte-macrophage colony forming units in the reinfused PBSC,complete response (CR,rate of relapse in site of distant organs,delayed hematologic recovery,Median overall survival (OS,disease recurrence or progression,multiple organ toxicity, including venoocclusive disease, refractory thrombocytopenia, and hypertension,peripheral blood stem cells (PBSCs,time to disease progression,excessive renal and gastrointestinal toxicity,feasibility, safety and efficacy,severe mucositis and erythema with superficial peeling,rate of TRM,delayed-type hypersensitivity responses,partial remission (PR,Toxicity,hematologic recovery,toxicity of and event-free survival,early discontinuation of therapy due to toxicities,Haematological and gastrointestinal toxicities,5-year progression-free survival (PFS) and overall survival (OS,recurrence,total 2-year survival rate,Hematologic recovery in HDCT2,Median time to WBC recovery,complete remission,Median survival,symptoms of acute appendicitis,Synovial sarcoma (SS,absolute neutrophil granulocyte count,5-year survival rates,PBSC,rhabdomyoblastic differentiation,regional lymph node invasion,TTP and survival rates,efficacy and toxicity,total 5-year survival rate,complete remission (CR) and three in partial remission (PR,died of toxicity,died of progressive disease and one child died of therapy-associated complications,patient died of infection,recurrences or deaths,Peripheral blood stem cells (PBSC,Life-threatening or fatal toxicity,Leukopenia,disease-free survival,mortality (TRM,Median PFS,abdominal distention, vague abdominal pain, and vomiting,Overall survival (OS,hemopoietic recovery,survival benefit,Median progression-free survival,complete remission (CR,partial remission (PR) and stable disease,progressive disease,mean DI,glomerular filtration rate,Hematopoietic toxicity,Tumor response to chemotherapy,food intolerance,toxic death,multiple lung metastases,2-year EFS rate,progression-free survival,mortality,toxicity,frequency of relapse,Neutrophil recovery,5-year survival and 5-year event-free survival estimates,survival,median PBSC collection,2-year event free survival (EFS) rate,Karnofsky index > 80%, R (0) resection and first-line ASCT,toxicity, six died of disease,Median time to progression and median overall survival time,CR rate,Objective tumor regression,platelet transfusion independence,partial remission,Desmoplastic round cell tumor (DSCT,maximum plasma concentration (Cmax) and area under the curve (AUC,prolonged infection,sustained complete remission (CR,severe toxicity,Major nonhematologic toxic effects were mucositis, nutritional impairment, hypotension, and peripheral neuropathy,partial response and partial response,antitumor effect,probability of disease-free survival,side effects|The probability of disease-free survival at 2 years after HDCT2 in the SHG and DHG were 66.7 and 25.0%, respectively (P-value=0.031).
129|incidence of meningitis,frequency of extra-neurological infections and of asymptomatic pulmonary bacterial colonization,overall incidence of infectious complications,overall rate of meningitis,patient's Glasgow Coma Scale score, sex, and age, as well as for an intradural location of air, air volume, presence of cerebrospinal fluid (CSF) rhinorrhea or CSF otorrhea, radiological sign of a skull base fracture, or intracranial hemorrhage,frequency of asymptomatic bacteriuria,Meningitis,rates of meningitis,basilar skull fractures|The efficacy of chemoprophylaxis in the treatment of basilar skull fractures was studied in 129 patients over a 2-year period; antibiotics were found ineffective in preventing central nervous system infections, and in some cases may have proved harmful.
66|mean number of postoperative infectious episodes,aerobic gram-positive flora, anaerobes, and yeast,Biopsy-proven rejection and nosocomial pneumonias,serious adverse events,nosocomial pneumonias,Portal and systemic endotoxemia, colonization and infection rates, severity of illness (organ system failures, Acute Physiology and Chronic Health Evaluation II score, Therapeutic Intervention Scoring System score), antibiotic costs, and hospital survival rates,postoperative infection,sepsis episodes, sepsis-related deaths, and rejection,incidence of post-operative bacterial infections,bacterial infection rates,Rates of infection,Total costs,white blood cell count,microbiologically-documented infection, biopsy-proven rejection, number of treatments for rejection, length of stay in the intensive care unit and hospital, graft survival, death, and adverse events,median peak white blood cell count,infection rate at SBD key sites (abdomen, bloodstream, surgical wound, and lungs,gastrointestinal intolerance and noncompliance,Overall rates of bacterial and/or yeast infections,incidence of infection,Thirty-day infection rate, length of hospital stay, duration of antibiotic therapy, non-infectious complications and side effects of enteral nutrition,graft loss,Rates of infection, death, and charges for medical care,mean number of postoperative bacterial and fungal infections,duration of antibiotic therapy,tolerated,death,charges for medical care,stool colonization,infection, rejection, or survival,survival rates,Infection and rejection,pulmonary infections and enteric, aerobic, and Gram-negative bacillary colonization,length of stay,severe infections,infection rate,biopsy-proven rejection|The incidence of post-operative bacterial infections was significantly reduced; being 48% with only fibers and 3% with LAB and fibers.
621|lumbar spine degeneration,multiple positive findings,Low back pain (LBP,contusion or abrasion,tenderness,yield of explanatory x-ray findings,abnormal physical examination,radiological interval changes|The yield of explanatory x-ray findings was over three times greater among patients with indications for radiography than among those without.
110|median CD4+ cell count,disseminated MAC infection,RNA levels,time to death or number of deaths,M. avium complex infection,Overall survival,incidence of taste perversion,Plasma HIV-1,efficacy and safety,M. avium complex bacteremia,ranges of minimal inhibitory concentrations,frequency of disseminated M. avium complex infection,elevation in alkaline phosphatase, and hospitalization,bacterial pneumonia,M. avium complex disease or bacterial pneumonia,safety and efficacy,substantial morbidity and reduces survival,adverse events,rectal disorders,CD4,Adverse effects,frequency of more severe adverse events,rate of M. avium complex infection,MAC disease,MAC infection,episodes of confirmed M. avium complex disease,adverse effects,HIV RNA value,MAC infection followed by death,bacteremia,CD4+ cell count,Risk of MAC disease,median prior nadir CD4+ cell count,signs and symptoms associated with disseminated M. avium complex infection, adverse events, hospitalization, and survival,CD4 lymphocyte count,rate of progression of HIV disease nor the mortality rate,delayed fatigue, fever, decline in the Karnofsky performance score,Episodes of non-MAC bacterial infection,survival differences,hemoglobin level,cell count,mortality|Reduction in CD4 lymphocyte count to < 50/mm3 is a significant predictor of the development of disseminated MAC infection.
16|vascular resistance,Antihypertensive efficacy,peak flow,lowering supine and standing systolic and diastolic blood pressure,supine and standing blood pressure and heart rate,peripheral blood flow,drug fever,arterial blood flow,cardiovascular and gastrointestinal complaints, headaches, and sleep and sexual disorders,blood pressure and in peripheral resistance,systolic, diastolic and mean arterial blood pressures,lying and standing blood pressures,mean supine blood pressure,blood pressure and peripheral resistance,calf blood flow and vascular resistance,safety and efficacy,heart rate, blood pressure as well as on resting and hyperaemic calf blood flow and vascular resistance,blood pressure,normotension [diastolic blood pressure (DBP,Adverse effects,blood pressure, arterial blood flow and peripheral resistance,calf blood flow,hyperaemic flow,efficacy and adverse reactions,adverse effects,peripheral arterial circulation,psychometric performance,blood pressures,blood pressure, impaired card-sorting time and digital symbol substitution score,tolerated and the side-effects,lying diastolic pressure,rate of normalization|Methyldopa (250 mg tid) for 14 days significantly reduced blood pressure, impaired card-sorting time and digital symbol substitution score, and caused trends for impairment of other psychometric tests.
14|negative symptoms,Striatal and extrastriatal occupancies,D2 occupancies,positive psychotic symptoms,Clinical response, side effects, striatal ([11C]-raclopride-positron emission tomography (PET)), and extrastriatal ([11C]-FLB 457-PET) D2 receptors,antipsychotic effect|Striatal D2 occupancy predicted response in positive psychotic symptoms (r=0.62, p=0.01), but not for negative symptoms (r=0.2, p=0.5).
28|attack rate of CMV pneumonitis,incidence of reactivation infections,symptomatic herpes-simplex infections,cytomegalovirus and herpes simplex virus infections,severe hypogammaglobulinemia,incidence of positive shell vial assays,serum creatinine levels,incidence of CMV pneumonia,CMV reactivation,actuarial patient or allograft survival,number of positive CMV isolates from urine and saliva,CMV reactivation infections,CMV viremia or pneumonitis,Patient and allograft survival,severity score,CMV-related death,marked leukopenia,incidence, timing, or severity of symptomatic CMV infections,incidence of rejection and graft loss,CMV infection,incidence of CMV disease and visceral involvement,average episodes of > or =grade 2 rejection,acute rejection or bronchiolitis obliterans syndrome,incidence of invasive CMV infection,efficacy, safety, and cost,duration of CMV excretion,CMV viremia,Clinical signs of cytomegalovirus infection,incidence of CMV excretion,Reversible leukopenia and thrombocytopenia,patient and allograft survival,Survival,Moderate hypogammaglobulinemia,graft survival,CMV disease,transplant survival or patients survival rates,mild CMV disease,renal transplantation,CMV infection and disease,Fungal or parasitic superinfections,Incidence of primary CMV infection,Cytomegalovirus excretion began earlier and viremia,incidence of virologically confirmed CMV-associated syndromes,severity of CMV infection,occurrence of viral infections,severe disease,graft loss,minimal toxicity,viral infections,tolerated,onset of CMV excretion,acute rejection and bronchiolitis obliterans syndrome and the survival rate,severity or duration of fever, leukopenia, or hepatic enzyme elevations,Cytomegalovirus pneumonitis,adverse effects,rate of CMV disease,incidence of CMV isolation, viremia, or disease,severity of the CMV infection,cytomegalovirus disease,survival; episodes of rejection, bacteremia, or fungemia; use of immunosuppressive agents; and incidence of leukopenia or thrombocytopenia,Disease onset,toxicity,site of CMV excretion,severity of primary CMV infection,incidence of posttransplant CMV disease,number of days febrile and days hospitalized secondary to CMV illness,incidence of viremia,cytomegalovirus reactivation syndromes,mild leukopenia,major non-CMV (including no EBV) viral infections,Reactivation infections,1-year survival,rejection treatment with OKT3 or ATG, severity of CMV disease, and graft loss,incidence of infection,Cytomegalovirus viremia,Opportunistic superinfections (Aspergillus fumigatus and Pneumocystis carinii,death or graft loss,CMV disease slightly later,serious CMV-associated disease,episode of viremia,incidence of CMV transmission,Cytomegalovirus-associated glomerulopathy,rates of viral isolation or seroconversion,Moderately severe CMV infections,incidence of CMV disease,symptomatic CMV infections|Among those who developed CMV infections, prophylactic IgG had no effect on the severity or duration of fever, leukopenia, or hepatic enzyme elevations.
265|Cotinine-validated cessation rates during pregnancy,self-report and urinary cotinine/creatinine ratios,degree of clustering at the midwife level,7-day point-prevalence abstinence,rates of full breast feeding,relapse rates,Smoking status,smoking status and cigarette consumption,quitting rates,distribution of risk factors and demographic, obstetric, and psychologic characteristics,smoking cessation rates,Fetal growth outcomes,exhaled carbon monoxide levels,cotinine validated rates,salivary thiocyanate level and reported smoking,birth weight and length of gestation,number of cigarettes smoked,number who quit smoking,quit rate,quit smoking,mean birth-weight,Mean birth weight difference,smoking status based on self-report combined with a urinary cotinine level of <115 ng/mL, and birth-weight,mean birthweight,intervention increased end-of-pregnancy cessation rates,adjusted odds ratio (OR) for smoking cessation,incidence of preterm delivery,opinions about content and acceptability of the videotape, and smoking behavior change during pregnancy,cessation rates,frequency of smoking during pregnancy,rate of preterm delivery,7-day abstinence, continuous abstinence, and partner smoking at 6 weeks post-intervention (T1) and 6 weeks postpartum (T2,prevalence abstinence,Birth weight,smoking cessation rate,rates of cessation or reduction,stress scores,rates of smoking cessation,Postnatal telephone questionnaire measured client satisfaction,urinary cotinine/creatinine ratios,Self-reported cessation rates during pregnancy,levels of smoking status assessment by clinic staff; (2) proportion of women identifying as having been smokers at their first visit who reported receiving cessation advice; (3) proportion of these women who had quit (self report and expired air carbon monoxide (CO)); and (4) smoking prevalence,absolute quit rates,Efficacy and cost-effectiveness,birthweight and length,smoking cessation or smoking reduction,relapse,validated abstinence rates,Salivary cotinine levels,size at birth,number of cigarettes smoked per day, confidence in ability to quit, exposure to passive smoke, and educational level,cost-to-benefit ratios,Smoking outcomes,smoking behavior,reducing smoking,lower trait anxiety,smoking cessation,SCN levels,Validated smoking cessation rates,smoking cessation validated by cotinine measurement at the end of the second trimester of pregnancy,cigarette smoking,Self-reported cigarette consumption,self-report, exhaled carbon monoxide, and urinary cotinine,CO level,Long-term relapse rates,serum thiocyanate or end expiratory carbon monoxide,mean action, stage of readiness, and motivation to quit scores,larger quit rates,acceptability and efficacy,7-day abstinence,smoking behaviour,weight related to smoking,stopped smoking or maintained smoking changes,cigarette consumption,behavior and utilization of health resources,Self esteem,median self reported daily cigarette consumption,smoking rates,psychosocial measures,birthweight,Cotinine-validated 7-day tobacco abstinence rates,Cessation rates,point prevalence and consecutive quit rates,diet, cigarette and alcohol consumption, maternal physical strain, lactation at 40 days postpartum, and utilization of health facilities,Quitting rates,cotinine-verified quit rates,Prevalent abstinence,quit rates,perinatal outcome, health-related behavior, or utilization of health facilities,mean infant birthweight,number of cigarettes smoked daily,Infant birth weight,Urine cotinine concentrations,rate of low birth weight,Self-report and saliva cotinine assessments of tobacco exposure,mean birth weight,postpartum relapse to smoking,number of cigarettes they smoked,mean value of cotinine in saliva,estimated fetal weight, femur length and abdominal circumference,urinary cotinine/creatinine ratio,Efficacy,cigarette abstinence rates,chance of quitting smoking,late pregnancy,self-reported smoking cessation,smoking consumption,rate of negative birth outcomes,Smoking cessation rates,kidney infections,rate of low birthweight,Relapse prevention,Rates of cigarette smoking,Smoking habits,expired carbon monoxide,rate of failed biochemical validation,point-prevalence abstinence,knowledge of seven of the nine alarm signs,30-day abstinence rates,smoking habit and 4% increased their consumption,patients quit smoking,average number of days abstinent,smoking habits,birth weight and preterm delivery,Efficacy and effectiveness,birth weight,body length,quitting,smoking abstinence|A significantly higher percentage of patients quit smoking in the experimental group (17.3%) than in the control group (8.8%).
                
not found|full-scale IQ scores,verbal IQ, performance IQ, and achievement scores,Mullen Scales of Early Learning, Wechsler Preschool and Primary Scale of Intelligence-Revised, Wechsler Intelligence Scale for Children, Wide-Range Achievement Test, and Child Behavioral Checklist,cognitive, attention, and achievement scores,Neurodevelopmental outcomes|Subjects with moderate CH had higher full-scale IQ scores than subjects with severe CH, regardless of the initial treatment dose.
not found|students' resistance or decision-making skills; substance use intentions, expectancies, or normative beliefs; or lifetime and recent substance use,1-year covariate-adjusted smoking rate,cigarette smoking or bidi smoking,likelihood of heavy cigarette use adoption,health knowledge, beliefs, and values,relapse rates,rapid increases in smoking,30-day use of alcohol, marijuana, and illegal drugs excluding marijuana, and drinking to intoxication,smoking,drinking or antisocial behavior,health knowledge and attitude toward smoking,smoking prevalence rates,systolic and diastolic blood pressures, ponderosity index, triceps skinfold thickness, postexercise pulse recovery rate, serum total and high density lipoprotein (HDL) cholesterol, and serum thiocyanate,quit smoking,lifetime and 30-day use of cigarettes, alcohol, marijuana, and inhalants,extracurricular activities,negative attitude towards smoking, increased social self-efficacy levels,positive norms, and social pressure to smoke,multiple measures of initiation and current use of alcohol, tobacco, and marijuana,Prevalence, initiation and cessation rates,Social pressure,odds of baseline nonsmokers initiating smoking,prevalence rates of the uptake of smoking relative,rates of tobacco, alcohol, and marijuana use,systolic and diastolic blood pressures, plasma total and high-density lipoprotein (HDL) cholesterol, serum thiocyanate, ponderosity index, triceps skinfold thickness, and postexercise pulse recovery rate,refusal/self-efficacy, smoking intentions, or behavior,diastolic blood pressure and thiocyanate,smoking initiation rates,smokeless tobacco use rates,objectively assessed smoking (carbon monoxide breath measure,uptake smoking,regular smoking rates,Grade 10 smoking rates,weekly smoking and monthly smoking,self-reported use of cigarettes, bidis (small hand-rolled, often flavored, cigarettes), and chewing tobacco and future intentions to smoke or use chewing tobacco,refusal skill quality,sensation seeking, physical maturity, antisocial behavior and parental smoking,prevalence of daily smoking,attitude scores,marihuana and organic solvents,normative expectations and knowledge concerning substance use, interpersonal skills, and communication skills,30-day smoking prevalence,New regular cigarette smoking,students' general and specific attitudes toward drugs, the capability to resist peer pressure, and estimated level of drug use by peers,alcohol consumption,school-level clustering effects, socio-economic status, gender and family smoking,communication, self-instruction, self-praise, cigarette refusals, and noncompliance to smoke,adolescent alcohol, marijuana, and cigarette use,several cognitive, attitudinal, and personality variables,measures of non-smoking intentions, attitudes, predictions, problem-solving abilities, and peer interactions,knowledge and personality variables,prevalence of weekly cigarette use,rates of smoking initiation and regular smoking,smoking intentions, smoking knowledge, perceived peer and adult smoking norms, drug refusal skills, and risk taking,decisional balance against smoking and decreased temptations to smoke,lowering marijuana use,smoking-related beliefs,control schools,risk factors: systolic and diastolic pressures, HDL cholesterol, ratio of total to HDL cholesterol, fitness (postexercise pulse recovery rate), and smoking,new cigarette smoking,response rate,prevalence rate of smoking,prevalence of smokeless tobacco,Resistance to smoking, behavioral intentions to smoke, and cigarette use,self-efficacy and resistance skills,Smoking initiation,social and school work skills,smoking behaviour, health knowledge, beliefs, or values,Total cholesterol,mean knowledge scores,weekly smoking onset,behavioral determinants and smoking,smokeless tobacco, alcohol, and marijuana,alcohol consumption, alcohol initiation behaviors, alcohol use risk and protective factors, drug use behaviors, and exercise habits, and at 12-months for alcohol use risk and protective factors, cigarette use, and cigarette initiation,rates of substance use and antisocial behavior,cannabis initiation and prevalence,smoking behavior,resistance skill training,high risk of regular smoking uptake,Diastolic pressure,smoking cessation,sex distribution,adolescents' lifetime and 30-day use of cigarettes, alcohol, marijuana, and inhalants,uptake of smoking,proportion of non-smokers,growth trajectories of smoking, drinking, and antisocial behavior,levels of smoking onset,overall refusal skill quality,Smoking rates,knowledge and attitudes related to tobacco use,past 30-day use of alcohol,adolescent alcohol and cigarette use and other health behaviors,negative effect,efficacy,effectiveness of Project Towards No Drug Abuse (TND,alcohol, cigarettes, marijuana, cocaine, and other drugs, as well as on knowledge,lower probabilities of tobacco use,rate of smoking onset,ponderosity and improved fitness, and increased HDL cholesterol,smoking prevalence,tobacco use,health knowledge and nonsmoking intentions,knowledge and prevalence estimates and significant interactions of classroom and TV programming on knowledge (negative), disapproval of parental smoking, and coping effort,adolescent smoking,friends who smoke, outcome expectations for smoking, and smoking progression,initial and current drinking or for current and regular marijuana use,Student smoking behavior and curriculum implementation,probability of baseline non-smokers' initiating smoking,smoking behaviour,knowledge level, attitudes, and the development of refusal, decision-making, and problem-solving skills,Outcome assessment batteries measured youths' reported use of smoked and smokeless tobacco, alcohol, and marijuana,self-reported past-month and past-year use of tobacco, alcohol, and marijuana,students' smoking-related knowledge, attitudes and behaviour,rate of smoking,diastolic blood pressure, plasma total and high-density lipoprotein (HDL) cholesterol, serum thiocyanate, ponderosity index, triceps skinfold thickness, and postexercise pulse recovery rate,substance initiation index (SII) measuring lifetime use of alcohol, cigarettes, and marijuana and by rates of each individual substance,knowledge of alcohol pressures, effects, and skills to resist,cigarette smoking, marijuana use, and immoderate alcohol use,Intervention response,rate of first-time consumers of cigarettes,adolescents' smoking-related knowledge,behavioral intentions, perceptions of harm, or perceived peer norms,proportion of smokers,rate of attempting smoking,smoking rates,smoking uptake,grade 8 smoking rates,30-day smoking,illegal drugs excluding marijuana,Cigarette smoking,smoking prevalence and use of smokeless tobacco (ST,total cholesterol/HDL cholesterol ratio and for thiocyanate,adolescents' smoking behaviour,SFA effectiveness and the general thrust of school-based, life skills-based prevention programs,prevalence rate,smoking, drinking, drunkenness, inhalant use, and polydrug use relative,coronary heart disease risk factors,Smoking experimentation, pre-test smoking [odds ratio (OR) ,daily cigarette smoking,Changes in knowledge,social variables (e.g., peer resistance skills,mean 30-day smoking prevalence rates,number of students who started smoking,tobacco use and violence,probability of baseline experimental smokers' escalating to regular smoker,enhanced school commitment and class participation,regular smoking,smoking progression,Questionnaires, and saliva samples to validate self-reported smoking behavior,adjusted Prevalence Odds Ratio (POR,self-efficacy condition,technical assistance (TA) variables (e.g., effective collaboration with TA, frequency of TA requests,risk of smoking initiation,self-efficacy,past month use of cigarettes based on a self-reported questionnaire,dichotomous measures of substance use (cigarette, alcohol, marijuana, and hard drugs,early adolescent substance use and antisocial behavior,stop smoking,incidence of initiation of smoking,odds ratio of being a smoker,systolic pressure,girls' smoking rates,smoking intentions,Blood pressure reduction,delaying or preventing the onset of tobacco use,Smoking prevalence rates,smoking knowledge,rate of passive smoking,tried smoking and 30-day smoking prevalence,episodes of drunkenness,cigarette smoking,tobacco knowledge, attitudes, offers, use, and intentions,weekly cigarette smoking,new "smokers|Further, in both classes, more rapid increases in smoking were observed for the control group as compared to the intervention group (OR=1.22, p<0.01 slow escalators; OR=1.54, p=0.08 rapid/moderate escalators).
16|psychophysiologic health level,Perceived Stress Scale (PSS) and Rathus Assertiveness Schedule (RAS,quality of care,burnout symptoms, relaxation, and life satisfaction,levels of stress,mean scores on the Nurse Stress Checklist (NSC) and the Chinese General Health Questionnaire (CGHQ,attitude scale concerning work (alienation), a personality measure (hardiness), and one of each scale for work satisfaction and for sources of satisfaction and dissatisfaction,Anxiety measures,quality of working relationships,efficacy and effectiveness,absenteeism,morale, quality of care, and reduced absenteeism,work-related anxiety,emotional exhaustion and lack of personal accomplishment, two dimensions of burnout|In comparison with 14 wait-list control participants, 16 participants in the mindfulness intervention experienced significant improvements in burnout symptoms, relaxation, and life satisfaction.
16|Basmajian scale,knee and ankle minimum flexion angles,timed ambulation,Velocity of gait, cycle time, and symmetry of stance phases,mild EMG, severe EMG, mild control and severe control,EMG feedback and the restoration of motor control,higher arm function scores,muscle strength,recovery of functional locomotion,physical scores for active movement, mobility and ADL over time,ankle active range of motion,active movement, muscle tone, sensation, proprioception, mobility and activities of daily living (ADL,recovery of foot-drop,electromyographic activity,active range of motion and surface EMG potentials,gains in knee and ankle joint angle measurements,orientation, memory, spatial performance, language and IQ,Adams scale|Electromyographic biofeedback patients showed significantly increased scores on the Adams scale (P < .05) and Basmajian scale (P < .01).
32|Electromyographic (EMG) activity,motor control and motor function,distal part score of the FMA,temporal and spatial efficiency,motor performance, daily function, functional use of the affected arm, and quality of life,total movement time,movement time, higher peak limb velocity,active elbow range of motion,Modified Barthel Index, Hospital Anxiety and Depression Scale, and Nottingham Health Profile,online error correction,activation in precentral (P<.001) and postcentral gyri,functional gains,bilateral symmetrical activities,Action Research Arm Test (ARAT), Rivermead Motor Assessment upper-limb scale, and Nine-Hole Peg Test (9HPT,EMG activation levels,reasonable strength, inter-limb coordination,Upper Arm Function scale,fMRI response,motor performance, daily functions, and quality of life,positive intralimb transfer,motor reaction time (peripheral component), and (4) faster total reaction time,electromyogram (EMG) activation levels,Chronic hemiparesis,peak acceleration (P<.001) and velocity,motor control and functional performance,upper limb function,brain activation during elbow movement assessed by functional magnetic resonance imaging (fMRI) and functional outcome assessed using arm function scores,Motor Assessment Scale (MAS), Motor Status Scale (MSS), and muscle strength,movement time,FMA,MSS and measures of strength,muscle activity,hemispheric activation,higher muscle activation levels,voluntary EMG activation levels,Reaction time,kinematic analyses assessing motor control strategies for unilateral and bimanual reaching and clinical measures involving the Fugl-Meyer Assessment (FMA) of motor-impairment severity and the Functional Independence Measure (FIM) and the Motor Activity Log (MAL) evaluating functional ability,ARAT pinch section,varying levels of weight on the nonparetic hand,motor impairment,time to complete components of the tasks; comparison between sides; deviation of the hands from a linear trajectory; coordination of the two sides as indicated by relative phase angle,Nonparetic peak acceleration,peak acceleration, velocity, and movement time,proximal UL motor impairment,Reduced skilfulness of arm motor behaviour,motor impairment scale,Fugl-Meyer Assessment (FMA), Functional Independence Measure (FIM), Motor Activity Log (MAL), and Stroke Impact Scale (SIS,slower movement, lower maximal movement velocity, feedback control dominant and discontinuous movements,motor capabilities,velocity,functional task, (2) chronometric reaction times to initiate movements, and (3) sustained muscle contraction capability,functional outcome,Changes in activation,motor control performance,impairments (motor function, grip strength, gross and fine manual dexterity and motor co-ordination), (2) arm disabilities in tasks related to daily activities, and (3) functional independence in activities of daily living (ADL) and instrumental ADL (IADL,movement time of the impaired limb and increased upper limb functional ability|Nonparetic peak acceleration was higher (P=.015), velocity was unchanged, and movement time increased (P=.005) in the bilateral compared with the unilateral task.
11|akathisia,neuroleptic-induced akathisia|Neither propranolol nor placebo treated patients showed a significant improvement in akathisia.
not found|rates of cocaine abstinence,duration of sustained abstinence,detoxification,Objective and subjective measures of efficacy (urine toxicology, retention, craving, and withdrawal symptoms,Abstinence Orientation Scale,Safety,retention rates,abstinence reinforcement,rates of opioid-positive urine samples,rates of cocaine-positive urine samples,retention, opioid use, and opioid craving,Rates of abstinence from illicit opioids,Lifetime sedative dependence,illicit heroin,median time,illicit drug use, program retention and attendance, and global staff judgments,rates of abstinence from illicit opioids,percentage of opiate-negative urine specimens,illicit opioid use,Prognostic factors,cocaine-positive urine samples,Relative efficacy,Retention time,opiate-negative urine specimens (thrice weekly urinalysis,rate of opioid-positive urine samples,retention rate,reduced self-reported frequency of use and self-reported craving,overdose mortality,percentage of urine samples negative for opioids|Patients taking > or = 60 mg/day and 30-59 mg/day were respectively 70 and 50% more likely to remain in treatment than those receiving a < 30 mg daily dose.
1168|Pregnancy outcome, time of onset and duration of vaginal bleeding, subjective complaints, and hormone changes,incidence of diarrhoea,suction aspiration,measured blood loss,pregnancy,overall successful termination rate,Success rates,complete abortion rates,efficacy or side effects,success rates,Successful abortion without surgery,number of women who passed the fetus within 4 h of receiving the prostaglandin,Timing of expulsions and duration of bleeding,Fever, chills and gastrointestinal side-effects (nausea, vomiting and diarrhoea,overall complete abortion rate,uterine contractility,serum levels,abortions,total bleeding 11.2 ,side-effects and number of complete abortions,complete medical abortion by the first or by the second follow-up visits,rate of complete abortion and the side-effects,blood transfusion,efficacy and side effects,complete abortion,Overall acceptability and route acceptability,complete medical abortion rates,median amount,risk of failure of complete abortion,Nausea,rate of continued pregnancy,mean duration of uterine bleeding,duration and amount of vaginal bleeding,complete abortion rate,Pain and subject acceptability,percentage of women with continuing pregnancies,incomplete abortion,surgical abortion,successful abortions,Successful abortion,shivering,Nausea, vomiting and diarrhoea,Satisfaction and acceptability,failure to complete abortion,success rate determined by the number of women who aborted without surgery,successful abortion (complete abortion without requiring a surgical procedure) and side effects,Complete abortion rates,Complete abortion rates, the frequency and severity (patients' perception) of gastrointestinal side effects, and blood pressure changes,efficacy, adverse effects and acceptability,incidence of side-effects, such as vomiting, nausea, headache, diarrhea and lower abdominal pain,days of bleeding,uterine sensitivity,continued pregnancy,incidence of complete abortion, hemoglobin levels, duration of vaginal bleeding, and incidence of side effects,Successful medical abortions,safety and efficacy,Cortisol,Efficacy and adverse effects,mean duration (range) of vaginal bleeding,diastolic pressure,gastrointestinal side effects,Overall, complete abortion without surgical intervention,prolactin,vomiting,diarrhea,nausea/vomiting and headache/dizziness,nausea, diarrhea, and warmth or chills,number requesting opiate,pregnancy rate,Adverse effects,Complete abortion without surgical intervention,risk of failure to abort,Blood samples for blood group, hemoglobin, beta-chorion-gonadotrophin, aspartate-aminotransferase and creatinine,complete abortions,efficacy of treatment to achieve complete abortion and to terminate pregnancy,unpleasant mouth taste,success rate of complete abortion,Expulsion of the conceptus without the need for a surgical procedure,Complete abortion,abortion rates,fever,efficacy,human chorionic gonadotropin-beta level,bleeding necessitating a blood transfusion, no serious side effects,experience diarrhoea,beta-hCG level,efficacy, adverse effects, and acceptability,serious adverse events,blood transfusions,nausea and/or vomiting,side effects, timing of expulsion and duration of bleeding,Intrauterine pregnancy and gestational age,overall ongoing pregnancy rate,median duration of vaginal bleeding,fever and chills,surgical termination,blood pressure,nausea and vomiting,satisfaction,clearance rates,frequency of complaints, bleeding patterns, and changes in hemoglobin, beta-human chorionic gonadotropin, estradiol, and progesterone,Lower abdominal pain,Efficacy outcomes,gynecological examination, the level of beta-hCG and ultrasonography,Vomiting and diarrhea,side effects such as vomiting and fall in haemoglobin, as well as the need for emergency curettage and blood transfusion,expulsion of the conceptus without the need for a surgical procedure, and abortion,Methotrexate levels,tolerated,number of women who had aborted by Day 8, side effects and acceptability,longer duration of induced bleeding,detectable fetal heart activity,rate of continuing pregnancies,pregnancy advanced,complete abortion without surgical intervention,onset of crampy abdominal pain,incidence of side-effects such as diarrhoea,rates of success, side effects, or acceptability,Side effects,severe pain,rate of complete abortion,maximum concentration of methotrexate and the area under the curve,vaginal bleeding,Cramping and nausea,bleeding duration,incomplete abortion rate,mean gestational age of the successful abortions,effectiveness, side effects, and acceptability,Efficacy outcome,tolerance and efficacy,success rate (complete abortion,Pain,Ongoing pregnancy,side effects and acceptability,duration of bleeding,Vaginal bleeding,incomplete abortions with symptoms requiring a surgical aspiration,early medical abortion,Nausea, vomiting, and heavy bleeding,crude complete abortion rate,time elapsed between RU 486 intake and expulsion of the conceptus,rates for complete abortion, incomplete abortion and treatment failure,incomplete abortions,efficacy and side-effects,rates of complete abortion,overall success rate,treatment failures,efficacy rate,duration and amount of bleeding,amenorrhoea length,Vaginal bleeding followed by complete abortion,actual blood loss,diarrhoea,shorter bleeding time and a lower volume of blood loss,heavy bleeding, necessitating emergency curettage,efficacy of medical termination of pregnancy,rate of continuing pregnancy,frequency of side effects,need for surgical evacuation,fever or chills,Successful abortion, duration of vaginal bleeding, side effects, and change in beta-human chorionic gonadotropin (beta-hCG) level,Prolonged vaginal bleeding,Abortion success,troubled by diarrhoea,pregnancy-related symptoms,success rate,Methotrexate clearance rates,serious complication,pregnancy-related symptoms (nausea, vomiting, breast tenderness, fatigue, dizziness, headache), drug-related side effects (diarrhoea, fever, rash and blood pressure change), side effects related to the abortion process (lower abdominal pain) and women's perceptions of the method,efficacy, safety, and acceptability,Abortion status,likelihood of complete abortion,pain,Nausea, vomiting or diarrhoea,relative risk of failure,side effects|Surgical intervention was indicated for continuing pregnancy at the second follow-up visit, excessive bleeding, or persistent products of conception 5 weeks later.
40|slight gain in BMC,bone resorption markers,vertebral bone mass and serum estradiol and calcitonin,lumbar spine bone mineral density (BMD,bone mass,Trabecular BMC of the 3rd lumbar vertebra,androgenic side effects,trabecular bone mineral content of the lumbar spine and femoral neck,Bone loss with LA,bone mineral density,Significant loss of bone mineral,Bone mass,Mean lumbar bone loss,serum calcium, phosphorus, alkaline phosphatase, and urinary calcium/creatinine ratios,control values; urinary calcium-creatinine ratio,bone loss and vasomotor symptoms,hot flushes and sweating,Lumbar spine bone mineral density,Bone formation markers,Serum estradiol and the biochemical parameters of bone metabolism,Hypoestrogenic effects,endometriosis scores,Pelvic pain scores,Bone loss,Bone mineral density of the lumbar spine,hypoestrogenic effects,bone metabolism,bone mineral,verbal rating scale,BMC,Crosslaps (CTx) and deoxypyridinoline (D-Pyr,Urinary levels of pyridinium crosslinks,Mean (SD) endometriosis scores,Bone formation and resorption markers,bone resorption,bone loss and symptomatic side effects,Biochemical markers except urinary calcium and hydroxyproline,libido,BMD changes,trabecular vertebral bone mass, serum E2, and serum calcitonin,bone densities,hot flushes,Bone resorption markers,Daily symptom diary for hot flushes and bleeding episodes, laparoscopic scoring of endometriosis, endocrine and biochemical changes, and bone mineral density scans,vertebral trabecular bone mass,frequency of hot flushes and sweating episodes,Revised American Fertility Society score,Endocrine effects,efficacy and acceptability,Gain or loss of bone mass,serum follicle stimulating hormone (FSH) levels,bone mineral density changes,endometriosis, dysmenorrhea, and pelvic pain; effects,lumbar spine bone mineral density,lumbar spine values,Serum estradiol levels,endometrial implants score,lumbar spine and femoral neck,cumulative bone loss,chronic pelvic pain,mean subjective signs and symptoms scores,urinary calcium-creatinine ratio and serum alkaline phosphatase,Mean bone mineral density,bone demineralization seen,BMD,serum estradiol (E2) levels,mean serum oestradiol levels,physical examination, laboratory indices, occurrence of adverse events, and bone mineral density changes,hypoestrogenic side effects,menstrual pain scores,serum estrone and estradiol levels,bone density,serum E2 levels,Bone turnover,Serum E2 levels,bone loss at the lumbar spine,lumbar spine and femoral neck bone mineral content,urinary calcium/creatinine ratio,bone mineral density loss,spinal trabecular bone mineral content,total pelvic pain scores,Bone mineral density,Total revised AFS score,sustained hypoestrogenemia and significant bone loss,association of B-ALP and D-Pyr,serum estrogen levels,positive spine BMD changes,Bone density,Z scores,Mean (SD) deep dyspareunia scores,bone assessments,frequency of genital bleeding,revised AFS endometriosis score,bone biochemical markers,Bone mineral density (BMD,pelvic endometriosis,Efficacy,efficacy and safety,bone mineral content (BMC,bone formation markers,bone mineral density and pyridinium crosslinks,Calcitonin levels,pelvic pain scores,adverse hypoestrogenic effects,tolerability,bone loss,serum calcium, phosphorus, alkaline phosphatase, and fasting urinary calcium/creatinine ratios,loss of bone density,Serum luteinizing hormone (LH) and 17 beta-oestradiol concentrations,estradiol and biochemical markers of bone metabolism,bone mineral measurement,bone alkaline phosphatase (B-ALP) and osteocalcin (OC,Serial serum levels of E2 and calcitonin,serum calcium levels,serum alkaline phosphatase,pelvic signs and symptoms scores and revised AFS endometriosis scores|Total revised AFS score as well as total pelvic pain scores decreased significantly (P < .001) in both groups.
not found|KOOS subscales assessing pain, other symptoms, or function in daily life or in sport and recreation,muscle peak torques,extension and flexion strength of the right and left legs, the 50-foot walk time, range of motion at the knee joint, the Osteoarthritis Screening Index (OASI), and the Arthritis Impact Measurement Scale (AIMS,pain and function,joint stability or walking endurance,self-reported disability score (range, 1-5,physical activity, muscle strength, and functional performance,knee pain scores and quadriceps muscle strength,visual analogue scales (VAS) for pain on stairs and walking and WOMAC physical function scores,rate of loss,peak torque and CSA of knee muscles,physical function, pain, and mobility,flexibility and upper-body or knee muscle strength,arthritic symptoms, balance, and physical functioning,Overall compliance,quadriceps strength, on knee pain and disability,function scores,undergone knee arthroplasty,knee pain questionnaire,incidence and progression of knee osteoarthritis,muscular strength,isokinetic and isometric quadriceps strength, pain and function determined by categorical and visual analog scales, and overall status using physician and patient global evaluations by the Arthritis Impact Scale, version 2, Western Ontario McMaster's Arthritis Index, and Medical Outcome Study Short Form 36,leg; isometric strength,pain measurements,safe, effective, and well tolerated,body weight,lower extremity pain,walking speed,knee pain (Western Ontario McMaster Osteoarthritis index (WOMAC,walking speed and decrease of disability,weight loss, 6-minute walk distance, stair-climb time, WOMAC pain and stiffness scores, and joint space width,physical performance, quality of life, and self-efficacy,changes in joint space width,pain using the Western Ontario McMaster (WOMAC) pain, physical disability, and stiffness subscales and a 10 point visual analog scale (VAS) before and after self-paced walking (SPW) and stepping (SPS) functional tasks; (2) physical function using the time to complete a self-paced 40 m walk (SPW) and 20 cycles of 2 steps (SPS): (3) physical activity level using the Physical Activity Scale for Elderly (PASE); (4) clinical measures of knee functioning (range of motion,Functional capacity (rising from a chair, walking, stair climbing and descending) and pain during rest and activities, peak torque, and cross-sectional area (CSA,pain, physical function, and health related quality of life,time to descend and ascend stairs,isokinetic lower-extremity strength and highly standardized knee radiographs,aerobic capacity,pain scores,VAS scores for pain,pain reduction,pain, medication use (nonsteroidal antiinflammatory drugs, NSAID) and observed disability,knee pain,psychological disability,Physical function scores,disability,muscle-strength gain,pain, balance, muscle strength, and perceived difficulties in physical functioning,disability, physical performance, and pain,range of motion and functional tasks,pain score,Exercise tolerance, disease-related measures, and self-reported health status,exercise knee pain,leg flexion and extension,6-minute test of walking distance and scores on the physical activity, arthritis impact, pain, and medication subscales of the Arthritis Impact Measurement Scale (AIMS,knee joint pain,clinical knee examination, muscle strength, physical performance measures, and questionnaires to measure quality of life variables,6-min distance walk,pain or function,Levels of KS and hydroxyproline,mean reductions in pain scores,hamstring and low back flexibility,mean rate of joint space narrowing (JSN,strength and exhibited less frequent progressive JSN,pain and physical function (Western Ontario and McMaster Universities Osteoarthritis Index), general health status (Medical Outcomes Study Short Form 12 Health Survey [SF-12], version 2), psychological well-being, and physical performance (Up and Go test, 50-foot walk time, timed stair climb,functional capacity and decrease pain,WOMAC, knee pain scale, SF-36, assessment of quality of life index, quadriceps strength, and balance test,balance,global improvement,faster times on the lifting and carrying task,Global improvement,weight-loss,reduction in pain,activity and activity related pain,exercise adherence,clinical signs and symptoms of osteoarthritis (OA,daily steps,knee extensor strength and fast walking speed,health status, physical capacity, and joint tenderness,strength, pain, physical function and quality of life,physical activity (daily step counts and total activity vector magnitude as measured by a pedometer and Tritrac-R3D accelerometer), quadriceps femoris strength (isometric peak torque), and functional performance tasks (100-foot walk-turn-walk, timed stair climb, timed chair rise, and pain status,Knee pain,aerobic capacity, 50-foot walking time, depression, anxiety, and physical activity,self-report measures (WOMAC, SF-36) and objective measures of physical performance (gait analysis and muscle strength,frequency of knee OA progression in JSN consensus ratings,KOOS subscale quality of life,isokinetic strength of the quadriceps,efficacy and adherence measures,physical activity,functional capacity and symptoms,average WOMAC scores,range of motion and ambulation speed,incidence and progression of knee OA,functional health status,muscle strength of the hip,overall status,WOMAC pain score,quadriceps and hamstring strength,functional capacity,observed disability,physical fitness, strength, pain coping, and self-efficacy,Muscle strength across the knee (extension and flexion), Algofunctional Index (AFI), pain (0 to 10 point scale), walking speed, clinical findings,lower extremity stiffness,total activity vector magnitude,joint tenderness,mean baseline function score,ability to walk and bend,WOMAC scores,function, pain, and stiffness subscores of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC,time to lift,Synovial fluid keratan sulfate (KS) and hydroxyproline,physical symptoms and fitness, body mass index, cardiovascular functioning, and perceived difficulties in physical functioning,knee extension strength,pain and disability,pain and stiffness,Western Ontario and McMaster Universities Osteoarthritis (WOMAC) index pain and physical function subscales,Pain levels,quality of life,Lequesne's index, knee range of motion, peak muscle torques of knee flexion and extension, and ambulation speed,right leg flexion and left leg extension,walking distance relative,Mean baseline WOMAC pain score,SF-12 physical component summary score,functional capacity, especially stair climbing,activity related pain (VAS); and improvement in SPW and SPS test time, passive range of motion, and PASE,physical function,Synovial fluid,adverse effects,abdominal muscle strength,pain and physical function scores,angular velocity peak torques,changes of muscle power of leg flexion and extension,mobility,x-ray scores,pain, quality of life, activity restrictions, knowledge about OA, self-efficacy, body mass index (BMI), and mobility measures,extremity strength,health perception,pain reduction, disability reduction,reduction of pain,quadriceps strength of the index knee,physical function, gait, and knee extensor strength,change scores for flexibility, number of clinically active joints, duration of morning stiffness, or grip strength,mean (+/-SE) time to climb and descend stairs,visual analog scale pain and rates of attrition,pain and functioning,all strength measures,frequency of palpable joint effusions,knee pain score (range, 1-6), performance measures of physical function, x-ray score, aerobic capacity, and knee muscle strength,pain in the worse knee by 100 mm visual analog scale score, the disability domain of the Western Ontario and McMaster University OA index (WOMAC), and quadriceps muscle strength by maximum voluntary contraction,pain, quality of life, strength of the left M. quadriceps, knowledge, self-efficacy, BMI, physically active lifestyle, and visits to the physical therapist,mean (+/-SE) time to get in and out of a car,exercise efficacy,physical disability questionnaire,self-reported physical function,6-minute walk distance,self-efficacy,self-reported physical function as measured with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC,pain,AIMS physical activity subscale,pain measured by visual analogue scale and patient global change,average distance walked,muscle strength and walking performance,time to perform all 4 functional tasks,strength gains,knee specific physical function and stiffness (scored on WOMAC index), general physical function (scored on SF-36 questionnaire), psychological outlook (scored on hospital anxiety and depression scale), and isometric muscle strength,pain reductions,6-minute walk distance and WOMAC score,Frequency of crepitus,pain and physical functioning,isokinetic quadriceps strength,Physical activity,adverse health effects,isometric strength gain,functional status, pain, and use of medication,Change in Western Ontario and McMaster Universities osteoarthritis index (WOMAC,physical performance measures,self-reported pain, function and quality of life,arthritis pain,baseline WOMAC scores and walking distance,positive functional outcomes,physical functioning,self reported score for knee pain on the Western Ontario and McMaster universities (WOMAC) osteoarthritis index,stair-climb time,Knee injury and Osteoarthritis Outcome Score (KOOS,retention rate,average 6-minute walk distances,visual analogue scale, ambulation speed, and Lequesne index,physical fitness,arthritis activity,arthritis impact subscale,car task,health status, and a visual analog scale for pain assessment,perception of changes relating to osteoarthritis of the knee and general condition|Program participants also experienced a significant decrease in lower extremity pain and a borderline significant improvement in efficacy to adhere to exercise over time at 6 months (p =.052).
59|efficiency, efficacy, comfort, and convenience of the Symphony breast pump (Medela, McHenry, IL) (SBP,morbidity and mortality rates,Milk volume, fat content, and pattern of milk flow,volume of milk expressed and its fat content,bacterial colony counts,Maternal response,breastfeeding problems,24-hour milk production,24-hour milk volume,maternal milk volume,milk volume,milk yield and prolactin and oxytocin release,BIBS,milk production,breastfeeding duration,efficiency and efficacy,Milk production,fat concentration,milk flow,Prolactin response,milk output,mean daily MMV,Volume of milk expressed per expression and its fat content,Mother's knowledge,exclusive breastfeeding,gradual improvement in breastfeeding practices, i.e., started breast milk expression earlier and had more breast milk expression frequency,shorter expression times,EBM,mean milk volumes,duration of breastfeeding,contamination rates,milk volume and fat content,milk volume or fat content,Gram-negative bacilli,rate of bacterial contamination of EBM,Breastfeeding Study (BIBS,fat content of the breast milk,breastfeeding knowledge questionnaire, observational checklist of mother's breastfeeding practices, breastfeeding diary, infant's and mother's profile form, and demographic information,average STAI scores; average prolactin levels; and weekly averages for number of pumping sessions, hours of pumping, and milk production in milliliters,breastfeeding knowledge and practices,Milk extraction efficiency,adequate production,several demographic characteristics, STAI scores, prolactin levels, number of pumping sessions per week, or weekly milk production,milk fat concentrations,daily milk production log, weekly serum prolactin levels, and a weekly State-Trait Anxiety Inventory (STAI,milk extraction, milk fat content, maternal hormone response, maternal satisfaction, long-term milk production, and duration of breastfeeding following return to the workforce,efficiency, efficacy, comfort, and convenience,milk flow and total volume,rate of bacterial contamination,onset of milk ejection|Milk extraction efficiency was greater (p = 0.001) with the standard pump.
61|Pelvic lymph node metastases,Conversion to laparotomy,Lymph node number and detection of lymph node metastasis,proportion of patients with an intraoperative major complication,Safety and efficacy data,operative time, blood loss, blood transfusion, intraoperative complications, postoperative complications, duration of hospital stay, and number of lymph nodes obtained,6-week morbidity and mortality, hospital length of stay, conversion from laparoscopy to laparotomy, recurrence-free survival, site of recurrence, and patient-reported quality-of-life outcomes,pain medication,Quality of life,disease-free survival,intraoperative adverse events,Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire,Hospitalization,proportion of major complications,blood loss and shorter hospitalization,feasibility, safety and morbidity,Blood loss and transfusion rates,Pelvic and para-aortic nodes,recurrence or disease-free survival,QoL change,complication rate,mean length of hospital stay,longer hospital stay,emotional and social wellbeing measures of FACT and the visual analogue scale,proportion of patients with a minor complication,disease-free (P = .512) survival,operative time,blood loss,Operating time,shorter hospital stay,bleeding,Wound infections,metastatic cancer,Postoperative serious adverse events,adverse events,deaths,mean number of harvested lymph nodes,mean blood loss,major complication rate,intraoperative complications,mean operative time,shorter hospital stay, less pain, and quicker resumption of daily activities,severe postoperative adverse events,overall detection of advanced stage (stage IIIA, IIIC, or IVB,postoperative major complication,quality of life (QoL,QoL,Overall and recurrence-free survival,Operative morbidity,cumulative recurrence rates,Yield of pelvic and para-aortic lymph nodes, duration of surgery, and incidence of postoperative complications,perioperative morbidity|This procedure is associated with significantly less blood loss and shorter hospitalization; however, it is associated with significantly longer operating time.
344|pad usage,continence grade and pad weight testing,stress urinary incontinence and urethral hypermobility,Postoperative contentness,short-term risk of urgency and urinary retention,Adverse events,Incontinence Quality-of-Life questionnaire score,adverse events,maximum urethral closure pressure (MUCP), functional urethral length (FUL), maximum flow rate and cough test,urge incontinence,Pad testing, Stamey Continence Grading, and urodynamics, including abdominal leak point pressures,Continence,standardized questionnaire, pad test, cough test and urodynamics,flow rate,urinary retention,MUCP and FUL,proportion of women who achieved a 50% reduction in urinary leakage on provocation testing,improvement of 1 continence grade,standardized incontinence questionnaire, 1-hour pad test and cough test|Outcomes at 12 months from last treatment failed to demonstrate that mid-urethral injected Zuidex was equivalent to cystoscopically injected Contigen in primary and secondary outcome variables.
39|prolongation of pregnancy, number of patients bleeding,presence of respiratory distress syndrome, intracranial hemorrhage, or culture-proved sepsis,units of blood transfused, birth weight, hospital stay and costs, and admission to neonatal intensive care unit,neonatal deaths,mean number of maternal hospital days,maternal and neonatal morbidity,blood transfusion,recurrent episodes of bleeding,neonatal morbidity,gestational age at delivery,mean birth weights,safety, efficacy, and costs|No statistically significant differences were observed between the two groups studied.
                
not found|TNA response,occurrence of systemic AEs,geometric mean titers (GMT) for lethal toxin neutralization activity (TNA,geometric mean concentrations (GMC,safety, reactogenicity, and immunogenicity,antibody response,clinically serious or dose-related toxicity or reactogenicity,immunogenicity and safety,peak anti-PA IgG antibody response,Safety, reactogenicity and immunogenicity,odds ratio for ordinal end point pain,Reaction rates,peak anti-PA IgG antibody levels,rate of injection site reactions such as erythema, induration and subcutaneous nodules,Systemic reactogenicity (mostly headache,Local reactogenicity (mostly pain,injection site reactions,occurrence of injection site AEs,IgG geometric mean concentration (GMC), geometric mean titer (GMT), and proportion of responders with a 4-fold rise in titer,Immunogenicity and tolerance,Peak antibody responses|Peak antibody responses to adjuvanted rPA given intramuscularly were equivalent to AVA, given either intramuscularly or subcutaneously, when measured by either assay.
                
36|number of attacks, the total duration of attacks and additional drugs taken,duration of the attacks and the number of analgesics,propranolol sleep disturbances including nightmares (6), tiredness (8), mental changes (e.g. irritability) (3) and weight gain (4,platelet function,VEP amplitude,efficacy parameters (migraine hours, migraine days, and migraine intensity,frequency of migraines and use of rescue analgesics,mean duration of migraine in hours (h) per month,5-HT supersensitivity,migraine,prophylactic effectiveness,medication relieving attacks,migraine index, frequency, duration, severity of attacks and headache days,patient profile, onset of response to therapy, final response to therapy, incidence of dropout from the trial or incidence of side-effects,VEP latency,attack frequency, migraine days, severity score, consumption of acute medication and subjective evaluation,Headache index,frequency of migraine attacks,attack frequency and headache index,Migraine index,number, duration, and severity of attacks,dizziness, fatigue, and fall in blood pressure,number of attacks,systolic blood pressure and heart rate,percentage and severity of side-effects,number of migraine attacks,reduced duration of headache,migraine index,blood brain barrier,Mean duration of attacks,average duration or severity of migraine attacks,anxiety or depression,hormones levels,prolactin (PRL), luteinizing hormone (LH) and growth hormone (GH) levels,weight gain,headache parameters,severe side effects,frequency and severity of headaches,mild adverse reactions,frequency, intensity, and duration of migraine attacks, nor on amplitude and latency of the VEPs,cardiovascular function,symptomatological profile of individual migraine attacks,headache frequency, headache severity, nausea frequency or severity,frequency of headaches,mean frequency of attacks,tolerated and safe,number of headache days or the number of migraine attacks,Adverse experiences,Efficacy and tolerability,migraine index, frequency of attacks and global evaluation,Headache response to medication,frequency of attacks and their total duration,consumption of analgesic drugs,VEPs,efficacy,global evaluation,Mean severity of attacks,efficacy and tolerability,vasomotor headache,average number of monthly crises,Plasma concentrations,VEP amplitudes,mean attack frequency,number of sickleave days and the use of symptomatic drugs,attack frequency,migraine symptoms,tolerated,Vasomotor headaches,efficacy parameter,headache index,migraine attacks,VEP amplitudes and longer latencies,migraine headache,headache or nausea,headache diaries,platelet aggregability,headache,median intensity of pain and the number of attacks,Efficacy,plasma concentration or serum production of TxB2,efficacy and safety,frequency of the attacks,migraine frequency,frequency of attacks,ADP-induced platelet aggregability, platelet cAMP, ATP and ADP levels, plasma cAMP and TxB2 concentration, as well as the serum production of TxB2,adverse events,severity of attacks and the number of analgesics,Migraine frequency,adverse drug reaction,tolerated and the number of reported side-effects,efficacy variables (headache attacks, days with headache, analgesic consumption,blood pressure and heart rate; flunarizine,Weight gain,severity nor duration of migraines,platelet and plasma cAMP levels,Serum prolactin,side effects|It is concluded from the results that there are no differences in efficacy between metoprolol and propranolol regarding the studied parameters.
325|incidence of curative re-operations,five-year survival rate,survival,local recurrence,scores for quality of life (physical component score,recurrence, time to detection and death rates,survival benefit,diagnostic efficacy and costs,anxiety,overall survival,Curative re-resection,recurrence,probability of overall survival,quality of life, SF-12; physical and mental component scores, (2) anxiety and depression: Hospital Anxiety and Depression Scale and (3) patient satisfaction: Patient Visit-Specific Questionnaire,rectal cancer,number of curative hepatectomies,asymptomatic chest radiography-detected lung metastasis,investigations, number and timing of recurrences and deaths,survival and recurrence resectability,Recurrence,Local recurrences,time of diagnosis,earlier detection of hepatic metastases,actuarial 5 year survival,patient satisfaction,asymptomatic CT-detected liver metastasis,Efficacy and cost of risk|On completion of 5-year follow-up, there was no significant difference in survival between the two groups.
157|clinical efficacy and safety,nausea and influenza-like symptoms,Suicidal feelings,five individual items, Hamilton depression scale,Hamilton Depression Scale Score,success rates,cognitive functioning,overall depression,Response rates, whether defined by end-of-treatment Hamilton Rating Scale for Depression (HAM-D) score,Clinical Global Impression (CGI) score,Montgomery and Asberg Depression Rating scale (MADRS) score,rate of positive treatment response,tolerability ratings,Clinical Global Impression (CGI), Therapeutic Index (TI), Tolerance Global Impression,body weight,overall depression and anxiety,overall incidence of adverse effects,baseline Montgomery and Asberg Depression Rating Scale (MADRS) total score,Tolerability,Sexual dysfunction,sleep efficiency, total sleep time, stage 2 sleep, and shorter wake time,REM sleep parameters,antidepressant and antianxiety efficacies,objective measures of sleep, i.e. suppression of REM sleep,agitation and psychic anxiety symptoms,frequency of adverse events,Hamilton Depression Rating Scale (HDRS), Montgomery-Asberg Depression Rating Scale and Clinical Global Impression (CGI,therapeutic efficacy and safety/tolerability,Vital signs and adverse experiences,anticholinergic effects, dizziness, drowsiness, somatosensory disturbance, and excessive sweating,Hamilton Psychiatric Rating Scale for Depression (HAM-D,change of HAMD17 total score,adverse drug reactions (ADRs,Hamilton Depression scale,safety and efficacy,Weight loss,final Hamilton Depression Rating Scale (HAM-D) score,tolerated and safe,Adverse effects,depression subscale of the irritability, depression and anxiety scale,initial Hamilton Rating Scale for Depression (HAM-D,relieving depression and accompanying symptoms of anxiety,Estimated probabilities of response and remission,HAM-D17, HAM-D17 response, and HAM-D17 remission rates,HAM-A scores,incidence of treatment-emergent adverse events,total Hamilton Depression Rating Scale score,STIs,MADRS,quality-of-life improvements,Therapeutic efficacy,Raskin Depression Scale, the Covi Anxiety Scale, and the Leeds Sleep Questionnaire,Hamilton Depression score,nausea, vomiting and diarrhoea,assessment criteria Geriatric Depression Scale (GDS) and Clinical Global Impression (CGI,complaints of dry mouth and dizziness on standing,HRSD items "psychic anxiety", "somatic anxiety", "agitation,Adverse Events Scale,work or productivity losses,Depression improvement,Hamilton Depression mood item,measures of depression, including remission of depressive symptoms,Anxiety measured by HAM-A total mean score,Efficacy and response time,Utilisation of medical resources,adverse effects,sleep efficiency or number of awakenings, Stage 1 or REM sleep, or REM latency,Leeds Sleep Evaluation scale and on SIP items relating to sleep and rest, emotional behaviour and ambulation,Mean scores for most depression scales,Anticholinergic side-effects,anxiety (anxious depression,dizziness,Hamilton Psychiatric Rating Scale for Depression (HAM-D), the Montgomery-Asberg Depression Rating Scale (MADRS), and the Clinician's Global Impressions-Severity of Illness scale (CGI-SI,percentage of HAMD responders,clinical global improvement severity of illness score,effectiveness and good tolerability,rate of adverse events,HAM-D and CGI-Severity scores,equivalent antidepressant efficacy,Discontinuations for adverse events,Sleep measures,occurrence of discontinuation rates and treatment-emergent adverse events and by measurement of vital signs and laboratory analytes,adverse events; tolerability profiles,21-item Hamilton Rating Scale for Depression (HAM-D), and depressive symptoms,overall symptoms of depression,HAMD score,Mean ,frequency or in severity of adverse events,baseline Hamilton Rating Scale for Depression score,Hamilton Depression Rating Scale (HDRS) and the Montgomery & Asberg Depression Rating Scale (MADRS,Hamilton depression rating scale (HAMD) total score,initial HAM-D score,excessive sweating,efficacy using the HRSD, Montgomery-Asberg Depression Rating Scale and Clinical Global Impression; for tolerability, adverse events,final ratings on the Hamilton Rating Scale for Depression (HAM-D21) total score, HAM-D21 depressed mood item, Montgomery-Asberg Depression Rating Scale total score, and Clinical Global Impressions Scale,objective, subjective, and clinician-rated measures of sleep,Safety assessments included treatment-emergent adverse events (AEs), reasons for discontinuation, and AEs leading to discontinuation,mean Hamilton Rating Scale for Depression (21-item HAM-D) total score,incidence of early patient withdrawals due to treatment-emergent adverse events,MADRS score,Hamilton Rating Scale for Depression (HAM-D) sleep disturbance factor score,nausea and headache,sleep efficiency and REM sleep,mean total score,mean total endpoint HDRS scores and percentages of CGI very good and good responses,health transition scale of the 36-item Short-Form Health Survey Questionnaire,individual HAM-D Items 9 (agitation), 10 (psychic anxiety), and 11 (somatic anxiety,Montgomery and Asberg depression scale (MADRS), the Hamilton depression scale, the clinical global impressions (CGI), and a checklist of symptoms and side-effects, sleep efficiency,efficacy and tolerance,HAMD sleep factor,nausea, headache, and dizziness with venlafaxine and nausea, headache, and insomnia with fluoxetine,Nausea,efficacy (MADRS, CGI, COVI) or in terms of safety, except for the CGI 'severity of illness,REM latency,incidence of AEs suggestive of activation or sedation,Final MADRS scores,body weight, blood pressure, pulse rate, temperature, physical conditions, laboratory tests, adverse experiences and concomitant medication,individual HAM-D items including item 4 (insomnia onset,nausea and nervousness for fluoxetine, and dry mouth, dizziness, and drowsiness for amitriptyline,weight gain,remission rates,constipation,depression (HAM-D, HAD, CGI,Compliance,generalized tremor,dry mouth, drowsiness/sedation, constipation, and dizziness/lightheadedness,clinical status at base line (diagnosis, history and duration of the depressive illness, MADRS and HARD diagram scores).(ABSTRACT,sleep efficiency, number of awakenings, percentage of awake and movement time, percentage of REM and Stage 1 sleep, and REM latency,frequencies of occurrence of adverse reactions,nausea, other gastrointestinal symptoms, nervousness, dizziness and sleep disorders,depressive symptoms,cardiovascular effects,remission, Clinical Global Impression severity of illness and global improvement scores and Montgomery-Asberg Depression Rating Scale,retardation pole of the mood, anxiety, retardation, danger scale,tremor, rash, nausea and headache occurring with fluoxetine, and drowsiness, dizziness and visual disturbance with dothiepin,overall response,antidepressant efficacy and tolerability,mean HAM-D total score,somnolence,low insomnia,Anxiolytic activity,Montgomery-Asberg Depression Rating Scale, CGI-Severity of Illness and CGI-Improvement, and Patient Global Impression of Improvement,nausea and diarrhoea,efficacy and tolerability,Average total scores on the Hamilton Rating Scale for Depression (HAM-D,sleep and anxiety,anxiety and suicidality,HAM-D sleep disturbance factor,agitation, nausea, fatigue, and insomnia,sleep,MADRS total score,nausea and vomiting,Mean HDRS,quality of life,incidence of adverse events,efficacy (HDRS, CGI) or safety (adverse events, laboratory examination, vital signs,antidepressant efficacy,Hamilton Depression Rating Scale (HDRS,REM latency and suppressed REM sleep,some clinician- and patient-rated sleep disturbance scores,dimensions measuring depression or mental health,17-item Hamilton Rating Scale for Depression (HAMD), the von Zerssen depression scale (DS), Clinical Global Impression (CGI), and patients' overall evaluation,agitation, anxiety, suicidality, and global impressions,nausea, dyspepsia, anorexia and insomnia,total HRDS score or in subscores for anxiety or suicidality,Hamilton Depression Rating Scale, a side-effect checklist and a regular ECG assessment,HAM-D, MADRS, and CGI-SI,mood and cognitive functions,HAMD-total score,17-item Hamilton Rating Scale for Depression (HAM-D) and the Clinical Global Impressions (CGI) scale,symptoms of depression,HAM-A response rate,Hamilton Rating Scales for Depression and Anxiety, the Montgomery Asberg Depression Rating Scale, Clinical Global Impressions Scale, Zung Self-Rating Scale for Anxiety and the Leeds Sleep Evaluation Questionnaire,mean scores on the Hamilton Depression Rating Scale,Covi Anxiety Scale,HAM-D-17 total score,17-item Hamilton Depression Rating Scale (HDRS), the Montgomery-Asberg Depression Rating Scale (MADRS) and the Clinical Global Impression (CGI,Headache and nausea,adverse events,sleepiness,psychological dimensions of general health and moderately impaired on physical dimensions,scores of the items "suicide", "psychic anxiety", "somatic anxiety", "agitation" and "insomnia,Sleep disturbances,tolerability and efficacy,success rate,HAMD total score,mean scores of all depression rating scales,QRS duration,nausea,anxiety scores,HAM-D) or remission,safety and tolerability profiles,degree of depression and anxiety improvement,CGI-Improvement responder rates,symptoms of dizziness,Good antidepressant efficacy,HAM-D depressed mood item,PR interval,clinician- and patient-rated measures of depression symptoms and factors, cognitive functioning, and quality of life, as well as plasma drug concentrations,tiredness, drowsiness and diarrhoea,incidence of discontinuation for adverse events,number of patients reporting at least one adverse event,mean score of Hamilton Rating Scale for Depression (HRSD,HAMD sleep disturbance scale,cognitive functions,response rates,effective and well tolerated antidepressant,weight increase and somnolence,heart rate,sleep disturbances, nausea, and headaches,antidepressant efficacy (HAM-D, CGI,subjective mood ratings,Widlöcher psychomotor retardation scale, Sheehan disability scale, and CGI,Additional efficacy assessments (Montgomery-Asberg Depression Rating Scale, Clinical Global Impression,Response and remission rates,global improvement,mean endpoint scores for all rating scales,effective and well tolerated,sleep quality,total REM sleep time,dry mouth,HAM-D-17 and HAM-D-Anxiety,total HAM-A score,depression ratings,total score on the Hamilton Rating Scale for Depression and the global improvement score on the Clinical Global Impressions scale,Efficacy and safety,quality of life and cognitive function,21-item Hamilton Rating Scale for Depression, Hamilton Rating Scale for Anxiety, Clinical Global Impressions, Raskin Depression Scale and Covi Anxiety Scale,Hamilton Anxiety Rating Scale (HARS) and of sleep disturbances,Clinical Global Impressions (CGI)-Severity of Illness scale score,Overall effectiveness,weight loss,weight changes,efficacy and acceptability,number of awakenings,HRSD, Zung Self Rating Scale for Depression, Montgomery-Asberg Scale for Depression, Clinical Global Impression for severity and improvement of depressive symptoms,21-item Hamilton Rating Scale for Depression (HRSD,HDRS score,HAM-D response rate,Hamilton Depression Rating Scale,ESRS scale for akathisia,number of hospitalisations and duration of stay,Montgomery Asberg Depressive Rating Scale (MADRS,self evaluation scales,haematological or clinical chemistry changes,Somatization Factor scores,Hamilton Rating Scale for Depression (HAM-D) and the Clinical Anxiety Scale,Anticholinergic side effects,antidepressant and anxiolytic efficacy,anxiety symptoms,Clinical Global Impressions,17-item Hamilton Rating Scale for Depression (HAM-D-17) total score,REM sleep,HDRS or MADRS total scores,patient response,depressive symptoms and concomitant anxiety,Antidepressant efficacy and quality of life in depression,adherence and efficacy and adherence,HAM-D remission rate,acute treatment efficacy and tolerability,antidepressant efficacy and safety,percentage of awake and movement time,Efficacy,efficacy and safety,clinical evaluation [Montgomery-Asberg Depression Rating Scale (MADRS), Clinical Global Impressions (CGI)] and quality of life [Functional Status Questionnaire (FSQ,mood and on objective, subjective, and clinician-rated measures of sleep,mean HAM-D, MADRS, and CGI-S scores,Overall, efficacy ratings,Sleep polygraphic recordings,Headache and blurred vision,objective, subjective, and clinician-rated measures of sleep disturbance,sedation, nausea and vomiting,total number of adverse events,baseline and endpoint depression and anxiety severity,final on-therapy scores on the HAM-D, Montgomery-Asberg Depression Rating Scale (MADRS), and Clinical Global Impressions Severity of Illness (CGI-S) and Improvement (CGI-I) scales,depression, anxiety, and quality of life,electrocardiogram (ECG) and systolic time intervals (STIs,established rating scales (MADRS, HAM-D, BPRS,rapid-eye-movement (REM) sleep or increase REM latency,Weight gain,Symptoms of anxiety,depression and insomnia,memory performance,Insomnia improvement,dry mouth and dizziness/lightheadedness,HAM-D responder rate,weight change: weight loss,Safety,sleep continuity and increased rapid eye movement (REM) sleep,safe and well tolerated,Hamilton depression scale scores,I, CGI-S), anxiety (Covi), sleep (Leeds Sleep Evaluation scale) and quality of life (SIP,full remission of their depression (HAM-D21 total score,complaints of dry mouth, constipation, and dizziness,HDRS total score,HAM-D sleep disturbance factor score,21-item Hamilton Rating Scale for Depression (HAM-D), and Clinical Global Impressions scale for severity and improvement,mean scores on the Montgomery-Asberg Depression Rating Scale,shaking. ,Montgomery Asberg Depression Rating Scale (MADRS), the HARD diagram, the check list for somatic symptoms and side-effects,antianxiety effects,Mean values,Constipation, dyspepsia, tremor, sweating and abnormal ejaculation,mean reductions in HAM-D total score,CGI,adverse event,good tolerability and safety profile,social functioning,dropout rate due to side effects,sleep continuity,Hamilton Depression Rating Scale, the Clinical Global Impression (Severity and Improvement) scales, and the Patient Global Impression (Improvement) scale,response rate,central nervous system events,side-effects,Mean total 17-item HAM-D scores,agitation, anxiety and insomnia,Severe depression,insomnia and asthenia,Hamilton Depression Rating Scale, the Raskin Depression Scale, the Covi Anxiety Scale, and a Clinical Global Impression,nausea and nervousness,sleep questionnaire covers the complaints listed in criteria for insomnia disorders,cardiac function,dropout rates,number of awakenings, Stage 1 sleep, and REM latency,blood pressure, pulse, or weight,efficacy,HAM-D scores,ECG or STIs,Hamilton Rating Scale for Depression, Hamilton Rating Scale for Anxiety, Clinical Global Impressions-Severity, and Clinical Global Impressions-Improvement,Hamilton Depression Rating Scale and the Montgomery-Asberg Depression Rating Scale (Montgomery and Asberg, 1979)--and a self-rating scale--Levine Pilowsky Depression questionnaire,21-item Hamilton Rating Scale for Depression (HAM-D) and the Clinical Global Impressions-Improvement scale (CGI-I), with scores of < or = 7 on the HAM-D and < or = 2 on the CGI,HDRS,patient and observer ratings of depression,Overall tolerance,adverse reactions,Hamilton depression rating scale (HDRS-17 items) and clinical global impression (CGI) scale,Sleep electroencephalographic (EEG) recordings,Hamilton Rating Scale for Anxiety,mild depressive episodes,tolerated,insomnia,steady-state levels,HAM-D, Clinical Global Impressions, the Visual Analogue Mood Rating Scale (VAMRS), and the Quality of Life Enjoyment and Satisfaction Questionnaire (QLESQ,Hamilton Rating Scale for Depression (HAM-D), Clinical Global Impression, and subjective mood ratings (45-item self-rating scale,motor nervousness or restlessness,symptoms of major depressive illness effectively,General Health Survey (SF-20) and 15D Measure of Quality of Life,sinus cycle length,Hamilton Rating Scale for Depression (HAM-D), Hamilton Rating Scale for Anxiety,Side effects,HAM-D and Clinical Global Impressions scale,rates or mean numbers of adverse events,drowsiness/sedation and excessive sweating,drowsiness and disturbed sleep,headache,proportion of REM sleep,Social Adaptation Self-evaluation Scale total scores,HAM-D,rates of treatment response,anxiety,normal objective, and clinician- and patient-rated assessments of sleep,24-item Hamilton Rating Scale for Depression and Clinical Global Impressions scale ratings,Hamilton Rating Scale for Depression,frequency and severity of volunteered adverse events,Antidepressant efficacy,Psychic Anxiety item,cognitive improvement on several measures,effective antidepressant activity,number of responders,Cognitive performance,nervousness/anxiety and nausea,positive treatment response rates,Hamilton Rating Scale for Depression (HRSD,Hamilton Rating Scale of Depression scores,ESRS scores for akathisia,total HAM-D score,Digit Symbol Substitution Test,side effects|Fluoxetine was comparable to amitriptyline in all efficacy measures except the HAMD sleep factor.
21|vibration perception thresholds, nerve conduction velocities, and nerve action potential amplitudes,Exercise LVEF,Tendon reflexes and blood pressure fall,median motor, median sensory, and peroneal nerves,Efficacy and safety evaluation,cardiovascular autonomic nerve functions, the ratio of the longest expiratory R-R interval to the shortest inspiratory R-R interval during deep breathing,Motor and sensory nerve conduction, thermal and vibration sensation thresholds, heart rate variation at rest, E/I ratio, pupillary dilation velocity and pupillary reflex latency,collagen and adenosine diphosphate (ADP,clinical examination, neurophysiological measurements, sensory threshold determinations and tests of autonomic nerve function,Coronary artery disease, left ventricular hypertrophy, and valvular heart disease,median motor NCV,maximum velocity of constriction,median motor and median sensory nerves, changes in velocities,nerve functions,sensory, electrophysiological, and autonomic function,peripheral or autonomic nerve function,Vibration perception,postural hypotension,mean motor NCV,Posterior tibial nerve conduction velocity,neurologic function, including nerve conduction studies (NCSs), quantitative sensory testing (QST), and clinical neuropathy rating scores,change in AER,NCV,postural hypotension deteriorated,symptoms of pain, numbness, or paresthesia,baseline neurophysiological parameters, duration of diabetes, and presence of retinopathy,resting LVEF,Peripheral nerve function,median sensory amplitude,fibrinolytic activities of the extrinsic, tissue-type plasminogen activator (t-PA), or in the intrinsic factor XII-dependent or factor XII-independent (urokinase-like) plasminogen activator systems,deterioration of motor nerve conduction velocity and vibration threshold,Deterioration of vibration threshold,cardiac output,motor (ulnar, median, and peroneal) or sensory (ulnar and radial) nerve conduction velocities, vibration perception thresholds, adjectival symptom scores or tests of autonomic function (mean electrocardiographic R-R interval variability on deep breathing and orthostatic blood pressure response,worsening of clinical measures of distal symmetric polyneuropathy,density of small-diameter,mean NCV of the four motor nerves,Objective, neurophysiological variables (biothesiometry, electromyography, nyctometri,Cardiac abnormalities,LV stroke volume,constriction ratio,nerve conduction velocity (NCV,early clinical signs and symptoms of diabetic neuropathy,peripheral nerve function,hypersensitivity reaction,number of fibers,cholecystic function,painful symptoms,lying-to-standing heart rate ratio,side effects,pupillary light reflex,pupillary light reflex and minimum latency of the F-wave,Sural sensory velocity,sural nerve zenarestat level and sorbitol suppression,motor or sensory nerve conduction velocity,neurologic decline,symptomatic diabetic neuropathy,nerve function,platelet reactivity and microalbuminuria,neurologic function,median nerve FCV,adverse reactions,exercise LVEF,severe symptomatic chronic peripheral neuropathy,transit time,electrophysiological measure,nerve conduction,median nerve FCV and minimal latency,oesophageal motility and vibration perception,median deterioration in AER,stroke volume,Metabolic control and severity of neuropathy,number of myelinated fibers per unit of cross-sectional area of nerve,cool thermal QST,heart rate variation and E/I ratio,percentage of regenerating myelinated nerve fibers,electrophysiological measurements of median and tibial motor nerve conduction velocity, F-wave minimum latency, F-wave conduction velocity (FCV), and median sensory nerve conduction velocity (forearm and distal), as well as an assessment of subjective symptoms,deep-breathing, maximum/minimum heart rate (expiration/inspiration ratio,measures (vibration QST, neuropathy rating scores, monofilament examination,pupillary light reflex test, cardiovascular autonomic function tests, and nerve conduction study,cardiovascular reflexes, pupil reflexes and skin vasomotor reflexes,Minimum latencies of F-wave of median and tibial motor nerves,pupillary light reflex and F-wave latency,analysed symptoms (pain and paraesthesias) and objective assessments (NCV-DB,Diabetic neuropathy,sensory thresholds,nerve sorbitol content,blood pressure, insulin use, or the presence of baseline abnormal heart rate variability,oesophageal transit time and cholecystic motility,Muscle capillary basement membrane thickness,vitro platelet aggregation, albumin excretion rate (AER) or muscle capillary basement membrane thickness,vibration perception,motor nerve conduction velocities and paraesthetic symptom scores,tibial and peroneal motor nerve conduction velocities,median distal motor latency,squatting vagal test,motor and sensory nerve conduction velocity,resting diastolic filling rates,Mild reversible elevations of hepatic transaminases,Cardiovascular reflex tests (squatting vagal and sympathetic tests, pressure gain, deep breathing, lying-to-standing, Valsalva maneuver, and orthostatic hypertension), vibration thresholds, tendon reflexes, and muscle strength,Subjective symptoms (including numbness, spontaneous pain, sensation of rigidity, paresthesia in the sole upon walking, heaviness in the foot, and hypesthesia,end diastolic volume,exercise cardiac output,deterioration in mean vibration threshold,Neuropathic symptom scores,paraesthetic symptoms,Painful and paraesthetic symptoms, vibration sensory threshold, and nerve conduction velocity (NCV,diabetic neuropathy,Painful and paraesthetic symptoms,glycaemic control|In vitro platelet responsiveness to collagen and adenosine diphosphate (ADP) increased in the placebo group (median change max% collagen + 8 (+2 to +30)%; ADP +4.5 (0 to +20)% compared with a fall in the Sorbinil treated patients (median change; collagen -17.5 (-2 to -40)%, p less than 0.05; ADP, -4 (0 to -25)%, p less than 0.05).
958|Abstinence proportions,Sustained abstinence rates,withdrawal, tension, fatigue, and coping frequency with decreased coping effort; coping-to-urge ratio,success rates,functional exercise capacity, and delays weight gain,rates of abstinence,mood, withdrawal symptoms, pleasant activities and events, self-efficacy, and optimism and pessimism,quit smoking,psychological smoking cessation,Mean birth weight difference,severe localized erythema,throat/mouth irritation and coughing,Body weight,Smoking reduction,Monitoring blood cotinine levels,withdrawal symptom relief,Transient mild or moderate erythema,knowledge, coping and support resources,Carbon monoxide-verified abstinence rates and St. George Respiratory Questionnaire (SGRQ,Rates of adverse pregnancy and birth outcomes,exhaled carbon monoxide,Skin irritation,abstinence outcomes,SGRQ scores,total abstinence,analyzed craving and withdrawal symptoms,Smoking behavior and compliance,Mean smoking rates,Mean nicotine substitution,relapse,prolonged abstinence from 2 weeks post-quit day through 6 months,cigarette taste,safety and efficacy,tobacco withdrawal symptoms and enhanced smoking cessation rates,validated point prevalence abstinence at discharge,Point abstinence,prolonged abstinence, assessed through self-report and verified with exhaled carbon monoxide (CO) levels,withdrawal symptoms and abstinence rates,overall success rate for sustained smoking reduction,frequency of nausea,quit rates and tobacco withdrawal symptoms,plasma cotinine, exhaled carbon monoxide and plasma thiocyanate,systemic side effects,Abstinence,continuous abstinence rates,Withdrawal symptom relief,expired carbon monoxide (CO) and serum and salivary cotinine,craving for alcohol,baseline smoking rate and baseline trough and peak blood cotinine levels,equivalent 1-year abstinence rates,7-day point prevalence smoking abstinence rate,point-prevalence abstinence rates,cotinine concentration,Withdrawal symptoms,smoking rates,substantial relapse rate,Nicotine abstinence rates,severity of some withdrawal symptoms,cardiovascular events,Safety and efficacy,initial cessation, number of days to lapse, number of days to relapse, and latency to relapse,smoking cessation and suppression of withdrawal severity,adverse effects,toxin intake,Time to relapse,smoking abstinence (cotinine plus carbon monoxide,sustained rate of smoking cessation,Plasma nicotine and cotinine values, expired carbon monoxide and withdrawal symptoms,quit rates,smoking reduction,tobacco withdrawal symptoms,mean nicotine substitution based on cotinine determinations,craving for smoking,Tenseness, difficulty in concentration and feelings of hunger,relative success rate,cessation efficacy,dividing serum nicotine and cotinine levels,birth weight and gestational age,signs of nicotine toxicity,7-day point prevalence abstinence at 1 week, 8 weeks, and 6 months after quitting and number of days to relapse,smokers' nicotine withdrawal symptoms,Six-month abstinence rates,Minor skin reactions,sustained abstinence rates,OR,12-month abstinence,6 month quit rates,28-day continuous abstinence,educational level, duration of smoking, number of cigarettes smoked per day, concomitant disease states or drug use, or Fagerstrom score,CO reductions,Quit rates,cessation,Smoking abstinence (verified by saliva cotinine and expired carbon monoxide), cessation self-efficacy, and physical fitness and body weight,adverse cardiovascular events,quitting rate,Success rates,smoking reduction (CPD and thiocyanate concentrations,functional exercise capacity,6-day inpatient stay, daily nicotine and cotinine levels,adverse pregnancy and birth outcomes,sleep disturbance and local skin irritation,self-reported smoking abstinence confirmed by expired carbon monoxide measurements,smoking abstinence rates,cessation rates,efficacy and tolerance,behavioural therapy,reduced craving and withdrawal,tolerated, and adverse events,smoking cessation rate,sustained cessation,28-day abstinence,complete abstinence (self-reported) and expired carbon dioxide concentration less,levels of expired CO,smoking cessation rates and tobacco withdrawal symptoms,Quit rate,Cotinine levels,Continuous smoking abstinence,successfully quit smoking,serum levels of nicotine and cotinine at baseline, and withdrawal symptom relief,Rates of sustained abstinence,skin reactions,higher long-term rates of smoking cessation,specific withdrawal symptoms (anger, anxiety, awakening, difficulty concentrating, depression, hunger, impatience, and craving,insomnia and headache,short- and long-term smoking cessation rates,success rate in quitting smoking,rates of point-prevalence abstinence,Overall duration and level of nicotine gum use,percentage of nicotine replacement,continuous abstinence, cotinine-verified abstinence, daily cigarette consumption, withdrawal symptoms and adverse events,continuous abstinence through 7 weeks after cessation,7-day point prevalence rates,cigarette consumption,frequency of respiratory symptoms,body weight nor cessation rates,early withdrawal symptoms,Abstinence rates,longer length of alcohol abstinence,duration of continuous smoking abstinence; abstinence rates,short-term smoking abstinence rates,risk for smoking lapses,point abstinence at 7 weeks, continuous abstinence at 6- and 12-month follow-up, and self-reported withdrawal symptoms,Lack of power, contamination, and low attendance,Abstinence outcomes,level of self-efficacy,higher quit rates,Smoking abstinence,nicotine-dependence score,abstinence from the date of smoking cessation until delivery, as validated by measurement of exhaled carbon monoxide or salivary cotinine,Smoking cessation,CO-validated abstinence rates,Withdrawal symptom reporting,Craving,Adverse events,adverse events,Smoking cessation rates,continuous and prolonged abstinence, lapse and recovery events, cost per additional quitter, and side effects and adherence,increase abstinence,6-week smoking-cessation rate,Birth weights,success rate,adverse event rates,prolonged abstinence,birth weight and preterm delivery,birth weight,prevalence abstinence rate,transient local erythema,nausea,Alcohol outcomes,smoking cessation rates,Sustained smoking cessation,number of daily cigarettes,nicotine dependence,Failure,Compliance rates for return visits,rate of preterm delivery,reduction of smoking,Overall sustained abstinence,Retention rates,rate of continuous smoking abstinence,expired carbon monoxide (CO) levels,complete abstinence rates,Withdrawal severity,weight change and cessation rates,Weight and smoking status,self-reported abstinence and end-expired air carbon monoxide (CO,abstinence rates,erythema with edema,systemic and local adverse drug events,year smoking cessation rates,saliva cotinine,7-day point prevalence abstinence rates,Demographic characteristics, smoking history, depression symptoms, and body mass index,carbon monoxide concentration,respective success rates,likelihood of quitting smoking,tolerated, and no serious adverse events,nicotine dependence and severity of withdrawal symptoms,compensatory smoking of low tar and nicotine cigarettes,vomiting,overall rate of relapse,Prolonged abstinence rates (CO<10 ppm,Efficacy and safety,expired carbon monoxide concentration,smoking cessation,rate of abstinence from the quit date until delivery,numbers of cigarettes smoked,smoking-cessation rates,successful abstinence,1-year quit rates,serious adverse events,continuous abstinence,cessation rate,Craving and withdrawal symptoms,Smoking reduction promotes smoking cessation,rate of smoking,10-wk continuous smoking abstinence,blood pressure,rate of success,probability of lapsing,Cessation success rates,Cessation rates,weight gained and relapse,daily cigarette smoking and cigarette craving,mean scores,stopped smoking,1-year abstinence rates,absolute rate of abstinence,rate of continuous abstinence,throat irritation (inhaler) and itching (patch,rate of low birth weight,Severe reactions,time and cotinine values,Efficacy,efficacy and safety,eventually achieving long-term abstinence,successful quitting,Withdrawal symptoms and nicotine toxicity,daily cigarette consumption or craving,daily cigarette consumption,initial abstinence,4-week abstinence rates,point-prevalence abstinence,ratings of adverse effects,Weight gain,CO or thiocyanate concentrations,Smoking cessation efficacy,nicotine toxicity, and withdrawal symptom relief,chances of recovery from lapses,Self-reported quit rates,daily cigarette smoking on cigarette craving,reduction rates and (b) psychological and physiological processes,relapse rate,breath carbon monoxide (CO,Mean compliance,relapse risks,Smoking status,expired air carbon monoxide measurement,quitting rates,Safety,rates of dropouts due to adverse events,withdrawal symptoms,efficacy of the skin patch,abstinence,number of cigarettes smoked,smoking outcomes,side effects and adverse events,highest quit rates,7-day point prevalence smoking abstinence,subjects smoking >16 cigarettes/day sustained cessation rates,abstinence proportions ratios,Continuous abstinence rates,Mild or moderate side effects,point-prevalence abstinence and continuous abstinence,Continuous abstinence,drinking outcomes,salivary cotinine levels,Higher smoking cessation rates,daily cigarette consumption and severity of withdrawal symptoms (Wisconsin scale,general distress,abstinence rate,craving for cigarettes, negative affect, and appetite,level of abstinence,Severe skin reactions,mood disturbance,cessation rates and postcessation weight gain,8-week smoking abstinence rate,Fagerstrom score,study (death, myocardial infarction, cardiac arrest, and admission to the hospital due to increased severity of angina, arrhythmia, or congestive heart failure); the secondary end points (admission to the hospital for other reasons and outpatient visits necessitated by increased severity of heart disease); any side effects of therapy; and abstinence from smoking,rate of abstinence from smoking until delivery or the risk of adverse pregnancy or birth outcomes,time to smoking relapse and prolonged abstinence,withdrawal symptoms, including craving,effectiveness and safety,ad lib smoking, smoking satisfaction, and craving,mean saliva cotinine concentrations,Cigarette smoking rates,higher cessation rates,SGRQ score,expired air carbon monoxide measurements,tolerated,Difficulty in sleeping,withdrawal symptoms composite score and abstinence rates,CO-confirmed prolonged abstinence rates,continuous abstinence rate,self-reported 7-day point prevalence smoking abstinence 6 months after quit day,mean value of cotinine in saliva,7-day point prevalence abstinence,smoking quit rates,7-day point prevalence,Baseline mucosal lesions,point prevalence cessation rates,rate of negative birth outcomes,rate of abstinence from smoking,smoking cessation efficacy,overall rate of treatment-related adverse events,mean success rates,tolerated, and adverse event profiles,short-term quit rates,side effects,smoking abstinence|A slight increase in adverse cardiovascular events was noted only in the open label-pay group in comparison with the placebo group.
                
40|cumulative dysphagia-free state,symptom scores, and lower oesophageal sphincter pressure, oesophageal barium column height, and oesophageal diameter,Clinical relapse,initial failure,symptom score and esophageal function test,Lower esophageal sphincter pressure,recurrent dysphagia,cumulative 12-month remission rate,symptom score, esophageal manometry, and scintigraphy,esophageal retention,relevant complication,Failure rates,Symptoms and esophageal function,Chi-squares, Wilcoxon rank-sum test, Kaplan-Meier method and log-rank tests,equal success rates,Pneumatic dilatation,pneumatic dilatation,superior long-term success,recurrence of symptoms,symptomatic remission,botulinum toxin injection,symptom scores,Symptom scores,LES pressure and maximum esophageal diameter,major complications,cumulative remission rate,relieving symptoms and improving esophageal function,LES pressure,surgical management of perforation|The cumulative 12-month remission rate was significantly higher after a single pneumatic dilatation (53%) compared to a single botulinum toxin injection (15%)(P < 0.01).
28|social domain,Spatial attention and alertness,saccadic amplitude,saccadic behavior,restoration of vision,saccadic behavior or visual fields,visual functioning,visual skills areas of recognition, mobility, peripheral detection, scanning, tracking, and visual memory,text reading,stimulus detection in high-resolution perimetry (HRP,ability to detect visual stimuli,visual skills categories,Detection performance,overall and separate skill improvement scores,stimulus detection in HRP,fixation performance,seeing side,patient's testimonials concerning their visual abilities,Outcome variables (response times [RTs] during natural search, number of fixations during natural scene exploration, fixation stability, visual fields, and quality-of-life scores,Natural search RT,saccadic behavior, natural search, and scene exploration,detection performance,Visual field size,fixation stability,static text reading speed|Only with EST did the number of fixations during natural scene exploration increase toward the blind and decrease on the seeing side (follow-up/pre difference, 238%).
173|CK-MB>5 times normal value,APACHE (acute physiology and chronic health evaluation,DO2 and VO2,Plasma concentrations of tumor necrosis factor-alpha (TNF), interleukin (IL)-6, IL-8, IL-10, and soluble tumor necrosis factor-alpha receptor-p55 (sTNFR-p55,oxidative stress and inflammation,Oxidative stress and inflammation generate edema,Urine N-acetyl-beta-D-glucosaminidase (NAG) and urine creatinine ratio, plasma creatinine, and serum cystatin C levels indicated renal function,15 (SD) yrs and Acute Physiology and Chronic health Evaluation,levels of the major cytokines, duration of ventilation and intensive care unit stay, gastric intramucosal pH and arterial oxygen tension/inspired fractional oxygen ratio,Plasma interleukin-6, interleukin-8, and soluble intercellular adhesion molecule-1 concentrations,lung injury score (LIS,liver blood flow, hepatosplanchnic oxygen transport-related variables, and liver function,Interleukin-8,plasma TNF, IL-6, or IL-10 levels,postoperative A-a oxygen gradient,GSH levels,MACR,1-month mortality rate,expired ethane and malondialdehyde (MDA), and oxidized (GSSG) and reduced glutathione (GSH,baseline SCr and calculated GFR,Plasma IL-6,myocardial damage,glomerular filtration rate (eGFR,oxygen extraction ratio by the liver,tissue oxygenation,Urine NAG/creatinine ratio,chest radiograph or on survival rate,Rates of deterioration and recovery of liver function,percentage of patients receiving ventilatory support,postoperative acute renal failure,cytokine levels and gastric intramucosal pH,urinary NAG/creatinine ratio,Global left ventricular function,overall survival,transplant-free survival and rate of transplantation,mean decrease of VO2,Fractional liver blood flow index (cardiac index-related liver blood flow index,fulminant hepatic failure,hemodynamic response to N-acetylcysteine,incidence of postoperative AF,serious adverse events, hospital mortality,hospital mortality,Survival; incidence of cerebral oedema, renal failure, and hypotension requiring inotropic support; liver function,PaO2/FiO2 ratio,mortality, morbidity or postoperative graft function,plasma creatinine and serum cystatin C concentrations,nuclear factor-kappa B activation and circulating cytokine and adhesion molecules,renal dysfunction,hospital mortality rate,Pulmonary compliance,II scores, Multiple Organ Failure scores,hypotension requiring inotropic support,serum cystatin C,Nuclear factor-kappa B activation,urinary albumin/creatinine ratio,Postoperative tracheal extubation,partial pressure of oxygen in arterial blood/fractional inspired oxygen 4 h after surgery,mechanical ventilation,cardiac index,postoperative organ dysfunction,cardiovascular state, liver function, and kidney function,Cardiomyocyte staining,Acute renal failure,postoperative eGFR,coma recovery times,liver function,hepatorenal ischaemia-reperfusion injury,Mean (SD), pooled mean arterial pressure (MAP), and cardiac index,postoperative biochemical markers (troponin T, creatine kinase MB, creatinine, hemoglobin, and platelets,VO2 and gastric intramucosal pH,Development of ARDS and mortality,hemodynamic effects of N-acetylcysteine,MAP, cardiac index, and left ventricular stroke work index,intubation time,hepatosplanchnic blood flow,median percent change in eGFR,hemodynamics, oxygen transport variables, and plasma levels of cytokines,oxygenation index (PaO2/FIO2,rate of AF,microalbuminuria/creatinine ratio (MACR,hemodynamic and pulmonary data (pulmonary capillary wedge pressure, pulmonary vascular resistance (PVR), cardiac index (CI), shunt flow, dynamic lung compliance and static lung compliance,systemic oxygenation,plasma neutrophil elastase activity,cerebral oedema,Activation,Plasma creatinine and serum cystatin C values,transplant-free survival,Release of myeloperoxidase (MPO,gastric intramucosal pH,cytokine levels, outcomes, or gastric intramucosal pH,serum cytokine levels and gastric intramucosal pH,simplified acute physiology score (SAPS,Respiratory dysfunction,Levels of urinary NAG/creatinine ratio, plasma creatinine and serum cystatin C,morbidity and mortality,proportion of patients with postoperative renal dysfunction,benefits of transplant-free survival,Severity of illness and degree of organ failure,length of ICU stay,daily Organ Failure Score,patients experiencing postoperative renal dysfunction,postoperative interventions and complications, the need for RRT,Pulmonary artery catheter-derived hemodynamics, blood gases, hemoglobin, and arterial lactate,mortality and the required days of inotropic support, mechanical ventilation, and intensive care,baseline SCr levels,proportion of patients developing postoperative renal dysfunction,cellular composition and mediators,Renal function,survival, graft function or risk of AKI,IL-8 and sTNFR-p55 levels,oxidative burst response of neutrophils,liver function tests, renal function tests, graft survival, patient survival, plasma GSH and duration of hospital and ICU stay,pulmonary fibrin uptake,hemodynamics and survival rates,liver blood flow,cardiac index (CI), left ventricular stroke work index (LVSWI,hemodynamics and graft function,mild vasodilatation, improve oxygen delivery and consumption,RBC glutathione,myocardial ischemia-reperfusion injury,cTnT levels,SOFA scores,AAGP and CRP values,whole-blood lactate levels,stable clinical conditions (hemodynamic values, body temperature, hemoglobin, FIO2,total antigenic human neutrophil elastase,MEGX,postoperative interventions and complications, the requirement for renal replacement therapy (RRT), adverse events, hospital mortality, and ICU and hospital length of stay,Liver blood flow index and MEGX,renal replacement therapy, length of ventilation, and length of stay in the intensive care unit and hospital,mortality rate,LIS and PaO2/FIO2 ratio,baseline serum bilirubin,plasma appearance of monoethylglycinexylidide (MEGX,VO2,Systemic oxidative stress,CK-MB,percent change in eGFR,MPO and MDA values,Overall survival,interleukin-6 production,GSH level,left ventricular cardiomyocyte staining,oxygen extraction,postoperative renal dysfunction, interventions, complications, or mortality,Transplant-free survival,cardiovascular, renal, hepatic, haematological and central nervous system,adverse reactions,hemodynamic variables, oxygen delivery (DO2), oxygen consumption (VO2), and oxygen extraction,periprocedural myocardial injury,relative change in serum creatinine, peak serum creatinine level, serum cystatin C, and in urinary output,ST segment depression,concentrations of TNF-α, IL-6, IL-8, and IL-10,ventilatory support,still receiving ventilatory support,six organ dysfunction parameters, length of intensive care stay, days of mechanical ventilation and mortality,Mortality,Postoperative clinical data (death, myocardial infarction, low-output syndromes, arrhythmias, bleeding, transfusion requirements, and intensive care unit and hospital lengths of stay) and biochemical markers (creatine kinase MB, troponin T, creatinine, hemoglobin, and platelet levels,ICU and hospital length of stay,ARDS,venoarterial carbon dioxide gradient (PvaCO2,malondialdehyde (MDA,nuclear factor-kappa B activation, interleukin-6, interleukin-8, and intercellular adhesion molecule-1 expression,myeloperoxidase (MPO), malondialdehyde (MDA), interleukin-6, Alpha1-acid glycoprotein (AAGP), and C-reactive protein (CRP,hepatosplanchnic flow and function,hemodynamics and postoperative graft function,nuclear factor-kappa B activation,demographic characteristics, ARDS categories, severity of illness (simplified acute physiology score [SAPS II,cardiovascular SOFA score,mortality rate, the need of ventilatory support, the intensive care unit stay, and the PaO2/FIO2 evolution,A daily Organ Failure Score,NAG/creatinine ratio and the albumin/creatinine ratio,Parasite clearance time,adverse effects,Ethane and MDA concentrations,ICU mortality and ICU length of stay,progression of multisystem organ failure,VO2 when DO2,microalbuminuria and organ dysfunction,levels of glutathione and cysteine,nutritive blood flow,PaO2/FIO2 ratio,Urinary F2-isoprostane metabolites,NAC improved oxygenation (increase in PaO(2)/FiO(2,acute renal failure,Mortality rate,static lung compliance,tolerated; only nausea and vomiting,MOD score,MOD score, use of vasopressor agents and fluid utilisation,survival rate,systemic and pulmonary hemodynamics, oxygen delivery, and oxygen consumption,oxidative response of neutrophils,mortality,clearance of indocyanine green,arterial and gastric mucosal carbon dioxide tension,mortality, lactate clearance times,overall mortality,II score and the sequential organ failure assessment (SOFA) score,serum creatinine (SCr) levels,luminol (specific for (*)OH, H(2)O(2), and HOCl(-) radicals) and lucigenin (specific for O(2) (*-)) levels and the difference ratios after reperfusion,hospital mortality and need for renal replacement therapy,renal replacement therapy, mortality, atrial fibrillation, vasoactive medications, and adverse effects,Interleukin-6 concentrations,oxygen delivery, cardiac index, stroke index, and left ventricular stroke work index,oxidative stress, inflammation, fluid requirement, multiple organ dysfunction (MOD) score and vasoactive drug requirement,splanchnic blood flow,haemodynamic parameters, nasopharyngeal temperature, arterial blood gas changes, plasma cytokine levels, biochemical parameters, intramucosal pH, length of stay in the intensive care unit, duration of of mechanical ventilation and mortality,tolerated, improved respiratory function, and shortened ICU stay,liver blood flow index,respectively Oxygen transport indices, arterial blood gas analyses, Pao2/Fio2 ratio, and shunt,systemic vascular resistance,reactive oxygen species-mediated myocardial stress,myocardial oxidative stress,renal or hepatic injury,liver graft performance,transplantation rate,absolute liver blood flow index,PSH level,Perioperative hemodynamic and pulmonary data,renoprotective effect,efficacy and safety,Creatine kinase-MB levels,severe adult respiratory distress syndrome (ARDS) and mortality rate,GSH,Hemodynamic parameters, oxygen consumption, oxygen delivery, oxygen extraction ratio, and lactates,development of ARF,postoperative increases in A-a oxygen gradient,higher survival rate,whole-body oxygen consumption (VO2), gastric intramucosal pH, and veno-arterial CO2 gradient (veno-arterial PCO2,Plasma creatinine,Levels of malondialdehyde, protein sulfhydril (PSH) groups, reduced gluthation (GSH), activity of myeloperoxidase, catalase and superoxide dismutase enzymes and induced free radical generating capacity,rate of survival,overall incidence of ARF,Hemodynamic data and calculated tissue oxygenation parameters,incidence of death, myocardial infarction, bleeding, transfusion requirements, intubation time, and hospital length of stay,Postoperative graft function,renal injury as measured by the increases in urinary N-acetyl-beta-d-glucosaminidase (NAG)/creatinine ratio (indicator of renal tubular injury) and urinary albumin/creatinine ratio (indicator of glomerular injury,organ function,pulmonary function,postoperative clinical course,Microsomal liver function,complex formation between elastase and alpha 1-proteinase inhibitor,postoperative atrial fibrillation,LIS,number of days of acute lung injury,Hemodynamic and oxygen transport indices,Hemodynamics and clinical outcomes,aminotransferases, prothrombin time, and monoethylglycinexylidide test,Creatine kinase MB isoform (CK-MB) mass levels,oxygen transport and uptake,renal function,absolute change in serum creatinine,Cardiac output,admission parasitemia,VO2, oxygen delivery, CI, LVSWI and PvaCO2,veno-arterial PCO2,lipid peroxidation of the lung epithelium,shorter ventilator requirement,progression of early postoperative organ dysfunction and improve oxygenation,total number of neutrophils, elastase, MPO and interleukin-8,serum creatinine,Serum cystatin C,cause mortality,microalbuminuria and organ failure,Tumor necrosis factor-alpha levels,serum creatinine level,Soluble intercellular adhesion molecule-1 concentrations,FIO2|The transplantation rate was lower in the NAC group but was not significantly different between groups (32% vs 45%; P = .093).
1001|Hemoglobin A(1c) levels,quality of life,Health professionals' knowledge scores,hospitalized with diabetes- or vascular-related admissions,Attitudes towards footcare,dermatologic abnormalities,Reduction of lower extremity clinical abnormalities,serious foot lesions,self-care,patients' attitudes regarding the value and importance of footcare, patients' footcare knowledge, healthcare professionals' footcare knowledge and pattern of service utilization,knowledge of diabetic foot care,baseline foot risk category,incidence of diabetes mellitus,knowledge and foot self-care scores,knowledge about diabetic foot problems,Diabetes-related quality-of-life scores,self-management behavior,prevalence of some minor foot problems|Over 85% of the results for the Semmes-Weinstein monofilaments were the same on the first and second measurement.
43|better respiratory and nutrition status, and shorter time to healing,deaths,Age, percent total and third-degree burn, resting energy expenditure, and calorie and protein intake,wound infection,infectious morbidity and shortens length of stay,Nitrogen balance, urinary 3-methylhistidine excretion, urinary cortisol, and clinical status,serum free cortisol,Corticosteroid-binding globulin and total and free serum cortisol,pneumonia,incidence of diarrhea, improved glucose tolerance, lower serum triglycerides, reduced total number of infectious episodes and trends toward improved preservation of muscle mass,3-methylhistidine excretion,protein metabolism, morbidity, and length of care,nitrogen balance|There was no difference in nitrogen balance between groups, and 3-methylhistidine excretion was higher and serum free cortisol was lower in log-fat--fed patients than in controls.
not found|muscular score and functional grade,Acetylcholine receptor antibody concentrations,efficacy and safety,efficacious and safe,failure rate,Treatment failure,mean duration of improvement after IVMP,muscle function,level of function,severe side effects,positive treatment response|No severe side effects were found.
331|partial responses,mild thrombocytopenia,Median OS,median survival time,longer progression-free survival (PFS) time,response and PFS,incidence of these toxicities,progression-free survival (PFS), or overall survival,response rate and progression-free survival (PFS,partial response,response rate, PFS, survival, and toxicity profile,overall survival,thrombocytopenia and leukopenia,hematologic toxicity,lower risk of death,overall survival (OS), with response rate, progression-free survival (PFS), and quality of life (QOL,QOL assessment,PFS and survival,Renal, otic, and peripheral nervous system toxicities,percentage of planned dosages,duration of complete plus partial remission,response rates,pulmonary toxicity,pain scores,complete remission rates, response duration, progression-free interval, and survival times,Greater myelosuppression,Toxicity,leukopenia and thrombocytopenia,objective response (OR) rate, progression-free survival (PFS) and overall survival (OS,serum creatinine level,QOL scores,response rate,rate of failure,neurotoxicity,Median survival,diarrhea,Nausea and vomiting,initial performance score,OR rate,median survival,mild diarrhea,Median overall survival,Gastrointestinal toxicity,myelosuppression, nausea and vomiting, mucositis, rash, and hepatotoxicity,Survival,leukopenia,severe complaints of asthenia,myelosuppression and nephrotoxicity,Median PFS,median times to progression or death,frequency of severe toxicity,median progression-free interval,Overall (FACT-G) scores,nephrotoxicity, peripheral neuropathy, myelosuppression, and ototoxicity,nausea and vomiting,survival time,neurotoxicity subscale,overall response rate,QOL,complete remission rate, response duration, progression-free interval, or survival,Response rates,response and adverse effects,toxicity,complete remission rates,Hematologic toxicity,survival,myelosuppression,response rate of Adriamycin,gastrointestinal toxicity,episodic hypersensitivity,grade 3/4 toxicities were leukopenia, neutropenia, anemia, thrombocytopenia, and nausea and vomiting,Leukopenia, renal toxicity, peripheral neurotoxicity, and CNS toxicity,incidence of complete and partial remission,patients' quality of life (QOL,overall QOL scores,antitumor responses,anemia,response rates, survival, side effects and quality of life,response rate and PFS duration,median duration of response,unadjusted hazard ratio for overall survival,rate of QOL,overall QOL and pain,Quality of life (QOL) outcomes,Objective response rates,response and survival rates,overall survival (OS,Functional Assessment of Cancer Therapy-Cervix (FACT-Cx), Neurotoxicity Subscale (FACT/GOG-NTX subscale), and Brief Pain Inventory (BPI|The continuous infusion regimen was associated with a significantly greater percentage of patients who experienced no nausea and vomiting (34% versus 18%, P = 0.002).
62|Trichophyton violaceum,treatment efficacy,Complete cure,mycologic cure and either clinical cure,Microsporum audouinii,Trichophyton mentagrophytes,therapeutic efficacy,hair regrowth,absence of clinical signs, hair regrowth or negative mycology,efficacy and tolerability,clinical deterioration,time for complete scalp clearing,mycological cure,clinical cure,subcutaneous skin damage requiring plastic surgery,efficacy and safety,overall outcome or tolerability,Adverse reactions,hepatotoxicity or other adverse reactions,mean time to a sterile culture,vomiting,efficacy, cost, and compliance,rapid clearance of tinea capitis,Adverse effects,cure rate,complete cure,Microsporum canis,adverse effects,cure rates,side effects,Mycological cure|Complete cure was observed at the end of study in 62% patients treated with terbinafine for 6 weeks, in 60% treated for 8 weeks and in 84% patients treated with griseofulvin for 12 weeks.
                
not found|blood flow,cumulative survival rate,bleeding complications,cumulative limb salvage rate,duration of hospitalization,hospital cost,risk of amputation or death,frequency of in-hospital cardiopulmonary complications,intracranial hemorrhage,hospital mortality,incidence of in-hospital cardiopulmonary complications,complete dissolution of thrombus,dissolution of the occluding thrombus,Major hemorrhage,amputation-free survival rate,mean ankle-brachial blood-pressure index,Amputation-free survival rates,Partial lysis,patient survival rates,limb salvage and survival,TOPAS|Amputation-free survival rates in the urokinase group were 71.8 percent at six months and 65.0 percent at one year, as compared with respective rates of 74.8 percent and 69.9 percent in the surgery group; the 95 percent confidence intervals for the differences were -10.5 to 4.5 percentage points at six months (P=0.43) and -12.9 to 3.1 percentage points at one year (P=0.23).
40|condition improved subsequently relapsed,clinical score,swelling or burning sensation,erosion,patient's pain scores,Safety,sustained remission of EOLP,complete clinical remission,tolerated, and only transient burning sensations,partial improvement,Discomfort scores,mucosal erosions and pain sensation,ulcerative areas,ulceration (alpha = 0.068) and erythema,patient quality of life,severity score,visual analog scale (VAS) and clinical improvement including lesion type and size,Symptom-free state,surface area of oral lesions,blood cyclosporine levels,pain score (by linear visual analogue scale; 0-100); (ii) clinical score; (iii) clinical resolution; and (iv) patient compliance,size of the erosive/ulcerated area,complete pain remission,daily cost of ciclosporin,VAS scores, a partial to complete response,efficacy, ease of application, and adverse effects,severe adverse events,EOLP,partial response, no response and worsening of the symptoms,side-effects,clinical scoring and grid measurement of the target lesion (reticulation, erythema, ulceration,VAS scores,complete remission,mean score,Relapse,clinical response,psoriatic lesions,severity of pain and burning sensation using visual analog scales,visual analogue scale (VAS), the McGill pain score, the Oral Health Impact Profile (OHIP), and Oral Health Quality of Life (OHQoL) questionnaires,Symptomatology,systemic side effects,Hospital Anxiety-Depression (HAD) scale,visual analogue scale (VAS,painful symptoms,reticulation,blood concentrations of pimecrolimus,visual analog scale score,total quality of life score,clinical and subjective improvement,partial to complete clinical improvement,clinical response, pain, burning sensation, area of reticulation, erythema, and ulceration,acceptability and efficacy,clinical improvement,OELP lesion size,log diary recording oral function and soreness scores,serious side-effects,blood level of pimecrolimus,symptoms and side effects,signs and symptoms of OLP,Blood levels,soreness scores,clinical signs and occurrence of side effects,erosive and ulcerative lesions,recurrence rates,transient burning sensation,quality of life,erythema,patient documentation, measurement of pimecrolimus levels and blood counts,adverse effects,mean scores,daily cost of ciclosporin treatment,Mean lesion sizes and mean pain measures,Side effects,total surface area of the lesions, including all white, erythematous, and ulcerative lesions,clinical and symptomatological improvement of OLP,painful symptoms measured by visual analog scale, the Oral Health Impact Profile score, and objective clinical score,efficacy and safety,soreness relief following immediate application, oral function and size of erosive/ulcerative area,Burning pain,change in symptoms,efficacy, relative safety, and tolerability,good response,Pain severity, burning sensation, and mucosal lesion extension,symptom scores,Oral Health Impact Profile score,symptoms and extension of lesions; adverse effects,relation to pain,initial therapeutic response,clinical candidosis,psychological disability domain and total OHIP-49 score,good or partial response,pain,side effects,erosive areas and recorded visual analog scale (VAS) scores|There was no significant difference between changes from baseline median values of pimecrolimus and triamcinolone groups after treatment termination in terms of visual analog scale score (-9.8 +/-
not found|symptom scores of PFR measurement,steroid dosage, visual analogue symptom scores, response to beta 2 agonist and peak expiratory flow rate (PFR) measurement,asthma control|In this study an 8 week treatment with hydroxychloroquine was of no benefit to patients with chronic steroid dependent asthma.
140|neonatal necrotizing enterocolitis,necrotizing enterocolitis (NEC,incidence of NEC,longer duration of hospital stay,Necrotising enterocolitis,necrotising enterocolitis,protection against necrotising enterocolitis,mortality|Infants with necrotising enterocolitis were associated with a significant increase in mortality (p = 0.026) and longer duration of hospital stay (p = 0.002).
                
645|24-hour PLT count,bleeding events,Mean pretransfusion bleeding times,therapeutic efficacy and safety,prolonged bleeding times and transfusion intervals,time to next PLT transfusion,1- and 24-h count increment (CI), 24-h CCI, time to next PC transfusion, red blood cell (RBC) use, bleeding and adverse events,CCI(1hour,transfusion-associated bacteremia,Transfusion reactions,24-h CCI, bleeding, transfusion requirement of red cells and PC, platelet transfusion interval and adverse transfusion reactions,posttransfusion PLT count increments,1 h corrected count increment (CCI,risk of bleeding,blood product utilization,Platelet transfusion dose, pretransfusion storage duration, and patient size,proportion of patients with World Health Organization (WHO) grade 2 bleeding,Number, frequency, and dose of PLT transfusions; acute transfusion reactions; and adverse events,average number of days to next platelet transfusion,incidence of grade 2 bleeding,number of platelet transfusions,Clinical hemostasis,Clinical hemostasis, hemorrhagic adverse events, and overall adverse events,Therapeutic efficacy and safety,platelet efficacy,incidence of grade 3 or 4 bleeding,Overall median time to next transfusion,corrected count increment (CCI,PLT and red blood cell utilization,mean 1-hour posttransfusion PLT corrected count increments (CCIs,1-hour count increment, time to next transfusion, hemostasis, transfusion reactions, and serious adverse events,1-hour corrected count increment (CCI,mean 1-hour posttransfusion platelet corrected count increment (CCI) ,mean 1-hour posttransfusion template bleeding times,bleeding times,Median time,clinical refractoriness,posttransfusion platelet count increments and days to next transfusion,PLT count increments and CCIs,Hemostatic efficacy|Transfusion reactions were fewer following PCT platelets (3.0% PCT versus 4.4% control; P =.02).
4|Biometric and perioperative data, hemodynamics and oxygenation,severe sepsis,Systemic hemodynamics and oxygenation (PaO(2), PaCO(2,subcutaneous oxygen tension and collagen accumulation,urine and chest tube outputs,Pulmonary shunt fraction (Qsp/Qt,pulmonary capillary wedge pressure, and ventricular arrhythmias,Time to reach HDS,Body weight,Arm and thigh circumferences,volumes of crystalloids and blood required in their resuscitation,Total postoperative fluid support,postoperative plasma volume,higher mortality,bleeding time,pulmonary artery wedge pressure (WP) and the WP-COP gradient,cumulative fluid balance,hemodynamic efficacy and safety,mean (+/-SD) numbers of days spent in the ICU,cardiac index,Blood pressure response; survival,total blood volume index (TBVI), intrathoracic blood volume index (ITB-VI) and extravascular lung water index (EVLWI,adequate cardiac output,48-hour mortality; secondary end points included pulmonary edema, increased intracranial pressure, and mortality or neurologic sequelae at 4 weeks,Hemodynamic response,Likewise, chest tube drainage,Maximum aggregation, maximum gradient of aggregation, and platelet volume,COP limit the postoperative albumin consumption,Oxygen consumption and cardiac output,length of intensive care unit stay (ICU-LOS,POP fell,longest recovery times,baseline Glasgow Coma Scale scores,nausea and vomiting, use of rescue antiemetics, severe pain, periorbital edema, and double vision,Sequential Organ Failure Assessment score, mean arterial pressure, lactate, or central venous oxygen saturation,sublingual microcirculation,APACHE II score,quality of postoperative recovery,relative risk of requirement for rescue colloid,PaO₂/FiO₂:248.4 ± 17.0,lactate clearance rate,Blood pressure,sex, age, cause of hypovolemia, revised trauma score (RTS), Glasgow index, and mean arterial pressure (MAP) on admission,risk of death,splanchnic oxygenation,superior 28-day survival,Physical parameters and hemodynamic variables,proportion of patients with new single-organ and multiple-organ failure,Colloid osmotic pressure (COP,Total quantity,platelet aggregation,serum sodium,degree and duration of coagulation impairment,thrombin/antithrombin complex,Cardiac output, EVLW, PCWP, serum colloid osmotic pressure (COP), and intrapulmonary shunt fraction (Qs/Qt,Arterial Lac,Platelet function,28-day survival,systolic blood pressure ≤ 70 mm Hg or systolic blood pressure,total volume,blood loss and change in platelet aggregation.(ABSTRACT TRUNCATED AT 250 WORDS,levels of urea and creatinine,blood volume deficit,Baseline values for PV, ISFV, ECFV, and oxygen delivery index,lactate clearance rate,blood products [packed red blood cell volumes,survival rate,splanchnic blood flow and tissue oxygenation,ventilatory parameters, blood gases, pulmonary function tests, ventilator days, or hospital days,plasma lactate concentrations,Endovenous volumes,mortality, coagulation, or pruritus,accuracy of colloid oncotic pressure (COP,Hemodynamic parameters (heart rate, capillary filling time, pulse volume, and blood pressure,survival to hospital discharge,days of mechanical ventilation,Initial hemodynamic stabilization,cardiac index with increasing pulmonary capillary wedge pressure,death from any cause during the 28-day period after randomization,levels of plasma PAI,maximum sequential organ function scores,diuresis,plasma volume and global end-diastolic volume, confirming plasma volume and preload augmentation,Cardiac output and pulmonary wedge pressure,28-day survival-HSD,resolution of acidosis,Platelet volume,positive balance,circulatory variables, alveolo-arterial oxygen tension difference, incidence of wound infection or postoperative restoration of intestinal activity,transcapillary fluid flux,Qs/Qt and AaDO2,severe bleeding,extracellular fluid volume, total body water and interstitial fluid volume,Serum concentrations of sICAM-1,Neurologic sequelae,Overall complication rates,hypotension, tachycardia, and oliguria,mean arterial blood pressure (MAP), systolic and diastolic pressure, central venous pressure (CVP), and pulmonary artery occlusion pressure (PAOP,SBP,pulmonary edema or increased intracranial pressure,cardiorespiratory functions,hemodynamic response and lung water following thermal injury,Pulmonary arteriovenous admixture,colloid osmotic pressure,colloid osmotic pressure (COP,hemodynamic parameters,Release of pro-inflammatory cytokines IL-6 and IL-8,Mortality rates,cardiorespiratory recovery with shorter extubation time,intrapulmonary venous admixture and improved PaO2,stroke index,Urine flow rates,EVLWI, pulmonary shunt fraction, and time on mechanical ventilation,left ventricular preload and left ventricular ejection fraction,mechanical ventilation,Infusion rates and 8-hour intake,severe trauma with respect to resuscitation, fluid volume, gastrointestinal recovery, renal function, and blood product requirements,clinical severity,low baseline Glasgow Coma Scale scores,concentrations of molecular markers of activated coagulation and fibrinolysis,prothrombin time (PT), activated partial thromboplastin time (APTT) and levels of plasma tissue plasminogen activator (t-PA), and plasminogen activator inhibitor (PAI,tissue oxygen tension (ptiO(2,systemic vascular resistances,blood loss and coagulation,intrapulmonary venous admixture, arterial oxygen tension, or time on respirator,total protein,postoperative nausea and vomiting and improves postoperative outcomes,obligatory contraction or expansion of ECV,frequency of adult respiratory distress syndrome,next morning (AM1), COP,blood loss,Plasma volume expansion,renal function and lactate clearance,Postoperative values of albumin concentration, circulating albumin mass and pis,ICU and hospital LOS, and area under the curve of SOFA score,multiple organ dysfunction,Total intravascular albumin,survival rates,Qt,COP-PCWP,Sublingual microcirculation,CVP and PAOP,burden of MODS,plasma volume, serum oncotic pressure (pis), serum albumin and total protein concentration, alveolar to arterial oxygen tension differences (AaDO2, FIO2 = 1.0), creatinine clearance, body weight, and fluid and sodium intake,coagulation and fibrinolytic system,mortality rate,ejection fraction,death or end-stage kidney failure (dependence on dialysis,postoperative lung function and circulatory adaptation,POP and MPAOP,platelet function and hemostasis,requirement for rescue colloid,postoperative course,nausea and vomiting,Postbypass blood loss,concentrations of coagulation factor XIII,Haemodynamic parameters and pulmonary function,hydrostatic pressures,crossmatching of blood,Cardiac response,net lung capillary filtration pressure,cardiac index and myocardial contractility (ejection fraction and mean rate of internal fiber shortening, Vcf,Blood pressure, infused volumes necessary to maintain SBP, and overall survival rates,larger amounts of fluid,hemorrhagic shock,survival,Blood loss,Adverse events,pulmonary edema,adverse events,arterial lactate acid concentration,Serum albumin,Haemodynamic data,left ventricular end-diastolic area,Coagulation parameters (prothrombin time, partial thromboplastin time, fibrinogen, and factor VIII,extravascular lung water (EVLW,Biochemical variables and haemodynamics (transpulmonary thermodilution,safety measures,calculated plasma volume expansion,activated partial thromboplastin time postsurgery,hemodynamic effects,extravascular lung water and cardiac index,pulmonary vascular resistance index,Hemodynamic, pulmonary, and renal variables,requirement for rescue colloid at any time after administration of the study fluid,blood pressure, pH, and urine output,gain of body weight,Cardiac index,Values of sELAM-1,Interstitial fluid volume (ISFV,Stat-Crit accuracy,tissue plasminogen activator,alveolar-arterial oxygen partial pressure difference,COP,plasma volume and hemodynamic stability,ETVL,serum albumin, A/G ratio and colloid oncotic pressure,pulmonary capillary wedge pressure,Acute renal failure,48-hour mortality,cardiac filling pressures,change in AaDO2,plasmin/alpha 2-antiplasmin complex,mean (SD plasma volume (saline--53.4,serum colloid oncotic pressure,PV expansion,intestinal edema,Fluid balance,serum colloid osmotic pressure,HS-HES and HS,fluid retention,Survival to hospital discharge,estimated blood losses (EBL,plasminogen activator inhibitor-1,Plasma volume (PV), ECFV, cardiac index, and arterial oxygen content,number of blood transfusions,requirement of inotropes, incidence of organ dysfunction and case fatality rate,pulmonary extravascular thermal volume (ETVL,Survival,postoperative hemoglobin level,preload-recruitable cardiac and left ventricular stroke work indices,Fluid balance and pulmonary functions,severe hypovolemia,MAP, arterial Lac, lactate clearance rate and APACHEII score,4-week mortality,filling pressures of the heart with improved cardiac output,COP measure,blood pressure,Mortality,Fluid balance, total fluid infused, sodium balance, total sodium infused, COP, or COP-PCWP,plasma sodium,plasma colloid osmotic pressure,mean plasma oncotic pressure (POP,Perioperative blood loss and coagulation profiles,intraoperative urine volumes,Hemodynamic stabilization (heart rate, capillary refill time, systolic BP in normal range), plasma volume at the end of fluid resuscitation and incidence of organ dysfunction,hct using the Stat-Crit, Coulter, and centrifuge methods, and sodium (Na), potassium (K), chloride (Cl), white blood cell count, total protein (TP), and albumin,percentage reduction in base deficit at 8 h. Secondary end points included death, the requirement for rescue therapies, and neurological sequelae in survivors,Maximum platelet aggregation,Wedge pressure,perioperative weight gains,Serum colloid osmotic pressure (COP), CO, PCWP, the gradient between COP and PCWP (COP-PCWP), and intrapulmonary shunt (Qs/Qt,PaO2,ITBV,time to recovery of bowel function or mortality,oliguria during a course of therapy, weight gain, number of IL-2 doses, tachycardia, hypotension, vasopressor use, hospital stay, and clinical response rates,Mean arterial pressure (MAP), oxygenation index (PaO₂/FiO₂),arterial lactate (Lac),lactate clearance rate, acute physiology and chronic health evaluation II(APACHEII) score,fluid infusion volume, urine output as well as incidence of multiple organ dysfunction syndrome (MODS), and mortality,Pulmonary artery occlusion pressure,cardiac index, colloid osmotic pressure (COP), pulmonary capillary wedge pressure (PCWP), COP-PCWP gradient, right and left ventricular stroke work indices, and amount of constant positive airway pressure,left ventricular stroke work index and PWP,Cardiac output and pulmonary wedge pressure (PWP,serum albumin and plasma oncotic pressure,plasma volume (PV) loss,mean COP,haemodynamic or lung function variables,overall survival rate, hypertonic infusion,Operation time, estimated blood loss, and transfusions,time to initial recovery,ICU-LOS,platelet function,left ventricular stroke work index,maximum gradient of platelet aggregation,fluid for successful resuscitation,Mean arterial pressure (MAP,Creatinine clearance values,plasma oncotic pressure, renal function and peripheral oedema,tissue oxygenation,central pontine myelinolysis; bleeding,EVLW,POP, MPAOP, POP-MPAOP difference, total sodium intake or net supply of non-colloid fluids,factor XIII,Blood pressure (BP,fluid requirements, superior hemodynamic performance, and shortened intensive care stay,capillary microvascular flow index, percent of perfused capillaries, and perfused capillary density,Bleeding manifestations, coagulation derangements, and severity of fluid overload,Oxygen delivery index,systemic vascular resistance index,platelet activation, platelet aggregation,total number of saline and albumin fluid boluses,perioperative blood loss,hematocrit, hemoglobin, protein, albumin, blood urea nitrogen (BUN), and creatinine,risk of intra-abdominal hypertension,ratio between plasma volume (PV) and ECV,weight,prothrombin fragment F1 + 2,sodium balances,worst multiple organ dysfunction score (MODS), excluding the cardiovascular component, to Day 14,systolic blood pressures and cardiac outputs,Lung water,filling pressures of the heart and improved cardiac output,Sublingual capillary density,Cardiac index, central venous pressure, pulmonary capillary wedge pressure, systemic and pulmonary vascular resistance indices, arterial oxygen tension, plasma osmolarity, electrolytes, and urinary output,Significant diuresis,Malaria status,severity of shock and status with respect to malaria, coma, sepsis, acidosis, and severe anemia,Urine output and improvement of the Glasgow Coma Score,intrapulmonary shunt (Qs/Qt,Serum concentrations of interleukin (IL)-6, IL-8 and IL-10 and soluble adhesion molecules (sELAM-1 and sICAM-1,plasma colloid osmotic pressure (COP,total body blood flow,mean arterial pressure, central venous pressure, pulmonary capillary wedge pressure, and cardiac index,extravascular lung water (EVLW - double indicator dilution technique,hemodynamic stability,IAP,plasma sodium content and cardiac index,efficacy,renal injury,larger diuresis,blood transfusions,albumin,response profile,Overall survival,normal blood pressure and urine output,adverse reactions,renal function and morbidity,incidence of MODS,Pulmonary function,hemodynamic stability and fluid requirements,lactate clearance,inflammatory response,incidence of complications,Plasma creatinine, urea, electrolytes, urinary volume, and sodium excretion,Plasma volume,Cardiac output and Qs/Qt,Tissue oxygenation,gastric intramucosal PsCO(2) and arterial PaCO(2) (Ps-aCO(2) gap), gastric intramucosal pH (pHi) and arterial lactate acid concentration 30 min after induction of anesthesia (baseline value), 1 h and 2 h after skin incision, and at the end of surgery,negative fluid balance,ECFV,Haemodynamic stability,mortality,thrombotic risk,Colloid oncotic pressures, serum albumin and albumin/globulin (A/G) ratios,anaphylactoid reactions,thrombin/antithrombin III complex, prothrombin F1 +2 fragment) platelet activation (betaTG) and compromised coagulation,perioperative blood loss (sum of bleeding during the intraoperative and postoperative 24-h period), transfusion requirements, modified thromboelastography and coagulation variables, hemodynamic parameters, and fluid balance,urine output,renal and thromboembolic complications,urine flow rate,plasma sodium content,plasma colloid osmotic pressure (COPP,fluid balance, major organ complications, the Acute Physiology and Chronic Heath Evaluation II score, and the serum levels of C-reactive protein, interleukin-6, and interleukin-8,mean pulmonary arterial occlusion pressure (MPAOP,PscO2,systolic blood pressure,systolic pressure,fluid balance and cardiorespiratory functions,postoperative weight gain,frequency of adult respiratory distress syndrome (ARDS,PV and ECFV,Ejection fractions,predicted survival,maintenance of arterial blood pressure, heart rate, and urine output|Survival to hospital discharge in patients with baseline Glasgow Coma Scale scores of 8 or less was correlated with treatment group (P < .05 by logistic regression and P < .01 by Cox proportional-hazards analysis; with survival in the hypertonic saline solution group [34%] vs lactated Ringer's solution group [12%]).
                
not found|depressive psychopathology,Overall adherence,adherence and adherence levels,completion of 28 days of PEP,adherence|The intervention was associated with the reading of the pamphlet (p=0.07) and an increased use of the diary (p=0.01), but did not reduce depressive psychopathology.
55|incidence of later candidiasis,adverse response|No adverse response to ceftazidime was noted, and the incidence of later candidiasis was similar to that after other broad-spectrum antibiotic combinations.
not found|Clinical response,extrapyramidal symptoms,mean change in Simpson Angus Scale,Barnes Akathisia Scale,efficacy and tolerability|Olanzapine was superior to conventional neuroleptic haloperidol in treatment safety with lower frequency and severity of extrapyramidal symptoms.
not found|forced vital capacity and peak expiratory flow rates,Bronchial reactivity rose on slow sodium,postexercise pulmonary function values,bronchodilator consumption,Forced expiratory volume in 1 s (FEV1,mean forced expiratory volume,Exercise-induced asthma (EIA,Regressing PD10 against urinary excretion of electrolytes,PEF or PEF amplitude,deleterious alterations,Dietary salt, airway inflammation, and diffusion capacity,Spirometry and degree of bronchial responsiveness (methacholine challenge test,index of asthma lability,forced expiratory volume in 1 s (FEV1,postexercise pulmonary capillary blood volume,peak expiratory flow rate,symptom score,bronchial reactivity,morbidity,evening peak expiratory flow rate,peak expiratory flow (PEF,preexercise pulmonary function values,Sodium intake,Pulmonary function,bronchial reactivity and mortality,mean (SD) urine sodium,deterioration of post-exercise pulmonary function,forced vital capacity (FVC), forced expiratory flow rate at 25%-75% FVC and peak expiratory flow rate,pulmonary function,FEV1,diary cards to record twice daily peak expiratory flow rates, daily symptom scores, and bronchodilator consumption,PEF measurements,LSD improved and HSD worsened postexercise pulmonary function values,lung function,urinary sodium excretion,peak expiratory flow,FEV1 (PD20,peak flow rate,pre-exercise (baseline) pulmonary function,severity of bronchial asthma,Postexercise-induced sputum neutrophil and eosinophil differential cell counts and induced sputum supernatant concentration of eosinophil cationic protein, interleukin (IL)-1beta, IL-8, leukotriene (LT) C(4)-E(4), LTB(4), and prostaglandin D(2,Pre- and postexercise spirometry, pulmonary diffusion capacity (DLCO) and its subdivisions, and induced sputum|Median differences between treatments were 5.6% (2.2% to 9.8%) for morning and 7.8% (3.9% to 12.9%) for evening peak expiratory flow rate.
                
31||A blinded, randomized, placebo-controlled trial was conducted to evaluate the effectiveness of theophylline and doxapram therapy in 31 infants with significant apnea of prematurity.
133|peri-operative outcome index, delayed union, revision surgery and symptoms beyond 16 weeks,lower complication rate,rate of delayed union,mean shoulder score,smaller wound size,shorter operative time|The superior plate group had a higher rate of delayed union and had more symptomatic patients than the 3D group (p < 0.05).
not found|pain,sleep bruxism,wear facets,signs and symptoms of temporomandibular disorders,Sleep variables, bruxism-related motor activity, and subjective reports (pain, comfort, oral salivation, and quality of sleep,number of sleep bruxism episodes,number of bruxism episodes per hour of sleep (Epi/h), the number of bursts per hour (Bur/h), and the bruxism time index,efficacy and safety,muscle activity,number of SB episodes,prevalence of TMD,pantographic reproducibility index (PRI,sleep bruxism and tooth-grinding activity,sleep bruxism motor activity,signs and symptoms of TMD,SB outcome variables,nocturnal bite plate,Clicking and pain|A significant reduction in the number of sleep bruxism episodes per hour (decrease of 42%, P < .001) was observed with the MOS.
294|Thromboembolic complications,Recurrence or extension of DVT,mean phlebographic score,bleeding complications,Overall mortality,incidence of serious complications,incidence of pulmonary embolism and of bleeding complications,deep vein thrombosis,hospital stay,pulmonary embolism,rate of new pulmonary embolism,Major bleeding,symptomatic non-fatal pulmonary embolism and one major bleeding episode,Minor bleedings,hemorrhagic complications,thrombus size,therapeutic efficiency,fatal pulmonary embolism,non-fatal pulmonary emboli,efficacy and safety,rate of symptomatic pulmonary embolism,incidence of major bleeding,initial anticoagulant response,major bleeding,recurrent or extension of DVT, bleeding, the number of days spent in hospital, and costs of treatments,safety and efficacy,Hospital stay,Pain and edema,Average treatment costs,recurrent venous thromboembolism,Retroperitoneal or intramuscular bleedings,episodes of major bleeding,Maximal Venous Outflow (MVO,Bleedings,D-dimer,hemostatic system activation,thrombosis of deep veins of the lower extremities,MVO,recurrent thromboembolic events,therapeutic anticoagulant response,Recurrent venous thromboembolism,frequency of hemorrhagic complications,Clinical pulmonary embolism,complete lysis,pulmonary embolism (LH) and only 1 minor bleeding episode (UH,median improvement of MVO and VC|Hospital stay in patients treated with LMWH was 1.2+/-1.4 days in comparison with 5.4+/-1.2 in those treated with standard heparin.
not found|Clinical Global Impression (CGI) and the Hamilton depression scale measured recovery,maternal mood and mother-infant interaction,Rates of depression,Edinburgh Postnatal Depression Scale, the Beck Depression Inventory, and the Hamilton Depression Rating Scale|The interpersonal psychotherapy treatment group showed significant improvement compared to the parenting education control program on all three measures of mood at termination.
82|Preoperative urinary RBP,myocardial injury,Serum and urinary markers of renal and cardiac injury,saccadic latency deteriorations,Urinary retinol binding protein (RBP) levels,Myocardial injury,incidence of myocardial and renal injury,renal impairment,incidence of myocardial injury,rates of renal impairment or major adverse cardiac events,Urinary retinol binding protein (RBP) and albumin-creatinine ratio (ACR,postoperative myocardial injury, myocardial infarction, and renal impairment,urinary biomarkers of renal injury,protective effect of RIPC on myocardial injury,cardiac troponin,saccadic latency deterioration,median urinary RBP,renal damage,median urinary albumin:creatinine ratio,serum troponin,myocardial infarction,median urinary RBP level,renal outcome indices,renal injury|In patients undergoing elective open abdominal aortic aneurysm repair, RIPC reduces the incidence of postoperative myocardial injury, myocardial infarction, and renal impairment.
68|Global VAS pain scores,Pain scores,pain medication,quality of postoperative analgesia,Visual analogue pain scores,pain level, amount of oral intake, or pain on full jaw opening,pain scores (VAS,pain level; (2) oral intake; (3) number of pain medication doses; and (4) level of pain on jaw opening,postoperative pain,Pain relief,postoperative analgesic consumption,Supplementary analgesic consumption,adverse effects,Cumulative acetylsalicylic acid requirements,analgesia,visual analogue scale (VAS,postoperative pain relief,pain,pain scores|Global VAS pain scores were lower in the groups treated with bupivacaine infiltration during the first 24 h after surgery (P < 0.05).
not found|number of high-risk|The option of telephone notification significantly increased the proportion of youth who received posttest counseling and results following community-based testing.
not found||The natural discharge pattern of a fatigue-resistant motor unit (eutrophic electrotherapy) was more effective than a uniform 10 Hz electrotherapy.
141|rate of fungal infection,Candida albicans, maximum recorded plasma D0870 concentration, cfu of culture or CD4 cell count,relapses of oropharyngeal candidiasis,episodes of orophayngeal candidiasis (OPC) or esophageal candidiasis (EC,rates of clearing of infection,efficacy, safety, and tolerability,CDC classification, CD4+ cell counts, and number of previous episodes of oropharyngeal or esophageal candidiasis,percentage of patients with negative cultures,esophageal lesions,safety and effectiveness,CD4 count,episodes of Candida esophagitis,complete response (clearance of all symptoms and signs) or marked improvement,microbiological resistance,mycological success,Oral candidiasis score,delaying onset of oral candidiasis,fungal colonization,episode of candidiasis,vaginal candidiasis,time to development of fluconazole-refractory OPC or EC,Microbiological resistance,Efficacy, tolerability and development of resistance,efficacy and tolerance,clinical response rates,maintenance of oral candidiasis-free period,history of oral candidiasis,Candida albicans carriage,Durability of clinical success,delayed time to onset of histoplasmosis,Clinical cure,time to recurrence of oral candidiasis,relapses and colonization,fluconazole-refractory OPC or EC infections,frequent relapses of oral candidiasis,Mild adverse events,safe and effective in preventing oropharyngeal and vaginal candidiasis,Drug tolerability,histoplasmosis and cryptococcosis,alcohol consumption,liver enzyme values,resistance,recurrence of oropharyngeal candidiasis,oropharyngeal and esophageal candidiasis,Resistance,Failure of prophylaxis,relapse,esophageal candidiasis,Serum amphotericin concentrations,safety and efficacy,severe chills,clinical response,Prophylaxis failure due to recurrent or refractory mucosal candidiasis,likely to remain asymptomatic,time to development of a fluconazole-refractory infection,median time to relapse,efficacy and toxicity,frequency of episodes of oral candidiasis,Clinical and renal toxicity,treatment creatine concentration,Clinical side effects,soreness, change in taste, erythema, removable white plaque, and extent of lesions,efficacy,Clinical success,oropharyngeal candidiasis,rates of colonization,total lymphocyte,clinical cure, colonization at the end of treatment, relapse at day 28, and relapse,Dermatophytosis and onychomycosis and cryptococcuria,time to oral candidiasis, as determined by potassium hydroxide (KOH) smear and fungal culture,seven with oesophageal candidiasis,tolerance, efficacy, and pharmacokinetics,clinical efficacy and tolerability,survival benefit,resolution of clinical lesions of oral candidiasis,clinical relapse,rate of relapse,Magnesium concentration,Negative culture plus clinical response,candidiasis on gingiva,oropharyngeal and/or esophageal candidiasis, and the rate of post-treatment relapse,lower response rate,tolerated,occurrence of oral candidiasis,transient rises in alanine or aspartate aminotransferase,Clinical tolerance (fever, chills, sweats, nausea, arterial pressure, and pulse rate); biological tolerance (serum creatinine, electrolyte, and magnesium values); clinical score of candidiasis; and serum concentrations of amphotericin,Safety and efficacy,eradication rate with nystatin,elevated serum glutamic-oxaloacetic transaminase levels,oral candidiasis,clinical response rate,higher clinical and mycological cure rates,survival,Severity of disease,Clinical failure,clinical success (cure or improvement,oropharyngeal candidiasis relapses,microscopy, time to cure, symptom scores, and safety outcomes,relapse-free,Efficacy,clinical cure,Mean rates of infection relapse,efficacy and safety,toxicity (rash,Oropharyngeal candidiasis,Adverse events,invasive fungal infections,gastrointestinal disorders and drug-related adverse events,Oropharyngeal infection,nausea, two hepatotoxicity and one rash,initial outbreak or recurrence of oral candidiasis,OPC or EC,severe nausea,oropharyngeal candidiasis (erythema, soreness/burning), extent of oral lesions, and the presence/absence of Candida species on fungal culture,bioavailability of itraconazole,Absolute risk reduction,median annual relapse rates,dysphagia,proportion of resistant isolates,side effects (diarrhea and abdominal pain,35 episodes of thrush, one of esophagitis, one of cryptococcemia, and one of dermatophytosis, and preexisting dermatophytosis and onychomycosis,clinical relapse of oropharyngeal candidiasis,time of recurrence; frequency of antifungal therapy|Patients enrolled in this study had a very high mortality (probability of death: 41.6% after 14 days).
645|rates of locoregional relapse (vaginal or pelvic recurrence, or both,vaginal recurrences,toxicity, date and location of recurrence, and overall survival,Dysuria, frequency, and incontinence,disease-free survival,2-year survival after vaginal recurrence,risk of recurrence and death,isolated pelvic recurrence,estimated 4-year survival,5-year survival rate,rate of vaginal recurrences,Late intestinal problems,vaginal recurrence,locoregional control and survival,distant metastases,Estimated 5-year rates of vaginal recurrence,overall survival,deaths and recurrences,locoregional recurrence and death, with treatment-related morbidity and survival after relapse,vaginal and pelvic recurrences,gastrointestinal toxic effects,quality of life,Survival after relapse,overall recurrence rate and survival,Grade 3-4 complications,5-year,pelvic and vaginal recurrences,locoregional recurrence rate,Actuarial 5-year overall survival rates,Endometrial-cancer-related death rates,5-year actuarial locoregional recurrence rates,Treatment-related complications,median duration,Rates of acute grade 1-2 gastrointestinal toxicity,locoregional recurrence,Side effects,rates of distant metastases,2-year cumulative incidence of recurrence (CIR|The rate of vaginal recurrences was 1.2% in the treatment group versus 3.1% in the control group.
160|Neonatal morbidity,mean birth weights, perinatal death rates, neonatal infections, or incidences of respiratory distress,Antepartum hospitalization,chorioamnionitis and fetal heart rate abnormalities,overall corrected perinatal survival,incidence of maternal and neonatal complications,endometritis rate,incidence of respiratory distress syndrome,ultrasonographically estimated fetal weight,hospitalization,risk of maternal infections,Maternal outcome, including chorioamnionitis and cesarean section rates,prolonged latencies to labor, delivery, and maternal hospitalization,frequency of prolonged hospital stay,Chorioamnionitis,incidence of chorioamnionitis and antepartum hospitalization,prolonged antimicrobial therapy,pregnancy outcome (ie, birth weight, intraventricular hemorrhage, necrotizing enterocolitis, sepsis, respiratory distress syndrome, and perinatal death,postpartum febrile morbidity,proven sepsis,mean gestational ages at delivery,maternal hospital stay,duration of hospitalization and infection,hospitalization, assessment for fetal heart rate abnormalities, chorioamnionitis, and labor,Neonatal sepsis,maternal age, gestation at PROM, maximum maternal temperature, birth weights, maternal hospital days, respiratory distress, maternal sepsis, or delivery routes|Neonatal outcome did not differ in mean birth weights, perinatal death rates, neonatal infections, or incidences of respiratory distress.
not found|episodic memory, perceived burden or depressive symptoms,recall and recognition of test material,negative coping strategies,goal performance and satisfaction, assessed using the Canadian Occupational Performance Measure,specific cognitive and functional tasks,Cognitive rehabilitation,improvement over time in cognitive outcomes,completed activities of daily living (ADLs) and everyday memory questionnaires,cognitive and behavioral performance,Gains in recall of face-name associations, orientation, cognitive processing speed, and specific functional tasks,brain function,hostility,recall of personal information, face-name recall, and performance on the Verbal Series Attention Test,memory, verbal fluency, and problem-solving ability, and caregivers were assessed on marital interaction, emotional status, and physical health, along with stress, coping, and social support,face-name association tasks, object recall training, functional tasks (e.g., making change, paying bills), orientation to time and place, visuo-motor speed of processing, and the use of a memory notebook,Questionnaires assessing mood, quality of life and career strain, and a brief neuropsychological test battery,depressive symptoms,Cognitive, behavioural and functional assessment,episodic memory performance,memory and functional performance,cognitive and behavioral functioning,ratings of goal performance and satisfaction,regional cerebral metabolic rate for glucose using positron emission tomography and 18F-2-fluoro-2-deoxy-D-glucose,additional neuropsychologic measures of dementia severity, verbal memory, visual memory, word generation, or motor speed, or to caregiver-assessed patient quality of life,Behavioral changes|The results showed that following collaborative intervention recall performance in two collaborative tasks became more equally shared between the spouses, reflected in a decrease in recall for the caregiver and in an increase in recall for the spouse with dementia between pre- and post-test; whereas for the other two groups the caregivers dominated collaborative recall both at pre- and post-test.
not found|cognitive functions of visual sustained attention and visual and movement skills,Positive and Negative Symptom Scale ratings,efficacy and safety,tolerated without any serious adverse effects,sustained attention and visual and movement skills,clinical symptoms, side effects, and quality-of-life scores|Compared with placebo, DHEA administration did not produce significant improvement in clinical symptoms, side effects, and quality-of-life scores.
40|FAC,Muscle tone,Fugl-Meyer motor assessment (FMA,power of hand flexion, wrist flexion, and wrist extension,Brunnstrom stages of motor recovery, spasticity assessed by the Modified Ashworth Scale (MAS), walking ability (Functional Ambulation Categories [FAC]), and motor functioning (motor items of the FIM instrument,FIM motor score,Muscle tone, Fugl-Meyer assessment, and power of wrist and hand,motor function as assessed by the Wolf Motor Function Test and Motor Activity Log.
                ,Brunnstrom stages of motor recovery, spasticity assessed by the Modified Ashworth Scale (MAS), and hand-related functioning (self-care items of the FIM instrument,scores of the Brunnstrom stages for the hand and upper extremity and the FIM self-care score,activation balance,sensory and attentional deficits,Fugl-Meyer scores of hand, wrist, coordination and power of hand extension,visual analogue scale score of pain at rest, on movement, and brush-induced tactile allodynia,FMA,Motor recovery and cortical reorganization,motor recovery,recovery of surface sensibility,grip force, spasticity, pain, dexterity, hand-use in daily life, and quality of life,pain and enhances upper limb motor function,distal function,blinded rating on the Action Research Arm test,neural activation patterns,Fugl-Meyer assessment score in the wrist, hand and coordination, as well as power of wrist|Mirror therapy combined with a conventional stroke rehabilitation program enhances lower-extremity motor recovery and motor functioning in subacute stroke patients.
63|clinical pyelonephritis,Recurrent infection,rate of persistent infection,radiological evidence of new scars of pyelonephritis,children renal growth|Recurrent infection in the treated group was common and was not significantly different from the rate of persistent infection in the untreated control group.
888|nausea,mean tender point pain threshold, number of tender points, FIQ fatigue, tiredness on awakening, and stiffness scores, Clinical Global Impression of Severity (CGI-Severity) scale, Patient Global Impression of Improvement (PGI-Improvement) scale, Brief Pain Inventory (short form), Medical Outcomes Study Short Form 36, Quality of Life in Depression Scale, and Sheehan Disability Scale,pain (realtime, daily and weekly recall,PGI-Improvement,Brief Pain Inventory (BPI) average pain severity score and Patient Global Impressions of Improvement (PGI-I) score,adverse events, and changes in vital sign, laboratory, and ECG measures,FIQ pain score,pain score and a rating of "very much improved" or "much improved" on the Patient's Global Impression of Change (PGIC) scale,Brief Pain Inventory average interference from pain score,FIQ total score,nausea and headache,Multiple Ability Self-Report Questionnaire,physical function (SF-36 physical functioning domain-100,fibromyalgia (FM) symptoms assessed by the Patient Global Impression of Improvement (PGI-I) scale,efficacy and tolerability,fatigue (Multidimensional Fatigue Inventory,headache,safe and efficacious,Safety,overall improvement,constipation,Multidimensional Fatigue Inventory,mood, stiffness, fatigue and functioning,efficacy and safety,Fibromyalgia Impact Questionnaire (FIQ,fatigue,FM composite responders,Adverse events,Fibromyalgia Impact Questionnaire pain score, BPI least pain score and average interference score, Clinical Global Impressions of Severity scale, area under the curve of pain relief, Multidimensional Fatigue Inventory mental fatigue dimension, Beck Depression Inventory-II total score, and 36-item Short Form Health Survey mental component summary and mental health score,several quality-of-life measures,physical function on the Short Form 36 (SF-36) physical component summary (PCS) score,SF-36 Mental Component Summary,PGIC,Brief Pain Inventory average pain severity score,adverse events,safe and well tolerated,CGI-Severity,number of tender points,pain and other symptoms,Fibromyalgia Impact Questionnaire (FIQ) total score (score range 0-80, with 0 indicating no impact) and FIQ pain score,fibromyalgia symptoms and pain severity,tolerated,Efficacy and safety,visual analog scale, 24-hour morning recall) and a rating of "very much" or "much" improved on the Patient Global Impression of Change scale,effective and safe,Brief Pain Inventory (BPI) average pain severity,mean tender point pain threshold,vital signs, laboratory measures, or ECG measures,Significant pain reductions,Short-Form 36 Health Survey (SF-36) Physical Component Summary,pain severity,pain, global status, fatigue, and physical and mental function,global status,Multidimensional Fatigue Inventory total score,FM pain composite responders,BPI average pain severity, mood (including BDI total), anxiety (patient-rated only), stiffness, CGI-S, fatigue, all SF-36 domains (except role-physical and physical component summary), and being less bothered by pain or sleep difficulties,Patient Global Impression of Change [PGIC] scale); and physical function (a > or = 6-point improvement on the 36-item Short-Form Health Survey [SF-36] Physical Component Summary score,24-hour and weekly recall pain score, PGIC score, SF-36 PCS and mental component summary scores, average pain severity score on the Brief Pain Inventory, Fibromyalgia Impact Questionnaire total score,Nausea,FIQ stiffness score,Overall discontinuation rates,nausea, headache, constipation, dry mouth, dizziness, diarrhea, and hyperhidrosis,global improvement with mean PGI-I scores,rates of FM composite responders and FM pain composite responders,BPI score,pain (visual analog scale 24-h morning recall), patient global impression of change (PGIC), and physical functioning (SF-36 Physical Component Summary,pain intensity,safe and well tolerated; nausea, hyperhidrosis, and headache,pain,BPI average pain severity, patient-rated scales assessing mood, anxiety, pain, sleep, and stiffness, Clinical Global Impression of Severity (CGI-S), Multidimensional Fatigue Inventory, Cognitive and Physical Functioning Questionnaire, Beck Depression Inventory (BDI), Beck Anxiety Inventory, and Medical Outcome Study Short-Form Health Survey (SF-36,pain reduction,remaining Brief Pain Inventory pain severity and interference scores, Fibromyalgia Impact Questionnaire, Clinical Global Impression of Severity, Patient Global Impression of Improvement, and several quality-of-life measures|Milnacipran was safe and well tolerated by the majority of patients during 27 weeks of treatment; nausea and headache were the most common adverse events.
                
not found|physiologic indicators of gastric, cardiac, or pulmonary functions occurred,global evaluation scores,total seizure frequency,efficacy and safety,seizure counts and safety,voice alteration and dyspnea|No changes in physiologic indicators of gastric, cardiac, or pulmonary functions occurred.
                
not found|pain, mobility, and functional ability,subjective pain relief and appreciation of improvement of mobility,pain, joint noise, jaw mobility, and dietary alterations,pain and function,functional result and in pain control,maximum incisal opening and pain scores; the overall success rate,arthroscopic lysis and lavage (ALL,pain relief,interincisal opening, lateral excursions, occlusal evaluation, deviation on opening, and tenderness to palpation,joint tenderness,function and diminishing pain,pain control,pain and improved mandibular function,maximum interincisal opening and protrusion, recording of clicking and crepitation, and palpation for tenderness of the TMJ and jaw muscles,visual analog scale (VAS) for pain and a mandibular functional impairment questionnaire (MFIQ,muscle tenderness and pain,Craniomandibular Index (CMI) and Symptom Severity Index (SSI) for jaw function and TMJ pain respectively,Therapeutic success,visual analog scale for pain and a questionnaire concerning mandibular functional impairment,severity of pain,Joint tenderness and pain on lateral palpation,MFIQ, VAS, maximum opening and protrusion, lateral joint tenderness, muscle tenderness, crepitation, and clicking,mobility,pain|Both groups had significantly less pain in the joint and better jaw opening one year postoperatively.
30|seriously ill or depressed, and average coping and quality of life scores,HIV-1 RNA level,safety and effectiveness,toxicities,dropout rate,mean reduction from baseline stool weight,therapeutic failures,efficacy and safety,mild adverse events (AE,Symptoms, HIV disease progression, HIV-1 RNA plasma viral loads, CD4 and CD8 cell counts, and scores on standard questionnaires for quality of life, depression, anxiety, and coping,pain intensity, pain relief, sensory perception, quality of life, mood, and function,median HIV-1 plasma viral loads,safety and efficacy,current pain scores,life satisfaction and symptoms,safe and well tolerated,quality of life, clinical manifestations, plasma virus loads, or CD4 cell counts,rate of disease progression,changes in life satisfaction, perceived health, and number and severity of symptoms,viral load,life satisfaction or symptoms,Efficacy and safety,Life satisfaction,Stool frequency and weights,serious adverse events or laboratory abnormalities,severe side-effects,Number of symptoms,plasma viral loads, CD4 cell counts, symptoms, and psychometric parameters,stool weight,median CD4 cell counts,current pain, worst pain, pain relief, sensory perception, quality of life, mood, or function at study entry or at any time,gastrointestinal disturbances,adherence, and changes in weight, CD4+ count, depression, anxiety, physical and social function, and mental health,abnormal stool frequency of three abnormal stools,relieving pain,stool weight and frequency,abnormal stool frequency,CD4 cell count|Number of symptoms was reduced in subjects receiving herbs (-2.2, 95% CI -4.1, -0.3) but not in those receiving placebo (-0.3, 95% CI -3.2, +2.7).
4|target behavior,reading condition (B) and the singing condition (C,mean frequency of the target behavior|The singing condition was significantly more effective than the reading condition only in Case Study III.
58|excessive number of groin relapses,survival,Metastatic involvement of the groin nodes,groin relapses,progression-free interval|The groin dissection regimen had significantly better progression-free interval (p = 0.03) and survival (p = 0.04).
                
32|clinical score,discomfort,Mean disease activity index,distal ulcerative colitis, proctosigmoiditis, and proctitis,distal ulcerative colitis,Clinical remission rates,BDP and 5-ASA,efficacy, tolerance, and acceptance,sigmoidoscopic and histological remission rates,endoscopy and histopathology scores,complete clinical remission,frequency of patients with an endoscopic remission,Haematology, chemistry and adverse events,physician-rated Disease Activity Index (DAI), which included symptom evaluations and sigmoidoscopic findings, by physician-rated Clinical Global Improvement (CGI) scores, and by Patient Global Improvement (PGI) scores,treatment tolerability and acceptability,Symptoms,disease activity index scores,mean disease activity index score,Disease Activity Index value,Histological remission,disease status,tolerability and practicality,difficulty in retention,Remission rates,complete relief of symptoms, and endoscopic and histological evidence of remission or improvement,A disease activity index (DAI,clinical activity,endoscopic and histologic remissions,time of initial presentation, symptom resolution, and endoscopic and histologic improvement,remission rates,Clinical improvement, remission and relapse,mesalazine enema (Disease Activity Index,Distal ulcerative colitis,Very Much Improved" or "Much Improved,recording of adverse events, laboratory variables and vital signs,Compliance,absorbed radioactivity,Improvement or remission,adverse event reports, clinical laboratory tests, and physical examination,Efficacy and tolerability,liquid stools,endoscopic and histological evaluation of colonic mucosa,adrenal function, monitoring of adverse events, vital signs, and laboratory parameters,amount of blood in stools, urgency, straining at stools, and abdominal pain in daily diaries,clinical and endoscopic activity,abdominal bloating,side effects,efficacy,efficacy, safety and patient tolerability,practicality and patient compliance,Remission,absence of blood in stools,clinical remission,Clinical remission,Clinical Activity Index, Endoscopic Index, Histological Index, and global efficacy assessment,disease activity index, which represents a score with four variables: stools frequency, rectal bleeding, mucosal appearance, and physician's assessment of disease severity,Endoscopic remission,efficacy and tolerability,histologic remission,Adverse events, primarily headache and nausea,total DAI scores,Mean DAI scores,Histological Index,clinical remission; endoscopic remission, histological changes, global assessment and standard safety measures,laboratory variables and vital signs,Histologic activity,tolerated,Disease Activity Index (DAI,tolerated and produced earlier and more complete relief of rectal bleeding,quicker clinical and sigmoidoscopic remission,Safety and efficacy,efficacy, tolerability and overall acceptability,Disease activity,determination of clinical, endoscopic, and histologic remission rates,Side effects,clinical remission (clinical activity index,CGI scores,Complete mucosal healing,rate of histologic remission,clinical and endoscopic remission,sigmoidoscopic and improved histological score,Total DAI scores and abbreviated DAI scores,active ulcerative proctitis,efficacy, tolerance and acceptance,Median DAIs,clinical and sigmoidoscopic remission,Efficacy,efficacy and safety,acute response and safety profile,morning cortisol levels,severe discomfort, pain and retention problems,Recovery,rectal bleeding,Endoscopic remission rates,DAI score,tolerability and safety,safety profile,adverse events,symptoms (number of bowel movements per day, quality of stools, presence of blood and mucus, and state of well-being,daily evacuations more than usual, evacuations containing blood, sigmoidoscopy appearance, and physician's overall assessment,tolerability and efficacy,Clinical symptoms, endoscopic and histological findings,Disease Activity Index,Endoscopic, clinical, and histologic improvement,anal burning,sigmoidoscopic remission,Disease Activity Index (DAI) score,median duration of response to alicaforsen enema treatment,PGI ratings,clinical remission rate|At the end of the study 5-ASA suppositories showed significantly better results in all the parameters recorded than placebo (p less than 0.01).
45|effectiveness and cost-effectiveness,disability,pain (visual analogue scale,duration of pain relief,low back pain (visual analogue scale,median duration of pain,immediate lessening of pain,cost-effectiveness ratio for pain, disability, and quality of life,clinical effectiveness and cost-effectiveness,median intensity of pain,duration of sick leave,pain, muscular contracture and mobility,pain relief|Moreover, neuroreflexotherapy intervention was associated with a significantly (P < 0.035) lower number of consultations to private or public specialists, fewer indications of radiographs by primary care physicians, lower cost of drug treatment, and less duration of sick leave throughout the follow-up period.
56|hospital anxiety and depression scale,Barthel index, the Functional Independence Measure (FIM), and the Newcastle Independence Assessment Form (NIAF,maximum FIM total score,indices of socializing, productive employment, anxiety, or depression,functional independence measure and the functional assessment measure (FIM+FAM,index of activities of daily living,average length of stay,level of depression, self-esteem, and socialization,levels of distress,Barthel index (BI) and the brain injury community rehabilitation outcome-39 (BICRO-39)) focused on levels of activity and participation,socialization and self-esteem,BI and the BICRO-39 total score and self organisation and psychological wellbeing subscales,Functional Independence Measure (FIM) (primary outcome) and Neurobehavioural Cognitive Status Examination (NCSE) total scores,elicit ratings of post-concussion symptoms (the Rivermead postconcussion symptoms questionnaire), and changes in work, relationships, leisure, social, and domestic activities (the Rivermead head injury follow up questionnaire,difficulties with everyday activities,social disability,longer hospital stay,motor, functional, and cognitive outcomes,Median changes on individual subscales,injury severity and shorter hospital stay,activity level,greater return-to-duty rate,rate of PCS and in life satisfaction,activity, assessed with the Assessment of Motor and Process Skill,Spasticity,General Health Questionnaire,Rivermead head injury follow up questionnaire, a validated and reliable measure of social disability,cognitive, behavioral, or quality-of-life measures,Defense and Veterans Head Injury Program (DVHIP,Spasticity changes,Ashworth Scale, motor status with Brunnstrom's stages, functional status with the FIM instrument, and cognitive status with the Mini-Mental State Examination,social morbidity and severity of post-concussion symptoms,Functional Independence Measure (FIM), Brunnstrom stages of motor recovery, timed mobility tasks, and the Jebson hand evaluation,shorter length of hospital stay,length of stay,emotional distress and how well-informed they felt about TBI and available resources,severe post-concussion symptoms,maximum Glasgow Outcome Scale (GOS) score|The different intensities of therapy employed in this study showed no evidence of a 'ceiling' effect and the 'intervention group' made significantly more rapid progress on tests of dependency during the period of admission.
53|fasting blood glucose levels,Body weight, fasting blood glucose (GP) (BFG), serum immunoreactive insulin (IRI), serum growth hormone (GH) and serum glycosylated proteins,mean insulin sensitivity index [ISI (composite,total cholesterol, HDL-cholesterol, and VLDL-cholesterol,HDL fractions,Coagulation factor VII and fibrinogen,systolic and diastolic blood pressure or blood glucose levels,Factor X. Mean blood pressure fell,Triglycerides,Hemostatic activity,glucose tolerance,change in glucose,enzyme serum levels,mean body weight,plasma cholesterol, lipoproteins including HDL subfractions, triglycerides or glucose concentration,carbohydrate metabolism, adrenal or thyroid function,CRP,SI and glucose utilization independent of insulin (Sg,metabolic and haemostatic effects,Lipid and biochemical changes,Fasting blood glucose,cholesterol and LDL-cholesterol,percentages of normal menstrual cycles and the percentages of cycles with intermenstrual and withdrawal bleeding,carbohydrate metabolism and its hormonal profile,Serum cholesterol levels,total, high-density lipoprotein (HDL) and low-density lipoprotein cholesterol and triglycerides,body weight, dietary habits, blood pressure, HDL-cholesterol or carbohydrate metabolism,mild insulin resistance,metabolic effects,adverse metabolic effects,Blood glucose and pyruvate, plasma insulin, and glucagon levels as well as erythrocyte insulin receptors,total insulin area,insulin sensitivity (SI,apolipoprotein B levels,lipids, hemostatic parameters and carbohydrate metabolism,SHBG,tolerated and equally efficacious regarding contraception and cycle control,Oral glucose tolerance test (OGTT,insulin sensitivity index (IS(OGTT,VLDL-C and triglycerides,Body weight and blood pressure,risk of diabetes or cardiovascular disease,cholesterol concentration,withdrawal bleeding episode,fasting glycosylated hemoglobin,carbohydrate and lipid metabolism,triglycerides,Mean ± SD HDL cholesterol,fasting serum glucose; insulin; triglycerides and total, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol,SI modifications,antithrombin III levels,carbohydrate metabolism and liver function,glucose metabolism and liver function,BFG,Mean ± SD prothrombin fragment 1 + 2 and D-dimer levels,change from baseline to cycle 6 for all indices,free thyroxine levels,SBP and CBG,rise in bilirubin,alkaline phosphatase,triglycerides, HDL-cholesterol and apoprotein A1,Levels of fibrinogen, plasminogen, Factor VII, Factor X and antithrombin III,SI decreased during OCs,haemostasis, lipids, carbohydrate metabolism, C-reactive protein (CRP) and sex hormone-binding globulin (SHBG,serum resistin level,blood glucose and C-peptide levels,metabolism and coagulation proteins,Concentrations of cortisol binding globulin and total cortisol,euglycemic glucose clamp test; lipid metabolism,LNG-OC decreased HDL(2)-C and increased HDL(3)-C; HDL-C,Hemostatic and metabolic effects,response of C-peptide to glucose,mean AUCs,coagulatory activity,metabolic and haemostatic parameters,circulating levels of resistin,Pancreatic beta-cell function,renin substrate and hemostatic parameters,mean glucose, insulin and log homeostatic model assessment,total, HDL and LDL cholesterol and SGOT,Blood glucose, serum insulin, serum growth hormone and serum glycosylated proteins,Sex hormone binding globulin,LDL-cholesterol,glucose and insulin parameters,fasting insulin and fasting C-peptide levels,carbohydrate metabolism (glucose, insulin, glycosylated hemoglobin); adrenal function (total cortisol, cortisol binding globulin, dehydroepiandrosterone sulfate); thyroid function (thyroid stimulating hormone, free thyroxine,Fasting glucose levels,carbohydrate metabolism and adrenal and thyroid function,glucose tolerance and insulin secretion,area under the curve for both glucose and insulin,A(1)C levels,mean levels of HbA1c and fasting glucose levels,serum resistin and insulin levels,serum triglycerides,fibrinolytic activity,carbohydrate metabolism,LNG/EE high-density lipoprotein cholesterol decreased and low-density lipoprotein cholesterol and triglycerides,carbohydrate metabolism, adrenal and thyroid function,HDL-cholesterol changes,fasting samples and plasma samples,Total cholesterol and HDL cholesterol,Glucose tolerance and insulin secretion,2-hour blood glucose and pyruvate, serum insulin, growth hormone and glucagon,glucose or insulin levels,mean levels of fasting glucose and insulin,Free fatty acid levels,fasting glucose and insulin levels,efficacy and tolerability,insulin response,oral glucose load (2-hours) levels of serum insulin, growth hormone, glucagon, cortisol and blood pyruvate,insulin secretion,LDL-C,hemostatic balance, lipid metabolism and glucose tolerance,fasting glucose and insulin levels and in glucose rate of disappearance,glucose tolerance and insulin resistance,atherogenic index, LDL/HDL cholesterol,fasting plasma glucose values,high-density lipoprotein (HDL)- and low-density lipoprotein (LDL)-cholesterol levels,blood pressure,lipid markers,SI,Insulin sensitivity and lipid metabolism,incidence of adverse events,mean insulin levels,Serum resistin levels,tolerated,mean plasma glucose levels,total cholesterol,LDL cholesterol,lipid, hemostatic or carbohydrate parameters,hemostatic balance, blood lipid levels and carbohydrate metabolism,mean blood glucose and pyruvate and in mean serum insulin, growth hormone and glucagon,procoagulant and profibrinolytic parameters,glucose and increased insulin responses,mean intraindividual relative changes from baseline to cycle 7 in high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol levels,lipid parameters, haemostatic parameters, sex hormone-binding globulin (SHBG), cortisol-binding globulin (CBG), carbohydrate metabolism parameters, blood pressure and body weight,apoprotein A1 (Apo-A1,body mass,Body weight, IRI and GPP,metabolic and hemostatic effects,antithrombin III, total and free protein S and fibrinogen,area under the curve (AUC) for glucose,total cholesterol, HDL and triglycerides,number of abnormal parameters,HDL-cholesterol,renin substrate,hemostatic measurements, lipid profile, glucose tolerance and adverse events,Levels of dehydroepiandrosterone sulfate,Glycosylated hemoglobin,Markers of lipid, carbohydrate and coagulation profiles,total cholesterol, HDL-cholesterol, LDL-cholesterol, VLDL-cholesterol, and triglycerides,hemoglobin, hematocrit and total protein levels but alkaline phosphatase, bilirubin and aspartate transaminase (SGOT,C-peptide and free fatty acid levels,glucose response,blood glucose levels,DSG-OC increased HDL-C, HDL(2)-C and HDL(3)-C; LDL-C,relative hyperglycemia,HDL/low-density lipoprotein cholesterol,haemostasis, lipids and carbohydrate metabolism,fasting and 2-hour glucose, triglycerides, total cholesterol, HDL-cholesterol, bilirubin, alkaline phosphatase, albumin, and total protein, but not aspartate aminotransferase,Basal insulin resistance (HOMA-IR,mean index for insulin resistance (homeostasis model assessment of insulin resistance, HOMA-IR,hepatic-induced parameters (SHBG, CBG) and carbohydrate metabolism,High-density lipoprotein (HDL) cholesterol (p=.02) and triglycerides,serum glucose levels,blood pressure, body mass, blood glucose and serum triglycerides,fasting blood glucose and pyruvate and serum insulin,plasma total cholesterol, LDL-cholesterol, LDL/HDL-cholesterol ratio and triglyceride concentration,Mean ± SD LDL cholesterol,Adverse events,free androgen and dehydroepiandrosterone sulfate levels,Thyroid stimulating hormone levels,All blood glucose and insulin values,lipid, carbohydrate and coagulation profiles,Metabolic and haemostatic effects,cycle control,glucose and triglyceride,changes in other lipid, hemostatic and carbohydrate parameters,haemostatic indices,lipid metabolism,C-peptide/insulin response,carbohydrate parameters,triglyceride and glucose concentrations,basal hormonal, metabolic and lipid levels,lipid profile,Carbohydrate metabolism,mean levels of fasting insulin and C-peptide,SI decreased with EE/DSG,triglyceride levels,insulin,SHBG increased 3-fold with DSG-OC|We found that serum resistin level remained unchanged in women receiving ethinylestradiol/desogestrel and was reduced in women treated with formulations containing gestodene.
not found|psychotic impairments|In some respects the residents of the hostel ward had fewer psychotic impairments than those remaining on the wards of the district general hospital, mainly because the latter seem to continue to acquire such defects, while the former have remained relatively unchanged.
11|Maximum concentrations and area under the concentration curve,Analgesia and pupil constriction,incidence of gastritis and esophagitis,GI motility,fentanyl requirements,small-bowel and colon transit,intestinal transit,Average time to first bowel movement,frequent bowel movement and better bowel movement quality,Volume of enteral feeding,transit time and the drug plasma concentration,Gastric emptying, small-bowel, and colonic transit,bowel frequency,bowel motility and analgesia,accelerated time to GI-2,median time to the first bowel movement,Pain estimation by visual analogue scale,Morphine analgesia and pupil constriction,gastric tube reflux, the frequency of pneumonia, and the time until first defecation,nausea, vomiting, and constipation,Laxation response, oral-cecal transit time, and central opioid withdrawal symptoms,rate of gastric emptying,colonic transit,maximum concentration or area under the concentration curve,laxative effects,pain scores,Mean time to the hospital discharge order written,Postoperative ileus (POI,time to GI-2 recovery (toleration of solid food and passage of stool) and hospital discharge order written (DCO,frequency of pneumonia,pain intensity and pain bothersomeness ratings,pain score,resting or active VAS,GI recovery and time to hospital discharge,gastrointestinal motility,risk of vomiting and pulmonary aspiration,complete reversal of analgesia,gastrointestinal motility and transit without affecting analgesia,safety and efficacy,Time to recovery of GI function,hospital stay, contribute to readmission, and increase morbidity,bowel motility and increased transit time,time to first bowel movement,overall colonic transit,mean colonic geometric center,time to return of gastrointestinal function,proportion of patients having at least one bowel movement (BM,analgesia,duodenogastral reflux,BM,nausea, vomiting, and hypotension; the incidence of nausea and vomiting,restoration of bowel function, and visual analog scales (VAS) for pain during rest and movement,morphine-induced subjective rating changes,colonic transit were geometric center of the colonic counts at 24 hours and time for 50% ascending colon emptying,recovery of gastrointestinal (GI) function,morbidity and extend hospitalization,gastrointestinal transit time,gastrointestinal recovery,small bowel transit time (SBTT) measured by the lactulose/hydrogen breath test, pain scores and the occurrence of adverse events,constipation and analgesia,gastric tube reflux and frequency of pneumonia,exhaled H2 concentration,Frequency of gastritis and esophagitis,Codeine delayed gastric, small-bowel, proximal, and overall colonic transit,transit time,Plasma concentrations,Stool frequency and symptoms related to constipation,oral-cecal transit time,Mean time to gastrointestinal recovery,time until first defecation, ventilation time, and length of intensive care unit stay,morphine-induced delay in oral-cecal transit time,tolerated,Urgency to defecate,time to the hospital discharge order written,intestinal hypomotility,adverse effects,average (SD) change,esophageal or gastral mucosal injuries,passage of flatus or stool and tolerating solid food,shorter time to the first postoperative passage of flatus,marked laxative effect,gastric reflux,Gastrointestinal transit time,oral-cecal transit times,recovery of gastrointestinal function,Gastrointestinal transit time (lactulose hydrogen breath test,Delayed gastrointestinal transit,pain relief,Weekly BMs and overall patient satisfaction,Efficacy,median time until patients were ready for discharge,antagonistic effect,Adverse events,analgesic effect,gastrointestinal transit,gastrointestinal motility and transit, without affecting analgesia,Whole-gut transit time,laxation and reverse slowing of oral cecal-transit time,Median gastric tube reflux volume,adverse events,Oral-cecal transit time,median time to the first passage of flatus,gastral reflux,reversal of analgesia,return of pain,gastric, small-bowel, and colonic transit time,time to gastrointestinal (GI) recovery (measured by toleration of solid food and passage of flatus/stool; GI-3,time to hospital discharge order written,gastric emptying,laxation response,median times to first BM,small bowel and colon (ascending colon and overall colonic transit,mean whole-gut transit time,composite of time to recovery of upper and lower GI function,postoperative pain relief,serum acetaminophen concentrations,GI recovery,side effects|No difference in maximum concentration or area under the concentration curve from 0 to 90 min was noted between placebo and methylnaltrexone coadministered with morphine.
                
244|mortality, requirement for mechanical ventilation, or incidence of pulmonary sequelae,mortality and complication rates,neonatal survival rate,outcome of HMD,morbidity or death,chronic lung disease of prematurity,length of stay or the duration of oxygen treatment,Pneumothorax,incidence of pulmonary air-leak,up-transfer or treatment failure,Oxygenation,risk of pneumothorax,total duration of oxygen therapy,mortality, respiratory outcome, the presence of cerebral ultrasound abnormalities, patent arterial duct, necrotizing enterocolitis, and retinopathy,death, length of nursery stay, time receiving oxygen therapy, cost of care, and other measures of morbidity,mean levels,overall survival rate,mean total duration of oxygen therapy,mortality, cranial ultrasound abnormalities, and pneumothoraces,mechanical ventilation|Secondary analysis showed that the use of CNEP was associated with an increase in mortality, cranial ultrasound abnormalities, and pneumothoraces, which were not statistically significant.
68|change in RBANS total score,Role Resumption List (RRL), and two other follow-up measures, the Treatment Goal Attainment (TGA) and the Executive Secretarial Task (EST), were indications of daily life executive functioning,change in RBANS delayed memory score,WCST performance,community functioning and quality of life,global cognitive functioning,CIQ (effect size [ES]=0.59) and PQOL,NP functioning, perceived self-efficacy, and community-based employment,daily life functioning,NP functioning,Self-Awareness of Deficits Interview (SADI), the Functional Independence Measure (FIM) and the Lawton Instrumental Activities of Daily Living Score (Lawton IADL,external inhibition, increased stimulus salience,Neuropsychological Status (RBANS) and Trail-Making, Controlled Oral Word Association, Wechsler Adult Intelligence Scale-III Similarities, and Stroop tests,meal preparation performance,subjects' cognitive functioning,Wisconsin Card Sorting Test (WCST) performance,cognitive outcome,RBANS total score,Community Integration Questionnaire (CIQ) and Perceived Quality of Life scale (PQOL,sustained moderate or severe TBI,task-specific self-awareness, general self-awareness or community integration,performance in neuropsychological tests assessing memory and executive functions,Rated quality-of-life,neuropsychological WM-demanding tests, rated occupational performance, satisfaction with performance and rated overall health,standardized measures of 'general' self-awareness with collateral reports by informants (e.g. Awareness Questionnaire); 'task-specific' self-awareness (e.g. Assessment of Awareness of Disability) and Self-Regulation Skills Inventory (SRSI,trained WM tasks,IADL performances and self-regulation,self-efficacy,self-awareness during IADL task performance,greater return-to-duty rate,level of awareness,cognitive, behavioral, or quality-of-life measures,Defense and Veterans Head Injury Program (DVHIP,Assessment of Motor and Process Skills (AMPS,neuropsychological WM-test results,cognitive functions,problem solving skills,self-awareness,productivity,verbal and visual memory functions,WM and attention,Individuals' problem-solving skills and self-efficacy,computerized version of the Paced Auditory Serial Addition Task (PASAT) and two computerized matching tasks,executive functioning,symptoms of cognitive problems|Intensive cognitive rehabilitation participants showed greater improvements on the CIQ (effect size [ES]=0.59) and PQOL (ES=0.30) as well as improved self-efficacy for the management of symptoms (ES=0.26) compared with standard neurorehabilitation treatment.
24|primary patency rates,risk of thrombosis,cumulative thrombosis rates,Thrombi,incidence of thrombosis,venous outflow resistance and systemic BP,rate of thrombosis of expanded polytetrafluoroethylene (ePTFE) grafts,vascular perturbations underlying synthetic graft thrombosis,overall rate of occlusion,relative risk of thrombosis,Survival analysis,frequency of side effects,likelihood of graft survival,PTFE graft survival,Six major bleeds,Actuarial analysis of Type,risk of early occlusion,rate of thrombosis,Time to graft failure|Survival analysis revealed a significant difference between fish oil-treated and untreated patients (P < 0.03, Mantel-Cox test), with a power of 90%.
30|corticosteroid side effects,unfavorable response,elevated liver enzyme levels,MPn clearance,determination of the lowest stable methylprednisolone dose and assessment of corticosteroid side effects,Efficacy and safety,forced expiratory volume in 1 second and pulmonary function,bronchial hyperresponsiveness,blood chemistry and hematology, adrenal function assessment; bone densitometry, and muscle strength testing,glucocorticoid pharmacokinetics and airway hyperresponsiveness,Methacholine response,methylprednisolone clearance,Symptom scores, blood chemistries, pulmonary function tests, airway response to methacholine, and glucocorticoid pharmacokinetics,serum IgG, fasting blood sugar, serum cholesterol, and progression of osteoporosis|Differences were observed between the two treatment groups in serum IgG, fasting blood sugar, serum cholesterol, and progression of osteoporosis.
1025|overall rate of complications,Systemic adverse events,Eleven intraoperative complications,systemic adverse event,rates of intraoperative events,cumulative rate of medical events,postoperative events,hypertension and arrhythmia (principally bradycardia,rate of complications,medical tests (electrocardiography, complete blood count, and measurement of serum levels of electrolytes, urea nitrogen, creatinine, and glucose,incidence of ophthalmologic and systemic complications,Ophthalmologic and systemic complications|The cumulative rate of medical events was similar in the two groups, 9.6% in the routine-testing group and 9.7% in the selective-testing group (P = 0.923).
46|remnant ablation rates,remnant cumulated activity per unit administered activity,Billewicz scale,Short Form-36 Health Assessment Scale scores,quality of life,serum thyroglobulin concentration less,MBq,TSH serum level,safe and effective and avoids hypothyroidism,successful thyroid ablation rate,Successful ablation,Quality of life,levels of thyroid stimulating hormone (TSH,Basal and rhTSH-stimulated serum thyroglobulin,small thyroid remnants,ablation rate,TSH, Tg and TgAb,rate of radiation clearance from blood, thyroid remnant, and whole body|The rh-TSH pre-treated patients seem to have a lower uptake compared to those in hypothyroidism induced by L-T4 withdrawal.
4060|overall mortality,quality of life,adverse drug effects,left ventricular function,incidence of hospital admission,majority of strokes,symptoms related to atrial fibrillation,Walking distance,pharmacological restoration of sinus rhythm,survival advantage,left atrium|Of the 3311 patients with echocardiograms, the left atrium was enlarged in 64.7 percent and left ventricular function was depressed in 26.0 percent.
99|safety, tolerance, and efficacy,size of lesions,response rate, tolerance, and patient compliance,Composite clearance rates,complete response rate,composite clearance rates (clinical and histological assessments) and histological clearance rates,serious adverse events,good cosmetic outcome,Complete response rates,complete response rate based on histologic assessment,adverse events and scoring of local skin reactions (LSRs,partial response (PR,safety and clinical efficacy,lesion clearance,cure of lesions,composite response rates (proportion of subjects with clinical and histological clearance) and response rates solely based on histology (proportion of subjects with histological clearance,Pathologic response,efficacy and safety,sustained response rate at 12 months and cosmetic outcome,Rates of recurrence of facial basal-cell carcinoma,response rate,local skin reactions,clinical complete response rate,complete response (CR,4-year actuarial failure rate,safety and efficacy,Adverse events,Noduloulcerative and superficial lesions,clearance rates,recurrence rates,initial inflammatory response,tumor-free rates,Increasing severity of erythema, erosion, and scabbing/crusting,Total operative costs of MMS,clinical efficacy,Basal cell carcinomas (BCCs,cure rate,Response rates,cosmetic outcome,Histological clearance,systemic adverse events,Basal cell carcinoma (BCC,Clinical and cosmetic responses,Composite clearance,Cost and safety,highest histologically complete response rate,Cosmesis and lesion recurrence,recurrence of carcinoma,highest clearance rate,efficacy,failure rate (persistent or recurrent disease,Histological clearance rates,histologic clearance,Cure rates|Intention-to-treat analysis revealed 100% (3/3) histologic clearance in the twice-daily regimen, 87.9% (29/33) clearance in the once every day regimen, 73.3% (22/30) clearance in the twice-daily 3 times/week regimen, and 69.7% (23/33) clearance in the once-daily 3 times/week regimen.
not found|tetanus neonatorum death rate,reduction in deaths,neonatal mortality,mortality rate|In the period up to 20 months following vaccination, the reduction in deaths among 4-14-day-old infants after a single dose of tetanus-diptheria toxoids was about the same as that after two doses.
400|quantity of total blood from placental delivery,occurrences of postpartum hemorrhage,complications or side effects,Complete blood count, urinalysis, liver and renal function, prothrombin time and activity,bleeding from placental delivery,postpartum blood loss,average blood loss,total blood loss,quantity of blood,Vaginal bleeding,blood loss|The average blood loss of group I and II was significantly less than group III and IV (P < 0.01), however, there was no significant difference between group I and group II (P > 0.05).
27|rate of implantation and clinical pregnancy,live-birth/ongoing pregnancy and clinical pregnancy rates,abortion rate,implantation rate,clinical pregnancy rates,clinical pregnancy rates and live birth rates,ongoing pregnancy rate,ongoing pregnancy/live-birth and clinical pregnancy rates,incidences of difficult transfers, blood and/or mucus on the catheter tip, spontaneous miscarriages, and ectopic pregnancies,pregnancy rates,frequency of easy transfers,clinical pregnancy rate,pregnancy rate,ectopic pregnancy, miscarriage and multiple pregnancy,number of clinical pregnancies,clinical pregnancy rate for ultrasound-guided embryo transfer,degree of confidence and satisfaction,highest pregnancy rate (32.3%/ET,Implantation and pregnancy rates,clinical pregnancy or live birth rates,pregnancy and implantation rates,live-birth/ongoing pregnancy rate|Although the clinical pregnancy rate was not statistically different (18.5% in the ultrasound-guided group vs. 17.4% in the clinical touch group), the use of abdominal ultrasound during the embryo transfer procedure provided a greater degree of confidence and satisfaction to both patients and physicians.
not found|Mortality and major morbidity,disabling symptoms,neurologic recovery,6-month FIM,Postoperative complications and functional outcome,efficacy and safety,Pulmonary (complications,motor recovery rates,sensation to pinprick,sick-leave profile,shorter hospital stay,Functional Independence Measure (FIM,neurologic outcomes,Motor and sensory functions,postoperative discomfort,severe sepsis and severe pneumonia,postoperative pain and length of hospital stay,pulmonary side effects,recovery of motor function,motor function (neurologic change scores,gastrointestinal complication,motor recovery,complete relief of back and radicular pain,postoperative narcotic analgesia,pulmonary complication with MPSS,complications and mortality,total number of sick days,1 full neurologic grade|Aged patients with cervical spinal injury may be more likely to have pulmonary side effects (P = 0.029) after high-dose therapy with MPSS and thus deserve special care.
224|Cardiac function,median survival time,Cardiotoxicity,left ventricular ejection fraction,left ventricular ejection fraction (LVEF,median duration of response and the median survival,median TTP,overall response rate (complete response and partial response [CR + PR,injection site toxicity,Activity,efficacy and tolerability,left-ventricular ejection fraction, assessed by serial multigated radionuclide angiography scans, or congestive heart failure (CHF,Gastrointestinal and hematological toxicities,congestive heart failure (CHF,superior response rate,complete plus partial response rate,grade 4 neutropenia,Antitumor efficacy,Reduced cardiotoxicity and preserved antitumor efficacy,alopecia,response rate,Median cumulative doxorubicin,median time to progression,symptomatic congestive heart failure,Clinical toxicities,neutropenia and stomatitis/mucositis,Overall response rates,cardiotoxicity and grade 4 neutropenia,Median survival times,Complete plus partial response,nausea and vomiting, stomatitis, and leukopenia,overall response rate,Median survival,Median cumulative doxorubicin dose at onset of cardiotoxicity,cardiotoxicity,Leukopenia, anemia, nausea, and vomiting,doxorubicin cardiotoxicity,median duration of response,efficacy and toxicity,disease progression or unacceptable toxicity,median time to treatment failure,palmar-plantar erythrodysesthesia,median survival,median time to disease progression,Vomiting, mucositis, and leukopenia,objective tumor response rates (World Health Organization criteria), time to progression, and survival,left ventricular failure,Protocol-defined cardiotoxicity,Response (overall response = complete + partial response rates), time to disease progression, overall survival and cardiac function (left ventricular ejection fraction,objective response rates|Clinical toxicities, commonly associated with doxorubicin, appeared less common with TLC D-99, although the difference was not statistically significant.
28|risk of syncope,withdrawal symptoms and side effects,Vasovagal syncope,orthostatic tolerance,Injurious events,recurrent tilt-induced vasovagal syncope,actuarial rate of absence of minor symptoms,Lead dislodgement or repositioning,CLS mode and no syncope,paced heart rate and avoid bradycardia, arterial hypotension and syncope,rate of positive responses,symptom reporting and mean SBP decrease after CSM,baroreceptor afferent flow,number of falls during one year of follow-up,asystolic response to tilt testing,time to syncope,Recurrence of syncope,syncope recurrence,tilt induced syncope,presyncopes and total vasovagal events,orthostatic hypotension,recurrence of cardioinhibitory vasovagal syncope,tilt-induced vasodilatation, syncope or elevated plasma adrenaline,time to syncope and severity of hypotension,median time to first syncopal recurrence,Syncopal events,heart rate,systolic pressure fall caused by carotid sinus massage,mean SBP decrease,syncopal recurrence,syncope recurrences,24-hour ambulatory BP,recurrence of Vasovagal Syncope (VVS,heart rate (electrocardiography), phasic blood pressure (digital photoplethysmography), and thoracic fluid index (transthoracic impedance plethysmography,SVRI,occurrence of symptoms,median number of previous syncopal episodes,therapeutic efficacy,recurrent syncope,pacemaker effect,plasma CA concentrations and syncope,severe side effects,symptoms requiring the withdrawal of VVI pacing and premature DVI/DDD reprogramming,syncope,syncopal recurrences,QOL scores,occasional presyncope and their quality of life,Initial mean,responses to head-up tilt,plasma adrenaline,relative risk reduction in time to syncope with DDD pacing,concentration of plasma CA increase and prevented syncope,change in health status,particular physical function,recurrence of syncope,intra-arterial monitoring, impedance cardiography, arterial blood sampling and tracer kinetics of simultaneously infused [3H]noradrenaline and [3H]adrenaline,recurrent neurocardiogenic syncope,syncopal attacks,symptom frequency, symptoms during head up tilt, and quality of life,Symptom reproduction and BP and heart rate changes,Reproducibility of carotid sinus reflex,median time to the first syncopal recurrence,mean number of syncopal episodes,risk of recurrent syncope,Symptom events,Syncope,Ambulatory 24-hour BP monitoring took place,spontaneous episodes of vasovagal syncope,actuarial rate of absence of syncopal recurrence,haemodynamic patterns of tilt-induced vasovagal reflex,acute tilt-induced syncope recurrence rates,presyncopal attacks,risk of syncope relapse,likelihood of syncope,median time to first syncope,syncopal episodes,syncopal events,incidence of first syncopal recurrence,median of 4 episodes of syncope,catecholamine (CA) concentration,actuarial rates of absence of syncopal recurrences,mean+/-standard deviation SBP decrease,global assessment of therapeutic response,abolishing syncope,recurrence of two VVSs,numbers of episodes of syncope and presyncope, and quality-of-life (QOL,repeat tilt testing,Spontaneous syncopal and presyncopal episode recurrence,upright pacemaker effect,positive for syncope,neurally mediated syncope,blood pressure,venous return,plasma CA concentration [norepinephrine (NE) and epinephrine (E,total number of syncopal and presyncopal attacks,QOL,hypotension and syncope, duration of tilt tolerance,blood pressure or heart rate,plasma adrenaline and systemic hypotension,syncopal recurrence burden,abnormal response to carotid sinus massage,recurrence of symptoms,profound hypotension,serious adverse effects,positive therapeutic response,symptomatic hypotension,Postural blood pressure measurements,rate of syncope,recurrence of neurocardiogenic syncope,loss of consciousness (or intolerable symptoms,permanent cardiac pacing (recurrence of syncope,refractory vasovagal syncope,mean interval between escape beats,pacemaker implantation,VVI (VVI, -31 (SD 19,low recurrence rate of syncope,asystolic response,likelihood of recurrent syncope,severity of attack,syncopal and presyncopal episodes and graded their well-being, expressed as the general evaluation of life, general activities, and everyday activities,energy and vitality,SVRI (systemic vascular resistance index) and magnitude of plasma adrenaline,recurrences of syncope,time to first recurrence of syncope,symptomatic recurrences,free of syncope,Falls (without loss of consciousness,first recurrence of syncope,prevention of syncope or presyncope provoked by head-up tilt testing,rate of symptom reporting and attenuated SBP decreases,mean time to a vasovagal episode (syncope or presyncope,haemodynamic modifications (heart rate and/or blood pressure fall,diastolic blood pressure,distribution of time of vasovagal events (syncopes or presyncopes,symptomatic pacemaker effect,mitral valve prolapse,response rates (negative TTT,ventriculo-atrial conduction,orthostatic hypotension while pacing DDI,Vasovagal Syncope International Study (VASIS,plasma CA concentrations,Baseline supine systolic blood pressure,occurrence of syncope,recurrent syncopal episodes,cardiovascular tests (vasodepression during carotid sinus massage, pacemaker effect, postural blood pressure measurements, and response to head up tilt), and symptoms,systolic blood pressure,vasovagal syncope,postrandomization risk of syncope,myocardial contractility,Pre-syncope,cumulative risk of syncope,mean 24-hour ambulatory BP,response rates (negative tilt test,sympathetic activity preceding syncope,milder symptoms,recurrence of syncope and presyncope,quality of life scoring scale,Acute reproducibility,complete abolition of syncope since pacing,mean duration of follow|Of the 15 patients initially given metoprolol, 2 (13.3%) did not respond; both were crossed over to verapamil, to which they remained unresponsive.
48|clinical asthma score,admission rates,serum magnesium concentrations,Hospitalization,Vital signs, O2 saturation by pulse oximetry, PEFR, forced vital capacity, forced expiratory volume at 1 second, and physical examination,forced vital capacity,forced expiratory volume,peak expiratory flow rate,short-term pulmonary function,admission rate and improved FEV1,PEFR and FEV1,blood pressure,PEFR,expiratory flow,FEV1,PEFR and SaO2,Hospital admission rates,peak expiratory flow,pulmonary function and decrease admission rate|Magnesium sulfate administration did not at any time significantly improve either FEV1 (F = 0.036, p = 0.96) or PEFR (F = 0.51, p = 0.61).
60|Piers-Harris Children's Self-Concept Scale and Harter's Perceived Competence Scale for Children (PCSC,prechange and postchange in MFBC,Piers-Harris Self-Concept Scale (P-H), the State-Trait Anxiety Scale (STAIC), and the Nowicki-Strickland Locus of Control test (NSLC,Changes in CBCL, STAIC, and NSLC scores,Monosymptomatic nocturnal enuresis,mean number of dry nights,relapse rates,levels of extroversion,rate of sustained continence,remission rates,history of upsetting life events and previous child psychiatric contact,Treatment efficacy,total score, and positive changes over time in only 2 Subscales, Scholastic and Social,P-H Scale,maximum functional bladder capacity (MFBC,Piers-Harris Subscales and in the CBCL Internalizing and Externalizing Scores, and the Social Thought and Attention Problems Subscales,response rate,fewest wetting episodes,success rate of Arousal Training,cumulative response,improvement rate,complete and partial response rates,dry nights,background demographic variables,bladder capacity,Maternal anger,number of wet nights,remission (28 continuous dry nights) and relapse,serious side effects,levels of neuroticism,wetting frequency,bed-wetting frequency,rate of cure,success rate,subjects' level of emotional and behavioral adjustment,Bed-wetting frequency,Improvement rate without cure,enuresis tolerance scale,Remission rates,Achenbach Child Behavior Checklist (CBCL,Behavioral and self-concept changes,rate of apparatus malfunction,weekly wetting frequency|Using Dunn's procedure, a planned comparison showed the control group and delay group did not differ significantly, but both differed significantly from the classic conditioning group (p less than 0.05).
not found|3-year relapse-free survival rates,time to recurrence,4-year event-free survival (intention-to-treat analysis,septic death,survival,3-year survival rates,relapse-free survival,risk of relapse,event-free survival,disease-free survival (DFS,overall survival,morbidity,frequent morbidity,relapse-free or overall survival advantage,4-year overall and relapse-free survivals,5-year DFS,disease-free survival rates,5-year overall survival,disease-free survival, overall survival, or the time to recurrence,3-year disease-free survival,relapse or death from breast cancer ,disease-free and overall survival,myelodysplastic syndrome or acute myeloid leukemia,mean number of positive nodes,overall and disease-free survival|The PEGASE 01 adjuvant therapy trial showed that 3-year disease-free survival was significantly better in the HDC arm but overall survival was unchanged.
not found|Cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog), Alzheimer's Disease Cooperative Study Clinical Global Impression of Change (ADCS-CGIC,degree of severity of dementia,Clinical Global Impressions (CGI Item 2) for psychopathological assessment, the Syndrom-Kurztest (SKT,psychometric tests (trailmaking test, ADAS, CGI) and electrophysiological investigations (EEG topography,mental/mnestic performance,frequency of therapy responders,cognitive performance and global assessment scores,ADAS-Cog,mental performance,Safety, compliance, and drug dispensation,efficacy and tolerability,percentage of baseline scores,ADAS cognitive and non-cognitive subscales,Digit Copying sub-test of the Kendrick battery,depression,cerebral disorders,efficacy and safety,Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog), Geriatric Evaluation by Relative's Rating Instrument (GERRI), and Clinical Global Impression of Change (CGIC,self-rating scale for instrumental activities of daily living (Nürnberger-Alters-Alltagsaktivitätenskala,number of patients reporting adverse events,activities of daily living as assessed by the Nürnberger-Alters-Beobachtungsskala (NAB,psychopathology and cognitive performance,CGIC,patient's performance,Mental Control Test (EMCT) measuring attention and concentration, Benton Test of Visual Retention-Revised (measures short term visual memory), Rey Test part 1 (measures short term memory and learning curve), Beck Depressive Inventory (BDI) measuring the presence and severeness of a depression in order to exclude depressive patients and Rey Test part 2 (measures long term memory: recognition,Clinical Global Impression score,Clinical efficacy,tolerated,learning rate,cognitive function,Number Connection Test,GERRI score,Furthermore, subjective perception of memory and concentration,sum score in the SKT-test for the determination of attention and memory,shortterm memory,little cognitive and functional decline,number of (gastrointestinal) side effects,Saccade duration|In the subjective test, the EMCT, the Rey 1 and Rey 2 no significant differences in improvement in time between the groups were observed.
554|mean DeMeester acid exposure score,lower oesophageal sphincter pressure,quality of life,overall gastroesophageal reflux disease symptom score,postoperative complications,time to treatment failure (Kaplan-Meier analysis,symptom relapse requiring titration,satisfactory symptom remission,tolerated,symptoms, pH control, and overall quality of life health index,frequency of gastroesophageal reflux dis-ease symptoms,Psychological General Well-being Index and the Gastrointestinal Symptom Rating Scale,chronic gastro-oesophageal reflux,mean gastrointestinal symptom and general well-being scores|The proportions of patients who remained in remission after 3 years were similar for the two therapies: 90% of surgical patients compared with 93% medically treated for the intention to treat population, p = 0.25
141|symptoms and signs, caloric lateralization on the electronystagmography (ENG), the presence of other pathologic findings in the ENG, and Dizziness Handicap Inventory scores,vertiginous symptoms,Vestibular function,occurrence of symptoms and signs, degree of caloric lateralization, presence of other ENG pathologic findings, and Dizziness Handicap Inventory scores,relapse of symptoms,peripheral vestibular function,Complete resolution,vertigo,relief of vertiginous symptoms,recovery of peripheral vestibular function,severity of vestibular paresis,earlier recovery of ENG lateralization|Analysis of variance showed a significant effect of methylprednisolone (P<0.001) but not of valacyclovir (P=0.43).
98|Functional Independence Measure (FIM), Motor Assessment Scale (MAS) and Rankin Disability Index measured functional outcomes,final upper limb function,visual analogue scale (VAS,presence of neglect or sensory loss,pain (SROMP) assessed passive range of movement and pain,Skin reactions,pain, range of movement or functional outcomes,pain,functional outcomes|Intention to treat analysis showed no significant difference in pain, range of movement or functional outcomes after the intervention phase or at the final assessment.
not found|severe signs of Cyclosporin A (CsA) nephrotoxicity,allograft function,Estimated graft survival,graft survival,Thrombosis leading to graft loss,Plasma levels of soluble interleukin-2 receptors,renal parenchymal diastolic blood flow velocities,cadaveric kidney transplantation,episodes of acute tubular necrosis,renal graft function,acute rejection rate, trough blood cyclosporine concentrations, blood pressure, number of antihypertensive drugs, hospitalization rate, and adverse event rate,Graft function assessed by serum creatinine concentration and glomerular filtration rate measured as plasma iohexol clearance,renal function and rejection,Renal plasma flow and anastomotic blood flow,donor or recipient characteristics, HLA-mismatching, and ischaemic time,blood concentration,graft function (plasma iohexol clearance), renal plasma flow, anastomotic arterial blood flow, deterioration of renal function, blood pressure, acute rejection, and hospitalization rate,rate of delayed graft function, the rate of rejections, time to first rejection, whole blood CsA concentration, or graft function,incidence and severity of delayed graft function,Primary graft function,rejection episodes,serum creatinine,Actuarial graft survival|Actuarial graft survival at 1 yr was different when the two groups were compared (P less than 0.05).
not found|rate of growth of the skinfolds,abdominal temperature,Growth velocities and individual amounts of breastfeeding,length of stay,rate of weight gain,birth weight stratum,number of infants returned to an incubator, the growth velocity in an open crib and during the first week at home, the proportions of breastfeeding at discharge and during the first week at home, and the hospital readmission rate,growth and thermal stability,mean 24-hour weight gains|The rate of weight gain correlated with gross energy intake only and did not differ within or between the two groups.
50|relapse rate,cumulative number of confirmed relapses,final 2-year relapse rate,Expanded Disability Status Scale (EDSS,total number of confirmed relapses,overall survival curves,T2 lesion volumes,disabled on entry (Kurtzke disability score,Disability,Progression rates,safe and well tolerated,unconfirmed progression, and progression of 0.5 EDSS units,clinical and MRI measures of inflammation and neurodegeneration,tolerated,Kurtzke Expanded Disability Status Scale,enhancing lesions,survival curves,frequency of relapses and the formation of active brain lesions,rate ratio,disability status scale change (entry expanded disability status scale,intention-to-treat analysis of time to 1,relapse rate and improves disability,MS relapse rate,clinical and MRI-monitored disease activity|More disabled patients worsened by 0.3 (Cop 1 group) and 0.4 (placebo group) unit.
44|intraoperative or postoperative thromboembolic complications,intraoperative blood loss,perioperative blood transfusion requirements,blood loss,blood loss and transfusion requirements,perioperative blood loss and the need for autologous blood transfusion,adverse drug effects,bleeding and transfusion requirements,thrombotic complications,blood transfusion,total amount of blood transfused,postoperative suction drainage,duration of intensive care unit admission,perioperative blood loss,Blood loss, transfusion requirements, coagulation parameters, and complications,amount of blood transfused,blood loss, transfusion requirements, days in the intensive care unit, and days in hospital,transfusion requirement,estimated blood loss,transfusion requirements|The study demonstrated a significant reduction in estimated blood loss (aprotinin 545 cc, placebo 930 cc) and transfusion requirements (aprotinin 1.1 U, placebo 2.2 U).
36|Survival,mortality rate,weight gain,Overall cost,LVO,mean arterial blood pressure (MABP), left ventricular output (LVO) and global cerebral blood flow (CBF,global cerebral blood flow,number of infants requiring inotropic support and death or chronic lung disease,hypotensive (systolic blood pressure less,intraventricular haemorrhage,creatinine clearance (CCr) or the urinary sodium excretion rate,duration of normotension, meeting criteria for second bolus, meeting criteria for vasopressor support and cost comparison,coagulation factors,arterial blood pressure,blood pressure,normotensive state,ratio of FIO2 to PaO2,volume expander to maintain normal blood pressure,plasma potassium concentrations,qualify for vasopressor infusion,Renal function,fractional urinary sodium excretion,pulmonary perfusion and/or ventilation,case fatality rate,CCr|Dopamine was effective in increasing MABP; both treatments increased LVO, whereas no significant difference between the treatment groups and the control group could be demonstrated with regard to CBF.
                
not found|numbers of people failing,missed initial appointments,attendance at the first appointment; secondary outcomes included hospitalization, transfer of care, continuing attendance, discharge, presentation at accident and emergency and death by 1 year|The orientation statement only group had significantly fewer missed initial appointments than the control group (28% vs. 56%).
40|serum morning cortisol values,interleukin-5 messenger RNA,total number of drug-related adverse events,CD-3,total X-ray photograph scores,Postoperative mean total score for several endoscopic parameters scores,PNIF,adrenal suppression,mucosal thickening,efficacy and tolerability,healing with MFNS,facial pain and sensitivity,total symptom scores,wound healing, leading to recurrences of sinusitis and polyps,efficacy and safety,Morning serum cortisol,recurrence rate of nasal polyps and chronic rhinosinusitis,total endoscopic scores,clinical outcome,Adverse events,nasal symptoms,density of cells expressing interleukin4,diary card scores,number of patients withdrawn because of recurrent or persistent diseases,nasal airway patency's parameters,allergic sinusitis,subjective nasal clinical symptoms (nasal discharge, nasal obstruction, postnasal drip and headache), (2) X-ray photographs (ethmoid and maxillary sinuses) and (3) cytokine levels (IL-1beta, IL-8 and TNF-alpha) by enzyme-linked immunosorbent assay,percentage of nasal deobstruction,symptoms, diary card, and rigid endoscopy scores, acoustic rhinometry, middle meatal swabs, blood tests--CRP, ESR, WBC, and eosinophil count,nasal congestion and discharge scores,clinical efficacy and adverse effects,Peak nasal inspiratory flow (PNIF,tolerated,Morning combined symptom scores (CSS,Efficacy and tolerability,patients' sense of smell,recurrence rate of chronic rhinosinusitis and nasal polyps,levels of IL-1beta and IL-8,total nasal symptom scores,symptom scores,endoscopic combination score (for inflammation, oedema, and polyps), a total symptoms score,adverse effects,wound healing,symptomatic response and improvement in nasal mucociliary clearance, nasal airway resistance, sinus radiographs, and intranasal bacteriology and appearance,nasal scores,bacterial sinusitis,risk of developing an infection,eosinophils,nasal and ocular symptoms,TNF-alpha level,airways' resistance via active anterior rhinomanometry and the volume and area section via acoustic rhinometry|Budesonide and antral irrigations reduced nasal symptoms more effectively than placebo, and there was a significantly greater reduction in facial pain and sensitivity in the budesonide group than in the placebo group.
52|median TTF,Skin reactions,Cutaneous reactions,rate of response based on intention|The rate of response based on intention to treat patients was 33.3% for miltefosine solution compared with 3.7% for placebo (P = .006).
109|odds ratio for behavioural problems,proportion of children with recurrence,free of seizures,acceptability and efficacy,Hyperactivity,preschool behaviour screening questionnaire (BSQ,Recurrence of convulsion and side effects,Serum drug levels,Efficacy,frequency of behavioural side-effects; behaviour,nausea, vomiting, dizziness, and sedation,failure rates,mean log-transformed scores on the behaviour rating scales,efficacy and toxicity,partial seizures,intolerable acute toxic effects,1-year remission,Side effects,Conners parent rating scale,Overall treatment success,dysmorphic effects and hypersensitivity,efficacy,libido and impotence|The mean log-transformed scores on the behaviour rating scales did not differ significantly between the phenobarbital and phenytoin groups (Conners 2.64 [SD 0.71] vs 2.65 [0.89], p = 0.97; n = 32 in each group: BSQ 2.12 [1.31] vs 2.18 [1.02], p = 0.94; n = 4 vs 3).
242|antibody responses,occurrence of pneumococcal bacteremia,pneumococcal isolations,morbidity and mortality,higher infection rates,incidence of infection|No pneumococcal isolations occurred in the penicillin group while receiving penicillin, although four isolations occurred within one year of stopping penicillin.
20|Local irritation and adverse events,histologic features, keratinocyte expression of HLA-DR and intercellular adhesion molecule-1, numbers of epidermal Langerhans' cells and epidermal and dermal T lymphocytes, and vascularity as measured by dermal endothelial cell area,roughness, mottled hyperpigmentation, fine wrinkling, and lentigines,vascularity,dryness, peeling, and acne,Skin biopsies,photoaging effects,skin elasticity index,degree of compaction of stratum corneum, thickness of the granular cell layer, and epidermal thickness,intraoperative pain,skin state,elasticity index,wrinkles and severity and duration of adverse effects,restoring actinic damage,skin wrinkles, mottled hyperpigmentation, laxity, lentigines and roughness,Postoperative erythema,duration of crusting, swelling, and itching postoperatively,postoperative crusting and more rapid reepithelialization,average upper lip phenol-treated wrinkle score,histologic evaluation,photoaging,Overall investigator scores,degree of epidermal pigmentation,overall severity of photodamage,fine wrinkling, mottled hyperpigmentation, roughness, and laxity,global responses,rate of resolution of erythema,fine wrinkling, tactile roughness, coarse rhytids, skin laxity/tone, sallowness/yellowing, and overall features,Ra and shadows north-south facial axis values,postoperative erythema,mean epidermal thickness,Changes in skin biopsies and silicone skin surface replicas,histologic changes,epidermal and granular layer thickness, decreased melanin content and compaction of the stratum corneum,permanent hyperpigmentation, hypopigmentation, or scarring occurred,variable pulse,Vivida,Rz, Ra, and shadows,epidermal thickening,photoaged skin,safety and efficacy,corrected epidermal atrophy and atypia and improved skin hydration properties,adverse experiences,Medium to deep (Grade III,clinical and microscopical manifestations of liver spots,skin roughness,hyperpigmentation and wrinkle reduction,efficacy,safe and effective,appearance of photo damaged skin,Side effects of erythema, peeling, and stinging were usually mild and well tolerated,mottled hyperpigmentation,swelling,crusting,Treatment response,dermal thickness,efficacy and tolerability,wrinkle improvement,erythema, crusting, pain, and pigmentary changes,objective skin changes,overall severity of photodamage and sallowness,epidermal thickness,erythemal index,photodamaged skin topography,permanent hyperpigmentation, hypopigmentation, or scarring,investigator's global evaluation,erythema,adverse effects,overall improvement in photodamaged skin,perioral wrinkles,global response,tolerated, and skin irritation,Improvement in rhytides, patients' subjective reports of postoperative pain, time to reepithelialization, degree of postoperative crusting, and duration of postoperative erythema,tolerated overall,average upper lip laser-treated wrinkle score,mottles and telangiectasis,Posttreatment erythema,skin wrinkles, tightness, colour and pores,duration of itching,Local adverse events,plasma retinoid levels,duration of crusting,mottled hyperpigmentation and fine wrinkles,efficacy and safety,appearance of photo-damaged skin,rhytide scores,wrinkle score,skin condition,adverse effects (burning, stinging, redness, peeling, dryness, discoloration, itching, and rash,wrinkle improvement and duration of adverse effects,fine wrinkling and pigmentation,erythema score,good response,erythema, crusting, pain, itching, swelling, pigmentary changes, and the day of first make-up application,photographs for erythema, pigmentation, and wrinkle improvement,immunologic markers,significant lightening of hyperpigmented lesions,average upper lip dermabrasion-treated wrinkle score,frequency of erythema,overall modest wrinkle improvement,general skin texture and discoloration,facial rhytids,irritant side effects (erythema and scaling,appearance of photodamaged skin,Fine wrinkling, mottled hyperpigmentation, and roughness,mean erythemal index,overall appearance of photodamaged skin,pain|The laser treatment had a significantly higher erythema score at 1 month and a small but significantly greater improvement in perioral wrinkles at 6 months.
120|Bleeding episodes,abortion rate,Live birth rate per transfer,Safety parameters,patient satisfaction scores,implantation and pregnancy rates,pregnancy rates and the implantation rates,vitro fertilization-embryo transfer (IVF-ET,Highest pregnancy rate,ongoing pregnancy rate,Clinical pregnancy rates,plasma progesterone concentrations,pregnancy rate, rate of spontaneous abortion, proportion of normally developing fetuses or rate of chemical pregnancy,pregnancy and embryo implantation rates,living birth rates per transfer,luteal-phase GnRH agonist administration increased luteal-phase serum HCG, estradiol and progesterone concentrations,serum progesterone (P) and 17-beta-estradiol (E2) and E2/P ratio levels of the luteal phase,safe and well tolerated,pregnancy, implantation and live birth rates,E2/P ratio,rate of implantation and abortion, number and reasons of withdrawals, as well as adverse events, assessment of tolerability, and acceptance,number of embryos transferred,Pregnancy rates,pregnancy rates per transfer,Pregnancy, embryo implantation, and live birth rates,Tolerability,late luteal progesterone concentrations,comparative efficacy and tolerability,Plasma P and 17 beta-Estradiol concentrations,specific symptoms and usual safety monitoring,pregnancy rates or implantation rates,pregnancy rates and ongoing pregnancy rates,Furthermore, Estradiol (E(2)), progesterone (P) levels and endometrial thickness,Live birth rates,median progesterone levels,ratio of newborn babies per embryo transferred,probability of pregnancy,implantation rate,implantation rate per embryo,Pregnancy rate,embryo implantation,ongoing pregnancy rates,efficacy, safety and tolerability,Implantation rate,implantation and live birth rates,rates of successful pregnancies,midluteal estradiol levels,ICSI clinical outcomes,implantation rates,probability of pregnancy in intracytoplasmic sperm injection (ICSI) cycles,biochemical rates,Clinical pregnancy rates, implantation rates and live birth rates,probability of conception,embryo quality,pregnancy rate,Efficacy and tolerability,Serum levels of P and E2,overall pregnancy rate and miscarriage rate,late-midluteal estradiol levels,implantation and pregnancy rate,implantation rate per embryo transfer,Ongoing pregnancy rate,early pregnancy loss,E2 or P levels, endometrial thickness,clinical outcome of intracytoplasmic sperm injection (ICSI) and embryo transfer (ET) cycles,E2 or P levels,clinical pregnancy,rate of withdrawals at the individual visits,Pregnancy and live birth rates,pregnancy rate and live birth rate,Pregnancy rates, ongoing/delivered, failed pregnancy rates, and product satisfaction scores,serious adverse events,Demographic parameters, infertility etiologies, number of gonadotropin ampules used, number of mature oocytes recovered, rates of testicular sperm usage, number of embryos transferred, and cycle and transfer cancellation rates,clinical pregnancy rates,Progesterone levels,levels of oestradiol and progesterone,PR per retrieval,luteal E(2) level,progesterone profiles and pregnancy outcomes,pregnancy rates (PR,pregnancy rates (PRs,Clinical pregnancy rate,vitro fertilization and embryo transfer,Ongoing pregnancy rates,pregnancy and delivery rates,Demographics, stimulation parameters and embryological data,LH,Estradiol (E2,Implantation and live birth rates,Conception rate,Serum P levels,luteal serum progesterone and oestrogen concentrations,P4 levels,clinical PRs,duration of LPS,Implantation, clinical pregnancy and multiple pregnancy rates,Clinical pregnancy, ongoing pregnancy, and live birth rates,Elevation of serum progesterone,Endometrial thickness,progesterone,number of beta-hCG-positive results,adverse event profiles,pregnancy and implantation rates,number of embryos transferred and the grade of the embryos,E2 levels,Vaginal discharge or irritation,delivery rates,Similar levels of luteal E2,rates of implantation and clinical pregnancy rates,Pregnancy rates and live birth rates,Clinical pregnancy rate per transfer and implantation rate,Efficacy,luteal phase serum P4 levels,efficacy and safety,spontaneous abortion rates,lower E2 levels,failed pregnancy rates,pregnancy or implantation rates,pregnancy rates,pregnancy rate per embryo transfer, early pregnancy loss, multiple pregnancy rate, and midluteal P and E(2) levels,Hormonal levels,luteal plasmatic values,Demographic profile and pregnancy and miscarriage rates,serum P4 levels,lower embryo implantation, clinical pregnancy, and live birth rates,clinical pregnancy rate,pregnancy outcome,rate of positive beta-human chorionic gonadotrophin per transfer,ongoing pregnancy rate per transfer cycle,Pregnancy rates (PRs) and live birth rates per ET,multiple pregnancy rate,LH levels,luteal P values,luteal serum E(2) and P profiles,miscarriage rate,number of good quality embryos,live birth rates,SD), number of oocytes,multiple pregnancy and live birth rates,mean number of oocytes retrieved and embryos|Although there was no significant difference in the number of good quality embryos transferred in both groups, the implantation and pregnancy rate were significantly higher in the GnRH-a - treated group compared with placebo controls.
not found|clinical efficacy and safety,maximal and painfree walking distances and blood viscosity,level of walking claudication pain,red blood cell filterability, plasma fibrinogen concentration and blood viscosity, resting and post-ischemic calf muscle blood flow, and the resting and post-exercise ankle/brachial systolic pressure ratio,ankle systolic blood pressure ratio ( ASBP -ratio,mean erythrocyte deformability,diabetes mellitus,initial and absolute claudication distances,walking performance, resting toe pressure, resting and postexercise ankle/brachial pressure ratio, and basal/postischemic toe-pulse ratio,maximal walking distance with constant-speed, variable-grade treadmill testing,VEGF levels,Reduction of lower limb paresthesias,withdrawal rates,efficacy, safety and cost,Nausea,farther walking distance of 2 miles,moderate level of pain,mean maximal walking distance,erythrocyte deformability,walking distances,Side effects (including headache, palpitations, and diarrhea,claudication distance and mean plasma fibrinogen concentration,flux,exercise flux (AEF,serum levels of pentoxifylline and its hydroxy-metabolite,frequency of minor side effects,postexercise distal flow, ratios, and pressures and enabling faster recuperation of basal pulse rates,maximal walking distances,vascular endothelial growth factor,Cilostazol,painfree walking distance,ankle-brachial index,efficacy, safety, and cost,serious drug-related side effects,Circulating VEGF levels,absolute claudication distance (ACD,Pentoxifylline efficacy,ACD,Mean maximal walking distance,red cell rigidity,efficacy, safety, and tolerance,Red cell rigidity ,blood flow,AEF,duration of COAD,plasma levels of VEGF,initial claudication, toe peak-flow time, pulse reappearance time (PRT/2), and maximum postischemic flow time,efficacy and tolerability,distal pressure and resting microcirculatory blood flow,PXF improved walking distance,adverse reactions,walking performance,blood viscosity,walking distance and quality of life,walking performance (absolute walking time and walking distance on a treadmill ergometer) and by acral plethysmography,quality of life,tolerated,peak ACD,maximal walking distance,walking distance,absolute subjective claudication distance,level of pain,pain-free walking distance,Claudication distance and walking distance,exercise performance or quality of life,exercise tolerance,pain relief,pain-free walking distance (PFWD,subjective response, ankle systolic indices, maximum limb blood flow or whole blood viscosity,walking distance and blood rheology,median of the maximal walking distance,levels of VEGF,initial claudication distance and quality of life assessment,Deaths and serious adverse event rates,total walking distance (TWD,whole blood or plasma viscosity,subjective response; claudication and maximum walking distances; ankle systolic indices; maximum blood flow in the lower limb by gravimetric plethysmography; plasma fibrinogen; erythrocyte deformability and whole blood viscosity,Subjective side effects|There was a 38% difference at 6 months and 39% at 12 months in favor of PXF.
79|overall mean satisfaction,Early recovery,Six minor complications,patient satisfaction, procedure and recovery times, neuropsychological function, and complications,10-cm visual analog scale,efficacy, safety and recovery characteristics,full recovery sooner,tests reflective of learning, memory, working memory span, and mental speed,overall satisfaction,Hemodynamic and respiratory data, pain, discomfort and sedation scores, patient and gastroenterologist satisfaction and recovery profiles,Heart and respiratory rates, blood pressure, and oxygen saturation,episodes of hypotension, 1 episode of bradycardia, and 1 rash,Dot Test score,minor complications (1 hypotension and bradycardia, 2 hypotension alone, and 1 tachycardia,transcutaneous partial pressure of carbon dioxide,recollection of pain,severe pain and discomfort,mean arterial pressure, heart rate and end-tidal CO2,Sedation and pain scores,Observer's Scale for Sedation and Alertness (OSSA) score,cardiopulmonary complication rates, pain scores, satisfaction scores, and patients' willingness to repeat colonoscopy,mean arterial blood pressure,respiratory rate and oxygen saturation values,Patient satisfaction,Mean time to sedation,hypoventilation,10-point visual analog scale,oxygen desaturation requiring mask ventilation and 4 episodes of hypotension,Drugs cost for NAPS,safety and efficacy,success, difficulty, or duration of the colonoscopy,nausea and vomiting,Oxygen saturation and hemodynamics,discharge times,patient satisfaction, procedure and recovery times, neuropsychologic function, and complications,systolic blood pressure,faster recovery time,recovery of cognitive function,Synergistic sedation,Nausea and vomiting,visual analogue scale,Recovery of cognitive and psychomotor functions,Pain and discomfort scores,lighter sedation (median sedation score,pain (visual analogue scale) and procedure time,duration of colonoscopy,patient satisfaction,Digit Symbol Substitution Test score,time to recover from sedation,Patient cooperation, endoscopist satisfaction, and level of sedation,effective analgesia, sedation, amnesia, patient comfort and stable recovery profile without respiratory depression,Pain and sedation score,endoscopist satisfaction,analgesia (median pain score,arterial pressure and heart rate,depth of sedation,pain,complete recovery,pain scores,oxygen desaturation develop|All patients treated with the synergistic sedation were able to participate (P=0.002), and performed better.
not found|nausea, vomiting and drowsiness,adverse effects,analgesia,adverse effects and/or inadequate relief,pain,postoperative pain,pain relief|In the multiple dosing phase, zomepirac was statistically better than dihydrocodeine. Non-parametric statistical tests indicated highly significant correlations between single- and multiple-dose analgesic measurements for both zomepirac and dihydrocodeine.
94|nausea,nausea, vomiting, and retching,Pain scores,maternal satisfaction,incidence of intra- and postoperative nausea or vomiting,incidence of PONV and side effects,overall rates for all emesis,incidence of intra- or postoperative nausea or vomiting/retching,patient's perception of the control of nausea and their overall satisfaction,total number of parturients with no vomiting and/or no antiemetic medication,incidence and severity of nausea and vomiting,Nausea or vomiting,frequency of intraoperative and postoperative vomiting,incidence of vomiting and treatment for vomiting,intraoperative vomiting,neonatal Apgar scores,perioperative nausea and vomiting,antiemetic efficacy and safety,patient satisfaction,Neonatal acid-base status and neurobehavioral exams,pruritus, nausea, and vomiting,severity of pruritus score,Sedation scores,perioperative nausea,ephedrine requirements,frequency,nausea than vomiting,hypotension after delivery,nausea, vomiting, retching, pain relief, itching, and adverse effects,frequency and severity of the nausea and vomiting episodes,incidence and severity of nausea,Cumulative nausea, vomiting, and pain scores,incidence of vomiting,intraoperative, postdelivery vomiting,total incidence of nausea and vomiting,frequent incidence of restlessness,pruritus score,nausea or vomiting,safety and efficacy,intraoperative nausea,emesis free,vomiting,Total ephedrine consumption,frequency of retching or vomiting,severity of nausea,postoperative nausea and vomiting,incidence of restlessness,Frequency and severity of postoperative (24-hour) pruritus, nausea and vomiting, surgical pain, and side effects,Nausea and vomiting,frequency of nausea,postoperative nausea or vomiting,frequency of intraoperative nausea and vomiting,frequency and the severity of nausea and vomiting,Analgesia and nausea,vomiting prior to delivery,Blood pressure,nausea scores,nausea free,hypotension and vasopressor use,Episodes and severity of nausea and vomiting, rescue antiemetic requirement, patient satisfaction, and side effects,nausea scores, number of vomiting episodes, or patient satisfaction with postoperative nausea and vomiting management,nausea and/or vomiting,need for rescue antiemetics,severity of hypotension,efficacy and tolerability,Overall satisfaction with postoperative care,pulse rate or blood pressure,emesis,incidence of vomiting and the severity of nausea,respiratory depression,antiemetic effect,cumulative pain score,severity of vomiting nor the incidence of nausea,vasopressor,total incidence of nausea and vomiting, incidence of > 4 vomiting episodes,intraoperative, postdelivery nausea,nausea, retching, and vomiting,mean arterial pressure,incidence, onset, duration, and severity of pruritus; the onset and severity of pain; and satisfaction,severe emetic symptoms,nausea and vomiting,respiratory depression (respiratory rate,severity or incidence of pain, or requests for analgesic or antipruritic medication,pruritus, nausea and vomiting,Intraoperative nausea,Neonatal outcome,Incidence rates for intraoperative nausea,Intraoperative antiemetic efficacy,Overall patient satisfaction,frequency of intraoperative nausea,complete response,incidence and severity of intraoperative emetic symptoms,emetic symptoms,Side effects,frequency of vomiting,antiemetic medication,retching or vomiting (1 = vomiting or retching, 0 = no vomiting or retching,supplementary intraoperative analgesia,postoperative nausea and vomiting/retching,antiemetic efficacy,Blood pressure, heart rate and vasopressor requirements,intraoperative nausea and vomiting (IONV,incidence of nausea,efficacy and safety,intraoperative nausea and vomiting,Maximum analog sedation score,frequency of respiratory depression,maternal characteristics,postoperative vomiting,severity of nausea and vomiting,cumulative perioperative pain score,nausea, retching, and vomiting intraoperatively,incidence of intraoperative/postoperative nausea,frequency of nausea and vomiting, sedative score, respiratory depression, and side effects,haemodynamic response,nausea and vomiting, sedative score, pain score, and side effects,incidence and severity of IONV,neurobehavioral exam results,verbal pain score,number of women who complained of nausea,nausea/vomiting score, pain score, sedation score, or shivering score,Severity of nausea and number of vomiting episodes,side effects,pruritus|There was also no difference between the two groups in nausea scores, number of vomiting episodes, or patient satisfaction with postoperative nausea and vomiting management.
99|adverse events,total mASEPSIS score,and/or tolerability,Ulcer area and healing,maceration,wound severity score,closure rate,ulcer area,clinical infection,delayed healing ulcers,Wound area,mean wear time,lymphangitis and/or fever,Poor dressing acceptability,exudate level,Odour, maceration, absorption capacity and leakage|According to the investigators, fewer wounds developed a clinical infection over the four-week follow-up in the test group (33% versus 46%; p = 0.223).
18|mean volume losses,circumference measurements,volume losses,wellbeing' score,symptom relief,number of patients subjectively improving,leg circumference,Volume losses|Analysis of covariance revealed significant mean volume losses for both experimental and control groups, with ponderal index the only significant covariate.
not found|fetal tachycardia and repetitive late decelerations|When misoprostol is used in women with previous cesareans, there is a high frequency of disruption of prior uterine incisions.
not found|maternal demographic characteristics,headaches, and with salbutamol, tremors and palpitations,Maternal side effects and haemodynamic changes,adverse side effects, mainly nausea and vomiting,birth weight, estimated gestational age at delivery, or neonatal complications,number of entry variables, including cervical examination, contraction frequency, and gestational age,Maternal side effects,Prolongation of pregnancy,fetal and neonatal outcome,maternal heart rate,efficacy and maternal, fetal, and neonatal outcome,Maternal pulse rate,neonatal deaths,systolic and diastolic blood pressure,efficacy and safety,maternal side-effects,time to uterine quiescence, time gained in utero, recurrence of preterm labor, failure of tocolysis, and pertinent maternal and neonatal outcomes,suppression of preterm labor,neonatal complications,maternal and fetal complications,mean term of delivery,severe maternal side effects,adverse medication effects and recurrent preterm labor,delay of delivery,percentage of deliveries,premature uterine activity,fetal vascular blood flow,Efficacy and safety,Apgar scores,Apgar scores and umbilical artery and vein pHs,Neonatal outcome,success rate,tocolytic efficacy and maternal tolerance,number of admissions to the neonatal intensive care unit (NICU,recurrent labor,recurrence of preterm labor necessitating further tocolytic attempts,time to uterine quiescence,maternal side effects,mean arterial and diastolic blood pressure,number of neonates admitted into intensive care nor the premature infant center,side effects|The patients in the magnesium sulfate group had more adverse side effects, mainly nausea and vomiting (P =.004).
130|neurodevelopmental handicaps,incidence of intraventricular hemorrhage (IVH,IVH/PVH percentage,brain hemorrhage,hemorrhage,weight, gestational age, Apgar score, way of birth, initial diagnosis, incidence of pneumothorax, mortality and days with MV,motor activity and intraventricular hemorrhage,global incidence of intraventricular hemorrhage,overall incidence of intraventricular hemorrhage,severity of intraventricular hemorrhage,Blood levels,blood glucose, blood pressure, mean airway pressure, PCO2, PO2,intraventricular hemorrhage,blood pH,incidence of ventricular dilatation,hemorrhages|We found that IVH/PVH percentage is lowest in newborns from group III, followed by newborns from group II and group I.
680|incidence of diarrhoea,iron and zinc for weight-for-age z score, knee-heel length, and BSID psychomotor development,plasma HIV-1 viral load,knee-heel length,change in plasma zinc,prevalence of cough,incidence of pneumonia and diarrhoea,energy intake,morbidity,mean percentage of CD4+ T lymphocytes and median haemoglobin concentrations,Morbidity information,Weight, length, and other anthropometric indicators,incidence of diarrhea,growth, psychomotor development, and incidence of infectious disease,plasma zinc concentration,rates of other respiratory tract infections,Supplement consumption,plasma HIV-1 viral load and the percentage of CD4+ T lymphocytes,growth, morbidity, or motor development,diarrheal morbidity,mean plasma zinc concentration,plasma zinc concentrations,growth and psychomotor development,small gain in height,Zinc deficiency affects adversely T-helper1 (TH1) functions and cell mediated immunity and interleukin (IL)-2 production,acute lower respiratory tract infection,linear growth gain,pneumonia-related deaths,growth, development, or risk of infection,mean log(10) HIV-1 viral load,baseline characteristics, attained weight or length at 10 mo, growth velocity, gross motor development, and morbidity,vomiting,falciparum malaria,interleukin-2 production,immunocompetence, growth, and zinc, copper, and iron status,developmental quotient, hearing and speech, and performance,incidence of pneumonia,Morbidity,get watery diarrhoea,lymphocyte and granulocyte zinc,Weight-for-age z score,All cause mortality,incidence of symptomatic falciparum malaria,BSID psychomotor development index,bacteriologically positive infections,plasma zinc concentration, morbidity, and growth of young children,rate of pneumonia and diarrhoea,mean number of malaria episodes,mean temperature, and mean parasite densities during malaria episodes, nor in malaria parasite rates, mean parasite densities, and mean packed cell volume,morbidity, growth, and micronutrient status,Safety and efficacy,Serum copper and haemoglobin concentrations,adverse effects,growth, morbidity, and motor development,plasma zinc and other indicators of micronutrient status,fever and cough,diarrhoea and pneumonia morbidity,markers of copper or iron status,clinical pneumonia and diarrhoea,incidence of infections and hospital admissions,delayed hypersensitivity skin reactions, enhanced lymphoproliferative response to PHA, and increased salivary IgA concentrations,episodes of diarrhea, dysentery, and respiratory illness,children's morbidity and physical growth,Growth and indexes of body composition and gross motor development,diarrhea incidence,Anthropometric indexes, developmental indexes (Bayley Scales of Infant Development; BSID), and morbidity,severity of malaria episodes, prevalence of malaria parasite, mean parasite densities, mean packed cell volume, prevalence of other morbidity, and all cause mortality,number of hospitalizations and decreased number of vaso-occlusive pain crisis,Growth, final serum copper, and final haemoglobin,diarrhoea,Morbidity data,Weekly morbidity histories,indicators of copper or iron status,Watery diarrhoea,incidents of pneumonia,pneumonia and mortality,Development (assessed by use of the Griffiths Mental Development Scales), length, and weight,diarrhoea and pneumonia,childhood morbidity|Weight-for-age z score was higher in the Zn group than in the placebo and Fe+Zn groups, knee-heel length was higher in the Zn and Fe groups than in the placebo group, and the BSID psychomotor development index was higher in the Fe group than in the placebo group.
300|quality of care,quality-of-life scores,satisfaction with care, communication, or the discussion of patient problems,knowledge, confidence, and satisfaction,Quality of life,breast reconstruction surgery,discussion of pain, and role function,scores for quality of life (physical component score,survival or rates of objective progression,quality of life outcomes,quality of life and carer burden,cognitive functioning,average pain,most satisfaction subscales,symptom distress, enforced social dependency, and health perceptions,average and worst pain,Patient satisfaction,length of survival,presence and severity of physical symptoms, psychiatric morbidity, use of and satisfaction with services, and carers' problems,quality of life, SF-12; physical and mental component scores, (2) anxiety and depression: Hospital Anxiety and Depression Scale and (3) patient satisfaction: Patient Visit-Specific Questionnaire,Social Support Questionnaire and an uncertainty questionnaire,patient satisfaction and confidence,pain level,incidence of wound complications,knowledge and beliefs,subscale QoL scores and carer burden,continuity of care,Leakage along the drain,emotional functioning,global Quality of Life (QoL) scores,explicit use of HRQL data,quality-of-life outcomes,patients' quality of life,pain management index (PMI,Measuring quality of life,physical well-being dimension of health-related quality of life,pain control, sleep, cancer-related symptoms, or analgesic dosing,Symptom distress, fatigue level, quality of life, and healthcare usage,depressive symptoms, symptom distress, functional status, comorbidities, length of hospital stay, age of patient, and stage of disease,survival and health-related quality of life, measured with the use of the Medical Outcomes Study 36-Item Short-Form General Health Survey (SF-36), one year after randomization,higher satisfaction,mental health,patient satisfaction,quality of life or NHS resource use,Health related quality of life (EORTC QLQ-C30,APMI score at baseline, patients' level of physical functioning, patients' level of social functioning, the extent of adherence to pain medication, patients' pain knowledge,synergistic effects,satisfaction with communication, participation in care, or quality of life,Uncertainty, mood states, well-being, charges, and reimbursement,EORTC QLQ-C30 scales/items,chronic nonspecific symptoms,peripheral neuropathy,SF-36 mental health subscale,Mean (SD) scores,depression,ability to perform activities of daily living, physical performance, utilization of health services, and costs,higher social support and lower disease uncertainty,patient HRQL over time, measured by the Functional Assessment of Cancer Therapy-General questionnaire, physician-patient communication, and clinical management, measured by content analysis of tape-recorded encounters,pain medication level,vomiting,SF-36 subscales, activities of daily living, and physical performance,type and use of cancer-specific therapies,pain (Brief Pain Inventory); secondary outcomes of interest were all other symptoms (Memorial Symptom Assessment Scale) and quality of life (Functional Assessment of Cancer Therapy Scale,duration of drainage,confidence treating patients who were receiving CT (confidence), knowledge of adverse effects and reasons to refer the patient to the treatment center (knowledge), and satisfaction with information and shared care of patients (satisfaction,sexual functioning and cancer worry,subscales of complexity, inconsistency, and unpredictability,patient survival, activities of daily living (ADL), cognitive functioning, or morale,symptom severity,quality of life or patient satisfaction,Outcome measures: Quality of life, patients' satisfaction, general practitioners' satisfaction, survival, symptom-free survival, progression-free survival, use of resources, and comparison of costs,QOL indicators,pain intensity, interference because of pain, adequacy of analgesics used, or pain relief,Incidence of complications,symptom distress and social dependency,global QoL measures,Pain and nausea levels,debilitating physical symptom,symptom distress, and better SF-12 mental and physical QOL over time,physical symptoms and health-related quality of life (HRQoL,1) disease-specific quality of life, including sexual, urinary, and bowel outcomes and cancer worry; 2) depression; 3) dyadic adjustment; and 4) general quality of life,relative hazard of death,Health services utilization,HRQL improvement,pain, mood disturbance, and concerns,confidence,recurrence, time to detection and death rates,analgesic prescriptions,pain control,QOL assessments included the Center for Epidemiological Studies-Depression Scale , the ambiguity subscale of the Mishel Uncertainty in Illness Scale , the Symptom Distress Scale, and the Short-Form Health Survey (SF-12,Overall costs,costs,severe dyspnoea,satisfaction,symptom distress, fatigue, quality of life, and healthcare usage,psychosocial morbidity,quality of life,2-year survival,Patient functioning, and patient and caregiver morale and satisfaction with care,physical and emotional functioning, pain, and psychologic distress assessed monthly by using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) questionnaire and Impact of Event scale (IES,patient satisfaction and arm function on the affected side 2 months after diagnosis,total per capita health care costs, including HBHC,psychological functioning,quality of pain treatment,complication rate, patient satisfaction, and psychosocial outcomes,median number of seroma aspirations per patient,health perceptions,Symptom Distress Scale, Brief Fatigue Inventory, and Functional Assessment of Cancer Therapy Scale-General version,quality of life (QOL) and cost outcomes,mortality,QOL, psychosocial functioning, or satisfaction,normal arm function,contact rates,Type of care, costs, patient satisfaction, ostomy adjustment, and time to achieve ostomy self-care,QOL summary scores (total and overall QOL,satisfaction survey and Maklebusts Ostomy Adjustment Scale,Telephone questionnaire,survival,cancer needs, QOL, or psychosocial functioning,pain relief,QOL outcomes,anxiety,pain levels,axillary dissection,psychosocial problems (uncertainty, anxiety, loneliness, disturbed sleep, loss of control, threat to self esteem), physical or psychological complaints, or in the coping strategies used,scales of depression,Total costs,symptoms or quality of life,quality of life and cost outcomes,patient satisfaction, arm morbidity, impact on community nurses, health service costs, surgical cancellations and in-patient nursing dependency,HRQL,incidence of pain,Satisfaction with care,ratings of pain intensity,levels of anxiety, depression and perceived needs,role-emotional and mental health subscales,investigations, number and timing of recurrences and deaths,periodic pain assessments,Psychosocial functioning, anxiety, and depression,hospital doctor,symptoms, HRQoL, mood and 'emotional bother' in 'full-PCT,global health status,usual pain intensity,general practitioners' overall satisfaction,QOL over time (measured by the Functional Assessment of Cancer Therapy-Lung questionnaire and the Palliative Care Quality of Life Index), discussion of patient problems, and satisfaction with communication and general care,Cornell Medical Index M-R scales (greater emotional disturbance,Global health status, emotional functioning, and cognitive functioning,Amsterdam Pain Management Index (APMI), consisting of an integrated score of patients' Present Pain Intensity, Average Pain Intensity, and Worst Pain Intensity,patient satisfaction or GP confidence,QOL, and psychosocial functioning and satisfaction with overall care received,average and worst pain levels,functional decline|Patients in the augmented group improved significantly over the control group in ratings of pain intensity at its worst, whereas patients in the basic group had better ratings of pain intensity on average.
not found|red blood cell count, hemoglobin level, and hematocrit returned to the preoperative levels,Perioperative blood loss,quality of the fixation,Inducible displacement,total blood loss,tibial components,Progressive radiolucent lines,perioperative blood loss|Between 1 and 2 years, 4 of 24 HA-coated and 10 of 23 cemented implants migrated >0.2 mm and were categorized unstable, which has been shown to have a prognostic value as regards future aseptic loosening.
not found|Vestibular time constants,posturography and subjective scores,vertigo,persisting peripheral vestibular deficit,subsequent relapse,motion sensitivity and dizziness handicap,dynamic gait index results and anxiety,dynamic posturography, vestibular time constants, and questionnaires concerning symptoms, symptom-triggers and emotional status,optokinetic reflex (OKN) response to 60 degrees/s constant velocity optokinetic stimuli,visual vertigo symptoms,balance performance,DVA-predictable,Increased independence and decreased vertigo,visual vertigo symptom scores,dynamic visual acuity,Vertigo decreased and independence in activities of daily living,cure rates,reduced symptoms, anxiety, handicap, and negative beliefs about dizziness,postural stability,visual acuity,reduction of symptoms,visual vertigo (SCQ,VOR gain, VOR time constant, and OKN gain,benign paroxysmal positional vertigo,hearing improvement,Timed Up and Go test, Tandem Gait and Dynamic Gait Index,single leg stance,VOR response,tinnitus, dizziness or increasing hearing ability,dizziness, only vestibular rehabilitation also improves balance,clear locomotor gains,psychological symptoms,symptom, disability, balance, and postural stability,perception of dysequilibrium,symptom remission,demographics data and duration and intensity of symptoms,Subjective improvement in health, enablement (ability to understand and cope with symptoms), and adherence,Anxiety and depression levels,mean scores of the VDI,physical indices of balance and subjective indices of symptoms and distress,peak-to-peak magnitude and total amount of anterior-posterior body sway, and of horizontal (shear) ground reaction force,vestibulospinal compensation,total SP values,Vertigo, Dizziness, Imbalance Questionnaire (VDI), which consists of two subscales, the VDI symptom subscale (VDI-ss) and the VDI health-related quality of life (VDI-HRQoL) subscale, and the Vertigo Symptom Scale (VSS,Odds ratios,Balance performance,vertigo intensity and frequency with the use of the Vertigo Symptom Scale, the Vertigo Handicap Questionnaire, the Vestibular Disorders Activities of Daily Living Scale, and the Dizziness Handicap Inventory,visual analogue scale anxiety score,changes of pitch and loudness,Symptoms, handicap, anxiety and depression, and negative beliefs about symptoms,standing balance, Timed Up and Go test and Tandem Gait,equilibrium scores in dynamic posturography, asymmetry index in rotation testing, motion sensitivity quotient (MSQ), and dizziness handicap inventory (DHI,VSI mean scores, VDIss mean scores, and VSS mean scores,posturography scores,normalization of OT and SVV,vertigo intensity and frequency, low-frequency vestibulo-ocular reflex (VOR), posturography and path integration,visual dependence,dysequilibrium and nausea,Vertigo intensity and frequency,cure rate,locomotor stability,Static balance tests, tandem walk test, Dynamic Gait Index and subjective rating of the intensity of vertigo,dizziness handicap questionnaire and a visual analogue scale for anxiety,subjective visual vertical (SVV) for perception, and 3) the total sway path (SP) values,gait velocity and stability,Dynamic Gait Index,eyes-opened length of the oscillations and eyes-opened and eyes-closed surface of the body sway,Changes in oscillopsia,symptoms (visual analog scale [VAS]), disability (Dizziness Handicap Inventory [DHI]), balance (Berg Balance Scale [BBS]), and postural stability (modified Clinical Test for Sensory Interaction on Balance [mCTSIB,standing balance performance,vestibulo-ocular reflex (VOR,postexercise VAS, DHI (emotional, functional, physical, total), BBS, and mCTSIB (standing on a firm surface with eyes open, standing on a foam surface with eyes open, standing on a foam surface with eyes closed, mCTSIB mean,dynamic visual acuity (DVA,symptoms, postural stability, and dizziness-related handicap,balance ability and functional gait performance,ability to hear,VSS,reductions of eyes-opened length and of eyes-opened correlation function between length and surface,hearing ability, tinnitus and dizziness,balance scores,symptom, disability, balance, and postural stability in chronic unilateral vestibular dysfunction,visual analogue scales,static balance and a dizziness handicap,central vestibulospinal compensation,adherence levels,VDI-HRQoL mean scores,Dizziness,parameters (VAS, DHI, BBS, mCTSIB,dizziness and imbalance,reduced handicap,baseline, 3-month, and 6-month assessment of self-reported spontaneous and provoked symptoms of dizziness, dizziness-related quality of life, and objective measurement of postural stability with eyes open and eyes closed,visual analogue scale, physical examination, and need to use the medication|The use of exercises in the treatment of patients with vestibular deficits has become increasingly popular, and evidence exists that these exercises are beneficial in patients with chronic vestibular deficits.
65|IOP reduction,final success rate,mean IOP,Adjunctive medication requirement,cumulative probabilities of success (intraocular pressure,mean intraocular pressures,Success rates,intraocular pressure,mean postoperative IOP,complications,severe complications,overall success rates,intraocular pressures (IOP,Surgical success,incidence of complications and the success rate,choroidal detachment,collagen synthesis,shallow anterior chamber,elevated IOP,serum markers of collagen synthesis,introcular pressure (IOP,visual acuity,Complete success rate,Intraocular pressure (IOP) and the appearance of the bleb,adjunctive medication requirement,cumulative success rate,preoperative mean IOP,frequency of complications,postoperative complications,postoperative intraocular pressure (IOP,mean IOP, number of glaucoma medications, and complications,Complications,Preoperative IOPs and visual acuities,Efficacy and safety,survival rates,Visual acuities,preoperative visual acuities,Visual acuities, implant-related complications, and average IOPs,shallow or flat anterior chambers with hypotony,rate of hypertension,Postoperative visual acuity, glaucoma medications, and complications,probability of success,Lower IOPs,Mean numbers of postoperative antiglaucoma medications,success rate with MMC and without MMC,1- and 2-year life-table success rates (success [survival,short- or intermediate-term success rates,Molteno tube shunt surgery,final postoperative visual acuities,cumulative probabilities of success,final intraocular pressure,Mean number of preoperative antiglaucoma medication,IOP,Mean preoperative intraocular pressures,cataract formation,incidence of complications,postoperative visual acuity, visual field, anterior chamber depth, and short-term or long-term complications,mean intraocular pressure,final intraocular pressure [IOP,Early postoperative hypotony,surgical outcome,hyphema,successful intraocular pressure control,Complications or inadequate pressure control requiring further surgical intervention,overall IOP control,intraocular pressure (IOP), visual acuity, and complication rates,transient elevations of IOP,hypertensive phase,IOP reductions,rate of complications,life-table success rates,Choroidal hemorrhages and/or effusions, corneal decompensation, flat anterior chambers, and phthisis bulbi,postoperative antiglaucoma medication,preoperative IOP, log mean angle of resolution (LogMar) visual acuity, or number of preoperative medications,postoperative pressure spikes,intraocular pressures,rate of hypotony and surgical complications,visual acuity, visual field, lens status, and final anterior chamber depth,devastating complication,Intraocular pressure, visual acuity, and complications,success rate,IOPs and the cumulative probabilities of success,Final visual acuity,intraocular pressure from preoperative level,Postoperative intraocular pressure,postoperative IOPs, visual acuities, number of medications used, and implant-related complications|The success rate with MMC and without MMC were 90.0%, 77.3% (P < 0.05) at the 1st year, 87.1%, 67.3% (P < 0.05) at the 2nd year, 83.3%, 61.1% (P < 0.05) at the 3rd year, 81.3%, 56.7% (P < 0.05) at the 4th year, and 75.0%, 50.0% (P < 0.05) at the 5th year using Kaplan-Meier life-table analysis.
215|Gleason score,3-year progression rate,median PSA level,serum prostate-specific antigen (PSA) measurements,serum PSA levels despite androgen blockade,Median cycle length and percentage of time off therapy,biochemical failure,time to androgen-independence of the tumor,biopsy Gleason score, and baseline serum PSA levels|Of the 157 cases treated with EBRT, 153 cases (97.5%) had no biochemical failure in the mean follow-up of 17.3 months.
                
230|Agranulocytosis,ejection fraction and plasma norepinephrine,Quality of life,hemodynamic parameters of left-ventricular performance,longer survival,morbidity,Maximal oxygen consumption,mortality and morbidity,Symptom score,adverse effect on survival,physical mobility score,hazard of death,adverse effect,frequency of worsened heart failure,mortality and quality of life,Heart failure symptoms,adverse cardiac events and physical activities,symptoms or exercise duration,exercise time, ejection fraction, frequency of ventricular premature complexes or ventricular tachycardia,combined adverse cardiac events,Increased ventricular arrhythmias,worsening heart failure,maximal treadmill exercise time,died,lower morbidity and mortality,treadmill exercise time,median exercise time,overall LWHF score,cardiovascular mortality,syncope,Diuretic doses,dropout rate,exercise tolerance, ventricular function, and symptoms of heart failure,severe worsening of heart failure,exercise capacity and adverse events,morbidity and mortality,early mortality,deaths,exercise capacity,treadmill exercise time, responses to the Minnesota Living With Heart Failure Questionnaire (LWHF), and clinical assessments,Adverse effects,physical activity,quality of life and for increased arrhythmias,exercise time,symptom limited exercise tolerance,oxygen consumption,Exercise time,degree of dyspnea and patient and physician assessments of clinical status,cardiac events,serious adverse cardiovascular reactions, including hypotension,left ventricular ejection fraction at rest,borderline significance,quality of life,placebo mortality,Heart rate, ventricular ectopic activity, and mortality rate,reversible neutropenia,tolerated,imazodan mortality,New York Heart Association classification,cardiac status,sudden death,mortality,cumulative incidence of combined adverse cardiac events,exercise duration, peak VO2, and quality of life,survival,Proarrhythmic effects (24-hour electrocardiography,mean Specific Activity Scale score,frequency of decompensation from heart failure,exercise tolerance,headache,Death and hospitalization for cardiac causes,Efficacy,efficacy and safety,subjective state, hemodynamic parameters, and arrhythmias,Adverse events,exercise performance,hospitalizations,adverse events,Peak VO2,exercise duration,exercise tolerance and quality of life,mean ejection fraction,ventricular arrhythmias,exercise duration (bicycle ergometry,Left ventricular ejection fraction,reduction in risk,quality of life measured with the Minnesota Living With Heart Failure Questionnaire,Mean heart rate and ventricular ectopic activity|Treatment with milrinone or digoxin significantly increased treadmill exercise time as compared with placebo (by 82 and 64 seconds respectively; 95 percent confidence limits, 44 and 123, and 30 and 100).
17802|rates of pulmonary embolism,pulmonary embolism or deep-vein thrombosis,venous thromboembolism,provoked venous thromboembolism,rates of venous thromboembolism,occurrence of symptomatic venous thromboembolism,rates of deep-vein thrombosis,symptomatic venous thromboembolism,rates of bleeding episodes|The rates of pulmonary embolism were 0.09 in the rosuvastatin group and 0.12 in the placebo group (hazard ratio, 0.77; 95% CI, 0.41 to 1.45; P=0.42), whereas the rates of deep-vein thrombosis only were 0.09 and 0.20, respectively (hazard ratio, 0.45; 95% CI, 0.25 to 0.79; P=0.004).
22|low white blood cell (WBC) count,geometric mean titers (GMT) and 4-fold rises in HAI titers,influenza virus susceptibility,Hemagglutinin-inhibition (HI) antibody titers,seroconversion rate,Immunoglobulin levels and neutropenia,seroresponse rates,Antibody responses,seroconversion and seroresponse rates,HI titers,Hemagglutinin-inhibition (HAI) antibody titers,protective antibody titres,hemagglutination inhibition titer,Seroconversion rates,hemagglutination inhibition (HI) titers,Seroresponse rates,response rate,protective" titers,Immune response,immune response,tolerated,Antibody titers,protective responses,protective response,HAI titers,titer of antibody,response rates,immune response and the peripheral white blood cell count,total white cell count or neutrophil count at immunisation, type of cancer, or length of time on treatment for acute lymphoblastic leukaemia,Protective titer rates,antibody titers,Immune responses|After the second immunization, children off therapy showed significantly higher antibody titers to both antigens than did children receiving therapy or controls (P less than 0.01 for both A/NJ/76 and A/Vic/75).
1702|community-acquired pneumonia,Treatment failure,very fast breathing,hypoxia,treatment failure (persistence of lower chest indrawing or new danger signs|Treatment failure was 19% in each group (161 patients, pencillin; 167 amoxillin; risk difference -0.4%; 95% CI -4.2 to 3.3) at 48 h. Infancy (age 3-11 months; odds ratio 2.72, 95% CI 1.95 to 3.79), very fast breathing (1.94, 1.42 to 2.65), and hypoxia (1.95, 1.34 to 2.82) at baseline predicted treatment failure by multivariate analysis.
                
182|final decision quality scores,degree of information provision; audiotape satisfaction and use; communication satisfaction with oncologist; mood state; and cancer-specific quality of life,perception of being informed about clinical trials, knowledge of information relevant to providing informed consent to a clinical trial, and satisfaction with communication during the consultation,Average recall,quality of medical consultations,recall of the information given during the consultation,Spontaneous (ie, unprompted) recall,patient satisfaction, psychologic adjustment, and recall of information,Satisfaction,levels of anxiety,recall, anxiety, or depression,retention of information,patient recall, anxiety and depression, satisfaction with and use of the communication aids, and patient preferences for six communication options,Levels of depression,quality of life,sociodemographics, preferences for information, coping styles, and clinical characteristics,recall of having discussed side effects,recall of diagnostic information,patient satisfaction with communication, mood state or quality of life,satisfaction, recall, and quality of life,patient satisfaction with communication, mood state, or quality of life,degree of information provision, audiotape satisfaction and use, communication satisfaction with oncologist, mood state, and cancer-specific quality of life,enhancing satisfaction,cancer patients' satisfaction, recall, and quality of life,length of time required for the consultation,patient satisfaction,total recall,state anxiety levels|Satisfaction with the tape and letter were uniformly high and they did not differentially affect recall, anxiety, or depression.
109|nausea,Survival,survival,5-year survival,5-year survival rate,Grade 3 and 4 toxicities (World Health Organization), mainly stomatitis,rate of intrahepatic recurrence and improve survival,Median time to failure (TTF,median disease free interval after hepatectomy,median time to progression,time to recurrence and hepatic disease-free survival, not overall survival,recurrence,TTF and survival,initial tumour relapse,Median survival,Two- and 5-year cumulative survivals,TTF,Intrahepatic recurrence,4-year liver recurrence-free rate,adverse effect,4-year recurrence-free rate,disease free survival,probability of remaining free of recurrent disease,1-year, 2-year, and 3-year disease free survival rates,median survival,1-year, 3-year, and 5-year cumulative survival rates,dead of disease,colorectal carcinoma develop liver metastases,risk of death|The 4-year liver recurrence-free rate was 43% in the control group and 67% in the chemotherapy group (P =.03).
not found|internal rotation,intensity of pain,shoulder pain with activity,range of motion in abduction and internal rotation,mean pain duration, activity of the extremity and hours of sleep,subscapularis pushoff,Pain,pain scores, range of motion, internal rotation impingement, muscular force, and patient outcomes,Age, sex, pain (measured with an analog visual scale) and adverse events,asymptomatic with activities of daily living,free of symptoms,internal rotation impingement,pain,external rotation,headache,mild pain|Topical glyceryl trinitrate treatment significantly improved pain scores, range of motion, internal rotation impingement, muscular force, and patient outcomes in patients with supraspinatus tendinopathy.
45|heart rate, NE requirements, and incidence of new-onset tachyarrhythmias,Splanchnic blood flow and VO2,rebound hypotension,acute coronary syndrome,oxygenation, PaO2/FIO2, heart rate, mean arterial pressure, and mortality,mean arterial pressure, PaO2/FIO2, and survival time,hemodynamics, lactate metabolism, and gastric tonometric variables,Acute Physiologic and Chronic Health Evaluation II score,oxygen delivery and oxygen consumption,splanchnic tissue oxygen utilization,time to vasopressor withdrawal,time course of SOFA score,arrhythmic events,90-day mortality,Oxygen delivery index,systemic vascular resistance index,blood flow distribution and regional oxygen transport,lactate/pyruvate ratio,intraoperative refractory arterial hypotension,time to vasoactive-free hemodynamic stability,Median time to achieve the MAP goal,systolic arterial blood pressure and heart rate,Gastric mucosal pH (pHi,Mean stay in the PICU,Mean arterial pressure and PaO2/FIO2,hemodynamic and tonometric parameters, arterial and mixed venous gases, and lactate and pyruvate blood levels,heart rate,Mean arterial pressure, cardiac index, stroke volume index, and left ventricular stroke work index,cardiac index,gastric mucosal acidosis and global metabolic changes,Global hemodynamic variables, oxygen consumption, urine flow, creatinine clearance, and arterial blood lactate levels,overall rates of serious adverse events,terlipressin-linked decrease in Svo2,28-day mortality rate,gastric mucosal blood flow,norepinephrine requirements,cardiac output and global oxygen supply,Regional blood flow and oxygen transport,splanchnic oxygen requirements,systemic and regional hemodynamics,mean arterial blood pressure,intraoperative maximum and minimum values of blood pressure and heart rate, and the time spent with systolic arterial blood pressure,cutaneous reactive hyperaemia or the oscillatory pattern of vascular tone,hemodynamic variables, organ dysfunction, and adverse events,rate of death,28-day all-cause mortality,PaO2/FIO2 rates, length of stay, and mortality rate in PICU,cause 28-day mortality,acute circulatory failure,systemic blood flow and VO2,Blood urea nitrogen, creatinine, AST, ALT, and urine output,systolic arterial pressure,Efficacy and safety,bilirubin concentrations,cardiac index and oxygen consumption,partial pressure of carbon dioxide (PCO2) gap (tonometer PCO2-arterial PCO2,normal systolic arterial blood pressure,Oxygen consumption (VO2,catecholamine requirements,28-day mortality,Renal function,oxygen uptake,Cutaneous vascular reactivity and flow motion response,achievement of MAP goal >24 h without vasopressors,cardiac output by decreasing heart rate, increased creatinine clearance, and improved SOFA score,oxygen transport,systemic and pulmonary hemodynamic or blood gas,mortality rate,number of days without need for organ support and the occurrence of adverse events,maintain mean arterial pressure (MAP,oscillation frequency of the Doppler signal before ischaemia,incidence of sinus tachycardia with DA,cardiac arrhythmias,adverse event rate ratios,arterial pressure,renal function and SOFA score,Hemodynamic parameters and Sequential Organ Failure Assessment (SOFA) score,Systemic, pulmonary, and regional haemodynamic variables,mean arterial pressure,catecholamine pressors withdrawn and blood pressure,Reactive hyperaemia and oscillatory changes in the Doppler signal,blood pressure,systemic hemodynamic measurements,organ dysfunction, hospital and intensive care unit length of stay, and safety (primarily occurrence of arrhythmias,time to haemodynamic success,arrhythmia,stroke volume,milrinone requirements,cutaneous microcirculatory response,Systemic and regional hemodynamics and oxygen transport,gastric tonometry,Gastrointestinal perfusion,Rates of serious adverse events,Urine flow and creatinine clearance,mortality, organ-failure-free days, length of critical care unit stay, and adverse events,mean arterial pressure (MAP) goal,hemodynamic profile, oxygen delivery, oxygen consumption (determined by indirect calorimetry), and gastric intramucosal pH (pHi) (determined by gastric tonometry,mortality,systemic vascular resistance,pHi,systemic and splanchnic oxygen utilization,time spent with systolic arterial blood pressure,efficacy and safety,platelet count,severe septic shock,hospital discharge,time to achieve MAP goals,adverse events,septic shock,lactate levels,Terlipressin and norepinephrine corrected arterial hypotension,Mean arterial pressure, systemic vascular resistance, pulmonary vascular resistance, and left and right ventricular stroke work,Mean arterial blood pressure,consumption index,Blood lactate concentrations,length of stay,died of refractory hypotension,new-onset tachyarrhythmias,peripheral blood flow or on renal blood flow,systemic and pulmonary hemodynamics (arterial and Swan-Ganz catheters), gastric mucosal blood flow (laser Doppler flowmetry technique), hepatic function (indocyanine green clearance), and blood gases,mortality rates,peripheral vasoconstriction (systemic vascular resistance,Total bilirubin concentrations,Arterial pressure and systemic vascular resistance|There were no differences among groups in terms of systemic and regional hemodynamics.
not found|metabolic parameters considered (24-hour mean blood glucose and glycosylated hemoglobin,need of insulin, the maternal body weight gain, the week and mode of delivery, the neonatal weight and the maternal and fetal complications,eventual presence of urinary keton bodies and hypoglycemic crisis,mean glycemic values,control of foetal growth,mean insulin requirement,mean insulin requirements,blood glucose levels|No significant differences in mean insulin requirement at the different stages of gestation were found between the patients receiving CSII and those receiving ICT of either group.
56|risk of pancreatitis,frequency, duration and extent of such temporary symptoms as abdominal discomfort, fever, leukocytosis, hyperamylasemia, hyperamylasuria and cholestasis,frequency of pancreatitis and bacterial complications,malignant distal strictures,normal biliary tracts,septic complications,absolute risk reduction,Bacteremia,Clinical success,CRP level, and leukocyte count,complications (pancreatitis, pancreatic and biliary sepsis,hyperamylasemia,cholangitis,post-ERCP pancreatitis,leukocyte count and liver function values,lack of antibiotic prophylaxis,frequency of cholangitis following ERCP,total rate of complications,liver chemical values,diagnosis of acute pancreatitis,septicaemia rate,serum amylase levels,clinical signs of acute pancreatitis with leukocytosis, CRP reaction, and pain,C-reactive protein (CRP) level,Acute cholangitis,bacteriologic failure (bacteremia,Incidence of bacteraemia,absence of fever, cholangitis, and clinical signs of sepsis,acute cholangitis,serum amylase level,number of septicaemias (bacteraemia with fever, rigor, circulatory reactions, leukocytosis or leukopenia|Incidence of bacteraemia was 6.1% (3 of 49) in group A, 16% (8 of 50) in group B, but this difference is not statistically significant.
25|Kurtzke functional and expanded disability status scales,visual analog scale (VAS,bout duration,rate of CNS IgG synthesis,P3 peak latency,pyramidal function,Expanded Disability Status Scale score,disability scores,CNS IgG production,frequency of improvement,Scripps Neurological Rating Scale (NRS) and Kurtzke Expanded Disability Status Scale,NRS score and answers to an efficacy questionnaire,serious adverse events,NRS scores,ERPs,clinical disability scores,NRS and VAS scores,VAS scores|Changes in NRS scores among methylprednisolone- and placebo-treated patients differed significantly in the first 3 weeks and after 8 weeks (p = 0.005 and p = 0.0007).
not found|recurrence of pain,significant relief from menstrual pain,urinary urgency,midline component of menstrual pain,relief of dysmenorrhea, pelvic pain, and deep dyspareunia after surgery according to a multidimensional and an analog pain scale,frequency and severity of dysmenorrhea, pelvic pain, and dyspareunia,efficacy of LPSN,dysmenorrhea,Acceptable pain,postoperative ischemic pain,age, history of abdominopelvic surgery, intraperitoneal adhesions, endometriosis, concomitant surgery, and operating time,frequency and severity of postoperative pain,frequency and severity of dysmenorrhea, dyspareunia, and chronic pelvic pain,relief of midline pain,Relief of lateral pain, back pain, and dyspareunia,cure rate,frequency and severity of dysmenorrhea,continued relief of menstrual pain,Dysmenorrhea improvement,abdominal pain postoperatively,Moderate or severe dysmenorrhea,recurrence of moderate or severe dysmenorrhea|Relief of lateral pain, back pain, and dyspareunia was variable in both groups.
not found|Time-to-onset of CMV disease and to viremia,demographics, primary renal disease, graft source, HLA matching, immunosuppressive therapy and donor-recipient CMV antibody status,symptomatic herpes-simplex infections,median time to onset of CMV infection,CMV,tissue invasive disease and recurrent CMV disease,infection, disease, or sequelae of cytomegalovirus infection,demography, immunosuppression, or donor/recipient CMV serology,incidence of investigator-treated CMV disease events,CMV-specific immunoglobulin M antibodies, CMV immunofluorescence assay [standard culture tube and shell vial] (blood) and virus isolation (urine and tissue,rates of CMV viremia and viruria, herpes simplex virus disease, and the use of inpatient medical resources,CMV infection, symptomatic CMV infection, and CMV disease,neutropenia with valganciclovir,rates of recovery of virus from the blood and urine,cytomegalovirus pneumonia,frequency of CMV or EBV disease,rate of biopsy-confirmed acute graft rejection,morbidity,opportunistic infections, and acute graft rejection,actuarial incidence of cytomegalovirus disease,cytomegalovirus (CMV) infection and disease,Acute rejection episodes,nephrotoxicity,CMV disease severity, CMV infection, acute rejection, opportunistic infections, ganciclovir resistance, and safety,risk of acute renal allograft rejection,incidence of CMV infection in both CMV antibody positive,CMV disease, plasma viremia, acute graft rejection, graft loss and safety,cytomegalovirus infection,Symptomatic CMV disease,confirmed CMV disease,Rates of acute rejection, opportunistic infections, adverse events, CMV UL97 ganciclovir-resistance mutations, and laboratory abnormalities,severe CMV disease,delayed CMV infection,rate of cytomegalovirus infection and disease without affecting the survival rate,cytomegalovirus syndromes,incidence and severity of CMV disease, length of hospitalization, and patient and allograft survival,Infection rates,concanavalin A stimulation,CMV infection,risk of CMV disease,incidence of cytomegalovirus disease,Pneumonitis and myocarditis,frequency of adverse events,occurrence of CMV infections,incidence of cytomegalovirus (CMV) disease,death from CMV disease,symptomatic CMV disease,12-month incidence of CMV disease,Hallucinations and confusion,excessive occurrence of cytomegalovirus disease,delayed acute rejection,safety and efficacy,incidence of documented cytomegalovirus infection,average CMV-associated costs per patient,incidence of CMV infection,neurotoxicity,Incidences of leukopenia, thrombocytopenia, renal failure, and other adverse events,efficacy, safety, and cost,CMV viremia,median time to CMV antigenemia,Efficacy and safety,laboratory-confirmed CMV disease,total mortality,risk of acute rejection,median time to onset of CMV disease,freedom from CMV disease (syndrome or tissue-invasive,Lymphocyte proliferation,Liver function tests,peripheral blood leukocytes (PP 65), shell vial culture (blood), and virus isolation/early antigen detection (urine,lower activated T-cell count (CD3(+)HLA-DR(+) cells,Cytomegalovirus disease,CMV diseases,obliterative bronchiolitis or time to onset of grade 2 bronchiolitis obliterans syndrome,prevalence of obliterative bronchiolitis (OB,estimated cost of valacyclovir treatment,CMV illness,morbidity of cytomegalovirus disease,Cytomegalovirus,leukopenia,CMV disease,probability of presenting CMV disease,Leukopenia,time to disease,renal transplantation,allograft survival,cumulative incidence of all CMV infections (including seroconversions,incidence of CMV disease, and delayed the onset of CMV infection,rate of biopsy-proven acute rejection,incidence of CMV disease and viremia,adverse reactions,time to asymptomatic CMV infection, symptomatic CMV infections, and end-organ CMV disease,duration of disease,incidence of overt CMV shedding and/or pneumonitis,Ganciclovir resistance,incidence of CMV disease 90 days after transplantation,lymphocyte function,incidence or delayed the onset of CMV disease,Severity of CMV disease,length of hospitalization,tolerated,rate of CMV infection,biopsy-confirmed acute rejection rate,number of rejection, steroid pulses, and OKT3 treatments,Reversible leukopenia,clinically effective and well-tolerated,serum creatinine concentrations,rate of CMV disease,sequelae of cytomegalovirus (CMV) infections,cytomegalovirus disease,Leucopaenia,CMV infection, CMV disease, rejection, opportunistic infections, and possible drug toxicity,frequency of clinical infections,incidence of symptomatic disease or viremia,time to CMV infection and disease the first 6 months after transplantation,episodes of biopsy proven allograft rejections,acute allograft rejection,rate of CMV infection and CMV disease,cytomegalovirus (CMV) disease,tissue invasive disease,PCR evidence for CMV viremia,CMV disease and infection,survival advantage,incidence of allograft rejection,CMV infection, disease, and disease severity without increased ganciclovir resistance or toxicity,time to development of CMV antigenemia,urine cultures positive for CMV,efficacy and safety,time to CMV disease,rates of other adverse events,rate of viral shedding,delayed infections,delay between transplantation and CMV infection,rate of EBV disease,Adverse events,CMV and OB,CMV infection and CMV disease) and secondary endpoints (rates of fungal and bacterial infection, allograft rejection, and survival after transplantation,opportunistic or other herpesvirus infections,safety profile,time to CMV disease or viremia,CMV serostatus, CMV disease, graft outcome, and ganciclovir side effects,adverse events,Overall patient survival,transplant function,tissue-invasive infection,detection of CMV DNA, virus infections other than CMV, acute rejection episodes, and serum creatinine levels,CMV colitis,number of bacterial infections,Surveillance blood cultures,cytomegalovirus disease and cytomegalovirus viremia,Time to CMV viremia,disease severity,infection with Candida albicans,incidence of CMV disease,symptomatic cytomegalovirus disease|This superior protection against CMV disease extends up to 1 year after transplantation and is not associated with ganciclovir resistance.
40|oral soft tissue disease and oral microbial burden,morbidity of concurrent chemotherapy and radiotherapy,radiation- and chemotherapy-induced mouth lesions,Toxicity incidences,OM,severity of late xerostomia,Stomatitis,time to development of severe mucositis,RTOG Grade 3 or greater mucositis,median total tumour and biologically effective dose (BED) Gy10,mouth pain and difficulty swallowing,plasma levels,varying degrees of radiation-induced mucositis,occurrence rate of grade 1-2 mucositis of the oral cavity,nutritional status and overall patient outcome as assessed by days receiving TPN, number of days required until oral intake resumed, length of hospitalization, number of days and highest grade of mucositis, and quantity and number of days of diarrhea,average mucositis score,median time of mucositis occurrence,grade three mucositis,Oral mucositis (OM,Toxicity profiles,Weight,tumor response or survival,grades of stomatitis and diarrhea,occurrence rate of skin, oral mucosal, pelvic visceral and systematic adverse reaction,grade of mucositis,xerostomia and mucositis,albumin and low molecular weight protein urinary excretion,severity of acute side effects,Grade > or =3 mucositis,occurrence of mucositis, the median duration of oral mucositis,colonization index of viridans streptococci,median duration of mucositis,average unstimulated salivary flow,lactulose-mannitol ratio,alleviate oral mucositis,frequency,toxicity, engraftment, supportive care, response and survival,neutrophil phagocytosis, superoxide anion generation (SAG), prevention of chemotherapy-induced side-effects and cost-effectiveness,mucositis and dermatitis,radiation-associated xerostomia,Objective Mucositis Score (OMS) and the World Health Organization (WHO) grading system,severe leukopenia,OM characteristics, fever of unknown origin (FUO) and other infections,intensity or duration of mucositis,Grade 0 mucositis,hematological toxicity,percutaneous endoscopic gastrostomy,frequency of grade 2 to 4 mucositis,safety and efficacy,morbidity and mortality,complete remission,Major toxicities,delays in radiotherapy because of grade 3 mucositis,Candida colonisation,proinflammatory cytokines (tumor necrosis factor, interleukin [IL]-1, and IL-6) and lower levels of anti-inflammatory cytokines (IL-13,risk of oral mucositis,WHO grade 1-4 oral mucositis,lower number of days with fever and a shortened duration of hospital stay,tooth staining,anesthetic mouth washing and their salivary lactoferrin and albumin levels,toxicity (eg, mouthwash-induced discomfort, taste alteration, and teeth staining,severe oral mucositis,prevention and reduction of severity of conditioning-induced oral mucositis (OM,degree of oral injury,detectable plasma concentration of GM-CSF,cervical muscular sclerosis,frequency or type of mouth lesions,cumulative asthenia,weight, prealbumin level, or blood cell count,salivary lactoferrin concentrations,grades of oral mucosa ulceration,subjective intolerance, mucositis, dysphagia, dermatitis and nausea,length of hospitalization or weight loss,total oral streptococci,Mucositis reduction,nausea and/or vomiting,Mucosal toxicity,oral toxicities,severe (grade 3 or 4) mucositis,Colonisation index of Candida species and Gram-negative bacilli,intestinal permeability (IP,pain control,pain on swallowing and use of pain medication specifically for mucositis,survival time,mean toxicity score for cryotherapy,standard error of the mean) maximum mucositis scores,frequency of chemotherapy-induced mucositis,Grade 2 or higher acute xerostomia,median length of stay and the median number of days of total parenteral nutrition (TPN,frequency and duration of severe oral mucositis,adverse effects,simple visual analogue scale,Mucositis grade 3-4,thickening of oral mucosa,grading of acute and late nonhematologic toxicities (mucositis, dysphagia, xerostomia,incidence of mucositis,radiation-induced mucositis,mean questionnaire scores,incidence rates of mucositis, pain, xerostomia and taste disturbance,earlier onset of mucositis,Subsequent mucositis,grade four mucositis,demographic parameters, medical status, quality of life survey and mucosal injury scoring table (based on World Health Organization scales for mucositis,urinary excretion of 51Cr-EDTA and the severity of mucositis,mucositis distribution,frequency and severity of therapy-induced oral mucositis,oral mucositis (OM) and diarrhea,rates of xerostomia and mucositis,Salivary lactoferrin,tolerance problems (vomiting, liver enzyme elevation, generalized erythema,degree of oropharyngeal and hematological toxicity, radiotherapy duration, and curative effect,pain requiring opioids (chi(2) exact test, NS,oral candida,partial remission,Neck dissection,oral mucositis grade, oral pain, use of analgesic drugs, weight loss, or survival,severity of OM,objective score of edema, erythema, erosion and ulcerations,Acute toxicity,grade of radiation mucositis and blood cell counts,OM severity,oral mucosal complications,Engraftment of neutrophil,Minimal or absent mucosal inflammation pain or dysphagia,intestinal permeability,grade 3/4 thrombocytopenia,GFR,incidence of grades 3-4 mucositis,median duration of grade >or= 2 mucositis,Nasogastric tube feeding,tumour control rates,Grade 2 mucositis and dermatitis earlier and sooner,unadjusted chi-square test, and time to first episode of mucositis,incidence of OM and diarrhea, safety, disease progression, and survival,salivation and decrease oral mucositis,complete remission (CR) rate,acute mucositis,2-year local-regional control, disease-free survival, and overall survival,frequency of Grade 2 to 4 mucositis,treatment-emergent adverse events (TEAEs,protective effect against 5-FU-induced mucositis,number of days with fever, number of oral lesions, plaque score, gingival bleeding score, or occurrence of candidiasis,median progression-free or overall survival times,mucositis and xerostomia,acute GVHD incidence or severity, survival, or day 100 relapse rates,mucositis incidence and severity,oral mucositis daily fraction,Mucositis, the inflammation and necrosis of mucosal membranes,Hemoglobin level,oral complications,oral pain,grade 2 xerostomia,Mucositis/stomatitis,occurrence of mucositis,expression of Ki-67 and PCNA antigens in breast carcinoma,Nausea,severity of radiation-induced oral/oropharyngeal mucositis,treatment duration, hematologic toxicity, and clinical outcome,soreness,incidence or severity of diarrhea or in overall survival,total duration of treatment,skin desquamation,median maximum neutrophil counts,weight loss, mucositis, pain, nutritional intake,pain and mucositis,delayed mucositis,severity (maximum extent) of acute radiation therapy side effects,plasma glutamine level, intestinal permeability (lactulose-mannitol test), and tumor size,radiation-induced oropharyngeal mucositis,mucositis area,incidence of grade 2 late xerostomia,Oral mucositis and selective elimination of oral flora,severity of oral pain,radiation-related mucositis,Antitumor treatment efficacy,duration and severity of stomatitis,ulcerative OM,neutrophil phagocytic function,Persistent clinical oral candidiasis,safety and tolerability,additional toxicity,estimated odds ratio (placebo/active) of developing an intermediate or thick pseudomembrane,outcome questionnaire; and daily symptom record diary,percentage of patients who developed intermediate or thick pseudomembranes,duration and severity of chemotherapy-associated stomatitis,WBC toxicity,frequency and duration of OM,incidence of chemotherapy-related oral mucositis,amelioration of mucositis,radiation-induced early oral mucositis,Oral mucositis,mucositis and mouthwash toxicity,duration and severity of objective oral mucositis,clinical evolution of iatrogenic tissue damage,plasma glutamine level,severity of mucositis,grade > or =2 acute xerostomia,mean total duration of mucositis,eosinophil counts,mucositis,oral mucositis,erythema and ulceration,skin reactions,objective and subjective mucositis scores,severity of radiation-induced mucositis,oral mucositis (OM,Skin and oral events,stomatitis severity, incidence of UOM, peak mouth pain, peak difficulty swallowing, amount of opiate analgesics used, or adverse event type or incidence,longer interval to the development of Grade 3 or greater mucositis,moderate/severe mucositis,acute and chronic xerostomia,leukopenia,disease-free survival,severity of stomatitis,duration of objective oral mucositis,grade 3 mucositis,feasible and well-tolerated,Grade 2 or higher late xerostomia,Local-regional control,probability of grade > or = 3 mucositis,average time for oral lesion,number of patients with severe objective mucositis,mucositis and dysphagia,Intensity of pain, severity of mucositis and use of opioids,quality of life by impairing eating, swallowing, and talking and by disturbing sleep,amount of food intake,acute oral mucositis,radiation mucositis and body weight, serum prealbumin level, and blood cell counts,quality of life,locoregional failure, progression-free survival, and overall survival,incidence of adverse events,mucositis/stomatitis of grade 2-4,colonization patterns of Candida species, Streptococcus faecalis, staphylococci, and Enterobacteriaceae, Pseudomonadaceae, and Acinetobacter species,Visual analogue scale for oral pain and oral function,incidence of WHO grade 2 or higher OM,need for feeding tubes,incidence of mucositis requiring morphine sulfate (MSO4,oral mucositis and pain,grade III skin reaction,leukocyte recovery,levels of selected cytokines and mucositis severity,mucosal pain,severity and duration of mucositis,percentage of patients with positive cultures of AGNB,swallowing difficulty,maximum mucositis scores,toxicity,incidence, days to onset, and severity of mucositis,mucositis grade,Severe oral mucositis,time until healing,Serum interleukin-6,mean duration of the use of this feeding tube,Acute nausea/vomiting,WHO toxicity scale for mucositis, oral assessment scale, and a subjective pain scale,frequency of fever and infections,degree of mouth-opening,Documented infections, use of broad-spectrum antibiotics, and number of days with fever,CR rate,oral mucositis (OMAS, NCI score), oral pain (VAS), oral function and salivary flow rate,burning sensation,Oral assessment of mucositis by using World Health Organization (WHO) oral toxicity scale,Acute mucositis,later onset of stomatitis,frequency of "severe pain,Adverse events,adverse events,Grade 3 or greater mucositis with morning RT,mean maximal intensity for NCI score,effective, safe, and well tolerated,mean patient-judged mucositis scores,Grade 4 mucositis,Patients' weight, taste, oral mucous reaction, and tongue mucous reaction,total of 11 dose-limiting toxicities (most often skin, respiratory, or oral mucositis,Acute toxicities (mucositis and dysphagia,incidence, severity and duration of oral mucositis,mean area under the mucositis curve,highest serum creatinine value,dysphagia,incidence of severe mucositis,influenza type symptoms,QOL scales,Mean weight loss,incidence and severity of oral/oropharyngeal mucositis,safety and for OM incidence and severity,pain,Mucositis score,need for percutaneous endoscopic gastrostomy placement,CR,symptomatic grade 3/4 mucositis,nausea,shorter mean radiotherapy duration,Radiation mucositis,Grade 3 or higher acute mucositis,alleviation of radiation-induced mucositis,incidence of renal insufficiency,incidence and severity of mucositis,incidence of use of total parenteral nutrition,stomatitis,healing of mucositis,number of severe (i.e., grade 3) mucositis scores,incidence of Radiation Therapy Oncology Group grade 3 mucositis,Mean maximum grade of objective oral mucositis,acute xerostomia and mucositis,mean toxicity score,Subjective reporting of discomfort, objective scoring of the severity of mucositis, and the maximal percent of body weight lost,erythema, ulceration, and pain associated with oral mucositis,incidence and severity of acute mucositis, acute and late xerostomia,ADM-induced mucositis,soreness of the mouth and throat,skin toxicity,incidence of severe (grade 3-4) oral mucositis,median interval to observation of grade > or =2 mucositis,hospitalization for mucositis,tolerance to head-and-neck radiotherapy, decrease mucositis, reduce soreness,absolute neutrophil count of > 0.5 x 10(9) cells/l,episodes of mucositis,acute grade 2 xerostomia,mean quality-of-life scores,mean pain sure and mucositis grade,preexisting colonization,Grade 2 xerostomia,IP test score,Duration of moderate/severe mucositis,Intensity of mucositis,median IP test score,duration of > or = Grade 3 subjective mucositis,pharyngeal, esophageal, and rectal mucositis,Some mucositis,ADM-induced oral mucositis,Numeric Rating Scale scores,median fall of the glomerular filtration rate (GFR,degree of mucositis,elevated mucositis score,OM grade (WHO,expression of Ki-67 and PCNA antigens,anorexia,C-reactive protein levels,Oral mucositis and symptoms,protective activity,Pain relief,pain, swallowing, drinking, eating, sleeping and taste alterations,mucositis scores,salivary gland function,maximum severity of mouth pain and difficulty swallowing,development of infection, mucositis and diarrhoea,healing of mucositis and dermatitis,Hypotension,neutrophilic granulocyte toxicity,severity of oral mucositis and pain scores,weight loss,CRP >50mg/L,weight changes,acute radiation morbidity,radiation reactions,mean duration of "at least Grade 3" mucositis (WHO,mucositis or oral pain,C-reactive protein (CRP) increase >50mg/L,positive gain in body weight,occurrence rate of grade 3-4 mucositis,duration of severe mucositis,maximal grade of toxicity, duration of Grade 2 or worse mucositis, quality-of-life scores, percentage of weight loss, use of pain medications, hydration requirement, oral infections, and prolonged radiation breaks,incidence of oral mucositis grade 2-4 and the duration of oral mucositis grade,4-year survival,radiation mucositis, pain, dysphagia and weight loss,platelet recovery, erythrocyte recovery, incidence of veno-occlusive disease, GVHD severity, relapse or survival,mucositis, skin reaction, dysphagia,nephrotoxicity, gastrointestinal side effects, haematopoietic recovery,median grade of oral mucositis,stage IV disease,mucositis, dysphagia, and xerostomia,tumor response rate,occurrence of severe oral and intestinal mucositis,progression of mucositis using the Oral Mucositis Assessing Scale (OMAS,severity and duration of mucositis, pain measurement, radiation therapy interruption, and quality of life,gastrointestinal bleeding,median number of amifostine doses,Toxicity data,complete eradication of AGNB,grade III/IV mucositis,deaths from disseminated candidiasis,Grade 3 mucositis,Stomatitis scores,oral candidiasis,Mucositis and oral pain,dental plaque levels and the degree of gingivitis and mucositis,Type of mouthwash, incidence, days to onset, and severity of chemotherapy-induced oral mucositis,acute oropharyngeal toxicity,aerobic,grade of oral mucositis,complete responses (CR) and 6 (24%) partial responses (PR,mucositis and ADM-induced leukopenia,Skin and mucosal reactions,aerobic pathogenic bacteria,frequency or severity of oral mucositis,efficacy and safety,severity (CTC-grading) and duration of OM,percentage of neutrophil phagocytosis and the SAG levels,diarrhoea,stomatitis and diarrhea,adverse effect of SOD injection,hazard ratio (HR,severe mucositis and dermatitis,rates of percutaneous endoscopic gastrostomy placement,proportion of patients with Grade 2 xerostomia,mean duration of oral mucositis,skin reaction,Oral pain,salivary flow, xerostomia, mucositis, and quality of life (QOL,mean mucositis scores,oral mucomembranous reaction,incidence of grade 3/4 mucositis,oral mucositis, pain, xerostomia and taste disturbance,narcotics and TPN,cure rates, extend survival, and reduce morbidity,mean weight loss,platelet toxicity,cumulative incidence of moderate to severe (grade 2 or higher) mucositis,efficacy/toxicity,Interval to healing,equal rate of non-compliance,acute xerostomia,incidence of grade > or =2 acute xerostomia, grade > or =3 acute mucositis, and grade > or =2 late xerostomia,duration of hospitalization,incidence and severity of oral mucositis,survival outcomes,total parenteral nutrition (TPN), narcotic use, hospitalization, weight loss and resumption of oral caloric intake,Oral Mucositis Assessment Scale (OMAS) and the World Health Organization (WHO) scale,safe and well tolerated,tumor growth and patient survival,radiation mucositis,degree of oropharyngeal mucosa reaction, dryness in mouth and radiation dermatitis in cervical region,mean of grade 1-4 mucositis, anorexia, difficulty in swallowing, and body weight change,development of Grade 3 mucositis and dermatitis,buccal toxicity,grades of mucositis,severe mucosal reactions,overall survival rate,risk of mucositis,duration of neutropenia,objective and subjective mucositis scores and microbiologic counts of the oral flora,serum cytokine levels and the severity of oral mucositis,Karnofsky performance status, body weight, cutaneous side effects, and alopecia,milder mucositis and dermatitis,CRP increase,chronic xerostomia grade,radiotherapy duration,incidences of grade III-IV mucositis and infection,neutrophil functions and prevention of chemotherapy-induced side-effects,World Health Organization (WHO) step analgesic medication and body weight change,severity of oral mucositis,mild radiation side-effects,tolerated and no adverse events,Mean body weight change,median time to development of severe mucositis,frequency of severe (WHO grades 3 or 4) mucositis,degree of mucositis and dermatitis,median time to percutaneous endoscopic gastrostomy removal,Whole saliva production,mean AUC values,incidence and duration of ADM-induced oral mucositis,alive without disease recurrence,total body irradiation (TBI,engraftment, acute GVHD, or survival,Mucositis, changes in the oral flora, quality of feeding and changes of total body weight,5-FU-induced mucositis,incidence of grade 4 oral mucositis,duration and severity of oral mucositis,duration of mouth pain,incidence of grade > or = 2 graft-versus-host disease,intensity of radiation-induced mucositis and oral discomfort,development and severity of mucositis,duration and severity of subjective oral mucositis,severity of radiation mucositis,median survival,severity and duration of oral mucositis,fever,acute toxicity,incidence of loss of taste,frequency of culture-positive herpes simplex virus,peak stomatitis NCI-CTC grade ,average repairing time,oral discomfort,Mucositis,oral ulceration,worsens oral mucositis,Saliva production,incidence of TEAEs,Stomatitis grade III/IV,median subjective pain scores, WHO scores, and oral assessment scores,safety, tolerability and efficacy,mean duration,salivary flow and QOL scores,Overall survival,incidence and severity of acute and late toxicities,Complete blood count,grade 3-4 mucositis,incidence of acute perineal skin and bladder toxicity,Confluent mucositis,suppression of oral flora and a lowering of the severity of mucositis,oral health,pain visual analogue scale (VAS) scores, mucositis index scores and medical and nursing charts,oral flora and irradiation mucositis,Mucosal reactions, pain and difficulty in swallowing,objective severity of mucositis, anorexia, and swallowing difficulty,incidence of HSV infection,numbers of salivary enterococci, enterobacteria, and/or Pseudomonas,tolerated,skin and mucosa reactions,5-year overall survival rate,parenteral nutrition and morphine, incidence of fever and infections, and duration of neutropenia and hospitalization,ulcer free,Grade 3-4 mucositis,similar time to engraftment,edema, infection, skin pain, or rash,oropharyngeal toxicity,incidence, mean duration, and mean area under the curve (AUC) of severe oral gross mucositis,IV degree toxicity,Median saliva production,frequency of mucositis grade,episode of febrile neutropenia,degree toxicity,bone pain,severity of subsequent mucositis,Grade 2 mucositis,Severity of mucositis,incidence of oral mucositis of World Health Organization (WHO) grade 3 or 4,functional activation of WBC,neutrophil and platelet engraftment,Local effectivity,Oropharyngeal mucositis,Adverse events, mainly rash, pruritus, erythema, mouth and tongue disorders, and taste alteration,numbers of aerobic and anaerobic bacteria,mean AUC of gross/functional scores and duration of moderate gross mucositis,degree of mucomembranous reaction,Nausea, vomiting, hypotension, and allergic reactions,body temperature or application of antibiotics,mean onset of mucositis,grade three or four mucositis,highest grade of mucositis,hematologic toxicity, transfusion requirements, duration of fever, and hepatic toxicity,reduced incidence and mean severity of mucositis,severe mucositis,severity and duration of chemotherapy-induced oral mucositis,incidence of severe oral mucositis,mean area under the curve stomatitis scores,median duration of fever,oropharyngeal ecology,delayed emesis,grade of mucositis, skin reactions and related parameters,radiation-induced oral mucositis,oral ulcerative mucositis|No difference in the visually assessed degree of mucositis or oral pain reported by the patients was found between the study and the control groups.
50|presence of symptoms and signs of TMJ dysfunction,globus symptom,subjective symptoms of CMD,disclusion time,frequency of headaches, facial pain, or pain on mandibular movements,occurrence of TMD signs,occlusal centric slides,myofascial pains symptom status,frequency of headaches, facial pain, pain on mandibular function, or duration of headaches and facial pain,incidence of temporomandibular disorders,disclusion time, as well as, myofascial pains muscular symptom remissions,disclusion times,number of tender muscles,muscles of mastication and/or jaw joint,symptom remissions,cumulative incidence rate,subjective symptoms|There were no significant differences between groups with regard to frequency of headaches, facial pain, pain on mandibular function, or duration of headaches and facial pain.
325|odds of experiencing fluorosis,early forming (Fluorosis Risk Index (FRI) classification I) enamel surfaces,prevalences of TF ,Fluorosis prevalence,severity of fluorosis,Fluorosis,Overall prevalence,dental caries experience,Prevalence of dental fluorosis,early toothbrushing habits,TF index the child and tooth prevalence of opacities,Demographic information, details of F history, and dental attendance data,mean DMF score,fluorosis community index (FCI,risk of dental fluorosis prevalence,dental fluorosis,Fluorosis Risk Index (FRI,Thylstrup and Fejerskov (TF) index for fluorosis and the modified Developmental Defects of Enamel (DDE) index,TFI score,dental fluorosis prevalences,child's birth weight and liking for or swallowing of toothpaste,prevalence of caries,prevalence of dental caries,Caries prevalence,Risk factor exposure,mild fluorosis,prevalences of fluorosis,Social deprivation,prevalence of fluorosis by TF1+ case definition,Dental fluorosis (TF index,Enamel opacities and dental caries,TFI scores,prevalence of aesthetically important DF ('Mild' and 'Moderate,DF levels,Caries (DMFT, WHO criteria, no radiographs) and dental fluorosis (TF index, dry permanent incisors,risk of fluorosis,prevalence of dental fluorosis,Thystrup-Fejerskov Index (TFI) scores,Mean DMFT values,Jarman score,prevalence of fluorosis,behavior problems and dental fluorosis,risk of enamel fluorosis,mainly TFI score,moderate to severe fluorosis,Overall, levels of fluorosis|The prevalence of fluorosis among children in ACORN group A-C was significantly greater than in groups D-F.
                
||
163|release of troponin T,length of hospital stay,cardiac, renal, and neurologic outcomes,cardiac sympathetic activity, myocardial blood flow and metabolism, and central hemodynamics,tracheal intubation time and length of hospital stay,incidence of postoperative arrhythmias and improves pain control and overall quality of recovery, allowing earlier extubation and hospital discharge,Postoperative pain management,postoperative hospital length of stay and patients' perception of their quality of recovery,perioperative stress response and postoperative myocardial ischemia,perioperative atrial fibrillation,Regional left ventricular function,VAS score, SS, and postoperative PaO2,respiratory tract infections,atrial fibrillation (AF,forced vital capacity, forced expiratory volume in 1 s (FEV1.0) and peak expiratory flow rate (PEFR,regional left ventricular function after myocardial revascularization, assessed by transesophageal echocardiography,Length of stay and time to eligibility for hospital discharge,serum amyloid P-component (SAP,troponin I, time to tracheal extubation, and analgesia,mean arterial pressure (MAP), great cardiac vein flow (GCVF), and regional myocardial oxygen consumption (Reg-MVO2,overall incidence of episodic hypoxemia,incidence of arrhythmias and the median intubation time,consumption of anesthetics,postoperative global quality of recovery score,shunt, VA/Q matching, or oxygenation,Ischaemic damage,recovery time,Levels of postoperative stress, serum cortisol, and beta-endorphin,hospital discharge time,Simultaneously plasma colloid osmotic pressure (COPpl,Forced vital capacity and forced expiratory volume,postoperative stress,cardiac sympathetic nerve activity, myocardial blood flow and metabolism, and central hemodynamics,Pain relief, degree of sedation, ambulation, and lung volumes,survival free from myocardial infarction, pulmonary complications, renal failure, and stroke,acute confusion,30-day survival free from myocardial infarction, pulmonary complications, renal failure, and stroke,Myocardial, inflammatory, and stress responses,stress response and pain scores,ELISA, CRP and SAP mere measured with rocket immunoelectrophoresis (RIE,number of patients showing ventricular fibrillation (VF), atrial fibrillation or heart block after release of the ACC,mean pulmonary arterial pressure,heart rate and mean arterial pressure,postoperative myocardial ischemia or infarction,heart rate,catecholamine response,quality of recovery,cortisol response,Thirty-day survival free from myocardial infarction, pulmonary complications, renal failure, and stroke,time to tracheal extubation, duration of postoperative intensive care unit stay, duration of postoperative hospitalization, pain control, urinary free cortisol, cardiopulmonary complication rate, and total hospital charges,Blood glucose values,cardiac index,pain scores,faster extubation times,Mean arterial blood pressure poststernotomy and systemic vascular resistance,troponin,physiotherapy cooperation,perioperative arrhythmia,Bcl-2 positive cardiomyocytes,CRP concentrations,Mean troponin T levels,arterial oxygen tension,cytokine levels,Serum epinephrine levels,arrhythmia, inotropic support, intubation time, perioperative myocardial infarction, neurologic events, intensive care stay, pain scores, and analgesia requirement,quality of recovery score,analgesia, early tracheal extubation and shorter ICU stay,Immunostaining intensity,postoperative ischemia,postoperative analgesia,total and cardiac sympathetic activity,haemodynamic effects,splanchnic blood flow nor oxygen delivery and consumption,epinephrine serum levels,Postoperative length of stay, time to eligibility for hospital discharge, pain and sedation scores, degree of ambulation, lung volumes, and organ morbidities,Troponin I, 8-isoprostane, cortisol, C3alpha, interleukin (IL)-6, IL-8, and IL-10,spirometric data, arterial oxygenation, pulmonary shunt, haemodynamics, use of vasoactive drugs and fluid balance,effective analgesia,cytokine production,constant hypoxemia,postoperative pain,Hospital stay,Pulmonary shunt and alveolo-arterial oxygen difference,Pif,IL-6 and IL-8 levels,Pain relief,Plasma levels,time to endotracheal extubation, oxygen withdrawal time and intensive care unit length of stay,intramyocardial oxygen partial pressure,need vasoconstrictors intraoperatively,cardiac function,recovery time, postoperative pulmonary and cardiac parameters, visual analog scale (VAS) scores, and sedation scores (SS,hemodynamic stability,morphine analgesia,time to tracheal extubation,Postoperative pain relief and stress hormones,subcutaneous interstitial tissue,troponin T release,Plasma epinephrine increased perioperatively,transcapillary COP-gradient (COPpl-COPif,CI,intensity of the immunostaining,ITA free blood flow,cardiac norepinephrine spillover, MAP, systemic vascular resistance index (SVRI), pulmonary capillary wedge pressure (PCWP), GCVF, and Reg-MVO2,myocardial oxygen availability,hemodynamic changes,adequate postoperative pulmonary and cardiovascular functions; nausea and vomiting,systemic vascular resistance (SVR,posttraumatic stress subscales,New supraventricular arrhythmias,VA/Q matching, oxygenation, or atelectasis formation,myocardial sympathetic response,Incidence of perioperative arrhythmias such as atrial fibrillation, serum epinephrine levels, heart rate variability, and hemodynamic parameters,postoperative complications recorded to 14 days and mortality recorded to 720 days,vasoactive and inotropic drugs and fluid balance,transient and almost simultaneous proinflammatory and anti-inflammatory cytokine response,number of Bcl-2 positive cardiomyocytes,Interleukin-6 levels,blood flow of the ITA,Analgesia,cardiopulmonary bypass- and surgery-associated stress response and incidence of myocardial ischemia,IL-6,plasma concentrations of cardiac troponin,mean arterial pressure (MAP,Pulmonary function (maximal inspiratory lung volume,vasoactive medication, mean arterial blood pressure,extensive bilateral atelectasis,hospital length of stay, quality of recovery, or morbidity,ITA free blood flow significantly via increased VEGF, i-NOS, and adenosine-A2B receptor expressions,mean arterial pressure,levels of IL-10,Mean arterial pressure,the Starling forces" (COPpl, COPif, Pif,incidence of stroke,cardiac troponin,intraoperative hemodynamics or ventricular function,Haemodynamic effects,incidence of perioperative dysarrhythmias,rapid recovery and shorter hospital stay,Extubation,transcapillary forces (COPpl, COPif, Pif,PCT, TNF-alpha and leukocyte count,Psychologic morbidity, intraoperative hemodynamics, ventricular function, lung function, and physiotherapy cooperation,myocardial oxygen demand,perioperative lung functions and pain scores,ABG values and PaO2/FiO2 ratio,release of IL-6, IL-8, and IL-10,I concentrations,lower visual analog scores with coughing postextubation,Postoperative pain scores,troponin release,acute renal failure,myocardial ischemia,biochemical markers of myocardial damage,immunoreactivity rates,oxygen delivery and mixed venous oxygen saturation,hypoxemia,global and regional myocardial function,length of postoperative hospital stay,pneumonia,Interstitial fluid colloid osmotic pressure (COPif) and interstitial fluid pressure (Pif,Pain score,Natriuretic peptide concentrations,Pain,Arterial and mixed venous blood gases and hemodynamic variables,splanchnic blood flow,lung volumes and pulmonary function follows cardiac surgery,Time to awakening and time to extubation,mean (SD) peak concentrations of atrial natriuretic peptide,flow and endothelium of internal thoracic artery,levels of impairment for all pain domains and reduced morphine usage,SAP plasma levels,Procalcitonin (PCT), tumor necrosis factor (TNF-alpha), soluble TNF receptor, human soluble intercellular adhesion molecule-1, C-reactive protein (CRP) and leukocyte count,myocardial damage, inflammatory, and stress response,peak expiratory flow rate,Hemodynamic measurements and blood sampling,PaCO2,major postoperative complications,plasma levels of bactericidal permeability-increasing protein, lipopolysaccharide-binding protein, and C-reactive protein,plasma cortisol,Intraoperative sinus bradycardia,incidence of tachycardia,hemodynamic function and reduced arrhythmias,mean systolic arterial pressure,AF,postoperative heart rate,pulmonary function,Visual analogue scale at rest and on coughing,intramyocardial partial oxygen pressure,ventilation-perfusion (VA/Q) relationships, atelectasis, and oxygenation,transcapillary fluid balance,C3alpha, troponin I, 8-isoprostane, and cortisol release,postoperative myocardial ischemia,mean ITA free flow,postoperative depression,myocardial cell damage, inflammatory, and stress responses,neurologic complications,Ventilator dependency and analgesia,Tracheal extubation time, oxygen withdrawal time and ICU stay,regional left ventricular function,Median postoperative stay,Postoperative pain,length of stay,Hemodynamics, plasma epinephrine and norepinephrine, cortisol, the myocardial-specific contractile protein troponin T, and other cardiac enzymes,Minnesota Multiphasic Personality Inventory,metabolic (lactate) or electrocardiographic signs of myocardial ischemia,Time to extubation,perioperative arrhythmias such as atrial fibrillation,postoperative spirometry or chest radiograph changes,episodic hypoxemia,Vital Capacity,pain,brain natriuretic peptide,Serum morphine|In group E 22 of 44 (50%), in group E+A 10 of 35 (28.6%), in group A 10 of 36 (27.8%), and in the control group 20 of 48 (41.7%) patients developed AF (odds ratio amiodarone/nonamiodarone 0.47 [0.24-0.90]; P = 0.02).
                
60|postoperative pain and recovery,analgesic effects,Motor weakness, time to first micturition, postoperative nausea and vomiting (PONV), eating habits, sleep disturbance and behaviour,Analgesia,PONV, eating, sleeping or behavioural disturbance,motor weakness,incidence of vomiting,pain relief,induction-incision time,pain and caudal analgesia,modified objective pain score, and the time taken to first requirement of analgesia,duration of analgesia,Postoperative analgesia,Recovery of consciousness,efficacy, complication rates, and parental satisfaction,time interval between operation and subsequent analgesic administration and the number of analgesic doses,time to first micturition,Incidence of adverse effects,Postoperative pain,level of consciousness and apparent pain,time to first requirement for analgesia or number of doses of paracetamol,frequency of vomiting|There was no difference between the groups in time to first requirement for analgesia or number of doses of paracetamol given in the first 24 h. Almost half the boys in the caudal group had motor weakness, and there was a significant increase in time to first micturition in that group.
not found|Plaque indices,caries development,caries incidence,incidence of caries,approximal caries,dental caries,fluoride levels,caries incidence and plaque accumulation,mean approximal caries increment, including initial caries lesions|Frequent, but less than daily, topical fluoride therapy appeared to have little effect in pre-school children consuming water-borne fluoride and receiving other traditionally recommended modalities of prevention.
50|EPA improved CTRS inattention/cognitive subscale,Conners' parent and teacher rating scales (CRS-P,T), Strengths and Difficulties Questionnaire (SDQ), and Child Health Questionnaire (CHQ,eicosapentaenoic and docosahexaenoic acids,CGI scores,AD/HD-related symptoms,total omega-6/omega-3 ratios,plasma phospholipid fatty acid patterns, scores on laboratory measures of inattention and impulsivity (Test of Variables of Attention, Children's Color Trails test) while not taking stimulant medication, and scores on parental behavioral rating scales (Child Behavior Checklist, Conners' Rating Scale,ADHD symptoms,higher AA/EPA,Baseline EFA concentrations,Investigator-rated ADHD Rating Scale-IV and Clinical Global Impression (CGI) scale,alpha-tocopherol concentrations,disruptive behavior,higher AA/DHA ratios,attention-deficit/hyperactivity disorder(AD/HD) symptoms,Attention Problem and Motor Excess of the Revised Behavior Problem Checklist,visual short-term memory and errors of commission (continuous performance,EPA and DHA in the RBC and the teachers' Disruptive Behavior Disorders (DBD) Rating Scale for Attention,multiple outcomes,Efficacy,proportions of EPA, DHA, and alpha-tocopherol in the plasma phospholipids and red blood cell (RBC) total lipids,cognitive measures,plasma and erythrocyte FA profile and continuous performance test results (Test of Variables of Attention; TOVA,attention deficit, hyperactivity and impulsivity (AD/HD-related symptoms according to DSM-IV criteria); (2) aggression assessed by both parents and teachers; (3) visual perception (finding symbols out of a table); (4) visual and auditory short-term memory; (5) development of visual-motor integration; (6) continuous performance; (7) impatience,symptoms,omega-6 fatty acid concentrations,plasma PUFA composition,symptoms of attention-deficit/hyperactivity disorder (ADHD,parent version of the Conners' questionnaire,serum phospholipids and red blood cell membranes (RBC,sustained efficacy,n-3 PUFA safety and tolerability,oppositional defiant behavior,Total TOVA scores,blood fatty acid composition and visual sustained attention performance,tolerated,alterations in FAs and increased TOVA scores,Efficacy measure was Conners' Parent/Teacher Rating Scales (CPRS/CTRS,Fatty acids,AA/DHA,fatty acid (FA) composition,Abbreviated Symptom Questionnaire (ASQ,symptoms of ADHD,ADHD clinical symptoms,cognitive performance,ability to switch and control attention (Creature Counting,Plasma phospholipid DHA content,symptoms of attention-deficit/hyperactivity disorder,teacher-rated behaviour and oppositional symptoms,Parent impact-emotional (PE) subscale,blood FA composition and behavior,lower EPA concentrations,objective or subjective measure of ADHD symptoms,inattention and global Diagnostic and Statistical Manual of Mental Disorders, Fourth edition, total Conners' subscales,subscales scores,CTRS total score,FO|conduct problems rated by parents (-42.7 vs. -9.9%, n = 47, P = 0.05), and attention symptoms rated by teachers (-14.8 vs. +3.4%, n = 47, P = 0.03).
162|risk of recurrent venous thromboembolism,23 recurrences of venous thromboembolism,incidence of recurrent venous thromboembolism,idiopathic deep venous thrombosis,incidence of recurrence,higher risk of major hemorrhage,pulmonary embolism,gastrointestinal bleeding and one genitourinary bleeding,rates of recurrent symptomatic venous thromboembolism and bleeding,relative risk of recurrence,mortality or the rate of major hemorrhage,recurrence,recurrence of symptomatic, objectively confirmed venous thromboembolism,odds ratio for recurrence,recurrent venous thromboembolism,episodes of pulmonary embolism,initial episodes of deep-vein thrombosis,123 recurrences of venous thromboembolism,rate of recurrence,relative risk of major hemorrhage,26 recurrences of venous thromboembolism,recurrent episode of venous thromboembolism,recurrence of venous thromboembolism,major bleeding episodes,nonfatal major bleeding,rate ratio,recurrences and major, minor, or fatal bleeding complications,recurrent thrombosis,major bleeds,non-fatal major bleeding,rate of recurrent venous thromboembolism,duration of oral anticoagulant therapy,recurrence rate,recurrent VTE,rates of recurrence,mortality|Warfarin resulted in a 95 percent reduction in the risk of recurrent venous thromboembolism (95 percent confidence interval, 63 to 99 percent).
32|Cycle control, dysmenorrhea and premenstrual syndrome (PMS,therapeutic effect, sebum production, and hormone levels,unacceptable bleeding,Scheduled withdrawal bleedings,Investigator Static Global Assessment rating of acne,mean age, body mass index, acne lesion counts, SHBG, DHEAS, or free and total testosterone,mean objective acne score,sebum production and hair growth on the upper lip and chin,facial acne,sex hormone-binding globulin,levels of total and free testosterone, androstenedione, dehydroepiandrosterone sulfate (DHEAS), sex hormone-binding globulin (SHBG), and luteinizing hormone (LH,reduction rates,plasma levels of sex hormone binding globulin,acne and seborrhea,blood pressure and body weight,contraceptive efficacy,SHBG,excellent improvement" or "complete resolution" of moderate acne,Serum total and unbound testosterone and sex hormone binding globulin (SHBG,Acne resolution rates,clinician global and patient self-assessment scores,Tolerability,free testosterone,total lesions,symptoms of water retention and impaired concentration,3 alpha-17 beta-androstanediol,androgenic markers and acne,number of papules and/or pustules of the face from admission to Medication Cycle 6,Blood pressure and body weight,Pre-existing acne,Acne,total lesion count,reduction (+/-SD) rates,inflammatory, noninflammatory and total lesion counts,bioavailable,total testosterone and 3 alpha-17 beta-androstanediol glucuronide,acne lesions and plasma androstenedione (A), total testosterone (T), sex hormone binding globulin (SHBG) and "free androgen index" (FAI,Acne lesions, sebum production, and hair growth on the upper lip, chin, and chest,tolerability and quality of life,incidences of irregular bleeding and minor side-effects,objective and subjective severity of acne, and related biochemical variables such as sex hormone-binding globulin and free and total testosterone,Mean SHBG,SHBG and acne scores,normalization of the echogenic ovarian texture,mean acne score,Efficacy and acceptability,Efficacy and safety,Efficacy and tolerability,number of acne lesions,inflammatory lesion count,LNG reduced androgen levels,Early withdrawal bleeding,levels of SHBG,efficacy and acceptability,mean number of bleeding-spotting days per cycle,sex hormone-binding globulin (SHBG), dehydroepiandrosterone sulfate (DHEAS), and free and total testosterone,efficacy, cycle control and tolerability,Free testosterone,acne lesions,lesion numbers,signs of biochemical hyperandrogenism, including elevated FAI,occurrence rate of irregular bleeding and spotting,level of sex hormone-binding globulin (SHBG,inflammatory and total lesion count and the percentage of patients with acne improvement according to the Investigator Global Assessment,efficacy and tolerability,blood pressure and weight,percentage of severe/moderate acne,number of papules/pustules per half of the face present on admission,normalization of biochemical hyperandrogenism,relative frequency of women with complete resolution,severe acne category,echogenic texture of the ovaries,subjective acne scores,Somatic and psychological symptoms,severity of acne and SHBG,Biochemical markers of androgenicity,Emotional well-being,adrenal and peripheral androgens,proportion of subjects with acne,efficacy measures (total comedones, open comedones, closed comedones, papules, pustules, and the subject's self-assessment of study treatment,Hormone levels,hepatic tolerance,tolerated,elevated total T,clinical efficacy,Serum total an unbound testosterone (T) and sex hormone binding globulin (SHBG) levels,Estimated Pearl Indices for NOMAC/E2 and DRSP/EE,acne lesion counts and Investigator Static Global Assessment scale ratings,facial acne lesion counts, an investigator's global assessment, a subject's self-assessment, and an analysis of within-cycle variation (cycle 6) in lesion counts,SHBG elevation,self-administered questionnaires Psychological General Well-Being Index (PGWBI) and the Profile of Mood States (POMS,symptoms of water retention,relative numbers of comedones, papules, pustules and nodules at cycle 6,number of lesions and the degree of severity,time serum free testosterone,median reduction in papules/pustules,mean total scores of PGWBI or POMS,Type and frequency of adverse events,facial acne lesion counts, the investigator's global assessment, and the subject's self-assessment,acne lesion counts,withdrawal bleeding,Cycle control, quality of life and acne,Efficacy,efficacy and safety,inflammatory lesions,number of inflammatory and total lesions,irregular bleeding and minor side effects,Intracyclic bleeding/spotting,clinician global and patient self-assessments,objective (acne counts) and subjective (no, moderate, mild, severe) acne scoring of the facial area,Mean acne lesion counts,Changes in weight,initial values of plasma SHBG,Menstrual Distress Questionnaire (MDQ) normative T scores; the proportion of subjects with acne; and menstrual symptoms,Dysmenorrhea and PMS,SHBG with NETA than LNG, bioavailable testosterone (T,Acne lesion counts and clinician global assessment,Inflammatory, noninflammatory, and total lesion counts,Moderate papulopustular acne of the décolleté,number and severity of acne lesions,irregular bleeding and side effects,number of comedones, papules, pustules and nodules,median total acne lesion count|Both preparations increased plasma levels of sex hormone binding globulin and seemed to decrease those of total and free testosterone, but no statistically significant relationships between acne severity and biochemical variables could be detected.
                
44|safe and well tolerated,therapeutic gain,pain intensity differences, maximum pain intensity difference, number of patients with at least 50% pain reduction, time to 50% pain reduction, maximum pain relief and total pain relief,efficacy and safety,Efficacy and safety,Acute headaches,recurrence,analgesic efficacy,duration of the aura,pain,nausea, photophobia, and phonophobia,pain relief|Patients receiving dipyrone demonstrated a statistically superior improvement (P<.05 and P<.01) in pain and all associated symptoms compared with control subjects.
                
not found|Pain scores,visual analog scale,Pain relief,Mean postoperative days of analgesic use,postoperative pain relief,Mean postoperative days of pain,analgesic efficacy,pain,analgesic effect,pain levels twice daily using a visual analogue scale,postoperative hemorrhage|The efficacy of benzydamine hydrochloride (Difflam) spray to relieve pain from postoperative tonsillectomy was assessed, but it was found that it did not relieve the symptoms after operation when compared to matching placebo.
299|moderate toxicities,serum levels and response rates,overall response rate,Survival rates,life-threatening case of pulmonary embolism,longer survival,survival,response rate,median survival times,MPA levels,Median durations of progression-free survival,Overall response rates,probability of response included initial performance status, age, histologic grade, and progesterone receptor concentration,poorer progression-free and overall survival times,Median survival durations|The adjusted relative odds of responding to the high-dose regimen compared with the low-dose regimen was 0.61 (90% confidence interval, 0.36 to 1.04).
not found|risk of Parkinson's disease,incidence of Parkinson disease (PD,risk of developing PD,protective effect,relative risks,PD risk,risk of PD,Odds ratios,nonsteroidal anti-inflammatory drugs and PD,frequency of diseases of immediate-type hypersensitivity,risk reduction,PD and environmental measures (history, status, dosage, duration, and intensity) of smoking, coffee, caffeine, nonsteroidal anti-inflammatory drugs, and non-aspirin nonsteroidal anti-inflammatory drugs,risk of Parkinson disease,Increasing intensity of coffee drinking,onset of PD,total caffeine consumption,lower risk of PD|Compared with nonusers, the relative risks were 0.73 for users of fewer than 2 tablets/week, 0.72 for 2 to 6.9 tablets/week, and 0.62 for 1 or more tablets/day (p trend = 0.03).
35|proportion of patients who were pain-free without tramadol,severe pain, radiation or neurological deficit,Pain,compound pain subscore,platelet aggregation,effectiveness,numbers of pain,pain component,mean maximal arachidonic acid induced platelet aggregation,severe and radiating pain accompanied by neurological deficit,efficacy and safety,pain free without the permitted rescue medication (tramadol,maximal platelet aggregation induced by arachidonic acid,severity, duration, nature and accompaniments of their pain; and in laboratory indices of organ system function,Platelet aggregation,human platelet aggregation,efficacy rating "symptomfree" or "improved,adverse events,modified Arhus index, its pain component and the Total Pain Index,Responder rate,pain without rescue medication,systemic side-effects,Total Pain Index,finger-floor distance and the degree of lumbar extension,severe allergic reaction,partial pain scores, disability and mobility restriction subscores, the total score of the Arhus low back rating scale, the global evaluation of efficacy by investigator and patient, adverse events,VAS reduction,efficacy and tolerance,compound pain subscore of the Arhus low back rating scale (continuous variable), and a response criterion of a reduction in pain subscore=30,Adverse local drug reactions,pain free,Main efficacy parameter VAS reduction,adverse effects,severe and unbearable pain,number of pain-free patients (visual analogue scale score,severity of pain, duration, nature and accompaniments of their pain, the Arhus low back pain index and in laboratory indices of organ system function,number of subjects with adverse events (AEs), withdrawals due to an AE and adverse drug reactions (ADRs,spontaneous pain, muscular contracture and in both the patient's and physician's opinions,pain,pain scores|Acetylsalicylate had a significant inhibitory effect on platelet aggregation compared to Salicis cortex extract (p = 0.001) and placebo (p = 0.001).
28|number of symptom free days,concentration of histamine,lung volume or air flow obstruction,maximum flow at FRC (VmaxFRC,arterial oxygen tension,clinical effect,Values of thoracic gas volume (TGV), airway conductance (Gaw) and specific airway conductance (sGaw,arterial oxygen saturation,number of treatment failures,symptom score,sGaw,clinical symptoms or pulmonary function,clinical status (respiratory rate, degree of wheezing and accessory muscle use, total clinical score, and arterial oxygen saturation,Compliance and forced expiratory flows,improvement of Gaw,Symptoms of wheeze and cough,Lung function,pulmonary hyperinflation,clinical status and lung function,mean daily symptom score,symptom score or pulmonary function,Bronchial responsiveness,heart rate,bronchial response|No significant difference in clinical effect was shown between albuterol and saline in the youngest group of children.
14|respiratory rate, heart rate and transcutaneous oxygen saturation, however, oxygen desaturation episodes,Pulmonary resistance,mean TcPCO2 values,dynamic compliance, tidal volume/kg, and total, inspiratory and expiratory pulmonary resistance,static compliance and the work of breathing of spontaneous breaths,episodes of oxygen desaturation,Heart rate, respiratory rate, transcutaneous oxygen saturation and ventilatory parameters,arterial oxygen saturation,Transcutaneous oxygen pressure,spontaneous respiratory rate,motor activity,transcutaneous carbon dioxide tension,breathing increased and static compliance,blood gases and lung mechanics,oxygen saturation (SpO(2)), desaturation episodes (SpO(2) < 90% and >or= 20 seconds), and motor activity,transcutaneous oxygen and carbon dioxide pressures,transcutaneous carbon dioxide pressure,transcutaneous (tc) oxygen (tcPO2) and carbon dioxide measurements (tcPCO2,functional residual capacity, tidal volume, or dynamic lung compliance,proportion of ventilation to the good lung,mean tcPO2 or tcPCO2,TcPCO2 and PaCO2 values,TcPCO2,transcutaneous carbon dioxide tension values,lung mechanics and blood gases,vigorous motor activity and crying,pulmonary mechanics of spontaneous breaths or arterial blood gases,numbers of positive tracheal cultures,colony counts,duration of SpO(2,Sleep state,Median fraction of inspiratory oxygen,PaO2 or PaCO2,tcPO2 and tcPCO2,Decreased activity and oxygen desaturation,low birthweight and respiratory distress syndrome,mean length of the weaning process,blood gases and ventilation volume,thoracic gas volumes,cardiorespiratory stability and weaning outcome,heart rate,minute ventilation,tidal volume|There were no statistically significant differences in mean TcPCO2 values between the three positions (F = .45; df 2,39; P = .64).
100|Overall duration of labor, and first and second stage of labor,likely to deliver by cesarean section,shorter duration of active phase,Duration of labor,length of birth and use of oxytocin,duration of active labor, the amount of oxytocin given, and number of inductions,rates of cesarean section and induction of labor,labor spontaneously,time elapsed from the time of randomization to delivery,delivery time,Labor,cervical length,Mean time to delivery|Duration of labor was significantly reduced (mean difference 1.7 h, p=0.03) and there was significant reduction in the need for oxytocin infusion to augment labor in the study group compared to the control group (odds ratio 2.0, p=0.018).
not found|Adverse effects,conversion rate of HBsAg|Adverse effects were not observed in all patients receiving the plant.
91|toxicity,local and systemic side effects,Disease recurrence,pulmonary tuberculosis,response rate,efficacy,complete response (CR), disease-free interval and recurrence rate|The result was in favour of BCG, as shown by the measurements with complete response (CR), disease-free interval and recurrence rate.
not found|pain, depression, disability, pain behaviors, and intervening variables,Fibromyalgia Impact Questionnaire,pain, medicine use, activity, and depression,quality of life and self-efficacy,Self-efficacy,total direct health care costs,health care costs,chronic pain,exercise level since,depression, self-reported pain behaviors, observed pain behaviors, and myalgia scores,Arthritis Self-Efficacy Scale (ASES-S,pain control,work stability,patient made drawing of pain distribution, dolorimetry of tender points, ergometer cycle test, global subjective improvement, and VAS registrations of: pain, disturbed sleep, lack of energy, and depression,self-efficacy,fibromyalgia (FMS) symptoms and increasing physical and psychological well being,quality of life,pain reductions,ASES-S,Helplessness, number of days feeling bad, physical dysfunction, and pain in the tender points,helplessness and passive coping,pain ratings,pain coping,Indirect costs,knowledge about FM,rating scale utilities,health status,pain,rating scale or standard gamble utilities|Although improvement across time was found in depression, self-reported pain behaviors, observed pain behaviors, and myalgia scores, no differences in these criteria were found between the behavioral and education/control conditions.
not found|night-time symptom relief and sleep satisfaction assessments,nasal congestion/runny nose/cough/pain relief scores,symptom improvement,subjective methods and cough counts,symptom scores for the cough frequency and severity during the day, sputum quantity or ease of expectoration,nasal congestion, sneezing, postnasal drainage, and nasal discharge,suppression of cough at night,thoracic objectivity,nocturnal cough and sleep quality,satisfaction on sleep,sneezing and total symptom scores,nervousness,sedative effects,cough frequency and the subjective severity of cough,cough frequency,30-min intervals: cough bouts, cough components, cough effort, cough intensity, and cough latency,proportion of children considered "better" overall,quality of sleep,cough bouts, cough components, and cough effort,mean CSPL changes,frequency of drowsiness,sleep quality,cough counts, latency and total effort,nocturnal cough and sleep difficulty associated with upper respiratory infections,Insomnia,overall night-time relief,cough counts, intensity, latency and total effort expended,speed of action, and objective and subjective measures,child's runny nose, nasal congestion, cough, and sleep status,insomnia,cough latency,diurnal variation in cough frequency,severity of cough, nasal obstruction, nasal discharge, and throat-clearing,cough,Sleep quality,drowsiness,sputum quantity,nocturnal symptom relief,symptoms of upper respiratory tract infection,sputum thickness,cough sound pressure level (CSPL), cough frequency (CF) and subjective scores for cough severity,CSPLs, cough frequency or subjective symptom scores,Cough frequency and subjective scores of cough severity,fever,rate of regression of thoracic symptomatology,cough severity,cough: cough sound-pressure levels (CSPLs,individual symptoms,frequency, severity, and bothersome nature of the nocturnal cough,side effects,URI symptoms,body temperature, cough, thoracic objectivity, respiratory function indices|The results showed similar trends in both treatment groups with statistically significant reductions (P < 0.05) in cough sound pressure level (CSPL), cough frequency (CF) and subjective scores for cough severity within treatment groups but little difference between the treatment groups during the study period.
60|levels of C reactive protein,Remission,Powell-Tuck Index, Inflammatory Bowel Disease Questionnaire (IBDQ) score, and rectal histological activities,depression of the disease activity,Clinical remission rates,efficacy and tolerability,median prestudy clinical activity index (CAI,ulcerative colitis scoring system (UCSS) symptoms score and induction of endoscopically confirmed remission,Powell-Tuck Index,rectal histological scores,Serious adverse events,efficacy and safety,median endoscopic index,moderate side effects,Baseline characteristics and disease severity,Complete response,IBDQ score,Steroid reduction,rectal histological activity scores,IBDQ scores,active left-sided ulcerative colitis,Powell-Tuck Index, IBDQ score, and histological disease activity scoring,Clinical response,reduction of the CAI of 6 points or greater (response,Seven serious adverse events|The higher PegIFN dose was associated with a significant decrease in levels of C reactive protein (p=0.003, day 0 v 85).
                
95|tolerated and colonic transit time (CTT,total colonic transit time,total number of complete and incomplete defaecations per week, pain on defaecation, straining on defaecation, faecal incontinence, stool consistency, global assessment of treatment, adverse events and physical examination,defecation and encopresis frequency/week and successful treatment,Abdominal pain and flatulence scores,faecal impaction,fecal incontinence,taking PEG + E,straining on defaecation (p<0.001), stool consistency (p<0.001) and percentage of hard stools,pain on defaecation,flatus,PEG regarding stool consistency, appetite, fecaloma and use of additional laxatives,laboratory tests and physical examinations,stool consistency,number of stools,side-effect,constipation,vomiting and meteorism,abdominal faecal masses, presence and consistency of rectal mass, perineal soiling,frequency of incontinence episodes, and resolution of abdominal pain,defecation frequency,Abdominal pain,vomiting and flatulence,resolution of constipation, fecal incontinence, and abdominal pain,Total protein, albumin, iron, electrolytes, and vitamins B9 (folates), A and D (25OHD3,efficacy and safety,complained abdominal pain,Orocecal transit time,abdominal pain, straining, and pain at defecation,frequent bowel movements,Compliance rates,effective clearance of abdominal and rectal lumps,adverse events,safe and well tolerated,Bristol score of stool consistency,vomiting,efficacy, safety, acceptance, and 1-year outcomes,clinical complete remission rate of constipation,encopresis frequency,abdominal pain,Fecal incontinence and watery stools,Clinical efficacy,chronic functional constipation,Clinical tolerance,tolerated,mean number of complete defaecations,paediatric constipation and evaluate clinical efficacy/side effects,PEG + E,number of days on which normal stools,stool consistency and frequency,behavior scores,success rate,Stool consistency,bowel movement frequency, stool consistency, clinical complete remission rate of constipation and abdominal symptoms, and the safety of forlax and lactulose,Successful rectal disimpaction, defecation and fecal incontinence frequencies, occurrence of abdominal pain and watery stools, CTTs (before and after disimpaction), and behavior scores,serious adverse effects,incontinence frequency, stool consistency, presence of abdominal pain and flatulence, necessity for step-up medication, and dry weight of feces,stool consistency, frequency of bowel movements, fecal incontinence, abdominal pain, straining and acceptance of the drugs,week stool frequency,total incidence rate of adverse events seen,number and frequency of the side-effects,median weekly frequency of bowel movement,proportion of patients with a successful treatment response: >or=3 bowel movements (BM,fecal incontinence frequency,Successful disimpaction,consistency of stools,frequency of bowel movements,BM,abdominal pain and fecal incontinence,efficacy and acceptability,side effects,encopresis frequency meaningfully|Successful disimpaction was achieved with enemas (80%) and PEG (68%; P = .28).
47|dystonic reactions and akathisia,NOSIE scale, "manifest psychosis,BPRS scores,Clinical Global Impressions and Brief Psychiatric Rating scales,improvement rating of moderate or marked,Median time to tranquilization,diastolic blood pressure (lying and standing,anticholinergic effects, excitement, dizziness and faintness,Adverse reactions,discharge and termination rates,BPRS, CGI scale, Nurses' Observation Scale for In-patient Evaluation (NOSIE) or side-effect records,number and severity of adverse experiences,Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression (CGI,demonstrable anti-psychotic activity,Therapeutic efficacy and safety,BPRS, CGI, or Nosie items or factors or in the reduction of overall psychopathology,severity of illness on the CGI scale,clinical efficacy,BPRS and CGI,incidence and severity of side effects,side effects,Side effects,drowsiness and extrapyramidal signs,behavioral, extrapyramidal, and sedative,global severity of illness rating of mild or better|After 3-weeks' treatment, no significant differences were found between the two treatment groups according to the Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression (CGI)
56|quality of life domains,fibrinogen,low-density lipoprotein cholesterol,plaque area,incidence of coronary heart disease and stroke,absolute claudication distance,HDL-cholesterol, and positive instrumental changes,2 quality of life instruments, the Walking Impairment Questionnaire,serum cholesterol,Pain-free and total walking distance, resting and postexercise ankle-brachial indexes, and questionnaire scores,edge irregularity index,plasma LDL cholesterol concentration,maximum walking distance,total walking distance,arterial edge roughness or amount of aorto-femoral atherosclerosis,fibrinogen levels,pain-free walking time,walking performance, ankle-brachial pressure indexes, and symptoms of claudication,initial claudication distance (ICD,density lipoprotein-cholesterol (HDL-C) levels,mild adverse events,roughness of the femoral artery,frequency of patients reporting improvement of lower limb symptoms,Walking distances,change in treadmill exercise time and patient-reported measures of physical activity and quality of life based on questionnaires,ankle-brachial index,claudication symptoms,Rest Flow values--and consequently also Winsor's index,absolute claudication distance (ACD,vascular events,mean low density lipoprotein (LDL) cholesterol,coronary heart disease and of stroke,femoral atherosclerosis,density lipoprotein2 cholesterol levels,ambulatory ability,total high-density lipoprotein cholesterol,progression of atherosclerosis,adverse events (AE,change in atheroma volume estimated as change in lumen volume of the femoral artery assessed by quantitative arteriography,ankle/arm pressure index,efficacy and tolerability,mean plasma total cholesterol,nonfatal myocardial infarction,LDL-C,blood lipids,walking performance,red cell deformability,6 adverse events (AE,blood viscosity,walking performance and symptoms of intermittent claudication,Plasma fibrinogen,reduction of lower limb symptoms,initial claudication distance,tolerated,walking performance, ankle-brachial indexes, and questionnaire scores,cardiovascular events,Fibrinogen levels,blood triglycerides and fibrinogen,walking distance,lumen volume,viscosity,serious vascular AEs,blood pressure, blood lipids, and platelet responsiveness,claudication distance values,mean pain-free walking distance,Beneficial effects on non-fatal events,pain-free walking distance and community-based physical activity,total cholesterol (TC) and low-density lipoprotein-cholesterol (LDL-C,pain-free walking distance,ankle/arm pressure ratio,severity of intermittent claudication,blood pressure, red cell deformability, fibrinogen, and lipid levels,exercise tests or ankle/arm blood pressure,walking ability of peripheral arterial obstructive disease,doubling of the pain-free walking distance,Changes in ICD and ACD,total of 10 serious adverse events,Mean arterial blood pressure,walking distances and pressure indices,Maximal walking time,mean plasma triglycerides|After 6 months of therapy, policosanol significantly increased (p < 0.01) the initial claudication distance from 125.9 +/-
429|limit of detection (LOD,specificity for detecting M. tuberculosis,indeterminate rate of MTB/RIF testing,immediate identification of rifampicin (RIF) resistance,MTBDR, Xpert, and liquid culture,negative predictive value,RMP resistance,smear status and culture time-to-positivity,HIV prevalence,MTB/RIF test sensitivity,mycobacteria or mycobacterial DNA,overall sensitivity of the Xpert MTB/RIF assay for culture-positive TB,rifampicin resistance,M. tuberculosis,Xpert MTB/RIF Assay,overall sensitivity and specificity,Overall, Xpert MTB/RIF,sensitivity, specificity, positive and negative predictive values of Xpert MTB/RIF test,rapid diagnosis of tuberculosis and detection of rifampin (RIF) resistance,rapid TB case detection rate,sensitivity for smear-negative, culture-positive TB,reduced sensitivity,Median time to detection of tuberculosis,Rifampin resistance,total equivocal results,IS6110 LDT sensitivities,overall specificity,sensitivity of the Xpert MTB/RIF test,Median time to detection of resistance,Sensitivity and specificity of MTBDR for detection of isoniazid resistance,sensitivity, specificity, and positive and negative predictive values,MTB/RIF test sensitivity for rifampicin resistance,rifampin resistance,M. tuberculosis viability,Bactec 460TB 12B (BD Diagnostic, USA), Löwenstein-Jensen (LJ) culture and direct microscopy of smears stained with Ziehl,sensitivity of the MTB/RIF RUO assay,Unlike microscopy, MTB/RIF test sensitivity,Specificity,sensitivity and specificity of PCR,Mycobacterium tuberculosis,direct fluorescence microscopy, Genotype MTBDRplus assay (MTBDR), Xpert MTB/RIF assay (Xpert), and liquid mycobacterial culture|The GeneXpert MTB/RIF assay is a novel integrated diagnostic device for the diagnosis of tuberculosis and rapid detection of RIF resistance in clinical specimens.
176|Pa(CO2) values,pulse rate and blood pressure,mean PaO2,pulse rate of 8 beats per minute and 2 beats per minute,mean increase in PEF,relative tachycardia,Blood gas pressures,peak expiratory flow rate,PEF,PaO2,recovery time (no longer requiring inhaled salbutamol) and persistent moderate to severe asthma,mean proportionate increase in FEV,cardiovascular side effects,recovery time,rate of recovery,severe acute asthma,systemic side-effects,Beta agonist-induced hypokalemia,Peak expiratory flow rate,oxygen to maintain oxygen saturation,Relief of pulsus paradoxus,peak expiratory flow,oxygen tension,plasma theophylline concentration,Side effects, i.e. tachycardia, blood pressure changes and tremor,simple clinical score, the heart and respiratory rates, the peak expiratory flow (PEF) and the blood gases,heart rate,production of side-effects|There was a significantly larger increase in peak expiratory flow after the first inhaled dose in the group that received inhalation treatment than in the i.v.
54|rate of recovery of SDNN,hostility scores,hostility,severe cardiovascular adverse events,change in HRSD (for depression) or ESSI scores (for LPSS,death or recurrent MI,safety of fluoxetine, cardiac function,psychosocial outcomes,HAMD-17 scores,depression, anxiety, hopelessness, stress, and quality of life,heart rate,BDI-II scores,blood pressure or conduction intervals,HAM-D score of at least 18 and history of 2 or more prior episodes of MDD,Covariate-adjusted Hamilton scores,QTc interval,mean (SD) LVEF,Beck Depression Inventory, (2) natural killer cell cytotoxicity (NKCC) measured by 51Cr-release assay, (3) infectious illness episodes measured by the Modified Health Review, (4) interleukin (IL)-6 and C reactive protein (CRP,Adverse cardiac events,Depression,rapid rate of recovery,remission rates,event-free survival,response rate,efficacy, cardiovascular effects, and safety,Infection, depression, and immunity,safety and efficacy,Depression and hostility,CGI-I responder rates for sertraline,Efficacy and safety,antidepressive efficacy,depressive symptomatology on the 17-item Hamilton-Depression Rating Scale (Ham-D), and secondary outcomes the Beck Depression Inventory (BDI) and depression subscale of the Symptom Check List 90 items (dSCL-90) as well as the Clinical Global Impression (CGI) scale,BDI, dSCL-90, and CGI scale,24-item HAM-D, administered blindly during centralized telephone interviews,depressive symptoms,cardiac function,CGI-I and HAM-D measures,increase event-free survival,patient's emotional and functional outcomes,rate of recovery of HRV,recovery rate of cardiac autonomic function,cardiovascular safety, heart rate and rhythm, supine and standing systolic and diastolic blood pressures, electrocardiogram conduction intervals, indexes of heart rate variability, and rate of adverse events,depression and social isolation,mean (SD) change in HRSD score,IL-6,emotional distress,Hospital and Anxiety Depression Scale (HADS,12-week HAM-D scores,ventricular premature complex (VPC,mortality and recurrent infarction,left ventricular ejection fraction (LVEF); secondary measures included surrogate cardiac measures and cardiovascular adverse events, as well as scores on the HAM-D scale and Clinical Global Impression Improvement scale (CGI-I,SD of 24-hour N-N intervals (SDNN,Depressive symptoms,17-item Hamilton Rating Scale for Depression (HRSD); LPSS,HADS and the Workplace Social Adjustment Scale (WSAS,heart rate or rhythm or indexes of heart rate variability,hospital fevers and infectious illness,survival,17-item Hamilton Rating Scale for Depression,depression symptoms,self-reported Beck Depression Inventory II (BDI-II) score,efficacy and safety,postoperative infectious illnesses,Hamilton Rating Scale for Depression,Antidepressant efficacy,heart rate variability,Mean HAM-D response,Major depressive disorder (MDD,Beck Depression Inventory scores,17-item Hamilton Depression Rating Scale (HAMD-17) and the Hostility Scale of the 90-item Symptom Check List (SCL-90,depressive symptoms, inflammatory biomarkers, and post-CABG infections,baseline 24-item Hamilton Depression Rating Scale (HAM-D) scores of 20 or higher,Ham-D, BDI, and CGI,mean (SD) change in ESSI score,Remission of depression,mean HAM-D difference favoring clinical management,rate of serious adverse cardiac events|Also, hostility scores at week 25 were significantly reduced among patients receiving fluoxetine (p = .02).
68|platelet level of CD62p and serum content of TNF-alpha and IL-6,positive expression of platelet CD62p and the serum TNF-alpha and IL-6,positive expression rate of CD62p in platelet and content of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6,Levels of platelet CD62p and serum TNF-alpha and IL-6,total curative effect|The total curative effect in the treated group were significantly higher than that in the control group (P < 0.05).
243|local infection,infection or overall malfunction rate,cerebrospinal fluid infections,postoperative wound sepsis,infection rate with antibiotics,postoperative shunt infection,rates of infection,Efficacy,risk of shunt malfunction,Adverse reactions,overall rate of shunt infection,Time of development of cerebrospinal fluid infection,risk of catheter-related infections,Thirteen shunt infections,incidence of shunt malfunction,incidence of shunt infection or malfunction,CSF infection,Classical infection parameters,Positive CSF cultures,postoperative ventriculoperitoneal shunt infections,incidence of infections occurring,Postoperative infection,ventricular catheter,infection rates,average time to infection,wound sepsis,Leucocytosis and temperature,craniotomy infections,infection rate,hypotension|Among the patients receiving antibiotics there was an infection rate of 12%, versus 19% among patients receiving placebo.
5681|metabolic acidosis, defined as an umbilical cord artery pH,Apgar score, neonatal admissions, hypoxic-ischemic encephalopathy, or operative deliveries,rates of umbilical-artery metabolic acidosis,operative deliveries for "fetal distress,neonatal outcome,caesarean section rate,proportion of babies who had an umbilical arterial pH,rate of umbilical-artery metabolic acidosis,fetal blood sampling rate,rate of neonatal acidemia,incidence of FBS,metabolic acidosis,number of operative deliveries, low Apgar scores, neonatal admissions, and newborns with hypoxic-ischemic encephalopathy,rates of operative intervention, and neonatal outcome,VO rate,Neonatal acidemia (umbilical artery pH <7.10), neonatal metabolic acidosis (umbilical artery pH <7.05 and base excess <-12 mmol/l) and operative interventions: caesarean section rate, vacuum outlet (VO) rate and FBS rate,Fetal blood sampling (FBS,metabolic acidosis in blood, operative deliveries, Apgar scores, neonatal admissions, and hypoxic-ischemic encephalopathy,incidence of metabolic acidosis,fetal distress,neonatal acidemia,frequency of unsuspected acidaemia,operative delivery for fetal distress,low 5-minute Apgar scores|The number of operative deliveries, low Apgar scores, neonatal admissions, and newborns with hypoxic-ischemic encephalopathy was comparable in both groups.
                
not found|severe side effects of interferon-alpha,rate of chronic evolution of acute hepatitis C,persistent liver damage,Serum hepatitis C virus RNA,Biochemical, histological and serological parameters,serum HCV-RNA,normal ALT levels,Biochemical and virological parameters,recurrence,raised serum aminotransferase concentrations,normal serum ALT activity,normal ALT and no HCV RNA,Serum ALT levels,persistent undetectable serum HCV-RNA,normal serum aminotransferase,duration of the acute phase of hepatitis,aminotransferase flare-ups,severe hepatic lesions with lower histological activity,chronicity rate,normal ALT levels and no HCV RNA,serum alanine aminotransferase,Serum HCV-RNA measured by reverse transcription-polymerase chain reaction|Anti-hepatitis C virus seroconversion occurred later and at a lower rate in the group of patients who received interferon-alpha.
120|pain intensity, pain relief, and side effects,analgesic effects,uterine cramp, episiotomy, or surgical pain,relative efficacy, safety and time course of analgesia,pain intensity, pain relief and side effects,pain intensity differences and total pain relief,highest mean rating for summed pain intensity differences,stronger analgesia,uterine cramp and episiotomy pain,dizziness and drowsiness,pain intensity difference (SPID,analgesic efficacy,greatest analgesic response,uterine pain,pain intensity difference [SPID] scores,Highest summed analgesic ratings,analgesic response,pain intensity differences (PID,Adverse effects,mean pain intensity scores, began within 1 hr and had similar time-effect patterns,drowsiness,uterine cramps,aspirin analgesia,episiotomy pain,relative efficacy, safety, and time course of analgesia,postpartum pain relief,Side effects|Ketorolac 10 mg gave the highest mean rating for summed pain intensity differences (13.6, p = 0.0002 versus placebo), followed by aspirin (11.9, p = 0.012), ketorolac 5 mg (10.9, p = 0.072) and placebo (8.6).
75|Exercise tolerance, disease-related measures, and self-reported health status,change scores for flexibility, number of clinically active joints, duration of morning stiffness, or grip strength,aerobic capacity, exercise time, and joint counts,blood mononuclear cell subpopulations, proliferative response, or natural killer cell activity,emotional status and disease activity,effectiveness and safety,swollen joints,HAQ score,emotional status,activities of daily living and reduced joint pain and fatigue,deterioration of disease activity,aerobic capacity,functional ability (assessed by the McMaster Toronto Arthritis [MACTAR] Patient Preference Disability Questionnaire and the Health Assessment Questionnaire [HAQ,muscle strength, and joint mobility in the high intensity exercise programme,physical condition, muscle strength, joint mobility, daily functioning (HAQ), and disease activity,radiographic damage,heart rate at stage 2 and rate of perceived exertion,radiographic progression in large joints,plasma concentrations of interleukin-1 alpha, interleukin-1 beta, and interleukin-6,aerobic capacity, muscle strength, and joint mobility,aerobic capacity, joint mobility, and muscle strength,aerobic capacity, 50-foot walking time, depression, anxiety, and physical activity,morning stiffness, a pain score, number of swollen joints, a health assessment score, a functional score, ESR, Hb, the cost of medicine, and progression using X-rays of hands and feet,erythrocyte sedimentation rate, tender joints, or morning stiffness,MACTAR Questionnaire score,Resting levels of a number of immune parameters,functional ability,retention rate,Maximal O2 uptake,median radiographic damage of the large joints,disease activity|The results showed no effect of training on the disease activity or on the progression of the disease.
not found|endometriosis scores, pregnancy rates (PRs), and pain,pain symptoms,paid working life,CA-125 changes,frequency,serum concentrations of CA-125,Pain,concentration of CA-125,pelvic pain and dysmenorrhea,emotional balance,bone resorption,Serum concentrations of CA-125,cumulative pregnancy rate,safety and tolerability,dysmenorrhea,symptom score,efficacy and safety,severity of dysmenorrhoea,VAS score,mean lumbar BMD,mean total endometriosis scores,weight gain and acne,CA-125 concentrations,hirsutism,mild, moderate or severe degrees of lower abdominal pain, dysmenorrhoea and deep dyspareunia,sleep disturbances and anxiety-depression score,quality of life,lack of efficacy, pregnancy, elevated hepatic function tests,pelvic pain,leg cramps,breakthrough bleeding,anxiety-depression score,body weight increase,Hypoestrogenic effects,symptom scores,endometriosis scores,Total American Fertility Society scoring,Pain symptoms,pain pattern and quality of life,visual analogue scale (VAS,quality of life such as sleep disturbances and anxiety-depression,natural history of endometriosis or PRs,weight,painful symptoms of endometriosis,adverse event profile, laboratory parameters, bone mineral density (BMD), bone markers and bleeding patterns,bleeding episodes,anxiety-depression and sleep disturbances,side effects|During the 6-month follow-up after medication, the CA-125 concentrations tended to increase, especially in danazol-treated women.
207|survival times of patients after the operations and the application of an active drug or placebo,survival benefit,Median survival,CSF leak,Survival proportions,adverse reactions,survival,intracranial hypertension,median time from surgery to death,risk of death,Adverse events,survival advantage,6-month survival|This survival advantage was maintained at 1, 2, and 3 years and was statistically significant (P = 0.01) at 3 years.
52|number of patients in remission,Brief Psychiatric Rating Scale (BPRS), Scale for the Assessment of Positive Symptoms (SAPS), Scale for the Assessment of Negative Symptoms, and Hamilton Rating Scale for Depression,rate of side-effects and abnormal laboratory test results,positive and negative psychotic symptoms,baseline SAPS scores,Side-effects,total BPRS scores,plasma sulpiride levels and therapeutic response,adverse reactions,antipsychotic efficacy,time course of the total psychiatric rating scales (PRS,motor retardation, delusion, hallucination or disturbance of self-consciousness, social isolation or withdrawal, and recreation or work,total PRS,final global improvement rating,emotional withdrawal and hallucinatory behavior,16-item Brief Psychiatric Rating Scale (BPRS|The time course of the total psychiatric rating scales (PRS) showed a progressive decline during treatment for both drugs, and at the end of treatment clocapramine proved significantly lower in total PRS than did sulpiride.
not found|healing time,pressure ulcers,wound healing|Results showed that US/UVC treatment had a greater effect on wound healing than did nursing care, either alone or combined with laser.
                
472|basal serum retinol concentration,duration of hospital stay,relative mortality,mean number of days of hospitalization,overall duration of pneumonia and incidence of adverse outcomes,duration of signs of pneumonia,remission of respiratory signs,mean number of days of fever, rapid respiratory rate, or hypoxia|Children who received vitamin A, however, were less likely to have fever by day 3 (P = 0.008) and were 29% less likely to fail to respond to the first line antibiotic (P = 0.054).
                
not found|anxiety scores,conversion symptoms,Hypnotisability,Video Rating Scale for Motor Conversion Symptoms, the D(isabilities) code items from the International Classification of Impairments, Disabilities and Handicaps and the Symptom Checklist-90,Stanford Hypnotic Clinical Scale|Significant treatment results for all outcome measures were found for the total sample.
79|1-year probability of survival,probability of gram-negative infection,survival,Extraperitoneal infections,incidence of infections,SBP and sepsis,overall rate of infection or in survival,spontaneous bacterial peritonitis recurrences,mean time of observation,incidence of SBP,efficacy and safety,rate of mortality,duration of hospitalization,spontaneous bacterial peritonitis recurrence,probability of survival,SBP,median duration of follow,spontaneous bacterial peritonitis,Spontaneous bacterial peritonitis or spontaneous bacteremia,1-year probability of development of spontaneous bacterial peritonitis and hepatorenal syndrome,probability of spontaneous bacterial peritonitis recurrence,Six gram-negative bacilli infections,spontaneous bacterial peritonitis (SBP,Spontaneous bacterial peritonitis,adverse effects,gastrointestinal bleeding,probability of remaining free of bacterial infections,renal function (serum creatinine level,Death,bacterial peritonitis recurrences,peritonitis recurrence,hepatorenal syndrome,overall probability of spontaneous bacterial peritonitis recurrence,E. coli counts, quinolone susceptibility, and drug concentrations in feces,Cumulative one-year probability of peritonitis recurrence,lower incidence of extraperitoneal infections,1-year probability of developing spontaneous bacterial peritonitis,Side effects,Severe infections (spontaneous bacterial peritonitis, neutrocytic ascites and bacteremia|Norfloxacin was more effective in the prevention of peritonitis recurrence due to Enterobacteriaceae (0% vs 22%, P = .01).
85|duration of opioid therapy,Bayley Scales of Mental Development,Treatment failures,average duration of outpatient phenobarbital use,developmental status,total length of treatment/observation,median length of therapy,withdrawal symptoms,duration of hospitalization,restarting opium,hospital cost,severity of NOW,amount of opium required to control symptoms, number of treatment failures, and differences in blood pressure, heart rate, and oxygen saturation,Hypertension, hypotension, bradycardia, or desaturations,therapeutic response,shorter duration of hospitalization, less severe withdrawal, and reduced hospital cost,time with mild withdrawal,frequency of withdrawal symptoms,Severity of withdrawal and hospital cost,myocarditis, sudden infant death syndrome, and homicide|Results of one way analysis of variance revealed no differences in developmental status between groups (p greater than 0.10, F = 0.25).
not found|efficacy and safety,survival,free of neurologic complications,perinatal survival,cystic periventricular leukomalacia,survival of at least one twin at six months of age, and survival without neurologic complications|Infants in the laser group also had a lower incidence of cystic periventricular leukomalacia (6 percent vs. 14 percent, P=0.02) and were more likely to be free of neurologic complications at six months of age (52 percent vs. 31 percent, P=0.003).
                
24|total PTSS-C scores, PTSD-related symptom scale, and the subscales re-experiencing and avoidance,re-experiencing symptoms,PTSD-non-related symptom scale,Multiple traumas and higher levels of depression,waiting-list,severity of PTSD symptoms, level of functioning and physical health,serious adverse events,posttraumatic stress disorder and depression and increased functioning,PTSD symptom severity,PTSD symptom change,recovery rates,Health visits,total number of PTSD symptoms,symptoms of PTSD,Total child PTSD symptoms assessed using child and parent structured interview (Kiddie Schedule for Affective Disorders and Schizophrenia, Present and Lifetime Version,total K-SADS-PL,severe abuse-specific distress,posttraumatic stress disorder symptoms and self-reports of fear and anxiety,PTSD symptoms,scores on the K-SADS-PL (PTSD symptom clusters), Screen for Child Anxiety Related Emotional Disorders (SCARED) (anxiety), Children's Depression Inventory (depression), Kaufman Brief Intelligence Test (cognitive functioning), and Child Behavior Checklist (total behavior problems,RCMAS and CDI scores,CBT gains,PTSD symptoms and impairment in functioning,maladaptive cognitions,Children's Reaction Inventory (CRI,Preintervention and postintervention scores,depression symptoms, severity of suicidal ideation, feelings of guilt, and perceived stigmatization,symptoms of PTSD, feelings of shame, and abuse-specific parental distress,Symptoms of PTSD and trauma-related feelings of guilt,posttraumatic stress disorder and depression symptom severity,Symptoms of PTSD, depression, and related impairment,K-SADS-PL hyperarousal,global functioning,CRI scores,relation to parent-completed measures and clinician ratings of global functioning,Revised Children's Manifest Anxiety Scale (RCMAS) and the Children's Depression Inventory (CDI,PTSD diagnostic remission,SCARED,PTSD symptom scores,children's IPV-related PTSD and anxiety,K-SADS-PL avoidance,symptoms and functioning,symptoms of PTSD, depression, and anxiety,Posttraumatic Stress Symptom Scale,efficacy of cognitive-behavioral therapy|Compared to the WL group, participants who received CBT showed significantly greater improvement in symptoms of PTSD, depression, and anxiety, with significantly better functioning.
24|Success rate for delivery of placenta, blood pressure, pulse rate, blood loss, and various side effects,successful delivery of placenta, while removal of placenta|No adverse effects of clinical importance were registered.
                
90|MV duration, the length of RICU stay and hospital stay,duration of ETMV,probability of survival and weaning during ventilation,incidence of ventilation associated pneumonia (VAP,similar age, sex, APACHE scores, RR, HR, MAP, PaO2 and PaCO2 at the time of commencement and PIC window,shorter periods of invasive ventilation,mean period of daily ventilatory support,durations of invasive mechanical ventilation (MV) and total MV,shorter duration of invasive MV,durations of ICU and hospital stays and the 3-mo survival,lower rate of ventilator associated pneumonia (VAP,rate of weaning failure,need for tracheotomy to withdraw ventilation,90-day survival,Hospital mortality,hospital stays,intensive care unit (ICU,lower incidence of nosocomial pneumonia,occurrence of VAP, reintubation and hospital mortality,septic shock,Arterial blood gases, duration of mechanical ventilation, time in the intensive care unit, occurrence of nosocomial pneumonia, and survival at 60 days,severe hypercapnic respiratory failure,time of PIC window,nosocomial pneumonia,mean duration of mechanical ventilation,incidence of nosocomial pneumonia,shorter mechanical ventilation and length of stay, less need for tracheotomy, lower incidence of complications, and improved survival,duration of invasive MV, the risk of VAP and hospital mortality,type of chronic respiratory failure (CRF), pulmonary function data, age, Simplified Acute Physiology Score (SAPS II), and severity of ACRF on admission,60-day survival rates,incidence of reintubation,lower hospital mortality,total duration of ventilatory support,ICU,Survival rates,time in the intensive care unit,durations of RICU stay and hospital stay|11) days, P = 0.047] and lower hospital mortality (1/47 vs 7/43, P = 0.025).
                
61|elective nail removal,Durations of hospital stay, and time needed to achieve union,deep posterior compartment pressures,union and infection rate,Screw failure,deltaP values,delayed union and breakage of screws,average estimated blood loss,chronic anterior knee pain or functional impairment,Compartment pressures and deltaP ([diastolic blood pressure] - [compartment pressure,tibia fractures,Isokinetic thigh-muscle strength,time to fracture healing,healing and complications,anterior knee pain,Malunion,mal-union, delayed union, and device failure,average blood loss,open type I and II fractures,average time to fracture healing,Proximal screw failure,Peak average pressures,union time,Nonunions, time to fracture healing, and rate of malunions,duration of fluoroscopy,average total duration of the procedures performed without reaming|Ender nail still has its superior usefulness in some aspects of treatment of less comminuted unstable tibial shaft fractures, but for the more comminuted unstable tibial shaft fractures, the interlocking nail is undoubtedly better used.
282|free of hospitalization for exacerbation of schizophrenia,Positive and Negative Syndrome Scale (PANSS), Brief Psychiatric Rating Scale (BPRS), and Clinical Global Impression (CGI,tolerated,PANSS, BPRS, and CGI,Extrapyramidal symptoms (EPS,CGI final improvement score,effective, well tolerated,Time to treatment failure,movement rating scales, EPS-related adverse events, and use of anti-EPS medications,EPS-related events,EPS|Time to treatment failure was numerically superior in sertindole-treated patients compared with haloperidol-treated patients, although this difference was not statistically significant.
194|clinical score,hospital admissions,clinical scores or oxygen saturations,mean LOS ,respiratory rate,Clinical score, oxygen saturation and heart rate,mean percent oxygen saturation,oxygen saturation and clinical modified respiratory distress assessment instrument (MRDAI) scores,length of the hospital stay and the time until the infant was ready for discharge,oxygen saturation and MRDAI score,inspiratory, expiratory, and total pulmonary resistance,respiratory rate, blood pressure, or respiratory-effort scores,need for hospital admission or home oxygen,RR,degree of change in the respiratory rate, the heart rate, and the respiratory-effort score and the time that supplemental oxygen was required,room air oxygen saturation, elapsed time to meeting clinical criteria for ED discharge, hospitalization rate, and proportion of patients relapsed within 72 hours of ED discharge (relapse rate,hospital admission within 7 days after the day of enrollment (the initial visit to the emergency department,respiratory rate (RR), heart rate (HR), oxygen saturation (SpO(2)), Respiratory Distress Assessment Instrument (RDAI), and activity levels,mean clinical score, respiratory rate, and room air saturation over time,length of hospital stay (LOS,changes in clinical scores and oxygen saturations,heart rate, respiratory rate and Respiratory Distress Assessment Instrument (RDAI) score,median time,ED discharge,clinical score and respiratory rate,Adverse effects,length of the hospital stay,adverse effects,time from admission until the infant had normal hydration, oxygenation, and minimal respiratory distress,clinical score and pulmonary mechanics,RDAI score values,heart rate,acute bronchiolitis but L-adrenaline,SpO(2) or RDAI,Relapse rate|There were no significant overall differences between the groups in the length of the hospital stay (P=0.16) or the time until the infant was ready for discharge (P=0.86).
46|Postextubation problems,clinical or radiologic incidence of pneumonia|There was no difference in the clinical or radiologic incidence of pneumonia.
not found|problematic drinking, social functioning and beliefs about others,Diagnostic Interview Schedule,alcohol consumption,drug use and alcohol intoxication,personality disturbance,cost effective,lower anger expression,rates of cluster B personality disorders,alcohol misuse, mental state, beliefs and social functioning,counseling attendance and some indication of lower psychosocial impairment,Total costs,comparison of scores on the Social Problem Solving Inventory and the Social Functioning Questionnaire,overall social functioning,occurrence of any acts of verbal or physical aggression,personality disorder, psychiatric symptoms, early maladaptive schemas, interpersonal problems, and addiction-related psychosocial impairment,problem-solving skills,psychiatric symptoms, criminality, and psychosocial impairment,success; therapist's personal qualities,frequency of self-harm episodes,Substance abuse and personality disorders,parasuicide events|A 2-way analysis of variance showed that patients with ASPD were more likely to abstain from cocaine use during treatment than patients without ASPD.
490|major cardiovascular events,thickness of the intima/media complex degree of stenosis, interventricular septal thickness, crurobrachial pressure ratios of dorsalis pedis and posterior tibial arteries, distance to claudication and total vessel diameter,fasting lipids and on progression of peripheral atherosclerosis,IMT of combined carotid and femoral arterial walls,arterial intima-media thickness (IMT) of the carotid and femoral arteries and fasting lipid parameters,number of angina attacks,HDLc,recurrent stenosis,marked reduction in septal thickness,plasma lipid levels,thickening of the intima/media complex,ankle blood pressure index (ABI,morbidity and mortality,rate of restenosis,blood pressure and increases insulin resistance,tolerated,plasma lipids, insulin resistance and blood pressure,IMT,concentration of triglycerides,risk of clinical outcomes,arterial IMT,plasma lipids,intima/media thickness,IDLc,Blood pressure,visits systolic blood pressure,arterial wall thickness,Ankle brachial blood pressure index,mortality|Blood pressure was effectively reduced by perindopril irrespective of the associated disease.
77|median tympanic temperature at admission,relative risk of death by intractable shock,lactate concentration and O2 extraction ratio,Bladder and tympanic temperature,median tympanic temperature,improved survival,cardiac arrest, HF (with or without HT,complications,neurologic outcome,lower cardiac index, higher systemic vascular resistance, and hyperglycemia,survival to hospital discharge with sufficiently good neurologic function to be discharged to home or to a rehabilitation facility,survival,six-month survival curves,Mild hypothermia,survival with a follow-up time of six months,frequency of adverse events,CvO2,haemodynamics, electrolytes, lactate, arterial pH, CaO2, CvO2 and O2 extraction ratio|There was no difference in the frequency of adverse events.
                
200|creatine kinase-MB mass,SDF-1alpha, granulocyte colony-stimulating factor, and vascular endothelial growth factor,Plasma levels of interleukins (IL-6, IL-8, TNF-alpha), and systemic inflammatory response score (SIRS,systemic inflammatory response syndrome score,Blood samples,expression of NF-kappaB,cytokine release and neutrophil adhesion,SD values,precocious modulation of IL-6 expression,incidence of postoperative AF and the postoperative peak C-reactive protein (CRP) level,CD11b expression on neutrophils,hospital stay,P-selectin levels,myocardial damage,neutrophil-endothelial adhesion,operation time, blood loss, need for inotropic support, intubation time, and length of intensive care unit or hospital stay,systemic inflammatory response,MYocardial Dysrhythmia,Higher postoperative peak N-terminus pro-B-type natriuretic peptide levels,High-sensitivity C-reactive protein values,Cytokine levels,risk of complications, length of stay, and cost of care,leukocyte-endothelial cell interactions,myocardial disease,levels of IL-6, IL-8, TNF-alpha and SIRS score,Atrial fibrillation (AF,occurrence of postoperative AF; secondary endpoints were major adverse in-hospital cardiac and cerebrovascular events and identification of variables predicting postoperative AF,systemic inflammatory responses,amount of EPCs,occurrence of postoperative AF,plasma levels of cytokines and cholesterol,plasma levels,incidence of postoperative AF,levels of proinflammatory cytokines,Peak postoperative values of troponin,Plasma levels of interleukins 6 and 8, P-selectin, soluble intercellular adhesion molecule-1, and lactoferrin,plasma IL-1 and TNF-alpha,postoperative AF,preoperative and postoperative course,endothelial progenitor cells,Postoperative peak N-terminal pro-brain natriuretic peptide levels,Mean ,intraoperative inotropic agents,C-reactive protein (CRP,Plasma levels of selected inflammatory mediators,incidence of postoperative AF; secondary end points were length of stay, 30-day major adverse cardiac and cerebrovascular events, and postoperative C-reactive protein (CRP) variations,plasma levels of any cytokine and number of EPCs,postoperative atrial fibrillation,Systemic inflammatory response,Postoperative serum levels of both interleukin-6 and interleukin-8,inflammatory response,Postoperative clinical outcomes,EPC count,major adverse cardiac and cerebrovascular events, persistent AF at 1 month, and identification of the markers to predict inhospital postoperative AF,systemic inflammatory response and perioperative morbidity,postoperative CRP level,incidence of major adverse cardiac and cerebrovascular events and persistent AF,plasma CRP levels,Levels of interleukin, IL-6 and IL-8; tumor necrosis factor alpha; SDF-1alpha; granulocyte colony-stimulating factor; and vascular endothelial growth factor,incidence of AF,serum levels of the proinflammatory cytokines (IL-6, IL-8, TNF-alpha), and leukocytes, and the SIRS score,Peak CRP levels,sP-selectin values,incidence of major adverse cardiac and cerebrovascular events,length of stay,Concentrations of soluble P-selectin (sP-selectin,peak levels,length of ICU and hospital stay,risk of AF,postoperative interleukin-6 (IL-6) levels,Troponin I, myoglobin, creatine kinase-MB mass, and high-sensitivity C-reactive protein,high postoperative CRP levels|Atorvastatin significantly reduced the incidence of AF versus placebo (35% versus 57%, P=0.003).
not found|Recurrence of active CDD,recurrences,Clostridium difficile-associated diarrhoea (RCDAD,recurrence of CDD,initial CDD (recurrence rate,Effectiveness,Recurrence of clinical symptoms,relative risk (RR) of CDD recurrence,serious adverse reactions,safety and efficacy|No serious adverse reactions were observed in these patients.
20|sexual behavior,sexual risk,attitudes, behaviors and intentions related to sexual activity,intention to engage in sex and increased abstinence,sexual intentions, abstinence, and a trend toward fewer virgins initiating intercourse,self-efficacy,sexual consequences|Hierarchical logistic regression analyses showed significant effects for the intervention on sexual intentions, abstinence, and a trend toward fewer virgins initiating intercourse for the first time, 19 weeks after baseline.
not found|incidence rate of wound hematomas,graft performance,Graft patency rates, limb salvage rates, and survival rates,Primary patency rate,clotting of blood within the grafts or native vessels,30-day data for mortality, repeat operation, and recurrent occlusion,patent reconstruction at day 1, perioperative blood loss, and the percentage of patients requiring protamin,patency,survival,mortality rate,FPA,overall patency,Median blood loss,Major hemorrhagic events,major bleeding events,cumulative limb salvage rates,heart failure,limb salvage,cumulative 5-year survival rate,median durations of primary patency and limb salvage,anti Xa levels,incidence rate of postoperative hematoma,patency, limb salvage, and survival,FPA levels,Major complication rates and cardiovascular morbidity,rest pain or tissue loss,limb salvage or survival rates,rate of occlusion and bleeding,limb salvage rates,excessive bleeding,Heparin levels (Anti Xa,patient mortality, morbidity and bypass patency rates,patency rate,fibrinogen prothrombin complex, thrombin-antithrombin complex, platelets and antithrombin,secondary patency rates,levels of fibrinogen, FPA, thrombin antithrombin complex and FM,patency and limb salvage,30-day graft patency, operative blood loss, and hemorrhagic complications,graft reocclusion and limb loss,Soluble fibrin, measured as fibrin monomers (FM) and fibrinopeptide A (FPA,duration of patency, limb salvage rates, and complication rates,immediate postoperative primary graft patency rates,graft occlusion,graft patency,Graft patency,Benefits, morbidity, and mortality,early graft patency,serious bleeding complications,Perioperative blood transfusions and complications,reoperation because of bleeding,elevated levels of fibrinogen, fibrinopeptide A (FPA) and thrombin-antithrombin (T-AT) complexes,levels of FPA,intraoperative graft thrombosis,bypass patency, and mortality and morbidity,ages, indications, bypass graft types, risk classifications (ie, conduit, runoff, or graft failure), or comorbid conditions (except diabetes mellitus,limb salvage rate,Levels of FM,graft patency, limb salvage, and survival,risk of morbidity and mortality,primary patency of peripheral arterial bypass grafts (PABG,level of the reconstruction; survival,Patency,operative procedure, complication rate, and hospital course,overall complication rate|Preoperatively and during surgery the patients had elevated levels of fibrinogen, fibrinopeptide A (FPA) and thrombin-antithrombin (T-AT) complexes.
134|quality of life (QOL,social interaction,caregiver QOL, reducing burden related to patients' symptoms, and caregiving tasks,caregiver QOL,sleep quality and depressive symptoms,stimulus control, relaxation, cognitive therapy, and sleep hygiene elements,breathing difficulty and increased religious meaning,depression,emotional distress,preparedness to care, self-efficacy, competence, and anxiety,levels of caregiver strain,distress and depression,quality of life of dyads,Brief Symptom Inventory and Beck Depression Inventory,Legacy improved family communication,partners' ratings of their self-efficacy,quality of life and other psychosocial outcomes,presence and severity of physical symptoms, psychiatric morbidity, use of and satisfaction with services, and carers' problems,Legacy activity,vomiting,caregiving stress,stress,caregiving task burden,quality of life,Mean scores,Global family functioning,carer distress (GHQ-28,Actigraphs measured latency, duration, efficiency, and wake after sleep onset (WASO) scores,overall caregiving mastery, caregiver mastery specific to caregiving tasks, problem-focused or emotion-focused coping,PSQI and CES-D scores,caregiver QOL, caregiver burden due to patient symptoms, caregiver burden due to tasks, and caregiver mastery,hopelessness and less negative appraisal of illness,quality of life scores,burden of patient symptoms,negative appraisal of caregiving,sleep quality, depressive symptoms, and quality of life,quality of life, more self-efficacy, better communication, and less negative appraisal of caregiving, uncertainty, hopelessness, and symptom distress,family caregivers' QOL, burden, coping, and mastery,Pittsburgh Sleep Quality Index (PSQI), Center for Epidemiological Studies-Depression scale (CES-D), and Caregiver Quality of Life-Cancer scale (CQOLC,carer strain and quality of life, satisfaction with care, and bereavement outcome,positive caregiver experience,Brief Symptom Inventory, Beck Depression Inventory, and Social Adjustment Scale,appraisal variables (appraisal of illness or caregiving, uncertainty, hopelessness), coping resources (coping strategies, self-efficacy, communication), symptom distress, and quality of life|The intervention consisted of five sessions and addressed family involvement, optimistic attitude, coping effectiveness, uncertainty reduction, and symptom management.
                
94|nausea,Heart rate (HR), mean arterial pressure (MAP), peripheral oxygen saturation (SpO2), end tidal carbon dioxide (ETCO2) tension, forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC), and amount of remifentanil,Levels of sedation and co-operation,pain thresholds,P-deletion, reaction time, and critical flicker fusion tests revealed similar depression,cumulative scores of pain,NPY concentrations in FF,Number of oocytes retrieved and fertilization, cleavage and clinical pregnancy rates,Hemodynamic variables, sedation and pain scores and the number of patients with the maximum Aldrete recovery score,take home baby rate,VAS ratings,HR, MAP, ETCO2, SpO2, FEV1, and FVC,mean and maximum pain, and 'pain now,Pain relief and subjective well-being,plasma remifentanil concentrations,levels of vaginal and abdominal pain,pain-relieving effect,hemodynamic parameters,Time and drug consumption,State Trait Anxiety Inventory (STAI,p-deletion and critical flicker fusion scores,pain scores,Plasma remifentanil concentrations,hemodynamic parameters, pain, sedation, and recovery score,Pain intensity and psychological well-being were assessed by means of visual analogue scales (VAS); tiredness, nausea and vomiting and analgesic drug consumption,pain score,pain relief; secondary end-points were costs, time to discharge and clinical outcome parameters,implantation rate,abdominal pain, other pain, nausea and stress,severity of nausea, vomiting, dizziness, and drowsiness,prolactin,adequate peroperative analgesia,pain tolerance,Pain relief,plasma remifentanil concentrations and pulmonary function tests,pregnancy rate,Adverse effects,median abdominal pain levels,pregnancy rate and NPY concentrations,Fertility outcomes,visual analogue scale (VAS,Follicular cortisol,efficacy and acceptability,Pain and subjective expectations and experiences,incidence rate of abdominal pain,analgesia requirements,Intra-operative sedation and co-operation,Hemodynamic variables, sedation, pain, the Aldrete recovery score, and side effects,Visual analogue scales (VAS,Time to discharge and costs,pain directly related to oocyte aspiration, adequacy of anaesthesia during oocyte aspiration, abdominal pain, or degree of nausea,anaesthetic effect,pain relief, peroperative pain, clouding of memory and the surgeons' assessment of operating conditions,VAS pain ratings,harmful to oocytes or embryos,pain sensation,postoperative abdominal pain,average alfentanil dosage requirements,visual analogue scale,postoperative nausea,median pain levels,mean (SD) pain score,pain and anxiety,number of oocytes,Neuropeptide Y (NPY) concentrations in follicular fluid (FF,intraoperative analgesia,pain rating and pain score,Oxygen saturation levels,Overall, patient satisfaction,mean age, weight, duration of procedure and dose of alfentanil,analgesic effects,oversedation or peri-operative complications,rate of embryo transfers and pregnancies,Pain,IVF pregnancy rate,pain relief,time for mobilization, and costs for time and drug consumption,pain intensity and analgesic consumption,level of stress,pain levels,5-point scale while severity of pain, and doctor and patient satisfaction,abdominal pain,rate of gestation,time and costs for drug consumption,postoperative abdominal pain, nausea and stress,pain,A visual analogue scale (VAS|Auricular EA significantly reduces pain intensity and analgesic consumption of the opioid remifentanil during oocyte aspiration in IVF treatment.
52|steady-state blood pressure and serum concentrations of serum angiotensin-converting enzyme (ACE) and plasma renin activity or angiotensin II (AT-II,serum albumin levels,Ua/Uc ratio,Partial remission,Cosmetic side effects (hypertrichosis and gum hypertrophy,sustained remissions,Proteinuria,cushingoid features and serious infections,nephrotic-range proteinuria,mean urinary protein excretion, the mean serum proteins and plasma cholesterol,blood cholesterol levels,blood pressure and components of systemic RAS,efficacy and safety,urine albumin-to-creatinine (Ua/Uc) ratio and the percentage reduction,number of adverse events,hypertension and hypokalemia, while vomiting and reversible alopecia,proteinuria,values of 24-h urinary protein excretion,remission,blood pressure,complete remission,mean score,prestudy serum cholesterol levels,partial remission (urinary protein-creatinine ratio,remission of the nephrotic syndrome,Efficacy and safety,average CSA level and proteinuria change,fractional decline in GFR,diminution of their proteinuria,complete resolution of proteinuria,serum creatinine, triglyceride, cholesterol, urine protein and creatinine clearance,hyperlipidemia and proteinuria,proportion of patients who experienced relapse,serum creatinine and creatinine clearance,blood pressure and components of the renin-angiotensin system (RAS,severe renal or extrarenal toxicity,proteinuria and serum albumin levels,median Ua/Uc ratio,Systolic and diastolic blood pressure reductions,proteinuria and alleviated renal tubular damage,serum concentrations of urinary retinol-binding protein and beta(2)-microglobulin,Treatment failure,serum creatinine,Rates of remission,complete remission (urinary protein-creatinine ratio,Baseline clinical, biochemical, and histological features|Following treatment, complete remission was seen in 53.8% and 47.8% patients in groups I and II, respectively (P = 0.6).
12|cocaine dependence,weekly assessments of the frequency and quantity of drug and alcohol use, weekly urine toxicology screens and breathalyzer readings,rates of cocaine-negative urine tests,total number of weeks abstinent from cocaine,positive urinalysis,Visual Analogue Scales (VAS,number of cocaine-negative urine tests,medication adherence,quantity and frequency of cocaine,continuous cocaine abstinence|Results show that CBT treated subjects remained in treatment longer than those assigned to either DIS/CBT or NTX/CBT therapies.
208|postherpetic neuralgia,time to return to uninterrupted sleep,time to a first or a complete cessation of pain,lesion healing, resolution of pain, return to usual activity, and return to uninterrupted sleep,Pain reduction,post-herpetic neuralgia,time to return to usual daily activity,Time to total crusting and healing,total crusting,chronic pain and quality-of-life outcomes,accelerated time to cessation of acute neuritis,adverse events,quality of life,laboratory adverse events,frequency of postherpetic neuralgia,relieved pain,risk ratios,progression of the rash,resolution of pain,analgesic requirements each day, and adverse events and laboratory abnormalities|Time to total crusting and healing was accelerated for patients receiving acyclovir plus prednisone compared with patients receiving two placebos; the risk ratios were 2.27
29|respiratory syncytial viral (RSV) bronchiolitis,Baseline characteristics and respiratory status,shorter hospitalization period,hospital admissions,length of hospital stay,duration of oxygen therapy,median length of stay,rate of hospital admission, the respiratory status,Respiratory Assessment Change Score (RACS,chronic respiratory symptoms,admission rate,Oxygen saturation (SaO2,wheeze and hospitalization rates,time from study entry to resolution of respiratory distress, determined by a clinical score derived from the respiratory rate, occurrence of wheezing, chest retraction, and oxygen saturation,mean 4-hour RACS,hospital admission after 4 hours of emergency department observation,oxygen saturation, respiratory rate, RDAI measurement twice daily for the first 4 days, and the length of hospitalization,mean oxygen requirements, or length of hospital stay,clinical score, oxygen saturation, or IV fluid requirement,prevalence of post-bronchioltis wheezing,frequency of hospital release,heart and respiratory rate; respiratory distress index, oxygen saturation, and Silverman Andersen scores,Respiratory status,mean length of hospital stay,RDAI, heart and respiratory rate and SpO(2,hospital admission within 7 days after the day of enrollment (the initial visit to the emergency department,Poor RACS,Disease severity,Duration of hospital admission, time taken to become symptom free, re-admission rates, general practitioner consultation rates, and use of anti-wheeze medication,hospitalisation rate,mean duration of oxygen therapy,symptoms of acute bronchiolitis or prevented postbronchiolitic wheezing,RDAI score,heart rate, respiratory rate and Respiratory Distress Assessment Instrument (RDAI) score,mean duration of symptoms,length of hospitalization,RACS,time needed for resolution of respiratory distress,RDAI improvement,cumulative proportion of in-hospital stay,rate of hospitalisation or respiratory status,prevalence of post-bronchiolitis wheezing,respiratory distress assessment instrument (RDAI), heart and respiratory rates, and transcutaneous haemoglobin oxygen saturation (SpO(2,hospital stay, later medical visits or admissions, and adverse events,prevalence of wheeze, respiratory symptom scores, or proportion requiring bronchodilators or steroids,RDAI score values,evolution of respiratory rate, oxygen saturation, clinical score, or pulmonary function tests,hospital admission rate,length of hospital stay, duration of oxygen therapy and time to clinical improvement during the hospitalization,oxygen saturation, respiratory rate, and RDAI score,Respiratory re-admission rates,postbronchiolitic wheezing,Median time,clinical score or in the SaO2,duration of illness prior to enrollment, pretrial medication use, clinical severity of bronchiolitis, history of atopy, and family history of atopy,time to clinical resolution|No significant differences were found between the groups in evolution of respiratory rate, oxygen saturation, clinical score, or pulmonary function tests on day 3.
211|mean number of migraine days,nausea,paresthesia, fatigue, nausea, anorexia, and taste per version,migraine and headache days,mean monthly rate of acute abortive medication use, mean monthly migraine duration, and mean monthly migraine severity,mean weight gain,Quality of life,reduction in mean monthly frequency, intensity, duration, rescue medication use, migraine associated symptoms, and adverse events,mean standard deviation (SD) of monthly migraine frequency,mean weight loss,migraine frequency, responder rate, migraine days, and daily rescue medication usage,TEAEs of mild or moderate severity,migraine headache frequency, intensity, and duration,weight loss and improved weight satisfaction,paresthesia, fatigue, and nausea,migraine episodes,mean monthly severity of migraine-associated symptoms (photophobia, phonophobia, and nausea), change in the mean monthly frequency f migraine-associated vomiting, and response rates (based on monthly migraine days and total headache days,headache days and migraine headache days and generally well tolerated,28-day migraine frequency,role function-restrictive, role function-preventive, and emotional function domains of the MSQ,transformation of episodic migraine,headache duration,mean monthly migraine frequency,Frequency, intensity, duration, associated symptoms with headaches, analgesics use, as well as drugs' side effects,number of days with migraine,alpha-band phase synchronization,mean (+/-SD) of monthly migraine frequency,efficacy, safety, and side effects,mean reduction of the frequency of migraine attacks,fatigue,SD monthly migraine frequency,adverse reactions and weight changes,headache days,rate of mean monthly migraine episodes,number of migraine days,dry mouth,responder rate (proportion of patients with > or =50% reduction in monthly migraine frequency), reductions in mean number of monthly migraine days, severity, duration, and days a month requiring rescue medication, and adverse events,efficacy-evaluable,Responder rate,Mean monthly migraine frequency,Adverse effects,development of CDH,Efficacy and tolerability,Rescue medication use,Migraine-Specific Quality of Life Questionnaire (MSQ) and the Weight Satisfaction Scale Questionnaire,visual analog scale (VAS), and headache duration,weight loss,headache frequency, and migraine associated symptoms,weight increase,somnolence,paresthesia, weight loss, altered taste, anorexia, and memory impairment,efficacy and tolerability,mean monthly number of migraine episodes,monthly migraine frequency,chronic daily headache,paresthesia,Responder rate for frequency,quantity of symptomatic drugs taken,mean monthly (28-day) rate of days with migraine, mean monthly rate of days with headache (migraine and nonmigraine,mean SD of monthly headache frequency,number of days on acute medication,tolerated,overall deterioration in weight satisfaction,serious AEs (depression, abdominal pain, leg pain,hypoesthesia,migraine headache,satisfaction with tolerability,dizziness,responder rate,Side effects,number of days of disability,EEG synchronization,Frequency, intensity, and duration of migraine headaches as well as MIDAS score and symptomatic medications,Visual Analog Scale, and headache duration,mean functional disability scores,efficacy and safety,migraine frequency,Adverse events,reduction of headache severity,monthly headache frequency,mean monthly days and severity of headache,reduction in mean monthly migraine days and severity of headache,average weight change,symptoms with migraine,responder rate, time to onset of action, mean change in migraine days per month, and mean change in rescue medication days per month,mean 28-day migraine frequency,headache intensity,efficacy reduction in mean monthly migraine frequency,migraine status, quality of life, level of physical activity, and oxygen uptake,duration, monthly frequency, and intensity of headache,weight satisfaction,frequency of migraine crises,side effects|A significantly larger proportion of TPM-treated subjects had a > or =75% reduction in monthly migraine frequency compared with placebo (P=0.03).
427|esophageal endoscopic appearance or sphincter pressures,relapse rate,overall quality-of-life measures or the HAD scale,rate of complete resolution of heartburn,cumulative relapse rates,Quality of life,heartburn relief,erosive oesophagitis,total regurgitation,Median time to first 24-hour heartburn-free interval,healing,erosive esophagitis,Symptom relief,rate of sufficient relief from heartburn,frequency and degree of symptoms,total use of rescue antacid medication,percentage of patients self-rated as having minimal or better symptomatic improvement,relief of heartburn,esophageal erosions or ulcerations,gastrointestinal symptoms (epigastric pain, vomiting, nausea, flatulence, retching, and retrosternal feeling of tightness) and safety profiles,symptomatic improvement,symptoms of mild-moderate gastroesophageal reflux disease (GERD,median percentages of 24-h heartburn-free days,early satiety,daytime and nighttime heartburn,total heartburn relief defined as no heartburn symptoms,Frequency of gastro-oesophageal reflux disease symptoms and health-related quality of life,patient quality of life,heartburn-free,severity of heartburn and endoscopic grade,completely symptom free,GERD symptoms (heartburn, acid eructation, and pain on swallowing,proportion of patients in whom heartburn,symptom control,heartburn symptoms of reflux disease,Recurrences of moderate or severe heartburn,esophageal acid sensitivity,total heartburn relief,nights without heartburn,heartburn severity,GerdQ index,pathological gastroesophageal reflux,Reflux symptom relief,general health status dimensions of physical functioning, bodily pain, and vitality,mild heartburn,relieving heartburn,free of heartburn,symptomatic relief,erosive reflux oesophagitis, symptom relief,mean basal pressure,reflux score irrespective of H. pylori infection,effective and well tolerated,global scores,heartburn,percentage of heartburn-free days and the time to first and sustained resolution of heartburn,oesophageal acid hypersensitivity,clinical outcomes and quality of life,alginate/antacid relief medication,diarrhea,Quality-of-life effects,Efficacy and safety,effective and safe,heartburn-specific questionnaire,health-related quality of life,reflux dimension of the Gastrointestinal Symptom Rating Scale (GSRS) score,Endoscopic healing,gastroesophageal reflux disease and heals erosions and ulcerations,Complete resolution of heartburn,resolution of heartburn,Complete upper GI symptom relief,free from key GERD symptoms,complete relief from upper GI symptoms,mean number of heartburn episodes,endoscopic classification,frequency and severity of symptoms,Antacid consumption,percentage of heartburn-free days and antacid-free nights,adverse events and laboratory assessments,abdominal pain and diarrhea,complete endoscopic healing,Regurgitation and epigastric pain,Similar sensitivity,reflux score,mean heartburn pain scores,symptomatic response,Heartburn symptoms,lower-esophageal-sphincter pressure,adequate control of heartburn,median number of days off active treatment,severity of oesophagitis or frequency of positive acid perfusion tests,symptomatic relapse,gastro-oesophageal reflux disease symptoms,rapid relief of heartburn,Quality of life improvements,quality of life,lower severity of heartburn,tolerated,symptom frequency and severity,endoscopic appearance of the esophageal mucosa,frequency and the severity of heartburn,evidence of erosions and ulcerations,quality of life and symptom severity questionnaires,Symptoms and quality of life,symptomatic relief of heartburn,reflux,Gastroesophageal reflux disease (GERD,median times to relapse,rates of complete control of GORD symptoms,Relief of non-reflux symptoms,oesophagitis,heartburn symptoms,safety and symptom relief efficacy,Total time off active treatment, time to failure of intermittent treatment, and outcomes ranked from best to worst,rate of adverse events,relief of symptoms of gastroesophageal reflux,Response of low-esophageal-sphincter pressure,percentage of heartburn-free days,rapidity of symptom relief and 4-week efficacy,complete relief rate,anxiety,Heartburn-dominant, uninvestigated dyspepsia,efficacy and safety,concordance analyses, daytime and nighttime heartburn with antacid usage,Complete relief,Esophagoscopy, esophageal acid sensitivity, and lower esophageal pressures,adverse events,Reflux index scores, quality of life (SF-36), and the hospital anxiety and depression (HAD) scale and symptom relief,chronic heartburn,pain severity of both day and night heartburn,complete resolution of heartburn,free of regurgitation,Heartburn,Daily proportions of patients with no heartburn,relief from key GERD symptoms (heartburn, acid eructation, and pain on swallowing,proportion of patients with complete relief of daytime heartburn,nonerosive gastroesophageal reflux disease,incidence of possible or probable treatment-related adverse reactions,Total heartburn relief,acid regurgitation, dysphagia, epigastric pain, and nausea,symptom relief,Complete heartburn relief,frequency and severity of heartburn using the Gastrointestinal Symptom Rating Scale (GSRS) and a patient heartburn diary,percentages of 24-h heartburn-free days (primary) and nights without heartburn (secondary,GERD-associated symptoms (e.g., regurgitation, belching, early satiety|At two weeks there was no significant difference between placebo and ranitidine, regarding the proportion of patients with complete relief from symptoms or satisfied with treatment.
67|proportion of patients with granulation tissue,Diabetic foot ulcers (DFUs,DFU healing,wound area,All ulcer healing outcomes,Complete healing,AQAg-treated ulcers,Efficacy and tolerance,total number of dressing changes,Adverse events,healing outcomes and primarily healing speed,Pain on dressing change,overall ulcer improvement and less deterioration,pain on dressing changes, the number of dressing changes, and adverse events,Efficacy and safety,mean time to healing,success rate,efficacy and tolerance,Wound size|There was more overall ulcer improvement and less deterioration in AQAg subjects (P = 0.058), particularly in the subset initially using antibiotics (P = 0.02).
400|CD4(+), CD8(+), or CD3(+) cell counts,pregnancy outcomes, hematologic indicators, and T cell counts,severe preterm birth,HIV disease progression or pregnancy outcomes,birth weight, duration of gestation, or fetal and neonatal mortality,Hemoglobin concentrations,child survival,risk of fetal death,adverse birth outcomes,early infant death,risk of adverse pregnancy outcomes,neonatal or overall child mortality,birth outcomes, hematologic indicators, and counts of T lymphocyte subsets,birth outcomes and counts of T lymphocyte subsets,maternal CD4 cell counts or viral load,red blood cell count and in packed cell volume,rise in hemoglobin,CD4, CD8, and CD3 counts,risk of low birth weight,CD4 cell counts, viral load, pregnancy outcomes, and maternal and infant mortality,risk of low birthweight,risk of preterm birth,adverse pregnancy outcomes,reduced risk of low birth weight,risk of child mortality,30 fetal deaths,pregnancy outcomes and T cell counts,mean birth weights,maternal mortality|However, the rise in hemoglobin over this period was significantly lower (P = 0.03) in the zinc group (x +/-
not found|toxicity,health-related QOL,overall median TTF,Grade 3 or 4 nonhematologic toxicities,median survival time,percentage of CD4 or CD4 T-cell subsets,overall median survival,Nine complete (CRs) and 18 partial responses (PRs,survival,complete and partial response rate,Quality of life,OS, time to progression, or OR,Objective response (complete plus partial remission [CR + PR,Toxicity,survival advantage,TTF or survival,Five CRs and 20 PRs,Poor performance status (PS), hepatic metastases, and weight loss,median OS,toxicities,survival benefit,functional living index,overall survival, progression-free survival (PFS), objective response, and safety, and to assess health-related quality of life (QOL) and pharmacokinetics of both drugs and their metabolite, 5-(3-methyltriazen-1-yl)imidazole-4-carboximide (MTIC,incidence of grade 3/4 flu-like symptoms,durable responses,response or survival,severe and life-threatening toxic events,fatigue,median progression free survival,lymphopenia, evidence of immune activation,1-year survivals,tolerated with only additive toxicity,response rates, overall survival, and tolerability,fatigue, nausea and anorexia, flu-like symptoms and neutropenia,prolonged survival,total response rate,drug safety,overall response rate,Median survival,quality of life,constitutional, hemodynamic, and myelosuppressive toxic effects,complete response (CR) and seven partial responses (PR,death,median overall survival,Median duration of response,response rate, TTF, or survival,TTP and survival,Median time to progression (TTP,Response rates,acceptable level of toxicity,efficacy and toxicity,6-month survival,median durations of response,response rate, time to treatment failure (TTF), overall survival, and toxicity,progression-free survival or overall survival,median survival,Response or disease stabilization,severe toxicity,overall response rate of BCDT with IL-2/IFN-alpha,response rates,Objective responses, survival, and toxicity,tolerated and produced a noncumulative, transient myelosuppression late,nonhematologic toxicities,Median time to treatment failure (TTF) and median survival,duration of partial responses,overall survival (OS,severe thrombocytopenia,Median PFS time,percentage of CD56- (NK cells) and CD3/HLA-DR-positive (activated T cells) subsets|Toxicity was worse in the combination arm, with more patients experiencing fatigue, nausea and anorexia, flu-like symptoms and neutropenia.
not found|management of patients' problems,risk factor management,quality of care,total length of stay and ICU length of stay fell,Antibiotic prescribing rates and patients' symptom resolution,quality of rural ICU care,blood pressure and total cholesterol values,hyperlipidaemia OR,antibiotics in caesarean section and use of polyglycolic acid sutures,Quality of life,patient care processes (lab work, nursing, dietary management, ventilator management, ventilator weaning,proportion of appropriate outcomes following educational outreach [odds ratio (OR) ,time to symptom resolution,discontinuation rates,patient recall of FP advice about nicotine replacement patches and gum,index of preventive performance,Moderate rates of improvement,suspected urinary tract infections,diagnosis of dementia,Overall benzodiazepine prescribing,relative reduction in R05C1 prescription,quality of selective case finding and quality of diagnostic procedures,proportion of "correct" responses,back pain unit,Anxiety and insomnia diagnosis rates,rates of preventive services,cerebral and peripheral vasodilators (CPVD) and antibiotics,average prescribing cost,Compliance rates,overall index of preventive performance,psychotic disorder,rates of diuretic or beta-blocker use,mean stay in hospital,Mammography completion,levels of knowledge of prescribers about the appropriate management of acute diarrhoea,admissions to hospital or mortality,total antimicrobial use,prescription of CPVD,ADR reports,endorsement of PSA screening by professional bodies,tetanus immunization,drug usage, rate of influenza vaccination, functional status, or psychological wellbeing,influenza immunization,Mean costs of inappropriate prescriptions per practitioner per patient visit,antimicrobial usage,net annual cost (cost minimization,total costs,patient recall of assessment of smoking status and FP use of "quit dates," behavioral advice, and written materials,vaccination rates,discussion of dehydration during pharmacy visits,referral rates,appropriateness (based upon the guidelines) of sale or no sale of OTC anti-fungals,hospital ventilator days,tranexamic acid,Rates of ventouse delivery,benzodiazepine hypnotics,blood pressure control, defined as a blood pressure measurement,loss of memory,Length of stay, intensive care unit transfers, readmission rates, and in-hospital death rates,discontinuation of long-acting benzodiazepines,total cost of antibiotics prescribed by doctors,physician reporting of adverse drug reactions,mean stay in the ICU,knowledge about diarrhoea,Cost effectiveness,outpatient prescribing costs,pneumococcal vaccination rates,recording of review of inhaler technique, smoking habit, and review of asthma symptoms,physical activity, functional status, self rated health, immunisation status, social contacts, psychological wellbeing, drug usage, and rate of influenza vaccination,antidiarrhoeal sales,Intervention delayed time to first attendance with acute asthma,child diarrhoea,average prescription costs,prescribing of psychotics,diagnosis of depression,initial prescriptions,Antibiotic dispensing,total number of antibiotic prescriptions,higher self-reported and observed rates for several risk assessment questions and counseling recommendations,numbers of patients "at risk of stroke,influenza and pneumococcal immunisation rates,prescribing practice,proportion of residents with any psychotropic drug, polymedicine, and therapeutic duplication and proportion of residents with nonrecommended and acceptable drugs,Mammography,proportions of GPs implementing the programme and numbers of patients screened and intervened with,Prescribing behaviour,pneumococcal immunization,respiratory infections,Patient satisfaction scores,percentage of participants attending with acute asthma,overall cost,angina pectoris,minimal intervention" components of the kit, ratings of overall acceptability of delivery, perceptions of cultural and structural barriers to using the kit, and ratings of the overall acceptability of the kit,reduced mortality,quality of asthma care,hypertension control,CDE recommendation and performance rates,oral rehydration solution (ORS) usage,index of psychoactive-drug use, measuring both the magnitude and the probable inappropriateness of medication use,preventive care performance,prescribing for anxiety diagnoses,number of days that unnecessary levofloxacin or ceftazidime,preventive cardiovascular care,rate of unnecessary use of the 2 target antibiotics,prescription of first-line lipid-lowering drugs,Baseline prescribing costs,benzodiazepine prescribing,reporting ADRs overall,blood pressure,blood transfusion practice,net annual savings,quality of life,median PSA testing rate,mean cost,proportion of prescribing of the five most frequently used drugs,overall benzodiazepine prescribing rate fell,patient care processes, patient morbidity and mortality outcomes, and resource use,frequency and quality of counseling,Processes of care, patient symptoms, quality of life, costs, and work days lost,transfusion risks (eg, viral hepatitis,days of enteral nutrition,hypertension,prescribing quality and volume,influenza vaccination,clinical outcomes of mortality or nosocomial events,mean scores,percentage of records containing at least one periodontal diagnostic notation,influenza and pneumococcal vaccination rates,risky sexual behavior,diagnoses of hypertension,raised total cholesterol,effectiveness and cost-effectiveness,asthma related quality of life,volume of prescribing for ibuprofen, diclofenac and naproxen as a percentage of total NSAID prescribing,antibiotic use, diazepam prescribing, drug costs per patient, and a composite process index for diabetes care,effectiveness and efficiency,acute respiratory tract infection,physician behaviour,average improvement,anxiety,number of prescriptions written,blood pressure control,ADR reporting rates,PSA testing rates and GP knowledge in key areas relating to prostate cancer and PSA testing,baseline-adjusted CDE recommendation and performance rates,CDE recommendation and performance,health outcomes,mean global scores,cost-effectiveness,patient quality of life or symptoms,quantity of cholesterol testing,weight and physical activity level,primary outcome measure: practices receiving outreach visits,peak flow rate, review of inhaler technique, review of asthma symptoms, prophylaxis, occupation, and smoking habit; diabetes: blood glucose concentration, glycaemic control, funduscopy, feet examination, weight, and smoking habit); size of practice disease registers; prescribing in asthma; and use of structured consultation "prompts,Helicobacter pylori testing,mean rate of inappropriate prescribing per control practitioner,personal care scores,cognitive function,pattern of prescription of asthma medicines,sales of asthma medication,provision of preventive care,prescribing of tranexamic acid,steroid prescribing,frequency of pleasurable activities, and (c) self rated health,glycosylated haemoglobin, patient satisfaction with care and treatment, functional health status and professional ability to apply the intervention,clinical breast examination,global scores in 4 areas--quality of care, charting, prevention and overall use of medications--and patient ratings of satisfaction with care and preventive practices,risk factors,number of prescriptions of lipid-lowering drugs per month|No significant differences were found between the groups for the time to symptom resolution.
                
not found|Systemic infection or death,number of total catheters utilized,number of skin punctures,systemic infection (defined as a positive blood or cerebrospinal fluid (CSF) culture treated for at least 5 days) or death,systemic infection or death,number of painful IV procedures,incidence of phlebitis,sepsis rates,number of courses of antibiotics,Length of neonatal intensive care unit stay and incidence of sepsis and phlebitis,total duration of IV use,number of insertion attempts required for total IV therapy,sepsis rates and efficacy of PN delivery,incidence of sepsis,length of the neonatal intensive care unit stay and in the incidence of sepsis,skin punctures|Interim analysis (49 neonates) revealed no difference in sepsis rates (CVC group 46%, cannula group 40%, p = 0.57).
43|ambulatory cough meter, kept cough diaries,cough frequency or score, irrespective of the presence of AHR,frequency of cough|Salbutamol or beclomethasone had no effect on cough frequency or score, irrespective of the presence of AHR.
                
not found|histologic findings (reduced periportal necrosis and portal and lobular inflammation,percentage of hepatitis D virus RNA positivity,HDV-RNA levels,viral replication,HDV-RNA negative,serum alanine aminotransferase values,portal inflammation,normalization of serum ALT levels,Histological improvement,serum ALT levels,hepatic inflammation,normal serum ALT levels,serum alanine aminotransferase level becomes normal, HDV RNA,biological and/or virological relapse,histologic deterioration,Serum ALT levels,alanine aminotransferase values,antiviral activity (serum hepatitis delta virus RNA and intrahepatic hepatitis delta antigen,Serum HDV-RNA,relapses,sustained biochemical or virologic response,hepatitis D virus RNA levels,positive for hepatitis D virus RNA,clearance of serum HDV-RNA,anti-HD titer, IgM anti-HD and HBsAg concentration,complete response (normal levels of alanine aminotransferase and no detectable serum hepatitis delta virus [HDV] RNA,ALT levels|A decrease in the percentage of hepatitis D virus RNA positivity was observed in both groups at the end of treatment.
15|Residual GAD symptoms,Average weight gain,negligible weight gain,BSPS score,Social anxiety disorder (SAD,HAM-A psychic anxiety factor scores,Clinical Global Impression-Severity Scale (CGI-S) end point score,CGI-I,Brief Social Phobia Scale (BSPS), Social Phobia Inventory (SPIN), Liebowitz Social Anxiety Scale and Sheehan Disability Scale, as well as Clinical Global Impression-Improvement ratings,SAD,Hamilton Anxiety Scale (HAMA-A) score,Hamilton Rating Scale for Anxiety,core anxiety symptoms,Social Phobia Inventory (SPIN) and the Sheehan Disability Inventory (SDI,Headache, weight increase, and increased appetite,rates of remission,Brief Social Phobia Scale (BSPS) and the Clinical Global Impression of Improvement Scale (CGI,HAM-A total scores,change from baseline to week 4 endpoint in PaRTS-A.
                Improvement from baseline to week 4 endpoint in PaRTS-A total score,drowsiness and dry mouth,Anxiety,response rates,HAM-A scores,residual GAD symptoms|There was no significant difference in responders (CGI-I score of 1 or 2) versus non-responder (CGI-I score of 3 or more) across the groups.
59|House-Brackmann Scale,safety and potential efficacy,Facial Grading Scale scores,Facial Grading Scale change scores,amplitude of the compound motor action potential (CMAP,Facial Grading Scale subcomponents,Facial Grading Scale,House-Brackmann scores,overall improvement of clinical stage|Individualized facial neuromuscular re-education is more effective in improving facial symmetry in patients with Bell's palsy than conventional therapeutic measures.
65|Positive and Negative Syndrome Scale total score,severity of psychotic and extrapyramidal symptoms,changes in Positive and Negative Syndrome Scale (PANSS) total scores and rates of extrapyramidal symptoms (EPS,severe OCS,Total Positive and Negative Syndrome Scale scores and scores on the five Positive and Negative Syndrome Scale factors,motor side-effects, efficacy, safety and quality of life (QOL,comprehensive battery of tests to assess (1) motor skills, (2) attention span, (3) verbal fluency and reasoning, (4) nonverbal fluency and construction, (5) executive skills, and (6) immediate recall,PANSS total scores,Positive and Negative Syndrome Scale (PANSS) total, Brief Psychiatric Rating Scale (BPRS) total, and PANSS General Psychopathology scores,mean duration of illness,weight gain,Total scores on the Extrapyramidal Symptom Rating Scale,efficacy in negative symptoms (Scale for Assessment of Negative Symptoms summary score,WHO-QOL-BREF physical, psychological and health satisfaction domains,Positive and Negative Syndrome Scale (PANSS) total score, derived Brief Psychiatric Rating Scale (BPRSd) total score, as well as PANSS and BPRSd subscales,frequency and severity of extrapyramidal symptoms,total and negative symptom scores,PANSS total score,extrapyramidal symptoms,efficacy and safety,general cognitive index,severity of obsessive-compulsive symptoms (OCS,psychological QOL,core symptoms of schizophrenia and motor side effects,tolerated and efficacious,safety and efficacy,severity of OCS,psychotic symptoms,Brief Psychiatric Rating Scale, Scale for the assessment of Negative Symptoms and Montgomery and Asberg Depression Rating Scale scores,Neuropsychological change,adverse events,efficacy, safety,Positive and Negative Syndrome Scale factors for positive symptoms and anxiety/depression,EPS-related adverse events,PANSS positive and negative scores and Clinical Global Impression-Severity of Illness scale (CGI-S,Severity of extrapyramidal symptoms,overall response rate,tolerated,general antipsychotic efficacy,extrapyramidal side effects, hyperprolactinemia, and sexual dysfunction,Hooper Visual Organization Test,body weight,Obsessive-compulsive symptoms,Quality of Life Scale (QLS) Intrapsychic Foundation and Medical Outcomes Study Short Form 36-item instrument (SF-36) Role Functioning Limitations-Emotional subscale scores,Yale-Brown Obsessive Compulsive Scale (YBOCS,severity of positive and affective symptoms,Response rates,PANSS positive scale scores,Greater weight gain,five PANSS factor scores (positive symptoms, negative symptoms, disorganized thoughts, and anxiety/depression,dyskinetic symptoms,psychological domain of the World Health Organisation-Quality Of Life [Brief] (WHO-QOL-BREF) scale,total score on the Positive and Negative Syndrome Scale,efficacy,safe and effective,Quality of Life (QOL) measure,OCS|Exploratory within-group analyses of the 6 cognitive domains after a conservative Bonferroni adjustment revealed a significant improvement with olanzapine only on the immediate recall domain, and similar analyses of the 17 individual tests revealed a significant improvement with olanzapine only on the Hooper Visual Organization Test.
                
102|femoral head vitality,overall incidence of AVN,rate of union or the development of AVN|There was no significant difference between the groups in terms of union (p = 0.93) and AVN at two years (p = 0.85).
23|neck pain,involuntary activity,efficacy and safety profile,dystonia and neck pain,Tiredness,mean amplitude and increased ratio (turns/amplitude,Direction of head turning, severity of torticollis, and presence or absence of jerky movements,spontaneous remission,pain-free,Adverse events,Tsui scores,serious side effects,neck posture,Efficacy and safety,severity of torticollis, disability, pain, and degree of head turning,head position and pain,activities of daily living (ADL,serious or systemic side effects,Side effects,pain scores|The remaining 18 patients completed the study and showed a significant improvement after the injections of botulinum toxin in comparison with that of the placebo.
77|FVC,plasma cortisol or C-reactive protein levels,operation without injury to bile duct, viscera or vessels, minimal pain and discomfort at 4 weeks, no wound infection,Interleukin-1 receptor antagonist (IL-1ra), IL-6, and tumor necrosis factor (TNF-alpha,physical functioning and depression scores,Immune function,hospital stay,Forced vital capacity (FVC), forced expiratory volume at 1 second (FEV1), and forced expiratory flow,median post-operative hospital stay,Conversion to open cholecystectomy,hospital costs and social costs,hospital stay (postoperative nights in hospital,cytokine levels,hospital costs,C-reactive protein (CRP), alpha-1-antitrypsin (AAT), retinol-binding protein (RBP), transferrin, and albumin,Postoperative analgesia requirements,physical and social functioning,CRP,complications,mean operation time,Median operating times,hospital stay or postoperative recovery,mean hospital stay,total cost of each case included cost of investigations, cost of disposable articles for operation, cost of drugs, cost of hospital stay, and cost of operation including anesthesia,postoperative septic complications,serum CRP concentrations,Systemic concentrations of interleukin-6 (IL-6), interleukin-1 (IL-1), tumor necrosis factor (TNF), and C-reactive protein (CRP,Total cost for LC,Median sick leave and time for return to normal recreational activities,CRP, AAT, and albumin,success or failure,Pulmonary function,monocyte superoxide anion (O2-) and tumor necrosis factor release, neutrophil O2- levels and chemotaxis, total white blood cell counts, partial arterial oxygen pressure, and serum cortisol and C-reactive protein levels,duration of anesthesia and operation time, perioperative complications or postoperative need for analgetics,serious bile duct injury,rate of return to normal activities,Postoperative deficits of respiratory function,time back to work for employed persons,median time off work,FEV1,Peak expiratory flow rate, forced expiratory volume in 1 second, and forced vital capacity,postoperative pain, less restriction of total vital capacity,shorter hospital stay, less postoperative dysfunction, and quicker return to normal activities,pre- and postoperative white blood cell (WBC) counts, postoperative body temperature, and length of postoperative hospitalization,Operative time,successful, hospital stay,monocyte release of O2- and tumor necrosis factor, neutrophil release of O2- and chemotaxis, and white blood cell count,time to full activity,partial arterial oxygen pressure,incidence of complications,duration of convalescence,IL-6 increase,hospital stay and time off work,quality of life scores,pain and depression,postoperative hospital stay,IL-1 and TNF response,postoperative complication rate,plasma IL-6 levels,Median hospital stay,Systemic acute-phase response,hospital and social costs,Intraoperative complications|Patients with LCCE had significant less postoperative pain, less restriction of total vital capacity and a shorter postoperative hospital stay as parameters of a diminished operative trauma.
not found|Mean RI fell,mean number of diarrheal episodes,Mean RI values,Cause of death,Incidence of diarrhea and Acute Respiratory Infection (ARI,cumulative effect of toxicity,Mortality rate ratios,intracranial pressure,vitamin A intakes,relative risk of mortality,Milk retinol,vitamin A deficiency,MRR of vitamin A supplementation,fetal or early infant survival,rate of fetal loss,24-wk mortality rate,mortality; the mortality rate ratio,infant mortality,anthropometric status, or on overall or severe morbidity,mortality rate ratio,RI,morbidity and child growth,antipolio antibody titer, antitetanus toxoid antibodies, and avidity of antibodies to tetanus,Adverse events,potential acute side-effects,gram fat, milk retinol,Child growth,Infant serum retinol,Mortality,serum retinol,rate ratio to compare all deaths,safety and toxicity,incidence of diarrhea,rates of any sign or symptom,linear or ponderal growth or infectious disease morbidity,Antibody titers,miscarriage, stillbirth, maternal death, or live birth,episodes of bulging of the fontanelle,intracranial haemorrhage,fetal loss and early infant mortality,vitamin A status,fetal loss and survival,Seroconversion to OPV and geometric means of antibody titers,pregnancy-related mortality and all-cause female mortality,infant survival,Acute toxicity,Maternal serum retinol,serum retinol and infant stores,Breast milk retinol levels,serum retinol levels,milk retinol,Infant retinol stores,mortality through 24 weeks of age,risk of death,vitamin A status, signs of acute toxic effects, anthropometric indicators, and severe morbidity,side effects,Mortality, calculated as mortality rate ratios (MRRs,mortality|Vitamin A supplementation at birth was not significantly associated with mortality: the MRR of vitamin A supplementation compared with placebo, controlled for randomisation to "early BCG" versus "no early BCG" was 1.08 (95% CI 0.79 to 1.47).
60|clinical success rate,number of failures,presence of marginal gaps,failure frequencies|There was no difference between the number of failures caused by post decementations and the presence of marginal gaps observed in the 2 groups (95% confidence intervals, -9.7 to 16.2 and -17.8 to 9.27).
                
43|frequent sexual activity,adolescent compliance,Cumulative life table discontinuation rates,noncompliance level,condom and contraceptive use, rates of pregnancy and STDs, and other outcomes and mediators,repeat pregnancy,knowledge of OCs,clinic utilization or satisfaction,Questionnaire data,levels of condom and contraceptive use, and rates of pregnancy and STDs,number of missed pills per cycle,Study termination rates,oral contraceptive pill adherence,prolonged bleeding,menstrual changes,mean number of missed pills per cycle,rate of continuation and the rate of on-time injections|More women in the intervention group were not pregnant and still using contraception, and were able to successfully switch contraceptive methods compared to women in the control group.
not found|odds for anemia,Delayed clamping of the umbilical cord increases the infant's iron endowment at birth and haemoglobin concentration,maternal or newborn morbidity, in infant behavior in the first hour of life,iron stores,polycythaemia without symptoms,infant haematological status and iron status at 6 months of age, and analysis was by intention-to-treat,total serum bilirubin levels,shorter active labors,ferritin,rate of jaundice,total body iron,clinical jaundice or plethora,maternal perceptions of her infant and the experience of giving birth,Infant haematological status,beneficial haematological effect,rate of breast feeding,mean infant ferritin and Hb,infant and maternal safety,haematological status,6-month iron stores,Bilirubin concentration,adverse events,Delayed cord clamping and haemoglobin levels,mean corpuscular volume,Iron stores,odds ratio for iron deficiency anaemia,infant's hemoglobin and serum ferritin 3 months after delivery,Maternal and cord ferritin and hemoglobin values,mean infant haemoglobin level,maternal haemoglobin,Maternal haematological status,iron and haematological status,red cell mass,haemoglobin (Hb) change from cord values,duration of cord adherence and neonatal and maternal outcomes,serum ferritin and hemoglobin,haematological effects|Throughout the observation period infant Hb levels in both groups declined, but more rapidly in controls than in the DCC group [difference in Hb change from baseline at 4 months 1.1 g/dl, 95% confidence interval (CI) 0.2; 2.1].
not found|Berg Balance Scale score and weight-bearing ability, as measured by vertical ground reaction force during four standing tasks (rising from a chair and weight-shifting forward, backward and laterally,Postural balance and knee flexor strength,cardiovascular fitness (V(O2)max,quality of life,Berg Balance Scale scores, forward and backward weight-bearing abilities of the affected limbs, and knee flexor strength,postural balance and muscle strength,cardiovascular fitness, maximal workload, gait speed, and paretic lower-extremity muscle strength,generic health-related quality of life survey (SF-36,motor behaviour,muscle strength and gait,maximal workload, muscle strength, gait speed, and the Berg Balance Scale score,cardiovascular fitness,functional capacity, physical aspects, pain, general state of health, vitality, social aspects and mental health|Postural balance and knee flexor strength were improved after aquatic therapy based on the Halliwick and Ai Chi methods in stroke survivors.
198|parental HR and SCL,anxious,behavioral or physiologic measures of anxiety,low trait anxiety,median induction (coping) VAS level,number of anxious children,change in anxiety,maternal blood pressure and heart rate,anxiety,Observed anxiety in the holding area (T1), entrance to the operating room (T2), and introduction of the anesthesia mask (T3,percentage of inductions in which compliance of the child,Anxiety and compliance during induction of anesthesia,children's perioperative anxiety,preoperative anxiety,Posthospital Behavior Questionnaire (PHBQ,parental preoperative anxiety,infant behavioural distress,Hospital Fears Inventory (HFI) and Behavioural Questionnaire (BQ), and parental anxiety by the Parents' Questionnaire (PQ,Parental satisfaction,anxiety, health care attitudes and satisfaction with the anaesthesia and surgery experience,Post Hospitalization Behavior Questionnaire,anxiety changes,parental heart rate (HR), parental blood pressure, and parental skin conductance level (SCL,parental anxiety,incidence of electrocardiogram abnormalities,Modified Yale Preoperative Anxiety Scale (mYPAS) score,Posthospitalization Behavioral Questionnaire (PHBQ,Fear and anxiety,median recovery (coping) VAS levels,anxiety and distress,Mean arterial pressure,level of anxiety,Parental anxiety,cortisol concentrations,SCL changes over time,behavioral disorders,anxiety levels and health care attitudes,anxiety levels,Preoperative parental anxiety levels,anxiety and desire for information,anxious on entrance to the operating room,child's behaviour and the Visual Analogue Scale (VAS,Reducing anxiety,level of parental anxiety,Parental HR,preoperative anxiety levels,A Visual Analog Scale (VAS) and Modified Child Dental Anxiety Scale (MCDAS,perioperative outcomes,anxiety of the parent and compliance of the child during induction,emergence delirium,State anxiety and blood pressure,Postoperative behavioral disorders,State-Trait Anxiety Inventory (Y-1/Y-2) instrument (self-report anxiety behavioral instrument that measures trait/baseline and state/situational anxiety,Amsterdam Preoperative Anxiety and Information Scale (APAIS) questionnaires,Postoperative behavior changes,Sensory stimuli and anxiety,analgesia,Anxiety,Global Mood Scale (GMS,Preoperative anxiety,lower anxiety,frequency of behavior disorders,anxiety and satisfaction,quality of mask induction,maternal anxiety,behavioral and physiologic anxiety,level of anxiety postoperatively,pediatric preoperative anxiety,anxiety (mYPAS) and compliance (ICC,postoperative behavioral changes,parental anxiety scores|The Mann-Whitney U-test showed that the computer group coped significantly better than the control group at induction (P = 0.014) and significantly better than the cartoon group upon recovery (P = 0.016).
200|discomfort,Endothelial cell loss,4-point pain scale,Systolic and diastolic blood pressure, pulse rate and peripheral oxygen saturation,tissue manipulation,intraocular sensation,visual analog scale,cell density parameters or Kowa laser flare-cell meter measurements,minimal discomfort,5-point satisfaction scale,Best corrected visual acuity (BCVA,Intraoperative discomfort, postoperative discomfort, and discomfort,rate of potential visual acuity recovery,Intraoperative pain,safety and efficacy,blood pressure,patients' subjective experience of pain,visual analog pain scale,operative conditions, patient cooperation, and intraoperative complications,no sensation,BCVA improvement,subjective experience of pain,patient-reported pain scores for delivery of anesthesia,level of intraoperative discomfort,discomfort pain scores,intraoperative pain,Intraoperative pain scores,level of intraoperative pain,mean pain score ,Diastolic blood pressure,mean pain score,Safety and efficacy,pressure or pain,Systolic blood pressure, pulse rate, oxygen saturation and pain score,cell loss or adverse events,patient cooperation,patient satisfaction,Central endothelial cell counts,surgeon satisfaction score,discomfort or pain,10-point visual analogue scale,pain,pain scores|In a rigorously double-masked, prospective, randomized, controlled trial there was no significant reduction in intraoperative pain when intracameral 1% lidocaine was used during phacoemulsification under topical anesthesia.
153|repositioning and percentage of united fractures,processing time,pain relief treatment,pain score,consumption of analgesics of no clinical importance,Pain,pain medication,Visual Analogue Scale (VAS,pain experienced, the need for supplementary analgesics, or complications during the hospital stay,processing time or time to operation,pain relief,analgesic requirement,pain alleviation,total consumption of analgesics,pain suffered, analgesia required, frequency of pressure sores or ease of operation,intertrochanteric fractures,visual analog scale (VAS,femoral neck fractures,number of analgesic medications,VAS pain evaluation,peak pain score pattern,pain,pain reduction|There was a small significant increase in consumption of analgesics of no clinical importance in patients with skin traction, and no effect of traction type on the processing time or time to operation.
60|fracture healing, radial nerve recovery, infection, and elbow and shoulder discomfort,union time, union rate, functional outcome and the incidence of complications,ASES scores,shoulder range of motion (ROM,American Shoulder and Elbow Surgeons' Score (ASES,restriction of shoulder movements,complications,rate of non-union,elbow pain,function of the shoulder and elbow, as determined by the American Shoulder and Elbow Surgeons' score, the visual analogue pain score, range of movement, or the time taken to return to normal activity,average union time,Shoulder pain,union rate,rate of union and functional outcome,internal fixation of humeral shaft fractures,elbow ROM,fracture alignment, time to healing, delayed union, and nonunion,Healing times,Radial nerve palsy|Healing times did not differ between the two treatment groups (p>0.05).
58|number of infections,deep infection,infection rate,Superficial thromboplebitis|A statistically significant difference was found between the number of infections in the antibiotic groups and the number in the placebo group.